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II. Abstract 
Human African trypanosomiasis (HAT) and Chagas disease are caused by infection with the 
protozoan parasites Trypanosoma brucei and T. cruzi, respectively.  There has historically been 
a lack of investment into measures to control these diseases.  As a result, few drugs are 
available to treat HAT and Chagas disease, and there is an urgent need for novel alternatives. 
The enzyme L-threonine 3-dehydrogenase (TDH) initiates the conversion of L-threonine into 
acetyl-coenzyme A and glycine.  This pathway has been shown to play a vital role in T. brucei, 
particularly in fatty acid synthesis.  Exposure of T. brucei in culture to a potent TDH inhibitor, 
has been shown to be lethal(1) and dual blockade of the TDH pathway and a second pathway 
for acetyl-coenzyme A production, terminated by pyruvate dehydrogenase, completely inhibits 
the growth of T. brucei(2,3). 
Multiple three-dimensional structures of TDH, alone and in complex with ligands, were 
determined by X-ray crystallography.  In parallel, enzyme assays were carried out to investigate 
the kinetic behaviour of TDH and the modes of action of known TDH inhibitors.  The structural 
information on TDH was used in a virtual screen to predict the binding interactions between the 
enzyme and a library of around 3000 ligands.  These ligands were mainly selected for their 
diversity and for their inhibition of proteins related to TDH.  Subsequently, an in vitro screen was 
performed to test compounds identified by virtual screening, along with small molecules and 
fragments from commercial libraries. 
In total, 27 compounds were identified as TDH inhibitors.  Of these compounds, four were found 
to potently inhibit T. brucei growth.  This study has demonstrated the effectiveness of combining 
structural and functional data in rational drug discovery.  Novel aspects of TDH have been 
discovered, in addition to novel inhibitors that will aid in the design of a new class of 
antitrypanosomal drugs. 
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2. Millerioux Y, Ebikeme C, Biran M, Morand P, Bouyssou G, Vincent IM, et al. The threonine 
degradation pathway of the Trypanosoma brucei procyclic form: the main carbon source for lipid 
biosynthesis is under metabolic control. Mol Microbiol. 2013 Oct;90(1):114–29.  
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4 
 
IV. Table of contents 
 
I. Declaration ............................................................................................................................ 2 
II. Abstract ................................................................................................................................. 3 
IV. Table of contents ................................................................................................................... 4 
V. List of figures ......................................................................................................................... 7 
VI. List of tables ........................................................................................................................ 16 
VII. List of abbreviations ............................................................................................................ 17 
1. Introduction ........................................................................................................................ 20 
1.1 Rational Drug Discovery .............................................................................................. 20 
1.2 Trypanosomiasis and Neglected Tropical Diseases (NTDs) ......................................... 23 
1.2.1 The NTD health burden ....................................................................................... 24 
1.2.2 NTD policy ........................................................................................................... 25 
1.2.3 The Product Development Partnership (PDP) model ......................................... 27 
1.2.4 Imbalanced R&D priorities .................................................................................. 28 
1.2.5 Trypanosomiasis ................................................................................................. 29 
1.2.6 The current status of HAT and Chagas disease control ...................................... 36 
1.2.7 Trypanosomiasis R&D ......................................................................................... 37 
1.3 L-threonine 3-dehydrogenase (TDH) .......................................................................... 37 
1.3.1 The role of TDH in trypanosomes ....................................................................... 40 
1.4 Hypothesis ................................................................................................................... 42 
2. Methods .............................................................................................................................. 44 
2.1 Structural Studies of TDH ............................................................................................ 44 
2.1.1 Protein Expression and Purification .................................................................... 44 
2.1.2 X-ray Crystallography and Structure Analysis ..................................................... 48 
2.1.3 Crystallisation ...................................................................................................... 49 
2.1.4 Other Biochemical and Computational Techniques ........................................... 64 
2.2 Enzymatic Studies ....................................................................................................... 69 
2.2.1 Basic Kinetics ....................................................................................................... 69 
2.2.2 Optimisation and Alteration ............................................................................... 77 
2.2.3 Mode of Inhibition studies (MOI) ....................................................................... 77 
2.2.4 Further studies of enzyme activity ...................................................................... 80 
2.3 Virtual Screening ......................................................................................................... 81 
5 
 
2.3.1 Docking Software and AutoDock 4 ..................................................................... 82 
2.3.2 Screen Preparation ............................................................................................. 83 
2.3.3 Compound Libraries ............................................................................................ 86 
2.3.4 Screen Execution and Analysis ............................................................................ 90 
2.4 In vitro Screening ........................................................................................................ 92 
2.4.1 Libraries ............................................................................................................... 92 
2.4.2 Screening Assay & Format .................................................................................. 93 
2.4.3 Analysis ............................................................................................................... 96 
2.4.4 Trypanosome growth inhibition ......................................................................... 99 
2.5 Commercialisation of NTD drugs ................................................................................ 99 
3. Results ............................................................................................................................... 101 
3.1 Structural Information .............................................................................................. 101 
3.1.1 Protein Expression and Purification .................................................................. 101 
3.1.2 Crystal growth and data collection ................................................................... 106 
3.1.3 Primary Structure .............................................................................................. 111 
3.1.4 Secondary Structure .......................................................................................... 116 
3.1.5 Tertiary Structure .............................................................................................. 117 
3.1.6 Quaternary structure & Complex Formation .................................................... 129 
3.1.7 Ligand binding and Catalysis ............................................................................. 145 
3.2 TDH kinetics .............................................................................................................. 158 
3.2.1 Kinetic Characteristics of TDH ........................................................................... 158 
3.2.2 Alteration and Optimization of TDH activity ..................................................... 167 
3.2.3 TDH inhibition ................................................................................................... 178 
3.2.4 Preliminary enzymatic studies of TDH from Clostridium difficile ..................... 190 
3.3 Virtual Screening ....................................................................................................... 194 
3.3.1 Compound Libraries .......................................................................................... 194 
3.3.2 Assay Validation ................................................................................................ 200 
3.3.3 Hits .................................................................................................................... 202 
3.3.4 Binding Interactions .......................................................................................... 222 
3.4 In vitro Screening ...................................................................................................... 236 
3.4.1 Compound libraries ........................................................................................... 236 
3.4.2 Assay Validation ................................................................................................ 239 
3.4.3 In vitro screening hits ........................................................................................ 241 
3.4.4 Hit validation and characterisation ................................................................... 261 
6 
 
3.4.5 Inhibition of trypanosome growth .................................................................... 301 
4. Discussion .......................................................................................................................... 307 
4.1 TDH structure and function ...................................................................................... 307 
4.1.1 TbTDH as a GalE-like TDH .................................................................................. 307 
4.1.2 The relationship between TDH structure and function .................................... 312 
4.1.3 Catalytic activity ................................................................................................ 317 
4.1.4 The relationship between TDH and KBL ........................................................... 326 
4.1.5 Inhibition and stimulation of TDH ..................................................................... 327 
4.1.6 Evaluation of Investigative Methods ................................................................ 332 
4.2 Screening for the discovery of new inhibitors .......................................................... 340 
4.2.1 Utility of Virtual Screening ................................................................................ 340 
4.2.2 In vitro screening design ................................................................................... 344 
4.2.3 Most promising inhibitors ................................................................................. 346 
4.2.4 Lessons for the design of screening campaigns ................................................ 356 
4.3 Implications of the Research ..................................................................................... 358 
4.3.1 TDH as a target for trypanosomiasis ................................................................. 358 
4.3.2 Combination therapy ........................................................................................ 359 
4.3.3 Targeted polypharmacology ............................................................................. 360 
4.4 Future research ......................................................................................................... 362 
4.4.1 Further structural and functional studies of TDH ............................................. 362 
4.4.2 Towards the design of new leads for trypanosomiasis ..................................... 363 
4.4.3 Targeting other organisms ................................................................................ 367 
4.4.4 Drivers of NTD R&D ........................................................................................... 368 
4.4.5 Commercialisation strategies ............................................................................ 368 
4.4.6 Product development partners ......................................................................... 369 
4.4.7 Details of partnerships ...................................................................................... 378 
4.4.8 Benefits of different options ............................................................................. 387 
4.4.9 Evidence for Partnerships ................................................................................. 390 
4.4.10 The NTD R&D landscape ................................................................................... 393 
4.4.11 Development of a drug for a neglected tropical disease .................................. 395 
5. Acknowledgements ........................................................................................................... 396 
6. References ......................................................................................................................... 397 
7.     Appendix…......…...…...…...…...…...…...…………...……………...………...…………...………...……...…...420
7 
 
V. List of figures 
Figure 1.1.1 - Early-stage drug discovery and the steps to the development of a new 
investigational drug ..................................................................................................................... 23 
Figure 1.2.1 - The global distribution of the burden of NTDs in 2010 ......................................... 24 
Figure 1.2.2 - Diseases classified as NTDs ................................................................................ 25 
Figure 1.2.3 - Examples of PDP "Brokers" involved in product development for drugs, vaccines, 
diagnostics and insecticides for NTDs ........................................................................................ 28 
Figure 1.2.4 - Coloured electron micrograph of bloodstream form Trypanosoma brucei in 
mammalian blood ........................................................................................................................ 29 
Figure 1.2.5 - Summary of the life cycle of T. brucei .................................................................. 30 
Figure 1.2.6 - The distribution of HAT burden in the years 1990, 2000 and 2010...................... 31 
Figure 1.2.7 - The life cycle of T. cruzi ........................................................................................ 33 
Figure 1.2.8 - The distribution of Chagas disease burden in Latin America in 1990 and 2010 .. 34 
Figure 1.2.9 - A summary of the desired target product profiles (TPP) proposed for new drugs to 
treat HAT and Chagas disease ................................................................................................... 36 
Figure 1.3.1 - The catabolism of L-threonine to glycine and acetyl-CoA .................................... 38 
Figure 1.3.2 - The production of acetyl-CoA and acetate in T. brucei ........................................ 41 
Figure 2.1.1 - p-ET15b vector with multiple cloning sites ........................................................... 44 
Figure 2.1.2 - Schematic summarising the use of SDS-PAGE to analyse proteins ................... 46 
Figure 2.1.3 - X-ray crystallography schematic ........................................................................... 49 
Figure 2.1.4 - Crystallisation by the hanging drop vapour diffusion method. .............................. 50 
Figure 2.1.5 - The properties of a transverse wave .................................................................... 51 
Figure 2.1.6 - Bragg's law illustrated by the diffraction of two parallel waves............................. 53 
Figure 2.1.7 - A crystal unit cell ................................................................................................... 55 
Figure 2.1.8 - The Ramachandran plot (A) as a structure validation tool ................................... 63 
Figure 2.1.9 - Size-exclusion chromatography schematic illustrating the migration of proteins 
through a gel packed column ...................................................................................................... 65 
Figure 2.1.10 - Schematic illustrating the method used for estimating molecular weight by size-
exclusion chromatography. ......................................................................................................... 66 
Figure 2.1.11 - The chemical structure of dimethyl suberimidate. .............................................. 67 
Figure 2.2.1 - The absorbance of NAD
+ 
and NADH at 340nm.................................................... 70 
Figure 2.2.2 - An example of a progress curve during a kinetic enzyme assay ......................... 71 
Figure 2.2.3 - An example of raw data collected during a typical kinetic assay.. ....................... 72 
Figure 2.2.4 - An example of raw data collected during a typical kinetic assay using the 
FLUOstar OMEGA plate reader. ................................................................................................. 72 
Figure 2.2.5 - Scheme illustrating the derivation of kinetic parameters from data collected in 
enzyme kinetic assays.. .............................................................................................................. 76 
Figure 2.2.6 - Modes of enzyme inhibition .................................................................................. 78 
8 
 
Figure 2.3.1 - The identification of active molecules, 'hits', in drug discovery. ........................... 82 
Figure 2.3.2 - Schematic of virtual screening using AutoDock ................................................... 83 
Figure 2.3.3 - Wire representations of the four TDH models used as receptors for virtual 
screening with AutoDock ............................................................................................................. 84 
Figure 2.3.4 - The assignment of the search grid (search area) in ADT .................................... 85 
Figure 2.3.5 - Schematic summarising the different strategies employed in the virtual screening 
campaign against TDH ................................................................................................................ 91 
Figure 2.4.1 - The layout for PUT in 384-well plates .................................................................. 94 
Figure 2.4.2 - The construction of two-dimension path-based binary fingerprints using JChem 97 
Figure 2.4.3 - The NeuroScale model and it's use of the Radial Basis Function to define 
distances between data. ............................................................................................................. 98 
Figure 2.4.4 - A visualisation of a subset of the virtual screening library produced by the DVMS.  
. ................................................................................................................................................... 99 
Figure 3.1.1 - SDS PAGE of a successful expression test for TDH ......................................... 101 
Figure 3.1.2 - SDS-PAGE analysis of the purification of TDH from the supernatant obtained 
through protein extraction procedures ...................................................................................... 102 
Figure 3.1.3 - SDS PAGE analysis of a modified purification procedure .................................. 103 
Figure 3.1.4 - SDS PAGE of a successful expression test for KBL .......................................... 103 
Figure 3.1.5 - Extraction of KBL from an induced cell culture ................................................... 104 
Figure 3.1.6 - SDS PAGE analysis of KBL purification by affinity chromatography ................. 104 
Figure 3.1.7 - SDS PAGE analysis of TDH extraction and purification .................................... 105 
Figure 3.1.8 - SDS-PAGE analysis of TDH purification by ion exchange chromatography ..... 106 
Figure 3.1.9 - Amino acid sequence alignments of TDH from different organisms .................. 113 
Figure 3.1.10 - Phylogenetic tree connecting the different TDH sequences present in different 
organisms .................................................................................................................................. 115 
Figure 3.1.11 - Ribbon representation of a TDH monomer coloured by secondary structure .. 117 
Figure 3.1.12 - Protein topology diagram of TDH ..................................................................... 118 
Figure 3.1.13 - Ribbon representation of a TDH monomer ...................................................... 119 
Figure 3.1.14 - Ribbon representation of TDH, showing the conserved active site residues, 
Met81, Ser82, Thr119, Tyr144, Lys148, Thr186 and Trp280. .................................................. 120 
Figure 3.1.15 - Ribbon representation of TDH, coloured by the RMSD of α-carbon positions in 
each residue .............................................................................................................................. 121 
Figure 3.1.16 - Ribbon representation of TDH, coloured by the average B-factor of each residue
 .................................................................................................................................................. 122 
Figure 3.1.17 - Bar chart showing the RMSD of α-carbons per TDH residue .......................... 123 
Figure 3.1.18 - Bar chart showing the average B-factor per TDH residue ............................... 124 
Figure 3.1.19 - Bar chart showing the average B-factor per TDH residue ............................... 125 
Figure 3.1.20 - Bar chart showing the average B factor per TDH residue ................................ 126 
Figure 3.1.21 - Ribbon representations of two superposed monomeric TDH structures ......... 127 
Figure 3.1.22 - Surface representation of TDH with NAD
+
 and L-threonine bound .................. 128 
9 
 
Figure 3.1.23 - Surface representation of TDH with NAD
+
 and L-threonine bound .................. 128 
Figure 3.1.24 - Ribbon and surface representation of the TDH homodimer. ............................ 129 
Figure 3.1.25 - The TDH dimerisation interface ........................................................................ 130 
Figure 3.1.26 - The interaction between Glu86 and Trp157 ..................................................... 130 
Figure 3.1.27 - The interaction between Asp90 and Asp94 and Arg101 .................................. 131 
Figure 3.1.28 - Lys126 and Asp135 appear to be involved in another salt bridge stabilising the 
dimer. ........................................................................................................................................ 131 
Figure 3.1.29 - Visualisation of TDH structure TNADH4, from the .pdb file generated by pdbset.  
 .................................................................................................................................................. 136 
Figure 3.1.30 - Calibration of the size-exclusion chromatography column using standard 
proteins ...................................................................................................................................... 137 
Figure 3.1.31 - An example of a chromatogram from one of the size-exclusion chromatography 
experiments.. ............................................................................................................................. 138 
Figure 3.1.32 - Silver stain of an SDS-PAGE gel indicating the presence of TDH and KBL .... 142 
Figure 3.1.33 - SDS PAGE analysis of cross-linking experiments with TDH and KBL............. 143 
Figure 3.1.34 - SDS PAGE analysis of cross-linking experiments with TDH ........................... 143 
Figure 3.1.35 - SDS PAGE analysis of cross-linking experiments with KBL ............................ 144 
Figure 3.1.36 - SDS PAGE analysis of the pull-down assay to investigate complex formation 
between TDH and KBL ............................................................................................................. 145 
Figure 3.1.37 - Binding of NAD
+
 to TDH ................................................................................... 146 
Figure 3.1.38 - Binding interactions between TDH residues and NAD
+
 ................................... 147 
Figure 3.1.39 - Binding of L-threonine to TDH .......................................................................... 148 
Figure 3.1.40 - Interactions between TDH residues and L-threonine ....................................... 149 
Figure 3.1.41 - Binding of L-allo-threonine to TDH ................................................................... 150 
Figure 3.1.42 - Binding of pyruvate to TDH .............................................................................. 152 
Figure 3.1.43 - Hydrogen bonding between the side chain of Asn96 and main chain atoms of 
Ile80 ........................................................................................................................................... 154 
Figure 3.1.44 - Atoms within hydrogen-bonding distance of each other, which may form part of a 
proton relay system ................................................................................................................... 155 
Figure 3.1.45 - Binding positions in the active site of TDH occupied by glycerol (left) and 
acetone (right) ........................................................................................................................... 156 
Figure 3.1.46 - Two more binding positions of glycerol on TDH ............................................... 156 
Figure 3.1.47 - An interaction between two TDH monomers at the Loop 2 region (Pro44-Gly50)
 .................................................................................................................................................. 157 
Figure 3.2.1 - Kinetic plots and Lineweaver-Burk plots of rate of TDH activity (v) as a function of 
substrate concentration ............................................................................................................. 159 
Figure 3.2.2 - Drawing illustrating a Compulsory Ordered Bi Bi mechanism of enzyme catalysis
 .................................................................................................................................................. 160 
Figure 3.2.3 - Plots of catalytic rate (v) as a function of substrate concentration, showing signs 
of substrate inhibition ................................................................................................................ 161 
10 
 
Figure 3.2.4 - Plots of v against NAD
+
 concentration, measured at 37°C and 23°C ................ 162 
Figure 3.2.5 - Plots of v versus L-threonine concentration at 23°C and 37°C .......................... 162 
Figure 3.2.6 - Plots of v versus [L-threonine], with data points predicted using the inconstant 
exponent q................................................................................................................................. 164 
Figure 3.2.7 - Plot of q against corresponding L-threonine concentrations .............................. 164 
Figure 3.2.8 - Plot of v versus L-threonine concentration ......................................................... 166 
Figure 3.2.9 – A fit of v against TDH concentration .................................................................. 168 
Figure 3.2.10 - A plot of v against pH ....................................................................................... 169 
Figure 3.2.11 - The velocity of catabolism by de-tagged TDH, as a function of NAD
+
 
concentration ............................................................................................................................. 170 
Figure 3.2.12 - Plot of de-tagged TDH enzyme velocity against L-threonine concentration .... 170 
Figure 3.2.13 - Plot of de-tagged TDH velocity against L-threonine concentration .................. 171 
Figure 3.2.14 - The time-dependent inactivation of TDH by N-ethylmaleimide and 
iodoacetamide. .......................................................................................................................... 172 
Figure 3.2.15 - TDH activity at room temperature in the presence of different reaction mixture 
additives .................................................................................................................................... 174 
Figure 3.2.16 - TDH activity at 37°C in the presence of different reaction mixture additives ... 174 
Figure 3.2.17 - TDH activity as a function of incubation time, in the presence of glycerol and 
different alkali metal salts .......................................................................................................... 175 
Figure 3.2.18 - The effect of different concentrations of NaCl, KCl and RbCl on TDH activity. 175 
Figure 3.2.19 - The velocity of TDH catalysis as a function of NAD
+
 concentration, in the 
presence of NaCl or KCl. .......................................................................................................... 176 
Figure 3.2.20 - The velocity of TDH catalysis as a function of L-threonine concentration, in the 
presence of NaCl or KCl. .......................................................................................................... 176 
Figure 3.2.21 - Lineweaver-Burk plot of data in Figure 3.2.19. ................................................. 177 
Figure 3.2.22 - Lineweaver-Burk plot of data in Figure 3.2.20 .................................................. 178 
Figure 3.2.23 - Dose-response curves fit to data representing fractional enzyme activity as a 
function of log[inhibitor] concentration ...................................................................................... 179 
Figure 3.2.24 - Normalised TDH activity (fractional activity) as a function of NAD
+
 concentration, 
in the presence of different concentrations of L-allo-threonine ................................................. 180 
Figure 3.2.25 - Plot of fractional activity against L-threonine concentration, measured at different 
fixed concentrations of L-allo-threonine .................................................................................... 181 
Figure 3.2.26 - Plots of fractional activity as a function of NAD
+
 concentration, at fixed 
concentrations of pyruvate ........................................................................................................ 182 
Figure 3.2.27 - Plots of fractional activity against L-threonine concentration measured in the 
presence of different concentrations of pyruvate ...................................................................... 184 
Figure 3.2.28 - A plot of Fractional activity against NAD
+ 
concentration in the presence of 
different concentrations of methylglyoxal .................................................................................. 185 
Figure 3.2.29 - Plot of fractional activity at different L-threonine concentrations, in the presence 
of different concentrations of methylglyoxal .............................................................................. 186 
11 
 
Figure 3.2.30 - Plot of fractional activity at increasing incubation times of TDH with TETD. .... 187 
Figure 3.2.31 - Plot of kobs as a function of TETD concentration. ............................................. 187 
Figure 3.2.32 - Possible mechanisms of TDH inhibition by TETD ............................................ 188 
Figure 3.2.33 - Plots of kobs against TETD concentration ......................................................... 189 
Figure 3.2.34 - Plots of kobs as a function of substrate concentration ....................................... 189 
Figure 3.2.35 - Plots of CdTDH reaction velocity as a function of substrate concentration, at 
fixed concentrations of the second substrate (A = NAD
+
; B = L-threonine) .............................. 191 
Figure 3.2.36 - Lineweaver-Burk plots of the data plotted in Figure 3.2.35 .............................. 192 
Figure 3.2.37 - Plots of CdTDH reaction velocity as a function of L-threonine concentration at 
5mM NAD
+
. ............................................................................................................................... 193 
Figure 3.3.1 - Ribbon representations of the structures of TDH, UDP-GalE from Trypanosoma 
brucei and DFR from Vitis vinifera superimposed on each other ............................................. 195 
Figure 3.3.2 - Visualisation of the diversity all compounds in the virtual screening library ....... 196 
Figure 3.3.3 - A superimposition of an L-threonine-bound TDH structure (obtained by X-ray 
crystallography) on a Virtual Screening model with its predicted binding mode for L-threonine
 .................................................................................................................................................. 201 
Figure 3.3.4 - Predicted binding poses of NAD
+
 compared to the binding pose found by virtual 
screening ................................................................................................................................... 202 
Figure 3.3.5 - Venn diagram outlining the number of hits in each screen and the common hits 
between screens ....................................................................................................................... 203 
Figure 3.3.6 - Visualisation of the hits from Virtual Screen 1 .................................................... 209 
Figure 3.3.7 - Visualisation of the diversity of hits from Virtual Screen 1 ................................. 210 
Figure 3.3.8 - Visualisation of the diversity of the hits from Virtual Screen 3 ........................... 214 
Figure 3.3.9 - Visualisation of the diversity of the hits from Virtual Screen 3 ........................... 215 
Figure 3.3.10 - Visualisation of the diversity of the hits from Virtual Screen 4 ......................... 219 
Figure 3.3.11 - Visualisation of the diversity of hits from Virtual Screen 4 ............................... 220 
Figure 3.3.12 - Column chart representation of virtual screening hit rates ............................... 221 
Figure 3.3.13 - Column chart representation of virtual screening hit rates ............................... 221 
Figure 3.3.14 - The molecular structures of BPOB and L-threonine ........................................ 222 
Figure 3.3.15 - A predicted binding mode of BPOB, predicted by AutoDock in Virtual Screen 1
 .................................................................................................................................................. 223 
Figure 3.3.16 - The two predicted binding modes of BPOB in Virtual Screen 1 ....................... 224 
Figure 3.3.17 - Predicted binding mode of ZINC1673377 depicted in AutoDock Tools (ADT) 225 
Figure 3.3.18 - Predicted binding pose of ZINC1936250 depicted using ADT. ........................ 226 
Figure 3.3.19 - Predicted binding pose of α-solamargine in Virtual Screen 3, depicted in ADT.
 .................................................................................................................................................. 228 
Figure 3.3.20 - Binding pose of ancistrogriffithine A in AutoDock.  Depicted using ADT. ........ 229 
Figure 3.3.21 - Predicted binding pose of ZINC05492794, depicted in ADT. ........................... 230 
Figure 3.3.22 - Predicted binding pose of 3,23-dioxotirucalla-7,24-dien-21-al in Virtual Screen 3.
 .................................................................................................................................................. 231 
12 
 
Figure 3.3.23 - Predicted binding poses of ZINC17465983 (top two images) and 
podocarpusflavone A ................................................................................................................ 232 
Figure 3.3.24 - Predicted binding pose of astrogaloside III in Virtual Screen 4 ........................ 233 
Figure 3.3.25 - Predicted binding pose of stigmasterol D-glucoside in Virtual Screen 4 .......... 234 
Figure 3.4.1 - Visualisation of the diversity of all compounds in the in vitro screening library .. 236 
Figure 3.4.2 - Visualisation of the chemical diversity of all compounds in the Asinex library 
(20,000 compounds) screened by UCL ChemiBank, using GOLD........................................... 237 
Figure 3.4.3 - Graphical interpretation of the different signals recorded in the PUT ................ 240 
Figure 3.4.4 - Plots of fractional TDH activity against the log of inhibitor concentration tested in 
hit confirmation assays for Maybridge compounds ................................................................... 242 
Figure 3.4.5 - Plots of fractional TDH activity against the log of inhibitor concentration tested in 
hit confirmation assays for Maybridge compounds ................................................................... 243 
Figure 3.4.6 - Plot of fractional activity as a function of the concentration of confirmed hits from 
the Maybridge library. ................................................................................................................ 244 
Figure 3.4.7 - Plot of fractional activity as a function of the log concentration of five confirmed 
hits from the Maybridge library .................................................................................................. 244 
Figure 3.4.8 - Plot of fractional activity as a function of the log concentration of two potent 
confirmed hits from the Maybridge library ................................................................................. 245 
Figure 3.4.9 - Plots of fractional activity against the log concentration of hits from the 3D 
Fragment Consortium Library ................................................................................................... 246 
Figure 3.4.10 - Plot of fractional activity as a function of the concentration of confirmed hits from 
the 3D Fragment Consortium library. ........................................................................................ 247 
Figure 3.4.11 - Plot of fractional activity as a function of the log concentration of confirmed hits 
from the 3D Fragment Consortium library. ................................................................................ 247 
Figure 3.4.12 - Plot of fractional activity against the concentration of custom library compounds 
in the hit confirmation assay...................................................................................................... 248 
Figure 3.4.13 - Plot of fractional activity as a function of the log of the concentration of hits from 
the Custom library ..................................................................................................................... 248 
Figure 3.4.14 - Plots of fractional activity as a function of three-fold dilutions of hits from the 
Asinex library ............................................................................................................................. 250 
Figure 3.4.15 - Plot of fractional activity against the concentration of all confirmed hits from the 
Asinex library. ............................................................................................................................ 251 
Figure 3.4.16 - Plot of fractional activity against the log concentration of all confirmed hits from 
the Asinex library. ...................................................................................................................... 251 
Figure 3.4.17 - Hit rates of different subsets of the in vitro screening library and the entire library
 .................................................................................................................................................. 252 
Figure 3.4.18 - Visualisation of the diversity of all confirmed hits from in vitro screening ........ 253 
Figure 3.4.19 - Plot of fractional activity against log inhibitor concentration.  Confirmed hits from 
the Asinex library ....................................................................................................................... 261 
Figure 3.4.20 - Plot of fractional activity against log inhibitor concentration ............................. 262 
13 
 
Figure 3.4.21 - Plots of fractional activity versus inhibitor concentration .................................. 263 
Figure 3.4.22 - Plots of fractional activity as a function of SB02047 concentration .................. 264 
Figure 3.4.23 - Plots of fractional activity as a function of CC06013 concentration ................. 264 
Figure 3.4.24 - Plot of fractional activity against the concentration of fragments DD00771052 
and 4011502 ............................................................................................................................. 265 
Figure 3.4.25 - Plot of fractional activity versus log 4011502 concentration ............................ 266 
Figure 3.4.26 - The fractional activity of TDH following different incubation times with 
NSC132252, in the presence or absence of detergent ............................................................. 268 
Figure 3.4.27 - Time dependent inhibition of TDH by 1mM BPOB. .......................................... 269 
Figure 3.4.28 - Time dependent inhibition of TDH by BPOB over pre-incubation times of up to 
90 minutes. ................................................................................................................................ 269 
Figure 3.4.29 - Time dependent inhibition of TDH by 100µM myricetin. .................................. 270 
Figure 3.4.30 - The structural formulas of myricetin and quercetin .......................................... 270 
Figure 3.4.31 - Time dependent inhibition of TDH by 300µM quercetin. .................................. 271 
Figure 3.4.32 - Time dependent inhibition by 500µM NSC132249 and 800µM NSC128598. .. 271 
Figure 3.4.33 - Fractional TDH activity as a function of the concentration of confirmed inhibitors 
from the Custom library ............................................................................................................. 272 
Figure 3.4.34 - Fractional TDH activity as a function of the concentration of confirmed inhibitors 
from the Custom library ............................................................................................................. 273 
Figure 3.4.35 - Fractional TDH activity as a function of the concentration of confirmed inhibitors 
from the Custom library ............................................................................................................. 274 
Figure 3.4.36 - Fractional activity as a function of NSC132252 concentration ......................... 275 
Figure 3.4.37 - Plots of fractional activity versus NAD
+ 
concentration, at fixed concentrations of 
BPOB ........................................................................................................................................ 276 
Figure 3.4.38 - Plots of fractional activity versus L-threonine concentration, at fixed 
concentrations of BPOB ............................................................................................................ 277 
Figure 3.4.39 - Binding mode of BPOB predicted in Virtual Screen 3 ...................................... 278 
Figure 3.4.40 - Binding mode of BPOB predicted in Virtual Screen 4 ...................................... 279 
Figure 3.4.41 - Plots of fractional activity versus NAD
+
 concentration, at different fixed 
concentrations of Qc1 ............................................................................................................... 280 
Figure 3.4.42 - Plot of fractional activity against L-threonine concentration, at different fixed 
concentrations of Qc1 ............................................................................................................... 281 
Figure 3.4.43 - Predicted binding mode of Qc1 in Virtual Screen 3 ......................................... 282 
Figure 3.4.44 - Predicted binding mode of Qc1 in Virtual Screen 4 ......................................... 283 
Figure 3.4.45 - Plot of fractional activity versus NAD
+
 concentration, at different fixed 
concentrations of sanguinarine ................................................................................................. 284 
Figure 3.4.46 - Plot of fractional activity versus L-threonine concentration, at different fixed 
concentrations of sanguinarine ................................................................................................. 285 
Figure 3.4.47 - Binding mode of sanguinarine, predicted in Virtual Screen 4 .......................... 286 
14 
 
Figure 3.4.48 - Fits of fractional activity versus NAD
+
 concentration at fixed concentrations of 
myricetin .................................................................................................................................... 287 
Figure 3.4.49 - Plots of fractional activity as a function of L-threonine concentration, at different 
fixed concentrations of myricetin ............................................................................................... 288 
Figure 3.4.50 - Binding pose of myricetin predicted by AutoDock in Virtual Screen 3 ............. 289 
Figure 3.4.51 - Binding pose of myricetin predicted by AutoDock in Virtual Screen 4 ............. 290 
Figure 3.4.52 - Curves describing competitive inhibition fitted to data describing the relationship 
between NAD
+
 concentration and fractional activity, measured in the presence of different fixed 
concentrations of NSC132249. ................................................................................................. 291 
Figure 3.4.53 - Plots of fractional activity against L-threonine concentration, at different fixed 
concentrations of NSC132249 .................................................................................................. 292 
Figure 3.4.54 - Binding mode of NSC132249 predicted by AutoDock in Virtual Screen 4 ....... 293 
Figure 3.4.55 - The binding mode of NSC132249 predicted by AutoDock in Virtual Screen 3 294 
Figure 3.4.56 - Plot of fractional activity versus NAD
+
, at different fixed concentrations of 
NSC132252 ............................................................................................................................... 295 
Figure 3.4.57 - Plots of fractional activity as a function of L-threonine concentration, at different 
fixed concentrations of NSC132252 ......................................................................................... 296 
Figure 3.4.58 - Predicted binding mode of NSC132252 in Virtual Screen 4 ............................ 297 
Figure 3.4.59 - Plots of fractional activity against NAD
+
 concentration, at fixed concentrations of 
NSC132252 and in the presence of 0.01% Triton X-100 .......................................................... 298 
Figure 3.4.60 - Fit of fractional activity versus L-threonine concentration, at different fixed 
concentrations of NSC132252 and in the presence of 0.01% Triton X-100 ............................. 299 
Figure 3.4.61 - Predicted binding mode of NSC132252 in Virtual Screen 3 ............................ 300 
Figure 4.1.1 - TbTDH monomer with the conserved features of GalE-like TDHs ..................... 308 
Figure 4.1.2 - Comparison of the dimerisation interfaces of TvTDH (left) and FfTDH (right) ... 309 
Figure 4.1.3 - The dimerisation interface of TbTDH, as determined by X-ray crystallography . 309 
Figure 4.1.4 - Combined ribbon and surface representation of the structure of the TDH dimer
 .................................................................................................................................................. 311 
Figure 4.1.5 - Surface representations of the structures of the holo form of CnTDH ............... 311 
Figure 4.1.6 - Syn and anti configurations of NAD(H) .............................................................. 313 
Figure 4.1.7 - Schematic of the proposed mechanism of L-threonine oxidation by TDH ......... 313 
Figure 4.1.8 - Close up of TDH structure in model TNADH4 .................................................... 314 
Figure 4.1.9 - The water chain for proton relay in alcohol dehydrogenase from Drosophila 
lebanonensis ............................................................................................................................. 315 
Figure 4.1.10 - Models of cooperativity that may be applicable to TDH ................................... 320 
Figure 4.1.11 - Three illustrations of the morpheein concept ................................................... 321 
Figure 4.1.12 - Examples plots of substrate concentration as a function of product formation rate
 .................................................................................................................................................. 322 
Figure 4.1.13 - Kinetics of GalE from K. fragilis ........................................................................ 324 
Figure 4.1.14 - A Michaelis-Menten plot of monomeric GalE from K. fragilis ........................... 325 
15 
 
Figure 4.1.15 - The structural formulas of L-threonine and analogous compounds, L-allo-
threonine, pyruvate and methylglyoxal. .................................................................................... 328 
Figure 4.1.16 - The reaction of methylglyoxal with lysine and arginine side chains ................. 329 
Figure 4.1.17 - The production of methylglyoxal as a by-product of the glycolytic pathway in 
trypanosomes ............................................................................................................................ 330 
Figure 4.1.18 - The Hofmeister series ...................................................................................... 331 
Figure 4.1.19 - The investigation of time-dependent inhibition by time-curve analysis ............ 339 
Figure 4.2.1 - The most promising TDH inhibitors identified by screening ............................... 347 
Figure 4.2.2 - Binding of myricetin to DFR ................................................................................ 350 
Figure 4.2.3 - TDH structure (semi-transparent beige) superimposed over myricetin-bound DFR.  
 .................................................................................................................................................. 350 
Figure 4.2.4 - Binding of quercetin to DFR ............................................................................... 351 
Figure 4.2.5 - TDH structure (semi-transparent gold) superimposed on quercetin-bound DFR 
structure .................................................................................................................................... 351 
Figure 4.2.6 - TDH structure (green) superposed on a dihydroquercetin-bound DFR structure
 .................................................................................................................................................. 352 
Figure 4.2.7 - Inhibitors of TbGalE that also inhibit TDH .......................................................... 353 
Figure 4.2.8 - TDH structure (coloured green) superposed on TbGalE structure .................... 354 
Figure 4.2.9 - TDH structure (ribbon and surface representation) superposed on UDP-bund 
TbGalE structure ....................................................................................................................... 354 
Figure 4.2.10 - Binding mode of a NSC132249-related GalE inhibitor to TbGalE, predicted by 
virtual screening ........................................................................................................................ 355 
Figure 4.3.1 - Illustrative example of an isobologram ............................................................... 360 
Figure 4.3.2 - Strategies for the design of DMLs ...................................................................... 362 
Figure 4.4.1 - Myricetin, quercetin and other flavonoid classes ................................................ 366 
Figure 4.4.2 - Scheme illustrating potential commercialisation strategies for university- or 
PSNRI-originating research ...................................................................................................... 369 
Figure 4.4.3 - Global funding for NTD research in 2011, as reported in the G-FINDER report 370 
Figure 4.4.4 - Summary of the pharmaceutical development lifecycle ..................................... 390 
 
16 
 
VI. List of tables 
Table 1.2.1 - Current recommended treatment regimens for HAT and Chagas disease ........... 35 
Table 3.1.1 - Details of the crystallisation, data collection and structure solution of TDH ........ 108 
Table 3.1.2 - Organisms of pharmacological/medical interest that may possess TDH enzymes 
similar to that from T. brucei...................................................................................................... 116 
Table 3.1.3 - TDH quaternary structure identified by PISA and confirmed visually.. ................ 133 
Table 3.1.4 - Results of size-exclusion chromatography experiments.  Note that some results 
appear more than once, under different headings. ................................................................... 139 
Table 3.2.1 - TDH activity in the presence of 60mM of various amino acids ............................ 167 
Table 3.2.2 - The effect of different metal salts and covalent modifiers on TDH activity .......... 172 
Table 3.2.3 - The effects of different concentrations of monovalent cations on TDH activity. .. 173 
Table 3.3.1 - Mean chemical terms describing the compounds in different components of the 
virtual screening library. ............................................................................................................ 199 
Table 3.3.2 - Hit rates achieved in Virtual Screens 1, 3 and 4. ................................................. 203 
Table 3.3.3 – Mean chemical terms describing the features of the hits from the three successful 
Virtual Screens. ......................................................................................................................... 205 
Table 3.3.4 – The top 5 Hits from Virtual Screen 1, and one hit that later exhibited activity in 
vitro ............................................................................................................................................ 207 
Table 3.3.5 – The top 5 Hits from Virtual Screen 3 and hits which either exhibited activity in vitro 
or an analogue exhibited activity in vitro ................................................................................... 211 
Table 3.3.6 – The top 5 Hits from Virtual Screen 4 and hits which either exhibited in vitro or an 
analogue exhibited activity in vitro (see Section 3.4). ............................................................... 216 
Table 3.4.1 - Mean chemical terms describing the features of the compounds in the in vitro 
screening libraries. .................................................................................................................... 238 
Table 3.4.2 - All confirmed hits and descriptive chemical terms from the in vitro screen. ........ 254 
Table 3.4.3 – Residual TDH activity after pre-incubation with Asinex inhibitors for at least 72 
minutes, with or without detergent ............................................................................................ 262 
Table 3.4.4 - The effect on TDH activity of confirmed fragment inhibitors, with or without 
detergent ................................................................................................................................... 266 
Table 3.4.5 - The effect on TDH activity of confirmed inhibitors from the Custom library and 
TETD as a positive control, with or without detergent .............................................................. 267 
Table 3.4.6 - The percentage inhibition of BSF trypanosome growth, in the presence of 
confirmed hits from the in vitro screening experiments ............................................................ 302 
Table 3.4.7 - BSF T. brucei growth inhibitory concentrations of sanguinarine, myricetin and Qc1.
 .................................................................................................................................................. 306 
Table 4.4.1 - The assessment of drug targets for antiparasitic drug discovery ........................ 364 
Table 4.4.2 - New NTD products approved or recommended during 2000-11 ......................... 379 
Table 4.4.3 - Market segmentation matrix, adapted from G Moore's 'Crossing The Chasm' ... 389
17 
 
VII. List of abbreviations 
ADT AutoDock Tools DLiS Dynamic Light Scattering 
AIC Aikake's Information Criterion DLS Diamond Light Source 
AKB 2-amino-3-ketobutyrate DML Drug multiple ligands 
AMC Advance Purchase/Market 
Commitment 
DMS Dimethyl suberimidate 
ASAQ Artesunate and amodiaquine DMSO Dimethyl sulfoxide 
ASMQ Artesunate and mefloquine DNA Deoxyribonucleic acid 
AUC Analytical ultracentrifugation DNDi Drugs for Neglected Diseases 
initiative 
BLAST Basic Local Alignment 
Search Tool  
DTP NCI/NIH Developmental 
Therapeutics Program 
βM β-mercaptoethanol DVMS Data Visualisation Modelling 
System 
BPOB 2-{[3-(4-bromophenyl)-3-
oxopropyl]amino}-3-
hydroxybutanoic acid 
ESRF European Synchrotron 
Radiation Facility 
BSA Bovine serum albumin FDC Fixed Dose Combination 
BSF Bloodstream form 
(trypanosomes) 
FfTDH TDH from Flavobacterium 
frigidimaris 
BVGH BIO Ventures for Global 
Health 
FPLC Fast Performance Liquid 
Chromatography 
CdTDH TDH from Clostridium difficile GalE Uridine diphosphate-
galactose 4'-epimerase 
clogP Calculated log P GDP Guanosine diphosphate 
CnTDH TDH from Cupriavidus 
necator 
G-FINDER Global Funding for 
Innovation in Neglected 
Diseases 
CoA Coenzyme A GlmS Glucosamine-6-phosphate 
synthase 
CRO Contract Research 
Organisation 
GUI Graphical user interface 
DFID Department for International 
Development 
HAT Human African 
trypanosomiasis 
DFR Dihydroflavonol 
(Dihydrokaempferol) 4'-
reductase 
IC50 Concentration of inhibitor 
producing 50% inhibition 
  
  
18 
 
    
IC90 Concentration of inhibitor 
producing 90% inhibition 
NAD
+
 Nicotinamide adenine 
dinucleotide - oxidised form 
IDRI Infectious Disease Research 
Institute 
NADH Nicotinamide adenine 
dinucleotide - reduced form 
IHME Institute for Health Metrics 
Evaluation 
NCBI National Center for 
Biotechnology Information  
IOWH Institute for One World 
Health 
NCE New Chemical Entity 
IPTG isopropyl ß-D-
thiogalactopyranoside 
NCI National Cancer Institute 
KBL 2-Amino-3-ketobutyrate 
ligase 
NF New Formulation 
kcat Turnover number NGO Non-governmental 
Organisation 
Ki Inhibitory constant NI New Indication 
kinact Rate of enzyme inactivation 
(covalent/irreversible) 
NIH US National Institutes of 
Health 
KM Half-maximal/half-saturating 
substrate concentration; 
Michaelis constant 
NME New Molecular Entity 
KNF Koshland-Nemethy-
Filmer/Simple sequential 
interaction model of 
cooperativity 
NTD Neglected Tropical Disease 
kobs Rate of enzyme inhibition 
(time-dependent/slow-
binding) 
OD Optical density 
LB Luria Broth PDB Protein Data Bank 
logP Log octanol:water partition 
coefficient (P) 
PRV Priority Review Voucher 
LSHTM London School of Hygiene 
and Tropical Medicine 
PSA Polar surface area 
MA Marketing Authorisation PSNRI Public-Sector or Not-for-profit 
Research Institute 
MmTDHi Inhibitor of TDH from Mus 
musculus (mouse) 
PSSC Protein Structure Similarity 
Clustering 
MW Molecular weight PUT Plate uniformity test 
MWC Monod-Wyman-Changeux Qc Quinazoline carboxamide 
n.d. Not determined R&D Research and Development 
NAD 
(NAD(H)) 
Nicotinamide adenine 
dinucleotide 
RMSD Root-mean-square deviation 
19 
 
RNA ribonucleic acid TETD Tetra ethyl thiuram disulfide 
RNAi RNA interference TPP Target Product Profile 
S&T Science and Technology TPSA Topological polar surface 
area 
SAR Structure-activity relationship TvTDH TDH from Thermoplasma 
volcanium 
SD Standard deviation UDP uridine diphosphate 
SD Standard deviation UMP uridine monophosphate 
SDR Short-chain 
dehydrogenase/reductase 
USAID United States Agency for 
International Development 
SDS-PAGE Sodium dodecyl sulfate-
polyacrylamide gel 
electrophoresis 
V0 Void volume 
SIB  Social Impact Bond Ve Elution volume 
SlyD Peptidoylproline cis–trans 
isomerase 
VL Visceral Leishmaniasis 
SMILES Simplified Molecular Input 
Line Entry System 
(representation of chemical 
structure) 
Vmax Maximum velocity of enzyme 
activity 
SoP UCL School of Pharmacy VS Virtual Screen 
TbGalE GalE from Trypanosoma 
brucei 
WHO  World Health Organisation 
TbTDH TDH from Trypanosoma 
brucei 
WHO EML WHO Essential Medicines 
List 
TDH L-threonine 3-
dehydrogenase 
WHO PQ WHO Pre-qualified medicine 
TDP Thymidine diphosphate WHO TDR WHO Special Programme for 
Research and Training in 
Tropical Diseases 
TETD Tetra ethyl thiuram disulfide   
TPP Target Product Profile   
TPSA Topological polar surface 
area 
  
TbGalE GalE from Trypanosoma 
brucei 
  
TbTDH TDH from Trypanosoma 
brucei 
  
TDH L-threonine 3-
dehydrogenase 
  
TDP Thymidine diphosphate   
20 
 
1. Introduction 
1.1 Rational Drug Discovery 
Over the past century an unprecedented increase in the longevity and quality of human life has 
occurred.  That increase has been claimed by many to be largely influenced by the discovery, 
development and distribution of pharmaceuticals(1–3).  Steady increases in the development of 
new drugs in the second half of the twentieth century were accompanied by an increasing use 
of rational methods of drug discovery over empirical ones(4–9).  Rational drug discovery is the 
discovery and design of drugs based on information of a particular target molecule, typically a 
protein, that has been implicated in disease(4,5).  Certainly, the efficacy of this approach has 
been augmented by the introduction of several new technologies over the years.  Firstly, the 
completion of the human genome project and the completion of genomes for other organisms 
has created access to a huge repertoire of “druggable” targets(10–13).  Structural Biology, 
coupled with computational methods has been one of the greatest enablers of rational drug 
design.  In recent years, the increase in high-throughput technologies in chemistry and biology 
have driven the success of the field(5). 
The debate over whether rational target-based approaches or empirical approaches, which 
focus principally on the clinical and phenotypical effects of investigational drugs, are more 
effective for drug discovery is ongoing.  Drug candidates discovered through rational 
approaches are frequently unable to reproduce effects demonstrated in vitro once used in the 
clinical setting.  Furthermore, if a particular target has not been well validated (see Figure 1.1.1, 
‘Target Discovery & Validation’) then drugs affecting that target will fail to cause the desired 
effect.  This has been cited as a cause of several late-stage drug failures(14).  On the other 
hand, in empirical approaches to drug discovery, drugs are discovered and optimised based on 
their ability to produce a desired effect.  Although this seems like more of a ‘blind’ approach to 
drug discovery, it can avoid many of the problems associated with rational drug discovery.  
However, a lack of knowledge of a drug’s mechanism of action can mean that important events, 
such as side-effects and drug resistance, are more difficult or sometimes impossible to predict.  
Although empirical or phenotypic drug discovery is experiencing a renaissance, culturally, there 
is still an expectation that the mechanism of action of a drug be known before it is approved for 
use.  In the case of certain medical conditions, certain cell types will need to be targeted.  
Therefore, rational drug discovery and design is often favoured, particularly in anti-cancer drug 
discovery and in anti-infective drug discovery, where differences between the pathogen and 
host physiology can be exploited. 
Rational, structure-based drug design often proceeds along two arms – target-based 
investigations and ligand-based investigations – with an optimal interaction between the target 
and a ligand being the end-goal.  Target-based investigations focus on the characterisation of 
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the target’s function and on other characteristics, such as the target’s structure.  Ligand-based 
investigations tend to focus on the characteristics of ligands and on how these characteristics 
are associated with the ligand’s ability to modulate a target’s function.  Gaining information on 
the structure of a target and on how its structure relates to its function can be crucial to the 
advancement of a drug discovery project.  Structural studies feature a number of methods, 
including electron microscopy, nuclear magnetic resonance, and most prominently, X-ray 
crystallography.  X-ray crystallography can produce models of the molecular structure of a 
crystallised substance from the diffraction pattern produced by it upon exposure to X-ray 
radiation.  X-ray crystallography has had an extremely important role in drug design as it has 
been the way in which the most detailed and definitive data on small molecule or 
macromolecular structures have been obtained, and it has guided many successful lead 
development efforts(5,15–18).   
Ligand-based methods, those focusing on the chemical structure of active ligands and the 
development of structure activity relationships (SARs), are often used in the absence of 
structural information on the target, but find their most powerful application when combined with 
target information(9).  When an active ligand is discovered, it can be highly valuable to elucidate 
the molecular interactions between it and the target.  In that way, ligand effects on the function 
of the target can be linked to interactions with specific structural features of the target.  Then, 
the SARs of different ligands can be expanded to include activities related to specific molecular 
interactions(9,19,20).  X-ray crystallography is particularly useful for investigating ligand-
macromolecule interactions, due to its ability to determine structures at atomic or near-atomic 
resolution. 
 
Screening is used frequently in target-based approaches.  Although often criticised as not being 
effective in isolation, it can form a vital part of a rational drug design program(5).  The range of 
assays now used in screening experiments includes cell-based, biochemical and even 
biophysical assays.  Screening typically involves the testing of a large and diverse library of 
chemicals in the hope that a number of active compounds (hits) will be discovered.  
Alternatively, a ‘focused’ library of compounds related to a known active ligand may be 
screened.  The scale of screening can vary significantly, from a few thousand compounds to as 
many as millions of compounds, which would usually be achieved by high-throughput screening 
(HTS).  The hits identified in a screening experiment can serve many purposes.  Firstly, the hits 
may be used for further study of the target and for the development of SARs linked to molecular 
interactions.  Knowledge of specific pharmacophores, the features of a hit that are responsible 
for its effect, can then be used in the de novo design of new ligands.  In other situations, 
depending on the hits which are identified, an active compound can serve as a starting point for 
the design of a new drug.  This compound, a lead, is then chemically optimised to improve its 
activity and to alter its properties to make it more suitable as a drug.  In particular, properties 
that may affect the compound’s pharmacokinetics (absorption, distribution, metabolism, 
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excretion and toxicity) in man are considered imperative.  Fragment-based drug discovery 
makes use of SARs established by studying several ligands and also uses hits as starting 
points for lead design.  The fragment-based approach screens smaller active compounds 
(molecular weight ~100-250 Da) than those traditionally used in screening (molecular weight 
~300-600 Da).  Accordingly, fragments are usually of lower potency than higher-molecular 
weight hits.  However, fragments binding to different, adjacent parts of the target molecule can 
be linked together to form more active compounds.  Alternatively, the same outcome can be 
achieved by “growing” a fragment, by adding new functional groups to the original hit 
compound.  Building a lead from a low-molecular weight compound has allowed medicinal 
chemists to design potent leads, whilst maintaining good physicochemical properties of the 
compound(21,22).  Fragment-based drug discovery is now at the centre of many academic and 
industrial drug discovery programs, and it is often used in combination with more traditional 
approaches.  The impact of this approach on drug discovery is becoming evident, as several 
drugs discovered by fragment-based discovery are now in the clinic or late-stage 
development(21). 
 
Computational chemistry has grown as a discipline due to its ability to integrate data from 
several sources, such as X-ray crystallography and HTS, and to allow the testing and 
development of theories virtually before proceeding with in vitro studies(9,23).  Molecular 
docking programs, which attempt to predict interactions between a ligand and a target are 
particularly popular tools in computational drug discovery(24–29).  A great advantage of 
including such methods in drug discovery projects is that they can speed up the process and 
improve efficiency(9,30), thus expanding the range of environments in which such activities can 
take place(31).  This is particularly useful where high-throughput facilities are unavailable and 
screening large screening libraries (e.g. hundreds of thousands of compounds) is not feasible.  
Potential hit compounds can be identified in silico by a virtual screening experiment using 
molecular docking software.  Then, a focused library of virtual screening hits can be assayed in 
an in vitro screen, therefore reducing the number of molecules that need to be screened to 
identify hits. 
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Figure 1.1.1 - early-stage drug discovery and the steps to the development of a new investigational drug.  The 
steps represented by gold coloured arrows are those involved in the work included in this thesis.  
In recent years, the concept of “druggability”, which describes the ability of a target to be 
modulated by a drug, has arisen.  In one respect, a target’s druggability is affected by the ability 
of a drug, when administered, to accumulate to an efficacious concentration in the environment 
of the target.  Therefore, the tissue and cellular location of a target is very important.  In another 
respect, particularly important at the earliest stages of drug discovery, a target is considered 
more druggable if drug-like molecules are able to bind to it with high affinity and affect its 
activity.  Therefore, the structural and physicochemical features of a protein are essential in 
determining its suitability as a drug target(32–35).  This is exemplified by the fact that G-protein-
coupled receptors and enzymes are the most common targets of marketed drugs(10).  Many of 
these proteins have evolved to bind small-molecules, and so possess protein folds and binding 
sites suitable for high-affinity ligand binding.  Other factors influencing the selection of a drug 
target are related to the therapeutic area in which a drug is being developed. 
 
1.2 Trypanosomiasis and Neglected Tropical Diseases (NTDs) 
Neglected Tropical Diseases (NTDs) are mainly prevalent in developing nations with tropical 
climates.  They primarily affect the poor in these countries and therefore have received little 
investment from the pharmaceutical industry into new treatments(36,37).  Following the 
previous “neglect” of these diseases, both in research strategy and global health policy(38), 
there has been renewed interest in NTDs, following the coining of the phrase in 2005(36), and 
an increased prominence of NTDs in global/public health strategies(39–43).  The World Health 
Organisation (WHO) lists 17 NTDS, including: Onchocerciacis, Leishmaniasis, Schistosomiasis, 
Chagas disease, Human African Trypanosomiasis, Dengue Fever and Yaws, amongst 
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others(44).  NTDs contribute a particularly large part of the disease burden in the developing 
world and they perpetuate the poverty and underdevelopment of these regions(41,45,46).   
 
 
Figure 1.2.1 - the global distribution of the burden of NTDs in 2010.  Countries are coloured according to the 
percentage of the total disability-adjusted life years (DALYs) caused NTDs in that country.  NTDs are most 
prevalent in sub-Saharan Africa, Latin America & the Caribbean, and in South & Southeast Asia.  The map was 
attained using the ‘GBD Compare’ tool of the Institute of Health Metrics and Evaluation (IHME), University of 
Washington(47).  
 
1.2.1 The NTD health burden 
NTDs collectively represent an enormous health burden globally.  These diseases are infectious 
diseases, generally concentrated in the Global South.  The WHO has defined a list of 17 
NTDs(48), whilst a number of other diseases have been identified as NTDs by other 
organisations(41,49) (see Figure 1.2.2).  It has been estimated that NTDs represent 10-12% of 
the global disease burden(50–52), but receive a relatively small investment in R&D.  NTDs are 
now often referred to as diseases of “neglected populations”, as they often exist in communities 
that are socially excluded, sometimes due to their geographic location, but also as a result of 
their impoverished condition, to which infectious diseases contribute(41).  As a result of this 
situation, NTDs lie as a barrier to economic development and represent a significant 
expenditure to governments in disease-endemic areas (41).  For example, an estimated 
US$267million is spent annually on the treatment of Chagas Disease patients in Colombia 
alone(53).  Thus with such economic and social costs resulting from NTDs globally, it is within 
the interests of private, public and philanthropic organisations, both nationally and 
internationally, to bring them under control. 
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Figure 1.2.2 - Diseases classified as NTDs.  This list was constructed based on definitions by Hotez et al.(41) and 
the scope of the journal PLOS Neglected Tropical Diseases(49).  “The Big Three” are excluded from some 
definitions in the literature, as they receive much more attention than other NTDs. * indicates a disease included 
in the WHO list of 17 core neglected tropical diseases.  
1.2.2 NTD policy 
Historical 
In the disease endemic countries, many NTDs have been present for several thousands of 
years, periodically presenting as epidemics with several fatalities.  The human and economic 
costs of NTDs were recognised by the colonial powers of former colonies, which led to the 
implementation of mass screening, treatment and vector control programs(50,54).  In fact, many 
of the most burdensome NTDs once posed barriers to economic progress in Western countries, 
and their subsequent control and elimination increased the prosperity of affected areas.  
However after several of the former colonies gained independence and disease prevalence had 
decreased, control programs were relaxed and some of these diseases began to re-emerge.  
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Since that time, various famines, regional conflicts and political crises have exacerbated the 
situation. 
Awareness and policy 
There are a number of reasons for the persistence of today’s NTDs.  The WHO have described 
how certain diseases lack the appropriate “tools” (e.g. drugs, vaccines, diagnostics) to control 
them, whereas with other NTDs, we are limited by a lack of understanding by the disease 
pathology(55).  However, the reason most commonly cited as a cause of the “market failure” to 
encourage NTD research and product development, is their association with poverty.  Patient 
populations lack purchasing power, thus, there is little or no financial incentive for big 
pharmaceutical companies, the traditional developers of new drugs and vaccines, to create new 
treatments(50,52,56,57).  Consequently, large Pharmaceutical corporations have shied away 
from NTD product development, with research into new treatments for NTDs once coming to a 
virtual standstill(50).  For certain NTDs, this has prepared the way for a possible health crisis, as 
resistance to old drugs emerges and disease prevalence increases. 
The need for strong policy decisions and national and international governance to support the 
development of new NTD products has been argued for by several proponents(56,57).  
Unfortunately, for a time, programs to control/eliminate NTDs were deficient, and NTDs were 
not formally recognised by health organisations – the WHO originally failed to specifically 
mention several NTDs in their Millennium Development Goals(38).  In recent years, thanks to 
the restless awareness-raising activities of various researchers and NGOs, the fight against 
neglected diseases is now supported by clear policies in a number of institutions, globally.  This 
change has been accompanied by unprecedented structural changes in the pharmaceutical 
industry which have helped to spur the development of a number of new drugs and vaccines for 
NTDs(57,58). 
Recent advances 
Some of the policies designed to spur NTD product R&D can be categorised as “push” and 
“pull” mechanisms.  “Push” mechanisms are those that aim to encourage or enable R&D by 
cutting the costs of doing so.  Product researchers and developers usually gain access to these 
through collaborations with governmental organisations and charities.  “Pull” mechanisms 
encourage investment in R&D by creating financial incentives for this activity.  Examples of 
these are Advanced Market/Purchase Commitments (AMCs) and the US Food & Drug 
Administration’s (FDA) Priority Review Vouchers (PRV)(59,60).  Although the effectiveness of 
these “pull” mechanisms is yet to be proven(59,61–64), they do theoretically solve the problem 
of a deficient market to incentivize NTD product R&D.  The “push” mechanisms have already 
proven their worth in spurring several new R&D projects, whilst also re-engaging 
pharmaceutical companies(52,57).  The majority of this has happened against a backdrop of a 
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paradigm shift in pharmaceutical development for NTDs, the product development partnership 
(PDP)(57,65), which will be discussed in detail below. 
Although still much smaller than for other therapeutic areas, the global investment in 
pharmaceutical R&D for NTDs has increased vastly.  In 1999, it was estimated that less than 
US$70 million were invested into drug research for malaria, tuberculosis, HAT and 
leishmaniasis, combined.  In contrast, the 2012 Global Funding of Innovation for Neglected 
Diseases Report (G-FINDER) stated that US$ 3,045 million were invested globally in NTD 
research, with around 70% of that directed towards product development (as reported by 
respondents to the G-FINDER survey)(66).  Although funding, particularly from philanthropic 
and public donors, has declined since the global financial crisis, funding levels are still higher 
than in 2007(66), and much greater than 15 years ago(50). 
Many national governments are now some of the biggest funders of NTD R&D.  Most prominent 
are the US, through the US Agency for International Development (USAID), and the UK, 
through its Department for International Development (DFID).  Other countries, such as The 
Netherlands and Australia, have emerged as major NTD R&D funders(66).  Meanwhile, the 
WHO’s Special Program for Research and Training in Tropical Diseases (WHO TDR) continues 
its work with a wide range of private and public R&D partners around the world(66–68). 
1.2.3 The Product Development Partnership (PDP) model 
PDPs bring together several different partners with the goal of developing one or a related 
group of products.  PDPs are typically partnerships between public and private institutions, 
where the relative strengths of each individual institution can be exploited.  This is particularly 
useful in developing products for neglected tropical diseases, for a number of reasons.  
Philanthropic organisations are able to allocate resources to the researchers and developers, 
covering or reducing the costs of R&D.  Academic and other public-sector or non-profit research 
institutions (PSNRIs) are very-well placed to carry out discovery and early-stage development 
work(69–71), whilst biotechnology and pharmaceutical firms are well technologically resourced.  
Large pharmaceutical firms have a wealth of experience in conducting clinical trials, but this can 
also be supplemented by the knowledge and experience of institutions and NGOs operating in 
NTD-endemic countries.  This ability to leverage the strengths of each partner has likely 
contributed to the success of the PDP model.  It has resulted in clinical development times that 
are comparable with more profitable pharmaceuticals.  Also, average development costs are 
significantly cheaper than for the development of more profitable drugs, outside of the PDP 
model(57,72). 
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Figure 1.2.3 - examples of PDP "Brokers" involved in product development for drugs, vaccines, diagnostics and 
insecticides for NTDs. * indicates that they participate in the development of products to control 
trypanosomiasis(72–74).  
Several of the PDPs are co-ordinated by “Brokers”, such as the Drugs for Neglected Diseases 
Initiative (DNDi) and BIO Ventures for Global Health (BVGH).  These partnership brokers are 
important development partners, due to their extended networks, experience and central role in 
allocating funding.  Disease-specific alliances (e.g. The Medicines for Malaria Venture, MMV) 
have also emerged as important brokers of PDPs and as developers in their own right.   
1.2.4 Imbalanced R&D priorities 
Despite these positive changes, a number of concerns in NTD product development still remain.  
One is the gaps in research, which stem from the lack of sustainable funding for some diseases.  
This problem will be minimised if global funding increases, and if partnerships continue to be 
formed appropriately and managed effectively(57).  What may potentially be a bigger problem, 
from a global health perspective and from a researcher’s perspective, is the bias of product 
development for re-formulations and fixed dose combinations, rather than for new chemical 
entities(52)(see Table 4.4.2).  Trouiller and colleagues describe how the lack of appropriate 
“tools” to treat certain NTDs, requires that innovative new products are developed – new 
chemical entities (NCE)s and novel vaccines.  However, for drugs in general, and to a greater 
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extent for NTD drugs, very few NCEs are developed when compared to other registered 
products(51,52). 
1.2.5 Trypanosomiasis 
The two human diseases caused by trypanosome infections, human African trypanosomiasis 
(HAT) and Chagas Disease, are classic examples of NTDs.  They are debilitating and fatal 
diseases that primarily affect the poor.  HAT, which is prevalent in Sub-Saharan Africa, and 
Chagas Disease, which is concentrated in Latin America, both have a long history.  Recent 
efforts have led to improved control of both disease, but problems persist.   
 
 
Figure 1.2.4 - coloured electron micrograph of bloodstream form Trypanosoma brucei in mammalian blood.  
Image courtesy of Michael Duszenko, University of Tubingen.  
Trypanosomiasis is a NTD caused by infection with species of the genus Trypanosoma, a 
parasitic protozoan distinguished by a single flagellum.  This is the cause of two NTDs: human 
African trypanosomiasis (HAT), which is prevalent in sub-Saharan Africa, and Chagas disease, 
which is prevalent in Latin America(53,75).  HAT, also known as African Sleeping Sickness, is 
caused by the species Trypanosoma brucei, of which there are two main subspecies that cause 
disease in humans: T. brucei gambiense and T. brucei rhodesiense.  Other species of 
Trypanosoma, including T. brucei brucei and T. congolense, cause trypanosomiasis in 
animals(75–77).   
T. brucei is spread by vectors of the Glossina species, commonly known as Tsetse flies, and the 
parasite is spread to mammals through the saliva of the vector as it feeds on their blood.  
Trypanosomes live in the mid-gut of Tsetse flies as replicating procyclic trypomastigotes.  These 
trypanosomes transform into epimastigotes and migrate to the salivary glands, where they 
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multiply further.  The epimastigote trypanosomes mature into metacyclic trypomastigotes, and it 
is these trypanosomes that are transmitted to mammals when the Tsetse fly feeds.  Once inside 
the host, the trypanosomes transform into bloodstream form (BSF) trypomastigotes, which 
circulate around the body and replicate in the blood, lymph and cerebro-spinal fluid(76,78,79).  
Inside the host there is an interchange between “slender” BSF trypanosomes and “stumpy” 
forms, which are non-proliferative, but are pre-adapted for survival in the insect vector 
environment and so are transmissible(80,81).  The life cycle of T. brucei is completed when 
stumpy BSF trypanosomes are ingested by the Tsetse fly during a blood meal. 
 
Figure 1.2.5 - summary of the life cycle of T. brucei, presented by Lee et al.(79).  
HAT is characterised by an early stage and a late stage.  The disease presents initially with an 
early haemolymphatic stage, which is characterised by sporadic bouts of fever, and localised 
swelling at the site of the bite (chancre or Winterbottom’s sign).  If left untreated, the second, 
meningoencephalopathic, stage of HAT occurs when trypanosomes enter the central nervous 
system, leading to a range of psychological and cognitive symptoms, including dyskinesia, 
tremor, insomnia at night and daytime somnolence, coma and eventually death(76).  The 
pathogenesis of HAT is not completely understood, but symptoms are believed to be mediated 
largely through inflammatory processes(82).  The form of HAT caused by T. b. gambiense 
which accounts for 95-7% of reported cases progresses chronically, and the delay between the 
haemolymphatic and the meningoencephalopathic stage can be months to years.  The 
rhodesiense form of the disease, accounting for 3-5% of cases, progresses much more rapidly, 
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leading to coma or death within weeks to months if left untreated(54,75,76).  Not only is HAT a 
very debilitating disease, especially in the late stage, but it is also always fatal if left untreated. 
Only five drugs are available for HAT treatment, four of which were developed more than fifty 
years ago(43,44).  Pentamidine and suramin are used for early stage gambiense and 
rhodesiense HAT, respectively, and melarsoprol and eflornithine are used in the late stage.  
Melarsoprol is the only drug available for late stage HAT caused by T. b. rhodesiense.  
Nifurtimox has also recently been approved for use in late stage gambiense HAT in combination 
with eflornithine(38,40,43,45,46).  The characteristics of these drugs have numerous problems.  
First of all, pentamidine, suramin, melarsoprol and eflornithine are all administered by injection, 
which requires well-trained healthcare professionals and appropriate healthcare facilities.  This 
is particularly a disadvantage in the resource-poor settings that HAT is usually encountered.  
Secondly, several of these drugs are associated with severe side-effects and the hospitalisation 
and clinical monitoring of patients is recommended.  For example, pentamidine injection is 
painful and there is a significant risk of hypoglycaemia following administration(83).  Perhaps 
the most striking example of adverse effects caused by a trypanosomiasis drug is provided by 
melarsoprol.  The drug, used in late stage HAT, is associated with reactive encephalopathy, a 
severe side effect of the central nervous system that affects approximately 5-10% of patients 
and is fatal in around 5% of patients(76,84).  For this reason, the corticosteroid prednisolone is 
co-administered with melarsoprol(85).  Diagnosis of HAT is another difficulty as the majority of 
cases occur in remote rural areas; diagnosis requires detection of symptoms, and confirmation 
of the presence of trypanosomes in blood and/or cerebro-spinal fluid by lumbar puncture(75,76).   
 
 
Figure 1.2.6 - the distribution of HAT burden in the years 1990, 2000 and 2010.  Countries are coloured according 
to the percentage of total DALYs caused by HAT in that country.  Following an increase in the number of HAT 
cases and the burden of the disease in the late 20
th
 century, the burden has decreased markedly in several 
countries.  The problem still persists in other countries.  Maps were obtained using the IHME GBD Compare 
tool(47).  
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HAT is endemic to sub-Saharan Africa and affects mainly rural populations.  Approaches to 
tackle HAT include a combination of vector control, pharmacological treatment and prevention 
strategies.  Despite previous epidemics of HAT in sub-Saharan Africa, vector control and 
screening campaigns almost eradicated the disease by the mid-1960s.  However, a later 
relaxation of these programs, coinciding with regional conflicts and rising poverty have led to a 
resurgence in the number of HAT cases.  Although these factors still remain barriers to disease 
eradication, combined efforts of the WHO and various other organisations have helped to 
decrease the number of reported cases to fewer than 10,000 a year (estimated number of 
actual cases is 30,000)(75).  Animals can be a significant reservoir of T. brucei infection, 
particularly for T. brucei rhodesiense, which is usually transmitted from cattle to man.  
Furthermore, trypanosomiasis in cattle (also called nagana), can affect the livelihoods of 
farmers in affected areas.  Together, the impact of trypanosomiasis on humans and cattle can 
be a significant impediment to economic progress in the affected areas.  Despite the recent 
advances in the control of HAT, great vigilance is necessary as 70 million people are reported to 
be living in HAT-endemic areas(54,75). 
 
Chagas Disease, also known as American Trypanosomiasis, is caused by T. cruzi, which is 
spread by insect vectors from the Reduviidae family; vector species include Triatoma infestans, 
T. brasiliensis, Panstrongylus megistus, T. sordida and T. maculata(53,86).  As humans have 
encroached on the original habitats of these insects, Reduviid bugs have become adapted to 
living in domestic environments by feeding on the blood of humans and domesticated 
animals(86,87).  Trypanosomes are present in their replicating epimastigote form in the gut of 
the vector.  They mature into metacyclic trypomastigotes and migrate to the distal end of the 
intestine.  As the bugs feed on mammalian blood they defecate on the skin of the mammal, and 
T. cruzi are able to enter the bloodstream through mucous membranes or through the bite 
wound made by the bug during feeding.  The parasites circulate around the system as 
trypomastigotes before entering various cells, in which they replicate as the amastigote form.  
Amastigotes then differentiate into infective cell-derived trypomastigotes, which escape the cells 
and go on to invade yet more cells.  Amastigotes released from cells can also invade 
macrophages.  Transmission from mammalian host to insect vector occurs when a blood meal 
is taken from an infected mammal(87,88).  Other mechanisms for the spread of Chagas 
Disease include blood transfusions, infected food and congenital infections (maternal-to-foetal 
transmission)(86). 
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Figure 1.2.7 - the life cycle of T. cruzi, presented by Buscaglia et al.(88).  
Like HAT, Chagas Disease is characterised by an acute phase and a chronic phase.  The vast 
majority of acute infections are asymptomatic.  Clinical features of the acute phase include local 
inflammatory reactions at the site of parasite entry, such as bipalpebral oedema (Romaña's 
sign) or inoculation chagoma (localised swelling), and other symptoms, including conjunctivitis, 
fever and general malaise.  In more severe cases, organ-specific signs and symptoms may be 
observed, including, hepatosplenomegaly, myocarditis and meningoencephalitis(86,89).  The 
acute phase is followed by an asymptomatic/indeterminate phase that may last for 5-15 years 
before clinical signs of the chronic disease appear.  The most significant burden of Chagas 
disease is caused by the symptoms of the chronic disease which are thought to be caused by 
parasite-triggered autoimmune reactions, which begin in the acute phase and persist for several 
years, together with the presence of parasites in affected organs.  In the most common 
manifestations of chronic Chagas disease, the heart and the enteric tract are affected, with 
cardiomyopathy being the complication with the biggest contribution to morbidity and 
mortality(86,87,89).  There are only two clinically approved drugs to treat Chagas disease, 
benznidazole and nifurtimox.  Although both treatments have been shown to be effective in the 
acute phase of the disease, they have little efficacy in the chronic phase, where supportive 
treatments are required to deal with the complications.  Furthermore, the treatment courses are 
long, ranging from 1 to 3 months. The use of both drugs are associated with a high incidence of 
side effects, including headache, dizziness, nausea, vomiting and weight loss(90,91). 
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Figure 1.2.8 - the distribution of Chagas disease burden in Latin America in 1990 and 2010.  Countries are 
coloured according to the percentage of total DALYs caused by Chagas disease in that country.  The burden of 
Chagas disease is increasing and spreading to countries further from the original concentration in South America.  
Maps were obtained using the IHME GBD compare tool(47).  
Effective vector control and screening programs in central and south America, where the 
disease is most prevalent have been very successful in the control of Chagas disease, reducing 
the annual incidence to around 40 000(53).  However, the occurrence of Triatomine resistance 
to insecticides, the proliferation of new T. cruzi serotypes and the export of Chagas disease 
cases to North America and Europe are creating new risks(87).  Up to 10 million people are 
estimated to be living with Chagas disease, the majority of whom are concentrated in Latin 
America.  However, the incidence has been increasingly rapidly in central and North America, 
due to migration.  There are an estimated 300,000 people living with Chagas disease in the 
United States and several thousand more cases reported in Canada, Europe, Japan and 
Australia(92,93).  Together, these facts make Chagas disease not only one of the most 
common NTDs, but also one of the most neglected NTDs in the world(93,94). 
 
Clearly, both human forms of trypanosomiasis represent a significant medical and social need.  
No one method of control has proven to be totally effective, and the various methods are all 
limited by certain biological and environmental factors.  Furthermore, the physiology of 
trypanosomes may prevent the development of other tools to control their transmission, such as 
vaccines.   The surface coat of T. brucei is composed of a variable surface glycoprotein (VSG), 
of which there are more than a thousand variants.  Only one glycoprotein is expressed at any 
one time, but the ability to switch between different variants allows these trypanosomes to 
evade the immune system and for the infection to persist(76,82).  For this reason, it is also 
difficult to develop a vaccine for HAT(95).  Few drugs are available to treat HAT and Chagas 
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disease, and the available drugs cause a high frequency of side effects that are sometimes very 
severe.  The required methods of administration of these drugs, coupled with the lengthy 
treatment courses and associated costs makes them far from optimal for tackling 
trypanosomiasis in the relevant settings.  As resistance to drugs for trypanosomiasis is 
increasing, HAT and Chagas disease are good examples of NTDs for which the development of 
new classes of drugs could provide a significant benefit to health. 
Table 1.2.1 - current recommended treatment regimens for HAT and Chagas disease(76,83,90).  Treatment 
regimens vary, so those in this table are representative examples.  The recommendations are aimed at the 
treatment of non-pregnant adults. 
 Disease Treatment regimen 
HAT  
T. b. gambiense early 
stage 
Pentamidine: 4mg/kg intramuscular injection once daily for 7 
days 
T. b. rhodesiense early 
stage 
Suramin: 5 mg/kg intravenously as a test dose, followed by 20 
mg/kg on day 3, 10, 17, 24, and 31 
T. b. gambiense late stage NECT: nifurtimox 5mg/kg orally every 8 hours for 10 days; 
eflornithine 200mg/kg intravenously every 12 hours for 7 days 
OR 
Eflornithine: 100mg/kg intravenously every 6 hours for 14 
days 
OR 
Melarsoprol: 2.2mg/kg intravenously once daily for 10 days 
T. b. rhodesiense late 
stage 
Melarsoprol: 2.2mg/kg intravenously once daily for 10 days 
Chagas Disease  
Acute stage Benznidazole: 5-7 mg/kg per day orally in 2 divided doses for 
60 days 
Chronic stage Nifurtimox: 8-10 mg/kg per day orally in 3 or 4 divided doses 
for 90 days 
 
Desired target product profiles (TPP) for drugs to treat trypanosomiasis have been proposed by 
a number of researchers(13,96).  The TPPs for HAT and Chagas disease are similar, in the 
respect that an improved side-effect profile and shorter time course of treatment would provide 
benefits over currently available treatments.  Additionally, drugs are sought that would show 
efficacy against both early and late (or acute and chronic) forms of the diseases.  TPPs for a 
new HAT drug and a new Chagas disease drug are shown in Figure 1.2.9. 
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Figure 1.2.9 - a summary of the desired target product profiles (TPP) proposed for new drugs to treat HAT and 
Chagas disease(13,32,96). 
 
 In order to meet some of the criteria set out in the TPPs, an appropriate drug discovery strategy 
is required.  A new drug would need to be potent, but also selective and safe towards the 
human patient.  To achieve this, a rational, target-based approach to drug discovery is 
particularly effective because differences between host and parasite genomes/proteomes can 
be exploited.  Selecting a particular parasite biomolecule as a target would require that there 
are significant differences between that target and a human homologue.  A more desired 
property for such a target would be for it to be absent/not utilised in humans.  Given the highly 
unusual physiology of trypanosomes, there are numerous opportunities for target-based drug 
discovery for antitrypanosomal drugs. 
1.2.6 The current status of HAT and Chagas disease control 
There has been a significant decrease in the number of new cases of HAT(75).  Effective 
control programs led to a reduction of 68% between 1995 and 2006.  36 countries remain HAT-
endemic, although only seven of these have reported more than 100 cases per year in the 
period 1997-2006(54). However, given the situation in those countries of higher prevalence, 
along with the ever-present possibility of HAT re-emergence among an at-risk population of 70 
million(75), it is important that there are appropriate tools at the disposal of health authorities. 
Although control programs (involving screening, vector control and treatment programs) have 
proven very effective in reducing the number of HAT cases, the effect has been greater for one 
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form of HAT (the gambiense form), because an animal reservoir plays a significant role in the 
spread and persistence of the other (rhodesiense) form(54,75).  
Due to the chronic nature of Chagas Disease, diagnosis is challenging and infection often goes 
unnoticed for several years.  Between 7 and 8 million are estimated to be infected with Chagas 
disease worldwide, and it is spreading beyond its original geographical location to other 
continents.  The treatments are effective if used shortly after infection.  However, treatment 
regimens are long, and adverse reactions occur in up to 40% of patients.  The majority of 
patients will present with chronic infection, often with other complications, when the 
effectiveness of the usual treatments is limited. 
Control of the Chagas Disease-spreading vector, the triatomine bug is probably the most 
effective means of controlling Chagas Disease, although there are challenges of the re-
emergence of the disease in certain areas and the need for more effective treatments to treat 
chronic infection(53). 
1.2.7 Trypanosomiasis R&D 
Shortfalls 
The biggest shortfall in the control of HAT lies in the tools that are currently available.  A HAT 
vaccine is very challenging, due to the biology of the pathogen(97,98), so efforts are focused on 
vector control and treatments.  All treatment regimens involve some form of injection, which 
requires more resources and well-trained staff.  The length of some of these regimens puts a 
further strain on resources, which are often not well-developed in rural areas of developing 
countries.  The current drugs all suffer from a high incidence of side-effects, which can be 
burdensome or even fatal in some cases. Therefore, there is an urgent requirement for new 
drugs, with less side-effects and more suitable formulations(54,96). 
Chagas Disease treatments suffer from similar drawbacks to those of HAT treatments.  As 
stated, above, a new drug for Chagas disease should ideally be more effective than current 
treatments in chronic stages of the disease and should have a lower incidence of side effects. 
1.3 L-threonine 3-dehydrogenase (TDH) 
The amino acid L-threonine was first discovered in 1935 following the observation that rats were 
unable to survive when fed a diet based solely on the 19 known essential amino acids at the 
time(99,100).  Years later, pathways of threonine degradation were elucidated by studying the 
breakdown of threonine; conversion of threonine to glycine(100–102) and deamination(103) of 
threonine were some of the earliest processes studied.  There are now three known pathways 
of threonine catabolism, which are initiated by the enzymes L-threonine aldolase (EC 4.1.2.5), 
L-threonine dehydratase (also known as L-threonine deaminase; EC 4.2.1.16) and L-threonine 
3-dehydrogenase (TDH; 1.1.1.103), which is the dominant pathway in several prokaryotes and 
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eukaryotes(104–106).  The activity of L-threonine aldolase has been shown to be low or 
insignificant in prokaryotes(107) and eukaryotes(108) and no expression of the enzyme has 
been detected in humans(109).  In contrast, the pathway initiated by L-threonine dehydratase is 
a major pathway for L-threonine catabolism and can become the dominant pathway in certain 
metabolic states in animals(108).  The other major pathway for L-threonine catabolism is 
initiated by the mitochondrial matrix enzyme TDH, which appears to be the dominant pathway in 
many prokaryotes and eukaryotes(104–106).   
The TDH-initiated pathway, in which L-threonine is converted to glycine and acetyl-coenzyme A 
(A-CoA), was first described by Elliot(110,111).  Later, isolation and characterisation of TDH 
was achieved by Neuberger and Tait(112,113).  Prior to this, aminoacetone had been shown to 
be produced by the condensation of glycine and A-CoA(114) and the enzyme co-ordinating this 
was isolated and named aminoacetone synthetase(115).   By this time Urata and Granick 
(1963) had already shown a link between these two reactions(116).  It is now known that TDH 
and aminoacetone synthetase, now more commonly known as 2-amino-3-ketobutyrate ligase 
(KBL) work in tandem to catabolise L-threonine as illustrated in Figure 1.3.1 below(105):  
 
Figure 1.3.1 - the catabolism of L-threonine to glycine and acetyl-CoA.  The enzyme TDH oxidises L-threonine to 2-
amino-3-ketobutyrate (AKB).  KBL then converts AKB to glycine and acetyl-CoA.  Alternatively, AKB may undergo 
spontaneous breakdown to aminoacetone and carbon dioxide.  
In the first part of this two-step process, TDH oxidises L-threonine to 2-amino-3-ketobutyrate 
(AKB) in a reaction dependent on the cofactor nicotinamide adenine dinucleotide (NAD(H)).  
There is evidence that AKB is unstable and spontaneously breaks down to aminoacetone and 
carbon dioxide.  Thus it has been suggested, amidst other evidence, that TDH and KBL form a 
multi-enzyme complex to facilitate the completion of the second reaction, the breakdown of AKB 
to A-CoA and glycine by KBL(104,117) 
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TDH is a dehydrogenase/reductase (or oxidoreductase).  This enzyme family is divided into 
short-chain (SDR), medium-chain (MDR) and long-chain (LDR) dehydrogenases(118).  Several 
of the most studied TDH enzymes to date have been MDRs, showing a tetrameric quaternary 
structure and a requirement for divalent metal cations, such as zinc(104,119–123).  More 
recently, a second group of TDH enzymes that share features with the enzyme UDP-galactose 
4’-epimerase have been characterised.  These enzymes belong to the SDR family, and in 
contrast to the MDR TDH enzymes, they are dimeric and have no requirement for divalent 
cations(124–126).  The enzyme KBL has not been studied to the same extent, but the 
crystallographic structure of enzyme from Escherichia coli has been published(127). 
 
TDH seems to play important physiological roles in diverse organisms.  The TDH pathway has 
been implicated as an important nutritional source for energy production.  A species of 
Arthrobacter was able to grow in medium with L-threonine as its sole 2-carbon source.  
Metabolised through the TDH pathway, L-threonine was shown to also be a source of nitrogen, 
and the acetyl coenzyme A (acetyl-CoA) produced by the pathway was fed into the Krebs cycle 
and glyoxylate cycle for energy production, whilst glycine was thought to be converted to 
pyruvate(115).  Similar observations regarding the role of the TDH pathway were made in 
Pseudomonas spp.(107,128).  In several other bacterial organisms, including Bacillus sp., 
Flavobacterium sp. and Corynebacterium sp., the role of glycine produced from L-threonine by 
TDH and KBL was highlighted.  Glycine produced by the TDH pathway is further metabolised to 
L-serine or is probably involved in the ‘glycine cleavage system’ as a source of methylene 
units(129).  In E. coli, where L-threonine can act as a source of nitrogen, following TDH 
production of glycine and conversion to L-serine(130), an additional role for the pathway was 
identified: aminoacetone, the breakdown product of AKB, was shown to be converted to D-1-
amino-2-propanol, which is a precursor for vitamin B12 synthesis.   
The roles played by the TDH pathway in eukaryotes are just as varied.  In rats and pigs, TDH 
has been shown to play a role in L-threonine homeostasis, and its activity is regulated in 
response to different metabolic states(108,131,132).  Also in rats, L-threonine catabolism by 
TDH was shown to play a role in fatty acid metabolism through the production of acetyl-CoA.  
The TDH pathway is also subject to feedback regulation in this role(133).  Many of the 
contributions of the TDH pathway mentioned so far may be transferable between different 
organisms.  However, the pathway has also been implicated in some specialised organism-
specific processes.  When the plant pathogenic fungus Sclerotium rolfsii is grown on L-
threonine, there is an increase in branching of the fungus’ hyphae and increased formation of 
sclerotia, dense formations of hardened mycelium that are formed in response to stressful 
conditions and contain carbohydrate stores.  TDH was thought to provide the necessary energy 
and carbohydrate precursors by supplying acetyl-CoA and glycine to the glyoxylate  and 
glycine-serine pathways(134).  Perhaps the most interesting physiological role played by TDH 
has been discovered in mouse embryonic stem cells (ES cells).  The ES cells show a 
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dependence on L-threonine, and TDH activity is shown to be approximately 100-fold higher in 
these cells, compared to other mouse cells(135).  The dependence is so striking, that exposing 
those cells to a small molecule inhibitor of TDH was able to selectively kill ES cells.  As those 
cells were perceived to be in a highly energetic state, it was postulated that the glycine 
produced by the TDH pathway was necessary for the glycine cleavage system(136), as 
suggested in other organisms(129).  In 2012, Shyh-Chang and colleagues reported the 
fascinating observation that TDH activity correlated with S-adenosyl methionine (SAM) 
production, which in turn correlated with increased epigenetic regulation by histone methylation.  
This epigenetic regulation was shown to be essential in maintaining the pluripotency of mouse 
ES cells(137). 
 
1.3.1 The role of TDH in trypanosomes 
As in other organisms in which the TDH pathway has been studied, the pathway was found to 
play a pivotal role in the physiology of trypanosomes.  In 1975, Cross et al. reported that 
cultured T. brucei in mixed media preferentially and exhaustively consume L-threonine(138).  By 
using radiolabelled L-threonine, it was determined that the majority of the absorbed L-threonine 
was metabolised through the TDH pathway, producing acetyl-CoA and glycine.  Furthermore, it 
was discovered that exposure of T. brucei in culture to tetraethyl thiuram disulphide (TETD), an 
inhibitor of human aldehyde dehydrogenase and a potent inhibitor of TDH, caused the rapid 
death of the trypanosomes.  This trypanocidal effect correlated with the inhibition of 
TDH(138,139).  Thus, this represented the first identification of TDH as a potential drug target.  
TDH is believed to be important in T. brucei because the acetyl-CoA produced by the pathway 
is essential for fatty acid synthesis.   
In contrast to other parasites, which obtain their lipids from the host, parasites of the family 
Trypanosomatidae appear to synthesise fatty acids de novo(79,140).  In T. brucei, there are two 
mechanisms for fatty acid synthesis.  The dominant mechanism occurs through a number of 
endoplasmic reticulum-associated elongase enzymes (ELO), which synthesise and extend fatty 
acid chains, beginning with malonyl-CoA and butyryl-CoA.  The second mechanism occurs 
within the mitochondria and is mediated by a Type II fatty acid synthase.  ELO-mediated fatty 
acid synthesis has been shown to be essential for the production of myristate, which forms the 
glycosylphosphatidylinositol (GPI) anchor of the VSG expressed on the surface of BSF T. 
brucei(79).  Mitochondrial fatty acid synthesis has been estimated to constitute approximately 
10% of total fatty acid synthesis in procyclic T. brucei and it is thought to serve a specialised 
role related to the functioning of the mitochondria itself(79,140,141).  Firstly, the fatty acid 
synthesis is involved in the production of precursors of lipoic acid, a cofactor for pyruvate 
dehydrogenase (the importance of PDH will be discussed below) and other mitochondrial 
enzymes(141).  Secondly, the inhibition of mitochondrial fatty acid synthesis has been shown to 
inhibit respiration and effect the morphology of the mitochondrion in vitro(140).  Thirdly, 
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compounds that inhibit type II fatty acid synthesis have been shown to inhibit BSF trypanosome 
growth(79). 
The acetyl-CoA required for fatty acid synthesis in T. brucei arises from two distinct pools: one 
produced through the TDH pathway and a second pool produced by the glycolytic pathway, in 
which acetyl-CoA is produced by catabolism of pyruvate by pyruvate dehydrogenase 
(PDH)(142–144).  TDH, KBL and PDH all reside in the mitochondria, and acetyl-CoA is either 
used for type II fatty acid synthesis or it is converted to acetate and transported to the cytoplasm 
for use in fatty acid synthesis by ELOs.  Figure 1.3.2 illustrates the production of acetyl-CoA 
from L-threonine and glucose in T. brucei: 
 
Figure 1.3.2 - the production of acetyl-CoA and acetate in T. brucei.  Image presented by Mazet et al.(144).  AcCoA 
= acetyl-CoA; AOB = amino oxobutyrate (2-amino-3-ketobutyrate, AKB), DHAP = dihydroxyacetone phosphate; 
G3P = glyceraldehyde 3-phosphate; MAL = malate; PEP = phosphoenolpyruvate; PYR = pyruvate; SCoA = succinyl-
CoA; CoASH = coenzyme A.  Enzymes are indicated by the following numbers: 1 = pyruvate dehydrogenase (PDH); 
2 = acetate:succinate CoA-transferase; 3 = acetyl-CoA thioesterase; 4 = succinyl-CoA synthetase; 5 = L-threonine 
dehydrogenase (TDH); 6 = 2-amino 3-ketobutyrate ligase (KBL); 7 = acetyl-CoA synthetase.  
Although there is evidence that L-threonine is the preferred source of acetyl-CoA for the 
production of fatty acids in T. brucei (142), gene silencing studies have shown that inhibition of 
TDH alone is not lethal to parasites and does not inhibit growth(143–145).  Likewise, inhibition 
of acetyl-CoA production by PDH on its own does not inhibit trypanosome growth.  However, 
Millerioux et al. reported that dual inhibition of TDH and PDH by RNA interference (RNAi) 
caused powerful inhibition of the growth of procyclic form T. brucei.  Singular inhibition of TDH 
or PDH in the absence of glucose or L-threonine, respectively, also inhibited trypanosome 
growth(143), indicating that concomitant disruption of both routes to acetyl-CoA production is a 
powerful approach to killing trypanosomes.  Despite these results, there was still some doubt 
42 
 
over the effectiveness of inhibiting TDH as part of a strategy to treat trypanosomiasis.  The 
expression of TDH is known to be significantly up-regulated in procyclic T. brucei compared to 
bloodstream forms(139,146–148), apparently as part of the organism’s adaptation to the 
environment of the mid-gut of the Tsetse fly, where more L-threonine is available, but glucose is 
less abundant.  In the study of Millerioux et al.(143) and in the studies of Cross and 
colleagues(138,139) that showed TETD to be lethal to trypanosomes, the procyclic form of T. 
brucei was used in growth inhibition studies.  However, Mazet et al. recently reported that 
acetyl-CoA production from both glucose and L-threonine is still essential in BSF T. brucei.  The 
effects of dual inhibition of both pathways were the same as those observed in the procyclic 
parasites(144).  
There may be yet more ways in which TDH inhibition may be effective for treating 
trypanosomiasis.  Glycine produced from L-threonine by TDH has been shown to be 
incorporated into trypanothione in T. brucei(143).  Trypanothione is an essential thiol that is 
unique to kinetoplastids (includes Trypanosomatidae) and protects them against oxidative 
stress, heavy metals and toxic metabolites, in much the same way that glutathione does in 
humans(149,150).  The discovery of trypanothione’s importance has led to the selection of 
enzymes involved in its production as  drug targets for HAT, Chagas disease and 
Leishmaniasis, which is a NTD caused by parasites of another Trypanosomatidae genus, 
Leishmania(31,151).  Whether the TDH pathway in Trypanosoma undertakes some of the 
functions discussed for other organisms mentioned above remains to be discovered(152,153).  
Although Leishmania parasites lack TDH, the enzyme is present in T. cruzi, so TDH could be a 
suitable target for both African and American forms of trypanosomiasis. 
A key consideration in the selection of any target for drug discovery is whether inhibition of that 
target is likely to cause toxicity to a patient.  In this respect, TDH is viewed favourably as a 
target, as humans do not make use of the enzyme.  The TDH gene in humans is an “expressed 
pseudogene”; the TDH gene contains a number of mutations, which lead to the production of 
truncated, non-functional proteins when translated(106).  The complete absence of TDH activity 
has also been confirmed in new-born infants(154).  The data reported by Alexander et al. on the 
killing of mouse ES cells(136) using a TDH inhibitor is a testament to the effectiveness of TDH 
inhibition for selectively killing a particular cell type.  The mapping of the genomes of T. brucei 
and T. cruzi has now been completed, so genetic information on TDH is freely 
available(152,155).  This enables the further study of this important enzyme as a drug target. 
1.4 Hypothesis 
The aim of the work presented in this thesis was to employ rational methods to the discovery of 
novel inhibitors of TDH.  The results of this effort should provide information to enable the 
design of effective leads for the treatment of trypanosomiasis. Presented herein is a description 
of the structural and functional characterisation of TDH using a combination of X-ray 
crystallography, enzymatic assays and other biochemical methods.  The structural information 
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on TDH was used in a virtual screen of several thousand compounds to identify potential 
inhibitors of TDH.  Subsequently, some compounds identified by virtual screening were assayed 
alongside other compounds from commercial compound libraries in a medium-throughput in 
vitro screen.  The characteristics of these inhibitors will also be discussed in detail.  Finally, in 
view of the commercial and practical considerations necessary for advancing an NTD drug to 
market, a discussion of the various ways in which NTD products are advanced to the clinic is 
included. 
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2. Methods 
2.1 Structural Studies of TDH 
2.1.1 Protein Expression and Purification 
2.1.1.1 Transformation and Expression 
Prior to this work, a gene of L-threonine 3-dehydrogenase (TDH) had been amplified using 
standard high-fidelity PCR methods from genomic DNA from Trypanosoma brucei strain TREU 
427 and was kindly donated by Professor Jon Kelly from the London School of Hygiene and 
Tropical Medicine.  This DNA was introduced into a pET-15b vector (Novagen, Darmstadt).   
 
Figure 2.1.1 - p-ET15b vector with multiple cloning sites.  Highlighted sequences of relevance include the lac 
operator (allows induction of expression by lactose analogues), and the His-tag (a sequence of six histidine 
residues, useful for purification). 
 Escherichia coli BL21 (DE3) or Rosetta® cells (Novagen, Germany) were used as competent 
cells for the expression of protein.  Competent cells were transformed with the TDH DNA by 
introduction of a 45ng.ml
-1
 solution of DNA into a 50-100 µl suspension of competent cells.  The 
cells were then stored in an ice bath for ten minutes and it was periodically flicked to disperse 
the DNA.  These competent cells are stored without nutrients in a solution of calcium chloride to 
make them more permeable to DNA.  To further encourage the uptake of DNA, the cells were 
given a heat shock for 45 seconds at 42°C in a water bath, before being transferred to an ice 
bath for another ten minutes.  After this, they were transferred to room temperature and 1ml of 
autoclaved Luria Broth (LB) was added.  The cell population was grown by incubating in a 
rotating water bath at 37°C and 90 revolutions per minute (rpm) for 25 minutes.  This culture 
was then spun at 13,000rpm in a microcentrifuge for 1 minute.  This speed may be higher than 
that used in many labs, but it was suitable for the purposes of this procedure.   Excess broth 
was removed, and the remaining cells were re-suspended by trituration using a micropipette.  
This suspension was pipetted onto a previously made agar plate and spread across the surface 
using a glass spreader.  The agar plate was incubated overnight at 37°C.  The plate was then 
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stored at 2-8°C until ready for use.  Four separate cultures of these bacteria were prepared by 
inoculating 10ml LB in bijou bottles, using four isolated colonies picked from the agar plate.  The 
cultures were grown in the presence of 50 or 100µg/ml ampicillin to prevent contamination with 
other bacteria and to ensure that the expression vector was retained.  The cultures were grown 
overnight in a shaking incubator at 37°C and 120rpm.  These cultures were to serve as stock 
cultures of TDH-expressing cells, so a test of their ability to express TDH from the introduced 
DNA was carried out.  Four 10ml cultures in bijou bottles were prepared by inoculating LB plus 
ampicillin with 300μl of the stock cultures.  These cells were incubated at 37°C and 120rpm until 
they reached the mid logarithmic phase (optical density at 600nm [OD600] of 0.4-0.6).  Each 
culture was divided in two, leaving eight 5ml cultures, four of which would be experimental 
cultures and the other four would be controls.  The experimental cultures were all induced to 
express TDH by the addition of 1mM of the lactose analogue, isopropyl-β-D-1-
thiogalactopyranoside (IPTG).  All eight cultures were grown overnight in an Innova43 shaking 
incubator at 37°C and 120rpm as previously.  The IPTG-induced expression of TDH was 
detected using SDS-polyacrylamide gel electrophoresis (SDS-PAGE).  SDS-PAGE is able to 
detect and differentiate between proteins of different charge and mass, based on their 
differential migration through a polyacrylamide gel over time on application of an electrical 
current.  This migration is therefore governed by the polyacrylamide content of the gel, the 
electrical current and the mass-to-charge ratio of the protein.  Samples were prepared by 
centrifuging 300μl aliquots of each culture at 13,000rpm for 5 minutes, discarding the 
supernatant and re-suspending the cell mass by trituration in 50μl of Laemmli buffer.  Laemmli 
buffer contains a number of constituents which are very important for the method to work.  
Firstly, the die, bromophenol blue, allows researchers to visually track the movement of proteins 
through the gel.  Most importantly, another constituent, sodium dodecyl sulphate acts as a 
protein denaturant and surfactant that causes the unfolding of proteins and coats them in a 
negative charge, allowing them to be moved by electrophoresis.  Samples were boiled for 10 
minutes, to ensure protein denaturation, prior to loading into wells in 12% Tris-glycine SDS-
PAGE gels.  SDS-PAGE was performed by applying an electric current across the gel at 
30milliamps in a Bio-Rad Mini-PROTEAN II electrophoresis cell, powered by a Bio-Rad Power 
Pac 300 (Bio-Rad Laboratories Ltd., Hertfordshire, UK).  Protein molecular weight markers 
(Fermentas, part of Thermo Fisher Scientific Inc., Leicestershire, UK) were also loaded onto 
gels in a separate well.  Gels were stained with Coomassie blue and de-stained with a solution 
consisting of 10% v/v acetic acid, 10% v/v methanol and 80% v/v distilled water.  Successful 
expression was confirmed by the presence of a strong blue band corresponding to a molecular 
weight around 38kDa in the induced cultures.  Expression of KBL was performed using the 
same protocol.  KBL expression was confirmed by SDS-PAGE with the presence of a band at 
around 46kDa. 
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Figure 2.1.2 - schematic summarising the use of SDS-PAGE to analyse proteins.  Figure obtained from (156). 
2.1.1.2 Expression and Purification 
1 litre broth cultures for protein expression were prepared in 2-litre conical flasks by inoculating 
LB plus ampicillin with 10ml of TDH or KBL expression-inducible stock culture.  These cultures 
were then grown by either of the following methods: 
 ‘Normal’ method:  Cultures were grown to the mid logarithmic phase and induced with 
0.3mM IPTG.  Cells were then incubated overnight at 37°C in a shaking incubator at 
120rpm. 
 ‘Heat-shock’ method:  Cultures were grown to a level between the early log and mid log 
phases (OD600 0.3-0.4) before being transferred to a rotating water bath, where they 
were given a heat-shock, by incubating at 42°C whilst rotating at 90-100rpm for 30 
minutes.  Exposing the bacteria to heat stress leads to the increased expression of a 
number of heat shock proteins, which are molecular chaperones.  These proteins bind 
to hydrophobic regions of proteins, thereby assisting in the folding process and reducing 
the degree of misfolding and denaturation that often occurs during induced expression 
of high levels of recombinant protein(157,158).  After the heat shock, the cultures were 
cooled by swirling in an ice bath for 5-10 minutes before being induced with 0.3mM 
IPTG.  Cells were then incubated at 18°C in a shaking incubator at 90rpm for 48-72 
hours.  
Subsequently, cultures were transferred to appropriate containers and were centrifuged for 25 
minutes at 7000rpm in an Avanti J-26 XP centrifuge (Beckman Coulter, California, USA) with a 
JLA 8.100 rotor.  The supernatant was discarded and the cell mass re-suspended in ‘lysis’ 
buffer (50mM Tris.HCl, 100mM sodium chloride, 1mM β-mercaptoethanol (βM) and 10% v/v 
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glycerol, pH 7.5).  This suspension was then sonicated using a Soniprep 150 sonicator (MSE, 
London, UK) with an exponential probe, vibrating at an amplitude of 10 microns to lyse the cells.  
Fifteen 30-second cycles of sonication, separated by 30 second intervals were applied, before 
mixing the cells by stirring or shaking and then repeating the process once more.  The cell 
lysates were then poured into Oak Ridge tubes, and centrifuged at 18000rpm at 4°C for 40 
minutes using a JA 25.50 rotor (Beckman Coulter, California, USA).  Both the resulting 
supernatant and cell pellet were retained and samples were tested by SDS-PAGE, as described 
above.   
Once TDH was confirmed to be in the supernatant, it was purified by affinity chromatography 
using a HisTrap® HP nickel column (GE Healthcare).  The rationale behind this method is that 
the protein is ‘tagged’ with a tail of six histidine residues, which bind strongly to Ni
2+
 ions in the 
column, whilst other proteins flow through the column.  The purified protein can then be 
recovered by addition of a solution containing imidazole, which is able to out-compete histidine 
for binding.  The purification process was carried out using the following buffers: 
 Binding buffer: 50mM NaH2PO4, 300mM NaCl, 10mM imidazole, 1mM βM, pH8.0; 
 Wash buffer: 50mM NaH2PO4, 300mM NaCl, 20mM imidazole, 1mM βM, pH8.0; 
 Elution buffer: 50mM NaH2PO4, 300mM NaCl, 250-500mM imidazole, 1mM βM, pH8.0. 
The binding and wash buffers contain low concentrations of imidazole to prevent the non-
specific binding of other proteins, whilst the elution buffer uses high imidazole concentrations to 
elute the protein of interest. Buffers and the supernatant were introduced into the column 
through a 0.45micron filter using a 10ml syringe or a peristaltic pump and a protocol similar to 
the manufacturer’s instructions was used.  They were injected into the column in the following 
order: 5ml of elution buffer to clean the column, 10ml of binding buffer to equilibrate the column, 
the entire supernatant (containing protein), 10-15ml of wash buffer to remove non-specifically 
binding substances and finally 5ml of elution buffer was used to elute the protein from the 
column into 15ml of lysis buffer to maintain solubility of the protein.  According to the 
manufacturer, the HisTrap® HP column has a protein binding capacity of 40mg per ml of resin.  
To reduce the loss of unbound protein when this capacity was greatly exceeded, two HisTrap® 
HP columns were attached end to end.  The procedure was then carried out in the same way, 
but using double the volumes of each buffer.  All solutions flowing through the column(s) (“flow-
throughs”) were collected for SDS-PAGE analysis, where the success of the procedure was 
confirmed.  The eluted protein was concentrated and washed with around 40ml of lysis buffer 
using ultrafiltration in a 20ml, 10,000MW cut-off Vivaspin® 20 tube (GE Healthcare) to remove 
imidazole and to concentrate the protein.  The tube was spun in an Allegra X-12R centrifuge 
(Beckman Coulter) at 3000-3500rpm and at 4°C.  Centrifugation was continued until TDH was 
concentrated to a value of 1-20mg/ml.  Finally, the filtrate and retentate were tested by SDS-
PAGE as described above to confirm TDH purity.  The same procedure as that outlined above 
was used to purify KBL, except the heat-shock expression method was always used and the 
lysis buffer contained 300mM NaCl instead of 100mM NaCl. 
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In some cases, the purity was judged by SDS-PAGE to be sufficient for further studies.  The 
‘storage buffer’ used was the same as the ‘lysis buffer’: 50mM Tris.HCl, 10% v/v glycerol, 1mM 
βM, and 100mM or 300mM NaCl to store TDH or KBL, respectively. 
In circumstances where it was desirable to ensure higher purity (i.e. before the in vitro screening 
experiments), or when the enzyme solution still contained significant impurities, ion exchange 
chromatography was used.  Ion exchange chromatography works on the principle that charged 
molecules will bind to a polymer resin, and then those charged molecules can be displaced by 
the addition of ions.  Different molecules will either not bind or they will bind to the resin and 
later be displaced by increasing ion concentrations, thus allowing separation of a desired 
protein from impurities.  For this technique to work, the buffer used on the column, must have a 
pH > 1 unit above or below the relevant protein’s isoelectric point (pI, the pH value where a 
molecule is neutral/carries no charge) to ensure that the protein is positively or negatively 
charged.  Amino acid sequences for TDH and KBL were obtained from the TriTryp online 
database(155) and the pI values were predicted using the ProtParam tool on the ExPASy 
server(159).  Ion exchange chromatography was carried out on a column of approximately 
250ml Q Sepharose resin.  Q sepharose is a cross-linked polysaccharide resin with positively 
charged quaternary ammonium ionic groups that bind negatively charged molecules.  
Accordingly, the proteins were dissolved in buffers with pH values above their pIs, so that they 
carried a negative charge.  Prior to use, the column was washed of any bound substances 
using 1000ml of a ‘high salt’ buffer, containing 50mM Tris.HCl, 10% v/v glycerol and 1M NaCl.  
The column was then equilibrated with 1000ml of a ‘low salt’ buffer, containing 50mM Tris.HCl, 
10% v/v glycerol and 100mM NaCl.  The protein was then injected onto the column.  The 
column was washed with low salt buffer until some protein was eluted from the column, as 
detected by UV absorbance at 280nm.  This protein was collected and retained.  The procedure 
was continued by running a gradient of 1000ml solvent, progressing from 100% of the low salt 
buffer to 100% high salt buffer.  Ion exchange chromatography was automated by an ÄKTA 
Prime (GE Healthcare) Fast Performance Liquid Chromatography (FPLC) machine.  Eluted 
proteins were collected in fractions and concentrated and washed in storage buffer by 
ultracentrifugation, as described above.  The identities of proteins in the unbound and bound 
fractions were determined by SDS-PAGE. 
TDH and KBL solutions were stored in ice baths and refrigerated at 2-8°C.  Alternatively, 
solutions were stored for longer periods, frozen at -20°C. 
2.1.2 X-ray Crystallography and Structure Analysis 
X-ray crystallography is used to model the three-dimensional structure of small molecules and 
macromolecules, using the patterns formed by the diffraction of X-rays by crystallised 
substances.  From these diffraction patterns, the three-dimensional structure of the diffracting 
structure can be calculated by use of a Fourier transform.  The use of X-ray crystallography to 
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determine the structure of proteins, as used to determine the structure of TDH and KBL, will be 
outlined below. 
 
Figure 2.1.3 - X-ray crystallography schematic.  An X-ray beam is diffracted by a crystal.  Secondary X-rays are 
recorded on a detector.  The diffraction pattern can be used to calculate an electron density map of the 
diffracting substance. 
2.1.3 Crystallisation 
Proteins were crystallised by mixing solutions of proteins with crystallisation solutions.  3-5µl of 
protein solution was added to the same volume of precipitant solution to form droplets of 6-10µl.  
Crystallisation solutions contain precipitants, which promote the formation of crystals through a 
number of mechanisms, particularly by decreasing the solubility of the protein.  Molecular 
crowding agents, such as polyethylene glycol also help to encourage crystallisation by forcing 
different protein molecules into contact with each other.  Droplets of protein and precipitant are 
stored in a sealed container which contains a reservoir of crystallisation solution. In the sealed 
environment, crystals may be formed by vapour diffusion: as water evaporates from the 
reservoir and the protein-precipitant solution, the concentrations of both protein and precipitant 
increase, promoting crystallisation.  Crystallisation of TDH and KBL was attempted by the 
‘hanging drop’ method (see Figure 2.1.4), where the droplet of protein and precipitant solution is 
suspended from a siliconised glass plate (cover slip).  
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Figure 2.1.4 - Crystallisation by the hanging drop vapour diffusion method. 
The crystallisation of any particular protein can be affected by numerous factors, including the 
protein concentration, precipitant identity, precipitant concentration, pH, salt identity and salt 
concentration.  For this reason, crystallisation was attempted by combining different 
concentrations of protein with commercially available screens, which contain an array of 
crystallisation conditions that combine different precipitants, salts, buffers and pH values.  
‘Structure Screens 1 and 2’ (MD1-01 and MD1-02, Molecular Dimensions) and ‘JCSG plus’ 
(Molecular Dimensions) screens were used to identify conditions that produced crystals of TDH.  
Several TDH crystals produced from these screens were later used to collect diffraction data.  
The successful crystallisation conditions were reproduced using solutions prepared using the 
reported constituents.  With the aim of improving the quality of TDH crystals, some conditions 
identified in the commercial screens were altered by use of an optimisation matrix.  This 
involves combining different concentrations of precipitant with different pH values.  A similar 
process was used to promote crystallisation of KBL in conditions that produced amorphous 
solids, or crystalline-like solids. 
An important utility of X-ray crystallography in a drug discovery context is the ability to observe 
ligand-protein interactions.  Therefore, in order to obtain diffraction data from a protein 
interacting with its ligand, the ligand was introduced by one of two methods.  Using the method 
of co-crystallisation, the ligand is mixed with the protein prior to crystallisation.  Ligand solutions 
were made up in the same storage buffer as the protein or in DMSO if aqueous solubility of the 
ligand was low.  The ligand solution was then mixed with the protein solution and left for 30 
minutes to an hour before carrying out crystallisation as described above.  A second method, 
often called ‘crystal soaking’, involved transferring crystals to a droplet of crystallisation solution, 
which also contained ligand.  In this way, crystals were soaked in a solution containing the 
ligand for 5 – 60 minutes. 
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X-ray radiation damages biological materials, thus making it difficult to collect reliable or 
complete diffraction data.  To limit this damage, crystals are ‘cryo-cooled’ to low temperatures of 
around 100K and maintained at these temperatures throughout storage and data collection.  It 
is important that cooling happens rapidly and that crystals are not frozen, which would cause 
changes in the physical structure of the crystal.  With this in mind, after ‘harvesting’ protein 
crystals onto a fabric or plastic loop, they were cooled by one of three methods: 
 The loop and crystal were plunged directly into a bath of liquid nitrogen; 
 The loop and crystal were suddenly exposed to a stream of cryo-cooled nitrogen gas; 
 The loop and crystal were plunged into liquid ethane for one second and then into liquid 
nitrogen. 
To prevent damage to the crystals on cooling, the crystals were sometimes soaked in glycerol, 
which acts as a cryoprotectant.  Crystals were transferred to a drop of 10µl crystallisation 
solution, and 4 x 1µl drops of glycerol were added and mixed into this drop sequentially.  
Crystals were then harvested and cooled.  All cooled crystals were stored in a Dewar to 
maintain their temperature, prior to data collection. 
2.1.3.1 X-ray Diffraction 
The determination of macromolecular structures from X-ray diffraction patterns requires 
knowledge of the properties of waves.  X-rays are transverse waves and their properties are 
outlined in Figure 2.1.5.  The wavelengths of X-rays range between 0.1 and 100 Å, with the 
useful range for crystallography lying between 0.7 and 1.5 angstroms, as they match 
interatomic bond lengths (the typical carbon-carbon bond is 1.5 Å in length). 
 
Figure 2.1.5 - the properties of a transverse wave (shown in blue).  The sinusoidally oscillating wave is described 
by its amplitude, the distance from its equilibrium point to a wave crest, its wavelength, the distance between 
two wave crests, and its phase, the angle at a particular point along the wave’s trajectory.  The phases at the two 
round points at the top of each crest are the same.  
52 
 
When X-rays hit clouds of electrons orbiting atoms, they cause oscillation, which then leads to 
the emission of secondary X-rays in all directions.  This is the process termed diffraction.  When 
‘diffracted’ X-rays are recorded by a detector, it is referred to as a reflection, because the 
angular relationship between the primary beam and the secondary beam is analogous to 
reflection of light by a mirror.  As crystals consist of a regular 3D arrangement of the protein of 
interest, the diffraction pattern produced on the detector corresponds to the structure of the 
protein. 
Rotation of the crystal exposes different reflecting surfaces (or ‘planes’, discussed below), 
producing different diffraction patterns, depending on the crystal orientation.  Altering the crystal 
orientation in this way allows one to record a reciprocal 3D lattice of reflections, from which one 
can calculate the structure of the diffracting substance by use of the Fourier transform. 
 𝑓ℎ𝑘𝑙 =  𝑓𝑗𝑒
2𝜋𝑖(ℎ𝑥𝑗+𝑘𝑥𝑗+𝑙𝑧𝑗) 1 
The atomic structure factor, fhkl, defines the contribution of a single atom, j, to a reflection with 
the indices of h, k and l in the reciprocal lattice, at positions xj, yj and zj in the real lattice (see 
discussion of the ‘unit cell’ below).  The scattering factor, fj, is a mathematical representation of 
an atom’s electron density which depends on the particular element.  The integral sum of all 
atomic structure factors for the unit cell volume, V, results in the structure factor Fhkl:  
 𝐹ℎ𝑘𝑙 =  ∫ 𝜌(𝑥, 𝑦, 𝑧)
𝑉
𝑒2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧). 𝑑𝑉 2 
This equation can be rearranged to find ρ, the electron density: 
 
𝜌(𝑥, 𝑦, 𝑧) =  
1
𝑉
∑ ∑ ∑ 𝐹ℎ𝑘𝑙𝑒
−2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)
𝑙𝑘ℎ
 3 
Relating this back to the properties of a wave: the amplitude and frequency of Fhkl are known as 
the amplitude is related to the reflection intensity and the frequency of a diffracted beam is 
usually equal to the incident beam.  Therefore, the main hurdle to overcome in structure solution 
is the determination of the phase of Fhkl (160,161).  The phase is the angle describing a 
particular point along a wave’s trajectory.  This problem is commonly referred to as the phase 
problem, and methods used to overcome this will be discussed below. 
 
As the reciprocal and real lattices consist of a regular arrangement of points or reflections, then 
planes can be drawn across different points of the lattice, so that X-rays can be considered to 
be diffracted from planes within the crystal.  A condition that must be satisfied to produce 
measurable detection is described by Bragg’s law.  Bragg’s law states that a strong reflection 
will only be produced from these parallel planes, separated by interplanar distance dhkl, if an 
incident beam strikes the planes at angle θ and is diffracted at the same angle, whilst satisfying 
the condition in equation 4: 
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 2𝑑ℎ𝑘𝑙 . 𝑠𝑖𝑛𝜃 = 𝑛. 𝜆 4 
Where θ is the angle of incidence, n is an integer and λ is the wavelength. 
This can be explained further by observing Figure 2.1.6.  Two X-rays entering the crystal are in 
phase with each other.  But, due to the fact that the second beam travels further before being 
reflected at the same angle of incidence, the two X-rays leave the crystal out of phase.  
However, looking at Figure 2.1.6, if the distance between A to C to B, the geometrical path 
difference, is equal to an integral multiple of the wavelength, thereby equalling 2.dhkl.sinθ, then 
the two waves will be in phase and overlap to combine by constructive interference.  Therefore, 
the addition of several waves in this manner produces a reflection strong enough to be recorded 
by the detector.   Thus reflections in an individual diffraction pattern result from diffraction of 
many waves from parallel planes.     
 
Figure 2.1.6 - Bragg's law illustrated by the diffraction of two parallel waves at angle, θ, from two parallel planes 
separated by dhkl.  If two waves enter the crystal in phase, they will leave in phase if the geometric path distance 
(i.e. the distance travelled by wave 2 before it becomes parallel with wave 1 again), ABC, is equal to an integer 
multiple of the wavelength, λ.  Bragg’s law is satisfied when the distance ABC = nλ = 2.dhkl.sinθ.  
The angles of incidence (θ) differ based on the distance between sets of planes; with smaller 
distances (which produce higher resolution data) requiring larger angles.  The intensity of each 
reflection depends on electron density, and thus, the identity and number of the atoms along a 
reflecting plane.  An individual atom’s contribution also depends on its fractional distance from 
the plane, as this affects the phase. 
In summary, reflections are the sum of atom contributions along a plane, and include 
amplitudes and phases.  Different reflections produced by the same atoms will have different 
phases, whilst amplitudes remain the same.  Similarly, Friedel’s law states that “the magnitudes 
of the structure factors of centrosymmetrically related reciprocal lattice points are equal”(160).  
Thus: 
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 |𝐹ℎ𝑘𝑙| =  |𝐹ℎ𝑘𝑙̅̅ ̅̅ ̅| 5 
 
These laws arising from symmetry are exploited later in solving crystal structures. 
 
A deeper discussion of X-ray diffraction theory is beyond the scope of this thesis, but what has 
been described here should help to provide a context to the results presented herein. 
 
TDH diffraction data were collected from synchrotron sources, the European Synchrotron 
Radiation Facility (ESRF) and Diamond Light Source (DLS).  During data collection, crystals 
were mounted on a goniometer and maintained at low temperatures under a stream of nitrogen 
gas.   
During data collection it is important to try and collect a complete data set.  This requires that 
the crystal is rotated and that data is collected over a sufficient range to obtain an image of the 
full reciprocal lattice.  The quality of data collected can be improved by collecting data over a 
larger area of the crystal, so that errors can be corrected for by having redundant data.  Due to 
damage to the crystal caused by radiation over the course of the experiment, the extra data 
recorded may not be needed.  In addition, if one fails to collect diffraction data when the crystal 
is in its necessary orientation, a full data set may not be achieved.  For this reason, data 
collection can be performed by following a strategy, which stipulates the starting orientation of 
the crystal, the oscillation angle and the transmission of the incident X-ray required to make 
quality measurements on all unique reflections.  Data collection experiments of TDH crystals 
were guided by the strategies given by the programs EDNA(162) or Mosflm(163), which 
determine the symmetry of the crystal to advise on the crystal orientation, oscillation angle, 
number of images and the X-ray transmission to avoid detector overloads.  Alternatively, data 
were sometimes collected at small oscillation angles (0.5 – 1
0
 per image) over 180-360
o
 to 
increase redundancy of the data. 
2.1.3.2 Structure Solution and Refinement 
As stated earlier, a crystal is a regular array of repeating subunits.  In crystallography, these 
subunits are defined by the unit cell.  The unit cell is defined by the axes a, b and c and the 
angles α, β and γ, as illustrated in Figure 2.1.7. 
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Figure 2.1.7 - a crystal unit cell.  The unit cell is defined by the axes a, b and c, along the trajectories x, y and z, 
respectively, and by the angles α, β and γ.  
Within the unit cell, there are often several copies of a protein and other molecules.  The largest 
non-symmetrical unit that can be superimposed on other units in the cell is known as the 
asymmetric unit.  The symmetrical arrangement of repeats of the asymmetric unit in the unit cell 
is described by the space group, which describes the combinations of rotational and 
translational symmetry that relate all the copies of the asymmetric unit to each other.  A space 
group is denoted by a letter defining the lattice type and numbers that represent rotational and 
translational symmetry.  For example, the common space group, P21212, describes a unit cell, 
where the centres of symmetry are the vertices of the cell (denoted by P, a primitive lattice), and 
there are two screw axes (denoted by 2121), which are axes which rotate the asymmetric unit by 
180
0
 and translate it by one half of the axis length, and one two-fold rotational axis (denoted by 
2). 
 
Early data processing was either carried out manually or by use of the integrated data reduction 
pipeline, xia2(164), at DLS.  The first step in processing a crystallographic data set is integration 
of all the diffraction images.  When early data processing was carried out manually, this was 
carried out using the graphical user interface (GUI) version of Mosflm, iMosflm(165).  When 
automated processing was carried out by xia2, the program XDS was used.  The process 
referred to as integration here actually requires three steps: autoindexing, postrefinement and 
integration.  In iMosflm auto-indexing determines the lattice or unit cell parameters, crystal 
orientation and mosaic spread of the diffraction pattern using one image or a few images 
separated by several degrees of oscillation.  Once the lattice type and unit cell parameters have 
been determined, spot (reflection) positions are predicted and are displayed to the user.  The 
user can then choose the correct lattice type and unit cell parameters from a list based on 
probability scores and by visually checking the ability of each spot prediction to accurately 
locate spot positions.  Postrefinement uses two separated ranges (wedges) of images and 
observes the distribution of spot intensity over partial reflections to refine unit cell parameters 
and improve the accuracy of the prediction.  During integration the software takes the refined 
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unit cell and predictions of spot positions and counts the photons recorded at the predicted 
positions in each diffraction image, giving estimates of intensities. 
Indexing is able to predict the unit cell geometry and lattice type, but not the space group, which 
describes the arrangement of the asymmetric units in the unit cell.  The program 
POINTLESS(166,167) predicts the space-group of the crystal using a more thorough process 
than the integrating software.  Reflections related to possible symmetry elements (e.g. a 2-fold 
rotation) are scored according to the probability that they are correct.  Then, combinations of 
elements are combined and scored to detect the lattice symmetry.  Space group symmetry is 
then determined by use of systematic absences.  Systematic absences occur along screw axes, 
where symmetry related reflections cancel each other out.  For example, in a 21 screw axis, 
there is an absence of intensity at every second measurement along the affected axis.  
Observing systematic absences was performed using the program POINTLESS, or was carried 
out manually to determine the space group from a number of options that share the same lattice 
symmetry. 
During data collection, differences may arise between measurements of the same reflections.  
This is an issue, because it results in these measurements being on different scales.  These 
differences or errors can come from many sources: 
 The incident X-ray beam – e.g. variation in intensity, absorption by the crystal, 
variations in rotation speed and problems with shutter synchronisation;  
 The secondary (diffracted) X-ray beam – e.g.  absorption by the crystal and radiation 
damage to the crystal (resulting in weaker reflections); 
 The Detector: detector calibration, the beamstop and beamstop support shadows. 
In order to merge the data describing the same reflections together, the entire dataset needs to 
be scaled, which means to put the measured intensities on the same scale.  Most of the factors 
described above are constant for any given image or at any given time in the experiment.  
Scaling applies correction factors (B factor and scaling factor) for each image or phi angle (the 
oscillation angle or orientation of the crystal).  The knowledge of symmetry related reflections 
and Friedel’s law is exploited here to determine how each intensity measurement should be 
corrected/scaled. 
The programs Scala and its successor Aimless combine the processes of space group 
determination, scaling, merging, and conversion of intensities, I, to structure factor amplitudes, 
F.  They were used during manual data processing and as part of the pipeline employed in 
automatic data processing by xia2.  In all cases, the programs were set to exclude 5% of the 
data from processing to aid later analysis (see discussion of Rfree below).  The log files produced 
by these programs are very informative and report a number of data quality indicators, which 
will be outlined here because they were used to guide further refinement of the data. 
R-factors give measures of differences between multiple observations of the same reflection 
and indicate the success of the scaling and merging process.  They can also be used to decide 
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a resolution cut-off for data refinement and to compare scaling results between different space 
groups.   
 
𝑅𝑚𝑒𝑟𝑔𝑒 =  
∑ ∑ |𝐼ℎ𝑘𝑙,𝑗 − 〈𝐼ℎ𝑘𝑙〉|𝑗ℎ𝑘𝑙
∑ ∑ 𝐼ℎ𝑘𝑙,𝑗𝑗ℎ𝑘𝑙
 6 
An ideal value for the Rmerge is less than 10%, although data with an Rmerge of up to 20% can be 
useful. The usefulness of this parameter is limited by the fact that it increases with multiplicity 
(redundancy of the data), which actually improves data quality.  The multiplicity-weighted R-
factor, Rmeas improves on this – it reflects the higher accuracy achieved by having a  greater 
number of measurements.  
 
𝑅𝑚𝑒𝑎𝑠 =  
∑ (
𝑁ℎ𝑘𝑙
𝑁ℎ𝑘𝑙 − 1
)
1
2
∑ |𝐼ℎ𝑘𝑙,𝑗 − 〈𝐼ℎ𝑘𝑙〉|𝑗ℎ𝑘𝑙
∑ ∑ 𝐼ℎ𝑘𝑙,𝑗𝑗ℎ𝑘𝑙
 
7 
A newer parameter, the precision-indicating R-factor or Rp.i.m, decreases with increasing 
multiplicity and gives a better estimate of the precision of the scaled and merged intensity.   
 
𝑅𝑝.𝑖.𝑚. =  
∑ √
1
𝑁ℎ𝑘𝑙 − 1
∑ |𝐼ℎ𝑘𝑙,𝑗 − 〈𝐼ℎ𝑘𝑙〉|𝑗ℎ𝑘𝑙
∑ ∑ 𝐼ℎ𝑘𝑙,𝑗𝑗ℎ𝑘𝑙
 
8 
The Rp.i.m. is usually lower than the Rmerge so a value of less than 10% was considered desirable 
when making decisions on data quality.  Scala and aimless also present these parameters as 
calculated by batch of data, by intensity and by resolution. 
The metrics (I)/sigma(I), and the mean (I)/sigma(I) (Mn((I)/sigma(I)) give an indication of the 
ratio between intensity, I, and the standard deviation, sigma, between related measurements.  A 
high sigma, and thus a low (I)/sigma(I) may reflect error and such outliers may be rejected.  A 
minimum Mn((I)/sigma(I)) of 2 for the overall data set was considered as an appropriate value 
for the data described here.  As a lower (I)/sigma(I) may actually be valid for some reflections, 
especially high resolution reflections that refract weakly, a minimum (I)/sigma(I) of 1.0 was 
considered appropriate when choosing a resolution cut-off for data with an appropriate overall 
(I)/sigma(I).  These metrics can also be useful in identifying areas of poor data quality, such as 
badly integrated data, poor images and radiation damage. 
The completeness of a dataset is the proportion of all possible unique reflections that are 
recorded within the resolution limit.  During data collection, data can be lost or missed due to 
radiation damage, a poor collection strategy or anisotropy.  Completeness should ideally be as 
high as possible in all included resolution shells.  A cut-off of 90% completeness in the outer 
shell (highest resolution data) was chosen to decide whether it was appropriate to retain data 
recorded to that resolution.  For the datasets described here, most overall completeness values 
were close to 100%, as data was collected with the aim of achieving redundancy.  In addition, 
data was collected in a manner to ensure that the multiplicity of the entire dataset was at least 
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2, as this is a value that one would expect for a complete data set, according to Friedel’s law 
(see equation 5).  
A newer measure, the half-dataset correlation coefficient was introduced in the program 
Aimless, the successor of Scala. This randomly splits each set of observations in two and 
compares the intensities by calculating a correlation coefficient (1.0 corresponds to a perfect 
correlation).  This metric is independent of (I)/sigma(I), which is resolution dependent, so it is 
useful for picking a resolution cut-off. 
After scaling and merging was complete, the program ctruncate was executed (automatically by 
aimless/scala) to convert the intensities into structure factors.  Ctruncate estimates │F│ from I 
and sigma, using the average intensity in the same resolution range(168).  The scaled and 
merged data are output in a .mtz file. 
 
Once a scaled and merged dataset with structure factor amplitudes had been obtained, it was 
possible to begin building a model for the crystallised protein.  Before a model can be created, it 
is useful to know how many protein subunits (e.g. monomers) are in the asymmetric unit.  Most 
protein crystals have a solvent content in the range of 45-60%, with the solvent content of some 
proteins lying beyond this range – between 40-70%(169,170).  Knowledge of the partial specific 
volume of a protein (the ratio between the volume of a protein and its molecular weight), the 
molecular mass of the protein subunit and the space group allow the iterative determination of 
solvent content and the number of protein subunits in the asymmetric unit.  The CCP4 program 
Matthews_coef(171), will estimate the solvent content and the Matthews coefficient (VM, ratio of 
crystal volume to protein mass), which should lie between 2.0 and 3.0 Å
3
.Da
-1
, using different 
values for the number of subunits in the asymmetric unit.  The program outputs probability 
scores against each possible number of asymmetric units.  The probability scores are 
calculated on the basis of a dataset of validated protein structures(169–171).  The program 
Matthews_coef was used in this way to identify the likely number of TDH monomers in a unit 
cell.  This number would be useful in the next stage of crystallographic model solution. 
 
Despite having structure factor amplitudes at this stage, it is not possible to determine the 
absolute phases of the structure factors directly from an X-ray diffraction experiment.  Phase 
solution, which enables the solution of a protein structure model, was carried out by molecular 
replacement (MR).   The basic premise of MR is that a series of translation and rotation 
functions are applied to a ‘search model’, which is a 3D structure model of a similar or identical 
protein.  MR was performed using the CCP4 programs, molrep(172,173) or Phaser(174). 
Molrep performs molecular replacement by use of the Patterson function(175,176).  To perform 
MR in this study, molrep was executed with the option to perform MR by using rotation and 
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translation functions.  The .mtz file produced after earlier processing was used as input, and a 
.pdb file representing a previously solved TbTDH structure was used as the “search model”.  
The only additional non-default search parameter changed was the number of monomers in the 
asymmetric unit.  This option tells molrep how many copies of the search model to search for in 
the asymmetric unit.  Therefore, the value of this parameter was determined by the number of 
molecules in the asymmetric unit, as calculated using the Matthews coefficient (see above).  For 
example, for a structure predicted to contain six TDH monomers in the asymmetric unit, a .pdb 
file containing one TDH monomer would be used as the search model and the program would 
be instructed to search for six copies of this.  Alternatively, a search model that matched the 
predicted number of monomers in the asymmetric unit could be used.  For example, dimeric 
TDH structures were used to perform MR on data where the structure was predicted to contain 
two molecules in the asymmetric unit.  
The CCP4 program Phaser performs MR by a maximum likelihood method(177).  Like molrep, 
phaser uses the scaled and merged .mtz file and a search model .pdb file as inputs.  The 
particular .pdb files used as search models were chosen based on the same criteria as molrep.  
Phaser allows the user to define the percentage shared sequence identity between the search 
model and the target structure, so this value was set to 100.  Two additional important 
parameters were used to perform MR with Phaser.  The options under ‘Define composition of 
the asymmetric unit’ were used to instruct the protein of how many molecules of a certain 
molecular weight to search for.  Alternatively, Phaser was instructed to perform the search 
looking for a specified number of copies of the search model in the asymmetric unit.  This 
second option was particularly useful in some challenging cases.  With structure models 
containing six monomers in the asymmetric unit, sometimes molrep failed to provide a full 
solution, and only provided solutions for 2 or 4 of the monomers present.  Phaser was then 
useful in these cases, because two search models (called “ensembles” in Phaser) can be used 
to carry out MR simultaneously.  An example of this involved instructing the program to search 
for one copy of a partial MR solution consisting of four monomers, whilst simultaneously 
searching for two copies of a .pdb file containing a TDH monomer.  To develop initial models for 
TDH datasets, molrep was used in the majority of cases.  Phaser was used in cases where 
molrep had failed to find a solution, or when it had only found a partial solution.  After 
completing MR, the quality of the solutions were judged following refinement, as detailed below. 
 
At this stage in structure solution, phases have been obtained, and the molecular positions of a 
model structure have been established.  However, further refinement of atom positions is 
required. For this, an improvement in the accuracy of the calculated electron density map, which 
allows the discernment of fine molecular details, is desired. 
Real-space refinement involves the iterative calculation of electron density maps from models.  
These electron density maps are then compared to the observed maps obtained from the data.  
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Refmac5, another program included in the CCP4 software package, performs reciprocal-space 
refinement: it aims to reduce differences between all parameters represented in the Fourier 
transform.  Refmac5 uses a Maximum Likelihood method that incorporates Bayes’ theorem, 
where likelihoods or probabilities are dependent on prior probabilities.  In this context, the 
likelihood that a model is a correct representation of the structure that produced the data, is 
dependent on a number of parameters related to that particular protein, or to proteins in 
general.  One example of this is the use of restraints.  This increases the data-to-parameter 
ratio by restraining parameters to certain ranges of values (e.g. knowledge of amino acid 
geometry can be exploited to restrain main and side-chain torsion angles).   
Refmac was run using the processed .mtz file and the .pdb file output by molrep or Phaser as 
inputs.  As the TDH models often contained a non-protein molecule, NAD, a .cif file, which 
contains the restraints for that particular molecule, was also input into Refmac (see below for 
description of how .cif files were created for other ligands).  Refmac was typically executed with 
the setting to run 10 cycles of restrained refinement of TDH models, producing a refined model 
and electron density maps.  For later rounds of refinement, fewer cycles (5 or 3) were chosen, 
as additional cycles were observed to have little or no impact on indicators of the success of the 
refinement.  Other default refinement parameters which told Refmac to refine isotropic B factors 
(see below for discussion of B factors) and to use automatic weighting were used.  The default 
option to ‘use experimental sigmas to weight X-ray terms’ was turned off. 
The success of refinement can be indicated by the calculation of the residual index, or R-factor: 
 
𝑅 =  
∑|(|𝐹𝑜| − |𝐹𝑐|)|
∑|𝐹𝑐|
 9 
where R is the residual index, and Fo and Fc are the structure factors from the observed and 
calculated data, respectively.  The R-factor can be considered to be a measurement of the 
discrepancies between the observed and calculated data, and a lower number represents a 
lower discrepancy.  A value of 50% or less suggests at least some similarity between the data.  
As the Fo and Fc data are used themselves to minimise the discrepancies between them, the 
use of the above equation to calculate R means that R is a biased measurement.  For this 
reason, the same equation is applied to the 5% of data that was excluded from the refinement 
process.  Therefore, Refmac reports R for the ‘working’ data set, Rwork, and R for the ‘free’ 
dataset that was excluded from use in refinement, Rfree.  A well-refined model of data at 
resolution around 2.0Å, should give an Rwork of around 20%.  The Rfree is usually 5-10% above 
this.  During refinement of TDH structures, an initial Rwork of less than 30% for a MR solution 
was considered successful.  For models in later stages of refinement, Rwork values of around 
20% were desirable.  A large difference between the Rwork and Rfree can indicate an incorrect 
MR solution, large un-modelled areas of a structure, or over-fitting of the data, where areas of 
electron density caused by errors have been modelled with atoms.  Therefore, a limit of 10% 
was chosen for the difference between Rwork and Rfree in a refined structure.  
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Refmac outputs a .mtz, from which two electron density maps can be calculated that allow the 
manual and visual manipulation of structure models.  The two maps of use in achieving this are 
calculated: 
 2Fo minus Fc maps – by doubling Fo and subtracting Fc, areas where atoms have been 
placed correctly will have less electron density, and areas where atoms should be 
located should have greater density. 
 Fo – Fc maps (‘difference maps’) – positive electron density will show in areas where 
atoms are missing, whereas negative density will appear where atoms have been 
placed in error.  A perfect structure solution would produce an empty difference map. 
These maps can be displayed according to the root mean standard deviation (RMSD or σ), 
which is related to the probability of attaining a certain structure factor amplitude, given the 
model.  By setting the contours of electron density maps to a certain σ level, one can choose to 
place atoms with a specified degree of confidence. 
The structure visualisation and manipulation software, Coot(178,179), was used on Windows 
and Linux systems to carry out real space refinement and validation of structures.  Manipulation 
of structures was guided by 2Fo-Fc maps at σ levels of 1.5 and by Fo-Fc maps at σ levels of 
2.00.  The aim here is to achieve the best possible fit of the model to the electron density map.  
A number of tools within the Coot program were used during the refinement process.  Firstly, 
the ‘Real space refine zone’ was used to automatically manipulate a defined region of the 
protein to improve the fit to the electron density map.  Alternatively, the ‘Rotate Translate 
Zone/Chain/Molecule’ tool was used to manually manipulate the positions of atoms or defined 
regions of the protein to improve the fit in a more controllable way.  Manipulating protein 
structures in this way creates the risk that the model may take on biologically implausible 
orientations.  To counteract this, the tool ‘Regulate Zone’ automatically changed the orientation 
of a defined zone of the protein so that it conformed to the Refmac restraints defined earlier.  
Other tools used to quickly fix this problem include the ‘Flip Peptide’ tool and the ‘Change 
reidue’s phi and psi angles’ tool, which were used to alter the geometry around peptide bonds.  
Some amino acids, such as asparagine, glutamine and histidine are easily placed in the wrong 
orientation, due to their planar nature.  Using the apparent hydrogen-bonding networks as a 
guide, the “Auto-flip sidechain’ tool was used to flip the residue’s side chains by 180° when the 
orientation appeared to be incorrect.  On some occasions,  determining the orientation of more 
disordered parts of the molecule, where density was sparse, was not possible using the 
aforementioned tools alone.  Therefore, the residues in these regions of the model were deleted 
and re-added using difference maps as a guide, following multiple successive rounds of 
refinement of the model using Refmac.  In this case, the residues were added as L-alanine and 
then converted to the correct residue using the ‘mutate’ or ‘mutate & auto-fit’ tools. 
Two important parameters that are included in the PDB files are the B-factor (or temperature 
factor) and occupancy.  The B-factor is a measure of disorder in a crystal structure, with higher 
numbers indicating a greater degree of variation in the coordinates of an atom.  The occupancy 
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of an atom describes the degree to which a certain space in the unit cell is occupied by an 
atom, with full occupancy being represented by 1.0.  Altering the occupancy and B-factor can 
have a similar effect on protein models.  Altering B-factors is more appropriate for most 
macromolecular structure refinements, and thus was used to account for the variation of atom 
positions within adjacent areas.  Occupancy was used to model atoms which may not always be 
present in every asymmetric unit, for instance ligands which may be present in only a proportion 
of asymmetric units.  It is also possible to model atoms in ‘multiple occupancies’, and this was 
carried out when it was evident from the electron density map, that an atom or group of atoms 
occupied two or more distinct positions. 
To incorporate ligands into the model, structures were produced as .pdb files, along with 
restraints (stored in .cif files, used by Refmac), using the online ProDRG server(180).  Once 
placed in the desired area, the ligand was merged with the structure so that it was stored in the 
same PDB file.  It is common for solvent, precipitant or cryoprotective molecules to be found in 
structures.  Coot has a feature that was frequently used in this study to model several of these 
molecules into structures.  Restraints for these molecules are contained in the default Refmac 
restraint dictionary.  Water molecules were modelled into roughly spherical regions of electron 
density as oxygen atoms.  This was done automatically using Coot’s ‘find waters’ tool and 
manually by placing atoms. 
After each round of manipulation, the modified model, the .mtz file containing the structure 
factor amplitudes, and any .cif restraint files for ligands were input into Refmac5 before 
executing, to produce a new pair of electron density maps, along with a new, modified model. 
 
Towards the end of structure solution, it is vital to validate the model, using knowledge of 
protein structure, chemical bond geometry and ligand structures.  Bond distances and 
geometries, including those in hydrogen bonding networks, were observed visually and modified 
accordingly.  Coot has a number of useful tools for structure validation, such as the 
Ramachandran plot.  The Ramachandran plot can be used to identify amino acids with phi (φ) 
and psi (ψ) angles (see Figure 2.1.8), that lie outside of normal values.  This plot was used in 
this way to find and correct such errors. 
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Figure 2.1.8 - the Ramachandran plot (A) as a structure validation tool.  The planarity of peptide bonds, and the 
presence of amino acid side chains restrain the angles on either side of the amino acid α-carbon.  Thus phi (φ) 
and psi (ψ) are constrained to certain combinations of values (see image B).  These values appear on 
Ramachandran plots (see image A) as ‘preferred regions’ and ‘allowed regions’.  Residues with values outside of 
these regions of the plot (‘outliers’) suggest an incorrect geometry.  Note: the lack of a side chain on glycine 
residues mean that they often lie outside of the preferred and allowed regions for other amino acids.  
Another tool within Coot that was exploited to help validate and correct models was the rotamer 
analysis tool.  This tool observes the combination of torsion angles between amino acid side 
chains and highlights the residues where a combination has a low probability of existing in 
nature.  The rotamer analysis tool was used to correct side chain orientations in TDH structures. 
 
2.1.3.3 Sequence and Structure Analysis 
The Basic Local Alignment Search Tool (BLAST) is a suite of programs that are executed to 
generate alignments between query amino acid or nucleotide sequences and other sequences 
in the database.  This can provide an insight into the similarity between the query protein and 
proteins from other organisms.  The amino acid sequence and nucleotide sequence (both 
provided as single letter representations), for TDH and the TDH gene from T. brucei gambiense 
(Tb927.6.2560), respectively, were obtained from the TriTryp database(155).  Searches against 
these sequences were executed using the National Center for Biotechnology Information 
(NCBI) protein and nucleotide BLAST tools(181).  Sequence alignments were reported along 
with sequence identity matches (percentage), and the organism name.  Results of biological or 
pharmacological interest were noted. 
Protein structure models and their interactions with ligands were observed visually using 
PyMOL (Schrödinger LLC), Coot and UCSF Chimera(182).  To analyse the average B-factor for 
main chain atoms of TDH amino acid residues, nine representative monomer structures were 
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taken from different PDB files.  The CCP4 program baverage was then used to calculate the 
mean B-factor value across all of these structures.  To visualize the B-factor variance, the 
values output by baverage were input into an attribute file, which is used by UCSF Chimera to 
assign new attributes to a protein structure.  The attribute file, containing the average B-factors 
for each amino acid residue, was assigned to a structure of a TDH monomer.  The ‘colour by 
attribute’ feature of UCSF Chimera was then used to colour a ribbon representation of TDH by 
the average B-factor.  To measure the disorder of TDH by a different method, the same nine 
representative structures were superimposed using the ‘Matchmaker’ and ‘match→align’ tools 
in UCSF chimera.  The RMSD for the α-carbons (Cα) of each residue was then computed.  The 
RMSD values were output and used in the same way as the average B-factors to visualize the 
variation in positions of amino acid residues. 
The program PISA (Protein Interfaces, Surfaces and Assemblies)(183) in the CCP4 package 
was used to output the quaternary structures of TDH models.  This is done using the atomic 
coordinates from the PDB file and the space group, to generate all symmetry-related protein 
models. 
2.1.4 Other Biochemical and Computational Techniques 
2.1.4.1 Size-exclusion Chromatography 
Size-exclusion chromatography or gel filtration is a method of distinguishing between proteins of 
different molecular mass, by virtue of their differential migration speeds through a polymer gel.  
The schematic in Figure 2.1.9 outlines how migration through pores of certain size and 
tortuosity will determine the migration speeds of proteins through a gel-packed column.  Prior to 
an experiment, a gel filtration column must be calibrated with proteins of known molecular 
mass.  Then a linear gradient can be calculated for the relationship between their molecular 
masses and the volume of buffer required to elute them from the column (elution volume).  A 
protein or mixture of proteins may then be applied to such a gel.  Then, the elution volumes of 
the proteins can be used to estimate the molecular weights of the eluted molecules.  This can 
potentially inform on the quaternary structures of proteins and the existence of multi-protein 
complexes. 
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Figure 2.1.9 - Size-exclusion chromatography schematic illustrating the migration of proteins through a gel packed 
column (left and top right).  The elution of proteins as measured by UV absorbance at 280nm is used to estimate 
molecular mass.  
The sample buffer used for gel filtration was similar to the storage buffers used for TDH and 
KBL, with an intermediate NaCl concentration: 50mM Tris.HCl, 200mM NaCl, 1mM βM, 10% v/v 
glycerol, pH 7.5.  This buffer was cleaned and de-gassed by Buchner filtration.  First, the pumps 
of the FPLC machine (Controller LCC-501 plus) were lubricated with 20% ethanol and then 
washed with sample buffer.  A Superdex 200 10/300 GL column (Amersham Pharmacia 
Biotech, part of GE healthcare, Buckinghamshire, UK) was equilibrated with approximately 2 
column volumes of sample buffer.  All samples were centrifuged for 5 minutes to remove 
particulate matter prior to loading.  400μl samples were loaded with a syringe and the eluent 
was collected in 2ml fractions.  Samples were run at a flow rate of 0.5ml/min and a maximum 
pressure of 1.5MPa.  Before any experimental samples were run, the column was calibrated 
with the standards: β-amylase (MW 200 kDa), alcohol dehydrogenase (MW 150 kDa) bovine 
serum albumin (BSA) (dimer MW 132 kDa; monomer MW 66 kDa), ovalbumin (MW 45 kDa), 
carbonic anhydrase (MW 24 kDa) and cytochrome C (12.4 kDa).  A number of different 
experimental samples containing mixtures of different proteins and ligands were tested.  The 
various samples can be summarised as follows: 
 TDH alone; 
 TDH with ligands; 
 KBL alone; 
 KBL with ligands; 
 TDH and KBL; 
 TDH and KBL with ligands. 
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Control samples containing ligand only were also tested in case any of them interfered with the 
detection method.  The elution of protein was monitored by UV absorbance at 280nm by a UV 
M-II spectrophotometer (GE Healthcare).  Occurrence of retention peaks was recorded by a 
REC 112 chart recorder (GE Healthcare).  To calculate the void volume (V0), the minimum 
volume required to elute a protein from the column, which corresponds to the volume of fluid 
between the polymeric beads of the gel, a solution of blue dextran (MW 2000kDa) was ran.  
Blue dextran is so large that it does not flow through the pores of the gel beads, and thus elutes 
at the V0. 
 
Figure 2.1.10 - schematic illustrating the method used for estimating molecular weight by size-exclusion 
chromatography. 
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To calculate the molecular weights of proteins eluting at a particular elution volume (Ve), a plot 
of log10 molecular weight of standard protein against elution volume divided by void volume 
(Ve/V0) was made using Microsoft Excel.  A line of best fit was calculated for the points and the 
gradient of the line was used to estimate the molecular weights of proteins eluting at certain 
volumes, using the formula, y = mx + c. 
2.1.4.2 Cross-linking 
Another method of indicating the quaternary structure of proteins and for the identification of 
multi-protein complex formation is the use of cross-linking reagents.  These reagents react with 
amino acid side-chains on molecules that come into close contact with each other.  This 
maintains and stabilises the interaction, so that the sizes of complexes can be monitored by 
SDS-PAGE, which would usually disrupt the interaction.  Cross-linking studies of TDH and KBL 
were carried out using a method similar to that of  Davies and Stark(188), which employed 
dimethyl suberimidate (DMS) as the cross-linking agent.  DMS reacts with free amines on lysine 
residues to form covalent linkages.  The reactions predominate within oligomers, although non-
specific cross-linking can become apparent after long periods of time. 
 
Figure 2.1.11 - the chemical structure of dimethyl suberimidate. 
Protein concentrations and DMS concentrations were carefully chosen to avoid precipitation.  A 
number of different experiments were carried out to test: 
 The presence of a multi-enzyme complex between TDH and KBL 
 The quaternary structures of TDH and KBL  
 The effect of enzyme concentration on enzyme oligomerisation 
 The effect of temperature on oligomerisation 
 The effect of substrates on enzyme oligomerisation 
To confirm the quaternary structures of TDH and KBL, to test the effect of enzyme 
concentration and to detect the existence of a multi-enzyme complex, the following conditions 
were tested: 
 TDH (2.6 x 10
-2
mM [1mg/ml]) + DMS (7.3 mM [2mg/ml]) 
 TDH (1.3 x 10
-2
mM [0.5mg/ml]) + DMS (7.3 mM [2mg/ml]) 
 TDH (1.3 x 10
-2
mM [1mg/ml]) control 
 KBL (2.2 x 10
-2
mM [1mg/ml]) + DMS (7.3 mM [2mg/ml]) 
 KBL (1.1 x 10
-2
mM [0.5mg/ml]) + DMS (7.3 mM [2mg/ml]) 
 KBL (2.2 x 10
-2
mM [1mg/ml]) control 
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 TDH (2.6 x 10
-2
mM [1mg/ml]) + KBL (2.2 x 10
-2
mM [1mg/ml]) + DMS (14.6 mM 
[4mg/ml])  
 TDH (1.3 x 10
-2
mM [0.5mg/ml]) + KBL (1.1 x 10
-2
mM [0.5mg/ml]) + DMS (14.6 mM 
[4mg/ml])  
 Bovine Serum Albumin (1.5 x 10
-2
mM [1mg/ml]), DMS (7.3 mM [2mg/ml]) positive 
control 
All solutions were made up to 100µl in 200mM Tris.HCl buffer at pH 8.5.  Final protein 
concentrations were approximately 1mg/ml  Reactions were carried out in duplicate, at room 
temperature and at 2-8°C.  Reactions were incubated overnight and the reactions were halted 
by the addition of Laemmli buffer in preparation for analysis by SDS-PAGE.  Gels of 9% 
polyacrylamide, rather than the usual 12%, were used to increase the migration of higher 
molecular weight complexes. 
To test the effect of TDH substrates on its oligomerisation, the following conditions were tested: 
 TDH (2.6 x 10-2 mM [1mg/ml]) + DMS (7.3 mM [2mg/ml]) 
 TDH (2.6 x 10-2 mM [1mg/ml]) + 1mM NAD+ + DMS (7.3 mM [2mg/ml]) 
 TDH (2.6 x 10-2 mM [1mg/ml]) + 10mM NAD+ + DMS (7.3 mM [2mg/ml]) 
 TDH (2.6 x 10-2 mM [1mg/ml]) + 1mM NAD+ + 30mM L-threonine + DMS (7.3 mM 
[2mg/ml]) 
 TDH (2.6 x 10-2 mM [1mg/ml]) + 10mM NAD+ + 30mM L-threonine + DMS (7.3 mM 
[2mg/ml]) 
 TDH (2.6 x 10-2 mM [1mg/ml]) + 10mM NAD+ + 15mM L-threonine + DMS (7.3 mM 
[2mg/ml]) 
 10mM NAD
+
 + 30mM L-threonine + DMS (7.3 mM [2mg/ml]) control 
These experiments were carried out as above, but with a time course limited to 3 hours. 
To test the effect of KBL substrates on the oligomerisation of that enzyme, the following 
conditions were tested: 
 KBL (2.2 x 10-2 mM [1mg/ml]) + DMS (7.3 mM [2mg/ml]) 
 KBL (2.2 x 10-2 mM [1mg/ml]) + 0.5mM pyridoxal phosphate (PLP) + DMS (7.3 mM 
[2mg/ml]) 
 KBL (2.2 x 10-2 mM[1mg/ml])  + 15mM glycine + DMS (7.3 mM [2mg/ml]) 
 KBL (2.2 x 10-2 mM [1mg/ml])  + 2.5mM acetyl-coenzyme A + DMS (7.3 mM [2mg/ml]) 
 KBL (2.2 x 10-2 mM [1mg/ml])  + 0.5mM PLP + 15mM glycine + DMS (7.3 mM [2mg/ml]) 
 KBL (2.2 x 10-2 mM [1mg/ml])  + 0.5mM PLP +  2.5mM acetyl-coenzyme A + DMS (7.3 
mM [2mg/ml]) 
 KBL (2.2 x 10-2 mM [1mg/ml])  + 0.5mM PLP +  2.5mM acetyl-coenzyme A + 15mM 
glycine + DMS (7.3 mM [2mg/ml]) 
 KBL (2.2 x 10-2 mM [1mg/ml])  + 15mM glycine + 2.5mM acetyl-coenzyme A + DMS (7.3 
mM [2mg/ml]) 
 0.5mM PLP +  2.5mM acetyl-coenzyme A + 15mM glycine + DMS (7.3 mM [2mg/ml]) 
control 
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These experiments were carried out over 3 hours, as for the previous set, though reaction 
volumes were decreased to 50µl.  The volume was reduced to preserve resources because the 
reaction volume had no demonstrable effect on results, and only a small sample of the reaction 
mixture (10µl) was required for SDS-PAGE analysis. 
2.1.4.3 Pull-down Assay 
The pull-down assay is a simple method of testing for binding interactions between two or more 
proteins.  The pull down assay relies on the binding of a (usually, tagged) protein to a resin.  A 
second, untagged protein is added to the resin.  After washing the resin with a wash buffer to 
remove unbound proteins, an elution buffer is used to wash all bound proteins from the resin.  If 
the second protein is recovered with the eluted first protein, this suggests that there is a binding 
interaction between the two proteins, as it would otherwise have been removed with wash 
buffer.  The first step required was the removal of the poly-histidine tag from TDH.  The pET-15b 
vector encodes an amino acid sequence between the His-tag and the protein that is recognised 
and cleaved by thrombin.  1ml of TDH solution was incubated overnight in solution with 
approximately 5 units of thrombin, to give a ratio of 1 unit of thrombin to 1mg of protein.  This 
solution was then passed through a HisTrap® nickel column connected to a benzamidine 
column, to remove the cleaved histidine residues and the thrombin.  Cleaved TDH passed 
through the column.  For the pull-down assay, 1ml of KBL solution (13.1 X 10
-2
 mM [6mg/ml]) 
was loaded onto a nickel column.  The cleaved TDH solution was then loaded onto the column 
at a flow rate of approximately 0.5ml/min.  After incubating the column for 60 minutes, the 
column was washed with 10-20 volumes of wash buffer. Then 5 column volumes of elution 
buffer were added to elute the bound protein(s).  The success of the procedure was determined 
by SDS-PAGE.   
 
2.2 Enzymatic Studies 
2.2.1 Basic Kinetics 
An integral part of this research effort was the study of the enzymatic activity of the enzymes 
studied.  The activity may be affected by numerous factors, such as the concentration of the 
enzyme’s substrates and co-factors, and the pH of the environment.  Detailed experiments are 
necessary to gather enough information to characterise these effects in a way that is useful for 
describing the behaviour of the enzyme.  For this reason, it is equally important that a lot of 
attention to detail is applied to the design of assays. 
Some of the principal considerations are the mode of detection of enzyme activity and the type 
of assay.  For TDH assays, detection of enzyme activity is aided by the difference in 
absorbance of ultraviolet radiation (UV) at 340nm by the cofactor NAD
+
 and its reduced form 
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NADH.  Thus as the reaction proceeds, it can be monitored by the increase in absorbance at 
340nm (see Figure 2.2.1) 
 
Figure 2.2.1 - The absorbance of NAD
+ 
and NADH at 340nm.  The greater absorbance of by NADH at 340nm, 
relative to NAD
+
, can be used to measure the reaction of TDH. Image obtained from 
http://chemwiki.ucdavis.edu/Organic_Chemistry/Organic_Chemistry_With_a_Biological_Emphasis/Chapter_04%
3A_Structure_Determination_I/Section_4.3%3A_Ultraviolet_and_visible_spectroscopy.  
All enzyme assays were carried out using an UltroSpec 3000 (GE Healthcare) UV/Vis 
spectrophotometer or a FLUOstar Omega plus plate reader (BMG Labtech).  Enzyme assays 
are typically carried out by use of an end-point assay, where measurements are made at the 
beginning and end of an assay, or a kinetic assay, where measurements are made at multiple 
time-points to establish a rate of reaction.  For the studies described here, time-point assays 
were chosen for a number of reasons.  Firstly, time-point assays can be more simplistic 
because they do not require the addition of extra reagents to halt the reaction at a specific time-
point.  Secondly, time-point assays can help to reduce error – by calculating a gradient from 
measurements made over several time points, the effects of errors or artefacts (caused by 
bubbles, dirt, etc.) can be minimised.  In a kinetic assay, it is important to measure the initial 
velocity of enzyme activity, where the steady state assumption holds true(189).  At this time it is 
assumed that the reaction has reached equilibrium, but that the substrate concentration is so 
much higher than that of the enzyme and bound intermediates that the relative concentrations 
remain constant.  The increase in product concentration should be linear with time when the 
steady state assumption is true.  However, after some time, this linearity is lost as the 
substrates begin to become depleted.  Other phenomena that can cause error are present 
nearer the initiation of a reaction.  In some instances, there may be a lag before the enzyme 
reaches steady-state velocity.  Conversely, the reaction may begin with very high activity and 
then decrease to a second linear phase of lower activity.  The first phase is called the ‘burst 
phase’ and is believed to be caused by the fact that the enzyme may be bound to a substrate or 
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cofactor prior to reaction initiation, so there is a ‘burst’ in enzyme activity, as the binding of 
substrates has already occurred.  These considerations are illustrated in Figure 2.2.2. 
 
Figure 2.2.2 - an example of a progress curve during a kinetic enzyme assay.  Measurement should be delayed for 
the first few seconds, to avoid the 'burst' of activity that does not represent steady state kinetics.  Conversely, the 
earliest start of the progress curve can show a lag in activity.  Measurements should also be avoided too late in 
the assay, where the depletion of substrates means that the steady-state assumption is no longer true.  
Measurements should be made at the linear part of the curve, which represents the enzyme at the steady state.  
In a kinetic assay, it is also important that the mode of detection has a large enough signal 
window to measure differences in activity.  However, it is also important that the signal 
produced is valid and does not saturate the detector.  In spectrophotometric absorbance 
assays, light absorbance, which is a logarithm of light transmittance, is reported.  An 
absorbance measurement of 1.0 is equal to 10% of light transmittance and a measurement of 
2.0 is equal to 1% of light transmittance.  Depending on the sensitivity of the detector, it is 
desirable for the final measurement to not be significantly above an absorbance of 1.0.  The 
calculation of NADH concentration relies on the Beer-Lambert law(190): 
 
𝐴 =  𝜀𝑏𝑐 →  𝑐 =
𝐴
𝜀𝑏
 10  
using the absorbance, A, the pathlength, b (e.g. 1cm), and the extinction coefficient, ε, of 
NADH, 6220mol
-1
.  Deviations from this law can occur as the absorbance rises beyond 1.0.  
Therefore, for TDH assays carried out in the Ultrospec 3000, maximum absorbance 
measurements were aimed to be close to 1.0, whereas for assays carried out using the 
FLUOstar Omega plate reader, maximum measurements between an absorbance of 1.0 and 
2.0 were deemed appropriate.  This was achieved through choosing an appropriate enzyme 
concentration. 
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Figure 2.2.3 - an example of raw data collected during a typical kinetic assay.  Each data point is collected by an 
orange line, and the green line is the line-of-best-fit, from which the gradient is used to calculate the velocity of 
catalysis. 
 
Figure 2.2.4 - an example of raw data collected during a typical kinetic assay using the FLUOstar OMEGA plate 
reader.  The blue points represent absorbance (or optical density, OD) at 340nm, whilst the red points show 
absorbance at 320nm.  The pale green and brown points do not show an increase in absorbance as they represent 
absorbance values at 400nm and 500nm, respectively.  The rate of reaction was calculated from the linear 
gradient of the line fit to the relevant data points, as described in Figure 2.2.3 and Figure 2.2.5. 
To help determine the composition of the reaction mixture, assay design was guided by the 
TDH assays of McGilvray & Morris(191) and Boylan & Dekker(120).  The reaction buffer used 
contained 200mM Tris.HCl, adjusted to pH 8.5.  Preliminary assays of TDH activity were carried 
out to identify saturating substrate concentrations, the mechanism of action of the enzyme, and 
statistics such as the half-saturating substrate concentration, KM, and the maximal rate of 
reaction, Vmax.  Several reactions were performed over a range of fixed concentrations of one 
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substrate whilst varying the other.  The range of NAD
+
 concentrations tested was 0.1, 1, 5, 10, 
15 and 20mM.  The range of L-threonine concentrations tested was 1, 5, 10, 20, 30 and 40mM. 
100mM stock solutions of L-threonine and NAD
+
 were made by dissolving the appropriate 
masses in reaction buffer.  It was observed that NAD
+
 spontaneously degraded over prolonged 
periods of time.  Such degradation, which could have affected the results, was detected by an 
increased absorbance by the stock solution at 340nm.  This change was not considered 
appreciable within the first 24 hours, so NAD
+
 stock solutions were always made on the same 
day of the experiment or on the previous evening.  The reaction mixture was made by adding 
reaction buffer, L-threonine and NAD
+
 up to a total volume of 980μl in a 1cm path length quartz 
cuvette.  This mixture was incubated in a Grant SUB14 water bath (Grant Instruments) at 37°C 
(310K) for 5 minutes prior to initiating the reaction.  The enzyme was diluted with reaction buffer 
down to a concentration of 0.66mg/ml (17.5 µM), which was checked using the NanoDrop ND-
1000 (Nanodrop, part of Thermo Fisher Scientific, Leicestershire, UK), and it was this enzyme 
solution that was added to the reaction mixture (final concentration 0.0132mg/ml [3.5 µM]).  
Prior to initiation of the reaction, the opening of the cuvette was covered with Parafilm and the 
cuvette was inverted seven times to ensure thorough mixing.  Then, 20μl of enzyme solution 
was added to the reaction mixture, with stirring, to initiate the reaction.  The conversion of NAD
+
 
to NADH was monitored at 340nm in an Ultrospec 3000 UV/Vis spectrophotometer (GE 
Healthcare), taking measurements at 5 second intervals, beginning 10 seconds after the start of 
the reaction to allow for equilibration, up to 60 seconds.  Only measurements up to 50 seconds 
were considered in analyses as the increase in absorbance was deemed to be consistently 
linear up to this time across all tested conditions.  The catalytic rate was determined according 
to the Beer-Lambert law(190),using the gradient of a line of best fit from the measured 
absorbance, A.  Control experiments were run as above, but omitting the enzyme, L-threonine 
or NAD
+
.  The spectrophotometer was always blanked on the full mixture on the basis of the 
observation that there was some background absorbance when the enzyme was present, but 
one of the substrates was omitted.  It seemed possible that NAD
+
 co-purified with TDH so small 
amounts of activity were observed when NAD
+
 was excluded.  However, this activity was judged 
to be too small to significantly affect the results, considering the design of the assay (see 
discussion of burst phase kinetics above). 
Once saturating concentrations of NAD
+
 and L-threonine concentration were established at 
10mM and 30mM, respectively, more detailed studies were carried out at a saturating 
concentration of one substrate, whilst varying the concentration of the other substrate.  TDH 
activity was assayed at 1, 2.5, 5, 10, 12.5, 15, 20, 22.5, 25, 27.5 and 30mM L-threonine, and at 
0.1, 0.5, 1, 2, 3, 5, 7.5 and 10mM NAD
+
.  The assays were carried out as detailed above, at 
both 37°C and at room temperature (23°C). 
All preliminary assays were repeated up to a maximum of five times (on separate days) until 
three measurements of rate, v within a standard deviation of 10% were obtained.  If five values 
were obtained without this, the values that had the lowest standard deviation when averaged (at 
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least three measurements) were included in the analysis.  Kinetic constants were derived by 
use of non-linear least squares fitting to the Hill modification of the Michaelis-Menten 
equation(192–194): 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
ℎ
𝐾𝑀
ℎ + [𝑆]ℎ
 11  
where v is the rate of reaction, Vmax is the maximum rate, [S] is the substrate concentration, KM 
is the Michaelis constant (the substrate concentration that produces a half-maximal rate of 
reaction) and h is the Hill coefficient, which represents the minimum number (to the nearest 
integer) of active sites involved in cooperative interactions.  A value of h = 1 suggest there is no 
cooperativity and a value of h < 1 or h > 1 represents negative or positive cooperativity, 
respectively.  Positive cooperativity is usually manifest in sigmoidal v versus [S] curves.  A test 
for cooperativity was applied using the following equation: 
 
ℎ =  
log 81
log(
[𝑆]0.9
[𝑆]0.1
)
 12  
[S]0.9 and [S]0.1 are the substrate concentrations at 90% of the Vmax and 10% of the Vmax, 
respectively.  It is a useful indicator of non-hyperbolic increases in v with [S](194).  All analysis 
of this data was carried out using the following data analytical software: Microsoft Excel (2010), 
Origin Pro (Origin Lab, Massachusetts, USA) and Prism (version 6 for Windows, 2014, 
Graphpad Software, California, USA, www.graphpad.com). 
Figure 2.2.5 summarises the data analysis process of enzyme kinetic data, as described above.  
The raw data consists of measurements of the absorbance over different time points over the 
course of the experiment.  In Microsoft Excel, the rate of increase in absorbance was calculated 
from the gradient of a line-of-best-fit.  This value was then converted to the rate/velocity of 
catalysis by use of the Beer-Lambert law (see Equation 10).  The mean velocity values and 
standard deviations were then calculated from the results of repeat experiments in Microsoft 
Excel.  To determine kinetic parameters (e.g. KM, Vmax), the mean values and standard 
deviations were input into either Origin Pro or Prism software, which plotted the values on a 
graph.  These programs calculate the appropriate kinetic parameters by non-linear regression 
analysis by the least-squares method.  For example, the programs were used to fit curves 
described by an equation, such as Equation 12, to the plotted data.  The fit of the curve to the 
data is improved by iterative modification of the unknown parameters, until the squared 
differences between the curve and the data points are minimised.  To illustrate this further, 
consider the use of the Michaelis-Menten equation(195,196) by Prism:  
Y = Vmax*X/(Km + X) 
The value X is the substrate concentration, [S], and Y is the velocity of catalysis, v.  Both of 
these values are determined by the data, and so are fixed.  The data analytic software input the 
values of X into the equation and automatically modify the values of unknown parameters until 
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the differences between experimentally-derived Y values and calculated Y values are 
minimised.  The resultant plots consist of data points, error bars and the fitted curve.  Note that 
the error bars on the plots presented in this thesis relate to standard deviation (SD) values, so 
even when the SD relative to v is lower at higher values of v, the absolute value of SD is plotted, 
so larger error bars are often seen at higher values of v. 
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Figure 2.2.5 - scheme illustrating the derivation of kinetic parameters from data collected in enzyme kinetic 
assays.  Rates of reaction (v) calculated from raw data (top) were used to construct plots of v as a function of 
[substrate] (middle), from which non-linear curve fitting was used to calculate the parameters KM and Vmax. The 
reciprocals of v were plotted against the reciprocals of [substrate] in Lineweaver-Burk plots (bottom).  
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Recombinant TDH from the bacterium Clostridium difficile was expressed and purified by 
Professor Jon Cooper and Dr Peter Erskine at the Laboratory for Protein Crystallography.  In 
order to determine its kinetic behaviour, the enzyme was assayed in a similar manner to TDH 
from T. brucei.  At 37°C, enzyme activity was assayed at 0.1, 1, 5, 10, 15, 20, 30, 50 and 75mM 
L-threonine, and at 0.1, 0.5, 1, 3, 5, 10 15 and 20mM NAD
+
.  The assay was carried out using a 
FLUOstar Omega plate reader (BMG Labtech) and the data were analysed using the 
aforementioned software. 
2.2.2 Optimisation and Alteration 
The assay can be optimised, following the same principles as in assay design (see above).  The 
tests required for optimising assay conditions also offer an opportunity to discover more about 
the enzyme.  As the pH of the reaction buffer, the presence of ions and the concentration of the 
enzyme can all influence enzyme activity, these factors were altered to determine such effects.  
At saturating concentrations of L-threonine and NAD
+
, the rate of TDH activity was measured as 
previously described at pH 6.5, 7.5, 8.5, 9.5, 10.5, 11.5 and 12.5.  To measure the effect of 
enzyme concentration and to determine if the relationship between it and activity was linear, the 
activity of a series of two-fold dilutions of TDH was measured at saturating substrate 
concentrations. See below for a description of assays carried out to test the effect of numerous 
monovalent and divalent metal ions on TDH activity. 
As the testing of compounds for inhibitory activity against TDH would possibly involve the 
dissolution of compounds in DMSO, the effect of DMSO concentration of TDH activity was 
investigated.  DMSO concentrations of 0-20% were tested in combination with saturating 
concentrations of substrates, and the corresponding rates of reaction were compared. 
To investigate the possibility that the His-tag on TDH would affect its catalytic activity, the tag 
was removed, following the same protocol as described above (see pull-down assay).  Rates of 
reaction for His-tagged TDH and cleaved TDH were measured across ranges of [NAD
+
] and [L-
threonine]. 
2.2.3 Mode of Inhibition studies (MOI) 
To investigate the modes of inhibition of TDH, studies to characterise known inhibitors of TDH 
were carried out.  This was done with pyruvate(124,197), L-allo-threonine(119,198–201), 
methylglyoxal(202) and tetraethylthiuram disulphide (TETD or disulfiram)(138,139), all of which 
are reported in the scientific literature to inhibit a TDH enzyme.  For pyruvate, L-allo-threonine 
and methylglyoxal, stock solutions were made up in reaction buffer, and they were added to the 
reaction mixture, maintaining a final volume of 980µl, prior to reaction initiation.  Guided by 
published inhibitory concentrations, a range of inhibitor concentrations were tested against TDH 
in the presence of saturating concentrations of L-threonine and NAD
+
.  The resulting 
concentration-inhibition curve was used to inform on the inhibitor ranges to be used in further 
inhibitory assays. 
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To gain suitable data on the mode of inhibition (MOI) of a particular inhibitor, it is necessary to 
test the effect that a range of inhibitor concentrations has on the curve produced by also testing 
a range of substrate concentrations and measuring the rate of activity.  In this way, a fixed 
concentration of the inhibitor and a fixed concentration of one substrate were tested with a 
range of concentrations for one of the substrates.  The v versus [substrate] curves gained by 
repeating this over a range of inhibitor concentrations are then fit to equations describing 
different MOIs by multiple non-linear least squares regression.  The different modes of inhibition 
are described in Figure 2.2.6. 
 
Figure 2.2.6 - modes of enzyme inhibition.  A - competitive inhibition, where the inhibitor, I has affinity for the 
free enzyme, E, and competes with the substrate for binding.  B and C – noncompetitive inhibition, where the 
inhibitor has affinity for both the free enzyme and the enzyme substrate complex. (Note: such inhibitors do not 
necessarily have to bind to allosteric sites, as suggested in the diagram).  C – uncompetitive inhibition, where the 
inhibitor has more affinity for the enzyme-substrate complex.  
Prior to data analysis, the data were normalised by setting the mean maximum velocity of 
catalysis to a value of 1.0 and by calculating all other velocities as a fraction of this. Then, the 
analytical software Prism (Version 6, 2013, GraphPad Software, http://graphpad.com) was used 
for the fitting of the data to the equations describing: 
 Competitive inhibition: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
[S] + 𝐾𝑀 (1 +
[𝐼]
𝐾i
)
 13  
 Uncompetitive inhibition: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
[S] (1 +
[𝐼]
𝛼𝐾i
) + 𝐾𝑀
 14  
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 Mixed or noncompetitive inhibition: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
[S] (1 +
[𝐼]
𝛼𝐾𝑖
) + 𝐾𝑀 (1 +
[𝐼]
𝐾i
)
 15  
Ki is the inhibitory binding constant.  Here, the parameter alpha (α) can be used to calculate the 
affinity of the inhibitor for the free enzyme or enzyme substrate complex(203).  An α value of 1 
represents a situation where the inhibitor has equal affinity for the free enzyme and the enzyme 
substrate complex.  The R squared value, which is a figure between 0 and 1 describing the fit of 
the data to each equation, was used to determine the most probable MOI, as indicated by the 
data.  Assays to establish IC50 were carried out using the Ultrospec 3000 spectrophotometer.  
Because of the large number of assays required to gather enough data for MOI determination, 
those assays were carried out using the FLUOstar Omega plate reader.  Solutions of the 
relevant combinations of L-threonine, NAD
+ 
and reaction buffer were made up to a volume of 
190µl in wells on a clear, plastic, flat-bottomed 96 well plate and incubated at 37°C for least five 
minutes prior to the initiation of the reaction.  The enzyme was stored at a concentration of 0.10 
– 0.33 mg/ml (2.6-8.7 µM) in storage buffer and 10µl was injected into the solution to initiate the 
reaction.  Absorbance measurements were made at 320, 340, 400 and 550nm at five second 
intervals over a two minute period.  Measurements made between 10 and 50 seconds inclusive, 
were used to calculate the catalytic rate, as described above.  The plate reader automated this 
process for all assays set up in a plate. 
As TETD showed evidence of time-dependency, the assay had to be altered to allow pre-
incubation of the inhibitor with the enzyme, prior to the initiation of the reaction.  In these 
assays, the degree of inhibition was measured as a function of time to calculate the parameter 
kobs, which is the rate constant for time-dependent enzyme inhibition.   
 
𝑘𝑜𝑏𝑠 =
− (ln (
𝑣
𝑣0
))
𝑡
 
16  
v is the reaction velocity at time, t, and v0 is the reaction velocity at t = 0.  By measuring kobs at a 
number of inhibitor concentrations, it was possible to calculate inhibitory binding constants.  
MOI studies were carried out by determining kobs at a fixed concentration of TETD, but at a 
range of L-threonine and NAD
+
 concentrations.  The data were then fit to equations describing: 
 Competitive inhibition: 
 
𝑘𝑜𝑏𝑠 =  
𝑘
1 +
[𝑆]
𝐾𝑀
 17  
 Uncompetitive inhibition: 
 
𝑘𝑜𝑏𝑠 =  
𝑘
1 +
𝐾𝑀
[𝑆]
 18  
 Noncompetitive inhibition (α = 1):  
 𝑘𝑜𝑏𝑠 = 𝑘 19  
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In these equations, k is treated as an empirical value for curve fitting purposes(194).  As before, 
the most probable MOI was determined by observing the R squared value.  These assays were 
carried out in the plate reader in a similar manner to the other MOI assays.  However, TETD, 
which was dissolved in DMSO, was added to the enzyme solution in the appropriate 
concentration.  Every well on a particular plate contained fixed concentrations of substrates.  
The reaction was initiated as above with the addition of 10µl of enzyme solution (pre-incubated 
with TETD).  A control well, where the reaction was initiated with enzyme solution pre-incubated 
with an equivalent volume of DMSO was measured directly after each experimental well, so that 
the fractional activity or percentage inhibition could be determined by comparing the activity 
between each pair of wells.  The data were fit to the relevant equations using Prism.  The 
equations for time-dependent inhibition were built as custom equations, as they were not pre-
installed.  In the case that any of the data from MOI studies showed evidence of cooperativity of 
the inhibitor, modifications to the equations were made by applying a Hill coefficient to [I]. 
For some enzymes, high concentrations of substrate can also inhibit the enzyme, either by 
effects of the substrate itself, or by effects of the product.  To investigate substrate inhibition, 
another equation within the Prism software was used to model the phenomenon: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑀 + [𝑆] (1 +
[𝑆]
𝐾i
)
 20  
The equation is able to determine both the KM of enzyme activity and the Ki of enzyme 
inhibition.  
2.2.4 Further studies of enzyme activity 
The effect of naturally-occurring amino acids on TDH activity was investigated to explore the 
possibility that TDH is not fully selective for L-threonine and to see if any other amino acids 
inhibited TDH.  The following amino acids were tested in duplicate assays at 60mM 
concentrations in the presence of saturating concentrations of L-threonine and NAD
+
: L-alanine, 
L-cysteine, L-aspartic acid, L-glutamic acid, L-phenylalanine, glycine, L-histidine, L-isoleucine, 
L-lysine, L-leucine, L-methionine, L-asparagine, L-proline, L-glutamine, L-arginine, L-serine and 
L-tryptophan.  It was not possible to test L-tyrosine in this assay, due to its low solubility. These 
assays were carried out according to the protocol used for the MOI assays described above.  A 
second set of assays were carried out in the same way, but L-threonine was excluded to 
investigate the possibility that TDH can catabolise other amino acids. 
The effect of different monovalent and divalent cations on TDH activity was investigated using 
assays carried out at saturating substrate concentrations.  The following compounds were 
tested at 1mM by incubating with TDH in storage buffer overnight: Na2SO4, Zn(C2H3O2)2, 
ZnSO4, CoCl2, MnCl2, CdCl2, CuCl2, FeSO4, FeCl3, CaCl2.  They were then tested by comparing 
with the activity produced by a DMSO control.  Four assays were carried out for each condition 
and mean values of the relative activity were calculated.  Using the same assay, the following 
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compounds were tested in duplicate at 0.25mM, 0.5mM, 1mM, 2mM, 5mM and 10mM for their 
effect on TDH activity: KCl, RbCl, CsCl and NH4Cl.   
Following some interesting observations, more assays were carried out to determine the effect 
of reaction constituents on the rate of activity and the stability of TDH over time.  In these 
assays, TDH was pre-incubated in reaction buffer, with and without DMSO, for different lengths 
of time, prior to initiating the reaction with the addition of substrates.  The concentration of 
glycerol and the addition of salts, NaCl, KCl and RbCl, were investigated in this respect.  Then 
further assays were carried out to measure the effect of KCl and RbCl in the reaction buffer on 
the relationship between [L-threonine] or [NAD
+
] and rate. 
The following compounds were tested for time-dependent inhibition, using the same protocol as 
for the measurement of time-dependent inhibition of TETD: 1mM AgNO3, 1mM ZnSO4 and 1mM 
HgCl2.  The following compounds were also tested for inhibition of TDH, either by incubation 
overnight or using a time-dependent assay as described above: N-ethylmaleimide (0.5mM, 
time-dependent assay), iodoacetamide (5mM, time-dependent assay) and EDTA (5mM 
overnight). 
2.3 Virtual Screening 
The process of identifying of new active compounds during screening can be divided into three 
steps.  The first step, hit generation involves the identification of active molecules in a primary 
screening assay.  Secondly, hit confirmation is carried out in a secondary assay to confirm that 
the active compounds (hits) generated are indeed active.  Finally, hit validation is performed to 
verify the identity of the compound exhibiting activity, and to confirm that the activity is specific 
and not due to other factors, such as interference with the assay signal. 
Virtual screening formed a part of the hit generation strategy for the overall screening process 
presented in this thesis.  However, to effectively make use of virtual screening, it was necessary 
to carry out the three steps of hit generation, hit confirmation and hit validation. 
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Figure 2.3.1 - the identification of active molecules, 'hits', in drug discovery. The process illustrated applies to 
both virtual and in vitro screening. 
2.3.1 Docking Software and AutoDock 4 
Virtual screening is a powerful tool in drug discovery that is made readily-accessible by the wide 
availability of docking simulation software to academic and private-sector researchers.  Docking 
programs predict the strengths of interactions between different molecules, commonly between 
small molecules and proteins. 
AutoDock is the most cited of all the available docking simulation software packages(29).  
AutoDock uses information on atom-types, partial charges and the electrostatic potential of 
different atoms to predict the interaction between ligands and macromolecules (called the 
‘receptor’ in AutoDock).  It makes use of file formats called PDBQT (.pdbqt) files for both ligands 
and receptors that are similar to the .pdb files that are familiar to protein crystallographers, 
except they include additional information on AutoDock4 atom types, partial charges (Q) and 
rotatable bonds (T).  It simulates docking by the construction of a grid, which maps the possible 
interactions between all the different atom types on a ‘receptor’ molecule and atom types on a 
ligand molecule.  These grid maps are then used to calculate binding energies between a ligand 
and the atom types within the grid.  The program AutoGrid performs the calculation of grid maps 
and AutoDock performs the docking predictions.  They can be run entirely from the command 
line, but the GUI program AutoDockTools (ADT) was used to prepare the receptor and search 
grid, and to visualise some docking results.   
AutoDock can predict binding interactions by different methods: use of a genetic algorithm, by 
simulated annealing and by a local search.  The most effective method available in AutoDock 4 
is the combined genetic algorithm-local search (GA-LS) method, termed the “Lamarckian” 
genetic algorithm.  The GA-LS is based on the Lamarckian theory of evolution, which proposed 
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that phenotypic characteristics developed during an organism’s lifetime were passed on to their 
offspring(204).  AutoDock generates a population of ligand conformers, which undergo 
crossover and mutation of “genotypic” conformational characteristics before a local 
conformational search for energy minima is performed.  The “fittest offspring” – those 
conformers with the lowest internal energy – become parent conformers for future generations, 
which undergo a repeat of this cycle for a user-specified number of times.  Eventually one 
conformer with the lowest energy remains at the end of a docking run.  This conformer is then 
tested for the strength of interaction with the receptor which is calculated by combining the 
intramolecular energy of the ligand and the intermolecular energy of the ligand-receptor 
complex.  These calculations include terms that relate to the changes in Van der Waals forces, 
hydrogen bonds, electrostatics and desolvation that occur on binding(24,205).   AutoDock 
version 4.2 was used in this investigation.  The recommendations in the AutoDock 4 
tutorial(206) were used to guide the design of this experiment. 
 
Figure 2.3.2 - schematic of virtual screening using AutoDock.  Stick and ball figures represent conformations  of 
ligands.  More than 3000 compounds were screened in the virtual screening campaign.  The best conformations 
of those ligands were selected by the Lamarckian Genetic Algorithm and the interactions between these 
conformers and the target were simulated.  
2.3.2 Screen Preparation 
The importance of taking into consideration receptor or protein conformational flexibility in the 
design of virtual screening experiments is now widely recognised.  As TDH binds a cofactor, 
and was found to exhibit conformational flexibility, four virtual screens were planned using a 
different receptor each: 
 Virtual Screen 1 – NAD
+
-bound TDH in conformation A 
 Virtual Screen 2 – NAD
+
-bound TDH in conformation  B 
 Virtual Screen 3 – Unbound TDH in conformation A 
 Virtual Screen 4 – Unbound TDH in conformation B 
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Structures were taken from PDB files of TDH structures solved in this study.  If a PDB file 
contained several TDH monomers, one would be chosen on the basis of it having the best fit to 
the 2Fo-Fc electron density map.  For Virtual Screen 1, 2 and 3, the receptor file was cut from 
the text in PDB files.  For Virtual Screen 4, the same data as Virtual Screen 2 was used, but the 
NAD
+
 molecule was removed from the file. 
 
Figure 2.3.3 - wire representations of the four TDH models used as receptors for virtual screening with AutoDock. 
Blue structures represent TDH in its 'open' conformation and yellow representations show TDH in its 'closed' 
representation.  
 
Ligands and macromolecules can be converted to the necessary PDBQT files using the GUI, 
ADT.  First, hydrogen atoms are added wherever appropriate.  Then partial charges (Gasteiger 
charges) are computed for each item.  Then, non-polar hydrogens are merged (removed), as 
they are assumed not to affect charges, leaving just polar hydrogen atoms.  For receptor 
molecules, AutoDock4, is able to define amino acid side chains as flexible(24).  For this, a 
second PDBQT file needs to be written and this will contain information on the torsions, which 
are the rotatable bonds, of the side chain atoms. 
As stated earlier, AutoDock is able to predict intermolecular binding energies by calculating a 
map that carries information on all the atom types and charges in a specified area.  These maps 
are calculated across a grid that defines the search area for intermolecular interactions.  A 
cubed search grid of 60 points at 0.375Å spacing along each axis was set.  The C4 atom of the 
nicotinamide ring of NAD
+
, was chosen as the centre of the grid as this is believed to be the site 
of the TDH reaction(124).  When NAD
+
 was not present in the model, the oxygen atom of the 
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hydroxyl group of the nearby tyrosine residue (Tyr144, see section 3.1) was used to centre the 
grid.  Atom types were set ‘directly’ by entering a list of all atom types found in the compound 
libraries.  The program AutoGrid was run using these parameters to determine the map types to 
be used in docking. 
 
Figure 2.3.4 - the assignment of the search grid (search area) in ADT.  The yellow cross shows the centre of the 
grid, which is the C4 atom of the nicotinamide ring of NAD
+
.  
Once it was decided which TDH conformers would serve as receptors, it was important to 
ensure that each TDH model to be used was likely to give accurate docking predictions.  Based 
on the study of a similar TDH enzyme(124), the residues present in the active site in a T. brucei 
TDH model, and the result of a docking simulation with L-threonine, five active site residues 
were identified as being important in binding: Ser82, Thr119, Met81, Tyr144 and Thr186.  A 
number of docking simulations were carried out using default GA-LS parameters with different 
combinations of flexible residues and a completely rigid TDH model (designated for ‘Virtual 
Screen 1’; see above), using L-threonine, glycerol or pyruvate as a ligand.  The validity of the 
‘receptor’ model was judged based on the plausibility of the binding position for L-threonine, the 
predicted binding energies and the clustering of binding poses.  A completely rigid molecule 
was chosen for all screens due to the more plausible binding energies predicted for all ligands 
(see results section for more detail on this).   
A second series of experiments aimed to determine the most time-efficient parameters to run 
AutoDock with.  The AutoDock developers recommend that at least 50 docking runs are 
performed per ligand(207) so this value and 100 and 150 docking runs were compared.  The 
majority of the ligands in the compound library had less than six rotatable bonds, and it is 
recommended that a limit of between 250000 and 25 million energy evaluations is set for 
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ligands with 1-10 rotatable bonds, so 250000, 500000, 1.25million, 2.5million and 25million 
were tested.  Finally, initial genetic algorithm populations of 100, 200 and 300 were tested.  50 
docking runs and 1.25million energy evaluations were chosen as higher numbers had an 
insignificant effect on docking results but a detrimental effect on the simulation time.  A genetic 
algorithm population of 300 was chosen based on the assertion of Hetényi et al.(208) that a 
population of 300 produces better results and the fact that it does not increase simulation time 
significantly.  Other parameters were left as default settings. 
2.3.3 Compound Libraries 
In deciding which compounds to screen against TDH, several strategies were considered to 
increase the likelihood of identifying active compounds or ‘hits’.  Principally, these strategies 
aimed to increase the ‘diversity’ of the library by sampling a larger area of chemical space, to 
identify potential hits by exploiting knowledge of the structure of TDH and its ligands, and to 
increase the probability of finding hits by enriching the library with molecules that are known to 
have some bioactivity, such as natural products or known trypanocidal drugs.  With this in mind, 
the library used in the virtual screening can be classified as follows: 
 Diversity (NCI Diversity Set II) – A library of compounds that is designed for chemical 
diversity contains a large range of different chemical structures. 
 Ligand analogues – A library built from compounds that shared some structural 
similarity with known TDH ligands, glycerol, pyruvate and L-threonine. 
 Natural – A library of products from natural sources, where either the natural source 
(e.g. a medicinal plant) or the compound itself had published evidence of bioactivity. 
This library was also constructed to produce diversity in the library. 
 Knowledge – A library of compounds that were identified based on knowledge of their: 
trypanocidal activity, structural similarity to a trypanocidal compound, published activity 
against TDH from another species, or role as a ligand of enzymes sharing similar 3D 
structures with TDH. 
These libraries and how they were constructed will be discussed in more detail, below. 
NCI Diversity Set II 
The Diversity Set II of the US National Cancer Institute (NCI) is a library of compounds designed 
to represent the entire chemical diversity of the compounds held by the institute(209).  
Compounds were selected to represent a diverse range of different pharmacophores (the 
combination of molecular features that are responsible for a ligand’s action)(209).  ZINC is a 
free online database that currently holds more than 14 million purchasable compounds in a 
variety of chemical structure file formats(210).  The NCI diversity set II deposited in this 
database, classified as ‘usual’, which contains structures for all the tautomeric forms of the 
compounds across a pH of 5 to 9, was downloaded as .mol2 files.  There were 2044 files in 
total. 
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Ligand analogues 
It was thought that structures similar to known TDH ligands would be more likely to produce hits 
in a virtual screen.  A search for analogues of or similar molecules to L-threonine, glycerol and 
pyruvate was conducted in the ZINC database as follows:  an 80% similarity search based on 
the ligand, limiting results to those with less than 10 rotatable bonds (this was done based on 
published information citing decreased accuracy of AutoDock predictions with molecules 
possessing more than 10 rotatable bonds(24)).  The top 250 results from each search were 
downloaded as .mol2 files regardless of whether they were purchasable or not.  This was done 
because the primary concern at this stage was to identify hits and possibly some structure-
activity relationships (SARs); it has been suggested that a series within a compound library 
should contain at least 200 members in order to deduce SARs(211).  750 unique structures 
were selected, totalling 796 structures once different tautomers were included. 
Natural Products 
Natural products have served as sources of new drugs or inspiration for new drugs for a long 
time(212–214).  Although natural products are often said to lack “drug-like” properties, they 
represent an area of chemical space that isn’t as well represented by synthetic drugs(215–218) 
so they can be useful in identifying pharmacophores that otherwise would not be tested.  With 
this in mind, a library of 426 natural products was built by searching for natural products with 
potential or reported trypanocidal activity.  Using the Ovid SP server, a search was conducted in 
Embase using a combination of the Emtree terms “herb” OR “medicinal plant” with 
“Trypanosomiasis” executed with an AND operator.  This search was later expanded to include 
non-plant sources by searching for the keywords “natural product” AND “trypano*”.  Then, 
compound names were taken directly from literature reports describing activity for the 
compound or its biological source, or from literature describing the constituents of plants 
reported to have activity against trypanosomes.  One journal paper was found which had 
applied this approach for anti-trypanosomal drug discovery(219).  In that work, Ogungbe and 
Setzer screened compounds with reported trypanocidal activity against a number of promising 
drug targets and were able to discover a significant number of hits.  The structures of the 
natural products were obtained as Simplified Molecular Input Line-Entry System (SMILES) 
string (220–223) representations, which were obtained from the PubChem(224,225) database 
or by drawing the published structures in the Molinspiration(226) program (which can convert 
drawn structures to SMILES) embedded in the ZINC website.  A total of 426 unique molecules 
were obtained in this library.  It was noted that several of the natural products contained 
saturated rings.  AutoDock has previously been limited by the inability to perform energy 
minimisations on flexible ring structures(205).  Although AutoDock 4 has found a way around 
this with the introduction of ‘glue’ atoms, the incorporation of these atom types would be too 
laborious a task for hundreds of molecules.  Openbabel, an open-source chemistry program 
that can generate, filter, convert and analyse chemical structure files(227,228), was used to 
select molecules with flexible rings.  Then the program Balloon, which generates multiple 
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conformers of any structure by use of modifications directed by a genetic algorithm(229), was 
used to generate multiple conformers of these structures – a common strategy used for the 
virtual screening of ring-containing compounds(230). 
Knowledge 
Despite being the smallest of the four libraries classified here, this library includes a 
combination of several hit identification strategies.  The first strategy was to build a small 
collection of compounds with documented trypanocidal activity.  Many of the trypanocidal drugs 
used historically were developed empirically and therefore, have an unknown or poorly 
characterised mechanism of action(231).  Where a mechanism of action is known, there is still 
the possibility that the drug may act on multiple intracellular targets(37,84).  Therefore, a small 
collection of 21 compounds historically or currently used to treat trypanosomiasis was 
constructed.  Many of the molecules were identified through Steverding’s informative historical 
review of treatments for HAT(231).  Twenty-one compounds were downloaded as SMILES 
strings obtained in the same manner as the natural products library. 
A small selection of compounds, obtained from Dr Stephen Hilton at UCL School of Pharmacy 
(SoP), were found to inhibit TDH enzyme activity by a summer research student working in this 
lab.  As these compounds had structures analogous to TETD, they were included in the virtual 
screen.  PDB files of these compounds were generated using the ProDRG online server(180). 
In 2011, it was reported by Alexander et al. that a series of quinazolinecarboxamide (Qc) 
compounds were able to potently inhibit TDH from mouse embryonic stem cells(136).  Using the 
reported structures, PDB files were prepared in the same way as for the SoP compounds. 
PSSC 
The technique of Protein Structure Similarity Clustering (PSSC) was originally created by Koch 
and colleagues to identify scaffolds for the development of compound libraries for high-
throughput screening.  It stemmed from the observation that, despite the high degree of 
diversity in the primary structures (amino acid sequences) of proteins in nature, many proteins 
converge on a smaller set of tertiary structures than one would expect from this diversity.  Thus, 
proteins with low amino acid sequence similarity can share a high degree of 3D structure 
similarity(232).  Following this principle, a search for proteins with similar 3D structures to TDH 
was carried out.  A collection of compounds made from ligands of those proteins was then 
constructed.  The original PSSC approach searched for proteins with up to 20% amino acid 
sequence similarity with the target, and that had a root-mean-square deviation (RMSD) of less 
than 4-5Å when the catalytic cores of both protein structures were superimposed.  Results were 
also checked visually for structural similarity.  In a similar manner, proteins sharing similar 3D 
structures with TDH were sought using the same parameters, but with some additional 
parameters to focus the results.  Searches were carried out in two rounds: first using the 
catalytic domain of TDH, and second using an entire TDH monomer.  A search using the 
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catalytic domain was conducted initially to exclude the large number of results that would be 
found within the protein’s superfamily.  The second round, using the full structure of a TDH 
monomer was subsequently carried out to find any proteins that may have been unnecessarily 
excluded by following the first strategy. The search was executed on the PDBeFold(233,234) 
search engine, searching the Structural Classification of Proteins (SCOP)(235) and the entire 
PDB databases(236,237).  The PDBeFold search engine outputs a number of parameters 
describing the match between the query protein and a query result.  These included the 
percentage sequence similarity, the RMSD of superimposed alpha carbons (Cα) and the Q-
score, which gives a measure of structural similarity, whilst taking into account the number of 
aligned amino acid residues.  The P-score represents the probability that a better alignment 
could have been found by chance, and hence represents the validity of any match.  Therefore, 
all results with a P-score lower than 3 were rejected.  Once a protein meeting the criteria for 
PSSC had been identified, the model was downloaded and superimposed on the query TDH 
monomer using the ‘Matchmaker’ tool in UCSF Chimera(182).  The ‘matchalign’ tool was then 
used to calculate and confirm RMSD values.  Finally, the aligned proteins were checked 
visually, particularly in the active site region.  For proteins found in the second round of the 
PSSC search, the proteins were matched and aligned with the catalytic domain of TDH, and 
RMSD values were calculated for those matched regions, alone. 
Ligands and inhibitors of all proteins found by PSSC were found primarily through the online 
enzyme information database, BRENDA (BRaunschweig ENzyme Database)(238), as all the 
proteins identified were enzymes.  Additional inhibitors were found by searching the enzyme 
name and the word “inhibitor” on the search engine Google(239).  Further information was also 
found from the Binding database(240).  Structures of the reported ligands were sought from the 
PubChem(224) and ChEMBL databases, and compounds were downloaded as SMILES strings, 
where available.  Where SMILES strings were not readily available, published structures were 
re-drawn in the chemical drawing software Marvin Sketch (version 6.0.2, 2013, ChemAxon, 
(http://www.chemaxon.com)) and converted to SMILES. 
 
All SMILES were converted to .pdb or .mol2 file formats by Open babel, using the “-gen3d” 
option to generate stereospecific 3D coordinates in the case of SMILES.  Open babel was also 
used to split multi-molecule files.  As AutoDock 4 does not include parameters for arsenic 
atoms, they were replaced with phosphorus atoms in melarsoprol, melarsen and melarsen 
oxide.  This strategy has been used previously to mimic arsenic(241).  All .pdb and .mol2 files 
were converted to the appropriate format for AutoDock, PDBQT, by use of the 
‘prepare_ligand4.py’ script supplied by the Scripps laboratory.  To examine the atom types 
represented by the entire compound library, the ‘examine_ligand_dict.py’ script was invoked, 
outputting a file containing all atom types. 
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2.3.4 Screen Execution and Analysis 
To carry out the screening of such a large library of compounds, each individual ligand was 
organised into a folder that was linked to a common folder containing the ‘receptor files’ (grid 
maps, PDBQT files).  A Docking Parameter File (.dpf), which contained the settings for each 
screen was generated and contained in the folder for each ligand.  The screen was then 
executed by use of a c-shell script that executed each screen sequentially, according to the 
parameters set in the .dpf file.  Alternatively, the screen was executed across a cluster of four 
computers, managed by the Sun Grid Engine, with four screening experiments running 
simultaneously. 
A script provided with the AutoDock4 tutorial was modified to automate the summary and 
ranking of the results of virtual screening.  The results of all 50 docking experiments for each 
ligand were clustered into groups of results that varied by < 2.0 Å RMSD in their atomic 
coordinates.  The cluster of the largest size, with the best docking score (binding energy) was 
used to report the result for that ligand.  Comparing these binding energies, all ligands with a 
binding energy of -9.50 kcal.mol
-1
 or lower was considered a ‘hit’.  This threshold was chosen as 
it was thought that this would select a subset of molecules that scored highly and were therefore 
more likely to be in vitro hits of TDH.  Compounds for in vitro testing were validated visually by 
checking for steric clashes, unnatural conformations and appropriate binding modes using ADT 
and PyRx.  The sizes of the clusters and the variation between different docking results were 
also used to verify the consistency of docking predictions.  Where multiple conformations of a 
ligand had been represented by separate files, only the highest scoring of all the related files 
was counted.  
 
 
9
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Figure 2.3.5 - Schematic summarising the different strategies employed in the virtual screening campaign against TDH.  Ligand properties were taken into account when building 
compound libraries and different TDH models were used for screening to represent the variation in the target’s different conformational and bound states.
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2.4 In vitro Screening 
2.4.1 Libraries 
The in vitro screening experiments provided another opportunity to approach hit identification 
with several different strategies, as with the virtual screening experiments. 
Fragment-based drug design aims to identify molecules (fragments), which are typically smaller 
than drug molecules, and have low or moderate affinity for the drug target.  Once information on 
their binding sites are obtained, by X-ray crystallography, for example, fragments binding to 
different sites can be linked to form a single molecule that can have much higher potency than 
the original fragments(19).  To apply this approach to the discovery of TDH inhibitors, two 
fragment libraries were screened as part of the in vitro screening efforts.  A library of 500 
fragments was obtained from Maybridge and a library of 358 was obtained from the 3D 
Fragment Consortium.  The Maybridge fragment library is designed for diversity and has been 
designed for ease of synthesis, later in the drug design process(242).  The library designed by 
the 3D Fragment Consortium was designed to include fragments with more three-dimensional 
geometries than are typically contained in most commercial fragment libraries(243). 
Virtual screening has been shown to be a cost effective way of identifying in vitro inhibitors of 
drug targets.  Thus, a selection of the compounds identified by AutoDock as potent TDH 
inhibitors was compiled for screening in the virtual screening experiment.  Several of these 
compounds were obtained free of charge from the Developmental Therapeutics Program (DTP) 
of the NCI and US National Institutes of Health (NIH).  Others were obtained from commercial 
vendors.  This set of compounds will be referred to as the ‘custom library’. 
A more traditional approach to hit identification is to screen small molecules with “lead-like” 
qualities, in the hope that one can discover potent inhibitors.  Identification of such a molecule 
can potentially save time downstream in the drug discovery process, by reducing the amount of 
optimisation associated with molecules that lack lead-like or drug-like qualities.  The Asinex 
chemical libraries are designed to possess chemical diversity and include compounds with 
favourable properties related to absorption, distribution, metabolism, excretion and toxicity(244).  
Compounds from the Asinex library were selected in collaboration with UCL ChemiBank.  UCL 
ChemiBank screened their library of 20,000 Asinex compounds against two TDH structures in a 
virtual screen using the docking software GOLD.  The top 751 results were provided for 
screening against TDH.  A further 249 molecules from the Asinex library were provided by: 
 A similarity search for molecules sharing 0.85 structural similarity with hits from the 
AutoDock virtual screen; 
 A substructure search for compounds matching the structures of hits identified by 
screening of the Maybridge(242) and 3D Fragment Consortium(243) libraries. 
These searches were carried out using the chemical database manager Instant JChem (Version 
6.1, 2013, Chemaxon(http://www.chemaxon.com)). 
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2.4.2 Screening Assay & Format 
The screening of a large quantity of different molecules required a change in the enzyme 
assays described above.  To increase the chances of identifying inhibitors with competitive, 
noncompetitive and uncompetitive MOIs, screening was conducted at substrate concentrations 
that were close to their KM values or half-saturating concentrations.  In this way, competitive 
inhibitors would not be excluded by testing high substrate concentrations and uncompetitive 
inhibitors would not be excluded by testing inhibitors at substrate concentrations that were too 
low.  The NAD
+
 concentration used was 1.2mM, whilst the L-threonine concentration used was 
6mM.  A further alteration of the assay was required to be able to detect time-dependent 
inhibitors.  Therefore, the enzyme was pre-incubated with the test compounds and reaction 
buffer for 30 minutes before initiating the reaction with the addition of a mixture of L-threonine 
and NAD
+
.  Assays were prepared in 96- or 384-well plates (Greiner), using a 96-head fluid 
handler (FluidX).  After incubation in the plate reader at 37°C or 25°C
 
for at least 5 minutes, the 
reaction was initiated and measured automatically using a POLARstar Omega plate reader 
(BMG Labtech), as described above for the MOI studies.  To reduce the overall time taken to 
read a single plate of assays, the reaction time was shortened:  measurements were taken at 
two-second intervals and the rate of reaction was calculated from the gradient of the line of best 
fit between measurements taken from 10 to 22 seconds inclusive. 
Once the general format had been chosen, the assay was validated using known TDH 
inhibitors.  As there are resource constraints in screening experiments, it is useful to reduce the 
need for repeat experiments.  Validation of a screening assay can increase the confidence that 
the hits identified will not be false positives and that false negatives will be minimised.  The plate 
uniformity test (PUT) developed by researchers at the NIH and Eli Lilly and Company is a test 
that provides useful information on the accuracy of an assay and its ability to correctly identify 
hits(203).  The layout of a PUT is shown in Figure 2.4.1.  
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Figure 2.4.1 - The layout for PUT in 384-well plates.  H = 'High' signal; TDH was incubated alone with DMSO as a 
control. M = 'Mid' signal; TDH was incubated with disulfiram or L-allo-threonine to produce a signal around 50% 
of the maximum.  Assays in the High and Mid conditions were initiated by addition of substrate.  L = 'Low' signal; 
as for the ‘High’ well, but the reaction was initiated with buffer and not substrate to reflect the expected signal 
where there is zero activity.  
PUT assays were carried out using 40µM TETD or 7mM L-threonine in the ‘Mid’ conditions.  
Substrate was replaced with reaction buffer for the initiation of the assay in the ‘Low’ condition.  
TETD was replaced with DMSO and L-allo-threonine was replaced with reaction buffer in the 
‘High’ condition. 
Informed by the results of the PUT assay, the final conditions for the screening assay were 
established as follows: 
 The reaction buffer was changed to include 1mM KCl, in addition to 200mM Tris.HCl at 
pH 8.5.  The presence of KCl in the buffer conferred greater stability of TDH over the 
time course of measurement of one plate of reactions.  This became the ordinary 
reaction buffer for use in future TDH assays. 
 The storage buffer for TDH was also changed to include 100mM KCl, in place of 
100mM NaCl.  
 Reactions were prepared in 96 or 384-well plate format, with a final volume of 100µl. 
 10µl of 7.9 µM (0.3mg/ml) TDH was pre-incubated at room temperature for at least 25 
minutes with the test compound and reaction buffer, making a volume of 82µl. The 
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reaction mixture was mixed by five cycles of aspiration and dispensing with the FluidX 
liquid handler before pre-incubation. 
 After pre-incubation, the plate was further incubated for five minutes at 25°C in the plate 
reader. 
 Reactions were initiated by addition of 18µl substrate solution and measured at two-
minute intervals over 22 seconds automatically by the plate reader as described 
previously. 
All test compounds were stored in stock solutions of 10mM in DMSO, except for one compound, 
2-{[3-(4-bromophenyl)-3-oxopropyl]amino}-3-hydroxybutanoic acid (BPOB), which required 
dissolution with DMSO and 1% v/v 880-ammonia.  Fragments were tested for inhibition in 
duplicate, at 500µM.  Compounds in the custom library were tested once at 500µM and once at 
100µM.  All Asinex compounds were tested in duplicate at 100µM.  Each row in each plate 
contained a control well that contained DMSO in place of a test compound. 
Hits were identified using the following criteria: 
 Fragments – exhibiting > 50% inhibition (relative to control) at 500µM in two separate 
assays. 
 Custom Library – exhibiting > 50% inhibition at 500µM and significant inhibition at 
100µM. 
 Asinex – exhibiting > 50% inhibition at 100µM in two separate assays. 
For hit confirmation of all the observed hits, two-, three- or four-fold dilutions were prepared by 
mixing with DMSO using the FluidX liquid handler.  Compounds were then tested for 
concentration-dependent inhibition of TDH.  Compounds that failed to show this effect, or whose 
activity disappeared below the original test concentration, were rejected. 
Hit validation aims to establish that all hits exhibited a specific MOI and that their inhibition is not 
due to interference with the assay or non-specific denaturation of the enzyme.  One way in 
which compounds may appear as hits in a high-throughput assay is by self-aggregation to form 
colloids, which inhibit enzyme activity in a non-specific way.  This mode of inhibition has been 
well described by Feng, Shoichet and colleagues, who developed an assay that added 
detergent to the reaction buffer to prevent colloid formation, thereby abolishing the activity of 
“promiscuous” non-specific inhibitors(245,246).  Similarly, a reaction buffer that contained the 
detergent Triton X-100 at a concentration of 0.01% v/v was prepared for these assays.  L-
threonine and NAD
+
 stock solutions were then prepared with this reaction buffer.  Fragments 
were tested in the primary assay conditions at their IC50 against a DMSO control in duplicate: 
once in the ordinary reaction buffer, and again in the reaction buffer with detergent.  
Compounds from the custom library were tested in a similar manner, at concentrations that had 
showed inhibition during hit confirmation assays.  For the Asinex compounds, the hit 
confirmation assay was repeated in the ordinary reaction buffer and in the reaction buffer 
containing detergent.  If the percentage inhibition differed markedly between the detergent and 
ordinary conditions, then this was a suggestion that a compound was a non-selective or 
promiscuous inhibitor. 
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Where time and resources permitted, several of the confirmed hits were procured for further 
characterisation.  Another part of the hit validation effort is to determine a specific mechanism of 
action, so MOI studies were also carried out on some small molecule inhibitors.  The principal 
usefulness of fragments is in uncovering their binding sites, so detailed MOI studies were not 
conducted on them. 
Once greater quantities of the compounds were available, the IC50s of the available hits were 
determined again.  For fragments, they were determined at a range of concentrations between 
10 and 500µM, depending on the prior potency data.  Each experimental well was matched with 
a control well, containing an equivalent volume of DMSO.  The assay was otherwise carried out 
using the same conditions as in the screening assay.  IC50s for small molecules were 
determined at saturating concentrations of substrates, as their generally higher potency meant 
that less material was acquired for each assay.  Several of the small molecules showed 
evidence of time-dependent inhibition, so fixed concentrations of the relevant inhibitors were 
incubated for increasing amounts of time, before the reaction was initiated and measured using 
a FLUOstar Omega plate reader.  The incubation time required for these inhibitors informed the 
judgement that a pre-incubation time of 2 hours would be sufficient to ensure that all time-
dependent inhibitors would exhibit their full effect in any assay. 
Due to the limited supply of some of the small molecules, the MOI assays described above 
were modified slightly. A mixture of 10µl 7.9  µM (0.3mg/ml) TDH, reaction buffer (containing 
1mM KCl) and a range of concentrations of one of the substrates was made in each well.  The 
L-threonine concentrations tested were 1mM, 5mM, 10mM, 12.5mM, 15mM 20mM 22.5mM, 
25mM and 30mM.  The NAD
+
 concentrations tested were 0.1mM, 0.5mM, 1mM, 2mM, 3mM, 
5mM, 7.5mM and 10mM.  All conditions were compared with a control experiment, containing 
an equivalent volume of DMSO. The reaction was mixed by five cycles of aspiration and 
dispensing using a micro-pipette.  The reaction was then initiated by addition of 10µl of 100mM 
NAD
+
, or 30µl of 100mM L-threonine solution.  The reaction was monitored over 22 seconds, as 
in the screening assays.  To preserve the available compounds, only four inhibitor 
concentrations were used.  The data were fit to MOI equations as described earlier, using Prism 
(Version 6, 2014, GraphPad Software, http://www.graphpad.com).  MOI studies of time-
dependent inhibitors were carried out using the same format, rather than by establishing kobs.  
For those compounds, they were incubated for 1.5 hours at 2-8°C to prevent loss of activity, and 
then at room temperature for 30 minutes, prior to starting the assay.  The data for time-
dependent inhibitors were analysed in the same way as for non-time-dependent inhibitors. 
2.4.3 Analysis 
Two-dimensional chemical/molecular fingerprints are some of the most popular molecular 
descriptors used in computational chemistry(247–249).  Chemical fingerprints are 
representations of a molecule by use of a bit-string and can be constructed in a variety of ways.  
The most common form of chemical fingerprint is a path-based fingerprint, where the presence 
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of atom and bond types along a linear path is denoted by a particular number.  The program 
generatemd in the JChem package(250) was used to generate chemical fingerprints for all 
unique molecules screened.  The construction of chemical hashed fingerprints is shown in 
Figure 2.4.2 below. 
 
Figure 2.4.2 - the construction of two-dimension path-based binary fingerprints using JChem.  The presence of 
different atom types at certain positions in the model is represented by 1s or 0s in the binary code.  Patterns of 
atoms along linear paths, as well as the bond types that join them, are also represented in the code.  The figure 
shows how the presence of various atoms, bonds and patterns are represented by 1s in the binary code.  
Fingerprints were produced in binary format, as described in Figure 2.4.2.The path length was 
set to 7, the number of bits representing a pattern was set to two and the number of bits in the 
fingerprint was set to 512, supported by observations of the programmers(251).  The Tanimoto 
coefficient, a metric measuring similarity between two compounds(247,249,252), was generated 
by the program screenmd, also in the JChem package.  The widely applied Tanimoto coefficient 
is calculated using an equation of the form: 
 𝑇(𝐴,𝐵) =  
𝑐
𝑎 + 𝑏 − 𝑐
 21  
a is the number of “on” bits (“1) in the fingerprint of molecule A, b is the number of “on” bits in 
molecule B and c is the sum of “on” bits in both molecules.  T is a number between 0 and 1 
representing similarity between two molecules, with 1 meaning total similarity(247,248).  The 
program screenmd converts this to a dissimilarity score(253). 
 𝑇𝑑𝑖𝑠𝑠𝑖𝑚(𝐴,𝐵) = 1 −  𝑇𝑠𝑖𝑚(𝐴,𝐵) 22  
Higher numbers represent more dissimilar molecules.  The screening library and its component 
libraries were tested for internal dissimilarity by performing an all vs. all comparison carried out 
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using screenmd.  Values were averaged to determine average dissimilarity.  This analysis was 
repeated using pharmacophore fingerprints, also generated in generatemd. 
Although the Tanimoto coefficient is widely used, it has the drawback of reducing similarity 
measures of complex compounds to a single number.  To obtain a view of how the molecules 
are distributed across chemical space, the dissimilarity between the fingerprints was visualised 
using the Data Visualisation Modelling System (DVMS)(254).  This program uses statistical 
models to produce two-dimensional representations of sets of data.  The NeuroScale 
model(255),  uses a Radial Basis Function (RBF)neural network, where the distribution of data 
points is determined by distances from a number of RBF ‘centres’.  The equation describing the 
error function of the network is shown in Figure 2.4.3 below. 
 
Figure 2.4.3 - the NeuroScale model and it's use of the Radial Basis Function to define distances between data. 
N is the number of molecules in the data set, dij* is the distance between molecules i and j in the 
data, and dij is the distance between them in the visualisation space.  dij is given by the Soergel 
distance function, which is equivalent to Tdissim above(254).  A subset of the compounds tested 
in virtual screening is shown in a data visualisation below, as an example.  Note that the relative 
distances between each data point depends on the calculated differences between the 
molecules that they represent.  Also note that there are no axes on such visualisations. 
99 
 
 
Figure 2.4.4 - a visualisation of a subset of the virtual screening library produced by the DVMS.  Each data point 
represents the chemical fingerprint of one molecule.  The relative positions of all data points are determined by 
the differences between the molecules that they represent.  To illustrate this, a few representative molecules are 
shown with arrows pointing to the data points that they represent. 
 
2.4.4 Trypanosome growth inhibition 
Confirmed TDH inhibitors were supplied in stock solutions of 10µg.ml
-1
 for testing against 
bloodstream form trypanosomes (T. b. brucei strain 427, variant 221) in culture.  These assays 
were carried out by Professor Jon Kelly at the London School of Hygiene and Tropical 
Medicine.  Activity was reported as percentage inhibition of trypanosome growth. 
 
2.5 Commercialisation of NTD drugs 
The purpose of this chapter is to detail the various ways in which drugs and vaccines for 
neglected tropical diseases (NTD) are developed and advanced towards the market.  This 
chapter will explore factors affecting product (drug/vaccine) development for NTDs and will 
indicate how they apply to the development of a drug to treat HAT or Chagas Disease.  There 
are a few excellent resources that inform on the funding available for NTD product 
development.  One such resource is the Global Funding of Innovation for Neglected Diseases 
(G-FINDER) report(66) and database(73), the results of a survey on funding for NTD research & 
development (R&D), compiled by Policy Cures.   Another useful resource is BIO Ventures for 
Global Health’s (BVGH) Global Health Primer(74), a database that holds details on NTD 
products currently in development and the organisations involved in those development 
projects.  In addition to these, the research underlying this chapter was guided by a number of 
reviews of NTD product development activity(50,52,57,60).  However, there appears to be a 
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gap in the research, mainly pertaining to the different strategies used by researchers and 
developers to advance products towards the market and the availability of funding to advance 
development at specific stages in the pharmaceutical research and development (R&D) 
lifecycle.  Furthermore, the literature suggests that the formation of partnerships between 
different organisations is almost ubiquitous amongst NTD product development campaigns, 
although there is a scarcity of reviews providing specific details on such partnerships.  
Therefore, the research presented will cover the following areas: the different commercialisation 
strategies for new products to control NTDs, the level of evidence required when entering into 
partnerships, and the nature of partnerships formed during pharmaceutical development for 
NTD products.  The implications for NTD product developers were considered from the point of 
view of researchers in academic and public or not-for-profit research institutions (PSNRI), and 
recommendations on the most appropriate strategies to be utilised in the pursuit of the research 
discussed in this thesis will be given. 
 
In order to identify the gaps in the literature regarding NTDs, a literature search was conducted 
using combinations of the following keywords: “neglected tropical disease”, “NTD”, “drug” and 
“development”.  The basis of much of the background information supporting the research came 
from reviews of different aspects of NTD product development.  This background information 
was supplemented with specific examples of successful development projects in this area.  In 
order to undertake a more complete exploration of the topic, it was also important to gather 
more data relating to pharmaceutical discovery and development in general, as much of this is 
transferable to the development of NTD drugs.  In particular, information was sought on the 
originators of marketed drugs, and on the various parties involved in their development.  As the 
development of drugs for NTDs remains a special case within the pharmaceutical industry, 
examples of development strategies in other industries, where similar barriers to development 
are present (e.g. a lack of market incentive), were sought.  This involved gathering information 
from sources outside of the pharmaceutical and biomedical literature. 
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3. Results 
3.1 Structural Information 
3.1.1 Protein Expression and Purification 
Both BL21 (DE3) and Rosetta
TM
 competent cells were successfully transformed with TDH and 
KBL DNA using the methods described in Section 2.1.1.  Expression tests also showed that 
selective expression of the relevant genes was inducible by the addition of isopropyl ß-D-
thiogalactopyranoside (IPTG).  Figure 3.1.1 shows an SDS-PAGE gel that analyses an 
expression test for TDH-expressing bacteria. 
 
Figure 3.1.1 - SDS PAGE of a successful expression test for TDH.  M = standard molecular weight marker, UN = un-
induced cell and IN = induced cell.  Four colonies, numbered 1 to 4, were tested and the presence of TDH was 
confirmed by a large protein band corresponding to a protein of around 38 kDa in mass.  This is an example of a 
succesful expression test, as the cells were induced to over-express TDH, whilst the expression of other proteins 
remained constant. 
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Figure 3.1.2 - SDS-PAGE analysis of the purification of TDH from the supernatant obtained through protein 
extraction procedures.  M = standard molecular weight marker; PRE = solution eluted from Ni-NTA column prior 
to protein loading; SN = supernatant; FT = ‘flow-through’, solution flowing through the Ni-NTA column during 
initial loading of the supernatant; W = ‘wash’, the solution eluted from the column upon washing with binding or 
wash buffer; E1 = eluate collected following elution with 5ml of elution buffer; E2 = eluate following an additional 
5ml of elution buffer; VS-F = ‘Vivaspin filtrate’, formed during ultrafiltration in a Vivaspin
TM
 tube to concentrate 
TDH; VS-R = ‘Vivaspin retentate’, the solution retained during ultrafiltration to concentrate TDH.  This analysis 
shows that some protein was lost in the flow-through and wash, suggesting that the amount of protein exceeded 
the binding capacity of the Ni-NTA column.  Looking at lanes E1 and E2 also reveals that 5ml is actually 
insufficient to elute all of the protein from column, contrary to the manufacturer’s recommendations.  This may 
have been due to the fact that the quantity of TDH was above the column’s binding capacity.  Overall, this 
purification procedure was very successful, as TDH was purified from the supernatant, which contained a 
multitude of other proteins. 
  
When TDH was extracted from induced, cultured bacteria, a high concentration of soluble TDH 
was found in the supernatant after extraction, although a significant amount of protein was 
present in the insoluble cell pellet (see lane ‘CP’ in Figure 3.1.3).  Purification of TDH from the 
supernatant by affinity chromatography was very effective and was able to isolate highly pure 
protein (see Figure 3.1.2) in most cases.  However, an analysis of the SDS-PAGE result in 
Figure 3.1.2 shows that TDH was found in the solution that flowed through and was washed 
through the nickel column when following the procedure for affinity chromatography that is 
described in the methods.  This indicates that the quantity of TDH present in the supernatant 
exceeded the capacity of the column.  For this reason, the procedure was modified and two 
columns were attached end to end.  This ensured that protein was not lost as supernatant was 
initially loaded onto the column (see Figure 3.1.3).  However, some TDH was still lost in the 
wash step.  It was necessary to repeat the process, treating the wash fraction as one would the 
supernatant, in order to recover that protein.  
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Figure 3.1.3 - SDS PAGE analysis of a modified purification procedure.  M = standard molecular weight marker; CL 
= un-induced cell lysate; CP = cell pellet, containing insoluble protein; FT1/2 = flow through, solution flowing 
through the two connected Ni-NTA columns; W = wash, solution eluted from the column following washing with 
binding or wash buffer; VS-R = Vivaspin retentate; VS-F = Vivaspin filtrate.  Although a large amount of the 
expressed TDH was present in the insoluble cell pellet, a reasonable amount of protein was isolated from the 
supernatant (not analysed here).  Connecting two Ni-NTA columns together meant that all of the protein was 
initially retained on the columns.  However, some of the protein was still washed away with binding buffer.  
Nevertheless, a large amount of TDH was ultimately eluted from the column and concentrated by ultrafiltration.    
The protein extraction and purification processes were also effective for the purification of KBL, 
as shown in the figures below.  Figure 3.1.4 shows an expression test for KBL and Figure 3.1.5 
analyses the extraction of soluble KBL from KBL-expressing bacterial cell cultures.  Finally, 
Figure 3.1.6 confirms the purification of KBL by affinity chromatography. 
 
Figure 3.1.4 - SDS PAGE of a successful expression test for KBL.  M = standard molecular weight marker, UN = un-
induced cell and IN = induced cell.  Four colonies, numbered 1 to 4, were tested and the presence of a large 
protein band corresponding to a protein of around 46 kDa in mass was used to confirm successful induction.  The 
over-expression of KBL was only inducible in colonies 2 and 4, in this example.  
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Figure 3.1.5 - Extraction of KBL from an induced cell culture.  UN = un-induced cell; IN = induced cell; SN = 
supernatant; CP = cell pellet.  The presence of KBL was confirmed by the presence of a protein band 
corresponding to a molecular weight of approximately 46 kDa.  The analysis above shows that KBL was selectively 
induced and that it was present in both the supernatant and the cell pellet.  
 
Figure 3.1.6 - SDS PAGE analysis of KBL purification by affinity chromatography.  M = standard molecular weight 
marker; SN = supernatant; FT = flow-through, the solution that flowed through the Ni-NTA column upon loading 
of the protein; W = wash, the solution obtained after washing the column with binding or wash buffer; E = eluate, 
the solution eluted from the column by applying elution buffer.  This example shows the successful isolation of a 
pure KBL sample from the supernatant.  
In Figure 3.1.3 and Figure 3.1.7, it can be seen that there were some impurities in the final 
protein sample.  This occurred in a minority of cases, but when it did happen the most common 
impurity had a molecular weight of around 66-70 kDa.  This matches the molecular weight of the 
E. coli protein known as glucosamine-6-phosphate synthase or GlmS, which is reported to have 
a molecular weight of 67 kDa.  It is highly likely that GlmS was the contaminant, as it is known to 
co-purify with His-tagged proteins during affinity chromatography carried out using nickel 
columns(256).  Another common contaminant was sometimes apparent on SDS-PAGE gels, 
with a protein band corresponding to 25 kDa.  The identity of this contaminant is likely to be 
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Peptidoylproline cis–trans isomerase or SlyD, which is another well-known native E. coli protein 
that co-purifies with His-tagged proteins during affinity chromatography(256,257). 
 
Figure 3.1.7 - SDS PAGE analysis of TDH extraction and purification. M = standard molecular weight marker; CL = 
induced cell lysate; CP = cell pellet; SN = supernatant, FT = flow-through, the solution that flowed through the Ni-
NTA column when loading the protein; W = wash, the solution washed from the Ni-NTA column with binding or 
wash buffer; E = eluate, the solution obtained following application of elution buffer to the column.  In this 
example, TDH was present in large amounts in both the cell pellet and the supernatant.  The soluble TDH was 
purified from the supernatant without significant losses of protein in the flow-through or wash fractions (two Ni-
NTA columns, attached end-to-end) were used.  A small amount of a co-purifying contaminant, GlmS, was 
present in the final sample.  
For the purpose of removing impurities such as GlmS and SlyD, and to ensure a purer protein 
sample, ion exchange chromatography proved to be useful.  This is evident in the SDS-PAGE 
analysis in Figure 3.1.8.  When purifying TDH by this method it was observed that some of the 
protein was lost in the unbound fraction that flowed through the column shortly after column 
loading.  This suggests that the conditions of the equilibration or binding buffer were not optimal 
for the initial loading of the protein onto the column.  Despite this, the method did prove to be 
effective for purifying the protein of interest. 
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Figure 3.1.8 - SDS-PAGE analysis of TDH purification by ion exchange chromatography.  M = standard molecular 
weight marker; O = original impure TDH sample; F5 = fraction 5, containing solution corresponding to 50-60ml 
elution volume and including some of the un-bound protein fraction; F7 = fraction 7, containing solution 
corresponding to 70-80ml elution volume; F11 = fraction 11, containing solution corresponding to 110-120ml 
elution volume; VF1/2 = Vivaspin filtrate, the filtrate obtained following ultrafiltration of the purified TDH 
sample; R = Vivaspin retentate; C = control, a previously purified TDH sample.  Although the ion exchange 
chromatography procedure was useful, the presence of TDH in the early fractions, which corresponded to the tail 
end of a peak representing the un-bound fraction, suggests that a significant amount of protein did not bind to 
the column.  
Expression and purification of TDH using the methods described was able to produce 
expression yields of up to 1.48% (mass of protein following affinity chromatography, as a 
percentage of wet bacterial cell mass).  Similar quantities of purified KBL were obtained using 
the same processes, although no yield was calculated.  The type of competent cell (BL21 or 
Rossetta
TM
 cells) used did not appear to affect expression yields significantly.  The use of 
recently transformed bacteria, rather than cells that had been stored for long periods of time 
(more than one month), also seemed to correlate with purer final protein samples.  
The protein samples appeared to be stable when stored for long periods of time in storage 
buffer at approximately 4°C.  After storage periods of more than one month, small amounts of 
white precipitate could be seen at the bottom of storage vessels.  However, after filtering the 
protein solutions, the UV absorbance spectra appeared the same, and there was no significant 
loss of activity (for TDH).  It was possible to store the protein solutions for several months by 
freezing them at -20°C.  Upon thawing, the UV absorbance spectra remained the same, and 
there was no significant loss of enzyme activity observed during assays of TDH. 
3.1.2 Crystal growth and data collection 
Diffracting TDH crystals were successfully grown under a number of different conditions.  Most 
of the crystallisation solutions in which TDH was grown contained polyethylene glycol (PEG) 
4000 (4K) as the precipitant.  The conditions in which crystals that were used to obtain X-ray 
data were grown are listed in Table 3.1.1, along with data collection and refinement statistics for 
the related data sets.  No diffracting KBL crystals were produced by the conditions tested.  
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Crystals that grew in some of the conditions tested were confirmed as salt crystals by observing 
the X-ray diffraction pattern.   
The original protocol employed for cyro-cooling of crystals involved cryoprotection with 20-25% 
v/v glycerol (see section 2.1.3).  A number of TDH crystals were cryo-cooled, replacing glycerol 
with PEG 400 or ethylene glycol, or using no cryoprotectant at all, to determine whether this 
would affect the quality of data that could be collected from such crystals. It was found that 
quality data could be collected from crystals that were cooled with or without cryoprotectant.  
Subsequently, the X-ray models labelled TNADH4 and TM131 were derived from data collected 
from crystals that were not cryoprotected prior to cryocooling.  Quality data was also collected 
from a crystal that was cryoprotected with 20-25% PEG 400.  Data related to that crystal did not 
provide any new insights relevant to this study, so it is not presented in this thesis. 
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Table 3.1.1 - details of the crystallisation, data collection and structure solution of TDH.  Each crystal and data set was assigned an identity code, which is indicated in the second header 
row of the table. 
 
Model 
 
TK8 TS2 TIO8 TQ5 AAT1 TNADH4 TM131 
Crystallisation Conditions 
       
Conditions 
- 0.2M lithium 
sulphate, 
0.1M Tris, 
30% w/v PEG 
4K, pH 8.5 
- TDH (6.4 x 
10
-2
mM 
[2.4mg/ml]), 
KBL (3.8 x 10
-
2
mM[1.8mg/ml
]), NAD
+
 
(0.09mM), 
PLP 
(0.18mM),  
L-Threonine 
(7.33mM) 
- 0.1M MES, 
0.2M 
ammonium 
sulphate, 30% 
w/v PEG 5K 
MME, pH 6.5 
- TDH (9.0 x 
10
-2
mM 
[3.4mg/ml]),  
L-serine 
(50mM) 
- 0.1M tri-
sodium 
citrate, 30% 
w/v PEG 4K, 
0.2M 
ammonium 
acetate, pH 
8.5  
- TDH (3.7 x 
10
-2
mM 
[1.4mg/ml]), 
NAD
+
 
(10mM), 
BPOB 
(0.5mM) 
- 0.1M tri-
sodium 
citrate, 30% 
w/v PEG 4K, 
0.2M 
ammonium 
acetate, pH 
5.6 
- TDH (3.7 x 
10
-2
mM 
[1.4mg/ml]), 
NAD
+
 
(8.5mM), 
quinine 
(2.5mM 
[hydrochloride 
dehydrate]) 
- 0.1M tri-
sodium 
citrate, 30% 
w/v PEG 4K, 
0.2M 
ammonium 
acetate, pH 
5.6 
- TDH (10.4 x 
10
-2
mM 
[3.9mg/ml]), 
NAD
+
 
(10mM), L-
allo-threonine 
(30mM) 
- 0.2M sodium 
acetate, 0.1M 
Tris, 30% w/v 
PEG 4K, pH 
8.5 
- TDH (9.3 x 
10
-2
mM 
[3.5mg/ml]), 
NADH 
(10mM),  
L-Threonine 
(30mM) 
- 0.1M tri-
sodium 
citrate, 25% 
w/v PEG 4K, 
0.2M 
ammonium 
acetate, pH 
5.6 
- TDH (3.7 x 
10
-2
mM 
[1.4mg/ml]), 
NAD
+
 
(10mM), 
methylglyoxa
l (8mM) 
Cryoprotectant Glycerol Glycerol Glycerol Glycerol Glycerol None None 
        
Data Collection 
       
Beamline ESRF DLS I04-1 DLS I04-1 DLS  DLS I04-1 DLS I02 DLS I04-1 
Wavelength (Å) 0.9334 0.9173 0.9173 0.9173 0.92 0.9795 0.92001 
Space group P21212 P43212 P21212 P21212 P21212 P21212 P21212 
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Model 
 
TK8 TS2 TIO8 TQ5 AAT1 TNADH4 TM131 
Unit cell parameters 
       
a (Å) 132.04 91.76 90.40 90.07 133.03 83.45 133.45 
b (Å) 276.49 91.76 131.53 133.10 273.06 136.12 278.63 
c (Å) 55.74 93.60 55.02 55.61 55.80 55.69 56.27 
α (°) 90 90 90 90 90 90 90 
β (°) 90 90 90 90 90 90 90 
γ (°) 90 90 90 90 90 90 90 
Max. resolution (Å) 2.3 2.1 2.2 1.9 2.26 1.72 1.77 
No. of reflections 624537 301645 109277 203173 297998 435135 438691 
No. of unique reflections (used) 93173 23982 32475 61881 91289 67909 193067 
Solvent content (%) 46.34 52.83 42.88 43.94 44.98 41.24 46.7 
Matthews coefficient (Å
3
.Da
-1
) 2.29 2.61 2.15 2.19 2.23 2.09 2.31 
Resolution range (Å) 48.143 - 2.3 29.073 - 2.1 28.226 - 2.2 28.552 - 1.9 31.09 - 2.26 46.32-1.72 39.60 - 1.77 
Multiplicity 6.7 12.6 3.4 3.3 1.9 6.4 6.2 
Completeness (%) 99.188 99.98 95 97.7 90.4 99.5 99.6 
Mean I/σ 11.2 33.6 13.4 12.7 5.6 11 12.6 
Rmerge 0.12 0.054 0.067 0.074 0.151 0.094 0.121 
Rpim 0.049 0.016 0.04 0.048 0.181 0.04 0.055 
Rmeas 0.13 0.056 0.079 0.088 0.214 0.102 0.133 
        
Refinement 
       
Rwork 0.1746 0.1741 0.1643 0.1864 0.2073 0.1522 0.16071 
Rfree 0.2618 0.2400 0.2411 0.2321 0.2809 0.1976 0.20074 
RMS bond lengths (Å) 0.0178 0.0245 0.0201 0.0241 0.0128 0.0198 0.0201 
RMS bond angles (°) 1.764 2.059 1.826 1.99 1.6492 2.1037 1.9749 
Average B-factor (Å
2
) 21.09 26.769 26.234 22.138 33.76 27.689 19.218 
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Model 
 
TK8 TS2 TIO8 TQ5 AAT1 TNADH4 TM131 
Ramachandran favoured, % of 
total 
1830, 96.62% 309, 96.87% 613, 96.69% 618, 97.48% 1801, 95.14% 622, 97.65% 
1824, 
97.91% 
Ramachandran allowed, % of 
total 
61, 3.22% 8, 2.51% 18, 2.84% 14, 2.21% 82, 4.33% 13, 2.04% 33, 1.77% 
Ramachandran outliers, % of 
total 
3, 0.16% 2, 0.63% 3, 0.47% 2, 0.32% 10, 0.53% 2, 0.31% 6, 0.32% 
Molecules in the asymmetric unit 6 1 2 2 6 2 6 
Quaternary structure Dimer Dimer Dimer Dimer Dimer Dimer Dimer 
Residue range Pro3-Leu321 His1-Leu321 Pro3-Leu321 Pro3-Leu321 Pro3-Leu321 His1-Leu321 Met2-Leu321 
No. protein atoms per monomer 2493 2532 2493 2493 2500.5 2507 2533 
No. water molecules per 
monomer 
252.3 152 220.5 100.5 73.7 210 241.1 
NAD
+
 bound? Yes No Yes Yes Yes Yes (NADH) Yes 
Ligands bound, Mean B-factor - - - - 
L-allo-
threonine, 
39.53 
L-allo-
threonine, 
26.88 
L-threonine, 
26.06 
L-threonine, 
30.58 
- 
Other solvent molecules/ions 
glycerol, 
sulphate 
glycerol 
glycerol, 
acetate, Na
+
 
glycerol, 
acetate 
glycerol, 
acetate 
glycerol, Na
+
 
glycerol, 
acetate 
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The TDH structure models obtained through X-ray crystallography provide many insights on the 
structure and function of the enzyme.  As it was possible to co-crystallise TDH with NAD and 
other substrates, information on the binding of TDH with its substrates has also been gained.  
The structure of TDH and how this may relate to its function is discussed below, in light of the 
crystallographic data, as well as data from other experimental techniques. 
3.1.3 Primary Structure 
The protein and nucleotide BLAST searches (see Section 2.1.3.3) of TDH amino acid 
sequences and nucleotide sequences, respectively, presented several similar TDH proteins 
from other species that had high sequence similarities to TDH from Trypanosoma brucei.  
These proteins typically share approximately 40% sequence similarity with TDH from T. brucei.  
The sequences included some that correspond to previously studied TDH enzymes from other 
species.  The published amino acid sequences of these proteins are aligned with that of TDH 
from T. brucei TREU 927 strain in Figure 3.1.9.  Sequences of TDH from other Trypanosoma 
species or subspecies are also included. 
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GxxGxxG 
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Figure 3.1.9 - amino acid sequence alignments of TDH from different organisms.  The sequence of the TDH variant studied in this thesis is listed at the top (T. brucei strain TREU 927).  Each 
residue is represented by the corresponding single-letter code for that amino acid.  Sequences of non-aligning residues are represented by a dash.  Key conserved sequence segments are 
indicated by an arrow and bold text.  The glycine-rich sequence GxxGxxG, and the catalytic motif YxxxK have been highlighted, including a sequence that corresponds to a flexible loop 
(Loop 1).  The alignment was created using the software Seaview 4(258).  Sequences were identified through the NCBI protein and nucleotide blast searches(181).
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The TDH sequences from T. brucei strain TREU 927 and T. brucei gambiense were essentially 
identical, confirming that the TDH studied in this work is relevant to a disease-causing 
pathogen.  The animal disease-causing pathogen T. congolense has an unnamed protein that 
shares 78% sequence identity with the TDH studied here.  Therefore, there is a high probability 
that this protein is a TDH.  The sequence identity shared between TDH from T. brucei strain 
TREU 927 and the Chagas disease-causing pathogen, Trypanosoma cruzi, is 72%.  Thus, the 
TDH enzymes from a range of Trypanosoma species are closely related.  The phylogenetic tree 
in Figure 3.1.10 illustrates this and gives an indication as to the relationship between the 
enzymes in the species included. 
Other published TDH enzymes with a high sequence similarity to the enzyme studied in this 
thesis are the UDP-galactose 4’-epimerase-like (GalE) TDH enzymes from the bacteria 
Thermoplasma volcanium, Flavobacterium frigidimaris and Cupriavidus necator.  The 
corresponding enzymes from these organisms all have monomeric molecular weights reported 
between 35 and 37.2kDa(124–126,197), matching that of TDH from T. brucei.  The 
phylogenetic tree in Figure 3.1.10 indicates some variation between the sequences of TDH from 
the various bacterial species. 
Another group of related TDH enzymes originate from mammalian species: Gallus gallus 
(chicken), Rattus norvegicus (rat), Sus scrofa (boar/pig) and Capra hircus (goat).  Again, TDH 
enzymes from these species have been studied previously.  Reported molecular weights 
corresponding to TDH monomers from these organisms include 36 kDa for chicken (259) and 
37 kDa for pig(260). 
Looking at the sequences of the various TDH enzymes shows that they belong to the short 
chain dehydrogenase/reductase (SDR) superfamily of enzymes.  These enzymes catalyse 
oxidative or reductive reactions and share certain highly conserved structural motifs(261).  Two 
structural features that can be identified from the TDH sequence are highlighted in Figure 3.1.9.  
The first is a glycine-rich region, which is represented by the sequence GxxGxxG, where the 
letter x can be replaced by any amino acid.  The second feature consists of a tyrosine and a 
lysine residue separated by three other residues: YxxxK(118).  As can be seen in Figure 3.1.9, 
these motifs are highly conserved across the TDHs in different species. 
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Figure 3.1.10 - phylogenetic tree connecting the different TDH sequences present in different organisms.  
Different branches linking organisms to the same root indicate that those TDH enzymes have a common genetic 
ancestry.  The lengths of the branches (horizontal) are proportional to the degree of genetic change between 
species.  Hence, T. brucei strain TREU927 and T. brucei gambiense share identical TDH genes/proteins.  The TDH 
from Trypanosoma are grouped together, as are those from mammals and those from bacteria.  The genes of 
bacteria appear to vary to much greater extents than those of Trypanosoma and mammals.  This phylogenetic 
tree was created using the default settings of PhyML, which is integrated in Seaview4(258).  
The BLAST searches also revealed a number of similar sequences for proteins from other 
organisms of biological and pharmacological interest.  These proteins, and the relevance of the 
organisms from which they come from are listed in Table 3.1.2
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Table 3.1.2 - organisms of pharmacological/medical interest that may possess TDH enzymes similar to that from 
T. brucei. 
Sequence 
Identity 
Organism Role of organism Confirmed 
/Putative 
/ Unnamed 
46% Blastocystis hominis Possible role in gastrointestinal 
disease 
Unnamed 
45% Ascaris suum Causes roundworm infection in 
pigs 
Confirmed: TDH 
43% Phytophthora infestans Causes potato blight Putative: TDH 
42% Anopheles gambiae Malaria vector Unnamed 
43% Aedes aegypti Dengue, Chikungunya and 
Yellow fever vector 
Putative: TDH 
41% Culex quinquefasciatus Lymphatic filariasis vector Confirmed: TDH 
41% Glossina morsitans 
morsitans 
Tsetse fly Unnamed 
42% Enterococcus faecium Normal gut flora, but important 
source of nosocomial infections 
Putative: 
epimerase/reducta
se 
41% Pediculus humanis 
corporis 
Human body louse Putative: TDH 
42% Staphylococcal spp. 
(incl. Staph aureus) 
Several human infections Unnamed 
41% Mus musculus Study with inhibitors of mouse 
TDH (Alexander et al. 2011).  
Role in embryonic stem cells. 
Confirmed: TDH 
28% Haemophilus influenzae Human diseases, including 
meningitis 
Uncharacterised 
 
 
3.1.4 Secondary Structure 
X-ray models of TDH revealed that the structure is made up of a mixture of α-helices, β-sheets 
and disordered loops.  When observed visually, the distribution of secondary structure elements 
in TDH appears to be approximately 38% α-helices and 12% β-sheets, with the remaining 50% 
of the protein not forming specific folds.   
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Figure 3.1.11 - Ribbon representation of a TDH monomer coloured by secondary structure.  The cofactor NAD is 
shown in a stick representation.  
    
3.1.5 Tertiary Structure 
The TDH monomer can be divided into two domains: an NAD-binding domain, which includes 
the first 180-200 amino acids, and a catalytic domain at the C-terminal end of the protein.  
Though, in three dimensions, there is some crossover between the domains and the different 
portions of the amino acid sequence.  The arrangement of secondary structure elements is 
depicted in the protein topology diagram in Figure 3.1.12. 
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Figure 3.1.12 - protein topology diagram of TDH.  This diagram was drawn using Pro-origami(263) and a 
monomeric TDH structure model from TK8.  The diagram was drawn using the Dictionary of Secondary Protein 
Structure (DSSP) to assign secondary structure elements(264,265).  α-helices are represented by barrels and 
assigned a letter in alphabetical order.  Β-strands are represented by flat arrows and are numbered in ascending 
order.  The secondary structure elements are coloured from blue, starting at the N-terminus, through green, 
yellow and orange to red at the C-terminus.  
TDH possesses a pattern of parallel β-sheets, which are flanked by α-helices.  This motif, 
termed the Rossmann fold is common to NAD-binding proteins(266,267), and hence 
SDRs(118,261). The protein topology diagram in Figure 3.1.12 shows how the sequence of 
alternating β-strands and α-helices arrange so that the β-strands are parallel and spatially 
adjacent.  The 3D orientation of NAD in relation to the Rossmann fold can be seen in Figure 
3.1.13. 
119 
 
 
Figure 3.1.13 - ribbon representation of a TDH monomer.  The NAD-binding Rossmann fold is coloured according 
to secondary structure, whilst the remainder of the molecule is coloured grey.  The Rossmann fold is 
characterised by a six-stranded parallel β-sheet that is flanked by α-helices.  
The structural motif GxxGxxG, which is common to the ‘extended’ class of SDRs (eSDR), is 
located within the NAD binding region and is represented by the sequence Gly9-Ala10-Leu11-
Gly12-Gln13-Ile14-Gly15.  The motif appears to be involved in binding the diphosphate group of 
NAD.  Simultaneously, the YxxxK motif and several other conserved residues are located in the 
active sites of SDRs.  TDH from T. brucei is no exception.  These residues are displayed in 
Figure 3.1.14.  They include Met81, Ser82, Thr119, Thr186, Trp280, and Tyr144 and Lys148 of 
the eSDR YxxxK motif.
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Figure 3.1.14 - ribbon representation of TDH, showing the conserved active site residues, Met81, Ser82, Thr119, Tyr144, Lys148, Thr186 and Trp280. 
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Although no large domain movements were observed between the various TDH structure 
models, aligning different monomers from various models showed that there was a certain 
degree of variation in the relative positions of different atoms (see Section 2.1.3.3 for methods).  
The fact that different areas of the protein showed more variation than others suggested that 
there are regions within the protein that are more flexible.  This was illustrated clearly by 
observing the RMSD of α-carbon positions in the aligned residues.  Another indication of 
flexibility or disorder is given by looking at the average B-factor for each residue.  When the B-
factors are averaged across different structure models, one can see which areas of the protein 
tend to be more disordered.  Figure 3.1.15 to Figure 3.1.18 inclusive provide a visual description 
of the flexibility in TDH structure. 
 
Figure 3.1.15 - ribbon representation of TDH, coloured by the RMSD of α-carbon positions in each residue.  The 
RMSD was determined after aligning eight representative monomeric TDH models in UCSF Chimera(182).  The 
scale at the bottom of the diagram indicates the colour scheme relating to the RMSD measured in Angstrom.
Loop 1 
Loop 2 
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Figure 3.1.16 - ribbon representation of TDH, coloured by the average B-factor of each residue.  The average B-
factor per residue was calculated for eight representative monomeric TDH models using the CCP4 program 
baverage(268).  The mean of all the average B factors was then determined from these values.  The scale at the 
bottom of the diagram indicates the colour scheme relating to the B-factor, measured in Angstrom squared.
Loop 1 
Loop 2 
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Looking at Figure 3.1.15 and Figure 3.1.16, there are number of regions that appear to be 
flexible.  Firstly, there are two disordered loop regions: Loop 1 is between Thr179 and Ala185, 
and Loop 2 lies between residues 35 and 60.  There also appears to be a high degree of 
flexibility in the catalytic domain (on the right-hand side of Figure 3.1.15 and Figure 3.1.16).  The 
bar charts below highlight the positions along the TDH sequence that correspond to regions of 
flexibility. 
 
Figure 3.1.17 - bar chart showing the RMSD of α-carbons per TDH residue.  The lower horizontal dotted line 
represents the mean RMSD value of all residues.  Bars representing values higher than this are coloured gold.  
The upper dotted horizontal line is double the mean RMSD, and bars above this line are coloured red.  The RMSD 
was determined after aligning eight representative monomeric TDH models in UCSF Chimera(182).  
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Figure 3.1.18 - bar chart showing the average B-factor per TDH residue.  The dotted horizontal line indicates the 
mean B-factor across all residues.  Bars representing values higher than this line are coloured gold.  The average 
B-factor per residue was calculated for eight representative monomeric TDH models using the CCP4 program 
baverage(268).  The mean of all the average B factors was then determined from these values.    
The same flexible or variable regions are highlighted by comparison of average B-factors, as by 
comparison of RMSDs.  There appears to be flexibility in the NAD-binding region, particularly 
around Loop 2.  Although the B-factors are low, the RMSDs around residues 82 to 100 are 
particularly high.  This region lies at the dimerization interface (discussed below), indicating 
some conformational variability there.  The most striking evidence of conformational variability is 
found at the residues of Loop 1, Thr179 to Ala185.  The significance of Loop 1 and its different 
positions will be discussed in more detail below.  The region adjacent to Loop 1, including 
residues up to Pro205, is highly disordered and shows a lot of variation between TDH models.  
In three dimensions, this region can be seen as one of a pair of adjacent α-helices and β-
strands, which can be seen on the right hand sides of the structures in Figure 3.1.15 and Figure 
3.1.16.  The second disordered α-helix-β-sheet in this region occurs around residues 255-273, 
which also stands out as a disordered region in Figure 3.1.15 and Figure 3.1.16. 
Loop 1 was the region that showed the largest apparent change in its conformation (see Figure 
3.1.17).  The loop actually showed two distinctive positions, one where the loop was in an ‘open’ 
position, lying at a distance from the active site, and another where the loop is ‘closed’ and lies 
adjacent to the active site.  Therefore, for each model of a TDH monomer, the structure can be 
classified as ‘open’ or ‘closed’, on the basis of the conformation of Loop 1.  The structure 
models used in the analyses that produced Figure 3.1.15 to Figure 3.1.18 included structures in 
which Loop 1 lay in an open conformation and others in which Loop 1 was closed.  Comparing 
the average B-factors in open and closed structures can highlight any changes in flexibility or 
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disorder that accompany the change in the Loop 1 conformation.  Figure 3.1.19 shows the 
average B-factors of TDH residues in ‘open’ structures, whilst Figure 3.1.20 shows the average 
B factors of TDH residues in ‘closed’ structures. 
 
Figure 3.1.19 - bar chart showing the average B-factor per TDH residue, taken as a mean from the average B 
factors of residues in four of the eight representative monomers used in these analyses.  In each structure, Loop 1 
is in the 'open' conformation.  
In the ‘open’ structures, the highest B-factors are seen around the loop regions.  However, in 
the closed structures, although these same residues are above the mean all-residue B-factor, 
they are much less disordered.  The catalytic domain appears to be much more disordered, and 
residues 186-207 and residues 251-274 have particularly high B-factors.  The residues from 
Gln296 leading up to the C-terminus are also very disordered.  This was also observed during 
real space model refinement; these disordered regions were associated with less difference 
density. 
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Figure 3.1.20 - bar chart showing the average B factor per TDH residue, taken as a mean from the average B 
factors of residues in four of the eight representative monomers used in these analyses.  In each structure, Loop 1 
is in the 'closed' conformation.  
These findings indicate that there is a relationship between the conformation of Loop 1, and the 
flexibility of other regions of the protein, particularly the catalytic domain.  Three of the four 
‘closed’ structures examined were bound to NAD/NADH and another ligand, whilst only one of 
the four ‘open’ structures examined was bound to NAD and another ligand.  The different 
conformational changes do not appear to correlate with the space-group of the crystal from 
which the data was collected.   Thus, the specific conformation of Loop 1 and the flexibility of 
the catalytic region may actually be influenced by ligand binding. 
 
As discussed above, the change from an open conformation of Loop 1 to a closed conformation 
has a dramatic effect on the nature of the active site, and so warrants closer examination. 
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Figure 3.1.21 - ribbon representations of two superposed monomeric TDH structures.  One structure is the open 
conformer and is semi-transparent.  The other structure is the closed conformer, and this is opaque.  For 
emphasis, Loop 1 of the open conformer is coloured gold, whilst Loop 1 of the closed conformer is coloured red.  
The main difference between the two conformations manifests as a closure by Loop 1 over the active site.  
The NAD binding site and the L-threonine binding site lie adjacent to each other and are 
connected.  The side chain of Met81 appears to act as a barrier between the two active sites 
and may help in positioning the two substrates on their initial approach to the active site.  
Although the L-threonine binding site is much smaller than the NAD binding site, it is open to the 
exterior of the protein, so it could theoretically accommodate molecules that are larger than L-
threonine.  However, when Loop 1 is in its closed conformation, the active site is completely 
sealed off, leaving little room for a molecule much bigger than L-threonine.  This has clear 
implications for drug discovery, as will be discussed further. 
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Figure 3.1.22 - surface representation of TDH with NAD
+
 and L-threonine bound.  The image was created by 
superposing an NAD
+
-bound monomer from model TK8 and a NADH- and L-threonine-bound TDH monomer from 
model TNADH4.  The open conformer is shown here.  It can be seen that Met81 forms a partial barrier between 
the binding pockets of each substrate.  
 
Figure 3.1.23 - surface representation of TDH with NAD
+
 and L-threonine bound.  The image was created by 
superposing an NAD
+
-bound monomer from model TK8 and a NADH- and L-threonine-bound TDH monomer from 
model TNADH4.  The closed conformer is shown here.  Loop 1 is coloured red to highlight the fact that it seals off 
the TDH binding site from the external environment.  
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3.1.6 Quaternary structure & Complex Formation 
The studies described in this thesis provided several lines of evidence in support of TDH 
existing as a homodimer. Below, evidence from X-ray crystallography, size-exclusion 
chromatography and cross-linking studies are described. 
TDH was revealed to exist as a dimer during solution and refinement of X-ray crystallographic 
models.  When carrying out real space refinement using the software Coot, by default only the 
molecules in the asymmetric unit are shown.  Therefore, symmetry related molecules are 
hidden, so only a monomer would be visible sometimes.  In such cases the existence of the 
dimer was easily confirmed by selecting the option to display symmetry-related molecules.  
Further evidence of the existence of the dimer, and evidence that this was the largest oligomer 
present, was provided by Protein Interfaces, Surfaces and Assemblies (PISA) analyses.   
 
Figure 3.1.24 - ribbon and surface representation of the TDH homodimer. 
The dimerization interface consists of two α-helices (Pro89-Tyr110 and Val143-Tyr162) and a 
loop (lys126-Thr142), and the same regions on each monomer make contact in the dimer.  As 
can be seen in Figure 3.1.25, the dimer is stabilised by a large number of hydrophobic, polar 
and ionic interactions.  In particular, polar side chains of residues on each monomer form 
hydrogen bonds with each other and charged residues form salt bridges.  This probably gives 
greater stability to the dimer, whilst the length of some of the side chains allows their 
interactions to be maintained in the case of any change in the orientation of the two monomers. 
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Figure 3.1.25 - the TDH dimerisation interface.  The protein is represented by a ribbon and important interacting 
amino acids are shown in the stick representation.  Yellow lines represent potential contacts (when Van der 
Waals radii of nearby atoms overlap).  Red lines indicate atoms within hydrogen bonding distance.  The images 
labelled A and B show the interface from opposite angles.  
 
Figure 3.1.26 - the interaction between Glu86 and Trp157 appears to be one of the hydrogen bonds stabilising the 
dimer.  
A B 
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Figure 3.1.27 - the interaction between Asp90 and Asp94 and Arg101 appears to be a group of salt bridges 
stabilising the dimer.  The length and flexibility of Arg101, could help to maintain the interaction upon movement 
of the subunits of the dimer.  
 
Figure 3.1.28 - Lys126 and Asp135 appear to be involved in another salt bridge stabilising the dimer. 
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As is evident in Table 3.1.1, TDH models were derived from crystals with different 
characteristics.  Therefore, an analysis of the relationships between different subunits was 
carried out using the CCP4 software, PISA, to supplement the findings described above.  Table 
3.1.3 lists a number of different interfaces between different TDH subunits in the different 
structure models.  The only stable association between TDH subunits was the dimer 
relationship already described.  PISA detected one possible multimer involving four subunits in 
the model TNADH4, but could not determine whether this would be stable in solution.  
Therefore, another CCP4 program, pdbset, was used to generate a .pdb file containing all 
symmetry-related molecules in addition to those in the asymmetric unit.  As can be seen in 
Figure 3.1.29, the only quaternary structure evident is the TDH dimer.  The buried surface area 
was similar for the dimerisation interfaces from different crystals.  Differences in the buried 
surface area result from conformational changes around the dimer interface, as shown in Figure 
3.1.15 and Figure 3.1.17 (see residues 89-100).  There was no clear relationship between the 
nature of the dimerisation interface and the space group, TDH conformation (open or closed) 
and whether TDH was ligand bound. 
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Table 3.1.3 - TDH quaternary structure identified by PISA and confirmed visually. * ΔGdiss = dissociation barrier. 
Model Oligomer Accessible surface area 
(Å
2
) 
Buried surface area 
(Å
2
) 
ΔGdiss
*
 
(kcal.mol
-1
) 
Stable in 
solution? 
Visual 
confirmation 
Model: TK8 
Space group: P21212 
Unit cell parameters: 
a=132.04, b=276.49, 
c=55.74; αβγ=90° 
Molecules in the 
asymmetric unit: 6 
Dimer 24918.1 5470.9 3.3 Yes 
Dimer 24832.7 5449.2 2.6 Yes 
Dimer 24993.7 5428.6 2.3 Yes 
Model: TS2 
Space group: P43212 
Unit cell parameters: 
ab=91.76, c=93.60; 
αβγ=90° 
Molecules in the 
asymmetric unit: 1 
Dimer 25239.1 5028.6 3.2 Yes 
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Model Oligomer Accessible surface area 
(Å
2
) 
Buried surface area 
(Å
2
) 
ΔGdiss
*
 
(kcal.mol
-1
) 
Stable in 
solution? 
Visual 
confirmation 
Model: TIO8 
Space group: P21212 
Unit cell parameters: 
a=90.40, b=131.53, 
c=55.02; αβγ=90° 
Molecules in the 
asymmetric unit: 2 
Dimer 24519.8 4880.8 4.4 Yes 
Model: TQ5 
Space group: P21212 
Unit cell parameters: 
a=133.03,b=273.06, 
c=55.80; αβγ=90° 
Molecules in the 
asymmetric unit: 2 
Dimer 24264.3 7309.4 4.1 Yes 
Model: AAT1 
Space group: P21212 
Unit cell parameters: 
a=133.03, b=273.06, 
c=55.80; αβγ=90° 
Molecules in the 
asymmetric unit: 6 
Dimer 24167.7 4813.6 4.3 Yes 
Dimer 24294.1 4772.0 3.1 Yes 
Dimer 24217.8 4790.1 2.4 Yes 
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Model Oligomer Accessible surface area 
(Å
2
) 
Buried surface area 
(Å
2
) 
ΔGdiss
*
 
(kcal.mol
-1
) 
Stable in 
solution? 
Visual 
confirmation 
Model: TNADH4 
Space group: P21212 
Unit cell parameters: 
a=83.45, b=136.12, 
c=55.69; αβγ=90° 
Molecules in the 
asymmetric unit: 2 
Dimer 24587.0 5788.1 0.3 Yes 
Tetramer 46831.2 13919.2 -1.6 Uncertain x (see Figure 
3.1.29) 
Model: TM131 
Space group: P21212 
Unit cell parameters: 
a=133.45, b=278.63, 
b=56.27; αβγ=90° 
Molecules in the 
asymmetric unit: 6 
Dimer 24779.8 6050.2 4.5 Yes 
 24400.6 6351.1 4.1 Yes 
 24521.6 6357.1 3.1 Yes 
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Figure 3.1.29 - visualisation of TDH structure TNADH4, from the .pdb file generated by pdbset.  All symmetry-
related molecules are present, in addition to those in the asymmetric unit. 
 
 
Further information on the quaternary structure of TDH and KBL was gained through size-
exclusion chromatography experiments, as described in Section 2.1.4.1.  The elution volumes 
of TDH during size-exclusion chromatography also provided evidence that TDH is a homodimer.  
The elution volumes were found to be different under different conditions, suggesting that the 
quaternary structures of TDH and KBL, which were also studied by this method, were 
influenced by the presence of other proteins and substrates.  The results of a calibration of the 
gel filtration column with protein standards are shown in Figure 3.1.30.  In Table 3.1.4, the 
elution volumes of TDH, KBL and mixtures of both are listed, along with the molecular weights 
that those elution volumes correspond to, as calculated by interpolation from the standard curve 
(see Figure 2.1.10).  The fractions corresponding to peaks recorded during elution from the 
column were all analysed using SDS PAGE to confirm the presence of protein in that fraction.  
NAD
+
 caused very large peaks when eluting from the column (elution volume ~24ml), so the 
presence of protein in the corresponding fractions was excluded using SDS-PAGE and silver 
staining in those cases. 
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Figure 3.1.30 - calibration of the size-exclusion chromatography column using standard proteins.  The log 
molecular weights of the proteins are plotted as a function of their elution volume (Ve) divided by the void 
volume (V0).  The void volume was determined by measuring the elution of blue Dextran, which eluted at 8.4ml. 
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Figure 3.1.31 - an example of a chromatogram from one of the size-exclusion chromatography experiments.  This 
chromatogram is of a sample containing TDH at 1.1 x 10
-1
 mM and 30 mM L-threonine. 
Figure 3.1.31 shows an example of a chromatogram, from which the elution volumes 
corresponding to absorbance peaks were taken. Table 3.1.4 shows the various samples tested 
in size-exclusion chromatography experiments, together with the elution volumes and estimated 
molecular weights. 
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Table 3.1.4 - Results of size-exclusion chromatography experiments.  Note that some results appear more than once, under different headings. 
Sample Contents Ve (ml) Ve/V0 Interpolated 
MW (kDa) 
Multiple of MW Suggested 
Oligomeric State 
TDH 
 
 
   
TDH (1.1 x10
-1
 mM [4mg/ml]) 15.5 1.85 56.2 1.49 Monomer/Dimer 
TDH (1.8 x10
-1
 mM [6.8mg/ml]) 15 1.79 68.8 1.82 Dimer 
TDH (1.1 x10
-1
 mM [4mg/ml]) + 10mM NAD
+
 15 1.79 68.8 1.82 Dimer 
TDH (1.1 x10
-1
 mM [4mg/ml]) + 30mM L-threonine 16 1.90 46.0 1.22 Monomer 
TDH (1.1 x10
-1
 mM [4mg/ml]) + 10mM NAD
+
 + 20mM L-
threonine 
16.5 1.96 37.6 0.99 Monomer 
TDH (1.1 x10
-1
 mM [4mg/ml]) + 10mM NAD
+
 + 30mM L-
threonine 
16.1 1.92 46.0 1.22 Monomer 
TDH (4.8 x10
-2
 mM [1.8mg/ml]) + KBL (4.4 x10
-2
 mM 
[2mg/ml]) + 10mM NAD
+
+ 30mM L-threonine 
16.5 1.96 37.6 0.99 Monomer 
TDH (5.3 x10
-2
 mM [2mg/ml]) + 30mM L-allo-threonine 14 1.67 102.8 2.72 Trimer 
TDH (5.3 x10
-2
 mM [2mg/ml]) + 10mM NAD
+
 + 30mM L-allo-
threonine 
15 1.79 68.8 1.82 Dimer 
TDH (5.3 x10
-2
 mM [2mg/ml]) + 60mM pyruvate 15.2 1.81 63.4 1.68 Dimer 
KBL 
 
 
   
KBL (4.4 x10
-2
 mM [2mg/ml]) 14.4 1.71 87.5 1.91 Dimer 
KBL (6.54 x10
-2
 mM [3mg/ml]) + 20mM Gly 11 1.31 343.5 7.48 Octamer 
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Sample Contents Ve (ml) Ve/V0 Interpolated 
MW (kDa) 
Multiple of MW Suggested 
Oligomeric State 
KBL (4.4 x10
-2
 mM [2mg/ml]) + 1mM PLP 14.5 1.73 84.0 1.83 Dimer 
TDH (4.8 x10
-2
 mM [1.8mg/ml]) + KBL (4.1 x 10
-2
 mM 
[1.9mg/ml]) + 10mM NAD
+ 
+ 20mM L-threonine + 1mM PLP + 
1mM CoA 
16.5 1.96 37.6 0.82 Monomer 
TDH + KBL 
 
 
   
TDH (5.3 x10
-2
 mM [2mg/ml]) + KBL (4.4 x10
-2
 mM [2mg/ml]) 
- first peak 
12.5 1.49 187.7 
4.97 (TDH); 
4.09 (KBL) 
Multi-enzyme 
complex 
TDH (5.3 x10
-2
 mM [2mg/ml]) + KBL (4.4 x10
-2
 mM [2mg/ml]) 
- second peak 
16.8 1.99 34.0 
0.90 (TDH); 
0.74 (KBL) 
Monomers (TDH 
and/or KBL) 
TDH (4.8 x10
-2
 mM [1.8mg/ml]) + KBL (4.4 x10
-2
 mM 
[2mg/ml]) + 10mM NAD
+
+ 30mM L-threonine 
16.5 1.96 37.6 
0.99 (TDH); 
0.81 (KBL) 
Monomers (TDH 
and/or KBL) 
TDH (4.8 x10
-2
 mM [1.8mg/ml]) + KBL (4.1 x 10
-2
 mM 
[1.9mg/ml]) + 10mM NAD
+ 
+ 20mM L-threonine + 1mM PLP + 
1mM CoA 
16.5 1.96 37.6 
0.99 (TDH); 
0.81 (KBL) 
Monomers (TDH 
and/or KBL) 
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In several experiments involving TDH, the elution volume of the protein corresponded to a 
protein of molecular weight 63-68 kDa.  This suggests that TDH was present in its dimeric form, 
which would have a molecular weight around 74 kDa.  A very surprising finding was that TDH 
samples containing L-threonine eluted at a volume that corresponded to the molecular weight of 
a TDH monomer.  This raises the possibility that L-threonine binding or catalytic activity 
promotes the dissociation of the TDH dimer into monomers.  Samples containing NAD
+
 and the 
TDH inhibitors L-allo-threonine and pyruvate eluted at volumes corresponding to the TDH 
dimer, adding to the likelihood that catalysis causes the increase in elution volume.  There is 
one outlier, which had a higher elution volume corresponding to a protein of approximately 1.5 
times the molecular weight of a TDH monomer (56.2 kDa).  When compared with other findings, 
it appears likely that this corresponds to the TDH dimer.  A second outlier resulted from an 
experiment with a mixture of TDH and L-allo-threonine, without added NAD
+
.  The elution 
volume of TDH in this sample suggests a molecular weight corresponding to a trimer of TDH.  
Further investigations will be required to ascertain whether this is an erroneous result, or if there 
is another higher oligomer of TDH.  A sample containing a mixture of TDH and KBL together 
with NAD
+
 and L-threonine eluted together as one broad peak.  The elution volume at the peak 
of the tip suggests that the proteins had a molecular weight of 37.6 kDa, suggesting that 
monomers of TDH and KBL co-eluted and that the two proteins did not form a complex. 
Judging by the elution volumes of samples of KBL, it is highly probable that this protein exists 
as a dimer.  An elution volume of 84 kDa was measured which corresponds to a KBL dimer.  
The addition of pyridoxal phosphate (PLP) seemed to have no effect on the elution volume of 
KBL, which is to be expected, as PLP most probably exists as a covalently bound prosthetic 
group(127,269).  One of the substrates for the presumed reverse reaction catalysed by KBL is 
glycine, and addition of this substrate to KBL caused dramatic decrease in elution volume.  The 
corresponding molecular weight suggests that KBL eluted as an octamer in this experiment.  
The experiment was repeated (data not shown) and there was a very similar apparent 
molecular weight of 379.5 kDa.  A mixture of TDH and KBL, with NAD
+
, L-threonine, PLP and 
CoA, the final substrate required for catalysis of 2-amino-3-ketobutyrate to acetyl-CoA and 
glycine, eluted with a single peak that corresponded to a molecular weight of 37.6 kDa.  The 
elution volume suggested that monomers of the two proteins co-eluted as previously. 
Looking at the data listed in Table 3.1.4 permits a deeper exploration of the effect of TDH and 
KBL on each protein’s quaternary structure.  In the absence of the second protein, TDH and 
KBL appear to elute in their dimeric forms.  Both TDH and KBL appear to have different 
quaternary structures in the presence of their substrates.  The same is true, when the two 
proteins are tested together in the presence of substrates.  When a mixture of TDH and KBL 
was tested without adding any substrates two peaks were seen on the chromatogram, and 
SDS-PAGE and silver staining was used to confirm the presence of both TDH and KBL in the 
fractions corresponding to each peak.  Whilst the elution volume at the second peak suggested 
the presence of TDH and KBL dimers, the earlier peak corresponded to either a multimer of one 
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protein, or a multi-enzyme complex of the two proteins together.  Silver staining suggested that 
both proteins were present in the sample (see Figure 3.1.32). 
 
Figure 3.1.32 - silver stain of an SDS-PAGE gel indicating the presence of TDH and KBL in fractions that 
corresponded to peaks on the chromatogram resulting from the size-exclusion chromatography of a mixture of 
TDH and KBL.  1 = fraction at 12-14ml elution (peak at 12.5ml).  2 = fraction at 16-18ml(peak at 16.75ml).  The 
protein bands in Lane 1 are light, suggesting that the concentration of both proteins was very low.  This is 
consistent with the fact that the corresponding peak was low.  In Lane 2, which analyses a fraction corresponding 
to a much larger peak, the bands are less distinguishable, due to over-staining in this lane.  As the protein 
concentrations were high, bands corresponding to both proteins can still be seen.  
The cross-linking studies carried out using dimethyl suberimidate (DMS) provide more evidence 
in regards to the oligomeric states of TDH and KBL (see methods in Section 2.1.4.2).  In Figure 
3.1.33 it can be seen that there are protein bands representing the TDH dimer and the 
monomeric form.  Likewise, there are protein bands representing KBL monomers and dimers on 
the gel.  The concentration of the protein did not appear to affect these results.  These findings 
add strong support to the hypothesis that the native oligomeric states of both TDH and KBL are 
dimers.  There appear to be light protein bands near the top of the gel for which the molecular 
weight cannot be determined.  It is likely that these bands are formed from non-specific cross-
linking by DMS. 
1 2 M 
18.0 kDa 
25.0 kDa 
45.0 kDa 
35.0 kDa 
66.2 kDa 
116.0 kDa 
KBL 
TDH 
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Figure 3.1.33 - SDS PAGE analysis of cross-linking experiments with TDH and KBL, on a 9% polyacrylamide gel. 1 = 
TDH (2.6 x 10
-2
 mM[1mg/ml]); 2 = TDH (1.3 x 10
-2
 mM [0.5mg/ml]); 3 = TDH (2.6 x 10
-2
 mM [1mg/ml]) non-cross-
linked control; 4 = KBL (2.2 x 10
-2
 mM [1mg/ml]); 5 = KBL (1.1 x 10
-2
 mM [0.5mg/ml]); 6 = KBL (2.2 x 10
-2
 mM 
[1mg/ml]) non-cross-linked control; 7 = TDH (2.6 x 10
-2
 mM [1mg/ml])and KBL (2.2 x 10
-2
 mM [1mg/ml]); 8 = TDH 
(1.3 x 10
-2
 mM [0.5mg/ml]) and KBL (1.1 x 10
-2
 mM [0.5mg/ml]); 9 = BSA control (1.5 x 10
-2
 mM [1mg/ml]).  Note 
that the protein bands of samples exposed to DMS appear higher due to covalent binding with DMS, leading to a 
higher molecular weight.  This is also the cause of there being more than one band corresponding to a particular 
oligomer.  The results indicate that both TDH and KBL form dimers in solution, but there is no evidence here 
suggesting that they form a complex together.  Dimerisation was not affected by the protein concentration used 
in these assays.  
Experiments conducted with TDH and KBL together do not suggest that the two proteins are 
complexed in solution, as there are no additional bands present (Figure 3.1.33, lane 7 and 8), 
compared to when samples of the two proteins alone were tested (Figure 3.1.33, lanes 1, 2, 4 
and 5).  This conflicts with the finding presented in Figure 3.1.32.  Therefore, the existence of a 
TDH-KBL complex can neither be confirmed nor rejected, based on these findings. 
 
Figure 3.1.34 - SDS PAGE analysis of cross-linking experiments with TDH (at 2.6 x 10
-2
 mM [1mg/ml] 
concentration) on a 9% polyacrylamide gel. 1 = TDH; 2 = TDH and 1mM NAD
+
; 3 = TDH and 10mM NAD
+
; 4 = TDH, 
1mM NAD
+
 and 30mM L-threonine; 5 = TDH, 10mM NAD
+
 and 30mM L-threonine; 6 = TDH, 10mM NAD
+
 and 
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15mM L-threonine; 7 = 10mM NAD
+
 and 30mM L-threonine control.  The oligomerisation of TDH did not appear 
to be affected by the presence of substrates.  All TDH samples showed strong bands representing the dimer and 
the monomer.  
As in the size-exclusion chromatography experiments, the influence of substrates on the 
oligomeric states of TDH and KBL was investigated.  As can be seen in Figure 3.1.34, the 
oligomerisation of TDH, as indicated through cross-linking with DMS, does not appear to be 
significantly affected by NAD
+
 and/or L-threonine. 
 
Figure 3.1.35 - SDS PAGE analysis of cross-linking experiments with KBL (2.2 x 10
-2
 mM [1mg/ml]) on a 9% 
polyacrylamide gel. 1 = KBL; 2 = KBL and 1mM PLP; 3 = KBL and 30mM glycine; 4 = KBL and 5mM A-CoA; 5 = KBL, 
1mM PLP and 30mM glycine; 6 = KBL, 1mM PLP and 5mM A-CoA; 7 = KBL, 1mM PLP, 5mM A-CoA and 30mM 
glycine; 8 = KBL, 5mM A-CoA and 30mM glycine.  
Incubation of A-CoA and/or PLP with KBL and DMS does not seem to have an effect on the 
apparent oligomerisation of the protein.  Conversely, glycine appears to either inhibit 
dimerization or to promote dissociation of KBL.  In the absence of glycine, KBL appears 
predominantly as a dimer.  However, in the presence of glycine the majority of KBL is present 
as the monomer.  There is the possibility that glycine interacted with DMS, as the reagent reacts 
with free amines.  However, the reaction buffer contained 200mM of Tris, and this did not inhibit 
the other cross-linking reactions. 
 
The pull-down assay using His-tagged KBL and native TDH was in agreement with the data 
from the cross-linking studies and the majority of the data from size-exclusion chromatography 
studies, that TDH and KBL do not appear to form a complex with each other in solution.  When 
applied to the Ni-NTA column, non-tagged TDH was washed through with the wash buffer.  
Meanwhile, KBL was retained on the column, and elution with the 250mM imidazole elution 
35.0 kDa 
45.0 kDa 
66.2 kDa 
116.0 kDa 
M 2 4 6 3 5 7 1 8 
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buffer caused KBL to elute alone, demonstrating that the two proteins had not bound to each 
other or remained bound to each other. 
 
Figure 3.1.36 - SDS PAGE analysis of the pull-down assay to investigate complex formation between TDH and KBL.  
1 = original TDH sample; 2 = TDH and thrombin; 3 = TDH removed by washing the solution through a Ni-NTA 
column and benzamidine column attached end-to-end; 4 = eluate collected on elution of histidine tag from Ni-
NTA column; 5 = elution of thrombin (MW approx. 37 kDa) from the benzamidine column; 6 = solution flowing 
through Ni-NTA column as KBL is loaded; 7 = solution flowing through the Ni-NTA column as TDH is loaded; 8 = 
solution flowing through the Ni-NTA column as the column is washed with binding or wash buffer; 9 = eluate 
containing KBL after applying elution buffer to the column.  The His-tag was successfully removed from TDH and 
thrombin was separated from this mixture.  His-tagged KBL was retained on a Ni-NTA column, but the untagged 
TDH was not retained, despite being incubated in the column with KBL overnight.  This suggests that a stable 
complex does not form between the two proteins.   
The dimeric nature of TDH and KBL has been confirmed by size-exclusion chromatography, 
cross-linking and X-ray crystallographic models (for TDH).  Although the data on the existence 
of a TDH-KBL complex are inconclusive, the findings presented here give a strong indication 
that a number of different oligomeric states exist for both TDH and KBL.  Evidence from size-
exclusion chromatography indicates that L-threonine promotes the dissociation of TDH, either 
through binding or through the catalytic action of the enzyme on it.  Evidence from size-
exclusion chromatography and cross-linking studies also suggest that glycine effects the 
oligomerisation of KBL.  Finally, there is a possibility that TDH and KBL do affect each other’s 
quaternary structure, as indicated by the results of size-exclusion chromatography experiments.  
The inability to grow complexed crystals of TDH and KBL, adding to the negative cross-linking 
and pull-down assay results, suggests that a multi-enzyme complex does not exist.  However, 
this does not rule out the existence of a transitory complex, so this cannot be confirmed using 
these data alone. 
3.1.7 Ligand binding and Catalysis 
As can be seen in Figure 3.1.22 and Figure 3.1.23, the TDH substrates NAD+ and L-threonine 
occupy a deep cleft in the protein.  The L-threonine binding pocket and the pocket that is 
occupied by the nicotinamide group of NAD
+
 are partially separated by the side chain of Met81.  
6 
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Whilst the nicotinamide and the adjacent ribose groups bind in deep pockets of the protein, the 
rest of the NAD molecule faces the exterior of the protein.  NAD binds TDH through a 
combination of hydrogen bonds and hydrophobic interactions with several main chain and side 
chain atoms of TDH residues.  The interactions with important TDH residues are displayed in 
Figure 3.1.37 and Figure 3.1.38.  In addition to the interactions that NAD makes with the protein, 
the cofactor also hydrogen bonds with several water molecules.  This is particularly the case for 
the phosphate groups, the ribose hydroxyl groups and the nicotinamide amide. 
 
Figure 3.1.37 - Binding of NAD
+
 to TDH.  The interaction between TDH and NAD involves a combination of 
hydrogen-bonding and hydrophobic interactions.  TDH is shown in a ribbon representation with stick 
representations of the side-chains of residues that appear to interact with NAD.  Water molecules are shown as 
red spheres at the position of the oxygen atom.  Hydrogen bonds are shown by red lines.  
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Figure 3.1.38 - binding interactions between TDH residues and NAD
+
.  Hydrogen bonds are indicated by straight 
dotted lines.  Curved green lines indicate hydrophobic interactions, and the residues involved are also labelled in 
green text.  The diagram was created using PoseView(270–272), and the ligand files were converted to .sdf file 
format from .pdb files using Open Babel(227).  
The X-ray crystallographic model TNADH4, revealed the binding mode of L-threonine.  The 
enzyme was co-crystallised with NADH to prevent turnover.  L-threonine is bound predominantly 
through hydrogen bonds with active site residues.  The carboxyl group of L-threonine appears 
to hydrogen bond with side chain and main chain atoms of Ser82 and Thr186.  The amine 
group of L-threonine is seen to hydrogen bond with the side chain hydroxyl group of Thr86, with 
the nicotinamide carbonyl of NADH and with a nearby water molecule.  The side chain hydroxyl 
group of L-threonine is hydrogen bonded to Thr119 and Tyr144, whilst the methyl group is 
directed towards the hydrophobic amino acid Trp280.  This aligns the β-carbon with the C4 
atom of the nicotinamide ring.  The relevance of this will be discussed in more detail below.  All 
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of the residues involved in TDH binding are highly conserved (see section 3.1.3), so they are 
likely to be essential.  Another interesting feature of this model was that the flexible Loop 1 is 
closed over the active site, meaning that the exterior of the enzyme is no longer accessible to L-
threonine.  This was the case in both TDH monomers in the asymmetric unit of the crystal 
model, both of which were bound to NADH and L-threonine. 
 
Figure 3.1.39 - binding of L-threonine to TDH. TDH is shown in its ribbon representation, whilst the side chains of 
interacting amino acids and NADH are represented as sticks.  Red lines signify hydrogen bonds, for which the 
putative bonding distances are labelled in red text.  The top image is a close-up that clearly shows the 
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interactions between L-threonine and different TDH residues.  The bottom image shows how Loop 1 is closed 
over the active site, sealing it off from the external environment of the enzyme.  
 
Figure 3.1.40 - interactions between TDH residues and L-threonine, as determined from interatomic distances in 
the X-ray crystallographic model TNADH4.  Straight dotted lines indicate hydrogen bonds.  This image was 
generated by PoseView(270–272) and the ligand file was converted from the .pdb file to .sdf file format using 
Open Babel(227).  
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Figure 3.1.41 - binding of L-allo-threonine to TDH, observed in X-ray crystallographic model AAT1.  TDH is shown 
in a ribbon representation, and the side chains of interacting amino acids, NAD
+
 and L-allo-threonine are in stick 
representations.  In contrast to the L-threonine-bound TDH structure, Loop 1 is in its open conformation.    
The binding mode of L-allo-threonine that was found in the X-ray crystallographic model AAT1 
is very similar to that of L-threonine.  However, the change in the stereochemistry at the β-
carbon means that its orientation is changed slightly.  The carboxyl group of L-allo-threonine 
hydrogen bonds with the side chain hydroxyl group and the main chain nitrogen atom of Ser82 
in a similar manner to L-threonine.  It also seems likely that this group interacts with Thr86.  The 
side-chain hydroxyl group of L-allo-threonine is hydrogen-bonded by Thr119 and Tyr144, but 
the S configuration of this group means that the distance between the β-carbon and the C4 of 
the NAD nicotinamide group is increased.  The difference in stereochemistry of L-allo-threonine 
(2S,3S configuration), compared to L-threonine (2S,3R configuration), has been cited as a 
reason for the lack of catalysis of L-allo-threonine by TDH(200).  The difference in 
stereochemistry also affects the entire orientation of the molecule.  As a result, the amino group 
of L-allo-threonine is at a further distance from Thr186 and the nicotinamide amide than the 
amine group of L-threonine.  In model AAT1, the flexible loop 1 is in an open conformation in a 
monomer where L-allo-threonine is bound, which contrasts with the finding that the flexible loop 
is closed where L-threonine is bound in NADH4. 
In another TDH structure model, which was solved in this laboratory by Dr Peter Erskine, 
pyruvate is also seen to occupy the L-threonine binding site.  It seems to exploit similar binding 
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partners to L-threonine: Ser82, Thr119, Tyr144 and Thr186.  As was observed with L-threonine-
bound structures, Loop 1 was in its closed conformation. 
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Figure 3.1.42 - binding of pyruvate to TDH, as observed in an X-ray crystallographic structure.  As can be seen in 
the upper image, Loop 1 is in its closed conformation when pyruvate is bound.  The lower image shows the 
binding interactions from a closer perspective.  Pyruvate shares some of the same binding partners as TDH.  
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3.1.7.1 Mechanism of Action 
Having insight into the three-dimensional structure of TDH bound to its substrates provides 
information alluding to the mechanism of catalysis.  The nicotinamide and L-threonine binding 
pockets lie adjacent to each other and, when occupied by the respective substrates, they allow 
NAD and L-threonine to be in close enough proximity for catalysis.  The putative mechanism of 
reaction of TDH involves transfer of a hydride from the β-carbon of L-threonine to the C4 atom 
of the nicotinamide ring.  The data presented here confirm that the atoms involved in this 
reaction are well aligned and at a distance that would permit such a reaction to happen (see 
Figure 3.1.22 and Figure 3.1.39).  The catalytic process involves the extraction of a proton from 
the side chain hydroxyl group of L-threonine, which is converted to a carbonyl group as the 
negatively-charged oxygen atom forms a double bond with the electron-deficient β-carbon.  The 
removal of the proton from the hydroxyl group requires a number of structural features to be 
present in the enzyme, and a number of said features are found to be conserved in SDR 
enzymes.  One such feature is the presence of a “catalytic triad”, which in TDH from T. brucei 
includes Thr119, Tyr144 and Lys148.  The importance of these residues has been 
demonstrated above.  Another feature is a chain of water molecules that is believed to form a 
proton relay that transfers the proton to the bulk solution, allowing the enzyme to catalyse 
another reaction.  This water chain requires a certain orientation of residues to bind the water 
molecules.  One widely conserved feature in SDRs is an interaction between an asparagine 
side chain and the main chain of another residue.  In this case, the interaction occurs between 
Asn96 and Ile80.  The binding of the Asn96 causes a kink in the α-helix that it belongs to and 
changes the orientation of its carbonyl group.  This allows the carbonyl group to hydrogen bond 
one of the water molecules in the water chain.  Figure 3.1.43 shows that this feature was also 
confirmed to be present in TDH from T. brucei. 
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Figure 3.1.43 - hydrogen bonding between the side chain of Asn96 and main chain atoms of Ile80 changes the 
orientation of the carbonyl of Asn96, allowing it to hydrogen bond a water atom that is proposed to be important 
in the proton relay of SDR enzymes.  
In the putative proton relay, the proton is extracted from L-threonine by Tyr144.  The proton 
then passes to a ribose oxygen on NAD, then to the amine side-chain of Lys148 and then on to 
a chain of water molecules, including the water molecule that is hydrogen bonded by the main-
chain carbonyl of Asn96.  A full water chain that would allow the proton to be transferred to the 
surrounding solution was not identified in any of the structures presented here.  However, 
Figure 3.1.44 shows how the existence of a proton relay system is highly likely.  The distances 
between the important amino acids and the water molecules seem to confirm this.  Part of a 
water chain was present in each structure model solved. 
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Figure 3.1.44 - atoms within hydrogen-bonding distance of each other, which may form part of a proton relay system.  A proton extracted from the hydroxyl group of L-threonine could 
pass from Tyr144, to the NAD ribose oxygen, then to Lys148, to the water molecule that is hydrogen-bonded to Asn96, and then onto other nearby water molecules.  A complete water 
chain was not observed and it was not clear if a direct network of water molecules linking the Lys148 to the bulk solvent was present.
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3.1.7.2 Other features observed in crystallographic models 
Molecules from the storage buffer and from the crystallisation solutions co-crystallised with TDH 
were found to be bound to it.  Glycerol, acetate, sulphate ions and sodium ions were all 
observed in TDH structure models.  The molecules occupied various positions, but a few 
positions were occupied in a repeatable manner.  Most notably, glycerol and acetate bound 
within the L-threonine binding site (see Figure 3.1.45).  Glycerol was also found to bind to the 
same regions in different TDH models (shown in Figure 3.1.46). 
 
Figure 3.1.45 - binding positions in the active site of TDH occupied by glycerol (left) and acetone (right).  These 
positions were observed in more than one monomer and/or structure model.  The molecules interact with the 
same residues as L-threonine.  Glycerol binds predominantly with Ser82, whilst acetone binds with Thr119 and 
Tyr144.  
 
Figure 3.1.46 - two more binding positions of glycerol on TDH.  Glycerol molecules were often found adjacent to 
the residue Arg159 (shown left) and Asp17 (shown right).  
Typically, TDH monomers that were a part of different dimers would be separated from other 
monomers by an ordered array of water molecules.  However, one interaction between two 
monomers in separate dimers was observed in model AAT1.  Interestingly, the interaction is 
formed between residues of the flexible Loop 2 region (see Figure 3.1.15).  The interaction 
does not appear to be strong enough to be an important physiological interaction, so it is likely 
to be a result of the crystallisation process. 
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Figure 3.1.47 - an interaction between two TDH monomers at the Loop 2 region (Pro44-Gly50).  A ribbon 
representation with stick-represented side chains (left) and a stick representation (right) are shown.  
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3.2 TDH kinetics 
3.2.1 Kinetic Characteristics of TDH 
Initial studies of TDH kinetics in the presence of different combinations of NAD
+
 and L-threonine 
concentrations established the saturating concentration as 10mM and 30mM for NAD
+
 and L-
threonine, respectively (see methods in Section 2.2.1). 
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Figure 3.2.1 - kinetic plots and Lineweaver-Burk plots of rate of TDH activity (v) as a function of substrate concentration.  A - v as a function of L-threonine concentration at fixed 
concentrations of NAD
+
; B - v as a function of NAD
+
 concentration at different fixed concentrations of L-threonine; C - Lineweaver-Burk plot of A; D - Lineweaver-Burk plot of B.  Lines of 
best fit in A and B were fit to the Michaelis-Menten equation and/or Hill equation.  Rates of activity generally increased at higher substrate concentrations.  Fitted lines or curves are 
dotted where higher substrate concentrations cause a decrease in activity, relative to a lower concentration. See Figure 2.2.5 for the method of derivation of these graphs.
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The patterns of lines in the double-reciprocal plots (Lineweaver-Burk plots) in Figure 3.2.1 
indicate that TDH acts by an ordered sequential Bi Bi mechanism of action.  This means that 
one substrate binds to the free enzyme, prior to the binding of the second substrate.  The order 
of binding can be compulsory or random.  However, taking into consideration the data from X-
ray crystallography, it can be concluded that the observed kinetic behaviour is probably 
indicative of a compulsory ordered mechanism, with NAD
+
 binding first, as illustrated in Figure 
3.2.2.  The pattern of lines of decreasing slopes (from 1 – 5mM NAD+) in Figure 3.2.1C 
suggests that L-threonine binding is dependent on the NAD
+
 concentration, and thus, NAD
+ 
binding to TDH.  Conversely, in Figure 3.2.1D, the lines of best fit are more or less parallel with 
each other, suggesting that the L-threonine concentration, and therefore L-threonine binding to 
TDH, does not have a large influence on NAD
+
 binding.  This indicates that NAD
+
 is the 
substrate that must bind to TDH first, making this a compulsory ordered sequential mechanism. 
The structural data on TDH and its interaction with its substrates, and the data from inhibitory 
assays (see below) provide further confirmation of a compulsory ordered mechanism of action. 
 
Figure 3.2.2 - Drawing illustrating a Compulsory Ordered Bi Bi mechanism of enzyme catalysis.  The first 
substrate, NAD
+
 binds to the enzyme (E), then the second substrate, L-threonine (T), binds.  
In Figure 3.2.1, it can be seen that, above certain NAD+ and L-threonine concentrations, the 
catalytic rate decreases (see dotted curves and lines).  This is caused by inhibition of TDH at 
high substrate, and subsequently, at high product concentrations.  Figure 3.2.3 shows the 
effects of higher substrate concentrations on TDH activity.  Above 10mM NAD
+
, the rate of 
activity decreases significantly.  This effect is much more pronounced than the decrease in 
activity at L-threonine concentrations above 30mM. 
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Figure 3.2.3 - Plots of catalytic rate (v) as a function of substrate concentration, showing signs of substrate 
inhibition.  Curves are fitted to the data using an equation that accounts for the effect of substrate/product 
inhibition on rate.  
In the case of NAD
+
, it is possible that the inhibition is caused by inhibition with the product of 
the reaction, NADH.  The fact that the oxidised and reduced forms of the cofactor are almost 
identical means that there is a high possibility that TDH has a similar affinity for both.  Therefore, 
as the rate of NADH formation increases above a certain threshold, it begins to inhibit the 
binding of NAD
+
. 
 
The data for NAD
+ 
fit to an equation describing substrate inhibition with an R
2
 
value of 0.8457.  The predicted Ki was 43.5mM and the KM for NAD
+
 was 2.1mM. 
Up to concentrations of 10mM, the relationship between NAD
+
 concentration and rate 
conformed to normal Michaelis-Menten kinetics.  When fit to the Hill modification of the 
Michaelis-Menten equation (Equation 11), the calculated Hill coefficient was 0.97 at 37°C and 
1.03 at 23°C, suggesting that NAD
+
 binding is not cooperative.  Slightly different values of KM, 
0.99mM and 0.66mM, were calculated at 37°C and 23°C, respectively.  These values are 
similar to each other, but lower than that calculated by the substrate inhibition equation because 
they do not account for the inhibitory effect of NADH on the Vmax that would be achieved in the 
absence of inhibition. 
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Figure 3.2.4 - plots of v against NAD
+
 concentration, measured at 37°C and 23°C.  The data were fit to equation 
11.  
In contrast to the data obtained for NAD
+
, the data showing the relationship between L-
threonine concentration and rate exhibited an atypical, double-sigmoidal pattern that could not 
be described by the Michaelis-Menten equation or the Hill equation.  As the L-threonine 
concentration approaches 15mM, the rate of activity plateaus.  However, as the concentration is 
increased further, there is a sharp increase in activity up to 30mM L-threonine. 
 
Figure 3.2.5 - plots of v versus L-threonine concentration at 23°C and 37°C.  Data corresponding to lower and 
higher L-threonine concentrations were fit separately to equation 11, as the data were not well fit to a single 
curve.  
163 
 
Using the data analysis software, Origin Pro, the two sigmoidal portions of the curve were fit 
separately, giving two values each for KM,  Vmax, the maximal rate of activity at each plateau, 
and kcat, the turnover number or number of reactions catalysed by each active site.  At 37°C: 
KM
1
 = 5.34mM, Vmax
1
 = 5.22 x 10
-3
mM.s
-1
, kcat
1
 =14.95s
-1
; KM
2
 = 21.55mM, Vmax
2
 = 6.56 x 10
-
3
mM.s
-1
, kcat
2
 =18.78s
-1
.  At 23°C: KM
1
 = 8.16mM, Vmax
1
 = 3.39 x 10
-3
mM.s
-1
, kcat
1
 =9.70s
-1
; KM
2
 = 
22.73mM, Vmax
2
 = 4.78 x 10
-3
mM.s
-1
, kcat
2
 =13.70s
-1
.  Both curves show evidence of positive 
cooperativity, with similar Hill coefficients of 4 at 37°C and 4.7 at 23°C being calculated for the 
first portion of the curve.  However, the Hill coefficients calculated for the second portion of each 
curve are largely different: 23.3 at 37°C and 187.22 at 23°C.  The variance in values of h, 
coupled with the unfeasibility of these values as reflections of the number of cooperative active 
sites, clearly shows that the Hill equation is not entirely valid in this case. 
The variable exponent, q, proposed by Kurganov and colleagues(157) can be used to describe 
the cooperative behaviour of TDH at different concentrations of L-threonine: 
 
𝑣 = 𝑉𝑚𝑎𝑥
[𝑆]𝑞
[𝑆]0.5
𝑞 + [𝑆]𝑞
 23  
In this description of cooperative enzyme activity, the rate, v, is dependent on the relationship 
between Vmax, the maximal rate of activity, [S], the substrate concentration, and the invariable 
exponent, q. [S]0.5 is similar to the Michaelis-Menten constant KM and represents the substrate 
concentration that produces 50% of the Vmax.  Values of q at different concentrations of L-
threonine were determined iteratively using data collected at 37°C.  As q describes the 
relationship between substrate concentration and cooperativity, the values should be similar at 
any temperature.  When these q values were used to calculate estimates of v at 23°C using the 
modified Hill equation, an R
2
 of 0.98 was calculated. 
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Figure 3.2.6 - plots of v versus [L-threonine], with data points predicted using the inconstant exponent q (dark 
and light blue lines).  Values for q were calculated at each L-threonine concentration from the data collected at 
37
o
C and used to calculate data points, which are represented by a line.  
Although q does not provide information on mechanisms of cooperativity, it can describe the 
progressive change in binding affinity, and consequently catalytic activity, and the substrate 
concentration.  Figure 3.2.7 shows a plot of the q values corresponding to each L-threonine 
concentration in the equation 23, which describes the double-sigmoidal curves in Figure 3.2.6. 
 
Figure 3.2.7 - plot of q against corresponding L-threonine concentrations.  A curve described by a polynomial 
equation was fit to the data to highlight the relationship between q and increasing L-threonine concentrations.  
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In Figure 3.2.7 it can be seen that q increases with L-threonine concentration up to 7.5mM, at 
which point it starts to decrease.  The value of q reaches a minimum between 15 and 20mM L-
threonine, which corresponds to a plateau in activity, before increasing sharply as the 
concentration is increased further. 
An equation to which a double sigmoidal curve can be fitted was proposed by Selwood et al. to 
describe the catalytic activity of human porphobilinogen synthase(273).  This equation actually 
describes a model where the rate of activity is the sum of activity produced by two active sites of 
different affinity. 
 
𝑣 =
𝑉𝑚𝑎𝑥1 ∙ [𝑆]
𝐾𝑀1 + [𝑆]
+
𝑉𝑚𝑎𝑥2 ∙ [𝑆]
𝐾𝑀2 + [𝑆]
 24  
In the equation above, which describes activity of two different forms of an enzyme, KM1 and 
Vmax1, and KM2 and Vmax2 are the half-saturating substrate concentrations and maximal rates of 
reactions for a high-affinity form of the enzyme and a low-affinity form, respectively.  The high 
affinity form is predominantly responsible for the activity at lower substrate concentrations, 
whilst the low affinity form has a higher KM and is responsible for the activity at higher substrate 
concentrations.  As discussed above, when described separately, both halves of the curve show 
evidence of cooperativity.  For this reason, the Hill coefficient h was applied to the equation 
above, so that it resembled a summation of two Hill equations. 
 
𝑣 =
𝑉𝑚𝑎𝑥1 ∙ [𝑆]
ℎ1
𝐾𝑀1
ℎ1 + [𝑆]ℎ1
+
𝑉𝑚𝑎𝑥2 ∙ [𝑆]
ℎ2
𝐾𝑀2
ℎ2 + [𝑆]ℎ2
 25  
Two separate Hill coefficients are designated for each form of the enzyme, and hence each part 
of the curve: h1 and h2.  A plot of rate versus L-threonine concentration at 23°C, fit to equation 
25 is shown in Figure 3.2.8. 
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Figure 3.2.8 - plot of v versus L-threonine concentration.  The data were fit to a curve based on equation 25.  R
2
 = 
0.94.  The curve was fit by constraining KM1 to 6mM, Vmax1 to 3.4 x 10
-3
mM.s
-1
, h1 to > 2 and KM2 to 24mM.  
With a R
2
 of 0.94, the equation clearly described the data well.  However, in order for the data 
analysis software Prism to fit it, it was necessary to constrain several of the equation’s 
parameters.  In particular, it was necessary to constrain Vmax
1
 to one of the values from the first 
plateau in the curve, and the two KM values were constrained using values obtained by 
separately fitting each half of the curve to the Hill equation, as described earlier. 
 
The results of a test of the ability of different amino acids (at 60mM) to inhibit TDH activity, or to 
be catalysed by TDH (see Section 2.2.4) are displayed in Table 3.2.1. 
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Table 3.2.1 - TDH activity in the presence of 60mM of various amino acids.  The 'Inhibition' column shows the TDH 
activity (as a percentage of activity in control conditions) achieved with saturating substrate concentrations and 
the amino acid.  The 'Catabolism' column lists the percentage activity of TDH in the presence of 10mM NAD
+
 and 
60mM of amino acid.  
 Inhibition Catabolism 
Amino acid Percentage activity ± SD Percentage activity ± SD 
L-alanine 70.76% ± 3.57% 0.11% ± 0.56% 
L-cysteine 39.39% ± 4.78% -0.25% ± 0.80% 
L-aspartic acid 68.71% ± 4.20% 1.16% ± 0.52% 
L-glutamic acid 74.78% ± 0.08% 0.97% ± 0.51% 
L-phenylalanine 86.39% ± 2.32% 0.77% ± 0.84% 
glycine 80.44% ± 2.75% -0.48% ± 0.97% 
L-histamine 77.74% ± 0.34% 1.63% ± 0.12% 
L-isoleucine 88.30% ± 7.37% 1.82% ± 0.33% 
L-lysine 97.69% ± 2.20% 1.67% ± 0.54% 
L-leucine 93.14% ± 4.46% 1.75% ± 0.49% 
L-methionine 89.34% ± 22.19% -0.30% ± 2.07% 
L-asparagine 91.99% ± 11.85% -1.31% ± 1.31% 
L-proline 96.63% ± 3.73% -0.35% ± 0.52% 
L-glutamine 126.87% ± 2.95% 0.21% ± 0.15% 
L-arginine 101.64% ± 5.99% 0.30% ± 0.42% 
L-serine 99.22% ± 12.92% 0.91% ± 0.10% 
L-valine 92.72% ± 0.02% -0.27% ± 1.18% 
L-tryptophan 99.25% ± 41.58% 1.39% ± 3.17% 
 
Based on the results above, the following amino acids appear to inhibit TDH: L-alanine, L-
cysteine, L-aspartic acid, L-glutamic acid, L-phenylalanine, glycine, L-histamine, L-isoleucine 
and L-leucine.  L-cysteine is the most significant inhibitor of this list, causing more than 60% 
inhibition (39.4% residual activity).  Studies on the ability of TDH to catalyse an oxidative 
reaction in the absence of L-threonine, but in the presence of another amino acid, highlighted 
the following amino acids as possible substrates for TDH: L-histamine, L-isoleucine, L-lysine 
and L-leucine.  All of these amino acids show average activity rates that were less than 2% of 
the activity exhibited by TDH with 30mM L-threonine.  These data suggest that TDH is highly 
selective for L-threonine, although it may have weak affinity for other amino acids.  Another 
observation of interest is the apparent stimulation of TDH activity by L-glutamine.  As this amino 
acid does not appear to be a substrate for TDH, it raises the possibility that it could stimulate the 
enzyme by allostery. 
3.2.2 Alteration and Optimization of TDH activity 
The velocity of TDH activity is higher at 37°C than at room temperature, 23°C.  The plots of 
[substrate] versus rate at each temperature fit to curves with similar profiles and appear to be 
parallel (see Figure 3.2.5 and Figure 3.2.6).  Thus, the increase in rate may be explained simply 
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by an increase in the kinetic energy of substrates for the reaction as the temperature increases.  
To confirm this, a rearrangement of the Arrhenius equation: 
 
𝐸𝑎 = ln 𝑘𝑐𝑎𝑡 + ln (
𝑘𝐵𝑇
ℎ
) × (𝑅𝑇) 26  
where Ea is the activation energy for catalysis, kB is Boltzmann’s constant, h is Planck’s 
constant, T is temperature (in Kelvin) and R is the ideal gas constant, was used to calculate 
very similar Ea values from kcat
 
of 33.015kJ (7.891kcal) at 37°C (310K) and 31.375kJ (7.523kcal) 
at 23°C 296K. The difference in activation energy is not significant.  These results suggested 
that inhibitory assays and screening could be carried out at either temperature. 
 
The methods for various investigations of factors affecting TDH activity are described in Section 
2.2.2.  The results of those investigations are described below.  There was a linear relationship 
between the concentration of the TDH enzyme and the rate of catalysis at saturating substrate 
concentrations.  This implies that the catalytic eficiency is not dependent on the enzyme 
concentration, at least across the range of concentrations that provide an appropriate signal for 
measurement. 
 
Figure 3.2.9 – a fit of v against TDH concentration.  All points lie very close to a line fit by linear regression (R
2
 = 
0.9989).  
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TDH was found to catalyse at higher rates in the alkaline pH range (see Figure 3.2.10).  At pH 6, 
TDH activity is very low, relative to higher pH levels.  The rate of activity reaches its peak at an 
optimum that lies approximately between pH 8.5 and 9.5.  Above pH 9.5, the rate of activity 
lowers significantly, but appears to plateau between pH 10.5 and 11.5.  For this reason, the pH 
of the reaction buffer for enzyme assays was maintained at pH 8.5.  Measurement of the rate of 
TDH activity was not possible at pH 12.5 and above, as a spontaneous increase in absorbance 
at 340nm, presumably caused by breakdown of NAD
+
, was observed under these conditions. 
 
Figure 3.2.10 - a plot of v against pH.  The optimum pH for TDH activity appears to lie in the region of pH 8.5 - 9.5.  
The presence of other additives in the reaction buffer was shown to have no significant effect on 
TDH activity.  In assays where TDH was added to the rest of the reactants to initiate the 
reaction, the presence of glycerol, up to concentrations of 200mM, and Triton X-100, at 
concentrations up to 0.1% v/v had no significant effect on TDH activity. 
As most enzymatic assays were carried out using an enzyme carrying a poly-histidine tag (His-
tag), some TDH with the His-tag removed by thrombin cleavage (see Methods) was tested to 
ensure that the His-tag did not have any appreciable effect on the kinetic characteristics of TDH. 
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Figure 3.2.11 - the velocity of catabolism by de-tagged TDH, as a function of NAD
+
 concentration.  A curve 
describing the Michaelis-Menten equation is fitted to the data.  
The relationship between L-threonine concentration and reaction velocity also appeared to be 
similar to that shown in Figure 3.2.8, which indicated that the presence of the His-tag was not an 
underlying cause behind this atypical kinetic behaviour.  Figure 3.2.13 shows how the data may 
be described well by equation 25.  
 
Figure 3.2.12 - plot of de-tagged TDH enzyme velocity against L-threonine concentration.  A curve described by 
the Hill-modified Michaelis-Menten equation  (Equation 11) was fitted to the data.  
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Figure 3.2.13 - plot of de-tagged TDH velocity against L-threonine concentration.  A curve described by equation 
25 was fitted to the data.  
By measuring the effects of different monovalent ions, divalent ions and covalent modifiers on 
an enzyme’s activity, one can gain useful information on important structural features and 
functional groups.  Table 3.2.2 and Table 3.2.3 list the results of assays that measure the effect 
on TDH activity of incubating the enzyme with various metal salts, covalent modifiers and 
chelators.
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Table 3.2.2 - the effect of different metal salts and covalent modifiers on TDH activity. *The inhibitory activities of 
N-ethylmaleimide and iodoacetamide were determined by measuring activity at increasing incubation times (see 
Figure 3.2.14).  
Compound Percentage activity ± SD 
Na2SO4 108.5% ± 17.7% 
Zn(CH3CO2)2 -2.3% ± 2.9% 
ZnSO4 0.4% ± 5.3% 
CoCl2 72.4% ± 16.2% 
MnCl2 105.1% ± 8.8% 
CdCl2 -1.4% ± 4.0% 
CuCl2 -2.0% ± 5.5% 
FeSO4 59.3% ± 14.4% 
FeCl3 69.3% ± 16.6% 
CaCl2 80.8% ± 7.8% 
EDTA (5mM) 111.4% ± 11.4% 
AgNO3 2.5% ± 3.9% 
HgCl2 -1.6% ± 4.8% 
N-ethylmaleimide (0.5mM)* 0.0% 
iodoacetamide (5mM)* 0.0% 
 
The divalent cations, zinc, cadmium, copper, aluminium and mercury, all eliminated TDH activity 
at 1mM concentrations.  Cobalt and calcium ions also caused inhibition, but were less potent 
than the other ions.  Manganese had no effect on TDH activity at the concentration tested.  
Incubation of TDH with 5mM EDTA overnight did not inhibit catalytic activity.  This suggests that 
divalent cations are not necessary for TDH activity or stability.  Silver nitrate (AgNO3) and 
mercury (II) chloride were found to cause instant inhibition of TDH.  On the other hand, the 
covalent modifiers N-ethylmaleimide and iodoacetamide caused a gradual inhibition that 
increased with the time of incubation with TDH (see Figure 3.2.14). 
 
 
Figure 3.2.14 - the time-dependent inactivation of TDH by N-ethylmaleimide and iodoacetamide. 
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Table 3.2.3 - the effects of different concentrations of monovalent cations on TDH activity. 
Ion (salt) Concentration Percentage Activity ± SD 
K
+
 (KCl) 0.25 mM 107.7% ± 2.8% 
 0.5 mM 91.9% ± 2.7% 
 1.0 mM 103.6% ± 3.3% 
 2.0 mM 122.3% ± 4.9% 
 5.0 mM 122.8% ± 16.5% 
 10.0 mM 124.2% ± 0.1% 
NH4
+
 (NH4Cl) 0.25 mM 102.1% ± 0.8% 
 0.5 mM 105.6% ± 3.5% 
 1.0 mM 107.6% ± 1.0% 
 2.0 mM 108.4% ± 5.0% 
 5.0 mM 123.4% ± 0.5% 
 10.0 mM 121.3% ± 3.7% 
Rb
+
 (RbCl) 0.25 mM 119.0% ± 18.6% 
 0.5 mM 133.2% ± 13.5% 
 1.0 mM 131.3% ± 16.9% 
 2.0 mM 132.8% ± 12.5% 
 5.0 mM 151.9% ± 20.9% 
 10.0 mM 143.2% ± 27.2% 
Cs
+
 (CsCl) 0.25 mM 110.5% ± 12.5% 
 0.5 mM 112.6% ± 20.3% 
 1.0 mM 111.5% ± 12.0% 
 2.0 mM 102.1% ± 0.5% 
 5.0 mM 120.7% ± 8.2% 
 10.0 mM 107.9% ± 7.7% 
 
The data above suggest that potassium (K
+
), ammonium (NH4
+
) and rubidium (Rb
+
) all 
increased TDH activity, whilst caesium (Cs
+
) had no effect.  The stimulation by potassium and 
ammonium ions is comparable, whilst that of rubidium is slightly higher.  These findings indicate 
that monovalent cations may have a role in increasing the stability of TDH, or that they may play 
a role in the binding of substrates.  In these assays, the monovalent cations may have been 
competing with or exhibiting an effect that added to that of sodium ions in the reaction buffer. 
In assays where TDH was added to the reaction mixture to initiate the reaction, DMSO, at 
concentrations of up to 10% v/v, was not found to affect activity.  When TDH was incubated in 
reaction buffer with 1-5% v/v DMSO for long periods of time, activity was gradually lost (see 
discussion of the plate uniformity test and hit validation, below).  Therefore, the addition of 
different components of the storage buffer to the reaction buffer was tested to measure its 
effects on the enzyme’s stability. 
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Figure 3.2.15 - TDH activity at room temperature in the presence of different reaction mixture additives.  There is 
no significant decrease in activity as the incubation time in the reaction mixture increases.  
 
Figure 3.2.16 - TDH activity at 37°C in the presence of different reaction mixture additives.  In the absence of salt 
(100mM NaCl), there is a decrease in the rate of reaction as incubation time increases.  
At room temperature, changes to the buffer composition had no effect on TDH activity over the 
incubation times tested.  However, at 37°C, the TDH activity can be seen to decline after 
incubation times of 6 minutes.  Although 10% glycerol may offer some protection of TDH, it is 
clear that 100mM salt (sodium chloride) was able to preserve TDH activity independently of 
glycerol concentration.  Following on from these results and prior findings on the stimulatory 
effect of monovalent cations, similar assays were conducted, where TDH was incubated with 
glycerol and sodium chloride, potassium chloride or rubidium chloride at 37°C.  The results of 
these assays are plotted in Figure 3.2.17. 
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Figure 3.2.17 - TDH activity as a function of incubation time, in the presence of glycerol and different alkali metal 
salts.  NaCl is able to maintain activity over the incubation times measured, whilst added KCl and RbCl greatly 
increase enzyme activity.  
Not only did potassium and rubidium preserve TDH activity over the incubation times studied, 
they also stimulated activity to more than double that seen in the presence of sodium ions.  
Control conditions with no glycerol, salt or DMSO showed a similar decline in activity as when 
there was DMSO, but no glycerol or salt.  This suggests that the decline in TDH activity over 
time is not induced by DMSO. 
 
Figure 3.2.18 - the effect of different concentrations of NaCl, KCl and RbCl on TDH activity. 
Figure 3.2.18 shows the effect of different cation concentrations on TDH activity.  As in the 
previous assays, 100mM potassium and 100mM rubidium increased activity to similar extents.  
KCl is more likely to play a physiological role in TDH activity, and the increase in activity from 
1mM ion concentration to 100mM was judged to be small, so it was decided that 1mM KCl 
would be added to the reaction buffer for in vitro screening assays.  This also allowed a smaller 
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change to be made to the composition of the reaction buffer, thus reducing the chance of any 
unforeseen effects on other reaction mixture constituents. 
The NAD
+
 concentration required to reach half-maximal and maximal TDH rates was 
considered to be high for an enzyme co-factor.  The relationship between L-threonine 
concentration and rate was also unusual, so measurements of rate were made across a range 
of substrate concentrations in the presence of 100mM NaCl and 100mM KCl in the TDH storage 
buffers, and 1mM NaCl and 1mM KCl in the reaction buffers.  The profiles of the resulting plots 
were unchanged from previous assays and were similar with either NaCl or KCl present. 
 
Figure 3.2.19 - the velocity of TDH catalysis as a function of NAD
+
 concentration, in the presence of NaCl or KCl. 
 
Figure 3.2.20 - the velocity of TDH catalysis as a function of L-threonine concentration, in the presence of NaCl or 
KCl. 
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Lineweaver-Burk plots of the same data produce very different slopes, with the points 
representing data collected from KCl- containing conditions producing a line of best fit with a 
smaller slope.  On a Lineweaver-Burk plot, the equation representing a line of best fit 
 𝑦 = 𝑚𝑥 + 𝑐 27  
where m is the gradient or slope of the line and c is the y-intercept, is represented by a 
rearrangement of the Michaelis-Menten equation: 
 1
𝑣
= (
𝐾𝑀
𝑉𝑚𝑎𝑥
) (
1
𝐾𝑀
) + (
1
𝑉𝑚𝑎𝑥
) 28  
Therefore, the effect of different assay conditions on enzyme activity can be measured by 
observing the slope, which is equal to KM/Vmax, the y-intercept, which is equal to 1/Vmax, and the 
x-intercept, which is equal to 1/KM.  
 
Figure 3.2.21 - Lineweaver-Burk plot of data in Figure 3.2.19. 
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Figure 3.2.22 - Lineweaver-Burk plot of data in Figure 3.2.20. Data points corresponding to lower substrate 
concentrations are omitted.  
The lines in Figure 3.2.21 intersect close to the x-axis, but their y-intercepts differ.  This pattern 
suggests that the potassium has no effect on NAD
+
 binding, as the Vmax is increased, but the KM 
(as predicted by the x-intercepts) is roughly the same.  Conversely, the y-intercepts of each line 
in Figure 3.2.22 are different, but the apparent KM values, as would be predicted by observing 
the x-intercept are also different, and this suggests that K
+
 has an effect on L-threonine binding.  
It appears that potassium may aid L-threonine binding, as it decreases the concentration 
required to reach maximal inhibition.  More data is required to determine if this pattern holds 
over a range of KCl concentrations.  
3.2.3 TDH inhibition 
3.2.3.1 Rapid-reversible inhibition 
The modes of inhibition (MOI) of different TDH inhibitors were estimated by measuring rates of 
reaction over ranges of substrate concentrations, in the presence of fixed concentrations of 
inhibitor (see Section 2.2.3 for a detailed description of methods).  The data were fitted to 
different inhibitory equations using the data analysis software Prism.  The L-threonine 
analogues, L-allo-threonine, pyruvate and methylglyoxal, and their MOIs are discussed below.   
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Figure 3.2.23 - dose-response curves fit to data representing fractional enzyme activity as a function of 
log[inhibitor] concentration. A - the effect of [L-allo-threonine] on TDH activity; B - the effect of [pyruvate] on 
TDH activity; C - the effect of [methylglyoxal] on TDH activity.  
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L-allo-threonine inhibited TDH with an IC50 of 8.2mM, whilst pyruvate demonstrated weaker 
activity and inhibited TDH with an IC50 of 50.1mM.  Methylglyoxal demonstrated the most potent 
inhibition of TDH, exhibiting an IC50 of 6.3mM.  The curve in Figure 3.2.23A does not suggest 
that L-allo-threonine binding is cooperative and a Hill coefficient of 1.00 was calculated for the 
slope.  For pyruvate, a curve with a Hill coefficient of 1.6 was fit, suggesting that there may be 
some cooperativity involved in pyruvate binding, although this is not clear.  In contrast, the curve 
calculated for the plot of methylglyoxal concentration against rate had a Hill coefficient of 3.2, 
clearly showing that its action was cooperative.  Further investigations of the modes of inhibition 
(MOIs) of these compounds are discussed below.  
L-allo-threonine 
The data indicates that L-allo-threonine inhibition is uncompetitive in relation to NAD
+
.  This 
means that it preferentially binds the TDH-NAD
+
 complex.  When models representing 
competitive, uncompetitive and mixed/noncompetitive inhibition were fit to the data, the model 
with the best fit was for uncompetitive inhibition, and the global R
2
 value for all curves was 
0.946.  When fit to the model for mixed/noncompetitive inhibition (see equation 15), the data 
analysis software calculated an extremely small alpha value of ~5x10
-4
 and a very high Ki of 
14.71M.  This points very strongly to an uncompetitive MOI, and this model also fit the data with 
an R
2
 of 0.946.  An αKi of 7.8mM was calculated using the uncompetitive model. 
 
Figure 3.2.24 - normalised TDH activity (fractional activity) as a function of NAD
+
 concentration, in the presence of 
different concentrations of L-allo-threonine.  Curves described by an uncompetitive MOI (see equation 14) were 
fit to the data.  
As the models used to describe MOI are based on Michaelis-Menten kinetics, they were not 
ideal for analysing the data on L-threonine concentration and the rate of activity.  The data 
analysis software Prism was able to fit curves based on these models to high R
2
 values (>0.9), 
but they tended to overestimate the value of Vmax.  Despite this, as any particular MOI is defined 
by its effects on KM and Vmax, the data were fit to each equation and compared to determine the 
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most likely MOI, as was done for the data describing NAD
+
 concentration and rate.  The 
competitive inhibition model was the model that best described the inhibition in relation to L-
threonine.  The mixed model of inhibition was used to calculate a high alpha value of 62, which 
is in support of a competitive MOI (α > 1.0 indicates competitive inhibition).  A Ki of 1.6mM was 
calculated for L-allo-threonine. 
 
Figure 3.2.25 - plot of fractional activity against L-threonine concentration, measured at different fixed 
concentrations of L-allo-threonine.  Curves describing a competitive MOI (see equation 13) are fit to the data.  
The MOIs of L-allo-threonine that were calculated from enzyme inhibitory data are entirely 
consistent with the binding mode revealed by x-ray crystallography.  As the structure of the 
compound is so similar to L-threonine, it is not surprising that it preferentially binds to NAD-
bound TDH.  For the same reason, one would expect it to compete directly with L-threonine for 
binding. 
 
Pyruvate 
Both the noncompetitive and uncompetitive models of MOI fit closely to the data describing the 
relationship between NAD
+
 concentration, rate and pyruvate concentration.  The R
2
 values were 
0.944 and 0.955, respectively.  The mixed model of inhibition was the best fit for the data, with 
an R
2
 of 0.947.  This model calculated an alpha of 0.134, indicating an uncompetitive mode of 
inhibition.  However, the upper 95% confidence limit for alpha was 0.385 and some researchers 
stipulate that the upper confidence limit of alpha should be 0.25 for an uncompetitive 
inhibitor(274).  To determine whether the uncompetitive model or noncompetitive model was 
more appropriate, the two models were compared by calculating values for Aikake’s Information 
Criterion (AIC) using the data analysis software Prism.  AIC values for each of the compared 
models were compared to determine which model was most likely to generate the data.  This 
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calculation determined that the uncompetitive model was more likely to be correct (99.8% 
probability).  The same analysis was performed to ascertain whether the most appropriate 
model was a mixed noncompetitive-uncompetitive model or an uncompetitive model and the 
software indicated that the uncompetitive model was more likely to be correct, with a 65.5% 
probability of having produced the data over the mixed model. 
 
Figure 3.2.26 - plots of fractional activity as a function of NAD
+
 concentration, at fixed concentrations of pyruvate.  
The data are fit to curves describing uncompetitive inhibition (A) and cooperative uncompetitive inhibition (B), 
described by a modification of equation 14 that adds the Hill coefficient (see equation 30).  The fit of the curves 
to the data collected at 80 and 160mM pyruvate are slightly improved in the graph on the right.  
In graph A in Figure 3.2.26, it is evident that the data does not fit well to the data collected at 
80mM and 160mM.  This can be explained by the fact that the curve relating pyruvate 
concentration to fractional activity had a Hill coefficient of 1.6, suggesting that there may be 
some cooperativity involved in pyruvate binding (see Figure 3.2.26B).  To take account of these 
effects, the parameters relating to the inhibitor in the MOI equations were modified with the Hill 
coefficient, as in the Hill equation (or the Hill modification of the Michaelis-Menten equation).  
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The Hill modification of the equation for mixed model inhibition (equation 15) can be 
represented as: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
[S] (1 +
[𝐼]ℎ
𝛼𝐾𝑖
ℎ) + 𝐾𝑀 (1 +
[𝐼]ℎ
𝐾i
ℎ )
 
29  
 Similarly, the Hill modification of the model for uncompetitive inhibition (see equation 14) can 
be written as: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
[S] (1 +
[𝐼]ℎ
𝛼𝐾i
ℎ) + 𝐾𝑀
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Similar modifications to inhibitory equations can be found in the literature(275).  To ensure that 
any improved fits of the data were solely due to the addition of an extra parameter, an F test 
was used to compare the new models to the original models.  The F test calculates whether 
improved fits to data in more complex equations are statistically significant or just the result of 
having a higher number of degrees of freedom.  The test confirmed that the improved fits to the 
data (R
2
 = 0.961 for Hill modifications of uncompetitive and mixed models) were statistically 
significant.  Now, the MOI was more easily assigned as uncompetitive inhibition.  The Hill-
modified mixed-model calculated a very low alpha value of 0.0014.  The Hill-modified 
uncompetitive model calculated an αKi of 42.8 and Hill coefficient of 1.52, which is very similar 
to the Hill coefficient of 1.6 that was calculated for the curve relating pyruvate concentration to 
rate (see Figure 3.2.23B). 
Fits of the data from studies conducted at different L-threonine concentrations to different 
models of MOI strongly indicated that pyruvate acted competitively.  A mixed-inhibition model fit 
with a R
2
 value of 0.945 and a calculated alpha of 66.0, strongly suggesting that the MOI is 
competitive.  A competitive inhibition model was fit to the data, and produced an equivalent R
2 
value.  This model yielded a Ki of 17.1mM, which is similar to the value predicted by the mixed-
model, 17.6mM.  A Hill-modified mixed model slightly improved the fit to the data, producing an 
R
2
 of 0.946.  A very high alpha, indicative of competitive inhibition, was predicted again, and a 
modest value for h of 1.13 was calculated, suggesting that there was no cooperative behaviour 
or that cooperativity was only marginal.  This model predicted a slightly higher Ki of 19.5mM. 
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Figure 3.2.27 - plots of fractional activity against L-threonine concentration measured in the presence of different 
concentrations of pyruvate.  Curves were fit to the data using the mixed inhibition model (A) and the cooperative 
mixed inhibition model (B). The fits to the data are very similar and both models indicated that the MOI of 
pyruvate was competitive in relation to L-threonine.  
Once again, the results of these MOI analyses are consistent with structural data on the binding 
of pyruvate: pyruvate competes with L-threonine for its binding site.  Like L-threonine, pyruvate 
binding is also dependent on the presence of NAD
+
, thus it has a strong preference for binding 
to the holo form of TDH. 
 
Methylglyoxal 
As discussed earlier, the cooperativity of methylglyoxal inhibition was much more pronounced 
than that displayed for pyruvate.  Standard MOI equations could not be fit to data for all the 
methylglyoxal concentrations tested.  Therefore, using Hill-modified versions of the standard 
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equations, it was determined that methylglyoxal acted noncompetitively in relation to NAD
+
.  The 
Hill-modified mixed model of inhibition fit the data with an R
2
 of 0.976 and predicted an alpha of 
1.15 with the 95% confidence interval 0.5517 to 1.748.  This was highly suggestive of a 
noncompetitive model.  This was confirmed by fitting the data to a Hill-modified version of 
equation 15, which assumes an alpha value of 1.0 (indicating an equal affinity for free and 
substrate-bound enzyme): 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
([S] + 𝐾𝑀) (1 +
[𝐼]ℎ
𝐾i
ℎ )
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This equation also fit the data with an R
2
 of 0.976.  A Ki of 6.1mM was calculated and the Hill 
coefficient was 3.3, which is almost identical to that observed for the slope of methylglyoxal 
concentration and fractional activity (see Figure 3.2.23C). 
 
Figure 3.2.28 - a plot of Fractional activity against NAD
+ 
concentration in the presence of different concentrations 
of methylglyoxal.  Curves described by equation 31, which describes cooperative noncompetitive inhibition were 
fit to the data.  
A fit of equation 29 to the data regarding L-threonine concentration and rate fit with an R
2
 of 
0.971.  An alpha value of 49.0 signalled that the MOI was competitive.  A Hill-modified version 
of equation 13, describing cooperative competitive inhibition: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
[S] +  𝐾𝑀 (1 +
[𝐼]ℎ
𝐾i
ℎ )
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was used to fit the data, producing an R
2
 of 0.971.  The model was used to calculate a Ki of 
4.7mM.  Both the mixed and competitive models gave Hill coefficients of 3.4, which are similar 
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to the Hill coefficient of 3.2 that was calculated for the curve fitted to the plot of methylglyoxal 
concentration against fractional activity (see Figure 3.2.23C). 
 
Figure 3.2.29 - plot of fractional activity at different L-threonine concentrations, in the presence of different 
concentrations of methylglyoxal.  Curves were fitted using a cooperative competitive MOI (see equation 32).  
The noncompetitive MOI in relation to NAD
+
 and the competitive MOI in relation to L-threonine 
describes a mechanism that involves methylglyoxal interacting with TDH in a way that is 
mutually exclusive with L-threonine binding, but independent of NAD
+
 binding. 
 
The confirmation of MOIs of L-allo-threonine, pyruvate and methylglyoxal using enzyme assays 
demonstrates their utility as a way of predicting the MOI of new inhibitors. 
 
 
3.2.3.2 Time-dependent inhibition 
Inhibition by the human aldehyde dehydrogenase inhibitor, tetraethylthiuram disulphide (TETD 
or disulfiram), was a gradual inhibition of TDH that increased with the time that it was incubated 
with the enzyme.  Therefore, determining its MOI required different assays and data analysis 
techniques to the rapid-reversible inhibitors described above.  These assays are described in 
the methods section. 
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Figure 3.2.30 - plot of fractional activity at increasing incubation times of TDH with TETD. 
Data similar to that presented in Figure 3.2.30 were collected over the following TETD 
concentrations: 90, 175, 250, 350, 525 and 700 µM.  The value of kobs was calculated using 
equation 16, and this value was plotted against the relevant TETD concentration to determine 
the underlying mechanism behind the time-dependency of inhibition by TETD.  
 
Figure 3.2.31 - plot of kobs as a function of TETD concentration. 
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The plot in Figure 3.2.31 is sigmoidal, which rules out a reversible slow-binding mechanism, 
which would manifest in a plot that shows a linear relationship between kobs and inhibitor 
concentration.  Two further mechanisms are outlined by schemes A and B in Figure 3.2.32, 
below. 
 
Figure 3.2.32 - possible mechanisms of TDH inhibition by TETD.  Scheme A describes an initial binding step, which 
is characterised by the constants k3 and k4, followed by a slower step involving enzyme isomerization, which 
leads to stronger binding.  Scheme B also consists of an initial reversible binding step, but this is followed by 
irreversible inactivation of the enzyme by covalent modification. This second step is described by the constant for 
inactivation, k5 or kinact.  Note that if k6 in scheme A is very small, then the two schemes are indistinguishable from 
each other.  
The plots that would be explained by such binding mechanisms in Figure 3.2.32 should show 
hyperbolic relationships(194,276).  The sigmoidal relationship between TETD concentration and 
kobs raises the possibility of cooperative binding by TETD.  Therefore, the equations describing 
schemes A and B from Figure 3.2.32 were modified with the Hill coefficient.  The resulting 
equation used for mechanism A was: 
 
𝑘𝑜𝑏𝑠 =  𝑘6 + [
𝑘5[𝐼]
ℎ
𝐾𝑖
𝑎𝑝𝑝ℎ + [𝐼]ℎ
] 33  
The resulting equation describing mechanism B was: 
 
𝑘𝑜𝑏𝑠 =  
𝑘5[𝐼]
ℎ
𝐾𝑖
𝑎𝑝𝑝ℎ + [𝐼]ℎ
 34  
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The relationship between the apparent Ki (Ki
app
) and the true Ki depends on the MOI of the 
inhibitor.  The data in Figure 3.2.31 were fitted by non-linear regression to equations 30 and 31.  
The results are shown in Figure 3.2.33, below. 
 
Figure 3.2.33 - plots of kobs against TETD concentration.  Curves are fitted to the data using equation 33 (left) and 
equation 34 (right).  The curves fitted equally well to the data, and the y-intercept, which corresponds to k6, is 
very close to zero in the plot A, which corresponds to scheme A.  
The R
2
 values for the data fit to equations 30 and 31 are both 0.997.  A comparison using AIC 
highlighted mechanism B as the best fit for the data.  Furthermore, the value for k6 calculated 
using equation 33 was 0.002, compared to a k5 value of 0.118.  This makes the two 
mechanisms almost indistinguishable, but it suggests that the final step is virtually irreversible, if 
not truly irreversible.  The apparent Ki (Ki
app
) is calculated by equation 34 as 307.0µM.  The Hill 
coefficient was equal to 3.3. 
 
Figure 3.2.34 - plots of kobs as a function of substrate concentration.  The data in these plots were obtained by 
calculating kobs using the time-dependent inhibition observed by incubating 350µM TETD with TDH prior to 
adding different concentrations of one substrate in the presence of saturating concentrations of the other.  The 
relationships between kobs and substrate concentration are very distinct for different modes of inhibition. An 
inverse relationship is observed for competitive inhibition, whereas a direct relationship is observed for 
uncompetitive inhibition.  There is no relationship for noncompetitive inhibition. Curves describing competitive 
time-dependent inhibition (see equation 17) are fit to the data.  
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To determine the MOI in relation to the substrates L-threonine and NAD
+
, a single concentration 
of TETD was tested in the presence of a range of substrate concentrations.  The data show an 
inverse relationship between kobs and substrate concentration, suggesting an MOI that is 
competitive towards both NAD
+
 and L-threonine binding.  Accordingly, the true Ki of TETD may 
be estimated using the Cheng-Prusoff equation for competitive inhibition, where IC50 is replaced 
with Ki
app
: 
 
𝐾𝑖 =  
𝐾𝑖
𝑎𝑝𝑝
1 +
[𝑆]
𝐾𝑀
 35  
As the relationship between NAD
+
 concentration and rate follows Michaelis-Menten kinetics, 
using values of 10 mM for [S] (or [NAD
+
] and 1.0 mM for KM, the Ki of TETD is calculated as 
27.9 µM.  Note that this Ki represents the initial reversible binding of TETD to TDH, as the 
second step is governed by k5 (see Figure 3.2.32) and is irreversible.  The value for k5 or kinact 
for TETD was calculated as 0.12min
-1
. 
 
3.2.4 Preliminary enzymatic studies of TDH from Clostridium difficile 
The rate of catalysis of TDH from Clostridium difficile (CdTDH) was measured across a wide 
range of NAD
+
 and L-threonine concentrations.  The relationships between the substrate 
concentrations and reaction velocity are quite similar to those observed for TDH from 
Trypanosoma brucei. 
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Figure 3.2.35 - plots of CdTDH reaction velocity as a function of substrate concentration, at fixed concentrations 
of the second substrate (A = NAD
+
; B = L-threonine).  Curves were fitted using the Michaelis-Menten equation (A) 
or the Hill modification of the Michaelis-Menten equation (B).  Dotted curves are fitted to data where an increase 
in substrate concentration caused a decrease in reaction velocity, relative to a lower concentration  
The Lineweaver-Burk plot of data relating NAD
+ 
concentration to reaction velocity at different 
fixed L-threonine concentrations shows a pattern of lines with slopes that decrease as the L-
threonine concentration is increased.  This is a clear indication of a sequential ordered 
mechanism of action.  The lines intersect near to where they intercept the x-axis, suggesting 
that L-threonine concentration does not affect the binding affinity of NAD
+
.  In a way that is 
somewhat similar to the data obtained for TDH from T. brucei, the Lineweaver-Burk plot of the 
data relating rate of activity and L-threonine concentration produces a pattern of lines that show 
a mixed pattern of decreasing slopes with higher NAD
+
 concentrations, and lines that are 
parallel to each other.  
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Figure 3.2.36 - Lineweaver-Burk plots of the data plotted in Figure 3.2.35.  Dotted lines are fitted to data where 
an increase in the concentration of the other substrate led to a decrease in reaction velocity.  
 It is unclear whether the reaction mechanism is compulsory ordered or a random sequential 
reaction from these data alone.  However, the change in x-intercept at higher NAD
+
 
concentration does suggest that NAD
+
 may be the first substrate to bind. 
The saturating concentrations of NAD
+
 and L-threonine appear to be higher for CdTDH, than for 
TDH from T. brucei.  The saturating NAD
+
 concentration appears to be high, at 15mM.  The 
relationship between the NAD
+
 concentration follows Michaelis-Menten kinetics, and a KM of 
approximately 7mM is estimated using the curves in Figure 3.2.35.  The saturating 
concentration appears to lie somewhere close to 50mM.  The KM of L-threonine is estimated to 
be between 7 and 9mM.  It is possible that the relationship between L-threonine concentration 
and rate is double-sigmoidal, as with TDH from T. brucei.  However, data covering more L-
threonine concentrations would be needed to be sure of this.  
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Figure 3.2.37 - plots of CdTDH reaction velocity as a function of L-threonine concentration at 5mM NAD
+
.  The 
data are fit to the Hill-modification of the Michaelis-Menten equation (left) and to equation 25, which describes 
cooperative catalysis by two non-equivalent active sites (right). 
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3.3 Virtual Screening 
3.3.1 Compound Libraries 
3.3.1.1 Library compilation 
Compilation of the compound libraries for virtual screening was carried out successfully, as 
described in Section 2.3.3.  Please see the appendix for lists of ZINC database ID codes for the 
NCI diversity set II and for the ligand analogue library.  In the appendix, there is also a table 
listing all the natural products screened, and the literature sources for their names and/or 
structures.  The original search for proteins using Protein Structure Similarity Clustering (PSSC) 
found several proteins, which are listed in the appendix, along with their biological relevance, 
species and statistics describing their structural similarity to TDH.  Ligands from the following 
proteins were included in the virtual screen: UDP-galactose 4-epimerase (UDP-GalE), UDP-
sulfoquinovose synthase (SQD1), dTDP-glucose 4,6-dehydratase, GDP-mannose 4,6-
dehydratase, CDP-tyvelose/paratose 2-epimerase, ArnA decarboxylase/dehydrogenase,GDP-
4-keto-6-deoxy-D-mannose reductase, UDP-N-acetylglucosamine 4-epimerase, ADP-glycero-D-
mannoheptose 6-epimerase, GDP-L-fucose synthase, CDP-D-glucose 4,6-dehydratase, GDP-
mannose 3’,5’-epimerase, dTDP-6-deoxy-L-lyxo-4-hexulose reductase, 
dihydroflavonol(dihydrokaempferol) 4-reductase (DFR), progesterone 5β-reductase and S-
adenosylmethionine synthetase.  The ligands from these proteins are listed in a table in the 
appendix.  Figure 3.3.1 shows the superimposition of UDP-GalE and DFR monomers with the 
TDH monomer used in the PSSC search.  The figure illustrates the close relationship in 3D 
structure, shared between different proteins matched by PSSC.  All proteins had RMSDs of α-
carbon atoms between 1.8 and 2.7 Å.  
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Figure 3.3.1 - ribbon representations of the structures of TDH, UDP-GalE from Trypanosoma brucei and DFR from 
Vitis vinifera superimposed on each other.  This illustrates the degree of 3D structural similarity between the 
proteins, despite the fact that UDP-GalE and DFR share less than 20% sequence similarity with TDH.  
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3.3.1.2 Analysis of compound libraries 
Figure 3.3.2 shows the visualisation of all molecules screened and displays the successful 
sampling of chemical space by the compound libraries (see Section 2.4.3 for a description of 
how the visualisation is created).   
 
 
Figure 3.3.2 - visualisation of the diversity all compounds in the virtual screening library.  Each point represents a 
single compound in the library.  Its position on the diagram is determined by the difference between the 
compound and other compounds, as determined by the chemical fingerprint that characterises that compound.  
The NCI diversity set II exhibits a wide distribution, as expected.  A low mean Tanimoto 
similarity coefficient of 0.17 (0= no similarity, 1 = identical molecules) was calculated for the 
library by comparing all molecules against each other. 
The natural product library appears to sample a smaller area of chemical space, and the points 
representing those compounds are concentrated in the lower half and right side of the data 
visualisation in Figure 3.3.2.  In spite of this, the natural product library is still very diverse, as 
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represented by a Tanimoto coefficient of 0.21.  The ligand analogue library appears to be even 
less spread across the data visualisation and there are a number of similar molecules clustered 
together.  However, a low mean Tanimoto coefficient of 0.21 was also calculated for this library. 
The ‘Knowledge’ and PSSC libraries have a similar distribution across the data visualisation in 
Figure 3.3.2; they show a wide sampling of chemical space, however clusters of similar 
molecules can be seen in different parts of the diagram.  Although the knowledge library has a 
low mean Tanimoto coefficient of 0.18, there are groups of compounds that share very similar 
structures, notably the mouse TDH (MmTDH) inhibitors which have a high mean Tanimoto 
coefficient of 0.87.  The trypanosomiasis drugs and the compounds from the School of 
Pharmacy have Tanimoto coefficients of 0.15 and 0.33, respectively.  The PSSC library has a 
low Tanimoto coefficient of 0.23. The points representing most of the molecules from the 
Knowledge and PSSC compound libraries are located near molecules from other compound 
libraries, suggesting that they would not have contributed to the overall diversity of the 
screening library.  However, compounds from the PSSC library are represented by points near 
the top and left of the data visualisation – by occupying otherwise empty areas of the diagram 
(therefore, possessing previously unrepresented chemical structures), these compounds extend 
the sampling of chemical space of the entire library.  Overall, the visualisation of the diversity of 
the compounds in the screening library shows that the design of the library was successful in 
achieving chemical diversity. 
 
Although all of the compound libraries are diverse and the chemical terms listed in Table 3.3.1 
will vary from molecule to molecule, clear differences can be seen when the mean chemical 
terms of different libraries are compared.  The Lipinski rule of five describes a number of limits 
relating to different chemical features, which may determine a compound’s likelihood of 
possessing good properties relating to absorption, distribution, metabolism and excretion 
(ADME)(277):  
 No more than 5 hydrogen bond donors; 
 No more than 10 hydrogen bond acceptors; 
 A molecular weight (MW) of 500 Daltons or less; 
 A log octanol:water partition coefficient (logP) of 5 or less. 
As this is clearly important in a drug discovery context, the compliance with the rule of five is 
listed in Table 3.3.1.  More recently, the number of rotatable bonds and a compound’s polar 
surface area have been demonstrated to have an effect on solubility and permeability, 
irrespective of MW.  Upper limits of 10 and 140 Å
2
, for number of rotatable bonds and polar 
surface area (PSA, or topological PSA [TPSA]), respectively, have been demonstrated as 
predictors of oral bioavailability in drug molecules(279).  A stricter guideline proposed by 
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Congreve and colleagues, termed the rule of three(278), has also been designed for fragment 
screening libraries and stipulates that it a molecule should have: 
 No more than 3 hydrogen bond donors; 
 No more than 3 hydrogen bond acceptors; 
 A molecular weight (MW) of less than 300; 
 A calculated logP (clogP) of 3 or less. 
The following parameters may also be useful criteria: 
 No more than 3 rotatable bonds; 
 A PSA of no more than 60 Å
2
. 
These parameters and the compliance of each molecule with the rule of three (pertaining to all 
six criteria mentioned above) are also listed in Table 3.3.1. 
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Table 3.3.1 - mean chemical terms describing the compounds in different components of the virtual screening library. 
 Mean Chemical Term Value     
Library MW LogP TPSA Hydrogen-
bond 
Acceptors 
Hydrogen-
bond 
Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski Rule 
of Five 
Compliant? 
Less than 1 
Rule of Five 
Violation? 
Congreve 
Rule of Three 
Compliant? 
Mean 
Tanimoto 
NCI Diversity Set II 282.3 2.15 68.16 3.7 1.7 2.9 86.5%  
(1769 of 2044) 
96.5%  
(1972 of 2044) 
15.5%  
(316 of 2044) 
0.17 
Ligand Substructure 266.9 0.30 99.32 4.9 1.9 4.7 97.9%  
(734 of 750) 
100%  
(750 of 750) 
3.2%  
(24 of 750) 
0.21 
Natural 392.2 2.96 91.93 5.4 2.6 4.3 61.0%  
(260 of 426) 
84.3%  
(359 of 426) 
8.9%  
(38 of 426) 
0.21 
Knowledge 437.4 1.61 134.51 6.6 2.8 6.2 69.7%  
(23 of 33) 
81.8%  
(27 of 33) 
3.0%  
(1 of 33) 
0.18 
Trypanocidals 458.7 0.44 169.70 8.6 3.5 6.8 76.2%  
(16 of 21) 
76.2%  
(16 of 21) 
4.8%  
(1 of 21) 
0.15 
School of Pharmacy 313.1 2.40 77.90 3.7 1.7 4.3 100%  
(6 of 6) 
100%  
(6 of 6) 
0%  
(0 of 6) 
0.33 
MmTDHi 487.4 4.91 67.98 2.7 1.8 5.7 16.7%  
(1 of 6) 
83.8%  
(5 of 6) 
0.0%  
(0 of 6) 
0.87 
PSSC 365.5 -1.63 159.35 7.9 4.3 5.5 57.2%  
(99 of 173) 
65.9%  
(114 of 173) 
6.4%  
(11 of 173) 
0.23 
All 299.0 1.65 83.34 4.4 2.0 3.6 82.0%  
(2808 of 3426) 
91.6%  
(3138 of 3426) 
11.2%  
(383 of 3426) 
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The majority of the compounds screened were Rule of Five compliant, though some libraries 
were more compliant than others.  Only 61.0% and 69.7% of the molecules in the Natural 
product and Knowledge libraries, respectively, were Rule of Five compliant, compared to 82.0% 
of the compounds in the screening library as a whole.  This is probably due to the higher 
molecular weights of the compounds in these two libraries.  The PSSC library is the least 
compliant with the Lipinski rule of five – only 52.2% of the molecules screened complied with 
the rule and only an additional 8.7% had one violation.  The mean numbers of hydrogen bond 
donors and acceptors is the highest for this library, so it is likely that several of the molecules 
violate the rule of five in this regard.  As none of these libraries were designed to be fragment 
libraries, it is unsurprising that very few compounds in the screening library are compliant with 
the rule of three. 
 
3.3.2 Assay Validation 
Four different TDH structure models were used as receptors in the four screens:  Virtual 
Screens 1, 2, 3 and 4.  The model for Virtual Screen 1 was the monomer in subunit F bound to 
NAD
+
 in the structure denoted TK8.  The model for Virtual Screen 2 was a monomer (subunit C) 
and the bound NAD
+
 in the model TIO8, which had flexible loop 1 in a closed position over the 
binding site.  For Virtual Screen 3, the structure was taken from the model denoted TS2, which 
contained an apo-TDH structure, with the flexible loop in the open conformation.  Finally, for 
Virtual Screen 4, the same model as for Virtual Screen 2 was used, but the bound NAD
+
 
molecule was removed from the PDB file. 
As described in the methods (Section 2.3.2), five active site residues that were identified as 
being important in L-threonine binding (Ser82, Thr119, Met81, Tyr144 and Thr186), were 
chosen as variables, where they were set as rigid or flexible, to determine their effect on 
AutoDock docking predictions.  A number of docking simulations were carried out using default 
Lamarckian Genetic Algorithm parameters with different combinations of flexible residues and a 
completely rigid TDH, using threonine, glycerol or pyruvate as a ligand.  The validity of the rigid 
or flexible ‘receptor’ model was judged based on the plausibility of the binding position for L-
threonine, the predicted binding energies and the clustering of binding poses.  A completely 
rigid molecule was chosen, partly due to the more accurate binding energies predicted for all 
ligands.  Flexible models produced energies corresponding to Ki values in the micromolar and 
nanomolar range, compared to values of 1.42mM for L-threonine and 2.09mM for pyruvate 
which are within up to approximately one order of magnitude of published L-threonine KM 
values(139) and the Ki value of pyruvate determined in this lab, 12.7mM (note that a Ki of 
17.6mM was determined in this thesis).  Another reason for the choice of the rigid TDH model 
was the predicted binding poses of the ligands.  For example, when testing the proposed 
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models with glycerol, the poses that were most similar to those found in the TK8 model were 
produced by a rigid structure.  These binding poses were also repeatable and all ten AutoDock 
runs predicted poses within an RMSD of 2 Å from each other.  Conversely, the models with 
flexible residues often predicted widely different binding poses.  Although the rigid TDH models 
were ultimately selected for all TDH screens, models where the Cα→Cβ bonds in the side 
chains of Ser82 and/or Tyr144 were rotatable were able to predict ligand binding poses as 
accurately as the rigid model. 
The decision to screen rigid TDH models was largely based on the results of tests on variations 
of the model for Virtual Screen 1.  However, for subsequent TDH screens (2-4), validation 
studies were carried out to confirm the validity of the screening results.  Docking experiments 
with L-threonine against the model used for TDH screen 2 (which resembled the TDH 
conformation in the TNADH4 model, see above) gave binding poses that were very similar to 
those found in an X-ray crystallographic structure (TNADH4, see Table 3.1.1).  Figure 3.3.3 
demonstrates how a structural alignment of the TNADH4 structure with the docked L-threonine-
TDH prediction shows that the binding prediction is almost identical to the observed binding 
position. 
 
Figure 3.3.3 - a superimposition of an L-threonine-bound TDH structure (obtained by X-ray crystallography) on a 
Virtual Screening model with its predicted binding mode for L-threonine.  The crystallographic TDH model is 
coloured green, and the bound TDH model is coloured gold.  The predicted binding pose of L-threonine is 
depicted in pink and the model used in screening (in Virtual Screen 2) is removed for clarity.  It can be seen that 
the two binding positions are almost identical.  
As information on the binding position of NAD
+
/NADH was also available, more validation 
experiments were carried out using NAD
+
 as a ligand. 
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Figure 3.3.4 - predicted binding poses of NAD
+
 compared to the binding pose found by virtual screening.  TDH is 
coloured green and the bound NAD
+
 is coloured black and surrounded by a wire mesh to highlight the binding 
position.  Predicted binding poses of NAD
+
 are coloured light orange.  It can be seen that Autodock was unable to 
fully predict the binding pose of NAD
+.  
As can be seen in Figure 3.3.4, the accurate prediction of the NAD+ binding position was not so 
successful.  This is actually expected, due to the large number of rotatable bonds in the 
molecule and the limitation in AutoDock of accurately predicting the binding of ligands with more 
than 10 rotatable bonds(24). 
 
3.3.3 Hits 
There were huge differences in the hit rates of each TDH screen.  At a binding energy cut-off of 
-9.5 kcal.mol
-1
, the first Virtual Screen produced a modest hit rate of 2.2%, whilst Virtual Screen 
2 produced no hits at all.  Virtual Screens 3 and 4, however, produced much higher hit rates of 
7.3% and 8.5% respectively. 
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Table 3.3.2- hit rates achieved in Virtual Screens 1, 3 and 4. 
 Hit Rate 
Library Virtual Screen 1 Virtual Screen 3 Virtual Screen 4 
NCI Diversity Set II (n = 2044) 2.7% 5.3% 5.9% 
Ligand Substructure (n = 750) 0.9% 0.5% 2.5% 
Natural (n = 426) 3.1% 27.9% 29.6% 
Knowledge (n = 33) 3.0% 12.1% 15.2% 
Trypanocidals (n = 21) 0.0% 0.0% 4.8% 
School of Pharmacy (n = 6) 0.0% 33.3% 16.7% 
MmTDHi (n = 6) 0.0% 33.3% 50.0% 
PSSC (n = 173) 0.6% 8.1% 12.1% 
All (n = 3046) 2.2% 7.3% 8.5% 
 
 
Figure 3.3.5 - Venn diagram outlining the number of hits in each screen and the common hits between screens.  
The diagram was constructed using the software eulerAPE (280).  
In Virtual Screen 1, the NCI diversity set II, the Natural Product library and the Knowledge 
library all produced similar hit rates.  It is also evident that the NCI diversity set II had 
comparable hit rates across all successful screens.  In Virtual Screens 3 and 4, however, the 
natural product library produced huge hit rates of 27.9% and 27.6%, respectively.  The hit rates 
of the Knowledge and PSSC libraries were also greatly increased, although to a lesser extent 
than the natural product library.  These large differences in hit rate can most likely be attributed 
to the availability of the NAD
+
 binding site.  Referring back to Table 3.3.1, it can be seen that the 
average molecular weights of the natural product, Knowledge and PSSC libraries are 
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significantly higher than those of the other libraries.  Thus, with the absence of NAD
+
 from its 
binding pocket in TDH screens 3 and 4, the larger molecules have more space to bind and 
make stronger interactions with the protein.  The total lack of hits in the second virtual screen 
can be explained by the fact that NAD
+
 was present, whilst flexible loop 1 was in its closed 
conformation, leaving very little room for binding in the substrate binding sites.  Only the 
smallest molecules could be docked into the L-threonine binding pocket, whilst others bound to 
the exterior surface of TDH.  For this reason, the top scoring compound had a binding energy of 
-7.6kcal.mol
-1
, which is higher (or weaker) than the cut off of -9.5kcal.mol
-1
. 
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Table 3.3.3 – mean chemical terms describing the features of the hits from the three successful Virtual Screens. 
   Mean Chemical Term Value      
Library MW LogP TPSA Hydrogen-
bond 
Acceptors 
Hydrogen-
bond 
Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Less than 1 
Violation? 
Congreve 
Rule of 3 
Compliant
? 
Hit Rate 
Virtual Screen 1 362.18 1.34 91.62 5.4 2.6 3.5 72.7%  
(56 of 77) 
90.9%  
(70 of 77) 
2.6%  
(2 of 77) 
2.20% 
Virtual Screen 3 451.41 3.70 102.04 5.9 2.7 4.3 39.6%  
(99 of 250) 
78.0%  
(195 of 250) 
0.0%  
(0 of 250) 
7.30% 
Virtual Screen 4 440.32 3.45 102.77 5.8 2.8 4.4 42.5%  
(124 of 292) 
82.2%  
(240 of 292) 
0.0%  
(0 of 292) 
8.52% 
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The above observations are emphasised by the results in Table 3.3.3, above.  The mean 
molecular weights of the compounds in Virtual Screens 3 and 4 are higher than in Virtual 
Screen 1.  It is interesting that all of the mean molecular weights of the hits are higher than the 
mean molecular weight for all the compounds in the screening library.  This suggests that larger 
compounds were more likely to be predicted to bind more tightly.  Despite the higher molecular 
weights of the hits in Virtual Screens 3 and 4, the mean numbers of hydrogen bond donors and 
acceptors, and the number of rotatable bonds are similar across all screens.  The majority of the 
hits have one violation or less of the Lipinski rule of five, though the hits in screen 1 are more 
compliant with the rule.  This is probably due to the higher molecular weight and LogP of the 
hits in the other screens. 
 
Table 3.3.4 lists the top 5 hits and other hit compounds of interest, including their names and 
structures, from Virtual Screen 1, which had a hit rate of 2.2%. 
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Table 3.3.4 – the top 5 Hits from Virtual Screen 1, and one hit that later exhibited activity in vitro (see Section 3.4) 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors, 
Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-11.88, 1.96 ZINC01673377  
 
 
296.29 1.72 181.42 10 , 4 2   
-11.6, 3.14 ZINC19362650  
 
 
357.56 0.73 7.68 2 , 1 2   
-11.43, 4.19 ZINC01755448  
 
 
398.45 6.87 52.6 2 , 0 6   
-11.42, 4.26 apigenin-7-glucoside  
 
 
432.38 0.44 166.14 10 , 6 4   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors, 
Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-11.34, 4.87 daphneside  
 
 
502.42 -3.36 225.06 13 , 8 6   
-9.51, 106.92 ZINC04141542 
(BPOB) 
 
330.17 -1.01 94.04 4 , 2 7    
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The diversity of the hits from the first virtual screen is visualised in Figure 3.3.6.  Comparing this 
to the visualisation of the entire screening library in Figure 3.3.2, there is no indication that the 
hits constitute groups of very similar molecules.  
 
 
Figure 3.3.6 - visualisation of the hits from Virtual Screen 1.  Each point represents a hit and the relative positions 
of the points are determined by the differences between their structures, as in Figure 3.3.2.  
There does appear to be more sampling of the lower half of the diagram, but this portion was 
more populated to begin with.  Less of the compounds represented by points in the upper half of 
the diagram are hits than one would expect from a random selection from the screening library, 
so it is possible that compounds with certain structural features did not score highly in this 
screen. 
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Figure 3.3.7 - visualisation of the diversity of hits from Virtual Screen 1.  The compounds are represented by 
different shapes, according to their predicted binding energies.  
Looking at Figure 3.3.7, there is no clear relationship between the structures of hits, as 
represented by a point on the data visualisation, and their predicted binding energies.  The 
majority of the hits are in the lower binding energy ranges. 
 
The following table lists the top 5 hits and other hit compounds of interest from Virtual Screen 3. 
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Table 3.3.5 – the top 5 Hits from Virtual Screen 3 and hits which either exhibited activity in vitro or an analogue exhibited activity in vitro (see Section 3.4) 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-15.03, .01 α-solamargine 
(solasonine) 
 
 
 
884.06 0.34 258.71 17 , 10 8   
-13.62, .10 ancistrogriffithine A 
 
 
784.94 7.21 141.9 10 , 6 5   
-13.62, .10 ZINC05492794 
 
 
594.73 10.95 51.56 4 , 0 6   
-13.11, .25 3,23-dioxotirucalla-
7,24-dien-21-al 
 
 
452.67 6.42 51.21 3 , 0 5   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-12.72, .47 ZINC17465983  
 
 
546.52 5.67 173.98 10 , 6 0   
-11.48, 3.85 NSC132249 
(CHEMBL1173812) 
 
474.34 7.34 66.4 3 , 2 4    
-10.45, 21.88 Qc2  
 
 
549.95 5.48 79.9 4 , 2 6   
-9.96, 50.03 Qc6 
 
 
469.48 5.42 52.65 2 , 1 5   
-9.94, 51.75 NSC128598 
(CHEMBL1173453) 
 
 
423.44 6.28 66.4 3 , 2 4   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.8, 65.54 myricetin  
 
 
318.24 1.85 147.68 8 , 6 1   
-9.57, 96.63 NSC128608 
(CHEMBL1173811) 
 
 
467.51 7.34 66.4 3 , 2 4   




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Virtual Screen 3 had a much larger hit rate of 7.3%.  In further contrast with Virtual Screen 1, 
one can see that there are a number of very high affinity molecules at the top of Table 3.3.5.  
These molecules are of high molecular weight, and α-solamargine and ancistrogriffithine A, in 
particular, possess a large number of hydrogen bond donors and acceptors, so they are able to 
make a large number of interactions with the protein.  Another observation of the hits from this 
screen is that there are many more natural products represented in Table 3.3.5 than in Table 
3.3.4. 
 
 
Figure 3.3.8 - visualisation of the diversity of the hits from Virtual Screen 3.  Each point represents a different 
compound and the relative positions of the points are determined by the differences between their structures, as 
in Figure 3.3.2.  
As with the visualisation of the chemical diversity of the Virtual Screen 1 hits, there is no 
evidence of hits being clustered in certain areas of chemical space in this screen.  In fact, the 
hits in Virtual Screen 3 appear to be more diverse than those of the first screen.  There is also 
more sampling of space in the upper portion of the diagram.  
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Figure 3.3.9 - visualisation of the diversity of the hits from Virtual Screen 3.  Each point represents a single 
compound.  The compounds are represented by different shapes, depending on their predicted binding energies.  
The visualisation in Figure 3.3.9 suggests that there is no relationship between structure and the 
binding affinity predicted by AutoDock4.  The presence of more hits with higher binding affinities 
than in the first screen is evident. 
 
 
Table 3.3.6 lists the tip 5 hits and other hit compounds of interest from Virtual Screen 4.
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Table 3.3.6 – the top 5 Hits from Virtual Screen 4 and hits which either exhibited in vitro activity or have an analogue which exhibited activity in vitro (see Section 3.4). 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-14.88, .01 astrogaloside III  
 
 
784.97 -0.31 228.22 14 , 9 7   
-13.2, .21 stigmasterol-D-
glucoside 
 
 
574.83 5.71 99.38 6 , 4 8   
-12.62, .56 4'-O- 
demethylknipholone-
4'-O-β-D-
glucopyranoside 
 
 
582.51 2.80 231.51 13 , 8 4   
-12.48, .71 β-sitosterol glucoside 
 
 
576.85 6.07 99.38 6 , 4 9   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-12.39, .83 cis-p-
methoxycinnamoylox
yoleanolic acid 
methyl ester 
 
 
 
630.90 9.62 61.83 3 , 0 7   
-10.81, 
11.92 
Qc2 
 
 
549.95 5.48 79.9 4 , 2 6   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.31, 
27.71 
NSC128608 
(CHEMBL1173811) 
 
 
 
467.51 7.34 66.4 3 , 2 4   
-10.23, 
31.72 
NSC132249 
(CHEMBL1173812) 
 
 
 
474.34 7.34 66.4 3 , 2 4   
219 
 
 
The fourth virtual screen had the highest hit rate, at 8.5%.  The results of this screen share 
many similarities with the previous screen.  There are a large number of natural products which 
were hits and there are some high molecular weight compounds with very strong binding 
affinities.  The natural product astrogaloside III, for example, was predicted to bind with a Ki of 
10pM and has 14 hydrogen bond acceptors and 9 hydrogen bond donors. 
 
 
Figure 3.3.10 - visualisation of the diversity of the hits from Virtual Screen 4.  Each point represents a single 
compound and the relative positions between the points depend on the differences between the structures of 
the compounds they represent, as in Figure 3.3.2.  
The visualisation of the Virtual Screen 4 hits in Figure 3.3.10 is very similar to that of the Virtual 
Screen 3 hits in Figure 3.3.8.  Many of the same compounds seem to be represented in both 
diagrams and the distributions of the compounds are quite similar.  One of the main differences 
is that there are several more ligand analogues represented in Figure 3.3.10.  This is due to 
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their higher hit rate: this library had a hit rate of 2.5% Virtual Screen 4, compared to a hit rate of 
0.9% and 0.5% in Virtual Screens 1 and 3, respectively. 
 
 
Figure 3.3.11 - visualisation of the diversity of hits from Virtual Screen 4.  Each point represents a single 
compound.  Each compound is represented with a different shape, depending on its predicted binding energy.  
As with the other screens, there is no clear evidence of a relationship between the molecular 
structures of the hits and their predicted binding energies.  Comparing all the visualisations of 
hit diversity allows a comparison of each of the screens.  Virtual Screen 1 has the smallest 
sampling of chemical space and its visualisations are less populated.  As the area available for 
binding on the TDH model used in this screen was smaller, the compounds were able to make 
less interactions with the target and had lower binding energies.  Virtual Screen 3 hits seem to 
show the largest sampling of chemical space as the TDH model used in this screen had the 
largest binding site.  Virtual Screen 4 used a TDH model which also had no NAD bound, but 
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with flexible loop 1 in the closed conformation. The hits had slightly less sampling of chemical 
space than in the third screen, but the overall hit rate was higher.   
 
Figure 3.3.12 - column chart representation of virtual screening hit rates.  Hit rates are grouped according to 
compound library.  
 
Figure 3.3.13 - column chart representation of virtual screening hit rates.  Hit rates are grouped according to 
Virtual Screen.  
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The following section examines the binding modes of the strongest hits in each screen and 
highlights the relationships between the predicted binding modes and the TDH conformation 
used in each screen.  
3.3.4 Binding Interactions 
3.3.4.1 Virtual Screen 1 
BPOB 
The L-threonine analogue 2-{[3-(4-bromophenyl)-3-oxopropyl]amino}-3-hydroxybutanoic acid 
(BPOB or ZINC04141542) was predicted to bind TDH with a Ki of 107nM in Virtual Screen 1.  
An examination of the predicted binding poses of this compound helps to highlight the important 
binding interactions made by hits in Virtual Screen 1. 
 
Figure 3.3.14 - the molecular structures of BPOB and L-threonine 
AutoDock predicted two distinct binding modes: either with the bromobenzene group pointing 
into the L-threonine binding pocket, or with the bromobenzene group pointing outwards.  In both 
binding positions, the L-threonine binding pocket was occupied, and BPOB formed interactions 
with the same residues as L-threonine: Ser82, Thr119, Tyr144, Thr186 and Trp280.  It also 
interacts with other nearby residues and with the phosphate group of NAD
+
.  
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Figure 3.3.15 - a predicted binding mode of BPOB, predicted by AutoDock in Virtual Screen 1.  BPOB is surrounded 
by a semi-transparent molecular surface and is positioned with the bromine atom facing the interior of the 
protein.  Wire spheres are shown around TDH atoms that are interacting with the ligand.  
The two predicted binding modes are shown next to each other in Figure 3.3.16.  In the lower 
image, the L-threonine-like part of the molecule occupies the L-threonine binding pocket in a 
similar fashion to L-threonine itself (see Figure 3.1.39, in section 3.1), with the β-carbon of the L-
threonine moiety lying close to the C4 atom of the NAD
+
 nicotinamide group.   
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Figure 3.3.16 - the two predicted binding modes of BPOB in Virtual Screen 1.  The bromobenzene group binds 
inside the L-threonine binding pocket (top image) or points outwards from the active site (bottom image).  
Hydrogen bonds are shown by red lines and labelled with the bonding distances  
Similar interactions with TDH can be seen as one examines the binding modes of the other top 
hits. 
 
ZINC1673377 
The top scoring compound in Virtual Screen 1 was ZINC1673377, which was predicted to bind 
with a Ki of 1.96nM. 
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Figure 3.3.17 - predicted binding mode of ZINC1673377 depicted in AutoDock Tools (ADT).  The top image shows 
ZINC1673377 bound to a molecular surface representation of TDH.  The lower image highlights the binding 
interactions that it makes with TDH.  
ZINC1673377 makes interactions with the important L-threonine-binding residues Thr186 and 
Met 81.  Like BPOB, it also forms interactions with the phosphate groups of NAD
+
.  As it 
extends out from the binding pocket ZINC1673377 makes interactions with residues of flexible 
loop 1, Gly182 and Gly184.  Interactions with main chain atoms of nearby residues such as 
Val83 and Arg84 may also be important for this ligand. 
ZINC1936250 
The second highest ranked hit in Virtual Screen 1, ZINC1936250, has a predicted Ki of 3.14nM.  
This compound was predicted to bind deeply in the L-threonine binding pocket and makes 
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interactions with several of the important L-threonine-binding residues.  As with the previous two 
compounds examined, ZINC1936250, also interacts with an NAD
+
 phosphate group and with 
Val83 and Arg84.  The piperazine moiety extends outwards from the binding pocket and makes 
extensive interactions with the flexible loop, suggesting that this structural feature of TDH may 
be important in ligand binding. 
 
 
Figure 3.3.18 - predicted binding pose of ZINC1936250 depicted using ADT. 
Many of the hits in Virtual Screen 1 show similar binding interactions to those described for the 
ligands above.  Interactions with L-threonine-binding residues are important, as well as 
interactions with other amino acids in the binding pocket.  The phosphate groups of NAD
+
 
interact with many of the ligands in their predicted binding poses.  For molecules that bind on 
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the outer edge of the binding pocket, particularly larger molecules, interactions with residues of 
flexible loop 1 also play a role in binding. 
3.3.4.2 Virtual Screen 3 
Again, an examination of the binding poses of compounds with the highest predicted affinities 
will be used to illustrate the important interactions made with TDH by hits in Virtual Screen 3. 
Alpha-solamargine 
α-Solamargine was predicted to bind TDH with a binding energy of -15.03kcal/mol and a Ki of 
10pM, the lowest of any compound across all four screens. 
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Figure 3.3.19 - predicted binding pose of α-solamargine in Virtual Screen 3, depicted in ADT. 
Looking at Figure 3.3.19, it can be seen that Met81 (located near the centre of each image) acts 
as a boundary between the NAD
+
 and L-threonine binding sites (on the left and right of the 
image, respectively).  The large molecules that bound to both sites either bind on the inner side 
of Met81 in the nicotinamide binding pocket, or they bound on the outer side, as α-solamargine 
does.  Figure 3.3.19 shows that the molecule does not bind very deeply in the L-threonine 
binding pocket, but it benefits from additional interactions in the NAD
+
 binding site.  The binding 
pose on the outer side of the active site means that it also makes interactions with residues of 
flexible loop 1, which is in the open confirmation in Virtual Screen 3. 
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Ancistrogriffithine A 
 
 
Figure 3.3.20 - binding pose of ancistrogriffithine A in AutoDock.  Depicted using ADT. 
Ancistrogriffithine A, another natural product of high molecular weight, achieved a predicted K i 
of 100pM.  In Figure 3.3.20 it can be seen to bind deeply in the nicotinamide binding pocket.  
Rather than interacting with the L-threonine binding site, it makes extensive interactions with 
flexible loop 1 and even an interaction with Pro44 of flexible loop 2. 
ZINC05492794 
The symmetrical molecule ZINC05492794 was predicted to bind to TDH with an equal affinity to 
ancistrogriffithine A.  It provides a good example of a molecule binding both the NAD and L-
threonine binding pockets on the inner side of Met81. 
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Figure 3.3.21 - predicted binding pose of ZINC05492794, depicted in ADT. 
In Figure 3.3.21, ZINC05492794 can be seen binding deeply in both the L-threonine and NAD
+
 
binding pockets.  It makes interactions with several of the important L-threonine binding 
residues, including Met81, Thr119, Tyr144 and Thr186.  In the NAD
+
 binding site, it interacts 
with residues that are important in binding NAD
+
, such as Gly12, Gln13, Ile14 and Ile80.  The 
binding mode of ZINC05492794 is not affected by the position of the flexible loop, which can 
explain the fact that this compound was also one of the top scoring hits in Virtual Screen 4.  
3,23-dioxotirucalla-7,24-dien-21-al 
Like ZINC05492794 and many of the other highest ranked hits from Virtual Screen 3 (see Table 
3.3.5), 3,23-dioxotirucalla-7,24-dien-21-al was a hit in both Virtual Screen 3 and Virtual Screen 
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4.  It has a predicted binding affinity of 250pM in Virtual Screen 3 and it is another example of a 
molecule that is predicted to bind the L-threonine and NAD binding pockets simultaneously.  As 
it is much smaller than some of the higher ranking compounds, it binds more extensively in the 
L-threonine binding pocket, protruding into the nicotinamide pocket to a small degree. 
 
 
Figure 3.3.22 - predicted binding pose of 3,23-dioxotirucalla-7,24-dien-21-al in Virtual Screen 3. 
 
Two more examples of molecules binding to both TDH substrate binding sites can be seen in 
Figure 3.3.23. 
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Figure 3.3.23 - predicted binding poses of ZINC17465983 (top two images) and podocarpusflavone A (bottom two 
images) in Virtual Screen 3.  Both compounds bind deeply in the L-threonine binding pocket and nicotinamide 
binding pocket simultaneously.  
3.3.4.3 Virtual Screen 4 
In Virtual Screen 4, the high predicted binding energies of the highest ranked hits can be 
attributed to their binding to both substrate binding sites, as for the hits in Virtual Screen 3.  In 
the TDH model used as the receptor in Virtual Screen 4, flexible loop 1 is in the closed 
conformation.  For this reason, many of the hits in this screen were also predicted by the 
software to make interactions with residues of this loop. 
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Astrogaloside III 
The natural product, astrogaloside III is very large and makes extensive interactions across a 
large area of the protein. It has a predicted Ki of 12pM. 
 
 
Figure 3.3.24 - predicted binding pose of astrogaloside III in Virtual Screen 4.  Depicted in ADT.  
The closed conformation of the flexible loop precludes binding of astrogaloside III to the L-
threonine binding site.  Instead, it almost completely fills the NAD
+
 binding site and forms 
binding interactions with residues of the flexible loop from the exterior of the protein, rather than 
from within the L-threonine binding site.  
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Stigmasterol D-glucoside 
Stigmasterol D-glucoside (predicted Ki = 210pM) offers an example of a compound predicted to 
bind in both substrate sites simultaneously in this screen. 
 
 
Figure 3.3.25 - predicted binding pose of stigmasterol D-glucoside in Virtual Screen 4.  Depicted in ADT.  
The steroid moiety of stigmasterol D-glucoside can be seen to bind in the nicotinamide pocket, 
behind Met81.  The sugar moiety then protrudes into the L-threonine binding pocket and 
interacts with the threonine-binding residue, Tyr144.  Here, it also makes many interactions with 
the closed loop.  The hydrophobic tail at the other end of the molecule interacts with flexible 
loop residue Thr179 in a similar manner to astrogaloside III. 
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By observing these predicted intermolecular interactions it can be seen that the availability of 
both the NAD
+
 and L-threonine binding sites determines which molecules bind TDH, how they 
bind TDH, and the combined strength of all hydrogen bonds and Van der Waals interactions.  
The top scoring compounds in all screens interact with the same residues that are important for 
binding the substrates.  The open loop, in its different conformations, affects binding to the 
threonine-binding site, whilst also providing more bonding partners itself. 
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3.4 In vitro Screening 
3.4.1 Compound libraries 
 
 
Figure 3.4.1 - visualisation of the diversity of all compounds in the in vitro screening library.  Each point 
represents a single compound in the screening library, and a different shape and colour is used depending on 
which subset of the library the compound belongs to.  The relative positions of the points are dependent on the 
differences between their chemical structures.  
The visualisation of the compounds in the in vitro screening library (Figure 3.4.1) suggests that a 
reasonable degree of diversity was achieved.  The fragments appear to be concentrated around 
the centre of the diagram.  This is probably due in part to their smaller size.  The compounds 
are well distributed vertically, suggesting that a good degree of diversity exists within the limits 
of compounds that size.  The points representing the compounds from the 3D fragment 
consortium are noticeably more dispersed than those of the Maybridge library.  This is probably 
a reflection of the specific design of that library, which aimed to develop more compounds with 
3D geometries, as opposed to the flat structures often found in commercial fragment 
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libraries(243).  Figure 3.4.1 shows that the compounds in the custom library occupy diverse 
regions of chemical space and there are only a few groupings of similar molecules.  Conversely, 
the compounds of the Asinex library appear to be highly concentrated in one corner of the 
diagram, suggesting that these molecules do not cover a diverse range of chemical features.  
There is the possibility that their concentration in this part of the diagram is a consequence of 
those molecules having a molecular weight that is very different from the fragments represented 
in other areas of the diagram.  However, this pattern also raised the concern that the virtual 
screen carried out by UCL ChemiBank using the program GOLD, identified hits with a limited 
range of molecular structures.  This would have been in contrast with the results of the 
AutoDock virtual screens, which found hits with diverse chemical structures. 
 
Figure 3.4.2 - visualisation of the chemical diversity of all compounds in the Asinex library (20,000 compounds) 
screened by UCL ChemiBank, using GOLD. 
Figure 3.4.2 shows a data visualisation of the original 20,000 compounds in UCL ChemiBank’s 
Asinex library.  The compounds are again concentrated in the same area of the diagram, so the 
result in Figure 3.4.1 is not a consequence of a bias introduced by Virtual Screening. Rather, 
this confirms that GOLD found hits with diverse features from the original pool of compounds.  
This is similar to the performance of AutoDock in the virtual screens described above.   
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Table 3.4.1 - mean chemical terms describing the features of the compounds in the in vitro screening libraries. 
 Mean Chemical Term Value    
Library MW LogP TPSA Hydrogen-
bond 
Acceptors 
Hydrogen-
bond 
Donors 
Number of 
Rotatable 
Bonds 
Lipinski Rule of 
Five Compliant? 
Less than 1 
Rule of Five 
Violation? 
Congreve 
Rule of Three 
Compliant? 
Asinex 468.1 3.85 93.51 5.2 1.3 7.4 50.7%  
(507 of 1000) 
87.7%  
(877 of 1000) 
1.5%  
(15 of 1000) 
Maybridge 189.1 1.31 45.12 2.6 1.0 1.8 100.0%  
(500 of 500) 
100%  
(500 of 500) 
75.4%  
(377 of 500) 
3D Fragment 
Consortium 
195.1 0.21 47.20 2.5 0.9 1.9 100%  
(358 of 358) 
100%  
(358 of 358) 
72.1%  
(258  of 358) 
Custom Library 381.5 3.09 89.95 5.0 2.5 3.4 61.1%  
(33 of 54) 
90.7%  
(49 of 54) 
3.7%  
(2 of 54) 
All 341.6 2.48 72.08 4.0 1.2 4.8 73.1%  
(1398 of 1912) 
93.3%  
(1784 of 1912) 
34.1%  
(652 of 1912) 
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The Asinex compounds had the largest molecular weight on average, of the compounds 
screened in the in vitro inhibition assay.  Despite being designed for “lead-likeness”(244), 
approximately 50% of the compounds in the Asinex library violate Lipinski’s rule of five.  
However, the majority of compounds have one violation of the rule or less.  The majority of the 
compounds in the custom library also had one Rule of Five violation or less. 
 The two fragment libraries share very similar characteristics in regards to their molecular 
weights, hydrogen bonding partners and rotatable bonds.  However, there is a significant 
difference between their LogP values.  The higher LogP of the Maybridge compounds reflects 
the greater presence of aromatic ring structures in the Maybridge library, compared to the 3D 
fragment consortium library.  As is to be expected, 100% of the fragments obey the Lipinski 
Rule of Five.  The majority of these compounds also obeyed the Congreve rule of three for 
fragment screening libraries. 
3.4.2 Assay Validation 
The Plate Uniformity Test (PUT) developed by NIH and Eli Lilly researchers(203) was a useful 
diagnostic test for indicating the reliability of the in vitro screening assay (see Section 2.4.2 for a 
description of the PUT assay).  The visual information and the related calculated statistics 
(available in a Microsoft Excel file provided by the authors of the test) not only helped to identify 
problems with the assay, but also advised on the appropriateness of the assay design.  The 
signal window and the Z-score are two related parameters that describe the separation between 
the maximum and minimum signals in an assay.  Calculation of these parameters helped to 
judge the ability of the assay to distinguish inhibitors from false positives.  Figure 3.4.3 shows 
examples of the graphs and statistics calculated by the PUT Microsoft Excel file. 
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Figure 3.4.3 - graphical interpretation of the different signals recorded in the PUT.  The "Max" signal, relating to un-
inhibited TDH activity, is represented by green points.  The “Mid” signal, relating to 30-70% activity/inhibition, is 
represented by pink points.  The “Min” signal, which relates to zero enzyme activity is represented by dark blue points.  
The graphs under ‘A’ show an assay where the enzyme lost activity towards the end of the assay.  Under ‘B’, the results 
of an assay where the Max and Mid signals were highly variable are shown.  Under ‘C’, the results of a PUT using the final 
assay format are shown.  Under each letter, graphs arranged according to microplate rows and columns are displayed to 
help identify any effects related to wells on the edge of the plate.
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Figure 3.4.3 shows the results of the PUT of the final assay format, which used a reaction buffer 
with 1mM KCl included.  This test was close to the published limits for a screening assay (Signal 
Window > 2.0 or Z’-score > 0.4) where one concentration of each inhibitor is tested per plate.  
The importance of this during hit identification and hit confirmation will be discussed below.  
3.4.3 In vitro screening hits 
In vitro  screening, was carried out as described in Section 2.4.2.  Screening with the Maybridge 
library identified 44 compounds that met the hit criteria of exhibiting at least 50% inhibition of 
TDH in two separate assays.  This represents a hit rate of 8.8%.  After hit confirmation studies, 
only seven compounds were confirmed as TDH inhibitors.  The confirmed hit rate was therefore 
only 1.4% and the false positive rate was approximately 7.4%. 
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Figure 3.4.4 - plots of fractional TDH activity against the log of inhibitor concentration tested in hit confirmation 
assays for Maybridge compounds.  Hits from the primary screen were tested across a range of concentrations 
(three- or four-fold dilutions).  Points relating to confirmed hits are coloured and dose-response curves are fitted 
to the data.  Points relating to false positives are coloured grey.  
243 
 
 
Figure 3.4.5 - plots of fractional TDH activity against the log of inhibitor concentration tested in hit confirmation 
assays for Maybridge compounds.  Hits from the primary screen were tested across a range of concentrations 
(three- or four-fold dilutions).  Points relating to confirmed hits are coloured and dose-response curves are fitted 
to the data.  Points relating to false positives are coloured grey.
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Figure 3.4.4 and Figure 3.4.5 show the confirmation of hits as those showing a concentration-
dependent inhibition, starting at least 50% at 500µM.  Of the seven confirmed inhibitors, three 
compounds, RJF 01106, SB 02047 and CC 06013, were significantly more potent. 
 
Figure 3.4.6 - plot of fractional activity as a function of the concentration of confirmed hits from the Maybridge 
library. 
 
Figure 3.4.7 - plot of fractional activity as a function of the log concentration of five confirmed hits from the 
Maybridge library.  Dose-response curves are fit to the data.  
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Figure 3.4.8 - plot of fractional activity as a function of the log concentration of two potent confirmed hits from 
the Maybridge library.  Dose-response curves are fit to the data.  
It can be seen that several of the fractional activity values in the figures above exceed 1.0.  This 
is a consequence of the suboptimal assay used during these experiments.  The mean enzyme 
activity decreased gradually with time, so that activity values were lower in both control and 
experimental wells towards the end of the assay.  As the data have been normalised to the 
same scale based on the mean activity of the controls in each set of hit confirmation assays, 
several fractional activity values where there was no enzyme inhibition are above 1.0 and some 
are below one.  With knowledge of this potential source of error, the observation of 
concentration-dependent inhibition was a useful criterion to distinguish true hits from false 
positives. 
 
Figure 3.4.9 shows the results of confirmation assays for hits from the 3D fragment consortium 
library. 
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Figure 3.4.9 - plots of fractional activity against the log concentration of hits from the 3D Fragment Consortium Library.  Four compounds were confirmed as inhibitors and dose-response 
curves were fit to the data points representing those compounds. 
247 
 
Of 31 hits identified from the primary assay, only four were confirmed as hits.  This signifies a hit 
rate of 1.1%, with a false positive rate of 7.5%.   
 
Figure 3.4.10 - plot of fractional activity as a function of the concentration of confirmed hits from the 3D 
Fragment Consortium library. 
 
Figure 3.4.11 - plot of fractional activity as a function of the log concentration of confirmed hits from the 3D 
Fragment Consortium library. 
As with the Maybridge fragments, two of the hits, DDD00771052 and 4011502, appear to be 
significantly more potent than the other inhibitors. 
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Custom Library 
Of the eight compounds originally identified as hits from the Custom library, seven met the hit 
confirmation criteria of concentration-dependent inhibition of at least 50% at 500µM, and 
significant inhibition at 100µM.  In contrast to the previous assays, the false positive rate was 
very low. 
 
Figure 3.4.12 - plot of fractional activity against the concentration of custom library compounds in the hit 
confirmation assay.  The only false positive, STK676093 is coloured grey.  
 
Figure 3.4.13 - plot of fractional activity as a function of the log of the concentration of hits from the Custom 
library.  Dose-response curves are fit to the data representing the confirmed hits.  
Two compounds of interest were tested for inhibition in separate assays: BPOB and Qc1.  The 
L-threonine analogue, BPOB, which was identified through virtual screening (see above), was 
tested separately as prior assays had confirmed its in vitro activity under different conditions.  
BPOB was classified as a hit, as it was able to show significant inhibition at 500µM in the 
primary screening assay conditions.  The inhibitor of MmTDH, Qc1, failed to show inhibition in 
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the primary assay, but showed significant inhibition (6-60%) at higher concentrations of L-
threonine and NAD
+
.  Both of these inhibitors were included as hits, but with knowledge gained 
from outside of the screening assay.  To consider the hit rate in regards to the ability of the 
screening assay to identify hits, only seven compounds were identified initially, amounting to a 
hit rate of 13.0%.  If we consider the compounds discovered through separate assays, the hit 
rate is 16.7%, as reported in Figure 3.4.17. 
Asinex 
Of fourteen hits from the primary screen of the Asinex compounds, seven were confirmed as 
inhibitors with concentration-dependent inhibition of at least 50% at 100µM. 
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Figure 3.4.14 - plots of fractional activity as a function of three-fold dilutions of hits from the Asinex library.  Plots are shown as a function of inhibitor concentration (left, A and C) and log 
inhibitor concentration (right, B and D), with associated dose-response curves.
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Fewer errors are evident in the figures representing hit confirmation of the Asinex compounds, 
than for the other libraries.  This is due to the fact that these hits were identified and confirmed 
using a refined assay that included 1mM KCl in the reaction buffer (see PUT and Figure 3.4.3C, 
above).  Both the hit rate and false positive rate for this library were 0.7%. 
 
Figure 3.4.15 - plot of fractional activity against the concentration of all confirmed hits from the Asinex library. 
 
Figure 3.4.16 - plot of fractional activity against the log concentration of all confirmed hits from the Asinex 
library. 
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Figure 3.4.17 - hit rates of different subsets of the in vitro screening library and the entire library.  The overall hit 
rate of the in vitro screening experiment was 1.4%  
The overall hit rate for the in vitro screen is within expected ranges for a high-throughput 
screening assay(281).  The hit rate for the custom library is particularly high and the reasons of 
this will be discussed further in this thesis. 
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Figure 3.4.18 - visualisation of the diversity of all confirmed hits from in vitro screening.  Each compound is 
represented by a different point, depending on which subset of the screening library it belongs.  The relative 
positions of the points are determined by the differences between the chemical structures of the compounds, as 
in Figure 3.4.1.  
Given the modest library size, compared to libraries used in high-throughput screening, the 
screen was successful in identifying inhibitors with diverse chemical structures.  The 
combination of various approaches, including the identification of potential hits using virtual 
screening and the application of fragment-based hit discovery, creates more options for future 
structure-based drug design efforts.  The confirmed hits from the in vitro screen are listed below 
in Table 3.4.2. 
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Table 3.4.2 - all confirmed hits and descriptive chemical terms from the in vitro screen. 
 Name Structure MW LogP TPSA Hydrogen-
bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Congreve 
Rule of 
Three 
Compliant? 
Fragments          
Maybridge RJF 01106  
 
 
205.21 0.62 61.55 3 , 1 2  
 SB 02047 
 
 
220.27 0.85 43.78 3 , 1 1  
 CC 06013 
 
200.69 1.31 38.91 2 , 1 1  
 CC 12709  
 
 
147.17 1.30 36.02 1 , 2 1  
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 Name Structure MW LogP TPSA Hydrogen-
bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Congreve 
Rule of 
Three 
Compliant? 
 BTB 08846  
 
 
 
 
276.31 2.35 67.76 3 , 1 4  
 CC 40909 
 
 
167.23 1.33 25.16 1 , 1 1  
 SPB 00826 
 
 
198.31 2.74 20.23 1 , 1 1  
3D Fragment 
Consortium 
DDD00771052 
 
 
156.21 -0.03 41.99 2 , 1 1  
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 Name Structure MW LogP TPSA Hydrogen-
bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Congreve 
Rule of 
Three 
Compliant? 
 4011502  
 
 
162.19 0.76 55.12 2 , 2 0  
 EN300-93218 
 
 
219.71 -1.00 35.58 2 , 1 1  
 EN300-95115 
 
 
187.24 -0.24 21.26 2 , 1 0  
Small Molecules         
Asinex BAS 0792599  
 
 
 
461.53 4.56 75.47 6 , 0 9  
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 Name Structure MW LogP TPSA Hydrogen-
bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Congreve 
Rule of 
Three 
Compliant? 
 ASN 5580922  
 
 
 
497.63 3.68 87.74 4 , 2 9  
 BAS 0472148 
 
 
 
565.68 0.59 92.32 5 , 2 9  
 BAS 1066901 
 
 
 
477.51 3.40 113.08 5 , 3 4  
 BAS 3153732 
 
 
 
530.56 5.48 124.27 5 , 2 10  
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 Name Structure MW LogP TPSA Hydrogen-
bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Congreve 
Rule of 
Three 
Compliant? 
 BAS 1280267  
 
 
 
546.04 6.25 93.47 6 , 1 9  
 BAS 0247712 
 
 
 
490.64 3.40 115.22 6 , 2 12  
Custom Library myricetin 
 
 
318.24 1.85 147.68 8 , 6 1  
 quercetin 
 
 
302.24 2.16 127.45 7, 5 1  
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 Name Structure MW LogP TPSA Hydrogen-
bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Congreve 
Rule of 
Three 
Compliant? 
 sanguinarine  
 
 
332.33 -0.94 40.8 4 , 0 0  
 NSC 132249 
 
 
474.34 7.34 66.4 3 , 2 4  
 NSC 132252 
 
 
545.24 7.24 66.4 3 , 2 4  
 NSC 128598 
 
 
423.44 6.28 66.4 3 , 2 4  
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 Name Structure MW LogP TPSA Hydrogen-
bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Congreve 
Rule of 
Three 
Compliant? 
 NSC 128608  
 
 
467.51 7.34 66.4 3 , 2 4  
 2-{[3-(4-
bromophenyl)-3-
oxopropyl]amino}-3-
hydroxybutanoic acid 
(BPOB) 
 
 
330.17 -1.01 94.04 4 , 2 7  
 Qc1 
 
 
393.38 3.83 61.44 2 , 2 4  
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3.4.4 Hit validation and characterisation 
Hit validation is mainly centred on validating a hit’s activity and its identity.  In this study, hit 
validation involved verifying that the observed inhibition demonstrated by the hits was specific 
and not the result of interference with the assay.  To this end, assays to accurately measure the 
IC50 and to determine the mode of inhibition (MOI) of the inhibitors were carried out.  Tests for 
non-specific inhibition using detergent (Triton X-100) were also performed to exclude non-
specific inhibitors (see methods). 
3.4.4.1 Asinex Library 
It was not possible to obtain a further supply of the hits from the Asinex library, so stock 
solutions from the original supply for screening were used in hit validation studies.  To establish 
whether the Asinex inhibitors were acting by a specific mode of action, the hit confirmation 
assay was repeated using a reaction buffer containing 0.01% Triton X-100.  The results are 
plotted in Figure 3.4.19 and Figure 3.4.20. 
 
Figure 3.4.19 - plot of fractional activity against log inhibitor concentration.  Confirmed hits from the Asinex 
library were tested in the presence and absence of detergent (Triton X-100).  The inhibitors in this plot all showed 
similar levels of activity under both conditions.  
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Figure 3.4.20 - plot of fractional activity against log inhibitor concentration.  Confirmed hits from the Asinex 
library were tested in the presence and absence of detergent (Triton X-100).  The inhibitors shown above all 
lacked activity in  under both conditions.  
Only three of the compounds were able to show inhibition as before.  However, as these studies 
were carried out some months after the primary assay, the hit confirmation assay was also 
repeated without detergent.  It was evident that four compounds which had previously shown 
inhibition were now showing considerably less inhibition (around 90%) or none at all.  There 
was the possibility that these inhibitors were time-dependent, so the 30-minute pre-incubation 
time was insufficient (in the primary assay, inhibitors were pre-incubated with TDH for at least 
30 minutes).  The four inhibitors that had seemingly lost activity were re-tested at 100µM, after 
pre-incubation with TDH for at least 72 minutes, with and without detergent.  After this, just one 
inhibitor, BAS 1066901, exhibited activity at a level close to the hit criteria in the primary assay: 
it inhibited TDH by 52.7% in the presence of detergent and 73.2% inhibition without detergent.   
Table 3.4.3 – residual TDH activity after pre-incubation with Asinex inhibitors for at least 72 minutes, with or 
without detergent.  Only BAS 1066901 shows significant inhibition.  
 Percentage residual TDH activity 
Asinex ID With detergent Without detergent 
BAS 3153732 92.8% (± 2.8%) 91.7% (± 7.2%) 
BAS 1280267 85.5% (± 2.6%) 112.1% (± 8.8%) 
BAS 1066901 52.7% (± 1.6%) 73.2% (± 5.8%) 
BAS 0247712 76.8% (± 2.3%) 99.4% (± 7.8%) 
 
Based on the results available at present, only four inhibitors can be confirmed: BAS 0792599, 
ASN 5580922, BAS 0472148 and BAS 10660901.  IC50 values were calculated from the results 
of the first hit confirmation assays as 31.8µM for BAS 0792599, 84.3 µM for ASN 5580922, 
33.3µM for BAS 0472148 and 36.1µM for BAS 1066901. 
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3.4.4.2 Fragment Library 
Maybridge 
Assays to determine the IC50 values of the fragments were carried out at the same substrate 
concentrations as in the primary screening assay. 
 
Figure 3.4.21 - plots of fractional activity versus inhibitor concentration (top) and fractional activity versus log 
inhibitor concentration (bottom), for four previously confirmed hits from the Maybridge library.  
Six of the seven confirmed hits from the Maybridge library were re-procured from various 
commercial vendors.  When testing these compounds across a range of different 
concentrations, the compounds CC40909 and RJF01106 failed to show any inhibition matching 
that which was found in the primary screening assay.  SPB00826 showed weak inhibition, which 
was similar to the inhibition displayed in the primary screening assay.  The difference in 
fractional activity at 1000µM and 500µM was relatively small, suggesting that, this compound is 
a partial inhibitor of TDH.  The same conclusion may be made for BTB08846, which showed 
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around 71-85% inhibition over the same concentration range.  SPB00826 and BTB08846 
exhibited 21.5% and 46.8% inhibition, respectively at 500µM in the hit confirmation assay.  
However, fractional activity values at a third of this inhibitor concentration were 88.8% for 
SPB00826 and 119.6% for BTB88046.  Thus the results are not necessarily conflicting.  The 
higher inhibition in the screening and hit confirmation assays may have been caused by 
differences in the concentrations of stock inhibitor solutions.  By curve fitting a dose response 
curve in the data analysis program Prism (see lower plot in Figure 3.4.21), the IC50 values for 
these inhibitors were estimated at 1.20mM for SPB00826 and 2.46mM for BTB08846.  If they 
are indeed partial inhibitors, then their maximum inhibition values are approximately 50% at 
1mM, for SPB00826, and 75% at 1mM for BTB08846. 
As stated earlier, two potent fragments were identified in the Maybridge library: SB02047 and 
CC06013.  These inhibitors were active in the low micromolar range and the IC50 values were 
4.6µM for SB02047 and 132.8µM for CC06013.  
 
Figure 3.4.22 - plots of fractional activity as a function of SB02047 concentration (left) and log SB02047 
concentration (right).  
 
Figure 3.4.23 - plots of fractional activity as a function of CC06013 concentration (left), and log CC06013 
concentration (right).  
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3D Fragment Consortium 
The two stronger inhibitors from the four confirmed hits from the 3D fragment library were 
synthesized by Dr Sally Oxenford: DDD00771052, 4011502.  A range of concentrations were 
tested against TDH to establish the IC50 concentrations.  The results are plotted in Figure 3.4.24, 
below. 
 
Figure 3.4.24 - plot of fractional activity against the concentration of fragments DD00771052 and 4011502.  
DDD00771052 does not show significant inhibition across the range tested, whilst 4011502 reproduces the 
inhibition demonstrated in hit confirmation assays.  
DDD00771052 failed the validation assay and only demonstrated inhibition of up to 82% at 
1mM.  Conversely, 4011502 was able to demonstrate inhibition with similar potency to that 
seen in the primary and hit confirmation assays.  An IC50 of 111.8µM was established for this 
compound. 
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Figure 3.4.25 - plot of fractional activity versus log 4011502 concentration.  A dose-response curve was fit to the 
data and an IC50 of 111.8µM was determined.  
As with the Asinex library, the fragments were tested in the presence of 0.01% Triton X-100 to 
rule out non-specific inhibition by self-aggregation.  The results of this test are listed in Table 
3.4.4, below. 
 
Table 3.4.4 - the effect on TDH activity of confirmed fragment inhibitors, with or without detergent (0.01% v/v 
Triton X-100) in the reaction mixture.  The standard deviations of replicate measurements are shown in brackets.  
   Residual TDH activity  
(standard deviation) 
Compound Library ID Concentration Without 
detergent 
With detergent 
Maybridge SPB00826 500µM 44.7%  
(± 7.3%) 
56.4%  
(± 12.4%) 
 SB02047 20µM 51.1%  
(± 7.7%) 
47.5%  
(n.d.) 
 CC06013 100µM 45.9%  
(± 6.1%) 
43.9%  
(± 14.4%) 
 BTB08846 500µM 87.8%  
(n.d.) 
89.9%  
(n.d.) 
3D Fragment 
Consortium 
4011502 100µM 61.9%  
(± 7.0%) 
48.1%  
(± 26.5%) 
 
All of the inhibitors in Table 3.4.4 have undergone confirmation as specific inhibitors of TDH 
and 4011502 from the 3D Fragment Consortium is the most fully validated compound, having 
been synthesised, purified and characterised prior to testing. 
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3.4.4.3 Custom Library 
Table 3.4.5 shows the inhibition of TDH with fixed concentrations of inhibitors from the custom 
library, in the presence and absence of 0.01% v/v Triton X-100. 
Table 3.4.5 - the effect on TDH activity of confirmed inhibitors from the Custom library and TETD as a positive 
control, with or without detergent (0.01% v/v Triton X-100) in the reaction mixture.  The standard deviations of 
replicate measurements are displayed in brackets, where applicable. * - similar values of percentage activity with 
detergent were found for a range of concentrations of NSC132252 (250 – 25µM), prompting further investigation 
(see below).  
   Percentage residual TDH activity 
Compound 
Library 
ID Concentration Without detergent With detergent 
Custom Qc1 250µM 79.0% 65.0% 
 sanguinarine 100µM 50.5% (± 0.4%) 57.6% (± 5.9%) 
 myricetin 250µM 7.2% 5.4% 
 quercetin 50µM 73.3% (± 4.4%) 79.4% (± 11.5%) 
 NSC132249 100µM 73.3% (± 1.0%) 69.6% (± 2.4%) 
 NSC128608 100µM 87.6% 84.0% 
 NSC128598 125µM 71.4% 61.6% 
 NSC132252* 25µM 3.0% (± 4.4%) 49.0% (± 5.7%) 
 TETD 30µM 71.7% (± 6.7%) 65.4% (± 5.1 %) 
 
Most of the Custom library inhibitors exhibited comparable levels of inhibition in the presence 
and absence of 0.01% v/v Triton X-100.  The one exception was NSC132252, which showed 
inhibition with and without the detergent present, but inhibited TDH to very different extents 
under each condition.  The observation that the inhibition by NSC132252 was similar across a 
range of different concentrations also suggested that it was acting in a time-dependent manner 
(during the assay lower concentrations were tested after higher concentrations, so the lower 
concentrations of inhibitor had longer pre-incubation times).  To test this hypothesis, 
NSC132252 was incubated with TDH at a fixed concentration, with or without Triton X-100 and 
for different lengths of time before activity was measured at saturating substrate concentrations.  
The results of this test are shown in Figure 3.4.26. 
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Figure 3.4.26 - the fractional activity of TDH following different incubation times with NSC132252, in the presence 
or absence of detergent.  It is clear that inhibition is instant, in the absence of detergent, whereas inhibition is 
time-dependent in the presence of detergent.  
Figure 3.4.26 clearly shows that, rather than abolish activity, as would be expected for a non-
specific aggregating inhibitor, the addition of detergent appears to convert the activity of 
NSC132252 from that of a rapidly binding inhibitor to a time-dependent, slow binding inhibitor.  
There are a number of situations that could explain this.  Firstly, the compound may inhibit TDH 
non-specifically or interfere with the assay readout in the absence of detergent, and the rapid 
inhibition exhibited is the composite of both the non-specific and specific time-dependent 
activity.  An alternative explanation may be that NSC132252 inhibits TDH by two separate 
MOIs, one of which is interrupted by the presence of detergent.  IC50 values and information on 
the compound’s MOI were sought in the presence and absence of detergent to gain more 
information surrounding this inhibitor.  The results of these studies will be discussed below. 
In addition to NSC132252, several other compounds displayed time-dependent activity under 
normal conditions: BPOB, myricetin and the UDP-GalE inhibitors, NSC132249, NSC128598 
and NSC128608. 
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Figure 3.4.27 - time dependent inhibition of TDH by 1mM BPOB. 
BPOB demonstrated a time-dependent inhibition that manifest in a linearly decreasing rate of 
reaction with time.  At a concentration of 1mM, maximal inhibition had not yet been reached 
after 90 minutes of pre-incubation.  For this reason, during MOI studies with time-dependent 
inhibitors, TDH was pre-incubated with the compound of interest for at least 2 hours prior to 
initiation of the reaction. 
 
Figure 3.4.28 - time dependent inhibition of TDH by BPOB over pre-incubation times of up to 90 minutes. 
The discovery of myricetin’s time-dependent inhibition (see Figure 3.4.29, below), prompted the 
investigation of quercetin as a time-dependent inhibitor. 
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Figure 3.4.29 - time dependent inhibition of TDH by 100µM myricetin. 
As quercetin is highly similar to myricetin, it was highly likely that it was also a time-dependent 
inhibitor.  This was confirmed in an assay that measured TDH activity after pre-incubation times 
with quercetin of up to 110 minutes (see Figure 3.4.31). 
 
Figure 3.4.30 - the structural formulas of myricetin and quercetin.  The two differ by just one hydroxyl group.  
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Figure 3.4.31 - time dependent inhibition of TDH by 300µM quercetin. 
The UDP-GalE inhibitors, NSC132249 and NSC128598, caused a slow, linear decrease in TDH 
activity with increased pre-incubation time. 
 
Figure 3.4.32 - time dependent inhibition by 500µM NSC132249 and 800µM NSC128598. 
Taking this data and the data regarding NSC132252 into account, it was anticipated that this 
behaviour applied to the entire series of UDP-GalE inhibitors. 
 
The assays to determine the IC50 values of the hits from the Custom library were carried out at 
saturating substrate concentrations so that the results could be used to inform the inhibitor 
concentrations to be used for MOI assays.  As a consequence, the inhibitory concentrations 
presented here differ from those encountered in the primary screening and hit confirmation 
assays. 
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Figure 3.4.33 - fractional TDH activity as a function of the concentration of confirmed inhibitors from the Custom library.  Dose-response curves were fitted to the data to calculate IC50 
values of 291.4µM for BPOB, 713.9µM for NSC128598 and 188.7µM for NSC128608.  
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Figure 3.4.34 - fractional TDH activity as a function of the concentration of confirmed inhibitors from the Custom library.  Dose-response curves were fitted to the data to calculate IC50 
values of 49.55µM for sanguinarine, 27.15µM for myricetin and 58.21µM for quercetin.  
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Figure 3.4.35 - fractional TDH activity as a function of the concentration of confirmed inhibitors from the Custom library.  Dose-response curves were fitted to the data to calculate IC50 
values of 28.3µM for Qc1 and 52.2µM for NSC132249.
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The relative potencies of the hits were in agreement with those observed during hit confirmation 
assays. BPOB, NSC128598 and NSC128608 are the weaker inhibitors from this group of 
compounds.  Qc1, sanguinarine, myricetin, quercetin and NSC132249 all had similar potencies, 
with IC50 values below 100µM.  NSC132252 proved to be very potent, presenting an IC50 below 
10µM.  However, in the presence of detergent, its potency was comparable with that of 
NSC132249 (see Figure 3.4.35).   
 
Figure 3.4.36 - fractional activity as a function of NSC132252 concentration (A) or log NSC132252 concentration 
(B) without detergent or with detergent.  The potencies are very different under each condition.  The IC50 under 
normal assay conditions is calculated as 4.2µM, whilst the IC50 with detergent is 21.0µM.  
Following these results, detailed MOI studies were carried out on BPOB, Qc1, sanguinarine, 
myricetin, NSC132249 and NSC132252 (with and without detergent).  
 
BPOB 
The L-threonine analogue, BPOB is a time-dependent inhibitor.  BPOB is one of the weaker 
compounds and had an IC50 of 291.4µM.  The slope of a plot of rate as a function of BPOB 
concentration had a Hill coefficient of 1.54, suggesting that there may be some weak 
cooperativity involved in BPOB inhibition. 
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A curve based on the mixed model of inhibition was fitted to the data for fractional activity 
versus NAD
+
 concentration with a high R
2
 of 0.9180.  The value of alpha was 2.15, but as this 
value was not significantly higher than the neutral value of 1.0 it suggested the presence of 
mixed competitive-noncompetitive inhibition (α indicates the affinity of the inhibitor for the free 
enzyme and the substrate-bound enzyme; values much greater than 1 indicate a preference for 
free enzyme, whilst values close to zero indicate a preference for substrate-bound enzyme).  A 
competitive model fit to the data with a R
2 
of 0.9161, but an analysis using Aikake’s criterion 
(AIC) favoured the mixed model over the competitive model.  Furthermore, the noncompetitive 
model (α = 1.0) fit to the data with a R
2
 of 0.9177 and a comparison using AIC favoured this 
model over the mixed model.  This suggests that the MOI of BPOB is indeed noncompetitive in 
relation to NAD
+
.  As there was some evidence of cooperativity in BPOB binding, the data were 
fitted using a Hill-modified mixed model, which gave similar results and an R
2
 of 0.9184.  The Ki  
was calculated as 821.1µM and a Hill coefficient of 1.33 was determined.  
 
Figure 3.4.37 - plots of fractional activity versus NAD
+ 
concentration, at fixed concentrations of BPOB.  The data 
are fit to curves with the equation describing mixed inhibition (A) and cooperative mixed inhibition (B).  
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As discussed earlier, as the relationship between L-threonine and rate does not follow 
Michaelis-Menten kinetics, the equations did not fit as well to the standard models.  However, 
the relative fits of each model to the data was used to determine the most probable MOI.  In this 
way, a noncompetitive MOI in relation to L-threonine was determined as the most likely MOI for 
BPOB.  Both mixed and noncompetitive models fit with an R
2
 of 0.808 and the mixed model fit 
with an alpha of 0.87.  Fitting Hill-modified models to take account of cooperativity only brought 
marginal improvements to the fit to the data, and the Hill coefficient was small at 1.14. 
 
Figure 3.4.38 - plots of fractional activity versus L-threonine concentration, at fixed concentrations of BPOB.  
Curves were fitted using the equations describing noncompetitive inhibition (A) and cooperative noncompetitive 
inhibition (B).  The fits of the curves to the data are almost identical, suggesting that cooperativity does not play a 
role in this respect.  
With a noncompetitive MOI (when alpha=1.0), the Ki is equal to the IC50.  Using the IC50 stated 
previously, the Ki of BPOB can be estimated as 291.4µM.  
These findings contrast with an MOI that one would expect for an L-threonine analogue.  They 
also conflict with the binding modes predicted by Virtual Screening (see Figure 3.4.39 and 
Figure 3.4.40), which would have predicted an MOI that was competitive towards both 
substrates.  Noncompetitive MOIs can sometimes indicate a nonspecific mechanism of action, 
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and this may help to explain why co-crystallisation with TDH failed.  However, there was no 
other indication that the compound was acting non-specifically. 
 
 
Figure 3.4.39 - binding mode of BPOB predicted in Virtual Screen 3.  BPOB is predicted to bind both substrate 
sites, thereby competing with both substrates for binding.  See also, Figure 3.3.15 and Figure 3.3.16.  
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Figure 3.4.40 - binding mode of BPOB predicted in Virtual Screen 4.  BPOB is predicted to bind both substrate 
sites, thereby competing with both substrates for binding.  See also, Figure 1.2.15 and Figure 1.2.16.  
Qc1 
The IC50 of Qc1 was 28.3µM.  A Hill coefficient close to unity (0.85), suggested that there was 
no cooperativity involved in its action.  The results of data analysis of the relationship between 
NAD
+
 and fractional activity indicated that Qc1 had an uncompetitive MOI in relation to NAD
+
.  
The mixed model of inhibition fit with an R
2
 of 0.8362 and yielded an alpha value of 0.278.  The 
uncompetitive model fit with an R
2
 of 0.8353 and determined an αKi of 32.0µM.  When this value 
is converted to Ki by division with the alpha value of 0.278, it results in a value that is very 
similar to that predicted by the mixed model – the Ki is 115.0µM, compared to 132µM, predicted 
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by the mixed model.  These data suggest that Qc1 preferentially binds to the TDH-NAD
+
 
complex, but may also have low affinity for the apo-enzyme. 
 
Figure 3.4.41 - plots of fractional activity versus NAD
+
 concentration, at different fixed concentrations of Qc1.  
Curves describing mixed inhibition (A) and uncompetitive inhibition (B) are fitted to the data.  It is evident that 
the fits to the data are very similar, suggesting that they represent the same or very similar MOIs.  
The data obtained on the effect of Qc1 on the relationship between L-threonine concentration 
and rate of reaction varied significantly between replicate runs.  However, the trends showing 
Qc1 concentration-dependent inhibition were the same.  The MOI of Qc1 towards L-threonine 
was shown to be noncompetitive and the Ki was calculated as 46.7µM. 
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Figure 3.4.42 - plot of fractional activity against L-threonine concentration, at different fixed concentrations of 
Qc1.  Curves describing noncompetitive inhibition are fit to the data.  
The MOI implicated by the data analyses described above suggests that Qc1 may inhibit TDH 
by preferentially binding to the NAD
+
-bound enzyme, but not by competing with L-threonine for 
binding.  This is in disagreement with the binding modes predicted for Qc1 in Virtual Screens 3 
and 4, in which other members of the Qc series were hits. 
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Figure 3.4.43 - predicted binding mode of Qc1 in Virtual Screen 3.  The compound is predicted to bind in the NAD
+
 
binding  site.  
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Figure 3.4.44 - predicted binding mode of Qc1 in Virtual Screen 4.  Qc1 was predicted to bind in the NAD
+
 binding 
site, as in Virtual Screen 3.  
As with the L-threonine analogues, L-allo-threonine and pyruvate, one would expect an inhibitor 
with an MOI that was uncompetitive in regards to NAD
+
 to bind the L-threonine binding pocket.  
On the contrary, the MOI towards L-threonine was noncompetitive.  This raises the possibility 
that Qc1 may bind to a site other than the L-threonine and NAD
+
 binding pockets. 
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Sanguinarine 
The slope of the curve relating sanguinarine concentration with TDH fractional activity had a Hill 
coefficient of 1.2, suggesting that there was little or no cooperativity involved in the inhibition 
caused by sanguinarine.  An IC50 of 49.6µM was calculated. 
Analysis of data from enzymatic assays predicted that sanguinarine competes with NAD
+
 for 
binding.  MOI models for both competitive and mixed inhibition fit to the data with a R
2
 of 0.874.  
The mixed model calculated a very high alpha value of approximately 2x10
16
, which strongly 
indicates a competitive MOI. 
 
Figure 3.4.45 - plot of fractional activity versus NAD
+
 concentration, at different fixed concentrations of 
sanguinarine. A curve describing competitive inhibition is fit to the data.   
A competitive MOI in relation to L-threonine was also predicted by both mixed and competitive 
models, which fit with an R
2
 of 0.7325. 
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Figure 3.4.46 - plot of fractional activity versus L-threonine concentration, at different fixed concentrations of 
sanguinarine.  Curves describing competitive inhibition are fit to the data.  
With knowledge of the MOI of sanguinarine, the Ki could be estimated using its IC50.  Using the 
Cheng-Prusoff equation for competitive inhibitors, a Ki of 4.5µM was calculated.  The MOIs 
demonstrated in vitro are in agreement with those predicted by virtual screening.  Observing the 
predicted binding modes in Figure 3.4.47, one can see that in Virtual Screen 4, sanguinarine 
was predicted to bind in both the NAD
+
 and L-threonine binding pockets. 
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Figure 3.4.47 - binding mode of sanguinarine, predicted in Virtual Screen 4.  It largely occupies the NAD
+ 
binding 
pocket, but also binds L-threonine binding residues Met81 and Thr119.  
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Myricetin 
The inhibitor of dihydroflavonol 4-reductase (DFR), myricetin inhibited TDH potently with an IC50 
of 27.2µM.  The slope fit to the same data used to determine the IC50 had a Hill coefficient of 
0.78, suggesting that there may be some negative cooperativity involved in myricetin binding. 
 
Figure 3.4.48 - fits of fractional activity versus NAD
+
 concentration at fixed concentrations of myricetin.  Curves 
describing mixed inhibition (A) and competitive inhibition (B) are fit to the data.  
The best fitting model of inhibition describing myricetin’s behaviour towards NAD
+ 
was the 
mixed model of inhibition.  Alpha was predicted as 3.19, suggesting that the MOI was 
competitive or mixed noncompetitive-competitive.  AIC comparisons of different models 
suggested that the mixed model was a better description of the data than the competitive 
model, and that a noncompetitive MOI was actually the most appropriate MOI to be assigned to 
myricetin.  The Ki calculated by this model was 20.24µM. 
It was clear from the data analyses that myricetin exhibited a competitive MOI against L-
threonine.  A competitive model calculated a Ki of 41.7µM.  Fitting a Hill-modified competitive 
model resulted in slightly improved fits to the data, from an R
2
 of 0.794 to 0.810.  Consistent 
with the earlier evidence of negative cooperativity, a Hill-coefficient of 0.44 was calculated. 
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Figure 3.4.49 - plots of fractional activity as a function of L-threonine concentration, at different fixed 
concentrations of myricetin.  Curves were fit with the competitive inhibition model (A) and the cooperative 
competitive inhibition (B) model.  
All of the Ki values lie within a similar range, and the Ki that would be calculated by applying the 
Cheng-Prusoff equation for a noncompetitive inhibitor, equal to 27.2µM, is within the 95% 
confidence interval of the Kis calculated by non-linear regression.  The conclusions drawn from 
these results suggest that myricetin may inhibit TDH by competing for the L-threonine binding 
site, in a way that is independent of NAD
+
 binding.  This MOI can be compared with that 
predicted during Virtual Screening by observing Figure 3.4.50 and Figure 3.4.51, below. 
289 
 
 
Figure 3.4.50 - binding pose of myricetin predicted by AutoDock in Virtual Screen 3.  Myricetin is predicted to bind 
in the NAD binding pocket.  It also interacts with important L-threonine-binding residues Met81, Thr119 and 
Tyr144.  
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Figure 3.4.51 - binding pose of myricetin predicted by AutoDock in Virtual Screen 4.  As in Virtual Screen 3, 
myricetin is predicted to bind in the NAD binding pocket.  It also interacts with important L-threonine-binding 
residues Met81, and Thr119.  
In Virtual Screens 3 and 4, myricetin was predicted to bind in the NAD
+
 binding pocket, which 
conflicts with the conclusions of the MOI studies.  This inhibitor will be discussed further in a 
later section. 
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NSC132249 
The inhibitor of UDP-GalE from Trypanosoma brucei (TbGalE) NSC132249, was one of the 
most potent compounds in its series and inhibited TDH with an IC50 of 52.2µM.  A Hill coefficient 
of 1.33 was calculated for the slope fit to the plot of fractional activity as a function of inhibitor 
concentration.  This suggests a minor degree of cooperativity may be involved in its binding. 
The MOI of NSC132249 in relation to NAD
+
 was predicted to be competitive, with a Ki of 
67.5µM.  The competitive model was deemed by an AIC comparison to be more likely to have 
generated the data than a mixed model (which predicted an alpha of 5.38, also suggesting a 
competitive MOI). 
 
Figure 3.4.52 - curves describing competitive inhibition fitted to data describing the relationship between NAD
+
 
concentration and fractional activity, measured in the presence of different fixed concentrations of NSC132249.  
The MOI of NSC132249 in relation to L-threonine was more ambiguous, with mixed, 
uncompetitive and noncompetitive models all providing similar fits to the data.  Comparisons 
using AIC indicated that the uncompetitive model was the most appropriate.  However, an F-test 
confirmed that the uncompetitive model was the most appropriate, but only with a P-value of 
0.72.  For this reason, a mixed noncompetitive-uncompetitive model, where the value of alpha, 
and hence the affinity for the free enzyme, is low is assigned to NSC132249 in relation to L-
threonine.  The calculated Ki is high at 687µM, as would be expected for an uncompetitive 
inhibitor.  The αKi is calculated as 119.6µM.  This is higher than that which would be calculated 
from the IC50, using the Cheng-Prusoff equation for uncompetitive inhibitors: 41.2µM.  Once 
again, this is probably due to the over-estimation of Vmax when fitting equations to data that do 
not strictly conform to Michaelis-Menten kinetics. 
292 
 
 
Figure 3.4.53 - plots of fractional activity against L-threonine concentration, at different fixed concentrations of 
NSC132249.  Curves describing uncompetitive inhibition (A) and mixed inhibition (B).  
The data suggest that NSC132249 inhibits TDH by binding to the NAD site and that this binding 
is more likely to occur when L-threonine is bound to the enzyme.  Binding to the NAD binding 
site is supported by the predictions of AutoDock in Virtual Screen 4. 
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Figure 3.4.54 - binding mode of NSC132249 predicted by AutoDock in Virtual Screen 4.  The compound occupies 
the NAD
+
 binding site, but also interacts with Leu180, Pro181 and Gly182 of flexible loop 1, which is in its closed 
conformation.  
An uncompetitive MOI in relation to L-threonine becomes more plausible when it is considered 
that the binding mode depicted in Figure 3.4.54 occurs when flexible loop 1 (TDH residues 
Thr179-Ala185) is in its closed conformation.  The structural data presented herein suggest that 
this conformation may be promoted by L-threonine binding. 
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Figure 3.4.55 - the binding mode of NSC132249 predicted by AutoDock in Virtual Screen 3.  NSC132249 is 
predicted to bind the L-threonine binding pocket.  This conflicts with the prediction made in Virtual Screen 4, in 
which NSC132249 was also a hit.  
The binding mode predicted in Virtual Screen 3 (see Figure 3.4.55, above) would appear to 
contradict the prediction of an uncompetitive MOI towards L-threonine because NSC132249 
binds in the L-threonine pocket.  Alternatively, taking into account the cooperative nature of the 
relationship between L-threonine concentration and TDH rate, it may be possible that binding of 
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L-threonine to the active site of one monomer, increases the affinity of the second monomer for 
NSC132249.   
 
NSC132252 
As discussed earlier, NSC132252 required further study because of its different behaviour in the 
presence or absence of the detergent Triton X-100.  In contrast to the other compounds in the 
TbGalE inhibitor series, the onset of its inhibition is rapid. However, it becomes a time-
dependent inhibitor in the presence of Triton X-100.  This suggests that it may act as a non-
specific, promiscuous inhibitor unless this mechanism of inhibition is disrupted by detergent.  
Alternatively, the compound may possess two specific mechanisms of inhibition, one of which is 
disrupted by detergent.  In the absence of detergent, the compound’s IC50 is very low at 4.2µM.  
Conversely, the IC50 is somewhat higher in the presence of detergent: 21.0µM 
 
NSC132252 in the absence of detergent 
Titration of NSC132252 concentration produced data that fitted to a curve with a Hill coefficient 
of 1.7, suggesting that there may be some cooperativity involved in NSC13252 inhibition of 
TDH.  The MOI of NSC132252 in relation to NAD
+
 was determined to be competitive. 
 
Figure 3.4.56 - plot of fractional activity versus NAD
+
, at different fixed concentrations of NSC132252.  Curves 
describing competitive inhibition are fit to the data.  
Models for mixed, competitive and noncompetitive MOIs all fit the data relating to L-threonine 
concentration and rate with similar R
2
 values of 0.7623 – 0.7626.  The mixed model fit with an 
alpha value of 17.49, but with large margins of error.  This suggests that the relevant MOI is 
competitive or mixed noncompetitive-competitive.    
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Figure 3.4.57 - plots of fractional activity as a function of L-threonine concentration, at different fixed 
concentrations of NSC132252.  Curves based on mixed inhibition (A), competitive inhibition (B) and 
noncompetitive inhibition (C) all had similar fits to the data.  
An AIC analysis compared fits of competitive and noncompetitive models and reported that the 
competitive model was more likely to have produced the data, but only with a relative probability 
of 1.11.  Therefore, the MOI of NSC132252 in the absence of detergent is best assigned as a 
mixed noncompetitive-competitive MOI, where the inhibitor has a strong preference for binding 
when L-threonine is absent. 
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Figure 3.4.58 - predicted binding mode of NSC132252 in Virtual Screen 4.  The compound is predicted to bind in 
both substrate binding sites, simultaneously  
The data obtained do not suggest that the rapid-onset inhibition of TDH by NSC132252 is 
caused by a non-specific mechanism.  One would expect a noncompetitive MOI if this were the 
case.  Rather, the data indicate that NSC132252 may bind to both NAD
+
 and L-threonine 
binding pockets, as predicted in Virtual Screen 4 (see Figure 3.4.58). 
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NSC132252 in the presence of detergent 
In the presence of 0.01% Triton X-100, NSC132252 exhibited a time-dependent inhibition of 
TDH that was less potent than the rapid inhibition exhibited without detergent.  A fit of the mixed 
model of inhibition to the data relating to NAD
+
 resulted in an R
2
 of 0.842.  The alpha value was 
not much greater than 1, at 2.693, indicating the possibility that the MOI was noncompetitive or 
mixed noncompetitive-competitive towards NAD
+
.  Comparison of all possible models using AIC 
confirmed that noncompetitive is the most appropriate MOI to be assigned to NSC13252 in 
relation to NAD
+
 in the presence of detergent.  Hill-modified versions of the relevant equations 
brought statistically significant improvements to the fits.  A Hill coefficient of 2.2 was calculated 
by fitting a Hill-modified noncompetitive model to the data (R
2
 = 0.850).  A Ki of 14.0µM was 
calculated. 
 
Figure 3.4.59 - plots of fractional activity against NAD
+
 concentration, at fixed concentrations of NSC132252 and 
in the presence of 0.01% Triton X-100.  Curves describing cooperative mixed inhibition (A) and cooperative 
noncompetitive inhibition (B) provided similar fits to the data.  
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The MOI for NSC132252 in the presence of detergent was determined to be competitive 
towards L-threonine.  The mixed model of inhibition was used to calculate an alpha of 8.17, 
which indicates preferential binding to free enzyme.  An AIC analysis also confirmed the 
competitive model to be the most accurate description of the MOI.  In this case, the use of Hill-
modified equations for cooperative inhibition did not provide any significant improvement to the 
fits of each model to the data. 
 
Figure 3.4.60 - fit of fractional activity versus L-threonine concentration, at different fixed concentrations of 
NSC132252 and in the presence of 0.01% Triton X-100 
The data obtained in the presence of detergent suggest that NSC132252 acts by a MOI that 
primarily involves binding to TDH in a way that is mutually exclusive with L-threonine binding.  
However, the binding in relation to NAD
+
 was judged to be noncompetitive, which contradicts 
the binding poses predicted in Virtual Screens 3 and 4, which predict binding to the NAD
+ 
binding site. 
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Figure 3.4.61 - predicted binding mode of NSC132252 in Virtual Screen 3.  It is predicted to bind in the NAD
+
 
binding site.  See also the predicted binding mode in Virtual Screen 4 (Figure 3.4.58).  
The predicted MOIs of NSC132252 in the absence and presence of detergent are in part 
agreement with each other, in regards to L-threonine binding.  However, the non-linear 
regression analyses predicted that NSC132252 may compete with NAD
+
 in the absence of 
detergent, whereas NSC132252 appeared to be noncompetitive towards NAD
+
 in the presence 
of detergent.  There are a number of scenarios that can explain this difference.  Firstly, the 
possibility that the MOIs towards both L-threonine and NAD
+
 in the absence of detergent were 
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mixed noncompetitive-competitive, suggests that the mechanism of inhibition may not actually 
involve binding to TDH, but may impede binding of the substrates to the enzyme.  Another 
scenario that was mentioned earlier is that the inhibition shown in the absence of detergent may 
actually be a combination of non-specific inhibition (i.e. that caused by aggregates) and the 
specific inhibition that is demonstrated in the presence of detergent.  A third scenario, also 
alluded to earlier, is that NSC132252, may be able to bind TDH in two distinct binding modes.  
One of these binding modes could be disrupted by detergent, so the MOI of NSC132252 
presents differently under different conditions. 
Compared to the other TbGalE inhibitor, NSC132249, the MOI of NSC132252 is not entirely 
consistent.  The data indicate that NSC132249 binds to the NAD
+
 site, preferentially to L-
threonine-bound TDH.  The data on NSC132252 inhibition suggested that it may bind to the 
NAD
+
 site in the absence of detergent.  However, a noncompetitive MOI is implicated in the 
presence of detergent.  The possibility of NSC132249 also binding to the L-threonine site was 
raised above.  However, until crystallographic data can be gained on the actual binding 
positions of these inhibitors, the data on the MOIs of the TbGalE inhibitors remains 
inconclusive.  
 
3.4.5 Inhibition of trypanosome growth 
Hits from in vitro screening were tested for trypanosome growth inhibition by Professor Jon Kelly 
at the London School of Hygiene and Tropical Medicine, as described in Section 2.4.4.  The 
results of a preliminary round of assays testing the in vitro screening hits for their ability to inhibit 
the growth of cultured bloodstream form (BSF) T. brucei are presented in Table 3.4.6, below. 
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Table 3.4.6 - the percentage inhibition of BSF trypanosome growth, in the presence of confirmed hits from the in vitro screening experiments.  The names of the most potent compounds are 
emboldened and underlined.  
    Percentage inhibition of trypanosome growth (at 
molar concentration) 
Compound 
Library 
ID Structure MW 10µg.ml
-1
 5µg.ml
-1
 1µg.ml
-1 
Custom Library sanguinarine  
 
 
394.3 100% (at 25.4µM) 100% (at 12.7µM) 100% (at 2.5µM) 
 myricetin 
 
 
318.2 100% (at 31.4µM) 100% (at 15.7µM) 16% (at 3.1µM) 
 2-{[3-(4-bromophenyl)-3-
oxopropyl]amino}-3-hydroxybutanoic 
acid (BPOB) 
 
 
330.2 28% (at 30.2µM) 9% (at 15.1µM) 0% (at 3.0µM) 
 Qc1 
 
 
393.4 97% (at 25.4µM) 96% (at 12.7µM) 9% (at 2.5µM) 
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    Percentage inhibition of trypanosome growth (at 
molar concentration) 
Compound 
Library 
ID Structure MW 10µg.ml
-1
 5µg.ml
-1
 1µg.ml
-1 
 NSC 132249  
 
 
474.3 79% (at 21.1µM) 25% (at 10.5µM) 0% (at 2.1µM) 
 NSC 132252 
 
 
545.2 52% (at 18.3µM) 9% (at 9.2µM) 0% (at 1.8µM) 
 NSC 128598 
 
 
423.4 72% (at 23.6µM) 11% (at 11.8µM) 0% (at 2.4µM) 
 NSC 128608 
 
 
467.5 65% (at 21.4µM) 28% (at 10.7µM) 0% (at 2.1µM) 
Asinex BAS 0792599 
 
 
461.5 34% (at 21.7µM) 0% (at 10.8µM) 0% (at 2.2µM) 
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    Percentage inhibition of trypanosome growth (at 
molar concentration) 
Compound 
Library 
ID Structure MW 10µg.ml
-1
 5µg.ml
-1
 1µg.ml
-1 
 BAS 1066901  
 
 
477.5 0% (at 20.9µM) 0% (at 10.5µM) 0% (at 2.1µM) 
 ASN 5580922 
 
 
497.6 32% (at 20.1µM) 0% (at 10.0µM) 0% (at 2.0µM) 
 BAS 0472148 
 
 
565.7 n.d. 98% (at 8.8µM) 0% (at 4.4µM) 
Maybridge CC 40909 
 
 
167.2 24% (at 59.8µM) 0% (at 29.9µM) 0% (at 6.0µM) 
 SPB 00826 
 
 
198.3 51% (at 50.4µM) 10% (at 25.2µM) 0% (at 5.0µM) 
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    Percentage inhibition of trypanosome growth (at 
molar concentration) 
Compound 
Library 
ID Structure MW 10µg.ml
-1
 5µg.ml
-1
 1µg.ml
-1 
 SB 02047  
 
 
220.3 60% (at 45.4µM) 0% (at 22.7µM) 0% (at 4.5µM) 
 RJF 01106 
 
 
205.2 42% (at 48.7µM) 0% (at 20.4µM) 0% (at 4.9µM) 
 CC 06013 
 
 
200.7 26% (at 49.8µM) 0% (at 24.9µM) 0% (at 5.0µM) 
 BTB 08846 
 
 
276.3 51% (at 31.2µM) 9% (at 18.1µM) 0% (at 3.6µM) 
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The compounds with the most potent inhibitory activity were sanguinarine, myricetin and Qc1.  
Sanguinarine was particularly potent and inhibited trypanosome growth by 100% at 1µg/ml.  
Only one of the Asinex compounds exhibited significant inhibition of trypanosome growth – BAS 
0472148 caused 98% inhibition at 5µg/ml, which suggests that it may possess potency that is 
comparable with myricetin and Qc1.  None of the fragments, which would be expected to have 
lower potency at the drug target level, showed significant inhibition below 10µg/ml.  BPOB 
appears to be a weak inhibitor of BSF trypanosome growth.  Meanwhile, the TbGalE inhibitors, 
NSC132249, NSC132252, NSC128598 and NSC128608, demonstrated comparable inhibition, 
and inhibited BSF trypanosome growth modestly at 5µg/ml.  The compounds sanguinarine, 
myricetin and Qc1 were tested at a range of concentrations and in triplicate to more accurately 
determine the potency of BSF T. brucei inhibition.  The IC50s and concentrations causing 90% 
inhibition (IC90) are displayed in Table 3.4.7. 
Table 3.4.7 - BSF T. brucei growth inhibitory concentrations of sanguinarine, myricetin and Qc1. 
Compound IC50 ± SD (µM) IC90 ± SD (µM) 
sanguinarine 0.41 ± 0.04 0.48 ± 0.02 
myricetin 10.90 ± 0.20 12.30 ± 0.20 
Qc1 7.80 ± 0.36 11.1 ± 0.7 
 
In the second trypanosome growth inhibition assay, the potency of sanguinarine was 
demonstrated to be very high, and significantly lower than that detected in the preliminary 
assay.  The potencies demonstrated by myricetin and Qc1 were consistent with those observed 
in the preliminary assay.  As  some of the most potent inhibitors of TDH, the antitrypanosomal 
activity of sanguinarine, myricetin, Qc1 and BAS 0472148 is an encouraging sign of TDH-
mediated efficacy.  However, their relative degrees of trypanosome growth inhibition do not 
correlate entirely with their relative TDH inhibitory potencies.  These findings will be discussed in 
more depth in section 4. 
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4. Discussion 
4.1 TDH structure and function 
4.1.1 TbTDH as a GalE-like TDH 
L-threonine 3-dehydrogenase from Trypanosoma brucei (TDH or TbTDH) is a UDP-galactose 
4’-epimerase-like (GalE-like) TDH, sharing many features with the enzymes characterised from 
Flavobacterium frigidimaris (FfTDH), Cupriavidus necator (CnTDH) and Thermoplasma 
volcanium (TvTDH) in recent years(124–126,197).  Three-dimensional structures of TDH 
determined using X-ray crystallography revealed that TbTDH possesses features that are 
conserved amongst these enzymes, as well as other enzymes within the short-chain 
dehydrogenase/reductase (SDR) enzyme superfamily: a monomeric length of around 320 
residues, a glycine-rich region (GxxGxxG) within the NAD-binding domain, a structural motif 
including lysine and tyrosine (YxxxK) near the active site, and several other conserved residues 
in the active site (see Sections 3.1.3 and 3.1.5).  The TDH studied in this thesis appears to differ 
significantly from TDH in other species, such as E. coli, Pyrococcus horikoshii and 
Thermococcus kodakarensis, which are homotetrameric enzymes, rather than homodimeric, 
and which specifically bind divalent metal cations such as zinc(104,121,282).  The GalE-like 
TDHs are distinguished from GalE by the presence of a loop adjacent to the active site – this is 
the flexible Loop 1 in TbTDH.  At the end of this loop, a consensus sequence that may be used 
to further distinguish GalE-like TDH from GalE is a motif represented by the sequence 
GTTDY(125).  In the trypanosomal TDH enzymes, this sequence is replaced by GADDY, but it 
is unclear if this confers any difference between the enzymes from those organisms and the 
other known GalE-like TDHs.  The structural characteristics place TDH in the ‘extended’ 
category of SDRs (eSDR), and thus the enzyme is assigned the identifier SDR14E under the 
SDR nomenclature initiative(283). 
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Figure 4.1.1 - TbTDH monomer with the conserved features of GalE-like TDHs highlighted by colouring.  The 
conserved sequences GxxGxxG and YxxxK are coloured gold, and other conserved active site residues are 
coloured cyan.  The flexible loop 1 is coloured red.  
The TDH enzyme studied in this thesis was shown to be a homodimer, and the interface 
between each TDH subunit was shown to be stabilised by a number of Van der Waals 
interactions and hydrogen bonds (see Section 3.1.6).  A comparison of data from several X-ray 
crystallography experiments indicated that there may be some conformational flexibility in the 
regions making up the dimerisation interface.  Therefore, it is likely that hydrogen bonds and 
salt bridges between the subunits are important in stabilising the dimer.  Indeed, the same has 
been hypothesised about other GalE-like TDHs in the literature. Yoneda and colleagues 
demonstrated how the presence of a greater number of inter-subunit ion pairs in the dimers of 
TvTDH compared to FfTDH accounted for the greater thermostability of the former enzyme. 
Loop 1 
YxxxK: 
GxxGxxG 
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Figure 4.1.2 - comparison of the dimerisation interfaces of TvTDH (left) and FfTDH (right).  The original images 
were presented by Yoneda and colleagues(125).  
 
Figure 4.1.3 - the dimerisation interface of TbTDH, as determined by X-ray crystallography. The image focuses on 
the equivalent location to those displayed in Figure 4.1.2.  
Looking at Figure 4.1.2 and Figure 4.1.3, a comparison of the dimer interface of TbTDH and 
TvTDH shows that different inter-subunit ionic pairs stabilise the dimers in each enzyme.  For 
example, Glu115 in TvTDH is replaced by Lys126 in TbTDH. Arg132 and Arg134 in TvTDH are 
replaced by an asparagine and serine residue, respectively, which do not appear to make intra-
residue contacts.  Thus, it is reasonable to suggest that TbTDH’s lack of thermal stability 
(compared to TvTDH) can be attributed to weaker, or less numerous inter-subunit 
hydrogen/ionic bonds stabilising the dimer. 
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Loops analogous to Loop 1 (see Section 3.1.5) identified in TbTDH have been highlighted in 
TDH from other species(124,284). Indeed, the amino acid sequence corresponding to the loop 
appears to be a conserved feature among GalE-like TDHs.  The studies here provided 
crystallographic evidence of distinct conformations adopted by Loop 1.  The difference between 
them is characterised by a dramatic shift of up to 8 Å in distance, and the two conformations are 
easily classified as ‘open’ and ‘closed’.  The data here show several combinations of TDH 
conformation and enzyme form: 
 Apo TDH in an open conformation; 
 NAD
+
-bound TDH in an open conformation; 
 NAD
+
-bound TDH in a closed conformation; 
 NADH- and L-threonine- bound TDH in a closed conformation; 
 NAD
+
- and L-allo-threonine-bound TDH in an open conformation. 
Different combinations of TDH conformations have been seen in dimers: 
 TDH dimer with both subunits in the open conformation; 
 TDH dimer with one subunit in the open conformation and one subunit in the closed 
conformation; 
 TDH dimer with both subunits in the closed conformation. 
Although the data are not conclusive, one can hypothesise that Loop 1 can be in an open or 
closed conformation, regardless of whether L-threonine is bound or not.  It is possible that a 
change to a closed conformation is induced by binding of a ligand to the L-threonine binding 
site, as was observed with L-threonine- and pyruvate-bound structures.  However, the binding 
of L-allo-threonine did not necessarily induce a closed structure.  In consideration of the 
conformations adopted in different subunits of the TDH dimer, the data suggests that either the 
Loop 1 conformation in each monomer is adopted independently of the conformation in the 
other subunit, or that there may be a mechanism whereby the conformation of one subunit 
effects the conformation in the other subunit.  As will be discussed further below, it is possible 
that Loop 1 plays an important role in the mechanism of TDH binding to its ligands.  The loop 
remains open before and after NAD
+
 binding to accommodate L-threonine, but then closes over 
the active site once L-threonine is bound. 
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Figure 4.1.4 - combined ribbon and surface representation of the structure of the TDH dimer, determined in 
crystallographic model TQ5.  In one subunit (green ribbon, left) Loop 1 is in the open conformation.  In the second 
subunit (blue ribbon, right) Loop 1 is in the closed conformation.  Loop 1 is coloured red in both subunits.  
Recently, data from studies of TDH from Cupriavidus necator have also demonstrated that this 
loop region adopts different conformations in ‘open’ and ‘closed’ structures of TDH.  
Additionally, the authors of that study have suggested that the changes are induced by NAD
+ 
binding(284).
 
 
Figure 4.1.5 - surface representations of the structures of the holo form of CnTDH at the start (left image) and end 
(right image) of a molecular dynamics simulation.  Flexible regions are coloured orange.  It can be seen that the 
flexible loop region at residues 180-186 is closed over the active site in the image on the left, whilst it is in an 
open conformation in the image on the right.  Image taken from the study of Nakano et al.(284)  
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A combination of crystallographic data from apo and holo forms of CnTDH, molecular dynamics 
simulations and enzyme kinetics were used to build a hypothesis of ligand binding and 
structural changes in this enzyme. Nakano et al. proposed a model whereby NAD
+
 binding 
caused a rigidification of flexible regions in the NAD-binding domain, but Loop 1 remained open.  
Then, L-threonine binding causes Loop 1 to close over the active site, and this accounts for the 
selectivity of the enzyme(284). 
 
A detailed examination of the conserved features in TbTDH has also provided strong evidence 
that several other TDHs described in the literature are also GalE-like TDHs.  TDH from chicken 
liver, pig liver and Clostridium sticklandii have all been described as homodimers with similar 
molecular weights to TbTDH(259,260,285).  In addition to these enzymes, TDH from Capra 
hircus (goat), Mus musculus and Staphylococcus aureus also appear to share features with 
TbTDH and other GalEs.  Findings related to TDH structure and function will therefore be 
compared with findings from studies of related TDH enzymes in other species. 
4.1.2 The relationship between TDH structure and function 
By successfully collecting multiple crystallographic data sets, including those of ligand-bound 
TDH, more insights into the enzyme’s structure and function have been obtained.  The TDH 
cofactor NAD, was bound in several of the TDH structure models described here.  The 
nicotinamide ring was bound in a syn conformation, meaning that the hydride is transferred to 
the pro-S position on the C4 carbon (see Figure 3.1.37, Figure 3.1.38 and Figure 4.1.6).  It has 
been proposed that, in alcohol dehydrogenases, the conformation in which a particular enzyme 
binds NAD (anti or syn) is the result of an evolutionary selection, whereby said conformation 
depends on the reactivity of the second ligand.  Benner (1982) describes how a NAD 
conformation with weaker reducing power is used to reduce a relatively more reactive carbonyl.  
This supposedly helps to equalise the free energies of the bound substrates, thereby increasing 
catalytic efficiency.  Syn-NADH is a stronger reducing agent than anti-NADH, so it is used to 
reduce more reactive carbonyls(286).   Likewise, for TDH, the syn NAD, a weaker oxidising 
agent than anti-NAD, is balanced with a relatively less reactive carbonyl in 2-amino-3-
ketobutyrate (AKB). 
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Figure 4.1.6 - syn and anti configurations of NAD(H).  Image re-used from 
http://iop.vast.ac.vn/theor/conferences/smp/1st/kaminuma/UCSFComputerGraphicsLab/DH.html.  
The NADH and L-threonine-bound structure presented here (see Figure 3.1.39 and Figure 
4.1.8) is only accompanied by one other threonine-bound wild-type TDH structure(284). Both 
structures provide valuable insights into the mechanism of action of TDH.  Principally, the 
proposed mechanism of action, in which a hydride is transferred from the β-carbon of L-
threonine to the C4 atom of the nicotinamide ring of NAD appears to be confirmed, as all atoms 
lie in close proximity with each other. 
 
Figure 4.1.7 - schematic of the proposed mechanism of L-threonine oxidation by TDH.  The curved arrow indicates 
transfer of a hydride from the ß-carbon of L-threonine to NAD.  The dashed arrows indicate the proposed transfer 
of the proton from the ß-hydroxyl group of L-threonine to Tyr144, to NAD, to Lys148 and then onto a water 
molecule. This mechanism is supported by the crystallographic data.  
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Figure 4.1.8 - close up of TDH structure in model TNADH4.  L-threonine is bound in the active site and is situated 
close to the nicotinamide ring of NAD.  The green line shows the path from the β-hydrogen of L-threonine to the 
C4 carbon of the nicotinamide ring.  The red line highlights the path from the proton of the ß-hydroxyl group of L-
threonine, to the phenyl group of Tyr144 and then to the hydroxyl group of the NAD ribose.  
Hypotheses of roles played by important active site residues also gain support from the findings 
from crystal structure models of TbTDH.  Whilst residues such as Ser82 and Thr186 are shown 
to be binding partners for L-threonine, it is also plausible that Met81 and Trp280 play an 
important role in the correct positioning of L-threonine (see Figure 3.1.39).  Perhaps more 
importantly, the residues of the “catalytic triad”(287,288), which have been described in alcohol 
dehydrogenases and SDRs in general, have been identified as Thr119, Tyr144 and Lys148 in 
TDH.  The residues Thr119 and Tyr144 appear to hydrogen-bond the side chain hydroxyl group 
of L-threonine.  The interatomic distances between the oxygen atoms of the relevant groups on 
L-threonine and Tyr144 also seem to support the hypothesis that Tyr144 acts as a base and 
withdraws a proton from the substrate.  Molecular dynamics simulations in Drosophila alcohol 
dehydrogenase have demonstrated that this is made possible by the fact that the protonation 
states of the active site tyrosine and lysine residues are coupled(287–289).  The side chains of 
both groups will be deprotonated at the same time, as depicted in Figure 4.1.7.  Extrapolating 
this theory to the TDH mechanism of action, the lysine residue extracts a proton from a hydroxyl 
group on a NAD ribose group, which in turn extracts the proton from the tyrosine residue, thus 
allowing it to extract the proton from L-threonine.  In alcohol dehydrogenase this proton is then 
proposed to be transferred to a chain of eight water molecules, which relay the proton until it is 
removed from the interior of the enzyme.  In this way, the tyrosine residue is deprotonated again 
and is able to participate in the catalysis of another reaction(289,290).  The interatomic 
distances between the relevant groups observed in TDH structure models all seem to lend 
support to this theory.  The pH dependence of the protonation state of lysine and tyrosine may 
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also explain why the optimum pH in TbTDH and other GalE-like TDHs is around pH 8-
9(125,126,139,197,198,202,285,291).  A short chain of water molecules close to Lys148 was 
identified in several of the TDH structures obtained here, but a complete chain of eight water 
molecules, which has been shown to be essential for ADH activity(290), was not observed.  
There are a number of explanations for this.  Firstly, it may be that a shorter water chain is 
necessary for activity in TDH.  Secondly, it may be that the occupancies of other water 
molecules in the chain were not high enough for their positions to be determined in any of the 
TDH structure models solved.  Thirdly, a complete water chain may only be formed during 
catalysis, and the conformational state of TDH in which this water chain is complete has not 
been captured in any of the crystallographic models to date. 
 
Figure 4.1.9 - the water chain for proton relay in alcohol dehydrogenase from Drosophila lebanonensis.  NAD and 
important residues of the enzyme are shown in the stick representation, whilst the rest of the protein is shown in 
the ribbon representation.  Water molecules are represented by red spheres.  2Fo-Fc maps are shown for the 
water molecules.  Image taken from the study of Koumanov et al.(289)  
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TDH exhibits flexibility at several distinct regions.  Two disordered loop regions stand out most 
prominently.  One includes residues Thr179-Ala185 and was designated ‘Loop 1’, and another 
is located closer to the N-terminus at residues Asp35-Asn60, and was designated ‘Loop 2’ (see 
Figure 3.1.15 and Figure 3.1.16).  Other regions that appear to be flexible include Ser82-Thr100, 
Thr186-Pro205, Ser255-Ala273 and the last twenty or so residues leading up to the C-terminus.  
As previously discussed, the region showing the most significant variation in conformation is 
Loop 1.  The role of this loop in L-threonine binding may be crucial in achieving the high 
specificity of the enzyme.  Indeed, findings presented in this thesis show that TDH is very 
selective for catalysing the breakdown of L-threonine over other naturally-occurring amino 
acids.  The other flexible regions and indicators of their disorder, such as the average B-factor, 
may also help to explain the dynamics of TDH during catalysis.  Much of the conformational 
variability observed is in the catalytic domain of TDH.  Furthermore, when the average residue 
B-factors of TDH in the ‘open’ conformation are compared with those in the ‘closed’ 
conformation, the disorder in the NAD-binding domain shows a relative decrease, whilst the 
disorder in the catalytic domain shows a relative increase, except for Loop 1, which is rigid, 
when closed (see Figure 3.1.19 and Figure 3.1.20).  This suggests that disorder is maintained in 
the NAD-binding domain to allow the binding and release of the co-factor.  As some correlation 
between the binding of ligands to the L-threonine binding site and closure of Loop 1 has been 
observed, it is possible that binding to the L-threonine binding site is associated with 
conformational changes in the catalytic domain of TDH.  Hence, this may represent an induced 
fit binding mechanism.  
X-ray crystallography and molecular dynamic studies of TDH from Cupriavidus necator have 
gathered more evidence that would fit this mechanism of ligand binding.  Nakano et al. found 
that CnTDH shows flexibility in the same areas as TbTDH (residues 38-59, 77-87, 180-86 
[analogous to loop 1] and the catalytic domain) in a crystal structure of apo CnTDH.  The same 
regions were found to be rigid in an L-threonine-bound structure.  Molecular dynamics 
simulations indicated that the binding of NAD
+ 
induces a “rigidification” of flexible regions in the 
NAD-binding domain, whilst the flexible loop at residues 180-186 and the catalytic domain 
remain flexible to accommodate L-threonine binding(284).  These findings are in some 
agreement with those presented in this thesis, which suggest that changes in the conformation 
of Loop 1 and the catalytic domain of TDH happen in response to L-threonine binding.  The 
findings of Nakano et al. also support the existence of an induced fit mechanism of ligand 
binding for TDH.  Loop 1, forms a “lid” over the L-threonine active site, something that would 
restrict L-threonine binding if it happened prior to its binding.  Some researchers assert that all 
enzymes that form a lid over active sites must act by induced fit mechanisms(292); the findings 
on TDH structure would seem to illustrate this well.  However, structures of TDH in the closed 
conformation have been obtained where only a solvent molecule, such as acetate, is bound.  
This suggests that, at least in the case of NAD-bound TDH, Loop 1 can take on both the open 
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and closed conformations, prior to binding L-threonine.  The theory of conformational selection 
or conformational sampling takes a broader perspective on ligand binding by enzymes, whereby 
several conformations can be adopted by an enzyme prior to binding and catalysis.  Only some 
of these conformations can enable ligand binding or catalysis(293,294).  Thus, an induced fit 
mechanism may be seen as a subset of the wider process of conformational selection(295).  In 
the case of TDH, several different combinations of conformations of the aforementioned flexible 
regions may be present among the population of TDH enzymes.  The relative representation of 
each conformation may be influenced by the binding of ligands, but the fact that different 
conformations are sampled allows a greater variety of ligands to bind, beyond analogues of the 
natural substrates.  This has clear implications for drug discovery and design which will be 
discussed further below. 
 
4.1.3 Catalytic activity 
Detailed kinetic studies of TDH, supported by the X-ray crystallographic data, indicate that the 
enzyme acts by a Bi Bi compulsory ordered mechanism of action (see Section 3.2.1).  NAD
+
 
binds to the apo form of TDH prior to L-threonine binding.  Then, following catalysis, AKB or 
aminoacetone dissociates from the enzyme before NADH is released.  Evidence for such a 
mechanism was found for both TbTDH and TDH from Clostridium difficile (CdTDH).  Double-
reciprocal (Lineweaver-Burk) plots of the rate of catalysis observed at different combinations of 
substrate combinations showed a pattern that was indicative of a Bi Bi compulsory ordered 
mechanism, but not confirmative.  This was particularly the case for the data regarding TbTDH 
catalysis, where patterns of parallel lines were seen together with lines of decreasing slope 
gradients.  Other potential mechanisms of action for TDH are Bi Bi random ordered and ping 
pong mechanisms.  A ping pong mechanism is excluded by the fact there does not appear to be 
a group within the enzyme to which a hydride could be transferred to, before it is transferred to 
L-threonine.  A Bi Bi random ordered reaction exhibits the same patterns as compulsory 
ordered reactions on Lineweaver-Burk plots, therefore, they can’t be distinguished with these 
data alone.  However, it was possible to gain X-ray structures of TDH that was bound to NAD, 
independently of L-threonine binding.  Efforts to co-crystallise L-threonine and its 
diastereoisomer L-allo-threonine with TDH were only successful when NAD
+
 or NADH were also 
present.  Moreover, the uncompetitive inhibition shown towards NAD
+
 by threonine binding site 
inhibitors (e.g. L-allo-threonine) confirms this hypothesis.  Finally, researchers studying other 
TDHs have also made the conclusion that the enzyme acts by a compulsory ordered 
mechanism(197,291).   
 
The KM value and saturating concentration established for NAD
+
 were approximately 1mM and 
10mM, respectively.  These values may appear high when compared to other NAD-dependent 
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enzymes.  The KM values for NAD
+
 in other GalE-like TDHs have been reported to be as low as 
0.1 mM for CnTDH(126), 0.18 mM for mouse TDH(136), 0.18 mM for FfTDH(197) and 0.18mM 
for TvTDH(125).  However, several KM values published for other GalE-like TDHs are higher 
and closer to those presented here.  For chicken, goat and pig TDH, KM values for NAD
+
 have 
been reported as 0.98 mM(291), 1 mM(202), and 1 mM(201), respectively. Therefore, the NAD
+
 
value discovered for TDH from T. brucei is within the normal range to be expected for a GalE-
like TDH.  KM values for NAD
+
 of 0.2-0.25 mM were determined using methods similar to those 
employed here, but using TDH extracted from T. brucei and T. brucei brucei cell 
homogenates(139).  Although substrate inhibition has not been described for other TDHs, 
competitive inhibition of NAD
+
 by NADH has been reported frequently(197,282,291,296).  Thus, 
the affinity of NADH for the NAD
+
 binding site can explain the decrease in reaction velocity at 
NAD
+
 concentrations above 10mM NAD
+
: as the relative concentration of NADH compared to 
NAD
+
 increases, product inhibition by NADH occurs.  The affinity of TDH for NADH was also 
exploited to obtain a co-crystallised structure of NAD and L-threonine bound TDH, where 
turnover of L-threonine was prevented (see model TNADH4). 
 
The values reported in the literature for the KM and saturating concentrations of L-threonine are 
very similar amongst GalE-like TDHs.  The saturating concentration of 30mM for TbTDH found 
in this study is equal to the saturating concentration established in prior studies of 
TbTDH(139,146).  Similar results have also been found in studies of other GalE-like 
TDHs(125,126,202).  However, the double-sigmoidal curve relating L-threonine concentration to 
reaction velocity (see Figure 3.2.8) has not been reported for any TDH to date.  Bell & Turner 
studied TDH from several different organisms, including Flavobacterium sp. and Bacillus sp, 
and found that there was a sigmoidal relationship between reaction velocity and L-threonine 
concentration in all the enzymes tested(129).  This indicates that TDH action is cooperative.  
However, cooperativity is something that has been little addressed in other studies of TDH.  At 
present, the response to L-threonine concentration exhibited by TDH in these studies appears 
to be a unique feature. 
There are a number of possible causes of double-sigmoidal kinetic behaviour.  One possibility is 
that there are two different enzymes with different affinities for the substrate contributing to the 
observed catalytic activity(194,297).  The SDS-PAGE-verified purification process that TDH 
underwent makes this possibility very unlikely.  A more likely cause of the observed kinetic 
behaviour is an allosteric effect produced either by enzyme-substrate interactions or interactions 
between different TDH monomers (149,157–160).  This possibility is strongly supported by the 
kinetic data.  Size-exclusion chromatography results also strongly support the involvement of 
protein-protein interactions between TDH monomers, induced by substrate(s).   Looking more 
closely at the kinetic data (see Figure 3.2.8), the two portions of the double-sigmoid show 
different apparent Hill coefficients, which implies that the degree of cooperativity is different 
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across the lower and upper ranges of L-threonine concentration.  In the second portion of the 
curve, a greater degree of cooperativity is apparent than in the first part of the curve.  The 
ligand-induced conversion of a receptor to an activated state has been shown to cause 
increases in the hill coefficient.  Furthermore, such phenomena can manifest in complex, multi-
phasic dose-response curves for receptors and enzymes(302).  In light of this evidence, the 
catalytic behaviour of TDH alludes to the existence of two active TDH forms, with L-threonine 
inducing conversion between the two forms directly through binding in the active site or by 
acting at one or more allosteric sites.  The differences between the two forms may be a 
difference in affinity or catalytic efficiency.   
There are several different models to describe cooperative activity and they usually cite 
changes in binding affinity as a cause of such behaviour.  Two of the most widely cited models 
of cooperativity are the Simple Sequential Interaction Model proposed by Koshland et al.(303) 
(KNF) and the Monod-Wyman-Changeux Concerted Transition or Symmetry model(304) 
(MWC).  The KNF model describes a process by which binding of a ligand to a subunit of an 
enzyme oligomer causes a conformational change in that subunit, which in turn causes a 
conformational change in an adjacent monomer, increasing its affinity for the ligand.  This 
continues sequentially throughout the molecule until all monomers are activated(194,303).  The 
MWC model is somewhat simpler, in that it describes a concerted change of all enzyme 
monomers from a ‘tense state’, T, to a ‘relaxed’ state, R, upon ligand binding(194,304).  When 
the kinetic data is considered in conjunction with the gel filtration studies, it raises the strong 
possibility that association and dissociation of TDH monomers is the root of the allosteric effect 
observed.  Association/dissociation models have been used to describe kinetic behaviour of a 
number of enzymes in the past, and such models are also compatible with the KNF and MWC 
models of cooperativity.  However, the MWC model has found more use in this respect, due to 
its classification of the entire enzyme complex as either a ‘tense’ state or a ‘relaxed’ state, which 
is also easier to relate to macroscopic rate constants obtained from assays such as those 
carried out in the studies presented in this thesis.  The model of dissociating regulatory 
enzyme(297) is similar to the MWC model, but it describes different enzyme states in terms of 
their oligomeric forms.  Some enzyme systems described by this model can show a reliance on 
the enzyme concentration.  The size-exclusion chromatography data indicate that dissociation 
of the TDH dimer may occur.  However, the influence of enzyme concentration would need to 
be established using further experiments, which might include using other techniques, as 
described later on in this discussion.  The different models of cooperativity that could explain the 
cooperativity observed for TDH are summarised in Figure 4.1.10. 
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Figure 4.1.10 - models of cooperativity that may be applicable to TDH.  From top to bottom, schematic 
representations of the KNF, MWC and dissociating regulatory enzyme models are shown.  T = 'tense' state 
subunit; S = substrate; R = 'relaxed' state substrate.  
Although the kinetic behaviour discovered in the presented studies of TbTDH has not been 
reported for other TDH enzymes, similar behaviour has been reported for numerous other 
enzymes in the literature.  These enzymes have been reported to dissociate, and the subunits 
have different activities or affinities for their substrates.  In recent years, several of these 
proteins have been described by a concept known as the morpheein concept(305).   
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Figure 4.1.11 - three illustrations of the morpheein concept presented by Selwood and Jaffe(305).  Image a uses 
the analogy of four- and three-sided dice to illustrate how different protein conformations form different 
oligomers.  Image b schematically highlights the influence of allosteric regulators on the conformations of protein 
subunits and their oligomeric forms.  Image c shows an example of crystallographically-determined morpheein 
behaviour by porphobilinogen synthase.  
The morpheein concept describes enzymes that exist in multiple active oligomeric forms.  The 
activities of the enzymes in different oligomeric forms are different, and this may lead to some of 
the peculiar kinetic relationships observed for these enzymes.  In Figure 4.1.12, an example of 
the kinetic curve that can result from the presence of more than one morpheein form (or 
oligomeric form of an enzyme) is shown(305,306).   
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Figure 4.1.12 - example plots of substrate concentration as a function of product formation rate, exhibited by 
enzymes with classic Michaelis-Menten kinetics (black squares) and two co-existing, but kinetically distinct forms 
of an enzyme (black circles).  The dotted line represents an attempt to fit the data represented by black circles to 
the Michaelis-Menten equation.  Instead, the double-hyperbolic kinetics of that enzyme is modelled by an 
equation combining two Michaelis-Menten equations.  This figure is reproduced from a publication by Lawrence 
and Jaffe(307).   
A number of different enzymes that have been classified as morpheeins are 
dehydrogenases(305), suggesting that this may be a feature conserved across this class of 
enzymes.  The enzymes described by the morpheein concept and by the dissociating regulatory 
enzyme concepts include several regulatory proteins.  Given the role of TDH in several 
important cellular processes in T. brucei(138), and possibly several other organisms, it is a firm 
possibility that the apparent dissociation observed during size-exclusion chromatography could 
form an important part of the enzyme’s physiological mechanism of action.  For instance, it has 
been postulated that the increased TDH activity in procyclic T. brucei may occur in response to 
the greater availability of amino acids in the gut of the tsetse fly(138).  Further support is given 
by the fact that the related enzyme GalE has been shown to dissociate from a dimer into two 
monomers.   Brahma, Bhattacharyya and colleagues provide some of the most detailed studies 
of this effect in GalE from Kluyveromyces fragilis(308,309).  Similar to TDH, GalE from K. fragilis 
is a homodimer of around 75kDa in mass that has one catalytic site per subunit.  It has been 
demonstrated that, following partial digestion with trypsin, the monomeric subunits of GalE are 
catalytically active, independently of the other subunit(308).  In a similar fashion to TDH, the 
native enzyme showed non-typical Michaelis-Menten kinetics, with a biphasic increase in 
catalytic velocity in response to increasing substrate (UDP-galactose) concentrations (see 
Figure 4.1.13).  The kinetic behaviour of monomeric GalE (formed by treatment with p-
chloromercuribenzoate) was shown to be distinct from the native dimeric form and was 
monophasic (see Figure 4.1.14).  Finally, the selective inhibition of one active site confirmed that 
the biphasic kinetic behaviour was the result of two catalytically non-equivalent binding sites – a 
high-affinity site (active at lower substrate concentrations) and a low-affinity site (active at higher 
concentrations).  The authors who published this data concluded that the activity of GalE from 
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K. fragilis was regulated by allostery between the substrate-binding sites of the two 
subunits(309).  These findings are clearly in line with the findings of the kinetic behaviour of 
TDH which are presented herein: both enzymes show a biphasic response in catalytic activity 
towards the natural substrates.  For TDH, there is evidence that substrate binding causes 
conformational changes, and these changes may include the dissociation of the dimer into two 
monomers.  However, Brahma et al. demonstrated that the dimer was stable during catalysis, 
suggesting that fast association-dissociation between dimeric and monomeric forms does not 
occur in GalE.  They also showed that a bound inhibitor, 5’-uridine monophosphate (5’-UMP), 
was responsible for some of the lag between the two phases of the kinetic curve, implicating an 
allosteric site that is distinct from the catalytic site(309).   
These observations can be extrapolated to propose two other mechanisms for the regulation of 
TDH activity.  Firstly, the binding status of each TDH subunit may influence the affinity of the 
second subunit.  This situation is akin to a situation described by the KNF or MWC models.  
Secondly, an allosteric site that is distinct from the substrate binding sites may mediate the 
activity of TDH.  This site may be bound by L-threonine and/or other ligands.  As discussed 
previously, the MOIs exhibited by some inhibitors suggest that there may be binding sites on 
TDH where allosteric control can be exerted.  For example, the MmTDH inhibitor Qc1 appears 
to act uncompetitively in respect to NAD
+ 
(preferentially inhibits the TDH-NAD
+
 complex), but 
acts noncompetitively in respect to L-threonine (the presence of L-threonine does not influence 
Qc1’s activity).  This suggests that there is a site other than the substrate binding sites that Qc1 
interacts with to inhibit TDH activity.  Given the available information on TDH, none of the 
proposed models can be confirmed, but the existence of any one regulatory mechanism – 
dissociation of the dimer, allostery between the two active sites or ligand binding to an allosteric 
site – need not be exclusive, and several mechanisms may coexist and contribute to the kinetic 
behaviour observed.  Moreover, in this thesis multiple lines of evidence indicating the presence 
of these mechanisms are presented.  Behaviour that has previously been demonstrated for 
other dissociating proteins, including some morpheeins, has been observed in size-exclusion 
chromatography and enzyme kinetic studies.  The fact that the existence of two catalytically 
distinct oligomeric states has been demonstrated for the evolutionarily-related GalE also lends 
further support to the possibility that TDH may show similar behaviour.  Analysis of X-ray 
crystallography structures have highlighted that the enzyme undergoes significant 
conformational changes in its tertiary structure (see Section 3.1.5), whilst the results of size-
exclusion chromatography indicated changes in the quaternary structure of TDH (see Section 
3.1.6).  Together, these studies gave strong indications that such changes are ligand-induced, 
as is also indicated by the observance of cooperativity in enzyme catalysis.  Future studies can 
be geared towards obtaining more detailed insights into these processes. 
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Figure 4.1.13 - kinetics of GalE from K. fragilis published by Brahma et al.(309).  The largest plot shows the 
relationship between the velocity of enzyme catalysis and the concentration of UDP-galactose (UDP-Gal).  The 
solid bar represents the presence of bound 5’UMP ex vivo, and the hatched bar above it represents the gradual 
disappearance of the initial lag in catalysis.  A linear relationship could not be established between all data points 
on a single double-reciprocal plot.  Therefore, the phase of activity at low substrate concentrations is plotted on 
one plot (A, top centre) and the points relating to the second phase of activity are included on a separate plot (B, 
bottom right).  
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Figure 4.1.14 - a Michaelis-Menten plot of monomeric GalE from K. fragilis published by Brahma et al.(309). A 
double-reciprocal plot of the data is inset (top centre)  The kinetics of the monomeric form are monophasic.  
The modelling of TDH kinetic behaviour using equation 25, a modification of an equation 
proposed by Selwood, Jaffe and colleagues(273), was effective in describing the action of TDH 
as the model implies the co-existence of two different forms of the enzyme.  A similar equation 
was used by Brahma and colleagues to model the biphasic kinetics of GalE from K. 
fragilis(309).  As more information is gathered on the determinants of TDH kinetics, further 
parameters may be added to the equation, such as the contribution of each enzyme form to 
activity at different L-threonine concentrations and/or at specific TDH concentrations.  This 
could also aid in the development of inhibitory equations based on this model.  Unfortunately, at 
present the model does not reliably describe inhibition data better than normal Michaelis-
Menten and Hill equations.  The need to restrain several variables before fitting the equation 
means that some of the time-savings gained by using computer-based non-linear regression 
are lost. 
There may be other ways to model TDH kinetics that have not been attempted in this work.  The 
model that was used to describe the biphasic kinetics of TDH takes the assumption that each 
active site has a different affinity for L-threonine and/or a different catalytic efficiency.  However, 
a limitation of this model and several others that are derived from Michaelis-Menten kinetic 
theories is that it does not delineate the differential effects that L-threonine may have on its own 
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affinity and on the catalytic efficiency of TDH.  It is also implicit in the model described by 
equation 25 that the relationship between L-threonine concentration and rate is mediated by the 
same L-threonine binding interactions.  It has been proposed that stimulatory and inhibitory 
effects should be described by equations that include separate modifier terms that separately 
describe a ligand’s effects on substrate affinity and maximum reaction velocity(310).  An 
example of such an equation is equation 37.  The Michaelis-Menten equation, 
 
𝑣 =
[𝑆]
[𝑆] + 𝐾𝑀
𝑉𝑚𝑎𝑥 36  
which can calculate the catalytic velocity, v, at substrate concentration, [S], is expanded with 
terms for the effect of the modifier, X, on the substrate affinity, as indicated by the Michaelis 
constant, KM, and the maximum velocity, Vmax:  
 𝑣 =
[𝑆]
[𝑆]+𝐾𝑀1−(𝐾𝑀1−𝐾𝑀2)(
[𝑋]
[𝑋]+𝐾𝑋
)
𝑉𝑚𝑎𝑥1 − (𝑉𝑚𝑎𝑥1 − 𝑉𝑚𝑎𝑥2) (
[𝑋]
[𝑋]+𝐾𝑋
)  37  
 KM1 and KM2, and Vmax1 and Vmax2 describe the KM and the Vmax when a modifier is having no 
effect on them (‘1’)and when a modifier is exerting its maximum effect (‘2’), respectively.  The 
relationship between [X] and the degree of effect it has is described by the modifier constant, 
KX.  Although, such an equation would separately consider the effects of the modifier (L-
threonine, in the case of TDH) on enzyme kinetics, more data would still be needed to confirm 
whether this model is appropriate – no information is available on whether the change in 
kinetics is due to changes in affinity, changes in catalytic efficiency or both.  For this reason, this 
equation was not used to model TDH kinetics. 
 
4.1.4 The relationship between TDH and KBL 
The data from size-exclusion chromatography studies (see Section 3.1.6) support the 
classification of TDH as a dynamic dissociating protein and they indicate that it could potentially 
be a morpheein.  However, no observations from X-ray crystallography and cross-linking 
experiments support the L-threonine-induced dissociation observed in size-exclusion studies.  It 
is possible that L-threonine induces a large change in the shape of the TDH dimer, causing it to 
elute more slowly during size-exclusion chromatography.  No gross changes in TDH 
conformation that could cause a drastic change in shape can be seen in X-ray crystallographic 
models, so this is unknown.  There is actually more support for the dissociation of KBL and its 
morpheein-like behaviour, than there is for TDH dissociation.  Cross-linking studies showed that 
the native quaternary structure of KBL was likely to be a dimer.  In size-exclusion 
chromatography studies, three possible quaternary structures were suggested for KBL: a dimer, 
a monomer and an octamer.  Furthermore, cross-linking by dimethyl suberimidate (DMS) of KBL 
monomers to form KBL dimers appeared to be inhibited in the presence of its substrate glycine 
(see Figure 3.1.35).  It is unclear whether this effect was due to a preferential reaction between 
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DMS and glycine over KBL or if a higher oligomer such as an octamer was formed, but was not 
visible on the gel. The data on the dissociation of both TDH and KBL are inconclusive, as is the 
data that could support or reject the formation of a TDH-KBL complex.  Both the pull-down 
assay and cross-linking studies do not support the existence of a stable complex between the 
two, but this does not exclude the formation of a transient complex.  Efforts to co-crystallise 
TDH and KBL in a multi-enzyme complex also failed.  However, in size-exclusion 
chromatography studies, it was clear that the elution of each enzyme was altered in the 
presence of the other.  The enzymes co-eluted as monomers when they were injected onto the 
column in a single sample.  There was also evidence that a small population of the enzymes co-
eluted at volume that was suggestive of a higher molecular weight oligomer with a molecular 
mass of around 190kDa. 
As previously stated, more data is required to conclusively demonstrate that TDH and KBL 
dissociate and form a complex.  If TDH and KBL do form a multi-enzyme complex under certain 
conditions, the dissociating behaviour that has been suggested by data on both enzymes could 
be a part of the mechanism of complex formation.  In this scenario the morpheein concept could 
be extended: homooligomeric proteins could dissociate, and change conformation to allow 
heterooligomeric complex formation. 
 
4.1.5 Inhibition and stimulation of TDH 
The inhibitory assays carried out with TDH and various other substances were effective in 
discovering new inhibitors and also in confirming the published reports of previously known 
inhibitors of TDH (see results in Section 3.2.3).  L-allo-threonine, pyruvate and methylglyoxal 
are all reported to inhibit TbTDH or TDH from other species.  L-allo-threonine, a diastereoisomer 
of TDH, is perhaps the most widely investigated of these inhibitors.  L-allo-threonine or DL-allo-
threonine have been previously reported to inhibit TbTDH(200), as well as TDH from E. 
Coli(119,311,312) and S. aureus(198).  The Ki for L-allo-threonine determined here is 1.6mM, 
which is very similar to that determined by Klein and colleagues, 2.5mM(200).  The mode of 
inhibition (MOI) determined by enzyme inhibition assays, which indicated that L-allo-threonine 
competes with L-threonine for its binding site, was confirmed by X-ray crystallography.  The 
uncompetitive MOI shown towards NAD
+
, is expected because of the high similarity of the 
inhibitor to L-threonine, which preferentially binds NAD-bound TDH.  The inhibition of TbTDH by 
L-allo-threonine, coupled with the lack of inhibition by and catalysis of D-allo-threonine by the 
enzyme, indicates the stereospecific nature of TDH.  The L- orientation at the α-carbon is 
necessary for binding to TDH and this precludes the binding of the enantiomer of L-threonine, 
D-allo-threonine.  In addition, the R configuration at the ß-carbon is necessary for catalysis.  As 
a result, L-allo-threonine inhibits TDH(200).  Interestingly, Tressel and colleagues reported that 
TDH from pig liver catabolises L-allo-threonine, albeit at a rate 10 times slower than the rate of 
L-threonine catabolism(201).  The KM for L-allo-threonine catalysis by TDH from pig liver was 
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calculated as 16mM, but no evidence exists to suggest that TbTDH catalyses L-allo-threonine, 
either in these studies or in the literature.   
 
Figure 4.1.15 - the structural formulas of L-threonine and analogous compounds, L-allo-threonine, pyruvate and 
methylglyoxal. 
Pyruvate has been reported to inhibit TDH from F. frigidimaris(197) and T. volcanium(125).  Like 
L-allo-threonine, it was shown to bind within the L-threonine binding site of TDH in an X-ray 
crystallographic model.  Consequently, it shares the same MOI with L-allo-threonine, being 
competitive towards L-threonine, whilst acting uncompetitively towards NAD
+
.  Methylglyoxal, a 
close analogue of pyruvate, also inhibits TDH in a competitive manner, but is a noncompetitive 
inhibitor towards NAD
+
.  In contrast to the previous two inhibitors discussed, methylglyoxal 
inhibition was cooperative and apparent Hill coefficients of more than 3 were calculated from the 
experimental data.    Methylglyoxal is reported to inhibit TDH from goat liver, and the curve 
relating inhibition to methylglyoxal concentration was sigmoidal, suggesting that the inhibition 
was cooperative and allosteric.  Furthermore, treatment of goat liver TDH with trypsin 
differentially decreased the catalytic activity of the enzyme and the ability of methylglyoxal to 
inhibit it, indicating that methylglyoxal acts at an allosteric site and not at the L-threonine 
site(202).  This would appear to contradict the finding that methylglyoxal inhibition is competitive 
towards L-threonine.  Indeed, methylglyoxal was not observed in the L-threonine binding site in 
X-ray crystallographic models.  Methylglyoxal is produced as a toxic by-product of several 
physiologic pathways, most notably, glycolysis and is known to react with arginine and lysine 
residues on proteins (see Figure 4.1.16).  Therefore, it is plausible that the allosteric inhibition 
seen is due to the modification of key arginine and lysine residues, such as those at the 
dimerisation interface.  This would also explain the observations of Ray and Ray(202), that 
digestion of TDH from goat liver with trypsin, which selectively cleaves at the C-end of arginine 
or lysine residues(313), reduces the inhibition of methylglyoxal more than it does the catalytic 
rate of TDH.  However, there are still questions as to why methylglyoxal shows a competitive 
MOI towards L-threonine.  The only arginine or lysine residue that interacts directly with the 
substrates is Lys148, but binding to this residue would have manifested in an MOI that was 
competitive towards NAD
+
.  Sigmoidal inhibition curves can also be a sign of covalent 
modification, which would be explained by methylglyoxal’s known action.  It is possible that 
methylglyoxal binds reversibly to the L-threonine binding site, but also inhibits TDH by 
covalently modifying important residues.  Unfortunately, X-ray crystallography has not revealed 
any of the sites of methylglyoxal’s action.  
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Figure 4.1.16 - the reaction of methylglyoxal with lysine and arginine side chains.  Methylglyoxal is a reactive 
aldehyde that forms covalent adducts with the affected residues.  Reaction of lysine adducts with a second lysine 
residue can lead to cross-linking.  This figure was published by Bechara et al.(314).  
There is a possibility that the inhibition of TbTDH by pyruvate and methylglyoxal has some 
physiological significance in Trypanosomes.  Pyruvate is a by-product of glycolysis, and it is 
also the substrate for pyruvate dehydrogenase, which is essential in the alternative pathway for 
the essential production of acetyl-CoA(143,144,149).  Methylglyoxal is also a by-product of 
glycolysis in trypanosomes(149).  Therefore, inhibition of TDH by pyruvate and methylglyoxal 
may actually be a feedback mechanism between the two pathways, whereby the TDH pathway 
is inhibited when the availability of glucose is high.  In the goat, methylglyoxal is also produced 
by an amine oxidase from aminoacetone, the AKB breakdown product.  Therefore 
methylglyoxal may act as a form of negative feedback to L-threonine catabolism by TDH(202). 
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Figure 4.1.17 - the production of methylglyoxal as a by-product of the glycolytic pathway in trypanosomes.  The 
shaded box illustrates production of methylglyoxal from dihydroxyacetone phosphate (DHAP).  This figure was 
published by Wyllie and Fairlamb(149).  
Tetraethyl thiuram disulphide (TETD) is one of the most potent known inhibitors of TDH.  It was 
the trypanocidal activity of this compound that identified TDH as a potential drug target for 
human African trypanosomiasis (HAT)(138,139).  In this study, TETD was found to be a time-
dependent inhibitor of TDH.  An analysis of the relationship between the rate of inactivation of 
TDH and the concentration of TETD indicated that the mechanism of inhibition was irreversible.  
This is in line with the findings of Cross, Linstead and colleagues that the inhibition of TDH by 
TETD was progressive over time, and that this inhibition was caused by covalent action.  They 
also found that other sulfhydryl-reactive agents, including p-choromercuribenzoate, 
iodoacetamide and N-ethylmaleimide, inhibited TDH, indicating that there is an essential 
sulfhydryl residue in TDH(139).  These findings were corroborated in this study: iodoacetamide 
and N-ethylmaleimide showed a time-dependent inhibition of TDH in a similar manner to TETD.  
A likely candidate for this essential sulfhydryl residue is Cys56, which was shown in TDH 
structure models to be involved in binding NAD
+
.  Unfortunately, disulfiram and N-
ethylmaleimide were not successfully co-crystallised with TDH, so it has not been possible to 
confirm this as the site of action of TETD and other sulfhydryl-reactive agents.  
Overall, the enzyme inhibitory assays have been a valuable tool for characterising the different 
MOIs that compounds may show against TDH.  This knowledge is valuable in enzyme inhibitor 
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design because certain binding modes may be preferred.  For example, uncompetitive inhibitors 
can be useful as drugs because their inhibition causes the accumulation of substrate, thereby 
encouraging the formation of the enzyme-substrate complex for which they have greater affinity.  
Time-dependent inhibitors can also be attractive drug candidates as their longer residence time 
when bound to the target can reduce their likelihood of interacting with non-target proteins, 
potentially reducing the incidence of side-effects(315,316).   
 
TDH appears to be very selective for L-threonine as a substrate, although it may have some 
affinity for other standard amino acids, which were found to cause marginal inhibition at high 
concentrations (see Table 3.2.1).  L-cysteine (60 mM) inhibited TDH by approximately 40%.  
Hopefully, X-ray crystallography will be able reveal the mechanism of action of this inhibitor.  It 
is plausible that it binds within the L-threonine binding site, or it may react with an important 
sulfhydryl residue in the enzyme.  Another unexpected observation was that TDH activity was 
increased in the presence of L-glutamine.  This amino acid does not appear to be a substrate 
for TDH, so it may increase activity by binding to an allosteric site, or via another mechanism.  
Once again, X-ray crystallographic studies will be pursued to determine the cause of this effect. 
 
Despite the fact that no specific monovalent cation binding sites were observed in X-ray crystal 
structures, certain monovalent cations were found to stimulate the activity of TDH to more than 
two-fold the original activity (see Section 3.2.2).  In the presence of ammonium (NH4
+
), 
potassium (K
+
) and rubidium (Rb
+
) ions, the activity and thermostability of TDH appeared to be 
increased.  Stimulation of TDH by K
+
 has been reported for TDH from S. aureus(198,317,318), 
as well as for TDH from T. brucei(139).  Stabilisation of enzymes and stimulation of enzyme 
activity by ions can occur through specific effects (e.g. involvement in substrate binding) or 
through physical effects.  Ions can have a physical effect on enzymes through stabilisation or 
destabilisation of the structure of water.  Kosmotropes stabilise water, whilst chaotropes 
destabilise water.  Kosmotropic anions and Chaotropic cations, such as K
+
, NH4
+
 and Rb
+
 
stabilise enzymes(319–321).  If there is indeed no specific binding site for monovalent cations 
on TDH, then the effects observed may be physically mediated effects. 
 
Figure 4.1.18 - the Hofmeister series, showing the order of enzyme stabilising and destabilising effects caused by 
different ions.  This series was published by Zhao.(319)  
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The order of stimulating activity, NH4
+
,K
+
<Rb
+
 is similar to the order of ion chaotropism derived 
from the Hofmeister series(320–322).  The effects of different ions on water structure are 
related to their atomic radii and charge(319).  Thus, identifying the true cause of an ion’s effect 
on an enzyme is made more difficult by the fact that the selectivity of an enzyme for a particular 
ion is also related to the ion’s atomic radius and charge(323).  More structural and biochemical 
studies will be required to understand the nature of the relationship between the activating 
monovalent cations and TDH.  Crystallisation of TDH in solutions containing high concentrations 
of K
+
 or Rb
+
 failed, but a successful strategy that should be tried is to crystallise the protein of 
interest with Thallium ions(324,325).  These ions have a high electron density, so will be easily 
distinguished from water molecules and other solvent molecules in electron density maps.  
 
When the activity of TDH was measured in the presence of divalent cations, a very different 
effect to that seen with monovalent cations was observed.  Zinc (Zn
2+
), cadmium (Cd
2+
), copper 
(Cu
2+
), aluminium (Al
2+
), cobalt (Co
2+
), calcium (Ca
2+
) and iron ions (Fe
2+
 and Fe
3+
) all inhibited 
TDH activity.  This contrasts with the forms of TDH from E. coli, and Pyrococcus spp., which 
require divalent cations, such as Zn
2+
, Mn
2+
 and Cd
2+
 and Co
2+
(121,123,326).  Manganese ions 
had no effect on TbTDH and the other ions important in other forms of TDH inhibited it.  The 
inhibition of TDH by heavy metal ions, such as silver (Ag
+
) and mercury (Hg
2+
) provides further 
evidence that there is an essential sulfhydryl residue in the enzyme, and this is consistent with 
findings from other GalE-like TDHs, from F. frigidimaris and C. necator(126,197).  Inhibition of 
TbTDH by Ag
+
, Hg
2+
 and Cu
2+
 has also been previously reported(139). 
 
4.1.6 Evaluation of Investigative Methods 
The use of recombinant DNA for the production of TDH and KBL enabled the development of a 
repeatable and efficient method of protein production.  The yields were sufficient that enough 
protein could be obtained to carry out the necessary experiments over a reasonable period of 
time.  As the initial focus of the studies conducted here was X-ray crystallography, the main aim 
of the protein purification methods was to obtain a pure enough sample to allow successful 
crystallisation.  SDS-PAGE was used to measure protein purity at each stage.  Even in 
concentrated samples, stained TDH and KBL bands were visible, whilst no other bands were 
visible after the affinity chromatography step.  The purity of such samples was confirmed by 
size-exclusion chromatography experiments, which only detected protein elution under a single 
peak.  Although often carried out during the purification of enzymes, specific activity (often 
reported as units of substrate catalysed per mg of protein, per minute) was not used as a 
measure of protein purity.  As there is no reference value of specific activity for pure TDH or 
KBL from T. brucei, specific activity could not be used to estimate absolute purity.  However, for 
future studies of TDH, it would be useful to use specific activity as a reliable way to determine 
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the relative purity of the sample at each stage of the protein purification process.  The reliability 
of SDS-PAGE as a way to measure could be improved by applying a densitometric analysis to 
SDS-PAGE gels. 
 
In the pursuit of structural and functional information on TDH and KBL, the use of multiple 
orthogonal assays to gather supportive data brought many advantages.  For instance, to 
understand the structure of the enzymes, X-ray crystallography provided information on primary, 
secondary, tertiary and quaternary structure.  This information was enriched by data from SDS-
PAGE, which confirmed the primary structure, and size-exclusion chromatography and cross-
linking studies confirmed the quaternary structure.  In the same manner, the functional 
information gained from enzyme assays with TDH was enriched by the ligand-bound structures 
obtained by X-ray crystallography.  A primary motivation of this work was to initiate drug design, 
so the complementary information on inhibition that was gained from enzyme assays and X-ray 
crystallography is highly valuable.  Overall, the data from the various methods involved allowed 
the identification of relationships between structure and function.  Most notably, enzyme assays, 
X-ray crystallography, size-exclusion chromatography and cross-linking all produced data that 
indicated a relationship between protein-ligand interactions and protein structure.  Furthermore, 
this information was able to inform the design of virtual screening and in vitro screening assays 
(see Sections 4.2.1 and 4.2.2 for a more detailed discussion).  The consideration that different 
inhibitory compounds may bind to different conformational states of TDH, which may be present 
under different conditions, may have improved the success of screening and certainly allowed 
for the identification of inhibitors that were both chemically diverse and mechanistically diverse.  
In spite of all of the advantages brought by the approach used in this thesis, the information on 
TDH structure, function and inhibition remains incomplete.  One reason for this is that the 
methods employed all have limitations, particularly in regards to what they are able to detect.  
For example, there may be protein-protein interactions that are either difficult to detect or 
difficult to gain detailed information on using X-ray crystallography and size-exclusion 
chromatography.  Such a lack of information also limits the extent to which data can be 
analysed.  For example, having limited insight into the relationship between TDH-ligand 
interactions and TDH function made it more difficult to model TDH function.  The methods are 
evaluated in more detail below. 
 
X-ray crystallography is often considered the definitive method for the determination of 
macromolecular structure.  In this respect, it has found wide application in the elucidation of 
physiological processes and in the design of new drugs(15,17).  The presented investigation 
provides yet another example of this application.  Not only has the 3D configuration of TDH 
been determined, but the way in which the configuration of the enzyme varies has also been 
highlighted.  The absolute structure has been used to characterise the enzyme and to confirm 
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its place as a member of the SDR superfamily and as a GalE-like TDH.  Key conformational 
changes that may be related to ligand binding and catalysis also give insights into the enzyme’s 
mechanism of action.  Furthermore, the crystallography studies have identified the binding 
relationships between TDH and its natural substrates, NAD
+
 and L-threonine.  This is not only 
valuable from the perspective of investigating the enzyme’s mechanism of action, but it will also 
be valuable in the design of new inhibitors of TDH.  Indeed, X-ray structures of TDH bound to 
inhibitors have allowed an identification of the determinants of ligand binding, catalysis and 
inhibition.   
To obtain information on how TDH binds its ligands, two strategies were used: the enzyme was 
co-crystallised with ligands, or crystals of the enzyme were soaked in a solution containing 
ligands.  Only co-crystallisation proved to be successful.  This method may also be preferred 
because, as ligand binding may be associated with significant conformational changes of a 
protein, binding of a ligand to a crystallised protein may cause large changes in the unit cells of 
proteins and may cause the crystal to re-dissolve.  For ligands that were unsuccessfully co-
crystallised, crystal soaking may be required.  During crystal soaking experiments, TDH crystals 
were soaked in ligand solutions for up to one hour.  However, more time may be required, 
particularly for low-solubility or slow-binding ligands, for this to be successful.  The solubility of a 
ligand can limit the success of co-crystallisation or crystal soaking in obtaining enzyme-ligand 
complexes.  Several variables need to be optimised, including the enzyme concentration, ligand 
concentration, soaking time and solvents.  Another method that can improve the success of 
these approaches is the use of additives to improve ligand solubility(327).  Further optimisation 
of co-crystallisation and crystal soaking experiments should be employed in the future to obtain 
ligand-bound TDH structures. 
 
The use of other biochemical techniques for structural and functional characterisation of TDH 
was complimentary to X-ray crystallography, but may also have identified features of the 
enzyme that were not captured in crystallographic structure models.  Size-exclusion 
chromatography is an example of this because it was able to provide evidence that TDH and 
KBL may exist in multiple oligomeric forms, something that was not captured by crystallographic 
models.  A limitation of the size-exclusion studies carried out here is that a small change in 
elution volume amounted to a significant change in the predicted molecular weight of the 
sample.  For example, a change in elution volume of 2-3ml could change the prediction of the 
quaternary structure of TDH or KBL from a dimer to a monomer. Nevertheless, there were 
samples that eluted at volumes that would make quaternary structure predictions ambiguous.  
The size-exclusion data sometimes did appear to be able to distinguish between different 
oligomeric forms, but more confidence would be gained by confirming the findings using other 
techniques.  As discussed above, cross-linking studies served a similar purpose to size-
exclusion studies.  They corroborated the evidence for the dimerisation of TDH and KBL, 
something which has found agreement across three methods of structure determination used in 
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this study.  They also provided further evidence of the dissociation of KBL, although this needs 
to be confirmed in an optimised cross-linking assay. 
The findings relating to the formation of a multi-enzyme complex between TDH and KBL are 
conflicting.  Size-exclusion studies clearly showed that that the quaternary structures of both 
enzymes were altered in each other’s presence, but X-ray crystallography studies, cross-linking 
experiments and the pull-down assay all failed to find evidence to support this.  It is possible 
that, if a transient complex is formed, none of the techniques used is able to measure this.  
Alternatively, it may be that the assays need to be optimised.  It has been observed that ligands 
affect the conformation and quaternary structure of TDH and KBL, thus the presence and 
concentrations of different ligands can be varied.  The pull-down assay was carried out in the 
absence of any ligands, so the effects of different ligands, particularly NAD
+
, L-threonine and 
glycine, on the assay result should be tested. 
There are other biological techniques that may be used to answer the outstanding questions on 
TDH structure and function.  Dynamic light scattering (DLiS) measures the fluctuations in the 
absorbance of scattered light over time to calculate the hydrodynamic radii of particles in 
solution or suspension.  From this, the molecular weights of proteins can be calculated.  In 
contrast to chromatographic methods, DLiS is able to predict the molecular weight of molecules 
without potentially disturbing any protein-protein interactions, as in affinity chromatography.  
DLiS has been successfully used to identify and characterise protein-protein interactions in both 
permanent and transient protein complexes(328–330).  The different variables that can affect 
protein-protein interactions (e.g. pH, temperature, ionic strength) can easily be varied in DLiS 
experiments, without affecting the functionality of the assay.  Furthermore, DLiS has been 
successfully used to monitor the effect of small molecule ligands on oligomerisation and 
complex formation, so this could be a very useful technique for studying TDH and KBL(329).  
Isothermal titration calorimetry (ITC), a powerful tool for determining the thermodynamics of 
ligand-macromolecule interactions can also be used for the determination of protein-protein 
interactions.  Specifically, the binding enthalpy, stoichiometry of binding and the equilibrium 
binding constant can be determined for a particular process(331).  Like DLiS, ITC has been 
used to characterise transient protein-protein interactions(332).  
Analytical ultracentrifugation (AUC) can produce very useful data by studying the different 
migration of proteins in solution, on application of a centrifugal field.  This migration is influenced 
by the size and shape of the molecules being studied, so by understanding the relationship 
between gravitational force, particle mass and friction, the molecular weights of protein 
oligomers can be identified.  There are two methods of AUC that can be used to study 
oligomers and multi-protein complexes: sedimentation velocity, which involves studying the 
different rates of migration of particles to determine molecular weight, and sedimentation 
equilibrium, which involves studying the concentration distribution of protein species when the 
forces of sedimentation and diffusion are in equilibrium(333,334).  As AUC can be used to 
model molecular mass, hydrodynamic shape and stoichiometry of protein complexes, it could 
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potentially be very useful for studying the self-association of TDH and KBL monomers, as well 
as the formation of a TDH-KBL complex.  Modern advances in AUC techniques have also 
allowed the detection and characterisation of dynamic processes, such as transient protein 
interactions.  This would not only help to investigate any interactions between TDH and KBL, 
but it would also enable the study of the response of these proteins to ligand-binding. 
Nuclear magnetic resonance spectroscopy (NMR) is another technique that could be used to 
answer several of the outstanding research questions in this work.  NMR measures the energy 
released following changes in the spin states of nuclei induced by an applied magnetic field.   
The signals recorded are characteristic of the local environment of the nuclei and the method is 
able to detect effects caused by the coupling of spin states between geometrically close nuclei, 
which allows one to deduce the structure(s) of the substance of interest.  NMR is the second 
most common method for biomolecular structure determination, after X-ray crystallography, and 
has the advantage over crystallography that experiments can be carried out in solution, rather 
than in the crystalline state.  Thus, NMR studies can be complementary to X-ray 
crystallographic studies, or they can be used to gain insight where it is not possible to with X-ray 
crystallography(335).   For the further study of TDH, NMR would be useful for capturing the 
structure of TDH in the oligomeric states that have been suggested by some of the data, but 
that have not been captured by X-ray crystallography.  In particular, if TDH does indeed form a 
complex with KBL, which has not been successfully crystallised thus far, NMR could be used to 
confirm the existence of the complex and determine its structure.  The protein cyanovirin-N is an 
example of a protein that has been shown to form dimers by X-ray crystallography and has 
been shown to exist in monomeric form by NMR.  Barrientos et al. were able to confirm using 
NMR that the protein exists in two oligomeric states in solution, depending on experimental 
conditions(336).  It has also been demonstrated that NMR can capture weak, short-lived 
protein-protein interactions(337), which would be useful for studying a transient multi-enzyme 
complex (assuming a TDH-KBL complex has these characteristics).  Like X-ray crystallography, 
NMR can be used to probe ligand interactions.  As alluded to above, the ability to observe some 
ligand interactions by X-ray crystallography may be limited by the fact that the conformation of 
the protein that binds a particular ligand may not be crystallised as readily as other 
conformations.  This may have been the reason why it was difficult to co-crystallise TDH with 
some ligands, or to observe TDH-ligand interactions after using the crystal-soaking method.  
The kinetic behaviour of TDH is also suggestive of allosteric regulation by L-threonine and other 
ligands.  However, no allosteric sites have been identified.  NMR has been shown to be 
effective, not only for identifying multiple binding sites on proteins, but in combination with ITC, it 
has been used to obtain binding-site specific binding affinities, enabling a detailed description of 
the cooperative binding of ligands to human ileal bile acid binding protein(338).  Thus, NMR 
may be a highly effective way to study TDH and its interactions with small molecules more 
deeply. 
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The differential absorption of NAD
+
 and NADH is advantageous for the study of many NAD-
dependent enzymes.  The absorbance assays used in the experiments presented here were 
reasonably simple to design and scale up.  A drawback of measuring absorbance to monitor 
enzyme catalysis is that several other compounds absorb in the region of TDH.  This drawback 
was avoided by use of a kinetic assay, where absorbance measurements were made at several 
time-points, rather than an end-point assay, which would be more difficult to design to overcome 
this limitation.  NADH is also a fluorescent molecule and problems of assay interference by 
absorbing compounds can be avoided by the use of fluorescence as a signal for monitoring 
enzyme catalysis.  Fluorescence sensors are also more sensitive, so reagents can be spared 
as lower quantities are required(194).  Fluorescence capabilities were not available during the 
entire course of the studies of TDH, and switching to fluorescence measurements may have 
required a significant reformatting of the assay.  Therefore, the decision was made to use 
absorbance measurements and design the enzyme assays in an appropriate way to achieve the 
desired outcomes.  The availability of the Omega plate readers for inhibitory assays and in vitro 
screening allowed the collection of more data, and subsequently a more thorough analysis 
before drawing conclusions.  Lineweaver-Burk plots are a useful way of visually characterising 
enzyme mechanism of action and inhibitor MOIs, but having more data allowed the 
determination of these features using non-linear regression, which is now considered to be the 
preferred method(194,203).
 
 
Whilst biochemical techniques such as ITC can be useful and accurate in determining the 
properties of protein-ligand binding interactions, the use of enzyme assays as the principal tool 
for investigating TDH-ligand interactions is more appropriate as they are functional assays.  
What is of greatest interest is the effect of a ligand on the enzyme’s function, and other 
biochemical techniques, which may give more accurate information on binding parameters, are 
less effective in providing information on the inhibition of function.  The design of MOI assays, 
that tested the effects of varying the concentration of one substrate, at a fixed concentration of 
the second substrate, effectively yielded the data required for MOI determination.  It can be 
argued that inhibiting compounds could have been spared by fixing the substrate concentration 
at a concentration near to its KM, rather than at the saturating concentrations.  Moreover, when 
the inhibitor was a competitive inhibitor of the substrate at a fixed concentration, the saturating 
concentration of substrate may have meant that the inhibition observed was low, making it more 
difficult to determine the inhibitor’s effects in relation to the second substrate.  The decision was 
made to carry out the assays at saturating substrate concentrations because it increased the 
size of the signal (absorbance, due to a faster rate of NAD turnover), allowing inhibitory effects 
to be accurately measured across a broad range of concentrations of the second substrate. 
The binding relationships of the natural substrates of TDH and the MOIs of known TDH 
inhibitors were confirmed with X-ray crystallography, highlighting the effectiveness of the 
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enzyme assays.  However, MOI determination and parameter estimation (e.g. Ki) was more 
difficult when studying the stronger inhibitors of TDH.  The accuracy of the MOI predictions for 
some inhibitors is also yet to be confirmed by X-ray crystallography. 
One potential source of error during inhibitory assay analysis was that the models for inhibition 
were sub-optimal for modelling the interaction between inhibitors and L-threonine, due to the 
atypical kinetics of TDH in relation to L-threonine.  To improve on this situation, more knowledge 
is needed on the underlying processes causing the biphasic kinetics observed.  The effects that 
inhibitors may have on this kinetic signature will also need to be discovered before more 
accurate models can be developed.  Nevertheless, the current models used were able to 
differentiate between different MOIs, some of which were confirmed with crystallographic 
models.  For the purposes of calculating the Ki of inhibitors, different forms of the Cheng-Prusoff 
equation can be used to determine the Ki from the IC50.  The correct form of the equation can be 
selected on the basis of the observed MOI. 
A further complication of determining the MOI arises from the fact that the enzyme shows signs 
of cooperative behaviour and potential allosteric regulation.  Some of the inhibitors studied 
showed signs of cooperative inhibition, which could be a result of a number of different 
processes: binding to an allosteric site; disruption of the cooperative binding of L-threonine; 
inhibitor-induced conformational changes.  To model the inhibition of the compounds showing 
cooperative inhibition, standard inhibitory equations were modified by incorporating the Hill 
coefficient (see equations 29-34).  Such equations have been used by other researchers to 
model cooperative inhibition(275,339).  In modifying the equations in this way, there is a risk 
that the model is manipulated to allow it to fit to data.  To ensure that this was not the case, the 
Aikake information criterion (AIC) and the F-test were employed.   
One additional difficulty in the study of TDH enzyme inhibitors was that several of the inhibitors 
were time-dependent.  Therefore, the screening assays and all the assays for MOI 
determination were lengthy and required pre-incubation of the inhibitors with TDH.  Two assays 
were used for the investigation of time-dependent inhibitors.  For studies of TETD, the activity of 
TDH was measured after it had been incubated with the inhibitor for different periods of time.  
This was useful, as the rate of inactivation could be measured which was then used to 
determine the mechanism of inhibition of TETD.  However, this assay was quite cumbersome 
and required that the timing of initiation of each assay was consistent between repeat 
experiments.  In the assays to determine the MOI of TETD in relation to NAD
+
 and L-threonine, 
there was a wide variation in certain data points (see Figure 3.2.34).  On the other hand, the 
assays that were used to determine the MOI of the time-dependent inhibitors discovered 
through screening were simpler to carry out, as the enzyme was pre-incubated with the inhibitor 
for a fixed period of time, before the reaction was initiated with substrates.  In this way, the 
assays were very similar to the MOI assays for rapidly binding inhibitors.  However, these 
assays could not observe the effect of different inhibitor and substrate concentrations on the 
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rate of inactivation of the enzyme.  A more complete picture can be obtained by combining the 
two assays designed for studying time-dependent inhibitors, but both assays still have the 
disadvantage of being time-consuming. 
An alternative approach to studying time-dependent inhibitors is to follow the time course of a 
reaction in the presence and absence of inhibitors to measure the effect of time-dependent 
inhibition.  Time-dependent inhibitors will tend to cause the rate of product production over time 
to become non-linear, as illustrated in Figure 4.1.19. 
 
Figure 4.1.19 - the investigation of time-dependent inhibition by time-curve analysis.  A = plot showing linear 
product formation over time by an enzyme in the absence of an inhibitor.  B = plot showing a deviation from 
linearity of the velocity of product formation, v, caused by time-dependent inhibition.  The initial velocity, vi, 
gradually slows to a new steady-state velocity as the time-dependent inhibitor takes effect.  C = plot showing the 
effects of increasing concentrations of a time-dependent inhibitor.  The deviation from linearity occurs at an 
increasingly earlier point in time as the inhibitor concentration and the rate of inactivation, kobs increase.  The 
creation of this illustration was guided by similar illustrations in the literature(194,203).   
In the absence of a time-dependent inhibitor, the relationship between product concentration, 
[P], and time is related linearly with velocity, v, and this relationship can be described by the 
following equation: 
 [𝑃] = 𝑣𝑡 38  
The addition of a time-dependent inhibitor causes the time curve to become non-linear (see 
Figure 4.1.19, B).  As the inhibitor slowly binds, the initial velocity, vi, is gradually reduced to a 
slower steady-state velocity, vs.  The rate of enzyme inactivation, kobs, can also be derived from 
the rate of conversion between vi and vs.  Fitting equation 39 to measurements of [P] or 
absorbance over time can be used to derive the vi, vs and kobs.   
 [𝑃] = 𝑣𝑠𝑡 +
𝑣𝑖 − 𝑣𝑠
𝑘𝑜𝑏𝑠
[1 − 𝑒(−𝑘𝑜𝑏𝑠𝑡)] 39  
This type of analysis would allow kobs to be determined in single sets of replicate assays instead 
of in multiple assays conducted following different pre-incubation times.  For this analysis, the 
formation of product over time would have to remain linear over the time-course of inhibition.  
This could be difficult to achieve and would require extensive optimisation. 
Further information on the thermodynamics of binding can be obtained from complimentary 
biochemical techniques such as ITC, microscale thermophoresis (MST) and surface plasmon 
resonance spectroscopy (SPR), following the attainment of functional data. 
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4.2 Screening for the discovery of new inhibitors 
4.2.1 Utility of Virtual Screening 
It is difficult to assess the success of the virtual screening exercise in isolation, as its true utility 
is proved by its ability to identify in vitro inhibitors of the drug target.  The hit rate for the ‘Custom 
library’, which included compounds identified by virtual screening, was 16.7%.  Compared to a 
hit rate of 0.7% for the Asinex library, and an overall in vitro hit rate of 1.4%, it is clear that the in 
vitro hit rate was significantly higher for compounds identified in silico.  Even excluding 
compounds from the same chemical series (i.e. discounting myricetin or quercetin and all but 
one GalE inhibitor), the hit rate is 9.3%.  One important feature of the overall screening strategy 
was that the diversity of the screening library was maintained, whilst virtual screening was used 
to identify compounds that were more likely to be efficacious in vitro.  Therefore, amongst the 
resultant hits there are compounds with diverse chemical structures.  Furthermore, the 
representation of different TDH conformations as the target in virtual screening may have 
played a role in identifying inhibitors with different binding modalities.  Another contributing 
factor to the effectiveness of the virtual screening experiments was the selection of molecules 
with known bioactivity for inclusion in the screening library.   
 
Virtual screening has found increasing use in recent decades, both by academic and industrial 
research groups.  By being able to select a subset of molecules that are more likely to be 
effective in vitro, it can save on time and money by allowing one to screen smaller libraries of 
compounds in vitro.  There are now several available virtual screening or molecular docking 
programs.  As AutoDock is freely available and the most cited of such programs(29), it was 
chosen for screening in this study.  There was also a wealth of information on the use of 
AutoDock, due to the fact that it is so widely used.  It is difficult to rank the performance of any 
docking program over others, and the performance of individual programs is said to vary from 
target to target(29,340,341).  Therefore, accuracy of predictions was not a major criterion for 
selecting AutoDock.  Moreover, most docking programs share the same limitations, such as 
modelling protein flexibility, so those discussed below may be applicable to virtual screening in 
general, and not just to AutoDock(29). 
Most virtual screening or docking programs have been historically limited by their inability to 
model the conformational flexibility of the drug target.  Although programs such as AutoDock4 
can model the flexibility of amino acid side chains, modelling larger conformational changes of 
the target remains a large obstacle to accurately representing drug targets.  A common strategy 
to overcome this limitation is to run a virtual screen multiple times against different 
conformational states of the target(342–346).  Having the privilege of possessing 
crystallographic structures of different conformations of TDH, it was possible to follow a similar 
strategy in this study.  The significant differences between the hit rates and the highest scoring 
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compounds in each of the four virtual screens clearly shows that it was necessary to screen 
against multiple conformations to identify all of the hits that later proved to be effective in vitro. 
A rigid TDH structure was used, based on AutoDock’s ability to correctly predict the binding 
poses of known ligands to this structure (see Section 3.3.2).  This also appears to have been a 
rational choice, as there is little or negligible variation in the conformations of the side chains of 
active site residues in the crystallographic structures of TDH obtained.  However, with the 
available knowledge, it was not possible to know if the rigid structures were able to truly predict 
the binding of molecules larger than L-threonine and glycerol (ligands used to validate the 
virtual assay).  When the various flexible and rigid TDH structures were validated for the 
prediction of L-threonine binding poses, structures in which Ser82 and/or Tyr144 were flexible, 
performed similarly to totally rigid structures.  It is possible that allowing flexibility for these two 
important L-threonine-binding residues may have improved the accuracy of the binding 
predictions for other ligands. Additionally, modelling certain NAD
+
-binding residues as flexible 
may have significantly affected docking predictions, especially in Virtual Screens 3 and 4.  By 
screening only rigid structures, it afforded some consistency to the experiments, such that the 
changes in results could be attributed mainly to the differences in the overall conformation of the 
TDH model.   
In this study, compounds were selected from the hits of different Virtual Screens, but it was not 
possible to know whether the results of any one screen were more valid than the other.  Biasing 
the selection of compounds based on their predicted binding energy may have helped to identify 
compounds that would be more potent binders, but this depends on the assumption that the 
binding energy predictions are accurate.  Unfortunately, the accurate prediction of binding 
energies is the biggest limitation of molecular docking programs(29).  Some researchers have 
addressed this issue by selecting compounds on the basis of consensus or average docking 
scores after screening against ensembles of different target conformations(346).  This may not 
have improved results in the current study, as some of the hits were only identified in one of the 
four screens.  However, this approach could become more useful on the availability of more 
TDH models with different conformations.  One additional factor that may affect the efficacy of 
the chosen TDH models to predict the binding of potential ligands is the absence of water 
molecules.  Water molecules are known to be important in the binding of several ligands, and 
this has been shown to be the case for L-threonine (see Figure 3.1.39).  In a study of ligand 
docking to cytochrome P450 and thymidine kinase, the consideration of water molecules during 
docking was shown to improve the predictions of the binding poses of ligands(347).  X-ray 
crystallographic structures of TDH were solved at sufficient resolution to discern the positions of 
water molecules important for catalytic activity and/or ligand binding.  However, water molecules 
were not considered in these virtual screening experiments due to an early lack of knowledge 
about the benefits of modelling them.  Furthermore, de-solvation effects are already modelled 
by AutoDock, so the usefulness of modelling water molecules is limited until more information 
on how a greater range of TDH ligands interact with the protein and water molecules is 
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obtained.  Clearly, these factors can only be taken into consideration in the event of any future 
virtual screens against TDH or similar targets.  
 
The chemical diversity of both virtual and in vitro screening libraries is frequently stated in the 
literature(348–351) as being important for discovering novel hits.  The NCI Diversity Set II 
provided a convenient source of diverse molecules.  The NCI Diversity Set has been used 
successfully to discover novel ligands for other drug targets(346,351).  The ligand substructure 
library was designed to select compounds that would share the same ligand-protein interactions 
as the known TDH ligands: glycerol, pyruvate and L-threonine.  This approach is proved 
successful by the identification of the inhibitor 2-{[3-(4-bromophenyl)-3-oxopropyl]amino}-3-
hydroxybutanoic acid (BPOB), an L-threonine analogue.  However, the Ligand Substructure 
Library had the lowest hit rate in each Virtual Screen.  A particular disadvantage of basing a 
library on a similarity search of small flexible molecules is that it results in a series of 
compounds with flexible scaffolds which would suffer higher entropic penalties on binding.  The 
average number of rotatable bonds of compounds in the Ligand Substructure library is much 
higher than those in the natural product library, despite having a similar average molecular 
weight (see Table 3.3.1). 
The addition of a natural product library was successful in increasing the representation of 
chemical space within the screening library.  The high hit rate of the natural product library may 
be a result of various factors.  The decision to select compounds on the basis of reports of 
trypanocidal activity of individual compounds or their natural sources may have selected for 
compounds with activity against TDH(219).  However, many natural products have a high 
number of hydrogen bond donors and acceptors, so they can participate in a high number of 
interactions, leading to a favourable docking prediction(219).  In reality, such molecules are also 
likely to bind non-specifically to several different sites on a particular molecule and not 
necessarily to the active site that was the focus of the in silico search.  It is this character of 
many natural products that makes them promiscuous ligands(352) that exhibit biological activity 
by interacting with a range of different targets(216,352).  Hence, a particular compound with 
demonstrated trypanocidal activity may later be found to be acting on a number of different 
proteins.  Any particular natural product has an evolutionary basis behind its existence and it is 
highly likely to influence some biological function(216,353).  Thus, a natural product library can 
be expected to contain a higher proportion of compounds with biological activity.  Although 
compound libraries such as the NCI diversity sets contain naturally-derived compounds, here it 
has been demonstrated that the addition of a library built solely with natural products can 
improve the success of a virtual screen.  A similar strategy to that taken here, where a virtual 
screening library was built by selecting compounds with reported in vitro trypanocidal activity, 
was employed by Ogungbe and Setzer in a screen against three trypanosome targets.  In that 
study, it was found that several in vitro trypanocidal compounds were also identified in silico as 
ligands of important trypanosome drug targets.  Some of these ligands were predicted to bind 
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several of the targets included in the study, emphasising the pleiotropic character of some 
natural products, a property which may or may not be advantageous in drug design(216,218).  
Promiscuous natural products may possess privileged structures, a core structure that allows 
them to interact with a broad range of unrelated targets(354).  In this respect, identifying such 
compounds would be desirable as a starting point for lead design(355). 
Protein structure similarity clustering (PSSC) was originally proposed to identify molecules to aid 
the design of screening libraries(216,232) and it has been used successfully in this 
application(356).  PSSC does not appear to have been widely adopted in the identification of 
novel hits through virtual screening, but this present study serves as a case in support of its 
usefulness.  The majority of the in vitro hits identified by virtual screening were identified by 
PSSC.  As the 3D configurations of TDH and the proteins identified by PSSC are so similar (see 
Figure 3.3.1), inhibitors of those proteins are likely to exploit analogous binding partners.  
Moreover, as the inhibitors were selected on the basis of having experimental evidence showing 
that they inhibit the TDH-related target, this probably meant that they were more likely to inhibit 
TDH than compounds that were randomly selected (e.g. diversity set compounds). 
As with the PSSC library, the previously known bioactivity of some molecules, such as the 
MmTDH inhibitors, probably increased the likelihood that they would be active against TDH.  
The compounds which have analogous structures to known inhibitors (e.g. School of Pharmacy 
compounds that are similar to TETD) may also show activity against TDH.  In future studies it 
would be of great interest to see if the activity of other hits of the Knowledge library have 
comparable efficacy to Qc1 and other inhibitors identified thus far.  
 
One measure of the effectiveness of virtual screening is to compare the predicted binding poses 
to those determined experimentally.  There are no crystal structures of TDH bound to any of the 
inhibitors identified through screening, but the enzyme inhibition assays provide an insight into 
the likely binding modes of some of the inhibitors.  Judging from the apparent MOIs of the 
inhibitors identified by AutoDock, it appears that the virtual screening experiments did not 
predict the binding modes of all ligands accurately (see Section 3.4.4.3). AutoDock seemed to 
correctly predict that sanguinarine occupies parts of both the L-threonine and NAD
+
 binding 
sites, as sanguinarine was determined in vitro to compete with both NAD
+
 and L-threonine.  On 
the other hand, BPOB, which was also predicted to bind in the pockets of both substrates, has a 
noncompetitive MOI towards L-threonine and NAD
+
.  Qc1, which was predicted by AutoDock to 
compete with NAD
+
, actually appears to be uncompetitive with NAD
+
, so preferentially binds the 
TDH-NAD complex.  These two examples reflect an inability of the virtual screening 
experiments to model the inhibition of these inhibitors – the screen focused in and around the 
substrate binding sites, but may have excluded yet-to-be-discovered allosteric sites.  In other 
cases, the predictions made by AutoDock may have just been incorrect.  Myricetin was 
predicted to bind in the NAD
+
 binding site, but in enzyme assays it exhibited an MOI that was 
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noncompetitive towards NAD
+
.  It is possible that the correct binding pose was predicted by 
AutoDock, but this was not predicted in such a repeatable manner as the seemingly incorrect 
one (binding poses from the largest cluster of docking results [n=50] were considered as the 
result).  
 
In Section 3.3 it was noted that the virtual screens seemed to select for molecules of higher 
molecular weight and greater numbers of H-bonding partners.  This was likely to be due to the 
ability to form more extensive interactions with the target which would contribute to a higher 
binding energy.  The issue with such compounds is that they tend to possess a number of 
unfavourable properties that would make them undesirable drug candidates, as indicated by 
their non-conformance with rules such as the Lipinski rule of five(277).  However, although they 
serve as useful guides, the rigid use of different rules and metrics in drug discovery has been 
criticised in recent years, as not all successful drugs adhere to such rules(357,358).  When 
building the virtual screening library, it was decided that compounds should not be filtered for 
drug- or lead-likeness at such an early stage.  Even hits that are unsuitable to serve as lead 
compounds may provide valuable information, such as important TDH-ligand interactions. 
 
4.2.2 In vitro screening design 
The selection of compounds for in vitro screening was carried out in a similar manner to virtual 
screening.  The compounds identified by UCL ChemiBank using virtual screening began with a 
library designed for diversity, the Asinex library(244).  Screening fragment libraries expanded 
the approach, so that fragment-based discovery could be pursued alongside a standard lead 
discovery effort.  The fragment based libraries were also designed for structural diversity, so a 
chemically and structurally diverse range of small molecule and fragment hits were identified.  
The identification of these hits was enabled by an appropriately-designed assay.  The merits 
and shortfalls of the in vitro screening assay are described below. 
 
An advantage intrinsic to the target protein was that the assay for TDH kinetics was relatively 
simple and therefore, easy to scale up for medium throughput screening.  However, some 
difficulties were encountered on scale-up, the main one being that the enzyme was not 
sufficiently stable in the reaction buffer for the duration of the time taken to screen an entire 
microplate.  This led to a high false positive rate during initial screening experiments and much 
time was lost validating inactive compounds.  The value of the NIH plate uniformity test (PUT) 
as a validation tool was highlighted by this situation (see Section 3.4.2).  The PUT test indicated 
that the assay did not meet recommended thresholds for Z’-score and signal window, which are 
indicators of the ability of an assay to distinguish between active and inactive compounds.  
However, after the enzyme stability issues were solved with the addition of 1mM potassium 
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chloride to the reaction buffer, the PUT indicated that the assay was much closer to the 
recommended state, and accordingly screening with that assay format produced far fewer false 
positives.  As only 1912 compounds were screened in total, the sub-optimal screening assay 
during the initial experiments did not significantly affect the study.  However, in a larger 
experiment, validation of the assay in the final screening format using a tool such as the PUT is 
recommended, as the number of false positives could become unmanageable if the assay was 
not optimised. 
Despite the difficulties encountered, using the same general format of the TDH assay in the 
screen made the scale-up process simpler.  A kinetic assay was used, so that artefacts 
interfering with individual readings would not invalidate an entire assay, as might be the case if 
a single reading was taken (i.e. in an end-point assay).  When testing a wide range of 
compounds, several of which were coloured, there was the potential for interference with the 
assay if a test compound absorbed strongly within the region of 340nm.  This was not a 
significant problem at the concentration ranges used to screen the compounds (<500 µM), so 
an absorbance assay was used, rather than re-designing the assay to measure fluorescence.   
 
An important choice to be made in designing screening experiments is defining activity 
thresholds for accepting compounds as hits.  The intention is to identify a diverse range of 
promising hit candidates.  However, it is important to set the thresholds low enough so that one 
has a manageable number of compounds to investigate further.  With these considerations in 
mind, the IC50 thresholds of 500µM and 100µM, were optimal in this regard.  In fragment-based 
drug discovery, the original hits are often of a very low affinity, but when linked to other 
fragments they form a high-affinity compound(20).  There is a risk that, by setting an IC50 
threshold as stringent as 500 µM, several useful fragments would not be identified.  However, 
taking into consideration the comments above, a good number of fragments were identified with 
the thresholds that were used.  Furthermore, there is an opportunity for hit expansion by testing 
analogues of the fragments.  Therefore, it is not a disadvantage that less fragment hits have 
been identified than may have been identified by setting less stringent activity thresholds. 
As has been previously stated, it is not only important to identify chemically diverse hits in a 
screen, but it is also important to identify mechanistically diverse hits(359).  The substrate 
concentrations used for screening were fixed close to their half-maximal concentrations in an 
attempt to identify hits that had competitive, noncompetitive and uncompetitive MOIs.  Looking 
at the compounds for which an MOI has been characterised, it is evident that the screen was 
somewhat successful in achieving this.  However, Qc1 is one of the most promising inhibitors 
identified, but it was not identified using the screening assay format.  This compound showed 
very little or no inhibition in the presence of low concentrations of NAD
+ 
(1.2mM), but it was 
actually one of the most potent inhibitors at high NAD
+
 concentrations.  Thus, there is a case for 
designing future screens which test the inhibitors under different conditions: L-threonine and 
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NAD
+
 at half-maximal concentrations; L-threonine at half-maximal concentration and NAD
+
 at 
saturating concentration; L-threonine at saturating concentration and NAD
+
 at half-maximal 
concentration.  Such an assay design would probably require greater quantities of reagents, but 
it would ensure that a broader range of hits were identified.  Another mechanistic aspect to be 
taken into consideration is the time-dependent inhibition of TDH.  It was necessary to pre-
incubate all the test compounds with TDH prior to initiation of the enzyme assay.  Several time-
dependent inhibitors of TDH were identified with a minimum pre-incubation time of 30 minutes.  
However, given that the time taken for maximal inhibition of TDH by some time-dependent 
inhibitors can exceed more than 90 minutes, it can be argued that a pre-incubation time of 60-
90 minutes is preferred, to ensure that very slow-binding inhibitors do not become false 
negatives. 
 
4.2.3 Most promising inhibitors 
After screening, hits were validated and the MOIs of some hits were investigated in more 
enzyme assays.  Finally, most of the hits were tested for their ability to inhibit the growth of 
cultured bloodstream form T. brucei.  A few compounds now stand out as promising for future 
studies, due to the potency with which they inhibit TDH or the potency with which they inhibit 
trypanosome growth.  The compounds include small molecules from various virtual screening 
libraries, as well as some fragments. In Figure 4.2.1, the chemical structures of the most 
promising compounds are displayed alongside information relating to their activities. 
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Figure 4.2.1 - the most promising TDH inhibitors identified by screening. The structures, IDs, TDH inhibition potencies (IC50 or Ki/αKi [calculated using the Cheng-Prusoff equation]), MOI 
and T. b. gambiense inhibition potencies are displayed.
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The hit compounds have different MOIs against TDH, which opens up several avenues for 
further investigations of TDH inhibition.  From a lead identification perspective, it is encouraging 
to see that all of the compounds adhere fully to the Lipinski rule of five or have just one violation 
of the rule.  All of the fragments in Figure 4.2.1 adhere to the Congreve rule of three.  This 
suggests that they possess at least some of the properties that would allow them to be a 
starting-point for, or to help guide lead design.  At this early stage of drug discovery, it is also 
important that the hits are amenable to optimisation.  This is important during the development 
of leads or in the determination of structure-activity relationships (SARs).  Certainly for the 
fragments, but also for some of the small molecules, analogous compounds are available that 
negate the need for the synthesis of new analogues.  A few compounds exhibited potent 
inhibition of trypanosome growth, potentially making them excellent hits for research going 
forward.  The compounds will be evaluated in more detail below. 
Sanguinarine 
Sanguinarine is a rapid binding inhibitor of TDH that competes with both TDH substrates for 
binding.  Its inhibition of TDH is moderately potent, with a predicted Ki of approximately 4.5 µM.  
Sanguinarine was originally included in the natural product library because of its documented 
activity against T. brucei and T. congolense in culture(360,361). 
Sanguinarine was the most potent of all compounds and its IC50 for trypanosome growth was 
0.48 µM or approximately 0.16 µg.ml
-1
.  This is within the activity criteria (0.2 µg.ml
-1
) previously 
defined for anti-trypanosome hit discovery(96).  A slightly higher ED50 of 1.9 µM was reported by 
Merschjohann and colleagues for the trypanocidal activity of sanguinarine against T. 
brucei(360). Unfortunately, sanguinarine and other alkaloids that are active against 
trypanosomes are not selective and also tend to be cytotoxic towards human cell lines.  An ED50 
of 1.4 µM has been reported for sanguinarine against human HLA-60 cell lines(360).  It could 
still be of some value to measure how much inhibition of TDH contributes to sanguinarine’s 
efficacy against trypanosomes.  However it is highly likely that it interacts with other targets.  
Most alkaloids are believed to be lethal to trypanosomes by intercalating DNA(360).  The most 
promising use of sanguinarine in the discovery of anti-trypanosome drug targets will be gained 
by observing the molecular binding interactions that it makes with TDH. 
 
Myricetin (and quercetin) 
Like sanguinarine, myricetin was both a moderately potent inhibitor of TDH and a potent 
inhibitor of BSF trypanosome growth in culture.  As a TDH inhibitor, myricetin appears to 
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compete with L-threonine and with an IC50 of approximately 27 µM.  The compound is also a 
time-dependent inhibitor of TDH.  The close analogue of myricetin, quercetin shares very similar 
properties with the inhibitor. Both compounds are inhibitors of dihydroflavonol 4-reductase 
(DFR) from Vitis vinifera(362) and, as DFR is structurally related to TDH, both compounds were 
identified by PSSC.  Quercetin which was also included in the natural product library, is present 
in the bark and roots of Securidaca longepedunculata(363), a plant used in traditional medicinal 
systems worldwide.  Extracts of this plant have been shown to be effective against 
trypanosomes in vitro and they significantly reduced parasitaemia in mice infected with T. brucei 
brucei(364).  Over the last decade a number of in vitro studies testing myricetin and quercetin 
have been carried out, and their antitrypanosomal activities have been attributed to various 
targets(365).  For myricetin, these targets include trans-sialidase(366,367) and hexokinase 
1(368).  Quercetin’s activity against trypanosomes has also been attributed to inhibition of 
hexokinase 1(368,369) and to its metal-chelating properties(370).  The affinity of myricetin and 
quercetin for these other targets (IC50 4-50 µM) (366,369) is comparable to their affinity for TDH.  
It will be necessary to investigate the contribution of TDH inhibition to the antitrypanosomal 
activity of these compounds before they can be considered as leads.  The fact that both 
compounds inhibit TDH as well as hexokinase 1, a protein of the glycolytic pathway, is 
interesting as they may exemplify dual inhibition of the essential pathways for trypanosomal 
acetyl-CoA production by a single compound. 
The myricetin binding mode predicted by docking with AutoDock 4 is not in agreement with that 
determined using enzyme inhibitory assays.  The docking result suggests that myricetin 
competes with NAD
+
 for binding, but the enzymatic data indicates that it actually competes with 
L-threonine, and not NAD
+
.  In the case of myricetin and quercetin, and maybe other inhibitors 
of proteins identified by PSSC, the MOI of the inhibitor may be predicted by its binding mode 
towards its other target.  Crystal structures of DFR bound to myricetin and quercetin show that 
they bind NAD-bound DFR in the site of the natural substrate(362). 
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Figure 4.2.2 - binding of myricetin to DFR.  Myricetin is coloured green.  Two molecules are stacked in the active 
site.  
 
Figure 4.2.3 - TDH structure (semi-transparent beige) superimposed over myricetin-bound DFR.  The L-threonine 
binding site in TDH would not be likely to be able to accommodate two myricetin molecules.  However, a single 
molecule could feasibly bind within the site. 
The binding site occupied by myricetin in DFR is analogous to the L-threonine binding site in 
TDH.  The apparent binding mode is unusual, as two myricetin molecules are bound 
simultaneously in a stacked arrangement.  Figure 4.2.3 illustrates that the L-threonine binding 
site in TDH would not be able to accommodate two molecules of the inhibitor.  However it is 
possible that myricetin could adopt the conformation of one of the molecules shown above 
when binding to TDH.  Quercetin was shown to bind DFR in the same manner, and the same 
conclusions can be drawn about how that might interact with TDH. 
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Figure 4.2.4 - binding of quercetin to DFR.  Quercetin is coloured green.  Two molecules are stacked in the active 
site, in the same manner as myricetin (see Figure 4.2.2).  
 
Figure 4.2.5 - TDH structure (semi-transparent gold) superimposed on quercetin-bound DFR structure.  As with 
myricetin, it appears that only one quercetin molecule could be accommodated by the L-threonine binding site.  
Figure 4.2.6 shows a crystallographic model of DFR bound to a single molecule of 
dihydroquercetin(371), aligned and superposed on a TDH structure. It is very similar in structure 
to the inhibitors myricetin and quercetin, and may serve as an indication of how these molecules 
bind to TDH.   Confirmation of the binding modes of myricetin and quercetin to TDH would be 
extremely valuable. 
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Figure 4.2.6 - TDH structure (green) superposed on a dihydroquercetin-bound DFR structure  It appears that the 
DFR substrate could bind within the L-threonine binding site.  Analogues such as myricetin and quercetin could 
potentially bind TDH in the manner suggested.  
Qc1 
Under the conditions of the in vitro screening assay, Qc1 was not recognised as an inhibitor.  
This was surprising, given the potent (nanomolar range) inhibition displayed against 
MmTDH(136), a very similar target.  It was discovered that Qc1 is an uncompetitive inhibitor of 
TbTDH, having much higher affinity for the NAD-bound enzyme.  The MOI of Qc1 was 
noncompetitive to L-threonine.  A similar MOI, ‘mixed noncompetitive’, was reported for Qc1’s 
action against MmTDH, but an uncompetitive MOI towards NAD
+
 was not observed(136).  Qc1 
was one of the most potent inhibitors identified in the presented study, with an αKi (inhibition 
constant for binding to the TDH-NAD
+
 complex) of approximately 26 µM. 
Qc1 was identified as part of a series of quinazoline carboxamide (Qc) compounds in a high-
throughput screen against MmTDH.  Inhibition of TDH in mouse embryonic stem cells using Qc 
compounds was lethal(136).  It is not known why the activity of Qc1 against TbTDH appears to 
be several orders of magnitude lower than the activity against MmTDH.  It will be interesting to 
see if the same is observed for other members of the Qc series.  Looking at the amino acid 
sequences of each enzyme (see Figure 3.1.9) there appear to be some differences in the NAD-
binding domain that could affect the relationship between TDH, NAD
+ 
and Qc1. 
NSC132249 and TbGalE inhibitors 
NSC132249 was a potent time-dependent inhibitor of TDH with a Ki of approximately 9 µM.  The 
MOI towards NAD
+
 is competitive and the MOI towards L-threonine is uncompetitive.  The 
binding mode predicted during virtual screen is in some agreement with the observations from 
enzyme assays: NSC132249 is predicted to bind in the NAD
+ 
binding site whilst interacting with 
Loop 1, when it is in the closed conformation.  It is possible that NSC132249 binding to the 
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NAD
+ 
proceeds L-threonine binding.  The closure of Loop 1 following L-threonine binding would 
allow the inhibitor to bind residues on the Loop, thereby increasing the strength of the 
interaction.  A crystallographic structure would be required to confirm this. 
 
Figure 4.2.7 - inhibitors of TbGalE that also inhibit TDH.  Differences in structure may be enough to alter their 
binding modes and MOIs.  
The related TbGalE inhibitor NSC132252 may have a similar binding mode to NSC132249, but 
the MOI of that inhibitor remains slightly ambiguous due to the different behaviour exhibited in 
the absence and presence of Triton X-100.  NSC132252 may be a promiscuous inhibitor.  The 
differences between the structures of the GalE inhibitors identified as hits may be significant 
enough that the binding modes and MOIs are also different.  For this reason, a single binding 
MOI and binding mode cannot be assumed to be shared amongst the series without further 
information.  As TbGalE was identified by PSSC, comparison of the structure with that of TDH 
may provide some clues as to how the GalE inhibitors could interact with both enzymes. 
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Figure 4.2.8 - TDH structure (coloured green) superposed on TbGalE structure (light blue) bound to UDP (light 
blue, ball and stick).  L-threonine lacks the UDP binding pocket.  
 
Figure 4.2.9 - TDH structure (ribbon and surface representation) superposed on UDP-bund TbGalE structure.  
There is no available pocket for UDP to bind to TDH.  
The substrate binding sites of TDH and GalE differ markedly, in the respect that TDH lacks a 
binding pocket, where GalE usually accommodates UDP binding (see Figure 4.2.8 and Figure 
4.2.9).  The GalE inhibitors were identified in a virtual screen against the target(346).  Figure 
4.2.10 shows the predicted binding mode of the TbGalE inhibitors.  The two arginine residues 
that are predicted to bind the inhibitors are present in the UDP binding pocket, so, if this virtual 
screening prediction is correct, the inhibitors must bind TDH by a different modality. 
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Figure 4.2.10 - binding mode of a NSC132249-related GalE inhibitor to TbGalE, predicted by virtual screening(346).  
Although the anti-trypanosomal activity of NSC132249 and the other TbGalE inhibitors is less 
than that of sanguinarine, myricetin and Qc1, they are of interest because they are reported to 
inhibit a target that is closely related to TDH.  In the same study that identified them as TbGalE 
inhibitors, they were shown to inhibit the growth of cultured T. brucei.  NSC132249 
demonstrated similar antitrypanosomal efficacy to that presented here and showed an EC50 of 
28.5 µM.  The reported antitrypanosomal activities of other GalE inhibitors are also comparable 
to those reported here, apart from NSC128598 which showed significant activity in this study, 
but negligible activity in the TbGalE study(346).  It is possible that some of this anti-
trypanosomal activity can be attributed to TDH and not GalE alone.  This will be important to 
establish, as the authors of the study hypothesised that the activity of the compounds could be 
increased by reducing their lipophilicity, thereby increasing cell penetration(346).  If the 
mechanism of action is by dual inhibition of GalE and TDH, then this would also be an important 
consideration for improving the activity of the compounds.  The affinity of the GalE inhibitors for 
GalE appears to be higher than for TDH.  In contrast to TDH, GalE has been shown to be 
essential in T. brucei and T. cruzi(372–375), so this is more likely to be the principal target.  
However, any contribution of TDH inhibition to the antitrypanosomal action should be confirmed.  
BAS 0472148 
BAS 0472148 is the most promising compound from the Asinex library after it showed potent 
inhibition of trypanosome growth in preliminary assays.  It was unfortunate that the supply of 
this compound was limited, as its activity is comparable to the other promising compounds 
mentioned above.  Little information appears to have been published on this compound.  In 
addition to the accurate determination of its inhibition of trypanosome growth, the contribution of 
BAS 0472148 inhibition of TDH should be investigated as a priority.  BAS 0472148 is also quite 
complex, so the binding mode should be investigated by X-ray crystallography. 
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Fragments 
There are up to eight fragments identified in this assay that warrant further study.  Of these 
fragments, two compounds from the Maybridge library, SB02047 and CC06013, and one 
compound from the 3D fragment consortium library, 4011502, are particularly promising due to 
their moderate to high affinity for TDH.  The Maybridge compound SB02047, in particular, 
demonstrated very high potency for a fragment, and this potency is similar to that of the larger 
inhibitors.  As one might expect, none of the fragments showed potent inhibition of trypanosome 
growth in culture.  Despite this, the current hits serve as a good starting point for fragment-
based drug design.  The binding interactions of the most potent fragments may also give an 
insight into a structural feature of TDH that can be exploited for increasing the potency of all 
candidates. 
 
Other compounds 
If time or resources persist, much valuable information can be gained by investigating some of 
the other hits, as discussed for the most promising compounds.  The enantiomeric purity of 
BPOB was not specified by the manufacturer/wholesaler, and there is the possibility that only 
one stereoisomer is active as a TDH inhibitor.  A pure form of the active stereoisomer would 
therefore exhibit higher potency than that exhibited by the BPOB tested so far.  The Asinex 
compounds collectively represent a diverse range of structures, so determining the interactions 
made between these compounds and TDH would be very valuable for future lead design.  
 
4.2.4 Lessons for the design of screening campaigns 
The strategy taken in the design of the virtual and in vitro screening libraries can be considered 
one of the main reasons for the success of those experiments.  A focus on achieving diversity 
has resulted in a number of chemically and mechanistically diverse inhibitors of TDH.  It is also 
evident that taking a knowledge-based approach, which involved screening ligands with known 
bioactivity, particularly against trypanosomes and enzymes structurally related to TDH, enriched 
the library and increased the number of hits.  It is important to employ a balance of empirical 
and knowledge-based strategies, however.  Although there is evidence to suggest that 
compounds identified through virtual screening were more likely to be in vitro hits, a screen 
relying solely on such compounds could preclude the discovery of inhibitors that were not 
correctly identified by the virtual screening experiments.  In this study, the virtual screens carried 
out with AutoDock 4 and with GOLD (carried out by UCL ChemiBank) focused on the substrate 
binding sites, so they may not have identified compounds binding to allosteric sites or other 
sites, such as the dimerisation interface.  The screening of fragment compounds not only 
enabled the pursuit of a fragment-based approach, but also enabled the identification of hits 
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from a pool of compounds that were free of any biases imposed by virtual screening 
experiments. 
Prior experience with the TDH assay reduced the time to design and set-up the in vitro screen.  
In addition, the knowledge of the different modes of inhibition exhibited by the known TDH 
inhibitors helped in the selection of substrate concentrations that would allow the identification 
of diverse hits.  As mentioned previously, full validation of the assay in a format similar to that 
used for screening is highly recommended to ensure accuracy and reproducibility of results.  
Statistical validation of the assay, using tools such as the NIH PUT assay, is also effective in 
ensuring the appropriateness of the assay.  A well validated assay can save on time and 
resources, and this is particularly advantageous during a large screen.  In a biochemical screen 
such as the one presented in this thesis, one would ideally want to carry out the following within 
a reasonably short space of time: 
 production and purification of the target protein; 
 execution of the screen using the primary assay; 
 confirmation of hits using a secondary assay. 
This is mainly for reasons of stability – confounding results can be avoided by ensuring that the 
same batch of protein is used to assay all compounds, that the protein remains pure and intact, 
and that the compounds do not break down over time.  Furthermore, once hit compounds have 
been obtained from a new source, validation studies should also be carried out across a 
reasonably short time span for the same reasons. 
If possible, hit compounds should be validated by several methods.  In this study, where 
material was available, compounds were tested in enzyme assays to confirm dose-dependent 
inhibition, determine their MOIs and to test for the disruption of non-specific inhibition using 
Triton X-100.  The compounds will be validated further if crystallographic data is obtained. 
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4.3 Implications of the Research 
4.3.1 TDH as a target for trypanosomiasis 
TDH was first highlighted as a drug target for trypanosomiasis by the research of Cross and 
colleagues in the 1970’s.  The compound TETD, a human aldehyde dehydrogenase inhibitor 
marketed as a drug for the treatment of alcohol dependence (disulfiram or Antabuse), was 
found to potently inhibit TDH.  Exposure of cultured trypanosomes to TETD caused their rapid 
death and this trypanocidal effect was shown to be accompanied by a drastic reduction in the 
production of acetate from L-threonine(138,139).  In the last few years, research has been 
published on the essentiality of acetate production in both procyclic and bloodstream form 
trypanosomes.  Dual blockade of the two pathways for acetate production, the TDH pathway 
and the glycolytic pathway, is lethal to trypanosomes(143,144).  This effect highlights the 
therapeutic potential of inhibiting this pathway, which is believed to play a role in several 
processes, including fatty acid synthesis and energy metabolism(138,141).  In other organisms, 
TDH has also been shown to play a key role in metabolic regulation, allowing organisms to 
survive in conditions with limited resources.  Interestingly, in recent years the TDH pathway has 
been said to play a role in genetic regulation in mouse embryonic stem cells(137,376).  
Considering the roles played by this enzyme in various organisms, it is likely that the enzyme 
has evolved as a key metabolic regulatory enzyme.   The TDH gene is upregulated as the 
morphology of T. brucei adapts to new environments in the gut of the tsetse fly(138).  Similar 
changes in the morphology of the parasite are reported to take place within humans as the 
parasite switches to a transmissible ‘stumpy’ form(81).  Therefore, disruption of the TDH 
pathway could also be a strategy to limit the spread of the parasite.   Looking at all the potential 
processes that could be affected by TDH, one hopes that new information will become available 
on other deleterious phenotypes caused by TDH inhibition.  
In consideration of the target product profile (TPP) for an antitrypanosomal drug, a key strength 
of TDH as a drug target is that humans do not have a functional copy of the enzyme, and so 
metabolise L-threonine using other pathways(106).  This presents an opportunity for the 
discovery of a drug with a lower chance of causing side-effects.  One note of caution is that 
TDH is a member of a very large superfamily of enzymes, many of which are utilised by 
humans(283).  Therefore, in order to achieve the desired TPP, selectivity profiling assays and 
judicious ligand design to avoid off-target effects will be essential. 
In light of the evidence that TDH knockdown is not lethal to T. brucei, it has been somewhat 
surprising to discover so many inhibitors of TDH that inhibit trypanosome growth.  As described 
previously, some of the most promising hits are known to inhibit other drug targets.  Previous 
work by Professor Jon Cooper at UCL and Professor John Kelly at the London School of 
Hygiene and Tropical Medicine showed that suppression of the TDH gene by gene knockdown 
rendered cultured T. brucei more susceptible to TETD, but this only showed that TDH inhibition 
contributes partly to the lethality of TETD towards trypanosomes.  TETD is known to be an 
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effective trypanocide towards T. cruzi.   This effect has been attributed to the compound’s 
metal-chelating ability(377–379) and to inhibition of delta-1-pyrroline-5-carboxylate 
dehydrogenase(380,381).  It is possible that TDH forms an important part of the activities of all 
of the multi-target compounds discussed in this chapter.  If that is true, it is likely that a multi-
target drug discovery strategy is the best course of action for developing a TDH inhibitor-based 
antitrypanosomal drug. 
 
4.3.2 Combination therapy 
Whilst TDH blockade alone has not been demonstrated to be lethal to trypanosomes, dual 
blockade of TDH and pyruvate dehydrogenase, the other enzyme producing acetyl-CoA in 
trypanosomes, was shown to have a profound effect on trypanosome growth(144).  Therefore, 
there is a strong case for the development of a TDH-inhibiting drug, as part of a combination 
with an inhibitor of the glycolysis pathway.  Compared to a single drug, combination therapies 
can have numerous advantages, including: 
 possibility to achieve greater efficacy than a single drug targeted to a single target; 
 targeting more than one target can mitigate the effects of mutation-mediated drug 
resistance; 
 lower dose requirements for both drugs if the effects are synergistic or additive. 
Contrastingly, there are several valid arguments against the use of combination therapies in 
place of single drugs, some of which include: 
 if the drugs have different pharmacokinetics, their co-location at the desired site of 
action may not be easy to achieve; 
 side-effects may become more likely as the number of drugs is increased; 
 the risk of drug-drug interactions (for patients taking other medication) is increased with 
combination therapies(382). 
In order to truly exploit the benefits of a combination therapy, the effects of the two drugs should 
be synergistic.  For clarity, the concept of synergism warrants a brief explanation.  As drug 
combinations have become more common, particularly in anti-cancer and anti-infective drug 
design, methods have been developed for the detection and classification of drug effects in 
combination(383,384).  When the effect of two drugs in combination is the sum of the effects of 
both drugs in isolation, the combination is said to be ‘additive’.  When the effect amounts to less 
than the sum of the two drugs’ effects in isolation, then the combination is said to be 
‘antagonistic’.  The preferred situation for a drug combination is when the magnitude of the 
combined effect is greater than the sum of the drugs’ effects in isolation, in which case the 
combination is said to be ‘synergistic’(383).  The isobologram, a graphical depiction of the 
effects of drug combinations, shown in Figure 4.3.1 illustrates this concept. 
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Figure 4.3.1 - illustrative example of an isobologram, published by Tallarida(383).  The diagonal blue line 
represents the combination of doses of drug A and drug B that will achieve the same effect.  It is the additive 
effect of each drug in isolation.  A drug combination represented by point P lies close to the line, so can be said to 
be additive.  Conversely, the drug combination at point Q lies below the line, indicating that it is antagonistic.  
The combination represented by point R is synergistic as it is situated above the blue line.  
If a combination of a TDH-inhibitor and a glycolysis inhibitor was to show synergy, then this 
could prove to be a highly effective approach to the treatment of trypanosomiasis.  The 
magnitude of effect required by this combination would presumably need to be trypanosome 
death.  A synergistic combination, combined in a single dosage form, could help to meet the 
TPP by: 
 reducing the risk of side-effects by requiring lower doses of each drug; 
 increasing the activity against drug-resistant forms; 
 shortening the length of treatment and simplifying dosage regimens by having a more 
effective treatment. 
The potential for a synergistic combination of a TDH inhibitor with a glycolysis inhibitor should 
be investigated by use of small interfering RNA or selective inhibitors of each pathway.  
Combinations of TDH inhibitors with inhibitors of other essential processes could also potentially 
be explored.  
4.3.3 Targeted polypharmacology 
Some of the aforementioned benefits afforded by the use of combination therapies can also be 
achieved by drugs targeting multiple ligands.  It seems likely that several of the TDH inhibitors 
exhibiting T. brucei growth inhibition are active at other targets in addition to TDH.  Myricetin 
and NSC132252 are good examples of this.  As exemplified by the GalE inhibitors, the inhibitors 
identified by PSSC may be inhibiting trypanosomes by inhibiting both TDH and the 
trypanosomal PSSC-identified target.  All of these observations highlight the now well-known 
fact that several pharmacologically active substances mediate their effects through interactions 
at multiple targets.  The rational design of multi-targeted drugs, often called designed multiple 
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ligands (DML) has been increasingly used in drug discovery(382,385–387).  The rational design 
of a DML targeting TDH and other targets would be greatly aided if the target binding sites 
either share some structural similarity or a similar arrangement of pharmacophores.  For this 
reason, DMLs are usually targeted at proteins within the same family.  Kinases are a good 
example of such a family of proteins, and there are several examples of kinase inhibitors in 
development and in clinical use that exhibit serendipitous or targeted 
polypharmacology(382,388,389).  This requirement for target similarity is already met in the 
case of TDH and GalE.  Compounds such as myricetin and quercetin appear to show 
polypharmacology towards diverse targets.  This may be a reflection of the promiscuity of those 
compounds, but it could also be an indicator of the potential for the design of ligands targeting 
TDH and another diverse target.  Irrespective of this, the rational design of DMLs targeting 
proteins from different families is understandably much more difficult than designing DMLs for 
related protein targets(382,385).   
Although the discovery of multi-targeted ligands was not an aim of the presented study, a 
foundation for such an effort has been set.  Morphy and Rankovic describe two approaches to 
the design of DMLs: a “knowledge-based” approach, where pre-existing data on the biological 
activity of compounds is utilised, and a “screening-based” approach(385).  In the present study, 
both approaches were combined in the hope of increasing the number of hits.  As a result, 
compounds that are active at other targets in addition to TDH have been discovered. 
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Figure 4.3.2 - strategies for the design of DMLs described by Morphy and Rankovic(385).  The earliest phases of 
the lead generation phase have been conducted in this study.  The next stages can begin with selective ligands of 
the targets, or even non-selective ligands.  The design strategy is different depending on the types of ligands 
available.  
Figure 4.3.2 gives a succinct summary of the process that may be followed for the design of 
DMLs.  If this was to be considered an appropriate strategy for antitrypanosomal drug design, 
then information on the activity (including potency and MOI) of TDH inhibitors towards other 
drug targets would be required. 
 
4.4 Future research 
4.4.1 Further structural and functional studies of TDH 
The findings presented here will allow further drug discovery efforts to proceed – a good 
number of inhibitors have been identified and validated assays are available for the discovery 
and characterisation of new inhibitors.  However, there are still several basic research questions 
that remain to be answered, and other questions have arisen following the findings presented 
herein. 
Several lines of evidence support the variable nature of the TDH conformation.  The data from 
various structural biology studies suggest that some significant conformational states of TDH 
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remain to be seen.  In particular, the possible dissociation of TDH into active monomers needs 
to be verified and investigated further to establish if the phenomenon truly occurs.  It may be 
possible to induce dissociation by treatment with p-chloromercuribenzoate as was done to 
induce dissociation of GalE from K. fragilis(309).  There is plenty of scope for further studies 
using the techniques used in this study, as well as with other techniques not used here, such as 
DLiS. 
Novel discoveries have been made on the kinetic behaviour of TDH and the inhibition of TDH 
has been studied in more detail here than the majority of studies of the enzyme.  Nevertheless, 
more information is required to be able to model the action of the enzyme more completely.  
Firstly, the extent and nature of the substrate/product inhibition can be investigated and its 
impact on other kinetic parameters determined.  Secondly, a deeper insight into the variables 
influencing the biphasic kinetics of TDH will also help to model the kinetics.  From a drug 
discovery perspective this information will be useful for understanding the MOIs of inhibitors, 
which are likely to be more complex than standard models of MOIs suggest.  Gaining a 
crystallographic confirmation of the binding modes of various inhibitors could match certain 
inhibition patterns to different binding sites.  This, in turn, would provide more information on the 
structural determinants of TDH function. 
4.4.2 Towards the design of new leads for trypanosomiasis 
Without knowledge of the in vivo effectiveness of TDH inhibition for treating trypanosomiasis, it 
is not possible to make a conclusive statement on its attractiveness as a drug target.  However, 
taking several factors into consideration, there are several reasons why pursuing this target may 
be an effective approach.  Frearson et al. published a number of criteria for the assessment of 
drug target candidates for antiparasitic drug discovery(32).  The assessment is reproduced in 
Table 4.4.1, with an indication of how TDH would be assessed.  
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Table 4.4.1 - the assessment of drug targets for antiparasitic drug discovery.  The table is reproduced from the 
table presented by Frearson et al.(32).  The criteria for assessment are divided into a traffic light system, with 
‘green’ representing favourable characteristics and ‘red’ representing unfavourable characteristics.  The cells 
representing TDH characteristics are coloured. *Although there is no essential TDH homologue in humans, there 
is the structurally similar UDP-GalE.  
Criterion Red Amber Green 
Target validation 
No or weak evidence 
that the target is 
essential for growth 
or survival 
Either genetic or 
chemical evidence 
that target is essential 
for growth or survival 
Genetic and chemical 
evidence that target is 
essential for growth 
or survival 
Druggability 
No drug-like inhibitors 
are known and active 
site of target is not 
druggable 
Drug-like inhibitors 
are known or active 
site is druggable 
potentially 
Drug-like inhibitors 
are known and 
druggable active site 
(i.e. clinical precedent 
within the target 
family) 
Assay feasibility 
No in vitro assay 
developed and/or 
significant problems 
with reagents (cost or 
supply) 
In vitro assay exists, 
development into 
plate format feasible 
but not achieved 
Assay ready in plate 
format and protein 
supply assured within 
appropriate timelines 
Toxicity 
Human homologue 
present and little or 
no structural or 
chemical evidence 
that selective 
inhibition is possible 
Human homologue 
present but some 
structural or chemical 
evidence that 
selective inhibition is 
possible 
No human 
homologue present or 
human homologue 
known to be non-
essential* 
Resistance potential 
Target has multiple 
gene copies or 
isoforms within the 
same species and is 
subject to escape 
from inhibition 
Target has isoforms 
within the same 
species or might be 
subject to escape 
from inhibition 
Target has no known 
isoforms within the 
same species and is 
not subject to escape 
from inhibition 
Structural information 
No structure of target 
or closely related 
homologue 
Structure without 
ligand available 
and/or poor resolution 
(>2.3 Å) or 
opportunity to build a 
good homology 
model 
Ligand-bound 
structure of target (or 
ligand in closely 
related homologue) 
available at high 
resolution (<2.3 Å) 
 
Although TDH does not fare well on what is probably the most crucial part of the assessment, 
there are good opportunities to simultaneously target TDH and other targets, as discussed 
above. 
There are several approaches that could be taken for the design of a TDH inhibitor.  Whilst they 
may eventually provide valuable information on SARs, none of the current inhibitors stand out 
as a good candidate on which to base lead design.  The current hits are generally quite large, 
and some of them do not leave much room for optimisation.  A potent compound, of medium 
molecular weight and with a scaffold amenable to optimisation would be ideal.  To find such a 
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compound, and preferably one with higher affinity, the first action to be taken could be to run a 
larger scale, high throughput screen against TDH.  The screening library could be focused using 
virtual screening and the knowledge gained from the recently conducted screen. 
Alternatively, one could choose to begin lead design based on the currently available 
information and on information gained from the current pool of hit compounds.  Once structural 
data has been obtained on the binding of small molecule hits to TDH, de novo drug design 
could be guided by knowledge of the 3D configurations of important pharmacophores.  New 
scaffolds can be designed as bioisosteres of bound conformations of active compounds(390).  
A fragment based approach can also be followed.  The binding sites of individual fragments can 
be determined crystallographically, and ligands binding to different sites can be fused to form a 
compound of higher affinity.  As mentioned previously, more potent compounds may be found 
to replace each fragment by testing commercially available or synthesised fragments.  This 
approach has been exploited successfully to discover potent lead candidates in various 
fragment-based drug design efforts(20).  
Equally, there is scope for rapid SAR development  using the small molecule inhibitors.  Other 
members from the Qc series of MmTDH are commercially available.  Other TbGalE inhibitors 
identified by Durrant et al. and potentially many more analogues can be obtained free of charge 
from the NCI/NIH Developmental Therapeutics Program.  Perhaps the best opportunity for SAR 
determination and the identification of more potent hits lies with the flavonoids myricetin and 
quercetin.  Flavonoids are abundant in nature and widely studied for their bioactivity(365,366), 
so analogues of myricetin and quercetin could be obtained with ease. 
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Figure 4.4.1 - myricetin, quercetin and other flavonoid classes.  The flavone structure is numbered to highlight all 
the positions where substitutions can be compared to develop SARs.  
Virtual screening results suggested that the most potent compounds are those that can bind 
within the L-threonine and NAD binding pockets simultaneously.  However, at present it is 
unclear as to whether compounds of a certain size can feasibly do this, due to the location of 
the side chain of the residue Met81.  Different arguments can be made in support of designing 
ligands that bind exclusively to the L-threonine binding site and those that bind exclusively to 
the NAD binding site.  A molecule binding to the L-threonine site is more likely to be specific, as 
opposed to a molecule with affinity for the NAD-binding site, which possesses structural 
features that are widely conserved.  Furthermore, as L-threonine binding is mediated by fewer 
residues than NAD-binding, any mutation that would confer resistance to ligands of this site 
would be more likely to lead to a loss of function of TDH.  However, the L-threonine binding site 
is small, meaning that it may be difficult for a ligand to form enough strong interactions within 
such a small area to confer high affinity binding.  The size of this site is also influenced by the 
conformation of Loop 1, which may or may not permit binding of large ligands.  The NAD 
binding site, on the other hand, presents a larger area for a ligand to make interactions with a 
protein.  Therefore, more potent ligands may be designed by focusing on this site.  Although 
structural features of the NAD binding site are widely conserved, it may still be possible to 
achieve specificity, as demonstrated by the numerous selective kinase inhibitors targeting the 
ADP binding site(391).  Ultimately, the decision on which site to target will be influenced by the 
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results of X-ray crystallographic studies of TDH and the hit compounds.  Studies involving other 
trypanosomal protein targets may also help to determine if a targeted polypharmacological 
strategy is feasible. 
 
During the design of new TDH inhibitors, close attention must be paid to the structure-function 
relationship of the enzyme.  The exact nature of ligand-induced conformational changes may 
dictate which molecules will bind TDH with high affinity.  For instance, if NAD and L-threonine 
are bound by a classical induced fit mechanism, it may be that the most effective inhibitors will 
be those that have improved affinity upon induced fit binding to the enzyme.  Conversely, if the 
way that TDH binds substrates is more akin to the process described as conformational 
sampling, where multiple conformations are present in a given population of enzymes, then 
TDH could potentially bind a more diverse range of inhibitors, as sampled conformational states 
are only locked once certain binding moieties are present. 
 
The production of acetyl-CoA and glycine from L-threonine relies on the coupled actions of TDH 
and KBL.  Inhibition of TDH alone is likely to be sufficient to inhibit the pathway, as has been 
demonstrated in T. brucei and in mouse embryonic stem cells(135,136,138,139).  However, this 
should be confirmed for each inhibitor, either in coupled assays with KBL, or in cultured 
trypanosomes.  There is a possibility that interaction between TDH and KBL may alter the 
conformation of the former enzyme, potentially altering the affinity of an inhibitor for TDH. 
 
4.4.3 Targeting other organisms 
TDH has been identified in several other organisms of medical interest, including important 
pathogens such as Clostridium difficile, S. aureus and Enterococcus spp.  Illnesses caused by 
these pathogens all represent significant health burdens, and there is a need for novel 
antibiotics to treat multi-drug resistant forms, and to halt the spread of further resistance.  
Looking beyond systemic anti-infectives, TDH could also be a target for the discovery of new 
insecticides.  The insect vectors of human African trypanosomiasis, Dengue fever, malaria and 
lymphatic filariasis all appear to have TDH genes.  The role of TDH in many organisms remains 
to be determined.  However, there may be opportunities for TDH inhibition in combination with 
other strategies in each case. 
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4.4.4 Drivers of NTD R&D 
The main drivers of NTD product R&D come from philanthropic organisations, the 
pharmaceutical industry, governments, PDP brokers and other research institutions (academic 
and PSNRI).  Prior experience in NTD product R&D strongly indicates that partnering with one 
or several of these organisations would be imperative.  The research in this thesis focuses on 
NTD development from the point-of-view of researchers from an academic institution/PSNRI.  
Hence, the following discussions will analyse different commercialisation strategies and 
potential partners from that viewpoint.   
Groups from Universities or PSNRIs play a very important role in the discovery of new 
innovative treatments(69,392), but they also have several limitations as projects progress 
towards the market(70,393,394).  Therefore, partnerships are essential to them. 
 
4.4.5 Commercialisation strategies 
4.4.5.1 General strategies for pharmaceutical products 
The first step in commercialising scientific research typically entails the generation and 
protection of intellectual property (IP) pertaining to an invention.  With pharmaceuticals, this will 
usually involve filing a patent.  The holder of the patent can then seek to capitalise on this IP 
through licensing of the invention to a third party, who may have more resources to develop and 
distribute a marketable product.  Another strategy to reap rewards from IP is to form a spin-out 
company.  Funds to develop the invention are raised in the form of equity in the company.  The 
company may enter into a partnership with third parties to share risk and to co-develop the 
product.  The university spin-out company is increasingly becoming a method favoured by 
Universities to exploit new IP and this plays an important role in new product discovery and 
development(395).  This situation holds true in new drug and vaccine development by 
Universities(70) and companies alike.  Both academic institutions and new companies have 
been identified as important sources of new drugs(69,392). 
Given the high risks and capital costs involved in pharmaceutical R&D, the formation of co-
development partnerships is almost ubiquitous.  Large pharmaceutical corporations have looked 
to academic research institutions and small/medium biotechnology or pharmaceutical 
enterprises (SMEs) as sources of new drugs and vaccines(71).  Meanwhile, their smaller, less 
resourced partners are able to benefit from the extensive capabilities and product development 
experience of the larger firms.  Certain R&D activities are often outsourced to contract research 
organisations (CROs), often as a cost saving measure, but sometimes as a faster and more 
efficient way to advance products through clinical development.  When new product 
development is initiated by small companies, and sometimes when large companies are the 
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sole developer, it may be necessary to bring in a number of other partners (venture capitalists 
and other shareholders) to finance development.   
The following section discusses how different development partners may be involved in the 
development of drugs for a neglected tropical disease, such as trypanosomiasis.   
 
Figure 4.4.2 - scheme illustrating potential commercialisation strategies for university- or PSNRI-originating 
research.  IP is either licensed/sold directly to third parties, or to a spin-out company formed by the inventors’ 
institution. Solid arrows indicate technology transfer, whilst dotted lines indicate returns to the 
University/PSNRI.  
 
4.4.6 Product development partners 
4.4.6.1 The general picture 
NTD product development inherently faces the same risks as the development of developed-
world diseases.  However, as previously mentioned, there is a huge disparity between the 
collective or individual disease burdens of NTDs and the R&D activity aimed at controlling them 
(50).  Despite this, the funding for global NTD product R&D has increased dramatically over the 
previous decade, showing gradual increases up until 2009, and steady levels since then.  
71.4% of the US $3.045 billion NTD R&D funding in 2011 was in the form of external grants, 
with a reported $1.5 billion going to academic and private NTD product developers(66). 
The largest funders of NTD research are government institutions, presenting as aid agencies or 
research councils/science and technology (S&T) agencies.  They provide around 65-70% of 
370 
 
global funding for NTD research.  The other two major sources of funding for NTD research are 
industry (pharmaceutical and biotechnology) and philanthropy, contributing 17.2% and 18.7%, 
respectively, of all global funding in 2011(66). 
PDPs take a central role in NTD drug development.  They received 23% of global grant funding 
for NTD research in 2011(66).  Furthermore, the BVGH 2012 report on the product developer 
landscape showed that 40% of all drugs and vaccines in current development were being 
developed using the PDP model(396).  Hence, the PDP brokers are another key partner in NTD 
product development. 
4.4.6.2 Funding for trypanosomiasis 
4.3% (US $131.7 million) of global funding reported in the G-FINDER report was dedicated to 
research in diseases caused by kinetoplastids (leishmaniasis, HAT and Chagas disease).  Of 
this amount, 26% was granted to HAT and 18.7% to Chagas disease.  A total of roughly US$18 
million was spent on R&D for new drugs in 2011(66).  The funding landscape for these diseases 
appears close to the general picture: 73.3% of funding originates in the public sector and 17.3% 
is donated by philanthropic organisations.  The top three funders of research in kinetoplastid 
diseases are the US National Institutes of Health (NIH), The Bill & Melinda Gates Foundation 
(Gates Foundation) and The Wellcome Trust.  Industry plays a smaller role here, than in other 
disease areas, contributing only 9.5% of funding, but it is still the third largest source of funding. 
 
Figure 4.4.3 - global funding for NTD research in 2011, as reported in the G-FINDER report(66).  Funding by sector 
is presented as percentage of total funding.  
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4.4.6.3 The academic/PSNRI institution as a source of new products for NTDs 
In all disease areas, academic institutions and PSNRIs have proven to be important sources for 
new drugs and vaccines(69).  Analysis of some recently-registered NTD products shows 
academics and PSNRIs at the root of their discoveries(50).  A look at the BVGH Global Health 
Primer also reveals the involvement of such institutions in the development of several NTD 
products in the pipeline(74).  This role in product R&D is particularly important in the NTD 
setting; the development of innovative treatments is an inherent requirement to treat or prevent 
several NTDs(50).  Evidence to support an innovative role can be found in the literature.  In 
Stevens et al.’s analysis of new drug applications to the US Food and Drug Administration 
(FDA), they show that academics/PSNRIs were twice as likely as for-profit institutions to meet 
an unmet medical need when a new drug originated with them.  Academic/PSNRI inventors 
also contributed to 13.6% of new molecular entities (NMEs) included in the analysis, and 9 out 
of the 10 new drugs that were for new indications(69).  Similarly, in Kneller’s 2010 analysis of 
the origins of new drugs, Universities were shown to contribute to the R&D of 30% of drugs 
given the FDA’s priority review (see discussion of PRV, below) and to 31% of drugs considered 
to be scientifically novel, despite contributing to an estimated 24% of new drugs overall(392).   
The prominent role of public funders, coupled with the fact that around three-quarters of all 
public funding goes directly to researchers(254), means that academic and PSNRIs are 
collectively the largest recipients of NTD R&D funding.  There has also been an increase in 
intramural funding by PSNRIs and Universities(66).  This makes researchers in these positions 
the most common participants in NTD product development(396).  However, groups from 
Universities and other PSNRIs are often insufficiently resourced to progress new products 
towards the clinic alone.  The costs of preclinical drug development can cost hundreds of 
thousands of pounds at a minimum, which can be very inhibiting, particularly to a small 
academic group(394).  On the other hand, with the rise of Academic Drug Discovery Centres, 
particularly in the US, more academic and PSNRI researchers will find the necessary resources 
available to them(70).  Even small groups can collaborate with other groups within their 
institution or externally in order to carry out different studies using the grants of individual 
researchers.  When looking at the current NTD product pipeline, academic/PSNRIs can be seen 
to be involved at every stage of the product development lifecycle – from discovery through to 
clinical phases(74,396). 
An academic institution/PSNRI has the option to sell the IP of a particular invention to another 
product developer to take forward.  This is clearly the most convenient option and, in many 
cases, it is the most appropriate option, relieving researchers of duties that are outside of their 
area of expertise.  There are situations where the development of a product will benefit from the 
continued input of the original inventors, in which case it would be a good option to license the 
product to third parties and co-develop the product(397).  In addition to these strategies, 
academics/PSNRIs may spin-out a company to commercialise a product.  This has the added 
value of being able to attract more funds in the form of equity.  Being able to provide more funds 
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directly, means that the inventors take on more of the risk, but are in a more favourable position 
to reap the commercial rewards of any products that meet the market.  Thus, the decision to 
follow either of the last two strategies is largely dependent on the commercial value of the 
product being developed.  Universities often pursue the spin-out model as a more lucrative 
revenue source(71,397).  However, in the NTD space, most products would have little or no 
commercial value.  This is particularly the case for HAT and it is probably the case for Chagas 
disease.   
The contribution of academic/PSNRIs in overall drug discovery and development, beyond the 
discovery phase is confirmed by numerous sources(69–71,392).  However, in the vast majority 
of cases, there is some form of technology transfer from Universities/PSRIs to Pharmaceutical 
or Biotechnology companies, who complete late-stage development, and carry out registration, 
marketing and distribution.  In Kneller’s study of the origins of drugs, 8% of drugs originated 
from Universities that transferred their technology to Pharmaceutical companies, whilst 16% 
originated from Universities that transferred their technology to Biotechnology companies.  
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4.4.6.4 Partners for NTD product development 
PDP Brokers 
As previously described, the successes of several NTD drug and vaccine development 
programs have been attributed to the PDP model(72).  The PDP brokers play a central role in 
this and manage much of the global funding that is directed to NTD research and development 
(see above).  The characteristics of these brokers differ slightly.  There are those that focus on 
a particular project, whilst there are others that are focused on a particular disease or group of 
diseases (e.g. Medicines for Malaria Venture [MMV], Global TB Alliance) and manage several 
products.  Brokers such as DNDi and BVGH work across therapeutic areas in the NTD space.  
As the Brokers have extensive networks and are present at every stage of pharmaceutical 
development, it would be advantageous to engage a PDP early on in the process.  The multi-
project and multi-disease Brokers have the added advantage that they have more experience, 
as they tend to have existed for longer, and thus they are better connected.  One disadvantage 
of PDPs is that they do not generate their own income and rely on funding from external 
sources.  Theoretically, this would make them vulnerable to the same inconsistency in funding 
as academics/PSRIs.  However, this does not seem to be the case, judging by the literature and 
media reports. 
According to the BVGH Global Health Primer, DNDi and the Global Alliance for TB Drug 
Development, along with BVGH, are PDP brokers that are currently involved in trypanosomiasis 
drug development. 
Government 
The biggest proportion of global R&D funding for NTD research comes from government 
sources.  A lot of this funding is given in pursuit of international development goals or for 
scientific reasons.  According to the G-FINDER report, the US NIH (granting a huge US$1.16 
billion over five years) is by far the most significant funder of NTD research.  Researchers in the 
UK have access to funds from the European Commission (EC), UK DFID and The Medical 
Research Council, which are all in the top twelve funders of NTD research.  Aid agencies and 
Research Councils/S&T agencies of the US, Dutch and Australian governments are also 
present in the list(66).  There has been a shift over the years towards more basic research, with 
31.2% of funding being dedicated to this area.  Therefore, researchers are likely to find funds 
from these sources for discovery and early-stage development.  However, a substantial 
proportion of funds are still available for later development.  For example, in 2011-2012, the 
MRC released a Highlight Notice, prioritising translational research in NTDs(398).  This remains 
a priority for the MRC’s Infection and Immunity Board(399).  Funds from research councils/S&T 
agencies are usually disbursed through competitive grant systems, where researchers must 
submit project proposals in response to calls for applications. 
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A large part of the support from government aid agencies focuses on  implementation of mass 
treatment administration programs.  This certainly seems to be the main role of USAID(400).  
The UK DFID is also heavily involved in this area, but also places a lot of emphasis on research 
to combat NTDs(401).  Their contributions are delivered through the WHO TDR initiative and 
DNDi programs(402) 
Philanthropy 
Philanthropic donations for NTD research do not seem to be concentrated in any particular 
disease area.  This funding usually plays a contributing role to specific projects and is focused 
on product development.  Around half of all PDP funding comes from philanthropic 
organisations (principally The Gates Foundation)(66).  Thus, it is important to highlight that, 
although Philanthropists are not as prominent as governments in NTD research funding overall, 
they are often major sources of funding for the development of individual products.  The two 
largest philanthropic funders are The Gates Foundation, providing an average of US$120.3 
million annually in 2007-2011, and The Wellcome Trust, which gave an average of US$10.8 
million annually to NTD research over the same period(66).  The main areas of focus of The 
Gates Foundation are Global Health, Global Development, Education (in the US) and Global 
Policy & Advocacy(403).  Efforts to control NTDs receives strong support from the Gates 
Foundation’s Global Health Division and HAT is one of the “High Opportunity Targets” that they 
focus on(404).  Apart from funding PDPs and other global health organisations, The Gates 
Foundation also has a mechanism for giving grants to researchers.  Concepts with specified 
aims are developed internally, then researchers/organisations are either invited privately or 
publically to apply for grants in a similar way to how they would apply for research council 
grants(405).  The Wellcome Trust operates in a similar way to research councils.  Infectious 
Diseases are included in the list of ‘Research Challenges’ in the Trust’s 2012-2020 Strategic 
Plan(406).  There are also two specific programs which are applicable to NTD product R&D.  
Firstly, the Global Health trials scheme provides funding for late-stage clinical trials of 
‘interventions that will improve health’ in low- and middle-income countries(407).  Secondly, the 
Wellcome Trust’s Pathfinder Awards provide funding for Academic-Industry partnerships for 
R&D for NTDs and Orphan Diseases.  The aim of this initiative is to advance projects from an 
early-stage to a stage where there is enough credibility to attract funds from other sources(408).  
Target validation is not supported by this scheme, so it can be envisaged that this scheme 
would be attractive to researchers working in the discovery and pre-clinical development stages.  
Furthermore, similar lines of research could be funded through other, less specific Wellcome 
Trust Grants. 
There is little information on the role of Philanthropy by wealthy individuals in funding NTD 
research.  It is possible that these individuals will give their donations to PDP brokers, and other 
charities/non-profit organisations, so their contribution is unclear.  Given the engagement of 
such individuals in issues of social importance(409), they should be approached to support R&D 
for NTD product development. 
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Large Pharmaceutical Companies 
Pharmaceutical firms are one of the primary partners of academic/PSNRI organisations for drug 
and vaccine development.  They are also a key partner in NTD drug development.  A search of 
the G-FINDER database, and a review of the signatories to the London Declaration on NTDs 
reveals a significant number of large pharmaceutical corporations that are involved in NTD 
product R&D(43,66).  They are responsible for a large part of the industry participation in NTD 
product development and some companies are engaged in the development of several products 
at a time(396).  In addition to the potentially large amount of funds at their disposal, large 
pharmaceutical firms also contribute to a large extent with in-kind support, ranging from access 
to facilities/compounds, offering of expertise, etc.(66).  There has been a significant increase in 
pharmaceutical industry involvement in NTD product development(66), which has been 
attributed to social and ethical concerns, efforts to improve reputation, and long-term strategic 
considerations(57). 
Much of the increase in funding has been directed towards advancing particular products 
through late-stage trials.  Most of the funding directed towards controlling NTDs is spent 
internally by large pharmaceutical companies(66), so it is likely that one of the main ways of 
partnering with them is through some kind of technology transfer of an invention to the 
company.  Much of the partnering done by large pharmaceutical firms is now shifting to earlier 
stages of development(52,57,66).  One of the biggest strengths of this type of partner is that it is 
one of a few types of organisation that can advance a project from any point in the product life 
cycle to the market.  The 20 or so large, multi-national corporations also have wide networks to 
engage CROs and other partners to carry out different parts of the development work.  
Therefore, these firms can be approached for partnership at any stage in development.  Of the 
largest companies, work in the NTD space is dominated by four of them: GlaxoSmithKline, 
Novartis, Sanofi and Astra Zeneca.  Although they have large amounts of money at their 
disposal, this means that there are really only a small number of individual developers of this 
type to partner with, compared with the biotechnology cohort. 
Biotechnology/Small Pharmaceutical Companies 
It has been shown that technology transfer from Universities to biotechnology firms accounts for 
more new drugs and biologics than that from Universities to pharmaceutical companies (16% 
vs. 8%) (392).  Therefore, biotechnology companies should be considered as one of the primary 
partners for researchers seeking to develop NTD products.  It’s often the case that these 
companies will later partner with or transfer technology to large pharmaceutical companies, but 
some biotechnology companies will advance their products all the way from discovery to 
market(392).  This highlights the extent of some of their capabilities.  Funding from biotech and 
small-pharmaceutical firms accounted for 10.6% of 2011 funding from industry that was 
reported in the G-FINDER report, and made up large/majority contributions in some disease 
areas, such as helminth diseases or trachoma(66). 
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Compared to the biotechnology sector as a whole, a very small proportion of companies are 
involved in NTD product development.  However, participation by biotechnology companies in 
NTD product development is estimated by BVGH to be evident across 41% of the NTD product 
pipeline.  Their participation is also present through all phases of the pharmaceutical product 
development lifecycle, and it exceeds the participation of pharmaceutical companies at all 
stages of development before phase III.  It is possible that biotechnology companies are filling 
very important roles in different parts of the lifecycle, sometimes where large industry 
participation is absent(396). 
When it is appreciated that a main obstacle in finding funding to develop NTD products is a lack 
of commercial potential, it is encouraging that biotechnology firms have played a more 
significant role than large pharmaceutical firms in discovering and developing orphan drugs 
(drugs developed for rare diseases; see discussion on rare diseases and orphan drugs below), 
where the commercial value is typically lower(392).  This is analogous to the situation that has 
drawn some small companies to neglected diseases (this was the case for Zentaris in the 
development of miltefosine, for example) (57).  In lower-income countries, where NTDs are 
present, this may be a further encouragement to engage in NTD product R&D.  In 2011, 28.9% 
of funding reported by biotechnology and small pharmaceutical firms came from countries in 
lower-income countries.  Firms from the emerging markets of India and Brazil are playing a 
particularly prominent role, and there have been significant increases in research directed 
towards treating kinetoplastid diseases in Brazilian firms(66). 
Biotechnology and other smaller firms are limited by the funds available to them.  As their funds 
originate from investments, as opposed to the revenues of large pharmaceutical companies, 
they have less flexibility, thus typically contribute less to NTD product development(396).  
Furthermore, it can be expected that these firms are also less able to offer in-kind contributions 
than their larger counterparts.  PDPs often have to contribute more funding to biotechnology 
firms, than to pharmaceutical firms, making them a more expensive partner for PDP brokers to 
work with(72,396). 
Contract Research Organisations 
Whether conducting neglected disease R&D or not, CROs can be a useful partner for carrying 
out specific studies that researchers may lack the ability to do in their own facilities.  CROs are 
reasonably active in the field of NTD product R&D and partner extensively with PDPs: the DNDi 
website lists 28 different CROs from companies from both developed and developing countries 
as partners(410).  An analysis of traceable external PDP expenditure in 2007 shows that 20.9% 
went to CROs, larger than that which went to large pharmaceutical companies (18%) and 
biotechnology/small pharmaceutical companies (9.3%) (72).  
There are some companies that are combining the role of a traditional pharmaceutical or 
biotechnology company, with contract services.  Founded with money from equity investments, 
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the South Africa-based iThemba raises additional money through contract medicinal chemistry 
services and invests the profit into research for treatments of unmet medical needs in Africa.  
Using this business model, they have successfully generated a pipeline of leads and molecular 
scaffolds active against malarial parasites, TB and HIV(411).  Another company, called 
Scynexis, has played an important role in developing a late-stage HAT compound(412).  This is 
detailed in a case study, later in this chapter.  
Venture Capital 
When a researcher’s commercialisation strategy is to form a new company, after gaining 
seed/start-up capital, larger investments are often sought from venture capitalists(397).   
Venture Capital (VC) firms provide finance in exchange for some form of equity in the company, 
but individual deals can take many forms.  VC firms usually make an investment with the 
assumption that there will be a profitable ‘exit’, at a later date.  This will usually involve the 
company being purchased at a value that is higher than that invested in the company. 
In addition to Private VC firms, Corporate Venture Capital (CVC), coming from large 
corporations, is another source of equity.  There has been an increasing trend in venture capital 
investments to biotechnology/small pharmaceutical firms from large corporations, particularly 
large pharmaceutical companies.  Several large pharmaceutical companies now have venture 
capital arms.  Corporate venturing can be seen as another way that large firms can augment 
their pipelines and access new technologies.  As some private VC firms have moved away from 
the biotechnology sector, Corporate VC has become increasingly important.  Investments are 
reportedly on the increase, with a shift towards earlier stages of development, but these firms 
are often looking for companies that are already venture-backed(413).  
The lack of financial incentive for making such investments for companies in the NTD space is 
probably a reason why venture capital has not been looked at as a significant source for funding 
in this area.  However, this does not preclude it from playing a role.  There will be a number of 
cases mentioned in this chapter, where funds from equity investments have eventually played a 
role in NTD drug development.  Additionally, there is already evidence of a venture capital firm 
engaging in the fight to control neglected diseases.  The Legatum group, a Dubai-based private 
investment firm, is a founder of the END fund, which is a global fund committed to supporting 
mass drug administration to eradicate NTDs in Africa(414). 
Angel Investors 
Angels, wealthy individuals that are usually serial entrepreneurs, make investments in a similar 
manner to venture capitalists, and are another source of funding for new businesses.  Like the 
individual philanthropists, they are individuals who wish to invest in causes that they have some 
kind of interest in.  They often seek to have some influence on the company, too(397).  For 
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reasons already discussed, such an individual is likely to be a philanthropist in the area of NTD 
product R&D.  
4.4.7 Details of partnerships 
4.4.7.1 NTD product development in the 21st century 
One of the most striking things of Pedrique et al.’s analysis of new products for NTDs (see 
products in Table 4.4.2), is that there are very few new innovative products – the majority of 
products are repurposed drugs (denoted NI, for new indication), new fixed dose combinations 
(FDCs) of existing drugs or new formulations (NF) of existing drugs(52).  At first glance, there 
appears to be a promising number of new vaccines introduced in the period studied.  However, 
these only cover two diseases, and two vaccines originate from the same invention.  There are 
only four NCEs on the whole list(52).  As a result, this gives us little information on how a 
product may be developed from the discovery phase, through to product registration. On the 
other hand, they do show evidence of successful product development through the more 
expensive, later stages of development.  Therefore, there are several useful lessons to be 
learned from these successes. 
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Table 4.4.2 - New NTD products approved or recommended during 2000-11. Table reproduced from the work of Pedrique et al.(52), with an additional column on product development history 
(from media reports, WHO documents and scientific literature).  
Generic Name Marketed 
Name(s) 
Indication(s) Formulation Product 
Type 
Regulatory 
Body(s) 
Country Date of 
Approval 
MA Holder Comments on 
Development History 
artemotil   malaria injectable NCE MEB Netherlands 2000 Artecef BV Artecef BV was created 
by ACF Beheer S.A. for 
the purpose of 
developing Artemotil with 
the WHO.  Patent held by 
the WHO Scientific 
Working Group on the 
Chemotherapy of 
Malaria. 
atovaquone plus 
proguanil 
(paediatric) 
Malarone 
Paediatric 
malaria tablet NI FDA USA 2000 GlaxoSmithKline   
proguanil plus 
chloroquine 
Avloclor malaria tablet FDC AFSSAPS France 2001 AstraZeneca   
chloroquine plus 
primaquine 
  malaria tablet FDC ANVISA Brazil 2001 Industria 
quimica do 
Estado de Goias 
S/A - Iquedo, 
Brazil 
  
artesunate   malaria injectable NF ANVISA Brazil 2001 Silvestre Labs 
Quimica e 
Farmaceutica 
Ltda, Brazil 
  
artemether plus 
lumefantrine 
Coartem malaria dispersible 
tablet 
NF Swissmedic Switzerland 2008 Novartis 
Pharma 
Schweiz AG 
Ciba-Geigy, later 
Novartis entered into a 
partnership with the 
Academy of Military 
Medical Sciences in 
China and several private 
Chinese entities to 
develop Coartem.  
Originally marketed as 
Riamet for developed-
world travellers, but was 
produced non-profitably 
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later, following an 
agreement with the 
WHO.  Supported by the 
Global Fund. 
artesunate plus 
amodiaquine 
(ASAQ) 
Coarsucam malaria tablet FDC WHO PQ   2008 Sanofi-Aventis 
Group 
Combination developed 
in parallel by Sanofi and 
the FACT (Fixed Dose 
Artesunate Combination 
Therapy) Consortium - a 
group headed by DNDi, 
and involving 
Farmanguinhos/Fiocruz 
and various other 
academic, clinical and 
CRO partners.  They 
later teamed up to co-
develop the product.  
Compound registration 
and manufacture was 
also initiated in Morocco, 
to build capacity and aid 
registration in endemic 
countries. 
artesunate plus 
mefloquine 
(ASMQ) 
  malaria tablet FDC ANVISA Brazil 2008 Farmanguinhos/ 
Fiocruz, Brazil 
Combination devised by 
WHO TDR staff, with 
support from USAID and 
the Wellcome Trust.  
Developed in a  PDP led 
by the FACT consortium.  
A later technology 
transfer agreement 
allowed production and 
registration in India. 
artemether plus 
lumefantrine 
  malaria oral 
suspension 
NF CDSCO India 2008 Information 
unavailable 
  
arterolane maleate 
plus piperaquine 
phosphate 
Synriam malaria tablet NCE CDSCO India 2011 Ranbaxy labs Invented in a PDP, led by 
MMV, with UK, US and 
Swiss contributors.  MMV 
licensed the IP to 
Ranbaxy in 2003. 
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piperaquine 
tetraphosphate 
plus alpha 
dihydroartemisinin 
Eurartesim malaria tablet NCE EMEA Europe 2011 Sigma-Tau 
Industrie 
Farmaceutiche 
Riunite SpA 
Combination initially 
developed by Professor 
Li Guoqiao of Guangzhou 
University of Traditional 
Chinese Medicine and 
developed in a 
partnership with the 
Holley group, China.  
Further developed for 
Global use in a PDP 
involving MMV. 
artesunate   malaria suppository NF ANVISA Brazil 2000 Nova Quimica 
Farmaceutica 
Ltda, Brazil 
Supporting research was 
funded by WHO TDR, 
several governments and 
two PSNRIs. 
ethambutol plus 
isoniazid plus 
pyrazinamide plus 
rifampicin 
  tuberculosis tablet FDC WHO PQ   2003 Lupin Ltd, India Combination was 
introduced on advice of 
WHO Advisory 
committee. 
ethambutol plus 
isoniazid plus 
rifampicin 
  tuberculosis tablet FDC WHO PQ   2008 Macleods 
Pharmaceuticals 
Ltd, India 
Application submitted by 
MSF and The 
International Union 
against Tuberculosis and 
Lung Disease. 
isoniazid plus 
rifampicin 
  tuberculosis dispersible 
tablet 
NF WHO PQ   2009 Macleods 
Pharmaceuticals 
Ltd, India 
  
isoniazid plus 
pyrazinamide plus 
rifampicin 
  tuberculosis dispersible 
tablet 
NF WHO PQ   2009 Macleods 
Pharmaceuticals 
Ltd, India 
  
moxifloxacin   tuberculosis tablet NI WHO PQ   2010 Cipla Ltd, India Use is currently off-label, 
although recommended 
by WHO; Bayer (after 
withdrawing its patent in 
India) and TB alliance are 
conducting trials to 
register the product. 
levofloxacin   tuberculosis tablet NI WHO PQ   2011 Cipla Ltd, India   
ofloxacin   tuberculosis tablet NI WHO PQ   2011 Cipla Ltd, India   
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benznidazole 
(paediatric) 
  Chagas disease dispersible 
tablet 
NF ANVISA Brazil 2011 Pernambuco 
State 
Pharmaceutical 
Laboratory 
(LAFEPE), 
Brazil 
Partnership with DNDi 
and multiple funders to 
produce new formulation.  
DNDi supported product 
registration. 
miltefosine Impavido visceral 
leishmaniasis 
capsule NI CDSCO India 2002 German 
Remedies Ltd, 
Mumbai 
WHO TDR worked 
closely with Zentaris AG 
(original inventor) to 
clinically develop 
miltefosine for visceral 
leishmaniasis.  WHO 
TDR set up a 
development team and 
several Indian principal 
investigators were 
involved.  Strong 
agreements on patient 
access were put in place.  
Zentaris licensed it to 
German Remedies for 
manufacture and 
Distribution. 
paromomycin   visceral 
leishmaniasis 
injectable NI CDSCO India 2006 Gland Pharma 
United and One 
World Health 
(San Francisco 
[IOWH]) and the 
Bill & Melinda 
Gates 
Foundation 
  
miltefosine Impavido cutaneous 
leishmaniasis 
  NI CDSCO India 2008 German 
Remedies Ltd, 
Mumbai 
Zentaris appear to have 
sponsored further trials in 
this indication 
independently of TDR. 
nitazoxanide Alinia cryptosporidiosis/ 
giardiasis 
oral 
suspension 
NF FDA USA 2002 Romark 
Laboratories, LC 
See below 
nitazoxanide Alinia cryptosporidiosis/ 
giardiasis 
tablet NCE FDA USA 2004 Romark 
Laboratories, LC 
Originally discovered by 
Jean-Francois Rossignol 
in the Pasteur Institute.  
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Rossignol co-founded a 
Romarck to 
commercialise 
nitazoxanide. 
tosufloxacin 
tosilate hydrate 
Ozex cholera granules NF PMDA Japan 2009 Toyama 
Chemical Co, 
Ltd 
A reformulation of Ozex 
tablets. 
bivalent 
inactivated 
vaccine, killed 
whole cells of 
Vibrio cholerae O1 
and O139 
Shanchol cholera oral 
suspension 
vaccine CDSCO India 2009 Shantha Biotech International Vaccine 
Institute altered 
mORCVAX formulation of 
Vabiotech to meet 
International standards, 
with backing from the 
Gates Foundation and 
various international 
development agencies.  
The technology was then 
transferred to Shantha for 
production. 
live pentavalent 
vaccine, for 
prevention of G1, 
G2, G3, G4, and G-
serotypes 
containing P1A[8], 
in Vero cells 
RotaTeq rotavirus oral 
suspension 
vaccine EMEA Europe 2006 Sanofi Pasteur 
MSD, SNC 
Discovered by the 
Philadelphia Childrens 
Hospital and the Wistar 
Institute.  Product 
licensed to Merck and 
Royalty Interest of 
Philadelphia Children's 
Hospital and part royalty 
interest of Wistar institute 
was later sold to 3rd 
parties. 
Live, attenuated 
vaccine, rotavirus 
RIX4414 strain, for 
prevention of G1 
and non-G1 
serotypes (G3, G4, 
and G9), in Vero 
cells 
Rotarix rotavirus oral 
suspension 
vaccine EMEA Europe 2006 GlaxoSmithKline 
Biologicals SA 
Licensed from Avant to 
GSK. This vaccine was 
first registered for use in 
Mexico and the 
Dominican Republic in 
2004, and has been 
approved in more than 35 
countries and the 
European Union. 
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Japanese 
encephalitis virus 
vaccine, freeze-
dried, inactivated, 
Beijing-1 strain, 
Vero cell-derived 
ENCEVAC Japanese 
encephalitis 
injectable vaccine PMDA Japan 2006 Kaketsuken   
Japanese 
encephalitis virus 
vaccine, live 
chimeric viral 
vector 
Imojev Japanese 
encephalitis 
injectable vaccine TGA Australia 2008 Sanofi Pasteur 
Pty Ltd 
Developed by Acambis 
as ChimeriVax-JE.  
Marketing and 
distribution license 
granted to Sanofi.  Target 
markets in South-East 
Asia, presumably for-
profit. 
Japanese 
encephalitis virus 
vaccine, purified, 
formalin-
inactivated, whole 
virus vaccine 
strain SA14-14-2, 
in Vero cells 
Ixiaro Japanese 
encephalitis 
injectable vaccine EMEA Europe 2009 Intercell AG Intercell licensed relevant 
IP from Vaccgen 
International LLC and 
Sanofi Pasteur.  
Distribution by Novartis. 
Japanese 
encephalitis virus 
vaccine, live, 
attenuated strain 
SA14-14-2, in 
primary hamster 
kidney cell 
cultures 
mORCVAX Japanese 
encephalitis 
injectable vaccine CDSCO India 2010 Curevin Pharma 
Pvt 
Curevin are providing 
Vabiotech's vaccine (see 
Shanchol, above). 
Crotalidae 
polyvalent 
immune fab 
(ovine) 
  snakebite injectable biologic 
(anti-
venom) 
FDA USA 2000 Protherics Inc. Developed for North 
American market. 
nifurtimox 
(combination 
therapy with 
eflornithine 
  human African 
trypanosomiasis 
tablet NI WHO EML   2009 Drugs for 
Neglected 
Diseases 
Initiative (DNDi) 
Combination supported 
by research conducted 
by MSF and epicentre. 
zinc   diarrhoea tablet and 
liquid 
NI WHO EML   2006 Newborn and 
Child 
Research performed by 
academics, supported by 
 
 
3
85
 
Development 
Department of 
Child and 
Adolescent 
Health, WHO 
NGOs. 
ribavirin   viral haemorrhagic 
fevers 
intravenous 
and oral 
NI WHO EML   2007 Biorisk 
Reduction for 
Dangerous 
Pathogens 
Team (BDP), 
WHO 
  
386 
 
Regarding the products listed in Table 4.4.2, it can be seen that a variety of different 
organisations filed for registration and hold marketing authorisations (MA) (i.e. are authorised to 
market and sell the product).  The majority is made up of pharmaceutical manufacturers, mainly 
large pharmaceutical corporations and smaller firms in the industry.  There are also some PDP 
brokers and transnational organisations, serving a similar role to PDP brokers, in the list: DNDi, 
the Newborn and Child Development Department of Child and Adolescent Health of the WHO, 
and the Biorisk Reduction for Dangerous Pathogens Team of the WHO.   
The aminoglycoside antibiotic, paromomycin was launched in 2006 as a treatment for visceral 
leishmaniasis (VL) with joint marketing authorisation going to Gland Pharma United, the Institute 
for One World Health (IOWH) and the Gates Foundation.   IOWH has a role as a PDP broker, 
but also carries out R&D activities.  Originally discovered in the 1950s, paromomycin was 
shown to have efficacy in the treatment of VL in the early 1960s.  There was a long history of 
use and development of paromomycin by trans-national NGOs and public health authorities, 
MSF and WHO TDR, but the discontinuation of paromomycin production and the cessation of 
development almost prevented this treatment from having a place in VL therapy.  In 1999, 
IOWH began completion of paromomycin development and received funding from the Gates 
Foundation to realise this goal.  They partnered with Indian pharmaceutical company, Gland 
Pharma, to ensure production(415,416).  This is an example of a successful PDP, which 
highlights a number of key strategies.  IOWH is a non-profit developer, so they were able to 
develop a treatment where a significant commercial incentive did not exist.  They were able to 
do this, only with philanthropic support.  It was also important to engage a producer in a country 
where VL was endemic.   
The case of paromomycin highlights another important pattern seen in Table 4.4.2: 18 of the 33 
industrial MA holders are based in developing countries where NTDs are prevalent, India and 
Brazil.  These two countries are also the two largest developing country funders of NTD 
research(66). 
Most of the products in Table 4.4.2 were developed in a partnership, or there was some form of 
technology transfer between different entities.  Another trend seen here is that almost all 
products that are marketed in lower- or middle-income country markets and/or on a not-for-profit 
basis received some form of public, philanthropic or NGO support in their development.  The 
WHO or PDPs were involved in supporting research (see artemotil, Synriam®, ASMQ, 
miltefosine and others) and product registrations (see benznidazole [paediatric]).  State-owned 
pharmaceutical firms were involved in the development of several products in Brazil, and 
academic/PSNRIs were the home institutions of the original inventors of several of the products 
(e.g. artemisinin derivatives, such as artemether and artesunate).  Even in some cases, where a 
product was originally targeted towards developed country markets (e.g. Coartem® for 
travellers), engagement by one of the aforementioned organisations (the WHO in the case of 
Coartem®) was the key factor in enabling patient access in lower-income countries. 
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The results of the upsurge in NTD drug development and the emergence of new strategies have 
not yet been seen in full.  The analysis above provides a somewhat misleading picture of the 
current state of NTD drug development.  The BVGH global health primers shows 
pharmaceutical development projects at every stage in the development life cycle.  In March 
2012, 190 drugs and 225 drugs were reported as being in ‘active development’ for 23  different 
NTDs(417).  Thus it is important to analyse some of the partnerships of drugs in development.  
Fexinidazole, a new treatment for HAT is in late clinical trials and is a great example of the 
effectiveness of the PDP strategy for developing NTD products.  Case studies of other products, 
which have required the use of innovative business models or strategies, are discussed near 
the end of this chapter. 
Fexinidazole 
Fexinidazole is being developed in a PDP driven by DNDi in partnership with Sanofi, the Swiss 
Tropical Health Institute and HAT platform partners, a consortium of at least 18 national HAT 
control programs, research institutes and NGOs(74,418). Fexinidazole, a broad spectrum 
nitroimidazole antibiotic, was in preclinical development to treat bacterial infections in the 1970s, 
before efficacy against T. brucei infection was discovered in the 1980s.  It was not developed 
further for either indication, but it was re-discovered during a large characterisation of 700+ 
compounds, initiated by DNDi in 2005(419,420).   DNDi was responsible for much of the R&D: 
preclinical, clinical and pharmaceutical.  Sanofi carried out industrial development, registration 
and manufacturing.  Members of the HAT platform, particularly the national control programs of 
the Democratic Republic of the Congo (DRC) and the Central African Republic (CAR), along 
with Médecins Sans Frontières (MSF) were responsible for clinical trials.  DNDi list a number of 
funders, ranging from the Gates Foundation to government international aid departments(418).  
Fexinidazole is expected to be available on the market in 2014(421). 
4.4.8 Benefits of different options 
The presence of different potential partners at different stages of the development lifecycle 
means that several different approaches can be taken to commercialisation of research in this 
area.  Whether the IP protecting an invention is sold, licensed, or used as a foundation for 
forming a new company, partnering with other organisations is essential.  This is evident when 
looking at the development histories of most drugs for NTDs(50,57,72) (see Table 4.4.2), and is 
a key characteristic of pharmaceutical development when the IP originates from 
academic/PSNRI labs(392). 
Chesbrough & Schwartz describe how an effective product co-development partnership should 
look to leverage the capabilities of the respective partners.  In order for such partnerships to be 
successful, the business objectives of each partner should be aligned(422).  An example of 
business objectives for the commercialisation of the research presented in this thesis are: 
 Gain evidence of the efficacy of compounds that are effective in killing trypanosomes 
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 Optimise leads to increase efficacy 
 Prove in vitro and in vivo safety of new leads 
 Prove in-human efficacy of new anti-trypanosomal drug (clinical trials) 
 Register new treatment for HAT/Chagas Disease 
 Large-scale manufacture and distribution of new drug for HAT/Chagas Disease 
Perhaps, a reason for the success of the partnership models used in NTD product development 
is the alignment of these objectives.  Different partners can contribute to projects in a 
complimentary manner, utilising capabilities that are required for the success of the project, but 
without perceiving any threats to their core business model.  For example, a reason for the 
collaboration by large pharmaceutical companies in early stages of R&D (i.e. discovery) is that 
projects are pre-competitive at that stage – the outcomes do not bring the collaborators into 
competition with each other. 
The main questions for academic/PSNRI researchers to address when trying to commercialise 
research that could lead to a new NTD product, revolve around where to find funding, who to 
partner with and at what stage(s). 
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4.4.8.1 The most appropriate option? 
Table 4.4.3 - Market segmentation matrix, adapted from G Moore's 'Crossing The Chasm'(423). This tool is usually 
used to identify an initial market segment for a new product launch.  In a similar manner, here it is used to 
identify the most appropriate type of organisation to partner with.  A higher score indicates a more favourable 
option.  
Key Criteria for 
Partner 
Selection 
Segment 1 
Research 
Councils and 
Philanthropists 
Segment 2 
PDP Brokers 
Segment 3 
Large 
Pharmaceutical 
Companies 
Segment 4 
Biotechnology 
Companies 
Is the partner 
well-funded? 
Are they readily 
accessible? 
4 3 5 3 
Do they have a 
compelling 
reason to 
partner with us? 
5 5 3 2 
Can we, with the 
help of the 
partner, deliver 
a whole product 
to the market? 
2 5 5 3 
Is there no 
entrenched 
competition that 
could prevent 
us from getting 
a fair shot? 
3 3 4 4 
If we enter into 
partnership, will 
their references 
allow us to 
leverage entry 
into additional 
partnerships 
with others? 
4 5 4 3 
Total Score 
(5=high/certainly, 
3=medium, 
1=low/unsure) 
18 21 21 15 
 
Using Moore’s market segment rating grid(423), it is possible to compare the relative strengths 
of potential partners (or ‘market segments’).  PDP brokers and large pharmaceutical firms 
appear as the best initial partners.  In reality, partnership with one type of third party does not 
preclude a partnership with another.  The analysis does highlight PDP brokers as the most 
appropriate partner for a number of reasons.  They have access to funds, they have extensive 
networks with which to find partners and they have project management capabilities.  Large 
pharmaceutical companies share many of these capabilities.  However, PDP brokers have a 
business model that is designed specifically for the development of NTD products.  A large 
pharmaceutical company may actually be limited by their business model, which requires profit, 
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so a third party may need to be engaged to support non-profitable efforts, as has been the case 
with some NTD products developed in partnership with them.   
From an academic/PSNRI researcher’s perspective, an important advantage of engaging with 
one of the two preferred partners is that it relieves them of the significant effort of securing funds 
for several different development activities and then constructing partnership agreements with 
numerous third parties.  One concern in “handing off” projects, particularly when IP is sold or 
licensed without further participation from the inventors, is a loss of control over the progression 
of the product’s development.  Large pharmaceutical companies are sometimes forced to 
discontinue the development of a project for financial reasons(72).  In this respect, either 
engaging a PDP or ensuring that partnership agreements involve continued participation would 
be a safer option. 
In NTD product R&D, royalties are generally not a concern for academics/PSNRIs.  However, 
this would be more of a concern if a new company was formed around the IP.  For the institution 
as a whole, forming a new company and taking equity in it can have a significantly higher return 
than licensing to third parties(424).  Given the desire for profitability for traditional start-up 
funders (i.e. venture capitalists) it would not be advisable to follow this strategy, in the absence 
of a product that can become profitable. 
From a public health perspective, the most favourable outcome is an effective new drug to treat 
trypanosomiasis that is made available to the target population within the shortest time possible, 
and at the lowest cost to all parties involved.  It is clear that the available evidence strongly 
points to the PDP model as the most effective approach to achieve this(57,72). 
4.4.9 Evidence for Partnerships 
 
Figure 4.4.4 - Summary of the pharmaceutical development lifecycle, from discovery to registration and approval.  
Timelines and patient numbers informed by DiMasi et al.(425), S Blank(426) and the FDA(427).  
4.4.9.1 Technology transfer in the pharmaceutical industry 
Co-development partnerships are not unique to the NTD field, where pharmaceuticals are 
concerned.  When seeking a partner, it is important to understand their motivations for entering 
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a partnership, as well as anything that may discourage a potential partner from entering into an 
agreement.  An analysis of the evidence to support a particular project is warranted. 
Pharmaceutical development can be an incredibly costly and risky process.  An analysis of drug 
development success rates showed that only 19% of drugs entering clinical trials between 1993 
and 2004 eventually attained clinical approval.  This number was a little higher for co-developed 
(in-licensed or out-licensed drugs), than for drugs developed solely by one of the 50 
pharmaceutical companies analysed in the study (27% vs. 16%).  This may indicate that the 
licensors of new drugs usually prove efficacy at phase I or phase II, before licensing out to a 
third party.  Encouragingly, systemic anti-infective drugs had a higher success rate of 24%, 
particularly at the transition from phase II to phase III development.  This may be due to clearer 
clinical end points(428).   Achieving the dual objectives of forming an effective partnership and 
eventually gaining clinical approval rely heavily on gaining evidence to support your project. 
In an analysis of biologic drug licensing deals from biotechnology to large pharmaceutical 
companies, Kalamus and Pinkus report that the majority of deals occur between the preclinical 
phase and phase II.  However, phase II appears to be the preferred time(429).   
In their analysis, Kalamas and Pinkus show that both parties could generate value by entering 
into agreements earlier.  Under-pricing by large pharmaceutical companies was stated as a 
cause of delayed deal making(429).  With this problem removed in the case of not-for profit 
endeavours, deals should be made earlier, so that researchers can start to exploit the 
capabilities of their better-resourced partners sooner.  
It has been reported that, after a shift towards deals made after in-human proof-of-concept, 
early-stage pharmaceutical industry deals are re-emerging: they represented more than 60% of 
‘big buyer’ deals in 2011-2012.  Large pharmaceutical companies are also forming more early-
stage partnerships directly with academia.  These partnerships often involve payments at 
milestones, when key research objectives have been met.  They are sometimes tied to ‘options’ 
where, at the completion of all research objectives (i.e. phase II trials), the company can acquire 
the IP, or even an IP-holding company (where a small company is involved).  This kind of 
arrangement allows the large companies to reduce their exposure to risk, whilst still enabling 
researchers to advance projects(430).  
4.4.9.2 When to partner and with what supporting evidence 
The most favourable time to start partnering largely depends on the commercialisation strategy 
followed by the researchers.  In the absence of commercial considerations, it would even be 
advantageous to seek partners at the discovery phase.  If an academic/PSNRI researcher is 
developing a product that may have some commercial value, then they may wish to attempt 
technology transfer later in the development lifecycle.  In either case, researchers in an 
academic/PSNRI or in a small company may reach what is often termed “The Valley of Death” 
or the “Darwinian Sea”, which is the point where more funds are required to develop a product, 
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but there is a lack of willing partners to fund the development of a product, which may still carry 
a high risk of failure(431,432).  As highlighted by Kalamas & Pinkus, having the opportunity to 
use the capabilities of a well-resourced partner, early in the development process, should also 
be seen as an advantage(429). 
The vast sums of money and significant amount of labour required to optimise products and 
demonstrate their safety can be out of the reach of most academic/PSNRI researchers(70).  It 
can cost hundreds of thousands of dollars to outsource labour-intensive tasks, and in vitro and 
in vivo toxicology studies can cost over US$ 1million(394).  Animal studies, which can be very 
expensive, can play a vital role in demonstrating efficacy(431).  In these situations, an 
alternative to licensing to industry is to partner with a well-resourced academic drug discovery 
centre to carry out some of this work(70).  There are also a number of programs to support 
translational research originating from academic/PSNRI research.  One such program is the 
NIH’s Therapeutics for Rare and Neglected Diseases program (TRND).  TRND aims to 
collaborate with researchers of rare and neglected diseases “with the goal of moving promising 
therapeutics into human trials”(433). 
Aside from gaining access to funding, there are other advantages to partnering with larger 
partners (e.g. pharmaceutical companies) which are due to the partner’s greater experience.  A 
review of strategic alliances between biotech companies and pharmaceutical companies 
between 1988 and 2000, gives some clues as to what these advantages are.  It was shown that 
in the more complex trials of phase II and phase III, a drug is significantly more likely to proceed 
to the next phase, if the licensee (e.g. large pharmaceutical company) has more experience.  In 
phase I trials, which are less complex, there is only a small advantage in this respect(434). 
An advantage of being affiliated to academic institutions or PSNRI is that the capabilities (e.g. 
biological and clinical expertise) of the institution can be made use of at several points in the 
lifecycle, as has been done in the development of other products for NTDs or low-income 
markets (435).  Many academic institutions are now engaged in translational research and there 
are several established ‘drug discovery centres’ at institutions across the US(70,71).  However, 
once large scale trials are needed, these institutions become limited, so one should seek to 
partner with a PDP broker and/or large pharmaceutical company, and an organisation 
experienced in public health (e.g. WHO, MSF). 
There are now several studies that can be used to ‘de-risk’ drug development projects(436).  
They are often used in a standardised way in the pharmaceutical industry, but it is often said 
that, in respect to these studies, expectations held by licensees in large pharmaceutical 
companies and their licensors, are mismatched.  There is little specific information on these 
expectations and how they affect the partnering decisions of funders of NTD product R&D.  
Thus, this will be the subject of future research. 
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The reader is referred to the appendix for more details on alternative strategies for developing 
drugs for NTDs. 
4.4.10 The NTD R&D landscape 
A dramatic increase in awareness and advocacy for NTD product R&D has been witnessed 
over the last decade.  This is evident in the increased activity in the area and the evolution in 
product development and commercialisation strategies.  Public-Private partnerships have 
always been a feature of NTD product R&D, but the emergence of the PDP as the primary 
model for product development is welcome progress.  Unfortunately, reports of funding 
inconsistencies and research gaps for some diseases persist(52,396).  Following the global 
financial crisis, there has been a decrease in funding from philanthropic sources and some 
government aid agencies.  This is of concern because they are the principal funders of 
PDPs(66).  Despite these concerns, researchers working towards developing products for NTDs 
are in a better position to do so than a decade ago.  In addition to the increased funding and 
awareness, the experience of others is providing evidence of several new ways to attract 
funding to the cause.  Researchers and other stakeholders of NTD product development should 
also look to the future, as new incentives, such as tax credits(437,438) and Medical R&D 
treaties(439), could result from recent proposals. 
Limitations of this analysis 
This research has aimed at providing insight into the main considerations to be taken account of 
when developing a treatment for a NTD.  Thus, many aspects of pharmaceutical R&D, and how 
it is carried out for NTDs, have been broadly reviewed.  However, in reality, some concerns, 
such as the specifics of licensing deals, intellectual property and target product profiles all 
demand deep analyses of their own.  These concerns have all been eluded to here, but deeper 
analyses have focused on the most important and immediate problems faced when advancing 
this research.  Specific evidence on the best stage of development to transfer technology was 
found to be lacking, so this will be the subject of future research.  
 
4.4.10.1 How to commercialise this research 
Opinion on the best course of action 
Given the therapeutic area, the most appropriate mechanism for commercialising the results of 
this research would be through licensing to external partners.  In the absence of other, profitable 
indications, the effort and seed capital required to found a spin-out company would not be worth 
it.  If the drug/series of compounds showed efficacy in diseases with a market, then 
commercialisation along those lines should be carried out separately through licensing of the 
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original IP.  Profits from those endeavours could be used to support development of the original 
product. 
A large, well-resourced partner, such as a PDP broker or large pharmaceutical company, may 
be sought for partnership as early as possible to make use of their capabilities and accelerate 
development.  Ownership of IP and research objectives should be agreed upon and aligned as 
early as possible, to prevent any issues once co-development starts. 
PDP brokers seem to engage with researchers once a viable product (e.g. a lead compound 
with some in vitro efficacy) has been found.  Therefore, with this research, a partnership with a 
pharmaceutical or biotechnology firm should be used to bring the research to this point. 
The greatest possible number of funding sources, government incentives and other support 
should be taken advantage of.  The options will be different, depending on the 
commercialisation route followed; different options are available to non-profit organisations than 
to for-profit organisations.  Drawing support from numerous sources is advantageous and may 
prove to be essential to advance a product all the way to the market.
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4.4.11 Development of a drug for a neglected tropical disease 
With the emergent interest in combating neglected tropical diseases (NTDs), one can find 
numerous collaborators for drug discovery and development of NTD drugs.  Academia, industry 
and not-for-profits are all represented amongst the cohort of NTD stakeholders. 
The work presented in this thesis is an example of academic drug discovery in the early stages 
of the drug development lifecycle.  In order to complete the necessary experiments, numerous 
collaborations were formed both within UCL and outside of the institution.  First of all, access to 
relevant resources and enabling technologies was provided by funding from the University’s 
technology transfer company, UCL Business, and by working with colleagues at UCL 
Chemibank and the UCL Institute for Liver and Digestive Health.  As stated above, the 
trypanosome growth inhibition assays carried out by Professor Kelly at the LSHTM were 
essential parts of this study.  Future work could also be driven by similar collaborations.  For 
example, NMR and mass spectrometry facilities are available for the analysis of inhibitors in the 
UCL Department of Chemistry and at the UCL Royal Free Campus.  
Despite the achievements demonstrated so far, many challenges are faced when carrying out 
drug discovery in an academic environment.  Drug discovery inherently involves the collection 
of vast amounts of data.  Without automation, in the form of plate readers and liquid handling 
equipment, etc., this data collection can be very lengthy and laborious.  Additionally, there is a 
requirement for certain stages of the drug discovery process to be completed within a timely 
manner.  Therefore, resourcing drug discovery, in terms of material, labour and finances, can be 
a challenge in academia.  Industrial partners tend to have more resources, are better prepared 
to carry out drug discovery and often make use of automation for the large-scale collection of 
data.  Moreover, industrial partners, particularly large pharmaceutical companies, are more 
capable of sharing their capabilities in-kind.  Overall, drug discovery experience and expertise is 
concentrated in industry.  There are now several companies in the pharmaceutical industry that 
are active in NTD drug development and they are an excellent choice of partner for drug 
discovery. 
To finance drug discovery, there are numerous grants available from government and not for 
profit institutions.  This can help to advance development to a later stage, where more 
opportunities for partnership and more funds may be available. 
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7. Appendix 
7.1 Virtual Screening 
Table 7.1.1 - List of ZINC codes identifying all ligands from the NCI diversity set II.  Where ZINC codes are 
repeated, there are multiple tautomers available for that ligand, all of which were included in the screening 
assay. 
ZINC00000171 ZINC01572767 ZINC01706234 ZINC04771299 ZINC12341271 ZINC15990220 
ZINC00000179 ZINC01572960 ZINC01706740 ZINC04773602 ZINC12341321 ZINC15990245 
ZINC00000570 ZINC01572961 ZINC01706914 ZINC04775687 ZINC12341336 ZINC15990245 
ZINC00001018 ZINC01572962 ZINC01706915 ZINC04775707 ZINC12358863 ZINC15990245 
ZINC00001087 ZINC01572963 ZINC01707109 ZINC04775893 ZINC12363224 ZINC15990251 
ZINC00001228 ZINC01573467 ZINC01707130 ZINC04776634 ZINC12367936 ZINC15990251 
ZINC00001522 ZINC01573517 ZINC01707215 ZINC04777715 ZINC12368248 ZINC15990251 
ZINC00001785 ZINC01573531 ZINC01707482 ZINC04777716 ZINC12368665 ZINC15990251 
ZINC00001791 ZINC01573541 ZINC01707724 ZINC04777790 ZINC12417345 ZINC16051261 
ZINC00001947 ZINC01573829 ZINC01708688 ZINC04777791 ZINC12417345 ZINC16051261 
ZINC00002036 ZINC01573978 ZINC01709784 ZINC04777934 ZINC12504140 ZINC16051261 
ZINC00002106 ZINC01574246 ZINC01709785 ZINC04777935 ZINC12504141 ZINC16920429 
ZINC00005155 ZINC01574310 ZINC01710091 ZINC04777936 ZINC12504142 ZINC16920429 
ZINC00013246 ZINC01574615 ZINC01710099 ZINC04777937 ZINC12670903 ZINC16941278 
ZINC00014894 ZINC01574620 ZINC01710435 ZINC04783080 ZINC12670909 ZINC16948978 
ZINC00021557 ZINC01574971 ZINC01710961 ZINC04783140 ZINC12670914 ZINC16948978 
ZINC00024336 ZINC01575013 ZINC01711028 ZINC04783204 ZINC12670920 ZINC16948978 
ZINC00028671 ZINC01575013 ZINC01711796 ZINC04783229 ZINC12670933 ZINC16948978 
ZINC00031164 ZINC01575102 ZINC01712457 ZINC04783478 ZINC12671128 ZINC16948978 
ZINC00031165 ZINC01576406 ZINC01712458 ZINC04783479 ZINC12671501 ZINC16951318 
ZINC00031410 ZINC01577602 ZINC01712637 ZINC04783480 ZINC12671506 ZINC16951318 
ZINC00035663 ZINC01577889 ZINC01712658 ZINC04783481 ZINC12671886 ZINC16951320 
ZINC00035871 ZINC01578220 ZINC01712744 ZINC04786808 ZINC12671893 ZINC16951320 
ZINC00039221 ZINC01578333 ZINC01712829 ZINC04786811 ZINC12671898 ZINC16951320 
ZINC00039435 ZINC01579461 ZINC01712830 ZINC04786814 ZINC12671904 ZINC16954225 
ZINC00039490 ZINC01579687 ZINC01712866 ZINC04791992 ZINC12672222 ZINC16969114 
ZINC00041118 ZINC01579723 ZINC01713460 ZINC04797042 ZINC12672225 ZINC16978136 
ZINC00054469 ZINC01579734 ZINC01714961 ZINC04800001 ZINC12672231 ZINC16978136 
ZINC00056624 ZINC01579740 ZINC01714962 ZINC04821670 ZINC12672242 ZINC17105710 
ZINC00057263 ZINC01579877 ZINC01716722 ZINC04821957 ZINC12672252 ZINC17105710 
ZINC00057264 ZINC01580992 ZINC01717579 ZINC04822288 ZINC12959181 ZINC17108282 
ZINC00057677 ZINC01581342 ZINC01718481 ZINC04822383 ZINC13000556 ZINC17125976 
ZINC00057716 ZINC01581709 ZINC01718482 ZINC04822746 ZINC13042892 ZINC17147424 
ZINC00058294 ZINC01582372 ZINC01718485 ZINC04822747 ZINC13042892 ZINC17147426 
ZINC00061529 ZINC01583123 ZINC01718486 ZINC04823467 ZINC13086327 ZINC17147429 
ZINC00065175 ZINC01583649 ZINC01718899 ZINC04824022 ZINC13086327 ZINC17147431 
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ZINC00065182 ZINC01583786 ZINC01718905 ZINC04824024 ZINC13099024 ZINC17149563 
ZINC00066629 ZINC01584497 ZINC01719297 ZINC04824645 ZINC13099025 ZINC17149566 
ZINC00068268 ZINC01584862 ZINC01719567 ZINC04824902 ZINC13099027 ZINC17149568 
ZINC00073731 ZINC01585729 ZINC01719937 ZINC04830956 ZINC13099047 ZINC17149570 
ZINC00075241 ZINC01586128 ZINC01719953 ZINC04831099 ZINC13099048 ZINC17285513 
ZINC00076793 ZINC01586252 ZINC01721304 ZINC04831099 ZINC13099050 ZINC17285513 
ZINC00080747 ZINC01586330 ZINC01722140 ZINC04877299 ZINC13099051 ZINC17287324 
ZINC00081505 ZINC01586453 ZINC01722585 ZINC04878491 ZINC13099284 ZINC17287328 
ZINC00081510 ZINC01587328 ZINC01724003 ZINC04879418 ZINC13099549 ZINC17287332 
ZINC00084613 ZINC01587338 ZINC01724376 ZINC04887389 ZINC13099550 ZINC17287336 
ZINC00084617 ZINC01587338 ZINC01724593 ZINC04887558 ZINC13099551 ZINC17303059 
ZINC00084716 ZINC01588812 ZINC01724660 ZINC04896131 ZINC13110586 ZINC17353911 
ZINC00085895 ZINC01589060 ZINC01725942 ZINC04896472 ZINC13110587 ZINC17353912 
ZINC00086102 ZINC01589436 ZINC01726729 ZINC04896601 ZINC13110587 ZINC17353913 
ZINC00091200 ZINC01589497 ZINC01726736 ZINC04900076 ZINC13115350 ZINC17353914 
ZINC00091560 ZINC01589627 ZINC01726776 ZINC04900874 ZINC13115350 ZINC17375647 
ZINC00092157 ZINC01590480 ZINC01728118 ZINC04901375 ZINC13125763 ZINC17375649 
ZINC00093738 ZINC01590864 ZINC01728119 ZINC04918956 ZINC13125763 ZINC17375651 
ZINC00094441 ZINC01590927 ZINC01728120 ZINC04918963 ZINC13125795 ZINC17375653 
ZINC00095158 ZINC01591881 ZINC01728503 ZINC04918969 ZINC13125795 ZINC17379198 
ZINC00099494 ZINC01591915 ZINC01728821 ZINC04934182 ZINC13130011 ZINC17419163 
ZINC00099827 ZINC01591950 ZINC01728888 ZINC04962003 ZINC13130011 ZINC17419163 
ZINC00100248 ZINC01591957 ZINC01729467 ZINC04963162 ZINC13130011 ZINC17419163 
ZINC00102611 ZINC01592023 ZINC01729523 ZINC04963453 ZINC13130015 ZINC17424892 
ZINC00104475 ZINC01592410 ZINC01729524 ZINC04963778 ZINC13130016 ZINC17424892 
ZINC00105181 ZINC01592974 ZINC01729525 ZINC04963779 ZINC13130018 ZINC17465817 
ZINC00105309 ZINC01593556 ZINC01729526 ZINC04974338 ZINC13130018 ZINC17465824 
ZINC00110358 ZINC01593739 ZINC01729549 ZINC04974725 ZINC13130035 ZINC17465958 
ZINC00110365 ZINC01595620 ZINC01729578 ZINC04984366 ZINC13130183 ZINC17465965 
ZINC00113222 ZINC01596285 ZINC01729618 ZINC04990829 ZINC13130187 ZINC17465972 
ZINC00113984 ZINC01596698 ZINC01730238 ZINC05011996 ZINC13130187 ZINC17465979 
ZINC00115489 ZINC01597168 ZINC01731085 ZINC05011999 ZINC13130211 ZINC17465983 
ZINC00116869 ZINC01599183 ZINC01732051 ZINC05015095 ZINC13130211 ZINC17529946 
ZINC00117074 ZINC01601483 ZINC01732509 ZINC05027641 ZINC13132551 ZINC17529946 
ZINC00117074 ZINC01602509 ZINC01733235 ZINC05030617 ZINC13132551 ZINC17729070 
ZINC00119004 ZINC01602510 ZINC01733511 ZINC05033796 ZINC13136204 ZINC17729070 
ZINC00119372 ZINC01602855 ZINC01734080 ZINC05064462 ZINC13136204 ZINC17820077 
ZINC00121415 ZINC01602856 ZINC01734092 ZINC05086138 ZINC13139292 ZINC17858074 
ZINC00126096 ZINC01602938 ZINC01734413 ZINC05086225 ZINC13139292 ZINC17858074 
ZINC00135449 ZINC01602938 ZINC01734846 ZINC05105895 ZINC13139298 ZINC17858074 
ZINC00135453 ZINC01603961 ZINC01735469 ZINC05114817 ZINC13139306 ZINC17860685 
ZINC00135673 ZINC01604104 ZINC01735767 ZINC05115990 ZINC13139308 ZINC17860685 
ZINC00136890 ZINC01604214 ZINC01735773 ZINC05120864 ZINC13139308 ZINC17860685 
ZINC00136892 ZINC01605775 ZINC01736227 ZINC05120916 ZINC13139316 ZINC17861701 
422 
 
ZINC00136893 ZINC01606051 ZINC01736228 ZINC05120916 ZINC13139317 ZINC17861701 
ZINC00136894 ZINC01607786 ZINC01737161 ZINC05120920 ZINC13139331 ZINC17878196 
ZINC00137148 ZINC01608678 ZINC01737351 ZINC05120920 ZINC13140104 ZINC17885079 
ZINC00137187 ZINC01608684 ZINC01738764 ZINC05124931 ZINC13140224 ZINC17885079 
ZINC00137189 ZINC01608764 ZINC01738918 ZINC05124957 ZINC13140224 ZINC17886718 
ZINC00138096 ZINC01608817 ZINC01739349 ZINC05124960 ZINC13140225 ZINC17886718 
ZINC00138986 ZINC01608819 ZINC01739733 ZINC05137909 ZINC13140225 ZINC17949075 
ZINC00139367 ZINC01609078 ZINC01740602 ZINC05137909 ZINC13140234 ZINC17949075 
ZINC00139370 ZINC01609695 ZINC01741812 ZINC05176310 ZINC13140243 ZINC17949075 
ZINC00141916 ZINC01615121 ZINC01742542 ZINC05176310 ZINC13140243 ZINC17968970 
ZINC00143079 ZINC01616692 ZINC01744749 ZINC05180959 ZINC13140245 ZINC17968970 
ZINC00143743 ZINC01617170 ZINC01744953 ZINC05193477 ZINC13140246 ZINC17968970 
ZINC00145517 ZINC01617301 ZINC01745539 ZINC05193477 ZINC13140246 ZINC17970262 
ZINC00150151 ZINC01620955 ZINC01747258 ZINC05201470 ZINC13142971 ZINC17970262 
ZINC00151887 ZINC01621536 ZINC01747274 ZINC05208303 ZINC13142972 ZINC17995347 
ZINC00154608 ZINC01621931 ZINC01747299 ZINC05217440 ZINC13142989 ZINC17995347 
ZINC00154792 ZINC01621981 ZINC01747332 ZINC05217831 ZINC13142989 ZINC17995347 
ZINC00154832 ZINC01621997 ZINC01748006 ZINC05220390 ZINC13142991 ZINC18006265 
ZINC00154888 ZINC01622198 ZINC01748056 ZINC05220390 ZINC13142991 ZINC18006265 
ZINC00155089 ZINC01622269 ZINC01748097 ZINC05220390 ZINC13142993 ZINC18006265 
ZINC00155292 ZINC01625052 ZINC01748594 ZINC05279843 ZINC13143008 ZINC18010927 
ZINC00155857 ZINC01625094 ZINC01748908 ZINC05328871 ZINC13143009 ZINC18010927 
ZINC00156701 ZINC01625106 ZINC01749571 ZINC05369992 ZINC13143011 ZINC18030775 
ZINC00157210 ZINC01625114 ZINC01751425 ZINC05386901 ZINC13143011 ZINC18030775 
ZINC00157625 ZINC01625418 ZINC01751437 ZINC05390066 ZINC13143017 ZINC18038389 
ZINC00160306 ZINC01625444 ZINC01752308 ZINC05390471 ZINC13143019 ZINC18038389 
ZINC00160781 ZINC01625746 ZINC01752784 ZINC05392913 ZINC13143021 ZINC18043993 
ZINC00161631 ZINC01626802 ZINC01752973 ZINC05420911 ZINC13144115 ZINC18043993 
ZINC00161700 ZINC01626803 ZINC01753336 ZINC05420911 ZINC13144116 ZINC18055497 
ZINC00163247 ZINC01627101 ZINC01753723 ZINC05421282 ZINC13144542 ZINC18056732 
ZINC00163657 ZINC01627302 ZINC01753725 ZINC05421282 ZINC13144560 ZINC18056732 
ZINC00166215 ZINC01627329 ZINC01753735 ZINC05421739 ZINC13144560 ZINC18056732 
ZINC00188345 ZINC01627377 ZINC01753761 ZINC05421739 ZINC13144564 ZINC18056840 
ZINC00204666 ZINC01627439 ZINC01754899 ZINC05422109 ZINC13144566 ZINC18056840 
ZINC00214590 ZINC01628211 ZINC01755448 ZINC05422109 ZINC13144568 ZINC18057104 
ZINC00217297 ZINC01629421 ZINC01755627 ZINC05424472 ZINC13144613 ZINC18057104 
ZINC00225990 ZINC01629569 ZINC01757986 ZINC05424474 ZINC13144614 ZINC18057104 
ZINC00226959 ZINC01629851 ZINC01761347 ZINC05424691 ZINC13144616 ZINC18057933 
ZINC00227103 ZINC01632739 ZINC01761361 ZINC05424691 ZINC13144618 ZINC18057933 
ZINC00235625 ZINC01633473 ZINC01761642 ZINC05430677 ZINC13144621 ZINC18061739 
ZINC00235981 ZINC01633669 ZINC01761875 ZINC05434498 ZINC13145027 ZINC18067025 
ZINC00247785 ZINC01635676 ZINC01761888 ZINC05439444 ZINC13145028 ZINC18067025 
ZINC00258800 ZINC01635813 ZINC01764014 ZINC05439444 ZINC13145029 ZINC18067025 
ZINC00270777 ZINC01635835 ZINC01820901 ZINC05452603 ZINC13145030 ZINC18068040 
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ZINC00274634 ZINC01635869 ZINC01820901 ZINC05452603 ZINC13146918 ZINC18068040 
ZINC00274689 ZINC01637135 ZINC01834023 ZINC05459826 ZINC13146942 ZINC18068788 
ZINC00282116 ZINC01637139 ZINC01843029 ZINC05462670 ZINC13146950 ZINC18083898 
ZINC00283058 ZINC01637206 ZINC01843029 ZINC05462674 ZINC13146950 ZINC18083898 
ZINC00292958 ZINC01637653 ZINC01843030 ZINC05479118 ZINC13146954 ZINC18085106 
ZINC00293214 ZINC01638088 ZINC01843030 ZINC05479451 ZINC13146954 ZINC18085106 
ZINC00304325 ZINC01638353 ZINC01843071 ZINC05487838 ZINC13146957 ZINC18085106 
ZINC00306008 ZINC01638368 ZINC01845586 ZINC05487838 ZINC13152217 ZINC18098114 
ZINC00323854 ZINC01639633 ZINC01845598 ZINC05492794 ZINC13152217 ZINC18098114 
ZINC00329885 ZINC01639634 ZINC01846592 ZINC05493068 ZINC13152219 ZINC18098743 
ZINC00330473 ZINC01640145 ZINC01846592 ZINC05493736 ZINC13152221 ZINC18098743 
ZINC00330473 ZINC01640193 ZINC01848197 ZINC05498636 ZINC13152223 ZINC18098743 
ZINC00331547 ZINC01640205 ZINC01848198 ZINC05498636 ZINC13152225 ZINC18098743 
ZINC00331745 ZINC01640219 ZINC01855333 ZINC05499702 ZINC13152226 ZINC18107657 
ZINC00332365 ZINC01641160 ZINC01856534 ZINC05499876 ZINC13152237 ZINC18117772 
ZINC00337138 ZINC01641244 ZINC01865671 ZINC05499876 ZINC13152238 ZINC18121761 
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ZINC00387464 ZINC01644254 ZINC01871349 ZINC05518987 ZINC13152249 ZINC18141142 
ZINC00389747 ZINC01645454 ZINC01872881 ZINC05536814 ZINC13152277 ZINC18141294 
ZINC00389762 ZINC01646278 ZINC01873142 ZINC05541927 ZINC13152277 ZINC18141294 
ZINC00392897 ZINC01646387 ZINC02011568 ZINC05541929 ZINC13152278 ZINC18141294 
ZINC00393546 ZINC01646690 ZINC02015922 ZINC05541931 ZINC13152279 ZINC18141294 
ZINC00393598 ZINC01648249 ZINC02018030 ZINC05541933 ZINC13152282 ZINC18141294 
ZINC00393599 ZINC01649010 ZINC02018030 ZINC05550368 ZINC13152284 ZINC18142874 
ZINC00393651 ZINC01649013 ZINC02029995 ZINC05550368 ZINC13152291 ZINC18153859 
ZINC00393674 ZINC01649032 ZINC02030136 ZINC05550663 ZINC13152292 ZINC18153859 
ZINC00393856 ZINC01652261 ZINC02033748 ZINC05550663 ZINC13152294 ZINC18154478 
ZINC00393885 ZINC01652969 ZINC02034999 ZINC05550666 ZINC13152611 ZINC18154478 
ZINC00394316 ZINC01652984 ZINC02035165 ZINC05550666 ZINC13152612 ZINC18154478 
ZINC00394330 ZINC01652986 ZINC02036484 ZINC05551091 ZINC13152612 ZINC18156788 
ZINC00395036 ZINC01653222 ZINC02036556 ZINC05551091 ZINC13152613 ZINC18156788 
ZINC00395364 ZINC01655764 ZINC02038558 ZINC05551091 ZINC13152613 ZINC18157167 
ZINC00395576 ZINC01655914 ZINC02042220 ZINC05551760 ZINC13152614 ZINC18163183 
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ZINC00395872 ZINC01656026 ZINC02042811 ZINC05551760 ZINC13152615 ZINC18163421 
ZINC00397002 ZINC01656027 ZINC02042840 ZINC05552274 ZINC13152615 ZINC18163421 
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ZINC00399404 ZINC01665042 ZINC02154763 ZINC05580712 ZINC13154304 ZINC18173699 
ZINC00399512 ZINC01665187 ZINC02169824 ZINC05580712 ZINC13154305 ZINC18178799 
ZINC00400127 ZINC01665192 ZINC02476372 ZINC05581222 ZINC13154306 ZINC18183236 
ZINC00400410 ZINC01665194 ZINC02476372 ZINC05581222 ZINC13154307 ZINC18189380 
ZINC00400541 ZINC01665334 ZINC02476372 ZINC05581974 ZINC13154313 ZINC18189380 
ZINC00401809 ZINC01665703 ZINC02515938 ZINC05581974 ZINC13154314 ZINC18189380 
ZINC00404349 ZINC01665708 ZINC02670038 ZINC05594334 ZINC13154315 ZINC18192390 
ZINC00404427 ZINC01665801 ZINC02952832 ZINC05594334 ZINC13154315 ZINC18192390 
ZINC00404427 ZINC01665928 ZINC03100631 ZINC05640172 ZINC13154317 ZINC18193021 
ZINC00404427 ZINC01665940 ZINC03157611 ZINC05640410 ZINC13154317 ZINC18193844 
ZINC00404472 ZINC01666192 ZINC03258337 ZINC05640410 ZINC13154319 ZINC18193844 
ZINC00407984 ZINC01666568 ZINC03310974 ZINC05640600 ZINC13154320 ZINC18193844 
ZINC00408303 ZINC01666997 ZINC03647770 ZINC05640620 ZINC13154321 ZINC18207613 
ZINC00408598 ZINC01668114 ZINC03830315 ZINC05641037 ZINC13154324 ZINC18211623 
ZINC00409811 ZINC01668253 ZINC03830316 ZINC05647206 ZINC13154325 ZINC18212500 
ZINC00409897 ZINC01668429 ZINC03831067 ZINC05647206 ZINC13154326 ZINC18213583 
ZINC00410187 ZINC01668491 ZINC03831068 ZINC05647206 ZINC13154328 ZINC18217586 
ZINC00410188 ZINC01668601 ZINC03832421 ZINC05662861 ZINC13154328 ZINC18219562 
ZINC00410244 ZINC01668706 ZINC03832421 ZINC05664697 ZINC13154329 ZINC18219564 
ZINC00410252 ZINC01668896 ZINC03845141 ZINC05664697 ZINC13154329 ZINC18227443 
ZINC00410253 ZINC01669376 ZINC03850501 ZINC05665089 ZINC13207617 ZINC18825330 
ZINC00410269 ZINC01669572 ZINC03860856 ZINC05709639 ZINC13207617 ZINC18847035 
ZINC00410269 ZINC01669828 ZINC03860920 ZINC05723045 ZINC13208966 ZINC19205460 
ZINC00410312 ZINC01670127 ZINC03860960 ZINC05723051 ZINC13281671 ZINC19230120 
ZINC00433226 ZINC01670214 ZINC03860960 ZINC05732213 ZINC13282591 ZINC19322683 
ZINC00434844 ZINC01670291 ZINC03875548 ZINC05782788 ZINC13284902 ZINC19325788 
ZINC00442499 ZINC01670341 ZINC03878829 ZINC05785035 ZINC13451125 ZINC19325788 
ZINC00444253 ZINC01670393 ZINC03881813 ZINC05785035 ZINC13522091 ZINC19325788 
ZINC00475774 ZINC01670696 ZINC03881918 ZINC05810714 ZINC13542620 ZINC19325791 
ZINC00513614 ZINC01670877 ZINC03884497 ZINC05810741 ZINC13542620 ZINC19325791 
ZINC00538110 ZINC01671311 ZINC03884497 ZINC05824155 ZINC13542876 ZINC19325794 
ZINC00563913 ZINC01671321 ZINC03898665 ZINC05834946 ZINC13542876 ZINC19325794 
ZINC00600322 ZINC01671640 ZINC03898710 ZINC05834946 ZINC13597216 ZINC19325794 
ZINC00601312 ZINC01671654 ZINC03898822 ZINC05844151 ZINC13597216 ZINC19325794 
ZINC00607731 ZINC01671866 ZINC03947435 ZINC05979393 ZINC13597218 ZINC19362650 
ZINC00608128 ZINC01671868 ZINC03953394 ZINC05993141 ZINC13597218 ZINC19362651 
ZINC00608205 ZINC01671896 ZINC03953472 ZINC05997896 ZINC13597219 ZINC19366110 
ZINC00611334 ZINC01672033 ZINC03953805 ZINC06092501 ZINC13597219 ZINC19366557 
ZINC00611335 ZINC01672062 ZINC03953810 ZINC06092501 ZINC13597222 ZINC19456377 
ZINC00615883 ZINC01672214 ZINC03953920 ZINC06092503 ZINC13597222 ZINC19456379 
425 
 
ZINC00625965 ZINC01672597 ZINC03954247 ZINC06092503 ZINC13597230 ZINC19632726 
ZINC00639634 ZINC01672599 ZINC03954311 ZINC06095736 ZINC13597230 ZINC19701771 
ZINC00640726 ZINC01673377 ZINC03954351 ZINC06095736 ZINC13597232 ZINC19735376 
ZINC00640777 ZINC01673464 ZINC03954397 ZINC06188101 ZINC13597232 ZINC19735376 
ZINC00641093 ZINC01674390 ZINC03954507 ZINC06343280 ZINC13597237 ZINC19794764 
ZINC00641146 ZINC01674410 ZINC03954520 ZINC06381592 ZINC13597237 ZINC19794765 
ZINC00642588 ZINC01674943 ZINC03954552 ZINC06511573 ZINC13597273 ZINC19799271 
ZINC00728291 ZINC01675432 ZINC03954626 ZINC06511573 ZINC13597273 ZINC19909409 
ZINC00810178 ZINC01675804 ZINC03958471 ZINC06511656 ZINC13597276 ZINC19923695 
ZINC00815686 ZINC01675857 ZINC04006098 ZINC06511656 ZINC13597276 ZINC19923697 
ZINC00838233 ZINC01675858 ZINC04015433 ZINC06511739 ZINC13597278 ZINC20028475 
ZINC00849668 ZINC01675990 ZINC04015715 ZINC06511739 ZINC13597278 ZINC20421310 
ZINC00849668 ZINC01676023 ZINC04027061 ZINC06511825 ZINC13597281 ZINC21673561 
ZINC00896836 ZINC01676138 ZINC04027061 ZINC06511825 ZINC13597281 ZINC22267016 
ZINC00900951 ZINC01676139 ZINC04095812 ZINC06513204 ZINC13597298 ZINC22586514 
ZINC00967339 ZINC01676213 ZINC04127920 ZINC06513204 ZINC13597298 ZINC22910159 
ZINC00968360 ZINC01676257 ZINC04164657 ZINC06513918 ZINC13597334 ZINC22910179 
ZINC00977107 ZINC01676311 ZINC04212654 ZINC06513918 ZINC13597335 ZINC22910859 
ZINC00984004 ZINC01677276 ZINC04213833 ZINC06520320 ZINC13597335 ZINC22910942 
ZINC00990239 ZINC01677554 ZINC04213833 ZINC06576021 ZINC13597337 ZINC22911751 
ZINC01036792 ZINC01677761 ZINC04213833 ZINC06576021 ZINC13597337 ZINC22911751 
ZINC01036880 ZINC01677892 ZINC04214344 ZINC06576323 ZINC13597346 ZINC22911959 
ZINC01045051 ZINC01679310 ZINC04214836 ZINC06576323 ZINC13597348 ZINC22912001 
ZINC01045051 ZINC01679777 ZINC04217305 ZINC06576501 ZINC13597350 ZINC22912013 
ZINC01045089 ZINC01680284 ZINC04217587 ZINC06576501 ZINC13597354 ZINC22912016 
ZINC01045090 ZINC01680565 ZINC04237573 ZINC06857068 ZINC13597354 ZINC22918614 
ZINC01045530 ZINC01681130 ZINC04347718 ZINC06857068 ZINC13597363 ZINC23118752 
ZINC01045531 ZINC01681557 ZINC04353020 ZINC07996353 ZINC13597363 ZINC23118754 
ZINC01069082 ZINC01682029 ZINC04365786 ZINC08553055 ZINC13597368 ZINC23118770 
ZINC01081577 ZINC01682117 ZINC04366202 ZINC08553055 ZINC13597368 ZINC23118772 
ZINC01082213 ZINC01682520 ZINC04366261 ZINC08560067 ZINC13597372 ZINC23211906 
ZINC01082213 ZINC01682534 ZINC04366520 ZINC08580873 ZINC13597383 ZINC23211908 
ZINC01163259 ZINC01682798 ZINC04366893 ZINC08581164 ZINC13597383 ZINC24334040 
ZINC01196937 ZINC01683295 ZINC04367141 ZINC08581164 ZINC13597390 ZINC25783872 
ZINC01323776 ZINC01683317 ZINC04376856 ZINC08581166 ZINC13597390 ZINC26730911 
ZINC01481770 ZINC01683345 ZINC04403652 ZINC08581166 ZINC13597410 ZINC26780933 
ZINC01481981 ZINC01683531 ZINC04403653 ZINC08581317 ZINC13597410 ZINC26780935 
ZINC01530795 ZINC01683553 ZINC04409180 ZINC08581317 ZINC13597416 ZINC26780937 
ZINC01530836 ZINC01683648 ZINC04416197 ZINC08581421 ZINC13597416 ZINC26780939 
ZINC01532548 ZINC01685254 ZINC04416613 ZINC08581460 ZINC13597418 ZINC29589543 
ZINC01555262 ZINC01685697 ZINC04428312 ZINC08585953 ZINC13597418 ZINC29589553 
ZINC01555547 ZINC01685876 ZINC04428312 ZINC08603298 ZINC13597424 ZINC29589777 
ZINC01555676 ZINC01685881 ZINC04428581 ZINC08603298 ZINC13597426 ZINC29589785 
ZINC01555979 ZINC01685966 ZINC04428843 ZINC08603298 ZINC13597428 ZINC29589797 
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ZINC01556940 ZINC01686251 ZINC04428858 ZINC08613703 ZINC13597428 ZINC29589800 
ZINC01558226 ZINC01686363 ZINC04428999 ZINC08613703 ZINC13597430 ZINC29589816 
ZINC01559756 ZINC01686467 ZINC04429620 ZINC08615383 ZINC13597430 ZINC29589818 
ZINC01560078 ZINC01686683 ZINC04430482 ZINC08615531 ZINC13597432 ZINC29589820 
ZINC01560636 ZINC01686969 ZINC04430753 ZINC08615531 ZINC13597432 ZINC29589822 
ZINC01561127 ZINC01687247 ZINC04473135 ZINC08615799 ZINC13597717 ZINC29589824 
ZINC01561462 ZINC01687845 ZINC04522231 ZINC08616208 ZINC13597717 ZINC29589826 
ZINC01561576 ZINC01687910 ZINC04522477 ZINC08616208 ZINC13597721 ZINC29589828 
ZINC01561637 ZINC01688151 ZINC04531729 ZINC08617619 ZINC13597721 ZINC29589829 
ZINC01561931 ZINC01688347 ZINC04536747 ZINC08617619 ZINC13597728 ZINC29589831 
ZINC01562022 ZINC01688628 ZINC04536750 ZINC08618545 ZINC13597730 ZINC29589833 
ZINC01562304 ZINC01688646 ZINC04536752 ZINC08618968 ZINC13597730 ZINC29589835 
ZINC01562340 ZINC01688662 ZINC04537227 ZINC08622475 ZINC13597732 ZINC29589837 
ZINC01562352 ZINC01688752 ZINC04537229 ZINC08622475 ZINC13597732 ZINC29589855 
ZINC01562357 ZINC01689447 ZINC04537816 ZINC08627485 ZINC13597738 ZINC29589859 
ZINC01562359 ZINC01689932 ZINC04538450 ZINC08627502 ZINC13597741 ZINC29589876 
ZINC01562368 ZINC01690169 ZINC04547321 ZINC08637986 ZINC13597741 ZINC29589877 
ZINC01562588 ZINC01690171 ZINC04557220 ZINC08648354 ZINC13597743 ZINC29589879 
ZINC01563104 ZINC01690194 ZINC04557220 ZINC08648354 ZINC13597743 ZINC29589881 
ZINC01563302 ZINC01690208 ZINC04558887 ZINC08649723 ZINC13597746 ZINC29589883 
ZINC01563324 ZINC01690699 ZINC04578913 ZINC08649723 ZINC13597746 ZINC29589885 
ZINC01563325 ZINC01690722 ZINC04628938 ZINC08649758 ZINC13597758 ZINC29589888 
ZINC01563326 ZINC01691075 ZINC04683414 ZINC08649758 ZINC13597762 ZINC29589897 
ZINC01563327 ZINC01691548 ZINC04691860 ZINC08652230 ZINC13597762 ZINC29589899 
ZINC01563973 ZINC01691551 ZINC04692015 ZINC08652230 ZINC13597764 ZINC29589901 
ZINC01563997 ZINC01691651 ZINC04692016 ZINC08655995 ZINC13597764 ZINC29589906 
ZINC01563998 ZINC01691782 ZINC04701260 ZINC08655995 ZINC13597767 ZINC29589907 
ZINC01564760 ZINC01691943 ZINC04701343 ZINC08660420 ZINC13597767 ZINC29589912 
ZINC01566093 ZINC01691989 ZINC04705802 ZINC08672844 ZINC13597771 ZINC29589917 
ZINC01566193 ZINC01692470 ZINC04706168 ZINC08672844 ZINC13597771 ZINC29589923 
ZINC01566453 ZINC01693279 ZINC04707417 ZINC08772958 ZINC13597814 ZINC29589924 
ZINC01566685 ZINC01694053 ZINC04707457 ZINC08772958 ZINC13597816 ZINC29590257 
ZINC01566905 ZINC01694371 ZINC04707664 ZINC09211296 ZINC13597818 ZINC29590259 
ZINC01566917 ZINC01695372 ZINC04707767 ZINC09211296 ZINC13634510 ZINC29590262 
ZINC01567155 ZINC01695559 ZINC04707792 ZINC09230252 ZINC13634510 ZINC29590263 
ZINC01567413 ZINC01696555 ZINC04707806 ZINC11525688 ZINC13634517 ZINC29590275 
ZINC01567421 ZINC01697077 ZINC04715161 ZINC11525688 ZINC13634517 ZINC29590277 
ZINC01567747 ZINC01697110 ZINC04720969 ZINC11525688 ZINC13634519 ZINC29590287 
ZINC01568035 ZINC01697295 ZINC04720972 ZINC11535692 ZINC13634519 ZINC29590289 
ZINC01568661 ZINC01697912 ZINC04726283 ZINC11535830 ZINC14717925 ZINC29590292 
ZINC01568793 ZINC01699287 ZINC04726283 ZINC11535850 ZINC15881824 ZINC29590296 
ZINC01568966 ZINC01699937 ZINC04726283 ZINC11616854 ZINC15889046 ZINC29590298 
ZINC01569015 ZINC01700219 ZINC04726284 ZINC11616855 ZINC15889046 ZINC29590300 
ZINC01569236 ZINC01700953 ZINC04726284 ZINC11616856 ZINC15889046 ZINC29590302 
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ZINC01569237 ZINC01701112 ZINC04726284 ZINC11616857 ZINC15894745 ZINC29590304 
ZINC01569416 ZINC01701460 ZINC04726655 ZINC11677161 ZINC15924502 ZINC29590306 
ZINC01569482 ZINC01701513 ZINC04726869 ZINC11677168 ZINC15924502 ZINC29590308 
ZINC01569495 ZINC01702739 ZINC04742623 ZINC11677172 ZINC15924534 ZINC29590315 
ZINC01569498 ZINC01702835 ZINC04743527 ZINC11677178 ZINC15924536 ZINC29590323 
ZINC01569586 ZINC01703050 ZINC04744282 ZINC11681161 ZINC15924536  
ZINC01570210 ZINC01703105 ZINC04747919 ZINC11681164 ZINC15924541  
ZINC01570216 ZINC01703109 ZINC04748128 ZINC11681166 ZINC15924541  
ZINC01570386 ZINC01703286 ZINC04748141 ZINC11681170 ZINC15952559  
ZINC01570468 ZINC01705443 ZINC04758411 ZINC12153441 ZINC15952559  
ZINC01571105 ZINC01705919 ZINC04760065 ZINC12153442 ZINC15952559  
ZINC01571135 ZINC01705925 ZINC04769176 ZINC12340155 ZINC15952610  
ZINC01571136 ZINC01706083 ZINC04769447 ZINC12340238 ZINC15952610  
ZINC01572056 ZINC01706126 ZINC04769448 ZINC12340238 ZINC15990220  
ZINC01572309 ZINC01706223 ZINC04769600 ZINC12341271 ZINC15990220  
 
 
428 
 
Table 7.1.2 - ZINC codes identifying all the ligands screened in the Ligand Substructure library. 
ZINC00000066 ZINC00025057 ZINC00031967 ZINC01556388 ZINC00006373 ZINC02629278 
ZINC00000073 ZINC00025162 ZINC00140815 ZINC01556581 ZINC00020000 ZINC02636757 
ZINC00000079 ZINC00025502 ZINC00140817 ZINC01556707 ZINC00020001 ZINC02637030 
ZINC00000135 ZINC00025667 ZINC00140865 ZINC01556732 ZINC00022012 ZINC02641146 
ZINC00000136 ZINC00025668 ZINC00140867 ZINC01560152 ZINC00088505 ZINC02840177 
ZINC00000171 ZINC00025672 ZINC00159509 ZINC01562219 ZINC00120348 ZINC02922103 
ZINC00000238 ZINC00026217 ZINC00409994 ZINC01562556 ZINC00132664 ZINC02922160 
ZINC00000344 ZINC00026220 ZINC00895711 ZINC01564734 ZINC00156034 ZINC02922173 
ZINC00000351 ZINC00027448 ZINC00901485 ZINC01567073 ZINC00156040 ZINC02922204 
ZINC00000353 ZINC00027657 ZINC01529162 ZINC01568417 ZINC00156683 ZINC02922222 
ZINC00000376 ZINC00028212 ZINC01529165 ZINC01580781 ZINC00160722 ZINC03074214 
ZINC00000419 ZINC00031377 ZINC01529166 ZINC01581307 ZINC00188454 ZINC03074417 
ZINC00000425 ZINC00031378 ZINC01529167 ZINC01583273 ZINC00344019 ZINC03078171 
ZINC00000437 ZINC00031379 ZINC01529168 ZINC01583794 ZINC00374875 ZINC03078173 
ZINC00000450 ZINC00031380 ZINC01529331 ZINC01587239 ZINC00391960 ZINC03091289 
ZINC00000451 ZINC00032819 ZINC01529332 ZINC01587728 ZINC00402724 ZINC03102125 
ZINC00000458 ZINC00032820 ZINC01529333 ZINC01588564 ZINC00404775 ZINC03102127 
ZINC00000665 ZINC00033480 ZINC01529334 ZINC01588565 ZINC00405901 ZINC03138946 
ZINC00000745 ZINC00033887 ZINC01529422 ZINC01588566 ZINC00517939 ZINC03159486 
ZINC00000863 ZINC00035526 ZINC01529453 ZINC01590332 ZINC00600877 ZINC03160646 
ZINC00000964 ZINC00035527 ZINC01529613 ZINC01590993 ZINC00874515 ZINC03167464 
ZINC00001043 ZINC00035528 ZINC01529656 ZINC01591673 ZINC00895103 ZINC03194831 
ZINC00001063 ZINC00035529 ZINC01529657 ZINC01591674 ZINC00901628 ZINC03194832 
ZINC00001253 ZINC00035530 ZINC01529662 ZINC01591675 ZINC00901878 ZINC03201336 
ZINC00001332 ZINC00035531 ZINC01529702 ZINC01591676 ZINC00938080 ZINC03221617 
ZINC00001368 ZINC00035532 ZINC01529703 ZINC01591695 ZINC01000303 ZINC03260391 
ZINC00001457 ZINC00035533 ZINC01529717 ZINC01592347 ZINC01481961 ZINC03273581 
ZINC00001484 ZINC00036467 ZINC01529730 ZINC01592549 ZINC01484069 ZINC03273629 
ZINC00001505 ZINC00037880 ZINC01529739 ZINC01593340 ZINC01530328 ZINC03280808 
ZINC00001510 ZINC00039033 ZINC01529742 ZINC01594163 ZINC01530514 ZINC03295099 
ZINC00001714 ZINC00039093 ZINC01529771 ZINC01594165 ZINC01531686 ZINC03295466 
ZINC00001761 ZINC00039097 ZINC01529785 ZINC01594443 ZINC01532439 ZINC03296892 
ZINC00002053 ZINC00039105 ZINC01529791 ZINC01594996 ZINC01532464 ZINC03297153 
ZINC00002158 ZINC00039860 ZINC01529813 ZINC01594997 ZINC01532909 ZINC03313360 
ZINC00002159 ZINC00039896 ZINC01529814 ZINC01594998 ZINC01542081 ZINC03313499 
ZINC00002219 ZINC00039936 ZINC01529815 ZINC01594999 ZINC01560901 ZINC03314644 
ZINC00002270 ZINC00039940 ZINC01529816 ZINC01595997 ZINC01560905 ZINC03314942 
ZINC00002617 ZINC00040153 ZINC01529821 ZINC01596674 ZINC01564877 ZINC03314949 
ZINC00003758 ZINC00040169 ZINC01529835 ZINC01596916 ZINC01568160 ZINC03315231 
ZINC00003821 ZINC00040170 ZINC01529836 ZINC01597148 ZINC01576233 ZINC03365068 
ZINC00003901 ZINC00040750 ZINC01529837 ZINC01597149 ZINC01576240 ZINC03399313 
ZINC00003950 ZINC00040753 ZINC01529842 ZINC01597150 ZINC01576312 ZINC03412817 
ZINC00004023 ZINC00040762 ZINC01529843 ZINC01597151 ZINC01584749 ZINC03417739 
429 
 
ZINC00004235 ZINC00040788 ZINC01529844 ZINC01597152 ZINC01594604 ZINC03426346 
ZINC00004253 ZINC00040789 ZINC01529846 ZINC01597642 ZINC01594663 ZINC03450331 
ZINC00004302 ZINC00041059 ZINC01529847 ZINC01598781 ZINC01604030 ZINC03645182 
ZINC00004477 ZINC00041563 ZINC01529876 ZINC01600987 ZINC01605652 ZINC03776577 
ZINC00004489 ZINC00041578 ZINC01529879 ZINC01601594 ZINC01607133 ZINC03795528 
ZINC00004512 ZINC00041974 ZINC01529880 ZINC01601632 ZINC01608082 ZINC03798304 
ZINC00004564 ZINC00042934 ZINC01529882 ZINC01602330 ZINC01609614 ZINC03812004 
ZINC00004565 ZINC00046810 ZINC01529884 ZINC01603125 ZINC01615672 ZINC03812006 
ZINC00004611 ZINC00046935 ZINC01529894 ZINC01603935 ZINC01616666 ZINC03825190 
ZINC00004695 ZINC00047136 ZINC01529895 ZINC01604873 ZINC01618145 ZINC03851725 
ZINC00004775 ZINC00047505 ZINC01529896 ZINC01605141 ZINC01618870 ZINC03870147 
ZINC00004959 ZINC00049988 ZINC01529897 ZINC01606708 ZINC01626244 ZINC03950412 
ZINC00005057 ZINC00050168 ZINC01529904 ZINC01609019 ZINC01648586 ZINC03974740 
ZINC00005081 ZINC00051582 ZINC01529910 ZINC01610563 ZINC01670229 ZINC03982716 
ZINC00005285 ZINC00051583 ZINC01529911 ZINC01610564 ZINC01676922 ZINC03994526 
ZINC00005618 ZINC00051802 ZINC01529921 ZINC01613865 ZINC01677514 ZINC04005102 
ZINC00005619 ZINC00053379 ZINC01529927 ZINC01613871 ZINC01677635 ZINC04015559 
ZINC00005637 ZINC00054575 ZINC01529966 ZINC01613876 ZINC01677745 ZINC04017060 
ZINC00005744 ZINC00054811 ZINC01530017 ZINC01613879 ZINC01678285 ZINC04091747 
ZINC00005980 ZINC00054812 ZINC01530031 ZINC01616291 ZINC01680241 ZINC04095553 
ZINC00006044 ZINC00056325 ZINC01530142 ZINC01616296 ZINC01685560 ZINC04097222 
ZINC00006228 ZINC00056350 ZINC01530145 ZINC01616299 ZINC01687472 ZINC04097230 
ZINC00006508 ZINC00056426 ZINC01530146 ZINC01616305 ZINC01687705 ZINC04115756 
ZINC00006532 ZINC00056610 ZINC01530152 ZINC01616311 ZINC01690366 ZINC04141542 
ZINC00006614 ZINC00056649 ZINC01530154 ZINC01616324 ZINC01697988 ZINC04212164 
ZINC00007255 ZINC00056665 ZINC01530214 ZINC01616326 ZINC01700276 ZINC04218962 
ZINC00007502 ZINC00056702 ZINC01530215 ZINC01616847 ZINC01701174 ZINC04285766 
ZINC00008065 ZINC00056703 ZINC01530216 ZINC01617401 ZINC01708924 ZINC04286556 
ZINC00008288 ZINC00056707 ZINC01530217 ZINC01618272 ZINC01708940 ZINC04286569 
ZINC00008809 ZINC00056719 ZINC01530236 ZINC01618273 ZINC01714305 ZINC04286577 
ZINC00008846 ZINC00056733 ZINC01530238 ZINC01619910 ZINC01715387 ZINC04286584 
ZINC00009162 ZINC00056779 ZINC01530239 ZINC01620030 ZINC01727442 ZINC04286590 
ZINC00009698 ZINC00056780 ZINC01530250 ZINC01620619 ZINC01727446 ZINC04286600 
ZINC00009699 ZINC00056784 ZINC01530252 ZINC01620621 ZINC01728070 ZINC04286611 
ZINC00009700 ZINC00056785 ZINC01530288 ZINC01621156 ZINC01737910 ZINC04286619 
ZINC00009701 ZINC00056786 ZINC01530302 ZINC01621874 ZINC01737911 ZINC04286623 
ZINC00009702 ZINC00056787 ZINC01530327 ZINC01621895 ZINC01742240 ZINC04286630 
ZINC00010512 ZINC00056818 ZINC01530374 ZINC01624118 ZINC01759522 ZINC04286641 
ZINC00010937 ZINC00056834 ZINC01530375 ZINC01624131 ZINC01856861 ZINC04286652 
ZINC00011837 ZINC00057063 ZINC01530376 ZINC01624499 ZINC01888747 ZINC04286663 
ZINC00011953 ZINC00057124 ZINC01530549 ZINC01624526 ZINC01912288 ZINC04286672 
ZINC00012205 ZINC00057125 ZINC01530551 ZINC01624527 ZINC02012354 ZINC04286694 
ZINC00012206 ZINC00057160 ZINC01530552 ZINC01624528 ZINC02012356 ZINC04286709 
ZINC00012207 ZINC00057174 ZINC01532262 ZINC01624582 ZINC02020209 ZINC04286722 
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ZINC00012209 ZINC00057180 ZINC01532517 ZINC01624583 ZINC02134706 ZINC04294964 
ZINC00012210 ZINC00057182 ZINC01532519 ZINC01624584 ZINC02169490 ZINC04336688 
ZINC00012215 ZINC00057187 ZINC01532521 ZINC01624585 ZINC02242978 ZINC04343978 
ZINC00012216 ZINC00057191 ZINC01532540 ZINC01624619 ZINC02389623 ZINC04517289 
ZINC00012343 ZINC00057232 ZINC01532553 ZINC01627309 ZINC02389704 ZINC04521590 
ZINC00012425 ZINC00057259 ZINC01532558 ZINC01627834 ZINC02391019 ZINC04533814 
ZINC00012426 ZINC00057265 ZINC01532568 ZINC01628282 ZINC02392274 ZINC04536644 
ZINC00013840 ZINC00057268 ZINC01532569 ZINC01628572 ZINC02392314 ZINC04543577 
ZINC00014545 ZINC00057272 ZINC01532570 ZINC01628574 ZINC02506775 ZINC04760162 
ZINC00017142 ZINC00057276 ZINC01532571 ZINC01630373 ZINC02516985 ZINC04760877 
ZINC00017145 ZINC00057285 ZINC01532578 ZINC01632503 ZINC02517036 ZINC04761950 
ZINC00017591 ZINC00057286 ZINC01532584 ZINC01632504 ZINC02530801 ZINC04761954 
ZINC00017592 ZINC00057289 ZINC01532613 ZINC01632505 ZINC02540543 ZINC04761975 
ZINC00017654 ZINC00057290 ZINC01532617 ZINC01632506 ZINC02555050 ZINC04763802 
ZINC00018468 ZINC00057296 ZINC01532646 ZINC01632507 ZINC02555074 ZINC04771016 
ZINC00018469 ZINC00057301 ZINC01532647 ZINC01632508 ZINC02555075 ZINC04782844 
ZINC00018560 ZINC00057303 ZINC01532648 ZINC01632509 ZINC02555076 ZINC04817272 
ZINC00018570 ZINC00057318 ZINC01532649 ZINC01632510 ZINC02555094 ZINC04824842 
ZINC00019686 ZINC00057330 ZINC01532655 ZINC01632620 ZINC02555095 ZINC04829022 
ZINC00019968 ZINC00057331 ZINC01532684 ZINC01636511 ZINC02555097 ZINC04992328 
ZINC00020543 ZINC00057340 ZINC01532715 ZINC01636512 ZINC02555102 ZINC04992567 
ZINC00020956 ZINC00057341 ZINC01532721 ZINC01637108 ZINC02556509 ZINC05018126 
ZINC00020957 ZINC00057371 ZINC01532725 ZINC01637220 ZINC02556684 ZINC05053838 
ZINC00021027 ZINC00057376 ZINC01532726 ZINC01637452 ZINC02560007 ZINC05054972 
ZINC00021028 ZINC00057377 ZINC01532759 ZINC01640849 ZINC02560008 ZINC05085332 
ZINC00021247 ZINC00057381 ZINC01532776 ZINC01641636 ZINC02560349 ZINC05112434 
ZINC00021950 ZINC00057393 ZINC01532789 ZINC01645659 ZINC02561115 ZINC05116006 
ZINC00021951 ZINC00057394 ZINC01532800 ZINC01646394 ZINC02562507 ZINC05131962 
ZINC00022805 ZINC00057396 ZINC01532808 ZINC01646626 ZINC02567344 ZINC05131963 
ZINC00023158 ZINC00057398 ZINC01532854 ZINC01646924 ZINC02575124 ZINC05134904 
ZINC00024461 ZINC00057404 ZINC01532864 ZINC01646927 ZINC02583053 ZINC05167476 
ZINC00024462 ZINC00057405 ZINC01532865 ZINC01646928 ZINC02583054 ZINC05187268 
ZINC00024463 ZINC00057411 ZINC01532883 ZINC01653793 ZINC02583268 ZINC05215425 
ZINC00024464 ZINC00057415 ZINC01542524 ZINC01653813 ZINC02583269 ZINC05220648 
ZINC00024552 ZINC00057416 ZINC01542526 ZINC01656089 ZINC02583274 ZINC05246877 
ZINC00024609 ZINC00057418 ZINC01542529 ZINC01663914 ZINC02583275 ZINC05257628 
ZINC00024610 ZINC00057423 ZINC01542530 ZINC01670696 ZINC02583278 ZINC05357597 
ZINC00024912 ZINC00057424 ZINC01549072 ZINC01671135 ZINC02584638 ZINC05371120 
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Table 7.1.3 - virtual screening ligands included in the natural library.  References (listed in full underneath the table) are given for the publication(s) linking the ligand and/or natural 
source to antitrypanosomal activity. 
Name Source References 
Lawsone (2-hydroxynapthoquinone) Lawsonia inermis Okpekon et al. (2004) (1) 
Tingenone (Maitenin) n.k. Wright & Phillipson (1990) (2) 
lucidamine A Garcinia lucida Mbaya & Ibrahim (2011) (3) 
senecionine Crotalaria phillipsia Nibret et al (2009) (4) 
furanolactone (columbin) Aristolchia albidia Nok et al. (2005) (5)  
nimbin Azadirachta indica Mbaya et al. (2010) (6); Biswas et al. (2002) (7)  
bruceine A Brucea javanica Bawm et al. (2009) (8) 
bruceine B Brucea javanica Bawm et al. (2009) (8) 
bruceine C Brucea javanica Bawm et al. (2009) (8) 
brusatol Brucea javanica Bawm et al. (2009) (8) 
bruceantinol Brucea javanica Bawm et al. (2009) (8) 
bruceine D Brucea javanica Bawm et al. (2009) (8) 
anthecotulide Anthemis auriculata Karioti et al. (2009) (8) 
(-)-roemerine Annona senegalensis You et al. (1995) (9) 
linalool Annona senegalensis Noudogbessi et al. (2011) (10) 
(z)-b-ocimene Annona senegalensis Noudogbessi et al. (2011) (10) 
(E)-b-ocimene Annona senegalensis Noudogbessi et al. (2011) (10) 
Germacrene-D Annona senegalensis Noudogbessi et al. (2011) (10) 
carryophyllene oxide Annona senegalensis Noudogbessi et al. (2011) (10) 
beta carryophyllene Annona senegalensis Noudogbessi et al. (2011) (10) 
palmitic acid Annona senegalensis Noudogbessi et al. (2011) (10) 
caratuberside A Caralluma tuberculata Rizwani (1991) (11) 
gallic acid Securidaca longepedunculata Muanda et al. (2010) (12) 
chlorogenic acid Securidaca longepedunculata Muanda et al. (2010) (12) 
caffeic acid Securidaca longepedunculata Muanda et al. (2010) (12) 
epicatechin Securidaca longepedunculata Muanda et al. (2010) (12) 
P-coumaric acid Securidaca longepedunculata Muanda et al. (2010) (12) 
rutin Securidaca longepedunculata Muanda et al. (2010) (12) 
432 
 
Name Source References 
Quercetin Securidaca longepedunculata Muanda et al. (2010) (12) 
Quercetin 7-glucosyl Securidaca longepedunculata Muanda et al. (2010) (12) 
Quercetin dehydrate Securidaca longepedunculata Muanda et al. (2010) (12) 
cinnamic acid Securidaca longepedunculata Muanda et al. (2010) (12) 
apigenin Securidaca longepedunculata Muanda et al. (2010) (12) 
flazin Brucea javanica Su et al. (2002) (13) 
yadanzioside A Brucea javanica Su et al. (2002) (13) 
yadanzioside C Brucea javanica Su et al. (2002) (13) 
azeleic acid Brucea javanica Su et al. (2002) (13) 
(8S)-8-hydroxyhexadecanoic acid Brucea javanica Su et al. (2002) (13) 
vanillin Brucea javanica Su et al. (2002) (13) 
physcion Senna occidentalis Niranjan & Gupta (1973) (14) 
emodin Senna occidentalis Niranjan & Gupta (1973) (14) 
physcion 1-b-D-glucopyranoside Senna occidentalis Niranjan & Gupta (1973) (14) 
B-sitosterol Senna occidentalis Niranjan & Gupta (1973) (14) 
pinoresinol Brucea javanica Chen et al. (2009) (15) 
cleomiscosin B Brucea javanica Chen et al. (2009) (15) 
dihydrodehidrodiconiferyl alcohol Brucea javanica Chen et al. (2009) (15) 
secoisolariciresinol Brucea javanica Chen et al. (2009) (15) 
4-hydroxy-3-methoxybenzoic acid (vanillic acid) Brucea javanica Chen et al. (2009) (15) 
3,4-dihydroxybenzoic acid Brucea javanica Chen et al. (2009) (15) 
curcusone A Jatropha curcas Aiyelaagbe et al. (2011) (16) 
curcusone B Jatropha curcas Aiyelaagbe et al. (2011) (16) 
curcusone C Jatropha curcas Aiyelaagbe et al. (2011) (16) 
curcusone D Jatropha curcas Aiyelaagbe et al. (2011) (16) 
jatropholone Jatropha curcas Aiyelaagbe et al. (2011) (16) 
Alpha-pinene Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
Beta-pinene Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
Alpha-phellandrene Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
1,8-cineole Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
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limonene Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
terpinen-4-ol Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
aromadendrene Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
epiglobulol Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
globulol Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
piperitone Eucalyptus globulus http://www.essentialoils.co.za/essential-oils/eucalyptus.htm 
rhein Senna (Cassia) occidentalis Ibrahim et al. (2010) (17);Kaur & Ahmad (2014) (18) 
aloe emodin Senna (Cassia) occidentalis Ibrahim et al. (2010) (17);Kaur & Ahmad (2014) (18) 
chrysophanol Senna (Cassia) occidentalis Ibrahim et al. (2010) (17);Kaur & Ahmad (2014) (18) 
chrysophanol-8-glucoside Senna (Cassia) occidentalis Ibrahim et al. (2010) (17);Kaur & Ahmad (2014) (18) 
N-methyl morpholine Senna (Cassia) occidentalis Ibrahim et al. (2010) (17);Kaur & Ahmad (2014) (18) 
daphneside Senna (Cassia) occidentalis Makhija et al. (2011) 
daphnorin Senna (Cassia) occidentalis Makhija et al. (2011) 
pinoresinol di-O-β-D-glucopyranoside Senna (Cassia) occidentalis Makhija et al. (2011) 
lupeol Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
Beta-sitosterol glucoside Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
oleanolic acid Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
teferidine Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
teferin Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
ferutinin Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
retusin Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
kaempferol-3-O-glucopyranoside Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
acetamide Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
stearamide Solanum schimperianum Hochst Al-Oqail et al. (2012) (19) 
Harman Guiera senegalensis Fiot et al. (2006) (20)  
harmalan Guiera senegalensis Fiot et al. (2006) (20) 
tetrahydroharman Guiera senegalensis Fiot et al. (2006) (20) 
guieranone A Guiera senegalensis Fiot et al. (2006) (20) 
cycloartenol Tamarindus indica L. Khanzada et al. (2008) (21) 
Beta-amyrin Eucalyptus globulus Santos et al. (1997) (22) 
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Name Source References 
erythrodiol Eucalyptus globulus Santos et al. (1997) (22) 
uvaol Eucalyptus globulus Santos et al. (1997) (22) 
acetyloleanolic acid Eucalyptus globulus Santos et al. (1997) (22) 
acetylbetulinic acid Eucalyptus globulus Santos et al. (1997) (22) 
acetylursolic acid Eucalyptus globulus Santos et al. (1997) (22) 
betulinic acid Eucalyptus globulus Santos et al. (1997) (22) 
skimiamine Zanthoxylum chalybeum Olila et al. (2002) (23) 
nitogenin (diosgenin) Balanites aegyptiaca Dawidar & Fayez (1968) (24) 
stigmasterol Eucalyptus globulus Yang & Guo (2007) (25) 
euscaphic acid(1) Eucalyptus globulus Yang & Guo (2007) (25) 
euscaphic acid(2) Eucalyptus globulus Yang & Guo (2007) (25) 
2alpha-hydroxybetulinic acid Eucalyptus globulus Yang & Guo (2007) (25) 
macrocarpal B Eucalyptus globulus Yang & Guo (2007) (25) 
macrocarpal A Eucalyptus globulus Yang & Guo (2007) (25) 
3,4,3'-tri-O-methylellagic acid Eucalyptus globulus Yang & Guo (2007) (25) 
camaldulenside Eucalyptus globulus Yang & Guo (2007) (25) 
ellagic acid Eucalyptus globulus Yang & Guo (2007) (25) 
L-quebrachitol Paullinia pinnata Dongo et al. (2009) (26) 
warburganal Warburgia salutaris (ugandensis) Mashimbye et al. (1999) (27) 
polygodial Warburgia salutaris (ugandensis) Mashimbye et al. (1999) (27) 
salutarisolide Warburgia salutaris (ugandensis) Mashimbye et al. (1999) (27) 
muzigadial Warburgia salutaris (ugandensis) Mashimbye et al. (1999) (27) 
ugandensidial Warburgia salutaris (ugandensis) Mashimbye et al. (1999) (27) 
epipolygodial (isopolygodial) Warburgia salutaris (ugandensis) Mashimbye et al. (1999) (27) 
mukaadial Warburgia salutaris (ugandensis) Mashimbye et al. (1999) (27) 
zanhasaponin A Zanha africana Cuellar et al. (1997) (28) 
zanhasaponin B Zanha africana Cuellar et al. (1997) (28) 
pinitol Zanha africana Cuellar et al. (1997) (28) 
filiformin Cassythia filiformis II Chang et al. (1998) (29) 
cathaformine Cassythia filiformis II Chang et al. (1998) (29) 
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Name Source References 
cathafiline Cassythia filiformis II Chang et al. (1998) (29) 
actinodaphnine Cassythia filiformis II Chang et al. (1998) (29) 
predicentrine Cassythia filiformis II Chang et al. (1998) (29) 
ocoteine Cassythia filiformis II Chang et al. (1998) (29) 
(+)-syringaresinol Cassythia filiformis II Chang et al. (1998) (29) 
D-isoboldine Cassythia filiformis II Chang et al. (1998) (29) 
lysicamine Cassythia filiformis II Chang et al. (1998) (29) 
thalicmanine Cassythia filiformis II Chang et al. (1998) (29) 
stepharine Cassythia filiformis II Chang et al. (1998) (29) 
pronuciferine Cassythia filiformis II Chang et al. (1998) (29) 
O-methylflavinantine Cassythia filiformis II Chang et al. (1998) (29) 
( )-yangambin Cassythia filiformis II Chang et al. (1998) (29) 
isovanillin Cassythia filiformis II Chang et al. (1998) (29) 
Stigmasterol-D-glucoside Cassythia filiformis II Chang et al. (1998) (29) 
prosapogenin Foetidia africana Crublet et al. (2002) (30) 
16-deoxybarringtogenol C Foetidia africana Crublet et al. (2002) (30) 
Alpha-chaconine Solanum spp. Chataing et al. (1998) (31) 
Alpha-solamargine (solasonine) Solanum spp. Chataing et al. (1998) (31) 
tomatine Solanum spp. Chataing et al. (1998) (31) 
7,8-epoxylignan Brucea javanica Chen et al. (2009) (15) 
7'-hyroxy-lariciresionol Brucea javanica Chen et al. (2009) (15) 
4-methoxyguaiacyglycerol Brucea javanica Chen et al. (2009) (15) 
7-carbonylguaiacyglycerol Brucea javanica Chen et al. (2009) (15) 
Brucojavan 1 Brucea javanica Chen et al. (2009) (15) 
Brucojavan 2 Brucea javanica Chen et al. (2009) (15) 
Brucojavan 3 Brucea javanica Chen et al. (2009) (15) 
isoplumbagin Lawsonia inermis Makhija et al. (2011) (32)  
lawsoniaside Lawsonia inermis Makhija et al. (2011) (32) 
lalioside Lawsonia inermis Makhija et al. (2011) (32) 
lawsoniaside B Lawsonia inermis Makhija et al. (2011) (32) 
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Agrimonolide 6-O-β-D-glucopyranoside Lawsonia inermis Makhija et al. (2011) (32) 
(+)-Syringaresinol O-β-D-glucopyranoside Lawsonia inermis Makhija et al. (2011) (32) 
Syringaresinol di-O-β-D-glucopyranoside Lawsonia inermis Makhija et al. (2011) (32) 
isoscutellarin Lawsonia inermis Makhija et al. (2011) (32) 
hennadiol Lawsonia inermis Makhija et al. (2011) (32) 
30-nor-lupan-3β-ol-20-one Lawsonia inermis Makhija et al. (2011) (32) 
botulin Lawsonia inermis Makhija et al. (2011) (32) 
laxanthone I Lawsonia inermis Makhija et al. (2011) (32) 
laxanthone II Lawsonia inermis Makhija et al. (2011) (32) 
laxanthone III Lawsonia inermis Makhija et al. (2011) (32) 
lacoumarin Lawsonia inermis Makhija et al. (2011) (32) 
apigenin-7-glucoside Lawsonia inermis Makhija et al. (2011) (32) 
luteolin Lawsonia inermis Makhija et al. (2011) (32) 
Alpha-terpineol Lawsonia inermis Makhija et al. (2011) (32) 
Alpha-ionone Lawsonia inermis Makhija et al. (2011) (32) 
Beta-ionone Lawsonia inermis Makhija et al. (2011) (32) 
japodagrin Jatropha podagrica Aiyelaagbe et al. (2007) (33) 
japodagrone Jatropha podagrica Aiyelaagbe et al. (2007) (33) 
4Z-jatrogrossidentadion Jatropha podagrica Aiyelaagbe et al. (2007) (33) 
15-epi-4Z-jatrogrossidentadion Jatropha podagrica Aiyelaagbe et al. (2007) (33) 
2-hydroxyisojatrogrossidion Jatropha podagrica Aiyelaagbe et al. (2007) (33) 
2-epihydroxyisojatrogrossidion Jatropha podagrica Aiyelaagbe et al. (2007) (33) 
1-acetoxy-3,4,5-trimethoxyphenol Eucalyptus globulus Santos et al. (1997) (22) 
1-acetoxy-2,4,6-trimethoxyphenol Eucalyptus globulus Santos et al. (1997) (22) 
2,6-dimethoxy-p-benzoquinone Eucalyptus globulus Santos et al. (1997) (22) 
vomifoliol Eucalyptus globulus Santos et al. (1997) (22) 
Cis-p-methoxycinnamoyloxyursolicacid methyl 
ester 
Eucalyptus globulus Santos et al. (1997) (22) 
Trans-p-methoxycinnamoyloxyursolicacid methyl 
ester 
Eucalyptus globulus Santos et al. (1997) (22) 
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ursolic acid methyl ester Eucalyptus globulus Santos et al. (1997) (22) 
methyl 3beta,23-diacetoxy-12-ursen-28-oate Eucalyptus globulus Santos et al. (1997) (22) 
Cis-p-methoxycinnamoyloxyoleanolicacid methyl 
ester 
Eucalyptus globulus Santos et al. (1997) (22) 
Tetra-acetyldaucosterol Eucalyptus globulus Santos et al. (1997) (22) 
3-O-Methylellagic acid 3'-O-alpha-4''-O-
acetylrhamnopyranoside 
Eucalyptus globulus Yang & Guo (2007) (25) 
etandrolide Entandrophragma angolense Orisadipe et al. (2005) (34) 
3,23-Dioxotirucalla-7,24-dien-21-al Entandrophragma angolense Orisadipe et al. (2005) (34) 
3,4-Secotirucalla-23-oxo-4(28),7,24-trien-21-al-3,21- 
dioic acid (21-methyl ester) 
Entandrophragma angolense Orisadipe et al. (2005) (34) 
3,4-Secotirucalla-23-oxo-4(28),7,24-trien-21-al-3-oic 
acid 
Entandrophragma angolense Orisadipe et al. (2005) (34) 
paullinamide A Paullinia pinnata Dongo et al. (2009) (26) 
2-(4-hydroxy-3,5-dimethoxyphenyl)-3-
hydroxymethyl-2,3-dihydro-1,4,5-
trioxaphenanthren-6-one 
Paullinia pinnata Dongo et al. (2009) (26) 
5alpha-poriferastane-3beta,6alpha-diol Paullinia pinnata Dongo et al. (2009) (26) 
3alpha,7alpha-dideacetylkhivorin Khaya senegalensis Zhang et al. (2008) (35) 
1alpha,3alpha,7alpha-trideacetylkhivorin Khaya senegalensis Zhang et al. (2008) (35) 
mexicanoloid limonoid khayanone Khaya senegalensis Zhang et al. (2008) (35) 
1-O-deacetylkhayanolide B Khaya senegalensis Zhang et al. (2008) (35) 
khayanolide B Khaya senegalensis Zhang et al. (2008) (35) 
khayanolide E Khaya senegalensis Zhang et al. (2008) (35) 
1-O-deacetylkhayanolide E Khaya senegalensis Zhang et al. (2008) (35) 
6-dehydroxykhayanolide E Khaya senegalensis Zhang et al. (2008) (35) 
(-)-lyoniresinol Khaya senegalensis Zhang et al. (2008) (35) 
(-)-lyoniresin-9-yl-b-D-xylopyranoside Khaya senegalensis Zhang et al. (2008) (35) 
(-)-lyoniresin-4'-yl-b- 
D-glucopyranoside 
Khaya senegalensis Zhang et al. (2008) (35) 
438 
 
Name Source References 
cassyformine Cassythia filiformis II Chang et al. (1998) (29) 
D-mannitol Lawsonia inermis Chaudhary et al. (2010) (36) 
triacontanol Lawsonia inermis Chaudhary et al. (2010) (36) 
Apigenin-4'-glucoside Lawsonia inermis Chaudhary et al. (2010) (36) 
luteolin-7-O-glucoside Lawsonia inermis Chaudhary et al. (2010) (36) 
Luteolin-3'-O-glucoside Lawsonia inermis Chaudhary et al. (2010) (36) 
cosmossin (acacetin-7-O-glucoside) Lawsonia inermis Chaudhary et al. (2010) (36) 
acacetin Lawsonia inermis Chaudhary et al. (2010) (36) 
fraxetin Lawsonia inermis Chaudhary et al. (2010) (36) 
scopoletin Lawsonia inermis Chaudhary et al. (2010) (36) 
esculetin Lawsonia inermis Chaudhary et al. (2010) (36) 
1,2-dihydroxy- 4-o-glucosyloxy Naphthalene Lawsonia inermis Chaudhary et al. (2010) (36) 
apiin Lawsonia inermis Chaudhary et al. (2010) (36) 
3-methylnonacosane-1-ol Lawsonia inermis Chaudhary et al. (2010) (36) 
stearic acid Lawsonia inermis Chaudhary et al. (2010) (36) 
cinchonine Cinchona bark Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
quinine Cinchona bark Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
cinchonidine Cinchona bark Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
quinidine Cinchona bark Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
emetine Cephaelis ipecacuanha Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
berberine Many plant families Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
sanguinarine Many plant families Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
berbamine Many plant families, inc. Triclisia patens Hoet et al. (2004) (37);Merschjohann et al. (2001) (38) 
thalisopidine Triclisia patens Hoet et al. (2004) (37);Camacho et al. (2002) (39) 
pheanthine Triclisia patens Hoet et al. (2004) (37);Camacho et al. (2002) (39) 
dioncophylline A Ancistrocladaceae, Dioncophyllaceae Hoet et al. (2004) (37);Bringmann et al (2003) (40) 
dioncophylline B Ancistrocladaceae, Dioncophyllaceae Hoet et al. (2004) (37);Bringmann et al (2003) (40) 
dioncophylline E Dioncophyllum thollonii Hoet et al. (2004) (37);Bringmann et al (2002) (41) 
ancistroealaine A Ancistrocladus ealaensis Hoet et al. (2004) (37) 
ancistroealaine B Ancistrocladus ealaensis Hoet et al. (2004) (37) 
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dioncopeltine A ? Hoet et al. (2004) (37);Bringmann et al (2003) (40) 
ancistrogriffithine A Ancistrocladus graffithii Hoet et al. (2004) (37);Bringmann et al (2002) (41) 
O-methylmoschatoline Unonopsis buchtienii Hoet et al. (2004) (37);Waechter et al. (1999) (42) 
lysicamine Unonopsis buchtienii Hoet et al. (2004) (37);Waechter et al. (1999) (42) 
liriodenine Unonopsis buchtienii Hoet et al. (2004) (37);Waechter et al. (1999) (42) 
cassythine Cassythia filiformis Hoet et al. (2004) (37) 
dicentrine Cassythia filiformis Hoet et al. (2004) (37) 
pancracine Narcissus angustifolius subsp. 
transcarpathicus 
Hoet et al. (2004) (37);Labraña et al. (2002) (43) 
nangustine Narcissus angustifolius subsp. 
transcarpathicus 
Hoet et al. (2004) (37);Labraña et al. (2002) (43) 
haemanthidine Cyrtanthus elatus Hoet et al. (2004) (37);Herrera et al. (2001) (44) 
oxomaritidine Zephyranthes citrina Hoet et al. (2004) (37);Herrera et al. (2001) (45) 
galanthine Zephyranthes citrina Hoet et al. (2004) (37);Herrera et al. (2001) (45) 
lepadin D n.k. Hoet et al. (2004) (37) 
lepadin E n.k. Hoet et al. (2004) (37) 
lepadin F n.k. Hoet et al. (2004) (37) 
fascaplysin Hyrtios erecta Hoet et al. (2004) (37) 
ascididemin Marine metabolites Hoet et al. (2004) (37) 
G2-bromoascicidemin Marine metabolites Hoet et al. (2004) (37) 
cryptolepine Cryptolepis sanguinolenta Hoet et al. (2004) (37) 
neocryptolepine Cryptolepis sanguinolenta Hoet et al. (2004) (37) 
tryptanthrin Many plant species Hoet et al. (2004);Scovill et al. (2002)(46) 
camptothecin Camptotheca acuminata Hoet et al. (2004) (37);Bodley & Shapiro (1995) (47) 
ascofuranone Ascochyta visiae Hoet et al. (2004) (37) 
ethyl gallate Many plant families Hoet et al. (2004) (37);Koide et al. (1998) (48) 
punicalagin Combretum molle Hoet et al. (2004) (37);Asres et al. (2001) (49) 
G7,8-dihydroxyflavone n.k. Hoet et al. (2004) (37) 
quercetagetin n.k. Hoet et al. (2004) (37) 
chrysosplenetin Ehretia amoena Hoet et al. (2004) (37) 
chrysosplenol D Ehretia amoena Hoet et al. (2004) (37) 
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artemetin Ehretia amoena Hoet et al. (2004) (37) 
demethylpraecansone B Tephrosia aequilata Hoet et al. (2004) (37) 
praecansone B Tephrosia aequilata Hoet et al. (2004) (37) 
cissampeloflavone Cissampelos pareira Hoet et al. (2004) (37) 
amentoflavone Celaenodendron mexicanum Hoet et al. (2004) (31);Camacho et al. (2000) (50) 
podocarpusﬂavone A Celaenodendron mexicanum Hoet et al. (2004) (37);Camacho et al. (2000) (50) 
podocarpusﬂavone B Celaenodendron mexicanum Hoet et al. (2004) (37);Camacho et al. (2000) (50) 
curcumin Curcuma longa Hoet et al. (2004) (37) 
letestuianin C Aframomum letestuianum Hoet et al. (2004) (37) 
G(4Z,6E)-5-hydroxy-1,7-bis(4-hydroxyphenyl)hepta-
4,6-dien-3-one 
Aframomum letestuianum Hoet et al. (2004) (37) 
letestuianin A Aframomum letestuianum Hoet et al. (2004) (37) 
letestuianin B Aframomum letestuianum Hoet et al. (2004) (37) 
justicidin B Phyllanthus piscatorum Hoet et al. (2004) (37) 
piscatorin Phyllanthus piscatorum Hoet et al. (2004) (37) 
plumbagin Drosera spp. Hoet et al. (2004) (37);Bringmann et al. (2003) (40) 
Trans-isoshinanolone Drosera spp. Hoet et al. (2004) (37);Bringmann et al. (2003) (40) 
diospyrin Diospyros montana Hoet et al. (2004) (37);Yardley et al. (1996) (51) 
G2-(1-hydroxyethyl)-naphtho-[2,3-b]furan-4,9-
quinone 
Kigelia pinnata Hoet et al. (2004) (37);Moideen et al. (1999) (52) 
isopinnatal Kigelia pinnata Hoet et al. (2004) (37);Moideen et al. (1999) (52) 
kigelinol Kigelia pinnata Hoet et al. (2004) (37);Moideen et al. (1999) (52) 
isokigelinol Kigelia pinnata Hoet et al. (2004) (37);Moideen et al. (1999) (52) 
knipholone Kniphoﬁa foliosa Hoet et al. (2004) (37);Bringmann et al. (2002) (41) 
knipholone anthrone Kniphoﬁa foliosa Hoet et al. (2004) (37);Bringmann et al. (2002) (41) 
G4'-O-demethylknipholone Kniphoﬁa foliosa Hoet et al. (2004) (37);Bringmann et al. (2002) (41) 
G4'-O-demethylknipholone-4'-O-B-d-
glucopyranoside 
Bulbine frutescens Hoet et al. (2004) (37);Abegaz et al. (2002)  
gaboroquinone A Bulbine frutescens Hoet et al. (2004);Abegaz et al. (2002) 
gaboroquinone B Bulbine frutescens Hoet et al. (2004) (37);Abegaz et al. (2002) 
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azaanthroquinone Mitracarpus scaber Hoet et al. (2004) (37);Nok (2002) (53) 
alloaromadendrine Essential oils Hoet et al. (2004) (37);Mikus et al. (2000) (54) 
(-)-boscialin Boscia salicifolia Hoet et al. (2004) (37);Busch et al. (1998) (55) 
ilimaquinone Dactylospongia elegans Hoet et al. (2004) (37) 
pelorol Dactylospongia elegans Hoet et al. (2004) (37) 
helenalin Arnica & Inula spp. Hoet et al. (2004) (37) 
mexicanin I Arnica & Inula spp. Hoet et al. (2004) (37) 
kolavenol Entada abyssinica Hoet et al. (2004) (37);Freiburghaus et al. (1997) (56) 
G23-Hydroxy-5α-lanosta-7,9(11),24-triene-3-one Guarea rhophalocarpa Hoet et al. (2004) (37) 
G5α-Lanosta-7,9(11),24-triene-3α,23-diol Guarea rhophalocarpa Hoet et al. (2004) (37) 
G3-oxo-tirucalla-7,24Z-dien-26-oic acid Celaenodendron mexicanum Hoet et al. (2004) (37)  
vernoguinosterol Vernonia guineensis Hoet et al. (2004) (37) 
vernoguinoside Vernonia guineensis Hoet et al. (2004) (37) 
klaivanolide Uvaria Klaineana Hoet et al. (2004) (37) 
aculeatin D Amomum aculeatum Hoet et al. (2004) (37) 
senegaline Annona senegalensis Hoet et al. (2004) (37) 
squamocine Annona senegalensis Hoet et al. (2004) (37) 
diallyl trisulfide Allium sativum Hoet et al. (2004) (37) 
diallyl disulphide Allium sativum Hoet et al. (2004) (37);Nok et al. (1996) (57) 
ajoene Allium sativum Hoet et al. (2004) (37) 
manumycin A Streptomyces spp. Hoet et al. (2004) (37) 
sinefungin Streptomyces grizeolus & S. incarnatus Hoet et al. (2004) (37) 
O-methylancistrocladinine Ancistrocladus tarzanienses Gehrig & Efferth (2008) (58);Bringmann et al. (2004)  
O,N-dimethylancistrocladine Ancistrocladus tarzanienses Gehrig & Efferth (2008) (58);Bringmann et al. (2004) 
ancistrocladidine Ancistrocladus tarzanienses Bringmann et al. (2004) 
ent-dioncophylleine A Ancistrocladus benomensis Gehrig & Efferth (2008) (58);Bringmann et al. (2005) 
G5'-O-demethyl-ent-dioncophylleine A Ancistrocladus benomensis Gehrig & Efferth (2008);Bringmann et al. (2005) 
dioncophylline D Ancistrocladus benomensis Gehrig & Efferth (2008);Bringmann et al. (2005) 
G3-geranyloxy-6-methyl-1,8-
dihydroxyanthraquinone 
Vismia orientalis Gehrig & Efferth (2008);Mbwambo et al. (2004) 
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bianthrone A1 Vismia orientalis Gehrig & Efferth (2008);Mbwambo et al. (2004) 
lanaroflavone Gingko biloba Gehrig & Efferth (2008);Wenigal et al. (2006) 
bilobetin Gingko biloba Gehrig & Efferth (2008);Wenigal et al. (2006) 
ginkgetin Gingko biloba Gehrig & Efferth (2008);Wenigal et al. (2006) 
isoginkgetin Gingko biloba Gehrig & Efferth (2008);Wenigal et al. (2006) 
sciadopitysin Gingko biloba Gehrig & Efferth (2008);Wenigal et al. (2006) 
G3-hydroxyflavone n.k. Gehrig & Efferth (2008) (58); Tasdemir et al. (2006) (59) 
rhamnetin n.k. Gehrig & Efferth (2008) (58); Tasdemir et al. (2006) (59) 
G7,8,3',4'-tetrahydroxyflavone n.k. Gehrig & Efferth (2008) (58); Tasdemir et al. (2006) (59) 
crypthophilic acid A Scrophularia cryptophila Gehrig & Efferth (2008) (58); Tasdemir et al. (2006) (59) 
crypthophilic acid C Scrophularia cryptophila Gehrig & Efferth (2008) (58); Tasdemir et al. (2006) (59) 
buddlejasaponin III Scrophularia cryptophila Gehrig & Efferth (2008) (58); Tasdemir et al. (2006) (59) 
acetylastrogaloside I Astragalus baibutensis Gehrig & Efferth (2008)  
astrogaloside I Astragalus baibutensis Gehrig & Efferth (2008) 
astrogaloside II Astragalus baibutensis Gehrig & Efferth (2008) 
astrogaloside III Astragalus baibutensis Gehrig & Efferth (2008) 
harpagide Scrophularia cryptophila Gehrig & Efferth (2008) (58);Tasdemir et al. (2008) (60) 
acetylharpagide Scrophularia cryptophila Gehrig & Efferth (2008) (58);Tasdemir et al. (2008) (60) 
L-tryptophan Scrophularia cryptophila Gehrig & Efferth (2008) (58);Tasdemir et al. (2008) (60) 
G7-deacetylgedunin Pseudocedrela kotschyi Gehrig & Efferth (2008) 
G7-oxo-7-deacetylgedunin Pseudocedrela kotschyi Gehrig & Efferth (2008) 
kotschyin A Pseudocedrela kotschyi Gehrig & Efferth (2008) 
(E)-oroidin Agelas oroides Gehrig & Efferth (2008) (58);Tasdemir et al. (2007) (61) 
G24-ethyl-cholest-5a-7-en-3-b-ol Agelas oroides Gehrig & Efferth (2008) (58);Tasdemir et al. (2007) (61) 
G3-amino-1-(2-aminoimidazoyl)-prop-1-ene Agelas oroides Gehrig & Efferth (2008) (58);Tasdemir et al. (2007) (61) 
G4,5-dibromopyrrole-2-carboxylic acid methyl ester Agelas oroides Gehrig & Efferth (2008) (58);Tasdemir et al. (2007) (61) 
G4,5-dibromopyrrole-2-carboxylic acid Agelas oroides Gehrig & Efferth (2008) (58);Tasdemir et al. (2007) (61) 
cynaropiricin Centaurea & Cynara spp. Adams et al. (2010) (62) 
komaroviquinone Dracocephalum komarovi Suto et al. (2010) (63) 
melampyroside Melampyrum arvense Kirmizibekmez et al. (2009) (64) 
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mussaenoside Melampyrum arvense Kirmizibekmez et al. (2009) (64) 
mussaenocidic acid Melampyrum arvense Kirmizibekmez et al. (2009) (64) 
G8-epi-loganin Melampyrum arvense Kirmizibekmez et al. (2009) (64) 
benzoic acid Melampyrum arvense Kirmizibekmez et al. (2009) (64) 
muqubilone B Diacamus bismarckensis Rubio et al. (2011) (65) 
ent-muqubilone Diacamus bismarckensis Rubio et al. (2009) (65) 
sigmosceptrellin A Diacamus bismarckensis Rubio et al. (2009) (65) 
sigmosceptrellin A methyl ester Diacamus bismarckensis Rubio et al. (2009) (65) 
sigmosceptrellin B Diacamus bismarckensis Rubio et al. (2009) (65) 
epi-muqubillin A Diacamus bismarckensis Rubio et al. (2009) (65) 
Epi-nuapapuin B methyl ester Diacamus bismarckensis Rubio et al. (2009) (65) 
aerucyclamide B Microcystis aeruginosa Portman et al. (2011) (66) 
aerucyclamide C Microcystis aeruginosa Portman et al. (2011) (66) 
(-)-cubebin Zanthoxylum naranjillo Bastos et al. (1999) (67) 
apicidin Fusarium pallidoroseum Murray et al. (2001) (68) 
lunarine Lunaria biennis Hamilton et al. (2006) (69) 
lunaridine Lunaria biennis Hamilton et al. (2006) (69) 
tetrahydrolunarine Lunaria biennis Hamilton et al. (2006) (69) 
lunarinol Lunaria biennis Hamilton et al. (2006) (69) 
tetrahydrolunarinol Lunaria biennis Hamilton et al. (2006) (69) 
numismine Lunaria biennis Hamilton et al. (2006) (69) 
kukoamine A Lycium chinense & others Ponasik et al. (1995) (70) 
coronaridine Muntafara sessilifolia Girardot et al. (2011) (71) 
tabernaemontanine Muntafara sessilifolia Girardot et al. (2011) (71) 
tabernaelegantine A Muntafara sessilifolia Girardot et al. (2012) (72) 
tabernaelegantine B Muntafara sessilifolia Girardot et al. (2012) (72) 
tabernaelegantine D Muntafara sessilifolia Girardot et al. (2012) (72) 
violacein Chromobacterium violaceum Duran et al. (2011) (73) 
miltirone Salvia miltiorrhiza Slusarczyk et al. (2011) (74) 
methylenetanshinquinone Salvia miltiorrhiza Slusarczyk et al. (2011) (74) 
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hydrangdione A Salvia hydrangea Moridi Farimani et al. (2011) (75) 
hydrangdione B Salvia hydrangea Moridi Farimani et al. (2011) (75) 
arbusculin B Saussurea costus Julianti et al. (2011) (76) 
a-cyclocostunolide Saussurea costus Julianti et al. (2011) (76) 
costunolide Saussurea costus Julianti et al. (2011) (76) 
dehydrocostuslactone Saussurea costus Julianti et al. (2011) (76) 
parthenolide n.k. Julianti et al. (2011) (76) 
zaluzanin D Laurus nobilis Julianti et al. (2011) (76) 
eupatoriopicrin Eupatorium cannabinum Julianti et al. (2011) (76) 
allaxanthone C Allanblackia monticola Lenta et al. (2007,a) (77);Azebaze et al. (2006) (78) 
mangostin Allanblackia monticola Lenta et al. (2007,a) (77);Azebaze et al. (2006) (78) 
tovophyllin A Allanblackia monticola Lenta et al. (2007,a) (77);Azebaze et al. (2006) (78) 
rubraxanthone Allanblackia monticola Lenta et al. (2007,a) (77);Azebaze et al. (2006) (78) 
norcowanin Allanblackia monticola Lenta et al. (2007,a) (77);Azebaze et al. (2006) (78) 
friedelan-3-one Allanblackia monticola Lenta et al. (2007,a) (77);Azebaze et al. (2006) (78) 
zenkequinone A Stereospermum zenkeri Lenta et al. (2007,a) (77);Lenta et al. (2007,b) (79) 
zenkequinone B Stereospermum zenkeri Lenta et al. (2007,a) (77);Lenta et al. (2007,b) (79) 
sterequinone F Stereospermum zenkeri Lenta et al. (2007,a) (77);Lenta et al. (2007,b) (79) 
G6-O-methylcatalpol n.k. Ogungbe & Setzer (2009) (80) 
G6-O-b-D-xylopyranosylaucubin n.k. Ogungbe & Setzer (2009) (80) 
ajugol n.k. Ogungbe & Setzer (2009) (80) 
ajugoside n.k. Ogungbe & Setzer (2009) (80) 
aucubin n.k. Ogungbe & Setzer (2009) (80) 
catalpol n.k. Ogungbe & Setzer (2009) (80) 
ningpogenin n.k. Ogungbe & Setzer (2009) (80) 
scrolepidoside n.k. Ogungbe & Setzer (2009) (80) 
ancistrogriffine A n.k. Ogungbe & Setzer (2009) (80) 
ancistrogriffine C n.k. Ogungbe & Setzer (2009) (80) 
ancistrolikokine D n.k. Ogungbe & Setzer (2009) (80) 
ancistrotanzanine A n.k. Ogungbe & Setzer (2009) (80) 
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ancistrotanzanine B n.k. Ogungbe & Setzer (2009) (80) 
ancistrotanzanine C n.k. Ogungbe & Setzer (2009) (80) 
ancistrotectonine n.k. Ogungbe & Setzer (2009) (80) 
aromoline n.k. Ogungbe & Setzer (2009) (80) 
korupensamine A n.k. Ogungbe & Setzer (2009) (80) 
G3-O-acetylsanguinine n.k. Ogungbe & Setzer (2009) (80) 
G8-Hydroxyheptadeca-1-ene-4,6-diyn-3-ylacetate n.k. Ogungbe & Setzer (2009) (80) 
G8-Hydroxylheptadeca-4,6-diyn-3-ylacetate n.k. Ogungbe & Setzer (2009) (80) 
G16-Acetoxy-11-hydroxyoctadeca-17-ene-12,14-
diynyl acetate 
n.k. Ogungbe & Setzer (2009) (80) 
G1,7-bis(4-hydroxyphenyl)-heptane-3,5-dione n.k. Ogungbe & Setzer (2009) (80) 
G1,7-bis(4-hydroxyphenyl)-heptene-3,5-dione n.k. Ogungbe & Setzer (2009) (80) 
ambigol A n.k. Ogungbe & Setzer (2009) (80) 
ambigol C n.k. Ogungbe & Setzer (2009) (80) 
angoroside C n.k. Ogungbe & Setzer (2009) (80) 
chaetoxanthone A n.k. Ogungbe & Setzer (2009) (80) 
chaetoxanthone B n.k. Ogungbe & Setzer (2009) (80) 
letestuianin C n.k. Ogungbe & Setzer (2009) (80) 
vismione D n.k. Ogungbe & Setzer (2009) (80) 
G3-geranylemodin n.k. Ogungbe & Setzer (2009) (80) 
arnicolide A n.k. Ogungbe & Setzer (2009) (80) 
isoalantolactone n.k. Ogungbe & Setzer (2009) (80) 
ivalin n.k. Ogungbe & Setzer (2009) (80) 
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66.  Portmann C, Blom JF, Kaiser M, Brun R, Jüttner F, Gademann K. Isolation of Aerucyclamides C and D and Structure Revision of Microcyclamide 7806A: Heterocyclic 
Ribosomal Peptides from Microcystis aeruginosa PCC 7806 and Their Antiparasite Evaluation. J Nat Prod. 2011 Nov 1;71(11):1891–6.  
67.  Bastos JK, Albuquerque S, Silva MLA. Evaluation of the Trypanocidal Activity of Lignans Isolated from the Leaves of Zanthoxylum naranjillo. Planta Med. 1999 
Aug;65(6):541–4.  
68.  Murray PJ, Kranz M, Ladlow M, Taylor S, Berst F, Holmes AB, et al. The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. Bioorg 
Med Chem Lett. 2001 Mar 26;11(6):773–6.  
69.  Hamilton CJ, Saravanamuthu A, Poupat C, Fairlamb AH, Eggleston IM. Time-dependent inhibitors of trypanothione reductase: analogues of the spermidine alkaloid 
lunarine and related natural products. Bioorg Med Chem. 2006 Apr 1;14(7):2266–78.  
70.  Ponasik JA, Strickland C, Faerman C, Savvides S, Karplus PA, Ganem B. Kukoamine A and other hydrophobic acylpolyamines: potent and selective inhibitors of 
Crithidia fasciculata trypanothione reductase. Biochem J. 1995 Oct 15;311(Pt 2):371–5.  
71.  Girardot M, Deregnaucourt C, Deville A, Dubost L, Joyeau R, Allorge L, et al. New vobasinyl-iboga bisindole alkaloids with antiparasitic activities from Muntafara 
sessilifolia. Planta Med [Internet]. 2011 Aug [cited 2011 Nov 2];77(12). Available from: http://ovidsp.tx.ovid.com/sp-
3.4.2a/ovidweb.cgi?&S=GANFFPDMIMDDOEHONCBLEBFBJHPIAA00&Complete+Reference=S.sh.16%7c3%7c1 
72.  Girardot M, Deregnaucourt C, Deville A, Dubost L, Joyeau R, Allorge L, et al. Indole alkaloids from Muntafara sessilifolia with antiplasmodial and cytotoxic activities. 
Phytochemistry. 2012 Jan;73:65–73.  
73.  Durán M, Ponezi AN, Faljoni-Alario A, Teixeira MFS, Justo GZ, Durán N. Potential applications of violacein: a microbial pigment. Med Chem Res [Internet]. 2011 May 
[cited 2011 Nov 2]; Available from: http://www.springerlink.com/index/10.1007/s00044-011-9654-9 
74.  Ślusarczyk S, Zimmermann S, Kaiser M, Matkowski A, Hamburger M, Adams M. Antiplasmodial and Antitrypanosomal Activity of Tanshinone-Type Diterpenoids from 
Salvia miltiorrhiza. Planta Med. 2011 Mar;77(14):1594–6.  
75.  Moridi Farimani M, Bahadori B, Taheri S, Nejad Ebrahimi S, Hamburger M. Antiplasmodial and antitrypanosomal triterpenoids from Salvia hydrangea with rare carbon 
skeletons. Planta Med [Internet]. 2011 Aug [cited 2011 Nov 3];77(12). Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0031-1282576 
76.  Julianti T, Hata Y, Zimmermann S, Kaiser M, Hamburger M, Adams M. Antitrypanosomal sesquiterpene lactones from Saussurea costus. Fitoterapia. 2011 
Oct;82(7):955–9.  
77.  Lenta BN, Vonthron-Sénécheau C, Weniger B, Devkota KP, Ngoupayo J, Kaiser M, et al. Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds 
from Allanblackia monticola and Symphonia globulifera. Mol Basel Switz. 2007;12(8):1548–57.  
78.  Azebaze AGB, Meyer M, Valentin A, Nguemfo EL, Fomum ZT, Nkengfack AE. Prenylated xanthone derivatives with antiplasmodial activity from Allanblackia monticola 
STANER L.C. Chem Pharm Bull (Tokyo). 2006 Jan;54(1):111–3.  
79.  Lenta BN, Weniger B, Antheaume C, Noungoue DT, Ngouela S, Assob JCN, et al. Anthraquinones from the stem bark of Stereospermum zenkeri with antimicrobial 
activity. Phytochemistry. 2007 Jun;68(11):1595–9.  
80.  Ogungbe IV, Setzer WN. Comparative Molecular Docking of Antitrypanosomal Natural Products into Multiple Trypanosoma brucei Drug Targets. Molecules. 2009 Apr 
14;14:1513–36.  
449 
 
Table 7.1.4 - substances used for the treatment of trypanosomiasis(1).  The compounds were included in the 
'Knowledge' library for virtual screening.  Examples are historically used, currently used, or may be used in the 
future. 
Nagana Red 
Trypan Red 
Trypan Blue 
Afridol Violet 
Suramin 
Atoxyl 
arsenophenylglycine 
Tryparsamide 
Melarsen 
Melarsen Oxide 
Melarsoprol 
Synthalin 
Diamidino-1,11-n-undecane 
Stilbamidine 
Pentamidine 
2,5-bis(4-aminophenyl)-furan 
Nifurtimox 
Eflornithine 
Disulfuram 
N-ethylmaleimide 
Benznidazole 
 
Reference: 
1.  Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. 
Parasit Vectors [Internet]. 2011 [cited 2011 Sep 27];3(15). Available from: 
http://www.parasitesandvectors.com/content/3/1/15 
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Table 7.1.5 - proteins identified by protein structure similarity clustering.  The Q-score is a measure of structural similarity that takes into account the number of residues aligned.  The 
maximum value for a Q-score is (resulting from two identical proteins).  The P-score represents the probability of finding a better alignment by chance.  All results with a P-score lower 
than P were rejected.  Only results with a percentage sequence similarity (%ss) less than 20 were accepted. 
Protein ID Q-score P-score RMSD %ss Relevance 
Human GalE d1hzjb_ 
1HZJ:B 
0.272 8.35 1.919 12.8 Galactose metabolism 
E. coli GalE d1naia_ 0.264 7.77 1.988 12.9 Galactose metabolism 
Spinach SQD1 protein complex d1qrra_ 0.207 7.11 2.316 12.9 Phosphate stress in photosynthetic  membranes 
Strep. Venezuelae dTDP-glucose 
4,6-dehydratase 
d1r6da_ 0.266 2.03 2.213 14.8 6-deoxyhexose synthesis (cell wall glycans) 
Arabidopsis thaliana GDP-
mannose 4,6-dehydratase 
d1n7hb_ 0.260 6.24 2.245 11.9 Mannose & fructose metabolism 
Salmonella CDP-tyvelose 2-
epimerase 
d1orrb_ 0.263 4.37 1.827 15.4 tyvelose (O-antigens of some bacteria) synthesis 
Human GDP-mannose 4,6-
dehydratase 
d1t2daa_ 0.277 4.41 2.181 14.8 Mannose & fructose metabolism 
E. coli ArnA decarboxylase domain d1u9ja_ 0.230 4.22 2.438 13.0 Modification of Lipid A of LPS – cause of polymixin and 
cationic antimicrobial peptide (CAMP) resistance. 
P. aeruginosa GDP-4-keto-6-
deoxy-D-mannose reductase 
2pk3:B 0.289 6.55 2.122 8.7 L-fucose pathway.  L-fucose is in bacterial cell wall 
polysaccharide, LPS, human selectins – role in inflammation 
and metastasis. 
Bacillus Cereus UDP-N-acetyl-
glucosamine-4-epimerase 
3m2p:E 0.225 4.16 2.022 17.5 Initiation of O-glycosylation 
E. coli K-12 ADP-glycero-D-
mannoheptose 6-epimerase 
1eq2:F 0.225 3.92 2.364 11.7 ADP-D-glycero-D-mannoheptose and ADP-L-glycero-D-
mannoheptose interconversion – LPS synthesis 
Human FX protein (GDP-L-fucose 
synthase) 
4e5y:A 0.241 3.62 2.329 9.2 Human antigens and selectins – role in inflammation and 
metastasis; leukocyte adhesion. 
Salmonella typhii CDP-D-glucose 
4,6-dehydratase 
1wvg:A 0.525 21.58 1.913 17.4 First step in tyvelose synthesis – O antigens 
Trypanosoma brucei GalE 1gy8:A 0.483 17.97 2.071 17.6 Galactose metabolism, validated target 
Arabidopsis thaliana GDP-
mannose 3’,5’-epimerase 
2c59:B 0.471 10.03 2.037 16.7 Possible precursors for plant vitamin C biosynthesis. 
Salmonella enterica typhimurium 
dTDP-6-deoxy-L-lyxo-4-hexulose 
reductase (dTDP-4-
1n2s:A 0.430 7.10 2.589 15.7 L-rhamnose synthetic pathway – bacterial cell-wall anchoring 
and LPS. 
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Protein ID Q-score P-score RMSD %ss Relevance 
dehydrorhamnose reductase) 
Grape (Vitis vinifera) 
dihydroflavonol 4-reductase 
(dihydrokaempferol reductase) 
2c29:D 0.421 15.05 2.396 16.1 Flavonoid (anthocyanin and condensed tannin) synthesis – 
plant survival. 
Staph Aureus capsular 
polysaccharide synthesizing 
enzyme (CAPE) 
3w1v:B 0.335 12.09 2.264 15.8 Obvious drug target 
Digitalis lanata progesterone 5β-
reductase 
2v6f:A 0.323 9.11 2.738 10.4 digitalis cardenolide synthesis 
Human S-adenosyl-methionine 
synthetase, subunit beta  
2ydx:A 0.452 11.85 2.248 18.1 Essential to normal cell function and growth.  Cancer drug 
target.  Note two types: liver- & non-liver- (kidney-) specific. 
Human UDP-xylose synthase 
(UDP-glucoronic acid 
decarboxylase) 
4gll:B 0.452 14.14 2.117 19.8 Polyamine & proteoglycan synthesis – cell/tumor growth. 
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Table 7.1.6 - proteins and ligands identified using PSSC.  The ligands listed were included in the virtual screen against TDH.  The references are listed below the table. 
Protein Organism Ligands 
UDP-galactose 4’-epimerase (GalE) Saccharomyces fragilis phenylglyoxal; 1,2-cyclohexanediol; 2,3-
butanedione, 5’UMP(1); DTNB(2). 
 Kluyveromyces marxianus 2',3'-O-(2,4,6-Trinitrocyclohexadienylidene)uridine 
5'-monophosphate (3); diethyldicarbonate (4); L-
arabinose(5), UTP(6). 
 Bos taurus 2-Hydroxy-5-nitrobenzyl bromide; 
showdomycin(7). 
 Saccharomyces cerevisiae D-xylose, L-arabinose(8). 
dTDP-glucose 4,6-dehydratase E. coli dTDP-6-deoxy-D-glucose; dTDP-6-deoxy-D-
galactose(9). dTDP-xylose(10).   
 Streptomyces sp. C5 TMP, TDP, TTP(11). 
GDP-glucose 4,6-dehydratase Phaseolus vulgaris GDP-D-glucose, GMP, GTP, ITP(12). 
UDP-N-acetyl-glucosamine-4-epimerase Homo sapiens 6-Bromo-2-hydroxy-naphthalene-1-carbaldehyde 
O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-
dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime(13). 
GDP-L-fucose synthetase E. coli GDP, GDP-fucose(14). 
CDP-D-glucose 4,6-dehydratase Yersinia pseudotuberculosis CDP-6-deoxy-6,6-difluoro-d-glucose(15). 
Dihydroflavonol 4-reductase Onobrychis viciifolia DTT, diethyldithiocarbamate(16). 
 Salmonella enterica dTDP-6-deoxy-L-mannose(17),  
 Mycobacterium tuberculosis CHEMBL375328(NSC 9037), cid 
72722(Chembridge 5108509), 
CHEMBL175266(NSC 5426), 
CHEMBL205119(NSC 371300) (18). 
UDP-D-xylose synthase (UDP-glucuronic acid 
decarboxylase) 
Cryptococcus laurentii 3-acetylpyridine, 3-formylpyridine, 3-
propionylpyridine, AMP, UDP, UDP-glucose, UDP-
xylose, UMP(19) 
 Oryza sativa CDP, CTP, GDP, GDP-mannose, TDP, TMP, TTP, 
UDP-glucose, UDP-xylose(20). 
 Hordeum vulgare UDP-galactose, UDP-glucose, UDP-D-xylose(21). 
 Triticum aestivum UDP, UDP-arabinose, UMP(22). 
S-adenosylmethionine synthetase Rattus norvegicus (2S,4S)-amino-4,5-epoxypentanoic acid 
(AEP)(23).  L-buthionine-(S,R)-sulfoximine; S-
nitrosoglutathione; S-nitrosoglutathione monoethyl 
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ester(24).  Epoxy analogue I(a); epoxy analogue 
I(b); epithioaminoacid analogue II(a); epoxy 
analogue I(c); epithioaminoacid analogue II(b); 
epithioaminoacid analogue II(c)(25).  
CHEMBL608501(26).  CHEMBL609500(27).  
CHEMBL603986(28).  CHEMBL608502(26).  
CHEMBL1791426(27).  CHEMBL609078(29).  
CHEMBL606493(28).  CHEMBL611540(27).  
CHEMBL1791425(27).  AMPPNP(30).  
CHEMBL1791411(28).  CHEMBL1791415(31).  
CHEMBL607665(29).  CHEMBL1791416(29). 
 E. coli 1-(3-(2-ethoxyphenyl)ureidoacetyl)-4-(2-methyl-5-
nitrophenyl)semicarbazide; 1-(4-chloro-2-
nitrophenyl)-3-(4-sulfamoylphenyl)-urea(32).  
Adenyl-5'-ylimidodiphosphate; GTP; S-
carbamylcysteine(33).  Diimidotriphosphate(34). 
 Mycobacterium smegmatis 1-methyluric acid; 1-methylxanthine; 2,6-
diaminopurine; 2,6-dichloropurine; 2-amino-6-
carboxyethylmercaptopurine; 2-amino-6-
chloropurine riboside; 2-amino-6-chloropurine-9-
acetic acid; 2-aminopurine; 2-hydroxypurine; 3,7-
dimethyluric acid; 6-benzyloxypurine; 6-
bromopurine; 6-chloropurine; 6-chloropurine 
riboside; 6-cyanopurine; 6-
dimethylallylaminopurine riboside; 6-
dimethylaminopurine; 6-mercaptopurine; 6-
mercaptopurine riboside; 6-propoxypurine; 7-
hydroxypropyl theophylline; 7-methyluric acid; 7-
methylxanthine; 8-aza-2,6-diaminopurine; 8-
azaguanine; 8-chlorotheophylline; alpha-methyl-
DL-methionine; azathioprine; L-ethioninamide; L-
ethionine; L-methionine methyl ester; L-methionine 
sulfone; L-methionine sulfoxide; L-methionine 
sulfoxime; L-penicillamine; methylthio 
propionaldehyde; O-methylguanine; uric acid; 
xanthine (35).    
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 Catharanthus roseus ADP; CTP; ethionine; L-ornithine; GTP; 
putrescine; spermidine; spermine(36). 
 Saccharomyces cerevisiae Alpha,beta-methylene-ATP; beta,gamma-
methylene-ATP; CTP; dGTP; GDP; GTP; TTP; 
UTP(37).  AMP(38).  1-
aminocyclopentanecarboxylic acid; DL-2-Amino-
trans-4-hexenoic acid; GTP; S-Trifluoromethyl-L-
homocysteine(39). 
 Trypanosoma brucei brucei Cycloleucine; D-methionine; DL-ethionine; L-2-
Amino-4-methoxy-cis-but-3-enoic acid; S-
adenosyl-L-homocysteine; S-adenosylmethionine; 
seleno-L-methionine(40). 
 Mus musculus L-2-Amino-4-methoxy-cis-but-3-enoic acid; L-2-
Amino-4-methylthio-cis-but-3-enoic acid(41). 
 Arabidopsis thaliana nitrosoglutathione(42). 
 Leishmania infantum S-adenosyl L-ethionine(43). 
 
References: 
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Table 7.1.7 - hits from Virtual Screen 1, listed according to predicted binding affinity. 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-11.88, 1.96 ZINC01673377  
 
 
296.29 1.72 181.42 10 , 4 2   
-11.6, 3.14 ZINC19362650  
 
 
357.56 0.73 7.68 2 , 1 2   
-11.43, 4.19 ZINC01755448  
 
 
398.45 6.87 52.6 2 , 0 6   
-11.42, 4.26 apigenin-7-glucoside  
 
 
432.38 0.44 166.14 10 , 6 4   
-11.34, 4.87 daphneside  
 
 
502.42 -3.36 225.06 13 , 8 6   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-11.28, 5.39 ZINC19325791  
 
 
182.27 0.37 39.33 4 , 3 0   
-11, 8.65 lawsoniaside  
 
 
500.45 -2.48 218.99 13 , 9 6   
-10.93, 9.73 ZINC19325788  
 
 
182.27 0.37 39.33 4 , 3 0   
-10.77, 12.75 ZINC19325788  
 
 
182.27 0.37 39.33 4 , 3 0   
-10.76, 12.97 ZINC19325794  
 
 
182.27 0.37 39.33 4 , 3 0   
-10.75, 13.19 ZINC26730911  
 
 
428.42 -4.61 152.45 10 , 3 3   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-10.71, 14.11 ZINC01729523  
 
 
353.87 0.28 49.73 3 , 2 3   
-10.63, 16.15 ZINC19325794  
 
 
184.28 -8.00 48.49 4 , 3 0   
-10.59, 17.28 ZINC19325794  
 
 
184.28 -8.00 48.49 4 , 3 0   
-10.57, 17.87 ZINC18189380  
 
 
265.31 3.05 74.8 5 , 3 2   
-10.5, 20.11 brusatol  
 
 
520.53 0.24 165.89 8 , 3 5   
-10.42, 23.02 ZINC19325788  
 
 
184.28 -8.00 48.49 4 , 3 0   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-10.39, 24.21 luteolin-3'-O-
glucoside 
 
 
 
448.38 0.14 186.37 11 , 7 4   
-10.36, 25.47 ZINC26730911  
 
 
428.42 -4.61 152.45 10 , 3 3   
-10.35, 25.90 ZINC01481770  
 
 
292.39 -1.08 24.67 2 , 2 0   
-10.27, 29.65 ZINC01568966  
 
 
407.87 5.83 92.05 4 , 2 4   
-10.27, 29.65 ZINC01729525  
 
 
353.87 0.28 49.73 3 , 2 3   
-10.23, 31.72 CA60  
 
 
326.31 1.97 101.38 6 , 2 3   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-10.23, 31.72 ZINC04428843  
 
 
328.40 3.93 63.6 4 , 1 3   
-10.22, 32.26 ZINC13143009  
 
 
405.36 0.52 49.73 3 , 2 5   
-10.2, 33.37 ZINC18189380  
 
 
266.32 1.95 81.65 5 , 4 2   
-10.19, 33.93 ZINC04824902  
 
 
378.84 1.77 140.16 7 , 3 3   
-10.18, 34.51 3-O-Methylellagic acid 
3'-O-α-4''-O-
acetylrhamnopyranosi
de 
 
 
504.40 0.38 187.51 10 , 4 5   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-10.18, 34.51 ZINC19701771  
 
 
428.42 -4.61 152.45 10 , 3 3   
-10.13, 37.55 ZINC03647770  
 
 
379.88 1.45 118.36 5 , 3 3   
-10.13, 37.55 ZINC03875548  
 
 
392.40 5.92 52.6 2 , 0 4   
-10.12, 38.19 ZINC01573829  
 
 
353.44 5.74 38.67 3 , 0 3   
-10.11, 38.84 ZINC00001761  
 
 
349.38 0.01 125.55 8 , 4 4   
-10.09, 40.17 ZINC19325794  
 
 
182.27 0.37 39.33 4 , 3 0   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-10.09, 40.17 ZINC29589828  
 
 
396.91 4.54 35.94 4 , 1 6   
-10.08, 40.86 ZINC05487838  
 
 
404.24 4.51 71.7 4 , 2 3   
-10.04, 43.71 ZINC19701771  
 
 
428.42 -4.61 152.45 10 , 3 3   
-10.01, 45.98 ZINC29589888  
 
 
434.44 5.14 95.5 4 , 3 4   
-9.99, 47.56 ZINC01718486  
 
 
385.25 5.23 67.66 5 , 2 4   
-9.97, 49.19 ZINC03947435  
 
 
286.47 1.32 27.64 1 , 1 2   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-9.93, 52.63 ZINC01607786  
 
 
392.25 5.51 49.33 2 , 2 2   
-9.92, 53.52 ZINC01563325  
 
 
430.40 1.02 133.27 7 , 1 6   
-9.91, 54.43 ZINC22910159  
 
 
357.39 2.22 117.55 6 , 1 4   
-9.9, 55.36 cassyformine  
 
 
341.36 1.73 69.18 6 , 2 2   
-9.9, 55.36 ZINC01708940  
 
 
321.35 0.55 100.55 4 , 1 8   
-9.88, 57.26 ZINC04896472  
 
 
325.32 4.03 64.85 4 , 0 1   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-9.88, 57.26 ZINC18124911  
 
 
465.30 7.50 35.83 3 , 1 4   
-9.87, 58.24 ZINC01722585  
 
 
410.37 3.18 93.43 7 , 0 7   
-9.84, 61.26 quercetin 7-glucosyl  
 
 
464.38 -0.11 206.6 12 , 8 4   
-9.8, 65.54 ZINC01707215  
 
 
378.84 1.77 140.16 7 , 3 3   
-9.77, 68.94 isoscutellarin  
 
 
462.36 0.46 203.44 12 , 7 4   
-9.77, 68.94 ZINC02015922  
 
 
387.86 1.42 118.36 5 , 3 3   
466 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-9.77, 68.94 ZINC03831068  
 
 
340.44 -2.52 69.56 3 , 4 4   
-9.74, 72.52 ZINC03260391  
 
 
462.74 3.46 92.7 4 , 2 7   
-9.7, 77.59 ZINC01590993  
 
 
371.43 4.37 81.7 3 , 1 9   
-9.69, 78.91 ZINC13597738  
 
 
259.35 4.03 77.98 3 , 4 1   
-9.68, 80.25 ZINC00608128  
 
 
354.44 3.39 54.7 3 , 1 3   
-9.67, 81.62 ZINC02636757  
 
 
451.88 1.77 131.62 6 , 2 8   
467 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-9.67, 81.62 ZINC13143008  
 
 
405.36 0.52 49.73 3 , 2 5   
-9.67, 81.62 ZINC18189380  
 
 
265.31 2.59 74.8 5 , 3 2   
-9.66, 83.01 camaldulenside  
 
 
520.53 2.10 172.21 10 , 5 7   
-9.66, 83.01 ZINC05493736  
 
 
334.48 3.12 49.41 3 , 1 1   
-9.65, 84.42 luteolin-7-O-glucoside  
 
 
448.38 0.14 186.37 11 , 7 4   
-9.64, 85.86 ZINC01683345  
 
 
300.89 -3.18 28.5 3 , 3 3   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-9.62, 88.81 ZINC05647206  
 
 
263.27 2.65 73.04 3 , 3 1   
-9.58, 95.01 actinodaphnine  
 
 
311.33 1.91 59.95 5 , 2 1   
-9.57, 96.63 ZINC01665801  
 
 
345.43 5.45 29.54 2 , 0 3   
-9.56, 98.27 NSC128590 
(CHEMBL1172557) 
 
 
 
644.67 8.53 132.8 6 , 4 8   
-9.56, 98.27 ZINC18038389  
 
 
356.40 2.99 120.13 6 , 2 4   
-9.55, 99.94 ZINC05640620  
 
 
310.37 -3.07 67.84 4 , 2 3   
469 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-9.55, 99.94 ZINC29590277  
 
 
446.99 6.73 32.34 2 , 1 4   
-9.54, 101.65 ZINC19362651  
 
 
357.56 0.73 7.68 2 , 1 2   
-9.52, 105.14 ZINC06576323  
 
 
326.80 4.65 54.46 3 , 1 3   
-9.51, 106.92 D-isoboldine  
 
 
327.37 2.78 62.16 5 , 2 2   
-9.51, 106.92 ZINC00600877  
 
 
354.38 0.87 117.13 5 , 1 9   
-9.51, 106.92 ZINC04141542 
(BPOB) 
 
 
 
330.17 -1.01 94.04 4 , 2 7   
470 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS3? 
Hit in 
VS4? 
-9.5, 108.74 ZINC01584497  
 
 
361.40 4.75 96.87 5 , 2 6   
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Table 7.1.8 - hits from Virtual Screen 3, listed according to predicted binding energy. 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-15.03, .01 α-solamargine 
(solasonine) 
 
 
 
884.06 0.34 258.71 17 , 10 8   
-13.62, .10 ancistrogriffithine A 
 
 
784.94 7.21 141.9 10 , 6 5   
-13.62, .10 ZINC05492794 
 
 
594.73 10.95 51.56 4 , 0 6   
-13.11, .25 3,23-dioxotirucalla-
7,24-dien-21-al 
 
 
452.67 6.42 51.21 3 , 0 5   
-12.72, .47 ZINC17465983  
 
 
546.52 5.67 173.98 10 , 6 0   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-12.7, .49 podocarpusﬂavone A  
 
 
552.48 5.23 162.98 10 , 5 3   
-12.56, .62 ZINC17465979 
 
 
546.52 5.67 173.98 10 , 6 0   
-12.28, 1.00 Cis-p-
methoxycinnamoylox
yursolicacid methyl 
ester 
 
 
644.92 9.89 61.83 3 , 0 7   
-12.28, 1.00 luteolin-3'-O-
glucoside 
 
 
 
448.38 0.14 186.37 11 , 7 4   
-12.2, 1.14 lawsoniaside 
 
 
500.45 -2.48 218.99 13 , 9 6   
473 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-12.28, 1.00 Cis-p-
methoxycinnamoylox
yoleanolicacid methyl 
ester 
 
 
 
630.90 9.62 61.83 3 , 0 7   
-12.13, 1.28 amentoflavone  
 
 
538.46 5.09 173.98 10 , 6 2   
-12.07, 1.42 ZINC01755448 
 
 
398.45 6.87 52.6 2 , 0 6   
-11.87, 1.99 bruceantinol 
 
 
606.61 0.10 192.19 9 , 3 8   
-11.87, 1.99 tetra-
acetyldaucosterol 
 
 
689.06 10.07 55.38 6 , 0 17   
474 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-11.86, 2.03 chrysophanol-8-
glucoside 
 
 
 
416.38 1.21 153.75 9 , 5 3   
-11.81, 2.20 4'-O-
demethylknipholone-
4'-O-B-d-
glucopyranoside 
 
 
582.51 2.80 231.51 13 , 8 4   
-11.73, 2.52 ZINC05124931 
 
 
424.53 7.30 34.14 2 , 0 4   
-11.71, 2.61 stigmasterol-D-
glucoside 
 
 
574.83 5.71 99.38 6 , 4 8   
-11.68, 2.74 ZINC11616856 
 
 
 
 
656.65 2.78 160.83 12 , 3 6   
475 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-11.63, 2.99 ZINC12671904  
 
 
412.56 4.53 60.44 3 , 0 2   
-11.61, 3.09 physcion 1-β-D-
glucopyranoside 
 
 
462.40 1.40 183.21 11 , 6 4   
-11.49, 3.78 3-O-Methylellagic 
acid 3'-O-α-4''-O-
acetylrhamnopyranos
ide 
 
 
504.40 0.38 187.51 10 , 4 5   
-11.48, 3.85 NSC132249 
(CHEMBL1173812) 
 
 
 
474.34 7.34 66.4 3 , 2 4   
-11.37, 4.63 ZINC12671898 
 
 
412.56 4.53 60.44 3 , 0 2   
-11.36, 4.71 NSC128594 
(CHEMBL1173451) 
 
 
405.44 6.14 66.4 3 , 2 4   
476 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-11.36, 4.71 ZINC01726776  
 
 
398.84 7.10 52.83 3 , 0 4   
-11.35, 4.79 lanaroflavone 
 
 
538.46 5.24 162.98 9 , 5 4   
-11.3, 5.21 tabernaelegantine A 
 
 
706.91 6.53 99.89 5 , 2 8   
-11.3, 5.21 tovophyllin A  
 
 
464.55 5.36 96.22 6 , 3 4   
-11.27, 5.48 NSC127133 
(CHEMBL1172911) 
 
 
434.44 5.14 95.5 4 , 3 4   
-11.24, 5.77 astrogaloside III 
 
 
784.97 -0.31 228.22 14 , 9 7   
477 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-11.23, 5.87 ZINC13154307  
 
 
363.54 5.21 36.02 1 , 2 0   
-11.22, 5.97 vernoguinosterol 
 
 
486.64 2.84 96.22 6 , 3 3   
-11.19, 6.28 aculeatin D 
 
 
418.61 7.02 55.76 4 , 1 12   
-11.19, 6.28 mangostin 
 
 
410.46 6.00 96.22 5 , 3 5   
-11.18, 6.38 ZINC01572309 
 
 
474.56 6.43 108.04 4 , 4 4   
-11.17, 6.49 buddlejasaponin III  
 
 
899.07 -0.04 266.91 17 , 10 8   
478 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-11.15, 6.71 isoginkgetin  
 
 
566.51 5.38 151.98 10 , 4 4   
-11.11, 7.18 tabernaelegantine B 
 
 
 
 
 
706.91 6.53 99.89 5 , 2 8   
-11.05, 7.95 NSC128604 
(CHEMBL1173036) 
 
 
435.43 5.32 92.7 4 , 2 4   
-11.05, 7.95 ginkgetin 
 
 
580.54 5.53 140.98 10 , 3 5   
-11.04, 8.08 ZINC05124960 
 
 
359.37 5.53 86.63 5 , 3 4   
479 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-11.02, 8.36 astrogaloside II  
 
 
827.01 0.13 234.29 14 , 8 9   
-11.01, 8.50 tabernaelegantine D  
 
 
 
 
 
706.91 6.53 99.89 5 , 2 8   
-11.01, 8.50 ZINC01530836 
 
 
394.42 3.32 63.22 6 , 0 3   
-10.99, 8.79 cycloartenol 
 
 
426.72 7.55 20.23 1 , 1 4   
-10.99, 8.79 hennadiol 
 
 
442.72 6.86 40.46 2 , 2 1   
480 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.99, 8.79 ZINC17353912  
 
 
472.62 4.00 75.35 4 , 2 2   
-10.97, 9.10 α-chaconine 
 
 
852.06 0.61 220.46 15 , 8 7   
-10.97, 9.10 daphnorin 
 
 
514.44 0.42 170.44 10 , 4 6   
-10.94, 9.57 melampyroside 
 
 
450.44 0.28 155.14 9 , 5 7   
-10.92, 9.90 ZINC03417739  
 
 
530.77 3.06 119 5 , 2 7   
-10.86, 10.95 6-Bromo-2-hydroxy-
naphthalene-1-
carbaldehyde O-[5-
(2,4-dioxo-3,4-
dihydro-2H-pyrimidin-
1-yl)-3,4-dihydroxy-
tetrahydro-furan-2-
ylmethyl]-oxime 
 
 
476.28 1.48 131.69 7 , 4 4   
481 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.86, 10.95 vismione D  
 
 
410.50 5.23 86.99 5 , 3 6   
-10.86, 10.95 ZINC01705443 
 
 
394.42 3.32 63.22 6 , 0 3   
-10.86, 10.95 ZINC13099048 
 
 
447.63 5.52 50.19 3 , 1 2   
-10.84, 11.33 ZINC12670914 
 
 
446.62 4.22 91.67 5 , 2 4   
-10.83, 11.52 sigmosceptrellin A 
methyl ester 
 
 
406.60 6.27 44.76 3 , 0 6   
-10.83, 11.52 yadanzioside C 
 
 
726.72 -2.35 265.27 14 , 7 9   
482 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.79, 12.33 emetine  
 
 
480.64 4.49 52.19 6 , 1 7   
-10.77, 12.75 luteolin-7-O-
glucoside 
 
 
448.38 0.14 186.37 11 , 7 4   
-10.73, 13.64 sigmosceptrellin B  
 
 
378.55 5.82 55.76 4 , 1 5   
-10.72, 13.87 ZINC05462674 
 
 
546.52 5.67 173.98 10 , 6 0   
-10.71, 14.11 G4'-O-
demethylknipholone 
 
 
420.37 5.72 152.36 8 , 5 1   
483 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.71, 14.11 ZINC17995347  
 
 
432.24 4.90 130.56 7 , 3 5   
-10.7, 14.35 6-
dehydroxykhayanolid
e E 
 
 
 
500.54 1.27 132.5 6 , 2 4   
-10.66, 15.35 agrimonolide 6-O-β-
D-glucopyranoside 
 
 
476.47 1.95 155.14 9 , 5 7   
-10.66, 15.35 stigmasterol 
 
 
412.69 7.48 20.23 1 , 1 5   
-10.64, 15.88 ZINC13154306 
 
 
363.54 5.21 36.02 1 , 2 0   
484 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.62, 16.42 3-geranylemodin  
 
 
406.47 6.99 83.83 5 , 2 6   
-10.59, 17.28 sigmosceptrellin A 
 
 
392.57 6.12 55.76 4 , 1 5   
-10.58, 17.57 ZINC11681166  
 
 
 
 
542.55 -3.47 167.42 11 , 6 2   
-10.57, 17.87 camaldulenside 
 
 
520.53 2.10 172.21 10 , 5 7   
-10.56, 18.17 (+)-syringaresinol 
 
 
 
418.44 1.96 95.84 8 , 2 6   
485 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.54, 18.80 ZINC26730911  
 
 
428.42 -4.61 152.45 10 , 3 3   
-10.53, 19.12 caratuberside A 
 
 
656.80 1.05 184.6 12 , 6 7   
-10.53, 19.12 ZINC01855333 
 
 
356.46 5.37 34.14 2 , 0 0   
-10.52, 19.44 ilimaquinone 
 
 
 
358.47 4.37 63.6 4 , 1 3   
-10.52, 19.44 podocarpusﬂavone B 
 
 
 
 
566.51 5.38 151.98 10 , 4 4   
486 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.51, 19.77 5α-poriferastane-
3β,6α-diol 
 
 
 
432.72 6.94 40.46 2 , 2 6   
-10.51, 19.77 ZINC05493736 
 
 
334.48 3.12 49.41 3 , 1 1   
-10.51, 19.77 ZINC17949075 
 
 
402.23 5.47 75.19 4 , 2 3   
-10.49, 20.45 ZINC04783229 
 
 
 
 
 
476.57 5.60 64.68 2 , 2 4   
-10.48, 20.80 ZINC01736227 
 
 
392.45 6.01 42.52 4 , 2 3   
487 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.46, 21.51 apiin  
 
 
564.49 -0.84 225.06 14 , 8 7   
-10.45, 21.88 manumycin A 
 
 
 
 
550.64 3.06 145.33 7 , 4 12   
-10.45, 21.88 Qc2 
 
 
549.95 5.48 79.9 4 , 2 6   
-10.45, 21.88 ZINC05580600 
 
 
401.28 5.06 61.36 2 , 3 2   
-10.44, 22.25 isoscutellarin 
 
 
462.36 0.46 203.44 12 , 7 4   
-10.44, 22.25 ZINC04896472 
 
 
325.32 4.03 64.85 4 , 0 1   
488 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.43, 22.63 vernoguinoside  
 
 
858.96 3.27 205.72 11 , 1 16   
-10.43, 22.63 ZINC00001087 
 
 
348.35 1.22 79.73 4 , 1 1   
-10.43, 22.63 ZINC01645454 
 
 
370.44 3.79 64.99 4 , 1 2   
-10.42, 23.02 23-Hydroxy-5α-
lanosta-7,9(11),24-
triene-3-one 
 
 
438.69 6.68 37.3 2 , 1 4   
-10.42, 23.02 ZINC17949075 
 
 
402.23 5.47 75.19 4 , 2 3   
-10.41, 23.41 kigelinol 308.33 1.83 74.6 4 , 2 0   
489 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
 
 
-10.41, 23.41 cosmossin (acacetin-
7-O-glucoside) 
 
 
432.38 0.44 166.14 10 , 6 4   
-10.4, 23.81 apigenin-7-glucoside  
 
 
432.38 0.44 166.14 10 , 6 4   
-10.4, 23.81 pinoresinol 
 
 
358.39 2.28 77.38 6 , 2 4   
-10.4, 23.81 ZINC01573829 
 
 
353.44 5.74 38.67 3 , 0 3   
490 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.37, 25.04 1α,3α,7α-
trideacetylkhivorin 
 
 
 
460.56 1.99 112.66 5 , 3 1   
-10.36, 25.47 ZINC17465958 
 
 
429.92 6.62 47.03 3 , 0 4   
-10.35, 25.90 ascofuranone 
 
 
 
 
420.93 6.40 83.83 5 , 2 7   
-10.35, 25.90 ZINC03875548 
 
 
392.40 5.92 52.6 2 , 0 4   
-10.34, 26.34 B-sitosterol 
 
 
 
414.71 7.84 20.23 1 , 1 6   
491 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.34, 26.34 lunaridine  
 
 
437.53 1.16 96.53 5 , 3 0   
-10.32, 27.25 ZINC01729524 
 
 
353.87 0.28 49.73 3 , 2 3   
-10.32, 27.25 ZINC17353911 
 
 
472.62 4.00 75.35 4 , 2 2   
-10.31, 27.71 bruceine C 
 
 
564.58 -0.35 186.12 9 , 4 6   
-10.31, 27.71 ZINC13000556  
 
 
421.43 -5.26 136.47 6 , 3 3   
-10.29, 28.66 bilobetin 
 
 
 
566.51 5.38 151.98 10 , 4 4   
492 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.27, 29.65 ZINC01705925  
 
 
353.41 4.82 37.38 2 , 0 4   
-10.27, 29.65 ZINC08581460 
 
 
378.51 7.17 16.13 2 , 0 6   
-10.25, 30.67 ZINC01577889 
 
 
 
392.45 5.90 58.2 2 , 2 5   
-10.25, 30.67 ZINC01644254 
 
 
 
567.46 7.55 66.92 3 , 0 6   
-10.24, 31.19 ZINC00600322 
 
 
370.44 3.79 64.99 4 , 1 2   
-10.24, 31.19 ZINC13099027 
 
 
328.40 3.93 63.6 4 , 1 3   
493 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.23, 31.72 brusatol  
 
 
520.53 0.24 165.89 8 , 3 5   
-10.22, 32.26 pinoresinol di-O-β-D-
glucopyranoside 
 
 
682.67 -2.26 235.68 16 , 8 10   
-10.21, 32.81 ZINC13099025 
 
 
328.40 3.93 63.6 4 , 1 3   
-10.2, 33.37 apigenin-4'-glucoside 
 
 
432.38 0.44 166.14 10 , 6 4   
-10.19, 33.93 aerucyclamide B 
 
 
 
 
 
532.68 2.81 134.67 6 , 3 4   
494 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.18, 34.51 knipholone  
 
 
434.39 5.22 141.36 8 , 4 2   
-10.18, 34.51 sciadopitysin 
 
 
580.54 5.53 140.98 10 , 3 5   
-10.18, 34.51 ZINC13099050 
 
 
447.63 5.52 50.19 3 , 1 2   
-10.16, 35.70 trans-p-
methoxycinnamoylox
yursolicacid methyl 
ester 
 
 
644.92 9.89 61.83 3 , 0 7   
-10.16, 35.70 ZINC12671893 
 
 
412.56 4.53 60.44 3 , 0 2   
495 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.16, 35.70 ZINC13099051  
 
 
447.63 5.52 50.19 3 , 1 2   
-10.16, 35.70 ZINC18169477 
 
 
429.43 6.21 117.23 9 , 2 6   
-10.15, 36.30 ZINC01686969 
 
 
334.48 3.12 49.41 3 , 1 1   
-10.15, 36.30 ZINC04217305 
 
 
341.36 -3.47 98.33 6 , 2 4   
-10.14, 36.92 knipholone anthrone 
 
 
420.41 5.85 124.29 7 , 4 2   
-10.14, 36.92 ZINC29589829 
 
 
396.91 4.54 35.94 4 , 1 6   
496 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10.13, 37.55 lupeol  
 
 
426.72 7.45 20.23 1 , 1 1   
-10.13, 37.55 tetrahydrolunarine 
 
 
441.56 1.08 96.53 5 , 3 0   
-10.12, 38.19 astrogaloside I 
 
 
 
 
869.04 0.57 240.36 14 , 7 11   
-10.11, 38.84 NSC67692 
(CHEMBL1172978) 
 
 
419.43 5.50 83.47 4 , 2 4   
-10.11, 38.84 bruceine A 
 
 
522.54 0.05 165.89 8 , 3 6   
-10.1, 39.50 pelorol 372.50 5.56 66.76 3 , 2 2   
497 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
 
 
-10.05, 42.98 ambigol C 
 
 
484.97 8.29 38.69 1 , 1 4   
-10.03, 44.45 Syringaresinol di-O-
β-D-
glucopyranoside** 
 
 
742.72 -2.57 254.14 18 , 8 12   
-10.02, 45.21 dTDP-6-deoxy-L-
lyxo-4-hexulose  
 
 
 
546.31 -2.04 247.92 12 , 6 8   
-10.02, 45.21 ZINC01735469 
 
 
437.45 3.51 161.72 8 , 3 8   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-10, 46.76 GDP-L-glucose  
 
 
 
605.34 -4.77 327.43 17 , 10 9   
-10, 46.76 bianthrone A1 
 
 
768.93 14.22 133.52 8 , 4 13   
-10, 46.76 2-bromoascicidemin 
 
 
362.18 3.74 55.74 4 , 0 0   
-10, 46.76 ZINC05536814 
 
 
370.44 3.79 64.99 4 , 1 2   
-9.99, 47.56 CHEMBL1172759 
 
 
545.24 7.24 66.4 3 , 2 4   
-9.99, 47.56 sinefungin 
 
 
381.39 -5.14 208.65 11 , 6 7   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.97, 49.19 ZINC17995347  
 
 
432.24 4.90 130.56 7 , 3 5   
-9.96, 50.03 aerucyclamide C 
 
 
 
 
 
516.61 2.22 147.81 6 , 3 3   
-9.96, 50.03 Qc6 
 
 
469.48 5.42 52.65 2 , 1 5   
-9.96, 50.03 ZINC01568966 
 
 
407.87 5.83 92.05 4 , 2 4   
-9.96, 50.03 ZINC13154298 
 
 
493.24 7.70 37.81 3 , 1 4   
-9.94, 51.75 NSC128598 
(CHEMBL1173453) 
 
 
423.44 6.28 66.4 3 , 2 4   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.94, 51.75 nitogenin (diosgenin)  
 
 
414.62 4.93 38.69 3 , 1 0   
-9.94, 51.75 ZINC01735767 
 
 
370.27 6.04 29.1 1 , 1 4   
-9.93, 52.63 (4Z,6E)-5-hydroxy-
1,7-bis(4-
hydroxyphenyl)hepta
-4,6-dien-3-one 
 
 
 
310.34 3.99 77.76 4 , 3 6   
-9.93, 52.63 ZINC01639633 
 
 
 
507.37 6.97 91.49 2 , 4 6   
-9.92, 53.52 ZINC05487838 
 
 
404.24 4.51 71.7 4 , 2 3   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.92, 53.52 ZINC17287336  
 
 
533.62 3.18 116.11 6 , 2 7   
-9.91, 54.43 chaetoxanthone B 
 
 
354.35 3.95 74.22 5 , 1 1   
-9.91, 54.43 sterequinone F 
 
 
292.33 3.84 51.21 3 , 0 3   
-9.91, 54.43 ZINC02034999 
 
 
472.49 3.75 72.45 6 , 0 6   
-9.91, 54.43 ZINC13597348 
 
 
369.54 3.81 40.54 3 , 1 1   
-9.91, 54.43 ZINC17147431 
 
 
348.45 2.88 54.37 3 , 1 1   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.9, 55.36 rutin  
 
 
610.52 -0.87 265.52 16 , 10 6   
-9.9, 55.36 ZINC00001761  
 
 
349.38 0.01 125.55 8 , 4 4   
-9.9, 55.36 ZINC11616857 
 
 
656.65 2.78 160.83 12 , 3 6   
-9.9, 55.36 ZINC13597732 
 
 
347.35 -0.29 136.3 8 , 3 7   
-9.89, 56.30 ZINC01738764 
 
 
408.36 1.20 171.22 8 , 4 6   
-9.89, 56.30 ZINC01748097 
 
 
329.35 5.04 95.86 5 , 3 5   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.89, 56.30 ZINC03297153  
 
 
466.89 1.71 130.08 6 , 2 8   
-9.88, 57.26 3-geranyloxy-6-
methyl-1,8-
dihydroxyanthraquino
ne 
 
 
406.47 6.99 83.83 5 , 2 6   
-9.88, 57.26 ZINC17375647 
 
 
369.56 4.93 29.96 2 , 0 1   
-9.87, 58.24 ZINC03260391 
 
 
 
462.74 3.46 92.7 4 , 2 7   
-9.86, 59.23 progesterone 
 
 
314.46 4.15 34.14 2 , 0 1   
-9.86, 59.23 ZINC06511656 
 
 
373.19 4.51 70.72 4 , 1 2   
504 
 
Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.82, 63.36 komaroviquinone  
 
 
360.44 3.27 72.83 5 , 1 2   
-9.81, 64.44 epi-muqubillin A 
 
 
 
392.57 6.38 55.76 4 , 1 8   
-9.81, 64.44 ZINC01163259 
 
 
381.45 3.86 86.47 5 , 1 5   
-9.81, 64.44 ZINC17125976 
 
 
383.68 6.73 45.48 3 , 1 3   
-9.81, 64.44 ZINC17287328 
 
 
533.62 3.18 116.11 6 , 2 7   
-9.8, 65.54 CA60 
 
 
326.31 1.97 101.38 6 , 2 3   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.8, 65.54 myricetin  
 
 
318.24 1.85 147.68 8 , 6 1   
-9.8, 65.54 6-
dimethylallylaminopu
rine riboside 
 
 
335.36 -0.43 125.55 8 , 4 5   
-9.79, 66.66 ZINC17858074 
 
 
359.26 5.27 35.83 3 , 1 3   
-9.78, 67.79 ZINC13154302  
 
 
369.54 3.81 40.54 3 , 1 1   
-9.77, 68.94 ZINC06511656 
 
 
373.19 3.34 65.01 5 , 1 2   
-9.77, 68.94 ZINC06511656 
 
 
373.19 4.01 67.23 3 , 1 2   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.77, 68.94 ZINC18154478  
 
 
308.29 2.86 113.65 5 , 3 3   
-9.76, 70.12 ellagic acid 
 
 
302.19 2.32 133.52 6 , 4 0   
-9.76, 70.12 30-nor-lupan-3β-ol-
20-one 
 
 
 
428.69 6.33 37.3 2 , 1 1   
-9.76, 70.12 quercetin 7-glucosyl 
 
 
464.38 -0.11 206.6 12 , 8 4   
-9.76, 70.12 ZINC01729526 
 
 
353.87 0.28 49.73 3 , 2 3   
-9.75, 71.31 letestuianin A 
 
 
 
 
340.37 3.84 86.99 5 , 3 7   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.75, 71.31 ZINC01709784  
 
 
390.44 3.53 104.16 6 , 0 8   
-9.74, 72.52 ZINC01734413 
 
 
341.19 5.88 43.6 3 , 0 2   
-9.74, 72.52 ZINC04726284 
 
 
280.32 2.98 51.02 4 , 0 4   
-9.74, 72.52 ZINC18141294 
 
 
 
454.48 6.22 115.59 7 , 2 5   
-9.72, 75.01 (-)-cubebin 
 
 
356.37 3.18 66.38 6 , 1 4   
-9.72, 75.01 quercetagetin 
 
 
318.24 1.85 147.68 8 , 6 1   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.72, 75.01 ZINC13597346  
 
 
369.54 3.81 40.54 3 , 1 1   
-9.71, 76.29 ZINC18154478 
 
 
308.29 2.97 117.14 6 , 3 3   
-9.7, 77.59 violacein 
 
 
343.34 1.67 94.22 3 , 4 1   
-9.7, 77.59 ZINC17949075 
 
 
402.23 5.47 75.19 4 , 2 3   
-9.7, 77.59 ZINC26730911 
 
 
428.42 -4.61 152.45 10 , 3 3   
-9.69, 78.91 ZINC02476372 
 
 
292.29 2.99 63.6 3 , 1 3   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.68, 80.25 β-sitosterol glucoside  
 
 
576.85 6.07 99.38 6 , 4 9   
-9.67, 81.62 chlorogenic acid 
 
 
354.31 -0.27 164.75 8 , 6 5   
-9.67, 81.62 lalioside 
 
 
346.29 -1.30 177.14 10 , 7 4   
-9.67, 81.62 teferin 
 
 
388.50 4.40 75.99 4 , 2 5   
-9.66, 83.01 7'-hyroxy-
lariciresionol 
 
 
 
376.40 1.63 108.61 7 , 4 6   
-9.66, 83.01 ascididemin 
 
 
283.28 2.98 55.74 4 , 0 0   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.65, 84.42 ZINC01729578  
 
 
338.45 5.12 35.01 3 , 0 3   
-9.64, 85.86 1,7-bis(4-
hydroxyphenyl)-
heptene-3,5-dione 
 
 
310.34 4.36 74.6 4 , 2 7   
-9.64, 85.86 3-oxo-tirucalla-7,24Z-
dien-26-oic acid 
 
 
454.68 7.51 54.37 3 , 1 5   
-9.64, 85.86 ZINC18141294 
 
 
 
454.48 6.33 119.08 8 , 2 5   
-9.64, 85.86 ZINC29590277 
 
 
446.99 6.73 32.34 2 , 1 4   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.62, 88.81 ZINC06343280  
 
 
370.27 6.04 29.1 1 , 1 4   
-9.62, 88.81 ZINC08648354  
 
 
394.81 4.29 90.13 5 , 1 5   
-9.62, 88.81 ZINC18154478 
 
 
308.29 2.97 117.14 6 , 3 3   
-9.61, 90.32 CA64 
 
 
 
316.74 2.95 82.92 4 , 2 3   
-9.61, 90.32 ZINC00332365 
 
 
318.32 4.28 74.6 4 , 2 4   
-9.61, 90.32 ZINC13154305 
 
 
363.54 5.21 36.02 1 , 2 0   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.6, 91.86 ajugol  
 
 
364.35 -3.05 169.3 10 , 7 3   
-9.6, 91.86 scrolepidoside 
 
 
682.67 -1.19 232.52 15 , 7 12   
-9.58, 95.01 zenkequinone B 
 
 
292.33 3.26 54.37 3 , 1 0   
-9.58, 95.01 ZINC22911959 
 
 
384.43 2.94 100.52 5 , 2 3   
-9.57, 96.63 NSC128608 
(CHEMBL1173811) 
 
 
467.51 7.34 66.4 3 , 2 4   
-9.57, 96.63 acetylastrogaloside I  
 
 
911.08 1.01 246.43 14 , 6 13   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.57, 96.63 ZINC04428843  
 
 
328.40 3.93 63.6 4 , 1 3   
-9.57, 96.63 ZINC04701260 
 
 
265.31 3.13 46.17 2 , 1 4   
-9.57, 96.63 ZINC04900874 
 
 
346.42 2.77 40.62 2 , 0 2   
-9.55, 99.94 dioncophylline B 
 
 
363.45 3.51 61.72 4 , 3 2   
-9.54, 101.65 friedelan-3-one 
 
 
426.72 8.12 17.07 1 , 0 0   
-9.54, 101.65 8-epi-loganin 
 
 
390.38 -1.84 155.14 9 , 5 5   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.54, 101.65 numismine  
 
 
439.55 0.52 107.53 5 , 4 0   
-9.54, 101.65 ZINC00105309 
 
 
348.35 1.22 79.73 4 , 1 1   
-9.54, 101.65 ZINC01707109 
 
 
399.30 0.26 40.8 4 , 2 3   
-9.54, 101.65 ZINC04773602  
 
 
358.52 5.73 24.06 2 , 2 2   
-9.53, 103.38 ZINC01701460 
 
 
367.27 7.06 25.78 2 , 0 2   
-9.52, 105.14 lunarine 
 
 
437.53 1.16 96.53 5 , 3 0   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.52, 105.14 ZINC29589833  
 
 
 
396.91 4.54 35.94 4 , 1 6   
-9.51, 106.92 ZINC01757986 
 
 
297.31 0.29 118.9 7 , 2 3   
-9.51, 106.92 ZINC12672225  
 
 
400.47 -1.25 95.02 6 , 3 3   
-9.5, 108.74 tingenone (maitenin) 
 
 
420.58 4.92 54.37 3 , 1 0   
-9.5, 108.74 ZINC04824645 
 
 
392.50 4.49 48.12 4 , 4 0   
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Binding 
energy 
(kcal.mol
-1
), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit in 
VS1? 
Hit in 
VS4? 
-9.5, 108.74 ZINC05641037  
 
 
 
 
348.85 6.23 36.68 2 , 0 4   
517 
 
Table 7.1.9 - hits from Virtual Screen 4, listed according to predicted binding affinity. 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-14.88, .01 astrogaloside III  
 
 
784.97 -0.31 228.22 14 , 9 7   
-13.2, .21 stigmasterol-D-
glucoside 
 
 
574.83 5.71 99.38 6 , 4 8   
-12.62, .56 4'-O- 
demethylknipholone-
4'-O-β-D-
glucopyranoside 
 
 
582.51 2.80 231.51 13 , 8 4   
-12.48, .71 β-sitosterol glucoside 
 
 
576.85 6.07 99.38 6 , 4 9   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-12.39, .83 cis-p-
methoxycinnamoylox
yoleanolicacid methyl 
ester 
 
 
 
630.90 9.62 61.83 3 , 0 7   
-12.3, .96 ZINC05492794 
 
 
594.73 10.95 51.56 4 , 0 6   
-12.15, 1.24 melampyroside 
 
 
450.44 0.28 155.14 9 , 5 7   
-11.87, 1.99 luteolin-3'-O-
glucoside 
 
 
448.38 0.14 186.37 11 , 7 4   
-11.83, 2.13 tetrahydrolunarine 441.56 1.08 96.53 5 , 3 0   
519 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
 
 
-11.8, 2.24 tetra-
acetyldaucosterol 
 
 
 
 
 
689.06 10.07 55.38 6 , 0 17   
-11.76, 2.40 physcion 1-β-D-
glucopyranoside 
 
 
462.40 1.40 183.21 11 , 6 4   
-11.71, 2.61 3-O-Methylellagic 
acid 3'-O-α-4''-O-
acetylrhamnopyrano
side 
 
 
504.40 0.38 187.51 10 , 4 5   
520 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-11.67, 2.79 cissampeloflavone  
 
 
610.56 5.91 154.12 10 , 3 8   
-11.63, 2.99 bruceantinol 
 
 
606.61 0.10 192.19 9 , 3 8   
-11.63, 2.99 NSC128590 
(CHEMBL1172557) 
 
 
644.67 8.53 132.8 6 , 4 8   
-11.59, 3.19 GDP-4-dehydro-6-
deoxy-D-mannose 
 
 
587.33 -4.12 304.04 16 , 8 8   
-11.58, 3.25 β-sitosterol  
 
 
414.71 7.84 20.23 1 , 1 6   
521 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-11.55, 3.42 isoginkgetin  
 
 
566.51 5.38 151.98 10 , 4 4   
-11.54, 3.48 ZINC05580600 
 
 
401.28 5.06 61.69 4 , 3 2   
-11.54, 3.48 ZINC17353911 
 
 
472.62 4.00 75.35 4 , 2 2   
-11.54, 3.48 luteolin-7-O-
glucoside 
 
 
448.38 0.14 186.37 11 , 7 4   
-11.51, 3.66 manumycin A 
 
 
 
550.64 3.06 145.33 7 , 4 12   
522 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-11.47, 3.91 tovophyllin A  
 
 
464.55 5.36 96.22 6 , 3 4   
-11.44, 4.11 ZINC12671904 
 
 
412.56 4.53 60.44 3 , 0 2   
-11.41, 4.33 ilimaquinone 
 
 
358.47 4.37 63.6 4 , 1 3   
-11.41, 4.33 lanaroflavone 
 
 
538.46 5.24 162.98 9 , 5 4   
-11.4, 4.40 ZINC17353912 
 
 
472.62 4.00 75.35 4 , 2 2   
523 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-11.4, 4.40 GDP-L-fucose  
 
 
 
 
589.34 -3.72 307.2 16 , 9 8   
-11.39, 4.48 cis-p-
methoxycinnamoylox
yursolicacid methyl 
ester 
 
 
644.92 9.89 61.83 3 , 0 7   
-11.37, 4.63 cycloartenol 
 
 
426.72 7.55 20.23 1 , 1 4   
-11.21, 6.07 yadanzioside C 
 
 
726.72 -2.35 265.27 14 , 7 9   
-11.2, 6.17 ZINC01701460 
 
 
367.27 7.06 25.78 2 , 0 2   
524 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-11.18, 6.38 ZINC29590275  
 
 
446.99 6.73 32.34 2 , 1 4   
-11.18, 6.38 daphnorin 
 
 
514.44 0.42 170.44 10 , 4 6   
-11.18, 6.38 podocarpusﬂavone A 
 
 
552.48 5.23 162.98 10 , 5 3   
-11.18, 6.38 stigmasterol 
 
 
412.69 7.48 20.23 1 , 1 5   
-11.11, 7.18 agrimonolide 6-O-β-
D-glucopyranoside 
 
 
476.47 1.95 155.14 9 , 5 7   
525 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-11.11, 7.18 ginkgetin  
 
 
 
580.54 5.53 140.98 10 , 3 5   
-11.08, 7.56 korupensamine A 
 
 
379.45 3.13 81.95 5 , 4 1   
-11.05, 7.95 ZINC22911959 
 
 
384.43 2.94 100.52 5 , 2 3   
-11.05, 7.95 myricetin  
 
 
318.24 1.85 147.68 8 , 6 1   
-11.04, 8.08 ZINC00332365 
 
 
318.32 4.28 74.6 4 , 2 4   
526 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-11.02, 8.36 ZINC11681164  
 
 
 
 
542.55 -3.47 167.42 11 , 6 2   
-11.01, 8.50 apiin 
 
 
564.49 -0.84 225.06 14 , 8 7   
-10.99, 8.79 ZINC01690699 
 
 
548.59 6.78 115.56 4 , 4 6   
-10.99, 8.79 apigenin-4'-glucoside 
 
 
432.38 0.44 166.14 10 , 6 4   
-10.98, 8.94 ZINC17465983 
 
 
546.52 5.67 173.98 10 , 6 0   
527 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.97, 9.10 tingenone (maitenin)  
 
 
420.58 4.92 54.37 3 , 1 0   
-10.94, 9.57 ZINC13154305 
 
 
363.54 5.21 36.02 1 , 2 0   
-10.92, 9.90 ZINC01755448 
 
 
398.45 6.87 52.6 2 , 0 6   
-10.9, 10.24 CHEMBL1172759 
 
 
545.24 7.24 66.4 3 , 2 4   
-10.89, 
10.41 
ZINC05462670 
 
 
546.52 5.67 173.98 10 , 6 0   
-10.88, 
10.59 
ZINC03875548 
 
 
392.40 5.92 52.6 2 , 0 4   
528 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.82, 
11.72 
apicidin  
 
 
623.78 3.37 138.84 6 , 3 12   
-10.81, 
11.92 
ZINC00600877 
 
 
354.38 0.87 117.13 5 , 1 9   
-10.81, 
11.92 
chrysophanol-8-
glucoside 
 
 
416.38 1.21 153.75 9 , 5 3   
-10.81, 
11.92 
Qc2 
 
 
549.95 5.48 79.9 4 , 2 6   
-10.8, 12.12 ZINC00001761 
 
 
349.38 0.01 125.55 8 , 4 4   
-10.8, 12.12 NSC67692 
(CHEMBL1172978) 
 
 
419.43 5.50 83.47 4 , 2 4   
529 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.79, 
12.33 
brusatol  
 
 
520.53 0.24 165.89 8 , 3 5   
-10.78, 
12.54 
hennadiol 
 
 
442.72 6.86 40.46 2 , 2 1   
-10.77, 
12.75 
apigenin-7-glucoside 
 
 
432.38 0.44 166.14 10 , 6 4   
-10.76, 
12.97 
quercetagetin 
 
 
318.24 1.85 147.68 8 , 6 1   
-10.76, 
12.97 
NSC127133 
(CHEMBL1172911) 
 
 
434.44 5.14 95.5 4 , 3 4   
-10.73, 
13.64 
bruceine C 
 
 
564.58 -0.35 186.12 9 , 4 6   
530 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.69, 
14.59 
ZINC12671893  
 
 
412.56 4.53 60.44 3 , 0 2   
-10.65, 
15.61 
7'-hyroxy-
lariciresionol 
 
 
376.40 1.63 108.61 7 , 4 6   
-10.65, 
15.61 
amentoflavone 
 
 
538.46 5.09 173.98 10 , 6 2   
-10.64, 
15.88 
CHEMBL1172971 
 
 
391.42 3.07 81.7 4 , 1 9   
-10.63, 
16.15 
ZINC17287328 
 
 
533.62 3.18 116.11 6 , 2 7   
531 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.63, 
16.15 
(+)-Syringaresinol O-
β-D-glucopyranoside 
 
 
 
580.58 -0.31 174.99 13 , 5 9   
-10.61, 
16.70 
bruceine A 
 
 
522.54 0.05 165.89 8 , 3 6   
-10.6, 16.99 ZINC13099048 
 
 
447.63 5.52 50.19 3 , 1 2   
-10.59, 
17.28 
caratuberside A 
 
 
656.80 1.05 184.6 12 , 6 7   
-10.58, 
17.57 
ZINC13099050 
 
 
447.63 5.52 50.19 3 , 1 2   
532 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.58, 
17.57 
camaldulenside  
 
 
520.53 2.10 172.21 10 , 5 7   
-10.57, 
17.87 
nitogenin (diosgenin) 
 
 
414.62 4.93 38.69 3 , 1 0   
-10.55, 
18.48 
ZINC01855333 
 
 
356.46 5.37 34.14 2 , 0 0   
-10.53, 
19.12 
3,23-dioxotirucalla-
7,24-dien-21-al 
 
 
452.67 6.42 51.21 3 , 0 5   
-10.53, 
19.12 
emetine 
 
 
480.64 4.49 52.19 6 , 1 7   
533 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.52, 
19.44 
quercetin 7-glucosyl  
 
 
464.38 -0.11 206.6 12 , 8 4   
-10.5, 20.11 ZINC13099051 
 
 
447.63 5.52 50.19 3 , 1 2   
-10.49, 
20.45 
ZINC17287324  
 
 
533.62 3.18 116.11 6 , 2 7   
-10.48, 
20.80 
5alpha-poriferastane-
3β,6α-diol 
 
 
432.72 6.94 40.46 2 , 2 6   
-10.47, 
21.15 
30-nor-lupan-3β-ol-
20-one 
 
 
428.69 6.33 37.3 2 , 1 1   
534 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.46, 
21.51 
5α-Lanosta-
7,9(11),24-triene-
3α,23-diol 
 
 
 
440.70 6.11 40.46 2 , 2 4   
-10.45, 
21.88 
15-epi-4Z-
jatrogrossidentadion 
 
 
332.43 3.10 74.6 4 , 2 0   
-10.43, 
22.63 
ZINC04783229 
 
 
 
 
476.57 5.60 64.68 2 , 2 4   
-10.43, 
22.63 
hydrangdione A 
 
 
494.66 5.98 72.83 5 , 1 2   
535 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.43, 
22.63 
daphneside  
 
 
502.42 -3.36 225.06 13 , 8 6   
-10.43, 
22.63 
podocarpusﬂavone B 
 
 
 
566.51 5.38 151.98 10 , 4 4   
-10.41, 
23.41 
ZINC12670903 
 
 
446.62 4.22 91.67 5 , 2 4   
-10.4, 23.81 diospyrin 
 
 
374.34 4.40 108.74 6 , 2 1   
-10.37, 
25.04 
ZINC12670920 
 
 
446.62 4.22 91.67 5 , 2 4   
536 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.37, 
25.04 
chaetoxanthone A  
 
 
370.35 2.86 94.45 6 , 2 1   
-10.37, 
25.04 
3-geranyloxy-6-
methyl-1,8-
dihydroxyanthraquin
one 
 
 
406.47 6.99 83.83 5 , 2 6   
-10.37, 
25.04 
3-oxo-tirucalla-7,24Z-
dien-26-oic acid 
 
 
 
454.68 7.51 54.37 3 , 1 5   
-10.36, 
25.47 
ZINC01644254 
 
 
 
567.46 7.55 66.92 3 , 0 6   
537 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.36, 
25.47 
GDP-rhamnose  
 
 
 
589.34 -3.72 307.2 16 , 9 8   
-10.35, 
25.90 
ZINC01635676  
 
 
 
394.47 5.92 44.12 2 , 0 5   
-10.35, 
25.90 
24-ethyl-cholest-5a-
7-en-3-β-ol 
 
 
414.71 7.84 20.23 1 , 1 6   
-10.35, 
25.90 
pinoresinol di-O-β-D-
glucopyranoside 
 
 
682.67 -2.26 235.68 16 , 8 10   
538 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.35, 
25.90 
norcowanin  
 
 
464.55 7.51 107.22 5 , 4 7   
-10.34, 
26.34 
isoscutellarin 
 
 
462.36 0.46 203.44 12 , 7 4   
-10.32, 
27.25 
ZINC05124960 
 
 
359.37 5.53 86.63 5 , 3 4   
-10.32, 
27.25 
ZINC08581460 
 
 
378.51 7.17 16.13 2 , 0 6   
-10.32, 
27.25 
violacein 
 
 
343.34 1.67 94.22 3 , 4 1   
-10.32, 
27.25 
NSC128604 
(CHEMBL1173036) 
 
 
435.43 5.32 92.7 4 , 2 4   
539 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.32, 
27.25 
clorobiocin  
 
 
697.13 4.94 185.87 9 , 5 10   
-10.31, 
27.71 
ZINC01718486 
 
 
385.25 5.23 67.66 5 , 2 4   
-10.31, 
27.71 
sigmosceptrellin A 
methyl ester 
 
 
406.60 6.27 44.76 3 , 0 6   
-10.31, 
27.71 
NSC128608 
(CHEMBL1173811) 
 
 
467.51 7.34 66.4 3 , 2 4   
-10.3, 28.18 ZINC05487838 
 
 
404.24 4.51 71.7 4 , 2 3   
540 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.3, 28.18 methyl 3β,23-
diacetoxy-12-ursen-
28-oate 
 
 
 
556.86 7.73 44.76 3 , 0 7   
-10.29, 
28.66 
aculeatin D  
 
 
418.61 7.02 55.76 4 , 1 12   
-10.28, 
29.15 
ZINC05709639 
 
 
347.41 4.49 46.61 2 , 0 4   
-10.27, 
29.65 
ZINC04773602 
 
 
358.52 5.73 24.06 2 , 2 2   
-10.25, 
30.67 
ZINC12671898 
 
 
412.56 4.53 60.44 3 , 0 2   
541 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.24, 
31.19 
ZINC13154302  
 
 
369.54 3.81 40.54 3 , 1 1   
-10.23, 
31.72 
ZINC01081577 
 
 
340.44 -2.52 69.56 3 , 4 4   
-10.23, 
31.72 
ZINC01573829 
 
 
353.44 5.74 38.67 3 , 0 3   
-10.23, 
31.72 
ZINC13099047 
 
 
447.63 5.52 50.19 3 , 1 2   
-10.23, 
31.72 
1-O-
deacetylkhayanolide 
B 
 
 
 
546.61 0.71 144.89 7 , 3 6   
542 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.23, 
31.72 
NSC132249 
(CHEMBL1173812) 
 
 
 
474.34 7.34 66.4 3 , 2 4   
-10.22, 
32.26 
ZINC03313499 
 
 
465.90 2.80 119 5 , 2 7   
-10.22, 
32.26 
chrysosplenol D 
 
 
360.31 2.26 114.68 8 , 3 4   
-10.21, 
32.81 
Qc3 
 
 
485.48 5.04 70.67 3 , 2 6   
-10.2, 33.37 5'-O-demethyl-ent-
dioncophylleine A 
 
 
363.45 3.48 61.72 4 , 3 1   
543 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.19, 
33.93 
ZINC18141294  
 
 
454.48 6.22 115.59 7 , 2 5   
-10.18, 
34.51 
ZINC11681161 
 
 
 
 
542.55 -3.47 167.42 11 , 6 2   
-10.18, 
34.51 
ZINC03314942 
 
 
486.88 2.29 154.3 8 , 2 8   
-10.18, 
34.51 
ZINC03417739  
 
 
530.77 3.06 119 5 , 2 7   
-10.18, 
34.51 
quercetin 
 
 
302.24 2.16 127.45 7 , 5 1   
544 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.17, 
35.10 
ZINC00161700  
 
 
349.82 5.55 55.63 4 , 1 4   
-10.17, 
35.10 
khayanolide E 
 
 
544.59 1.47 141.73 7 , 2 6   
-10.16, 
35.70 
ZINC01568966 
 
 
407.87 5.83 92.05 4 , 2 4   
-10.16, 
35.70 
lawsoniaside 
 
 
500.45 -2.48 218.99 13 , 9 6   
-10.16, 
35.70 
bruceine B 
 
 
480.46 -1.38 165.89 8 , 3 4   
-10.15, 
36.30 
ZINC13099025 
 
 
328.40 3.93 63.6 4 , 1 3   
545 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.15, 
36.30 
gaboroquinone B  
 
 
450.39 3.93 161.59 9 , 5 3   
-10.15, 
36.30 
sigmosceptrellin A 
 
 
392.57 6.12 55.76 4 , 1 5   
-10.15, 
36.30 
NSC128596 
(CHEMBL1173452) 
 
 
405.44 6.14 66.4 3 , 2 4   
-10.14, 
36.92 
ZINC01163259 
 
 
381.45 3.86 86.47 5 , 1 5   
-10.14, 
36.92 
quercetin* 
 
 
302.24 2.16 127.45 7 , 5 1   
-10.13, 
37.55 
friedelan-3-one 
 
 
426.72 8.12 17.07 1 , 0 0   
546 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.12, 
38.19 
ZINC04286641  
 
 
408.86 2.55 116.49 5 , 2 7   
-10.11, 
38.84 
etandrolide 
 
 
440.70 7.54 26.3 1 , 0 4   
-10.1, 39.50 knipholone 
 
 
434.39 5.22 141.36 8 , 4 2   
-10.1, 39.50 komaroviquinone 
 
 
360.44 3.27 72.83 5 , 1 2   
-10.09, 
40.17 
ZINC04777937 
 
 
412.48 2.24 73.02 5 , 1 4   
-10.09, 
40.17 
ZINC18169477 
 
 
429.43 6.21 117.23 9 , 2 6   
547 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.09, 
40.17 
2α-hydroxybetulinic 
acid 
 
 
 
472.70 5.56 77.76 4 , 3 2   
-10.09, 
40.17 
(+)-syringaresinol 
 
 
418.44 1.96 95.84 8 , 2 6   
-10.08, 
40.86 
ZINC05124931 
 
 
424.53 7.30 34.14 2 , 0 4   
-10.08, 
40.86 
ZINC00057276 
 
 
349.38 0.01 125.55 8 , 4 4   
-10.08, 
40.86 
NSC128594 
(CHEMBL1173451) 
 
 
405.44 6.14 66.4 3 , 2 4   
-10.07, 
41.55 
ZINC01625746 
 
 
421.43 -5.26 136.47 6 , 3 3   
548 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.06, 
42.26 
oleanolic acid  
 
 
456.70 6.59 57.53 3 , 2 1   
-10.04, 
43.71 
ajugol 
 
 
364.35 -3.05 169.3 10 , 7 3   
-10.04, 
43.71 
NSC127134 
(CHEMBL1172616) 
 
 
421.44 5.06 86.63 4 , 3 4   
-10.03, 
44.45 
ZINC13145029 
 
 
386.48 0.95 77.95 5 , 3 3   
-10.03, 
44.45 
ZINC13154307 
 
 
363.54 5.21 36.02 1 , 2 0   
-10.03, 
44.45 
luteolin 
 
 
286.24 2.40 107.22 6 , 4 1   
549 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.02, 
45.21 
ZINC13145030  
 
 
386.48 0.95 77.95 5 , 3 3   
-10.02, 
45.21 
ZINC03450331 
 
 
482.89 0.98 148.1 7 , 3 8   
-10.02, 
45.21 
dioncophylline E 
 
 
363.45 3.51 61.72 4 , 3 1   
-10.02, 
45.21 
vernoguinosterol 
 
 
486.64 2.84 96.22 6 , 3 3   
-10.01, 
45.98 
ZINC01736227 
 
 
392.45 6.01 42.52 4 , 2 3   
550 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-10.01, 
45.98 
23-Hydroxy-5α-
lanosta-7,9(11),24-
triene-3-one 
 
 
 
438.69 6.68 37.3 2 , 1 4   
-10, 46.76 ZINC11677172  
 
 
496.57 3.65 93.06 6 , 2 3   
-10, 46.76 ZINC17465979 
 
 
546.52 5.67 173.98 10 , 6 0   
-9.99, 47.56 ZINC17465965 
 
 
445.34 0.31 247.3 13 , 5 8   
-9.99, 47.56 ascofuranone 
 
 
 
420.93 6.40 83.83 5 , 2 7   
551 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.99, 47.56 4'-O-
demethylknipholone 
 
 
 
420.37 5.72 152.36 8 , 5 1   
-9.98, 48.37 ZINC04217305 
 
 
341.36 -3.47 98.33 6 , 2 4   
-9.98, 48.37 ZINC12672231 
 
 
400.47 -1.25 95.02 6 , 3 3   
-9.97, 49.19 ZINC01572309 
 
 
474.56 6.43 108.04 4 , 4 4   
-9.97, 49.19 ZINC05105895 
 
 
374.52 6.77 25.36 3 , 0 9   
-9.95, 50.88 ZINC18169477 
 
 
429.43 6.10 113.74 8 , 2 6   
552 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.95, 50.88 ancistrotectonine  
 
 
407.50 4.08 59.95 5 , 2 3   
-9.94, 51.75 ZINC05493736 
 
 
334.48 3.12 49.41 3 , 1 1   
-9.93, 52.63 scrolepidoside 
 
 
682.67 -1.19 232.52 15 , 7 12   
-9.93, 52.63 vismione D 
 
 
410.50 5.23 86.99 5 , 3 6   
-9.92, 53.52 ZINC01608817 
 
 
310.39 5.84 24.06 2 , 2 4   
-9.92, 53.52 ZINC01691782 
 
 
304.34 3.90 54.98 2 , 1 2   
553 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.92, 53.52 ZINC13597348  
 
 
369.54 3.81 40.54 3 , 1 1   
-9.92, 53.52 ZINC23118772 
 
 
396.91 4.54 35.94 4 , 1 6   
-9.92, 53.52 chlorogenic acid 
 
 
354.31 -0.27 164.75 8 , 6 5   
-9.92, 53.52 (-)-cubebin 
 
 
356.37 3.18 66.38 6 , 1 4   
-9.91, 54.43 ZINC12670909 
 
 
446.62 4.22 91.67 5 , 2 4   
-9.91, 54.43 ZINC13000556 
 
 
421.43 -5.26 136.47 6 , 3 3   
554 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.91, 54.43 sinefungin  
 
 
381.39 -5.14 208.65 11 , 6 7   
-9.9, 55.36 ZINC01735767 
 
 
370.27 6.04 29.1 1 , 1 4   
-9.89, 56.30 ZINC29589888 
 
 
434.44 5.14 95.5 4 , 3 4   
-9.89, 56.30 ZINC01624619 
 
 
333.79 5.35 74.27 4 , 0 5   
-9.89, 56.30 sanguinarine 
 
 
332.33 -0.94 40.8 4 , 0 0   
555 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.89, 56.30 melarsoprol  
 
 
 
398.34 1.34 122.97 7 , 4 4   
-9.86, 59.23 ZINC01856861 
 
 
307.30 -1.72 123.5 5 , 3 5   
-9.85, 60.24 ZINC17949075 
 
 
402.23 4.59 71.7 4 , 2 3   
-9.85, 60.24 ZINC18057104 
 
 
507.56 3.89 130.51 8 , 4 5   
-9.85, 60.24 dioncophylline D 
 
 
377.48 3.80 50.72 4 , 2 3   
-9.84, 61.26 ZINC04896472 325.32 4.03 64.85 4 , 0 1   
556 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
 
 
-9.84, 61.26 lunarine 
 
 
437.53 1.16 96.53 5 , 3 0   
-9.84, 61.26 GDP-L-glucose 
 
 
605.34 -4.77 327.43 17 , 10 9   
-9.83, 62.30 ZINC01580992 
 
 
332.38 3.65 58.2 2 , 2 1   
-9.83, 62.30 ZINC05664697 
 
 
521.41 6.54 85.64 5 , 0 6   
-9.83, 62.30 ZINC13597346 
 
 
369.54 3.81 40.54 3 , 1 1   
557 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.83, 62.30 sigmosceptrellin B  
 
 
378.55 5.82 55.76 4 , 1 5   
-9.82, 63.36 ZINC05487838 
 
 
404.24 4.51 71.7 4 , 2 3   
-9.82, 63.36 ZINC16951318 
 
 
403.91 4.59 84.18 7 , 4 7   
-9.81, 64.44 ZINC12670914 
 
 
446.62 4.22 91.67 5 , 2 4   
-9.81, 64.44 ZINC29589835 
 
 
376.49 4.45 35.94 4 , 1 6   
-9.81, 64.44 ancistrotanzanine A 
 
 
405.49 4.60 60.28 5 , 1 3   
558 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.8, 65.54 ZINC17949075  
 
 
402.23 5.47 75.19 4 , 2 3   
-9.8, 65.54 ZINC18169477 
 
 
429.43 6.21 117.23 9 , 2 6   
-9.8, 65.54 ZINC29590277 
 
 
446.99 6.73 32.34 2 , 1 4   
-9.8, 65.54 ZINC02629278 
 
 
416.86 0.10 161.2 6 , 3 9   
-9.8, 65.54 ZINC03315231 
 
 
450.89 2.30 125.56 5 , 3 8   
-9.78, 67.79 ZINC01675858 
 
 
336.38 4.15 73.58 4 , 1 5   
559 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.78, 67.79 epi-muqubillin A  
 
 
392.57 6.38 55.76 4 , 1 8   
-9.78, 67.79 GDP-β-L-keto-
galactose  
 
 
601.31 -5.17 329.93 17 , 7 9   
-9.77, 68.94 ZINC11681166 
 
 
 
542.55 -3.47 167.42 11 , 6 2   
-9.76, 70.12 dioncopeltine A 
 
 
379.45 2.19 81.95 5 , 4 2   
-9.76, 70.12 kigelinol 
 
 
308.33 1.83 74.6 4 , 2 0   
560 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.76, 70.12 Qc5  
 
 
490.50 3.00 81.75 3 , 2 7   
-9.75, 71.31 ZINC16951320 
 
 
343.36 1.05 140 7 , 3 2   
-9.74, 72.52 ZINC18169477 
 
 
429.43 6.21 117.23 9 , 2 6   
-9.74, 72.52 macrocarpal B 
 
 
472.61 7.63 115.06 6 , 4 6   
-9.73, 73.76 ZINC01593340 
 
 
 
416.47 6.07 69.67 3 , 0 10   
561 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.73, 73.76 1α,3α,7α-
trideacetylkhivorin 
 
 
 
460.56 1.99 112.66 5 , 3 1   
-9.71, 76.29 ZINC00398390  
 
 
347.36 5.66 64.63 3 , 1 6   
-9.71, 76.29 ZINC13154298 
 
 
 
494.25 6.82 40.18 2 , 2 3   
-9.71, 76.29 acetyloleanolic acid 
 
 
498.74 7.04 63.6 3 , 1 3   
-9.71, 76.29 (4Z,6E)-5-hydroxy-
1,7-bis(4-
hydroxyphenyl)hepta
-4,6-dien-3-one 
 
 
 
310.34 3.99 77.76 4 , 3 6   
562 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.7, 77.59 ZINC01610563  
 
 
337.30 3.65 111.57 6 , 1 5   
-9.7, 77.59 6-
dehydroxykhayanolid
e E 
 
 
500.54 1.27 132.5 6 , 2 4   
-9.69, 78.91 ZINC23118770 
 
 
396.91 4.54 35.94 4 , 1 6   
-9.69, 78.91 ZINC03365068  
 
 
452.91 1.79 113.01 5 , 2 7   
-9.68, 80.25 letestuianin B 
 
 
370.40 3.68 96.22 6 , 3 8   
563 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.66, 83.01 ZINC15924502  
 
 
429.73 7.06 32.67 2 , 0 3   
-9.66, 83.01 ZINC17353914  
 
 
472.62 4.00 75.35 4 , 2 2   
-9.66, 83.01 ZINC00032820 
 
 
348.19 0.31 102.18 6 , 5 3   
-9.66, 83.01 ZINC03812006 
 
 
328.30 -0.69 130.27 5 , 1 6   
-9.65, 84.42 ZINC09230252 
 
 
400.47 -1.25 95.02 6 , 3 3   
564 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.65, 84.42 ZINC29589828  
 
 
396.91 4.54 35.94 4 , 1 6   
-9.65, 84.42 isokigelinol 
 
 
308.33 1.83 74.6 4 , 2 0   
-9.65, 84.42 cosmossin (acacetin-
7-O-glucoside) 
 
 
432.38 0.44 166.14 10 , 6 4   
-9.64, 85.86 ZINC01578220 
 
 
447.50 4.56 81.71 5 , 2 6   
-9.64, 85.86 ZINC04918956 
 
 
516.45 2.16 211.28 10 , 7 9   
565 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.64, 85.86 ent-dioncophylleine 
A 
 
 
 
377.48 3.80 50.72 4 , 2 2   
-9.64, 85.86 1-(3-(2-
ethoxyphenyl)ureido
acetyl)-4-(2-methyl-
5-
nitrophenyl)semicarb
azide 
(CHEMBL566045)  
 
442.43 2.45 171.57 6 , 5 8   
-9.63, 87.32 ZINC13154300  
 
 
369.54 3.81 40.54 3 , 1 1   
-9.63, 87.32 ZINC02134706 
 
 
562.63 0.37 190.36 9 , 4 10   
-9.63, 87.32 ancistrocladidine 
 
 
405.49 4.60 60.28 5 , 1 3   
566 
 
Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.62, 88.81 ZINC13154304  
 
 
363.54 5.21 36.02 1 , 2 0   
-9.62, 88.81 ZINC16951318 
 
 
402.90 4.74 105.31 7 , 3 7   
-9.62, 88.81 ZINC17465958 
 
 
429.92 6.62 47.03 3 , 0 4   
-9.61, 90.32 ZINC13597432 
 
 
342.39 2.42 78.53 4 , 1 4   
-9.61, 90.32 acetylharpagide 
 
 
406.38 -3.79 175.37 10 , 6 5   
-9.61, 90.32 praecansone B 
 
 
366.41 3.72 64.99 5 , 1 5   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.6, 91.86 ZINC00001087  
 
 
348.35 1.22 79.73 4 , 1 1   
-9.6, 91.86 ZINC01736228 
 
 
392.45 6.01 42.52 4 , 2 3   
-9.59, 93.42 ZINC00154888 
 
 
302.32 3.67 54.37 3 , 1 4   
-9.59, 93.42 ZINC08648354 
 
 
394.81 4.29 90.13 5 , 1 5   
-9.59, 93.42 ZINC13145028 
 
 
386.48 0.95 77.95 5 , 3 3   
-9.59, 93.42 dioncophylline B 
 
 
363.45 3.51 61.72 4 , 3 2   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.59, 93.42 1-O-
deacetylkhayanolide 
E 
 
 
 
516.54 0.47 152.73 7 , 3 4   
-9.57, 96.63 ZINC17949075 
 
 
402.23 5.47 75.19 4 , 2 3   
-9.57, 96.63 rutin 
 
 
610.52 -0.87 265.52 16 , 10 6   
-9.56, 98.27 aucubin 
 
 
346.33 -3.18 149.07 9 , 6 4   
-9.56, 98.27 CA60 
 
 
326.31 1.97 101.38 6 , 2 3   
-9.56, 98.27 GDP-4-keto-6-deoxy-
d-mannose 
 
 
587.33 -4.12 304.04 16 , 8 8   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.55, 99.94 ZINC01590864  
 
 
357.81 3.58 85.15 4 , 3 3   
-9.55, 99.94 ZINC11677178 
 
 
496.57 3.65 93.06 6 , 2 3   
-9.55, 99.94 ZINC17465972 
 
 
331.23 1.18 128.98 6 , 2 3   
-9.54, 
101.65 
ZINC02636757 
 
 
451.88 1.77 131.62 6 , 2 8   
-9.54, 
101.65 
sciadopitysin 
 
 
580.54 5.53 140.98 10 , 3 5   
-9.53, 
103.38 
ZINC01584497 
 
 
361.40 4.75 96.87 5 , 2 6   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.53, 
103.38 
ZINC01622198  
 
 
347.20 4.51 52.08 3 , 0 4   
-9.53, 
103.38 
ZINC29589831 
 
 
396.91 4.54 35.94 4 , 1 6   
-9.52, 
105.14 
ZINC03831068 
 
 
340.44 -2.52 69.56 3 , 4 4   
-9.52, 
105.14 
ZINC04824902 
 
 
378.84 1.77 140.16 7 , 3 3   
-9.52, 
105.14 
ZINC17375647 
 
 
369.56 4.93 29.96 2 , 0 1   
-9.52, 
105.14 
acetylbetulinic acid 
 
 
498.74 7.08 63.6 3 , 1 4   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.52, 
105.14 
knipholone anthrone  
 
 
420.41 5.85 124.29 7 , 4 2   
-9.52, 
105.14 
tabernaelegantine A 
 
 
706.91 6.53 99.89 5 , 2 8   
-9.51, 
106.92 
ZINC01711028 
 
 
352.43 -1.66 61.8 5 , 2 2   
-9.51, 
106.92 
ZINC18154478 
 
 
308.29 2.86 113.65 5 , 3 3   
-9.5, 108.74 ZINC00086102 
 
 
324.48 -0.64 40.67 3 , 3 4   
-9.5, 108.74 ZINC06343280 
 
 
370.27 6.04 29.1 1 , 1 4   
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Binding 
energy 
(kcal.mol-1), 
Ki (nM) 
Name Structure MW LogP TPSA H-bond 
Acceptors 
, Donors 
Number 
of 
Rotatable 
Bonds 
Lipinski 
Rule of Five 
Compliant? 
Hit 
in 
VS1
? 
Hit 
in 
VS3
? 
-9.5, 108.74 ZINC13154298  
 
 
493.24 7.70 37.81 3 , 1 4   
-9.5, 108.74 chrysosplenetin 
 
 
374.34 2.40 103.68 8 , 2 5   
 
573 
 
7.2 The development of products for neglected tropical diseases 
7.2.1 Foreword 
The purpose of this chapter is to detail the various ways in which drugs and vaccines for neglected 
tropical diseases (NTD) are developed and advanced towards the market.  This chapter will explore 
factors affecting product (drug/vaccine) development for NTDs and will indicate how they apply to the 
development of a drug to treat human African trypanosomiasis (HAT) or Chagas Disease.  There are 
a few excellent resources that inform on the funding available for NTD product development.  One 
such resource is the Global Funding of Innovation for Neglected Diseases (G-FINDER) report(1) and 
database(2), the results of a survey on funding for NTD research & development (R&D), compiled by 
Policy Cures.   Another useful resource is BIO Ventures for Global Health’s (BVGH) Global Health 
Primer(3), a database that holds details on NTD products currently in development and the 
organisations involved in those development projects.  In addition to these, the research underlying 
this chapter was guided by a number of reviews of NTD product development activity(4–7).  However, 
there appears to be a gap in the research, mainly pertaining to the different strategies used by 
researchers and developers to advance products towards the market and the availability of funding to 
advance development at specific stages in the pharmaceutical research and development (R&D) 
lifecycle.  Furthermore, the literature suggests that the formation of partnerships between different 
organisations is almost ubiquitous amongst NTD product development campaigns, although there is a 
scarcity of reviews providing specific details on such partnerships.  Therefore, this chapter will cover 
the following areas: the different commercialisation strategies for new products to control NTDs, the 
level of evidence required when entering into partnerships, and the nature of partnerships formed 
during pharmaceutical development for NTD products.  The implications for NTD product developers 
are presented from the point of view of researchers in academic and public or not-for-profit research 
institutions (PSNRI), and recommendations on the most appropriate strategies to be utilised in the 
pursuit of the research discussed in this thesis will be given. 
7.2.2 Introduction 
7.2.2.1 The NTD health burden 
NTDs collectively represent an enormous health burden globally.  These diseases are infectious 
diseases, generally concentrated in the Global South.  The WHO has defined a list of 17 NTDs(8), 
whilst a number of other diseases have been identified as NTDs by other organisations(9,10) (see 
Figure 7.2.1).  It has been estimated that NTDs represent 10-12% of the global disease 
burden(4,5,11), but receive a relatively small investment in R&D.  NTDs are now often referred to as 
diseases of “neglected populations”, as they often exist in communities that are socially excluded, 
sometimes due to their geographic location, but also as a result of their impoverished condition, to 
which infectious diseases contribute(9).  As a result of this situation, NTDs lie as a barrier to economic 
development and represent a significant expenditure to governments in disease-endemic areas (9).  
For example, an estimated US$267million is spent annually on the treatment of Chagas Disease 
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patients in Colombia alone(12).  Thus with such economic and social costs resulting from NTDs 
globally, it is within the interests of private, public and philanthropic organisations, both nationally and 
internationally, to bring them under control. 
 
Figure 7.2.1 - Diseases classified as NTDs.  This list was constructed based on definitions by Hotez et al.(9) and the scope 
of the journal PLOS Neglected Tropical Diseases(10).  “The Big Three” are excluded from some definitions in the 
literature, as they receive much more attention than other NTDs. * indicates a disease included in the WHO list of 17 
core neglected tropical diseases.  
7.2.2.2 NTD policy 
Historical 
In the disease endemic countries, many NTDs have been present for several thousands of years, 
periodically presenting as epidemics with several fatalities.  The human and economic costs of NTDs 
were recognised by the colonial powers of former colonies, which led to the implementation of mass 
screening, treatment and vector control problems(4,13).  In fact, many of the most burdensome NTDs 
once posed barriers to economic progress in Western countries, and their subsequent control and 
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elimination increased the prosperity of affected areas.  However after several of the former colonies 
gained independence and disease prevalence had decreased, control programs were relaxed and 
some of these diseases began to re-emerge.  Since that time, various famines, regional conflicts and 
political crises have exacerbated the situation. 
Awareness and policy 
There are a number of reasons for the persistence of today’s NTDs.  The WHO have described how 
certain diseases lack the appropriate “tools” (e.g. drugs, vaccines, diagnostics) to control them, 
whereas with other NTDs, we are limited by a lack of understanding by the disease pathology(14).  
However, the reason most commonly cited as a cause of the “market failure” to encourage NTD 
research and product development, is their association with poverty.  Patient populations lack 
purchasing power, thus, there is little or no financial incentive for big pharmaceutical companies, the 
traditional developers of new drugs and vaccines, to create new treatments(4,5,7,15).  Consequently, 
large Pharmaceutical corporations have shied away from NTD product development, with research 
into new treatments for NTDs once coming to a virtual standstill(4).  For certain NTDs, this has 
prepared the way for a possible health crisis, as resistance to old drugs emerges and disease 
prevalence increases. 
The need for strong policy decisions and national and international governance to support the 
development of new NTD products has been argued for by several proponents(7,15).  Unfortunately, 
for a time, programs to control/eliminate NTDs were deficient, and NTDs were not formally recognised 
by health organisations – the WHO originally failed to specifically mention several NTDs in their 
Millennium Development Goals(16).  In recent years, thanks to the restless awareness-raising 
activities of various researchers and NGOs, the fight against neglected diseases is now supported by 
clear policies in a number of institutions, globally.  This change has been accompanied by 
unprecedented structural changes in the pharmaceutical industry which have helped to spur the 
development of a number of new drugs and vaccines for NTDs(7,17). 
Recent advances 
Some of the policies designed to spur NTD product R&D can be categorised as “push” and “pull” 
mechanisms.  “Push” mechanisms are those that aim to encourage or enable R&D by cutting the 
costs of doing so.  Product researchers and developers usually gain access to these through 
collaborations with governmental organisations and charities.  “Pull” mechanisms encourage 
investment in R&D by creating financial incentives for this activity.  Examples of these are Advanced 
Market/Purchase Commitments (AMCs) and the FDAs Priority Review Vouchers (PRV)(6,18).  
Although the effectiveness of these “pull” mechanisms is yet to be proven(18–22), they do 
theoretically solve the problem of a deficient market to incentivize NTD product R&D.  The “push” 
mechanisms have already proven their worth in spurring several new R&D projects, whilst also re-
engaging pharmaceutical companies(5,7).  The majority of this has happened against a backdrop of a 
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paradigm shift in pharmaceutical development for NTDs, the product development partnership 
(PDP)(7,23), which will be discussed in detail below. 
Although still much smaller than for other therapeutic areas, the global investment in pharmaceutical 
R&D for NTDs has increased vastly.  In 1999, it was estimated that less than US$70 million were 
invested into drug research for malaria, tuberculosis, HAT and leishmaniasis, combined.  In contrast, 
the 2012 G-FINDER report stated that US$ 3,045 million were invested globally in NTD research, with 
around 70% of that directed towards product development (as reported by respondents to the G-
FINDER survey)(1).  Although funding, particularly from philanthropic and public donors, has declined 
since the global financial crisis, funding levels are still higher than in 2007(1), and much greater than 
15 years ago(4). 
Many national governments are now some of the biggest funders of NTD R&D.  Most prominent are 
the US, through the US Agency for International Development (USAID), and the UK, through its 
Department for International Development (DFID).  Other countries, such as The Netherlands and 
Australia, have emerged as major NTD R&D funders(1).  Meanwhile, the WHO’s Special Program for 
Research and Training in Tropical Diseases (WHO TDR) continues its work with a wide range of 
private and public R&D partners around the world(1,24,25). 
7.2.2.3 The Product Development Partnership (PDP) model 
PDPs bring together several different partners with the goal of developing one or a related group of 
products.  PDPs are typically partnerships between public and private institutions, where the relative 
strengths of each individual institution can be exploited.  This is particularly useful in developing 
products for neglected tropical diseases, for a number of reasons.  Philanthropic organisations are 
able to allocate resources to the researchers and developers, covering or reducing the costs of R&D.  
Academic and other public-sector or non-profit research institutions (PSNRIs) are very-well placed to 
carry out discovery and early-stage development work(26–28), whilst biotechnology and 
pharmaceutical firms are well technologically resourced.  Large pharmaceutical firms have a wealth of 
experience in conducting clinical trials, but this can also be supplemented by the knowledge and 
experience of institutions and NGOs operating in NTD-endemic countries.  This ability to leverage the 
strengths of each partner has likely contributed to the success of the PDP model.  It has resulted in 
clinical development times that are comparable with more profitable pharmaceuticals.  Also, average 
development costs are significantly cheaper than for the development of more profitable drugs, 
outside of the PDP model(7,29). 
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Figure 7.2.2 - examples of PDP "Brokers" involved in product development for drugs, vaccines, diagnostics and 
insecticides for NTDs. * indicates that they participate in the development of products to control 
trypanosomiasis(2,3,29).  
Several of the PDPs are co-ordinated by “Brokers”, such as the Drugs for Neglected Diseases 
Initiative (DNDi) and BIO Ventures for Global Health (BVGH).  These partnership brokers are 
important development partners, due to their extended networks, experience and central role in 
allocating funding.  Disease-specific alliances (e.g. The Medicines for Malaria Venture, MMV) have 
also emerged as important brokers of PDPs and as developers in their own right.   
7.2.2.4 Imbalanced R&D priorities 
Despite these positive changes, a number of concerns in NTD product development still remain.  One 
is the gaps in research, which stem from the lack of sustainable funding for some diseases.  This 
problem will be minimised if global funding increases, and if partnerships continue to be formed 
appropriately and managed effectively(7).  What may potentially be a bigger problem, from a global 
health perspective and from a researcher’s perspective, is the bias of product development for re-
formulations and fixed dose combinations, rather than for new chemical entities(5)(see Table 7.2.2, 
below).  Trouiller and colleagues describe how the lack of appropriate “tools” to treat certain NTDs, 
requires that innovative new products are developed – new chemical entities (NCE)s and novel 
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vaccines.  However, for drugs in general, and to a greater extent for NTD drugs, very few NCEs are 
developed when compared to other registered products(5,11). 
7.2.3 Trypanosomiasis 
The two human diseases caused by trypanosome infections, human African trypanosomiasis (HAT) 
and Chagas Disease, are classic examples of NTDs.  They are debilitating and fatal diseases that 
primarily affect the poor.  HAT, which is prevalent in Sub-Saharan Africa, and Chagas Disease, which 
is concentrated in Latin America, both have a long history.  Recent efforts have led to improved 
control of both disease, but problems persist.   
There has been a significant decrease in the number of new cases of HAT(30).  Effective control 
programs led to a reduction of 68% between 1995 and 2006.  36 countries remain HAT-endemic, 
although only seven of these have reported more than 100 cases per year in the period 1997-
2006(13). However, given the situation in those countries of higher prevalence, along with the ever-
present possibility of HAT re-emergence among an at-risk population of 70 million(30), it is important 
that there are appropriate tools at the disposal of health authorities. 
Although control programs (involving screening, vector control and treatment programs) have proven 
very effective in reducing the number of HAT cases, the effect has been greater for one form of HAT 
(the gambiense form), because an animal reservoir plays a significant role in the spread and 
persistence of the other (rhodesiense) form(13,30).  
Due to the chronic nature of Chagas Disease, diagnosis is challenging and infection often goes 
unnoticed for several years.  Between 7 and 8 million are estimated to be infected with Chagas 
disease worldwide, and it is spreading beyond its original geographical location to other continents.  
The treatments are effective if used shortly after infection.  However, treatment regimens are long, 
and adverse reactions occur in up to 40% of patients.  The majority of patients will present with 
chronic infection, often with other complications, when the effectiveness of the usual treatments is 
limited. 
Control of the Chagas Disease-spreading vector, the triatomine bug is probably the most effective 
means of controlling Chagas Disease, although there are challenges of the re-emergence of the 
disease in certain areas and the need for more effective treatments to treat chronic infection(12). 
7.2.4 Trypanosomiasis R&D 
Shortfalls 
The biggest shortfall in the control of HAT lies in the tools that are currently available.  A HAT vaccine 
is very challenging, due to the biology of the pathogen(31,32), so efforts are focused on vector control 
and treatments.  All treatment regimens involve some form of injection, which requires more 
resources and well-trained staff.  The length of some of these regimens puts a further strain on 
resources, which are often not well-developed in rural areas of developing countries.  The current 
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drugs all suffer from a high incidence of side-effects, which can be burdensome or even fatal in some 
cases. Therefore, there is an urgent requirement for new drugs, with less side-effects and more 
suitable formulations(13,33). 
Chagas Disease treatments suffer from similar drawbacks to those of HAT treatments.  As stated, 
above, a new drug for Chagas disease should ideally be more effective than current treatments in 
chronic stages of the disease and should have a lower incidence of side effects. 
7.2.5 Drivers of NTD R&D 
The main drivers of NTD product R&D come from philanthropic organisations, the pharmaceutical 
industry, governments, PDP brokers and other research institutions (academic and PSNRI).  Prior 
experience in NTD product R&D strongly indicates that partnering with one or several of these 
organisations would be imperative.  This chapter focuses on NTD development from the point-of-view 
of researchers from an academic institution/PSNRI.  Hence, the following discussions will analyse 
different commercialisation strategies and potential partners from that viewpoint.   
Groups from Universities or PSNRIs play a very important role in the discovery of new innovative 
treatments(26,34), but they also have several limitations as projects progress towards the 
market(27,35,36).  Therefore, partnerships are essential to them. 
 
7.2.6 Commercialisation strategies 
7.2.6.1 General strategies for pharmaceutical products 
The first step in commercialising scientific research typically entails the generation and protection of 
intellectual property (IP) pertaining to an invention.  With pharmaceuticals, this will usually involve 
filing a patent.  The holder of the patent can then seek to capitalise on this IP through licensing of the 
invention to a third party, who may have more resources to develop and distribute a marketable 
product.  Another strategy to reap rewards from IP is to form a spin-out company.  Funds to develop 
the invention are raised in the form of equity in the company.  The company may enter into a 
partnership with third parties to share risk and to co-develop the product.  The university spin-out 
company is increasingly becoming a method favoured by Universities to exploit new IP and this plays 
an important role in new product discovery and development(37).  This situation holds true in new 
drug and vaccine development by Universities(27) and companies alike.  Both academic institutions 
and new companies have been identified as important sources of new drugs(26,34). 
Given the high risks and capital costs involved in pharmaceutical R&D, the formation of co-
development partnerships is almost ubiquitous.  Large pharmaceutical corporations have looked to 
academic research institutions and small/medium biotechnology or pharmaceutical enterprises 
(SMEs) as sources of new drugs and vaccines(28).  Meanwhile, their smaller, less resourced partners 
are able to benefit from the extensive capabilities and product development experience of the larger 
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firms.  Certain R&D activities are often outsourced to contract research organisations (CROs), often 
as a cost saving measure, but sometimes as a faster and more efficient way to advance products 
through clinical development.  When new product development is initiated by small companies, and 
sometimes when large companies are the sole developer, it may be necessary to bring in a number of 
other partners (venture capitalists and other shareholders) to finance development.   
The following section discusses how different development partners may be involved in the 
development of drugs for a neglected tropical disease, such as trypanosomiasis.   
 
Figure 7.2.3 - scheme illustrating potential commercialisation strategies for university- or PSNRI-originating research.  IP 
is either licensed/sold directly to third parties, or to a spin-out company formed by the inventors’ institution. Solid 
arrows indicate technology transfer, whilst dotted lines indicate returns to the University/PSNRI.  
 
7.2.7 Product development partners 
7.2.7.1 The general picture 
NTD product development inherently faces the same risks as the development of developed-world 
diseases.  However, as previously mentioned, there is a huge disparity between the collective or 
individual disease burdens of NTDs and the R&D activity aimed at controlling them (4).  Despite this, 
the funding for global NTD product R&D has increased dramatically over the previous decade, 
showing gradual increases up until 2009, and steady levels since then.  71.4% of the US $3.045 
billion NTD R&D funding in 2011 was in the form of external grants, with a reported $1.5 billion going 
to academic and private NTD product developers(1). 
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The largest funders of NTD research are government institutions, presenting as aid agencies or 
research councils/science and technology (S&T) agencies.  They provide around 65-70% of global 
funding for NTD research.  The other two major sources of funding for NTD research are industry 
(pharmaceutical and biotechnology) and philanthropy, contributing 17.2% and 18.7%, respectively, of 
all global funding in 2011(1). 
PDPs take a central role in NTD drug development.  They received 23% of global grant funding for 
NTD research in 2011(1).  Furthermore, the BVGH 2012 report on the product developer landscape 
showed that 40% of all drugs and vaccines in current development were being developed using the 
PDP model(38).  Hence, the PDP brokers are another key partner in NTD product development. 
7.2.7.2 Funding for trypanosomiasis 
4.3% (US $131.7 million) of global funding reported in the G-FINDER report was dedicated to 
research in diseases caused by kinetoplastids (leishmaniasis, HAT and Chagas disease).  Of this 
amount, 26% was granted to HAT and 18.7% to Chagas disease.  A total of roughly US$18 million 
was spent on R&D for new drugs in 2011(1).  The funding landscape for these diseases appears 
close to the general picture: 73.3% of funding originates in the public sector and 17.3% is donated by 
philanthropic organisations.  The top three funders of research in kinetoplastid diseases are the US 
National Institutes of Health (NIH), The Bill & Melinda Gates Foundation (Gates Foundation) and The 
Wellcome Trust.  Industry plays a smaller role here, than in other disease areas, contributing only 
9.5% of funding, but it is still the third largest source of funding. 
582 
 
 
Figure 7.2.4 - global funding for NTD research in 2011, as reported in the G-FINDER report(1).  Funding by sector is 
presented as percentage of total funding.  
7.2.7.3 The academic/PSNRI institution as a source of new products for NTDs 
In all disease areas, academic institutions and PSNRIs have proven to be important sources for new 
drugs and vaccines(26).  Analysis of some recently-registered NTD products shows academics and 
PSNRIs at the root of their discoveries(4).  A look at the BVGH Global Health Primer also reveals the 
involvement of such institutions in the development of several NTD products in the pipeline(3).  This 
role in product R&D is particularly important in the NTD setting; the development of innovative 
treatments is an inherent requirement to treat or prevent several NTDs(4).  Evidence to support an 
innovative role can be found in the literature.  In Stevens et al.’s analysis of new drug applications to 
the US Food and Drug Administration (FDA), they show that academics/PSNRIs were twice as likely 
as for-profit institutions to meet an unmet medical need when a new drug originated with them.  
Academic/PSNRI inventors also contributed to 13.6% of new molecular entities (NMEs) included in 
the analysis, and 9 out of the 10 new drugs that were for new indications(26).  Similarly, in Kneller’s 
2010 analysis of the origins of new drugs, Universities were shown to contribute to the R&D of 30% of 
drugs given the FDA’s priority review (see discussion of PRV, below) and to 31% of drugs considered 
to be scientifically novel, despite contributing to an estimated 24% of new drugs overall(34).   
The prominent role of public funders, coupled with the fact that around three-quarters of all public 
funding goes directly to researchers(254), means that academic and PSNRIs are collectively the 
largest recipients of NTD R&D funding.  There has also been an increase in intramural funding by 
PSNRIs and Universities(1).  This makes researchers in these positions the most common 
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participants in NTD product development(38).  However, groups from Universities and other PSNRIs 
are often insufficiently resourced to progress new products towards the clinic alone.  The costs of 
preclinical drug development can cost hundreds of thousands of pounds at a minimum, which can be 
very inhibiting, particularly to a small academic group(36).  On the other hand, with the rise of 
Academic Drug Discovery Centres, particularly in the US, more academic and PSNRI researchers will 
find the necessary resources available to them(27).  Even small groups can collaborate with other 
groups within their institution or externally in order to carry out different studies using the grants of 
individual researchers.  When looking at the current NTD product pipeline, academic/PSNRIs can be 
seen to be involved at every stage of the product development lifecycle – from discovery through to 
clinical phases(3,38). 
An academic institution/PSNRI has the option to sell the IP of a particular invention to another product 
developer to take forward.  This is clearly the most convenient option and, in many cases, it is the 
most appropriate option, relieving researchers of duties that are outside of their area of expertise.  
There are situations where the development of a product will benefit from the continued input of the 
original inventors, in which case it would be a good option to license the product to third parties and 
co-develop the product(39).  In addition to these strategies, academics/PSNRIs may spin-out a 
company to commercialise a product.  This has the added value of being able to attract more funds in 
the form of equity.  Being able to provide more funds directly, means that the inventors take on more 
of the risk, but are in a more favourable position to reap the commercial rewards of any products that 
meet the market.  Thus, the decision to follow either of the last two strategies is largely dependent on 
the commercial value of the product being developed.  Universities often pursue the spin-out model 
as a more lucrative revenue source(28,39).  However, in the NTD space, most products would have 
little or no commercial value.  This is particularly the case for HAT and it is probably the case for 
Chagas disease.   
The contribution of academic/PSNRIs in overall drug discovery and development, beyond the 
discovery phase is confirmed by numerous sources(26–28,34).  However, in the vast majority of 
cases, there is some form of technology transfer from Universities/PSRIs to Pharmaceutical or 
Biotechnology companies, who complete late-stage development, and carry out registration, 
marketing and distribution.  In Kneller’s study of the origins of drugs, 8% of drugs originated from 
Universities that transferred their technology to Pharmaceutical companies, whilst 16% originated 
from Universities that transferred their technology to Biotechnology companies.  
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Table 7.2.1. Organisations engaged in the development of drugs to treat trypanosomiasis.  Organisations were identified as funders of drugs for trypanosomiasis who reported to the G-
FINDER survey(2), or as participants in current projects to develop trypanosomiasis drugs on the BVGH global health primer(3).  Some other organisations involved in NTD product R&D 
were identified through media reports or were signatories of the London Declaration to combat NTDs(40).  This list is not exhaustive.  In particular, the PSNRI included here probably 
represent only a small sample of all those that are involved in this area.  Several of these organisations are potential partners, whereas others, such as foreign government departments, 
will be funders of these partners.  The capabilities here are the main capabilities of each organisation in this area and were judged based on reports of past activity in trypanosomiasis or 
NTD drug development and on information posted on the organisations’ websites.  *SMEs are pharmaceutical or biotechnology companies with up to 250 employees.  Some of the 
PSNRIs, such as the Institute for One World Health and Seattle Biomed, have similar capabilities to the SMEs listed here.  
Name Type Capabilities Experience with 
HAT/Chagas 
Disease? 
Comments 
Abbvie Inc. Pharmaceutical Company R&D: entire lifecycle  A division of 
Abbott 
Anacor Pharmaceuticals SME* R&D: entire lifecycle  Has required 
partners to 
develop 
systemic 
products 
past 
preclinical 
stage 
aRigen Pharmaceuticals SME R&D: discovery - phase I   
AstraZeneca Pharmaceutical Company R&D: entire lifecycle   
Barcelona Centre for International Health 
Research 
PSNRI R&D: discovery - preclinical   
Bayer Healthcare Pharmaceutical Company R&D: entire lifecycle   
Belgian National Fund for Scientific 
Research (FWO) 
S&T Agency Funding   
Bill & Melinda Gates Foundation Philanthropy Funding; Partnership   
Biotechnology and Biological Sciences 
Research Council (BBSRC) 
S&T Agency Funding   
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Name Type Capabilities Experience with 
HAT/Chagas 
Disease? 
Comments 
Brazilian Development Bank (BNDES) Government Funding   
Brazilian Foundation Araucaria, 
Fundaçao Araucaria 
Government Funding   
Brazilian Ministry of Health: Department 
of Science and Technology (DECIT) 
S&T Agency Funding   
Brazilian Research Support Foundation of 
the State of Bahia, Fundaçao de Amparo 
a Pesquisa do Estado da Bahia (FAPESB) 
S&T Agency Funding   
Canton of Geneva Government Funding   
Carlos III Health Institute PSNRI R&D: discovery - clinical trials   
CDC, Centre for Global Health, Division of 
Parasitic Diseases and Malaria 
PSNRI R&D: discovery - preclinical   
Centre for Discovery and Innovation in 
Parasitic Diseases (Sandler Centre for 
Drug Discovery) 
University/PSNRI R&D: discovery - preclinical   
Developing World Health PDP broker Partnerships; Implementation   
Drugs for Neglected Diseases Initiative 
(DNDi) 
PDP broker Partnerships   
Dutch Ministry of Foreign Affairs - 
Directorate General of Development 
Cooperation (DGIS) 
International Aid Funding   
Eisai Company Pharmaceutical Company R&D: entire lifecycle   
Eli Lilly & Company Pharmaceutical Company R&D: entire lifecycle   
Epichem CRO R&D: discovery, 
pharmaceutical formulation 
  
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Name Type Capabilities Experience with 
HAT/Chagas 
Disease? 
Comments 
European Commission: Directorate-
General for Research and Innovation 
Government Funding   
French Ministry of Foreign and European 
Affairs, Ministere des Affaires Etrangeres 
et Europeennes (MAEE) 
International Aid Funding   
Genomics Institute of the Novartis 
Research Foundation 
Pharmaceutical Company R&D: discovery - preclinical  A subdivision 
of Novartis 
German Agency for Technical 
Cooperation (GTZ) Deutsche Gesellschaft 
für Technische Zusammenarbeit GmbH 
Government Funding   
Gilead Sciences Biotechnology Company R&D: entire lifecycle   
GlaxoSmithKline Pharmaceutical Company R&D: entire lifecycle   
Global Alliance for TB Drug Development PDP Broker Partnership; Funding   
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Name Type Capabilities Experience with 
HAT/Chagas 
Disease? 
Comments 
Global Health Innovation Technology 
Fund 
PDP Broker Partnership; Funding  Non-profit 
founded by 
Japanese 
firms 
(Astellas, 
Daiichi-
Sankyo, 
Eisai, 
Shionogi, 
Takeda), 
Japanese 
Government, 
UNDP and 
The Gates 
Foundation 
Global Network Philanthropist Implementation; Advocacy   
Immtech Pharmaceuticals SME R&D: discovery - preclinical   
Indian Department of Biotechnology, 
Ministry of Science and Technology 
(DBT) 
S&T Agency Funding   
Infectious Disease Research Institute PSNRI; PDP Broker R&D: entire lifecycle; 
Partnerships 
  
Institut Pasteur PSNRI R&D: discovery - clinical trials   
Institut Pasteur, Korea PSNRI R&D: discovery - preclinical   
Institute for One World Health PSNRI; PDP Broker Partnership; R&D: discovery - 
clinical trials 
 A subdivision 
of PATH 
Inter-American Development Bank Bank Funding   
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Name Type Capabilities Experience with 
HAT/Chagas 
Disease? 
Comments 
Janssen Pharmaceutical Companies Pharmaceutical Company R&D: entire lifecycle  A subdivision 
of Johnson & 
Johnson 
Johnson & Johnson Pharmaceutical Company R&D: entire lifecycle   
Malaysian Ministry of Science and 
Technology (MOSTI), including the 
National Biotechnology Division 
(BIOTEK) 
S&T Agency Funding   
MANLAB CRO R&D: preclinical   
Médecins Sans Frontieres/Doctors 
Without Borders (MSF/DWB) 
NGO Funding; Implementation   
Merck & co. Pharmaceutical Company R&D: entire lifecycle   
Mundo Sano PDP Broker; PSNRI Partnership   
National Program to Fight HAT, DRC Government Implementation   
National Scientific and Technical 
Research Council - Argentine (CONICET) 
S&T Agency Funding   
Novartis AG Pharmaceutical Company R&D: entire lifecycle   
Novartis Institutes for Biomedical 
Research (NIBR) 
Pharmaceutical Company R&D: discovery - preclinical  A subdivision 
of Novartis 
Otsuka Pharmaceutical Company Pharmaceutical Company R&D: entire lifecycle   
Pfizer Pharmaceutical Company R&D: entire lifecycle   
Pharmaceutical laboratory of 
Pernambuco state (LAFEPE) 
PSNRI R&D: pharmaceutical 
formulation 
  
Program for Appropriate Technology in 
Health (PATH) 
PDP Broker; PSNRI Partnership; R&D: discovery - 
clinical trials 
  
Roche Pharmaceutical Company R&D: entire lifecycle   
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Name Type Capabilities Experience with 
HAT/Chagas 
Disease? 
Comments 
RTI International PSNRI R&D: discovery - preclinical   
Sandoz Family Foundation Venture Capital Funding   
Sanofi Pharmaceutical Company R&D: entire lifecycle   
Sasakawa Peace Foundation NGO Funding   
Save the Children NGO; Philanthropist Funding   
Scottish Higher Education Funding 
Council 
Government Funding   
Scripps Research Institute PSNRI R&D: discovery - preclinical   
Scynexis, Inc. SME/CRO R&D: discovery - preclinical   
Seattle BioMed PSNRI R&D: discovery - clinical trials   
Spanish Ministry of Foreign Affairs and 
Cooperation for Development (MAEC) 
and/or Agency of International 
Cooperation for Development (AECID) 
International Aid Funding   
Swiss Tropical and Public Health Institute 
(Swiss TPH) 
PSNRI R&D: discovery - clinical trials   
Takeda Pharmaceutical Company Pharmaceutical Company R&D: entire lifecycle   
The END Fund Philanthropist Funding   
The Wellcome Trust Philanthropist Funding   
Therapeutics for Rare & Neglected 
Diseases (TRND) 
PSNRI R&D: preclinical - phase I  A subdivision 
of NIH 
Tres Cantos Open Lab Foundation PSNRI R&D: discovery - preclinical   
UBS Optimus Foundation Philanthropist Funding  Focus on 
Child well-
being 
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Name Type Capabilities Experience with 
HAT/Chagas 
Disease? 
Comments 
UK Department for International 
Development (DFID) 
International Aid Funding   
UK Medical Research Council (MRC) S&T Agency; PSNRI R&D: discovery - clinical trials   
US National Institutes of Health (NIH) S&T Agency; PSNRI R&D: discovery - clinical trials   
WIPO Re:Search (BIO Ventures for Global 
Health) 
PDP Broker Partnership  Managed by 
BIO 
Ventures for 
Global 
Health 
591 
 
7.2.7.4 Partners for NTD product development 
PDP Brokers 
As previously described, the successes of several NTD drug and vaccine development 
programs have been attributed to the PDP model(29).  The PDP brokers play a central role in 
this and manage much of the global funding that is directed to NTD research and development 
(see above).  The characteristics of these brokers differ slightly.  There are those that focus on 
a particular project, whilst there are others that are focused on a particular disease or group of 
diseases (e.g. Medicines for Malaria Venture [MMV], Global TB Alliance) and manage several 
products.  Brokers such as DNDi and BVGH work across therapeutic areas in the NTD space.  
As the Brokers have extensive networks and are present at every stage of pharmaceutical 
development, it would be advantageous to engage a PDP early on in the process.  The multi-
project and multi-disease Brokers have the added advantage that they have more experience, 
as they tend to have existed for longer, and thus they are better connected.  One disadvantage 
of PDPs is that they do not generate their own income and rely on funding from external 
sources.  Theoretically, this would make them vulnerable to the same inconsistency in funding 
as academics/PSRIs.  However, this does not seem to be the case, judging by the literature and 
media reports. 
According to the BVGH Global Health Primer, DNDi and the Global Alliance for TB Drug 
Development, along with BVGH, are PDP brokers that are currently involved in trypanosomiasis 
drug development. 
Government 
The biggest proportion of global R&D funding for NTD research comes from government 
sources.  A lot of this funding is given in pursuit of international development goals or for 
scientific reasons.  According to the G-FINDER report, the US NIH (granting a huge US$1.16 
billion over five years) is by far the most significant funder of NTD research.  Researchers in the 
UK have access to funds from the European Commission (EC), UK DFID and The Medical 
Research Council, which are all in the top twelve funders of NTD research.  Aid agencies and 
Research Councils/S&T agencies of the US, Dutch and Australian governments are also 
present in the list(1).  There has been a shift over the years towards more basic research, with 
31.2% of funding being dedicated to this area.  Therefore, researchers are likely to find funds 
from these sources for discovery and early-stage development.  However, a substantial 
proportion of funds are still available for later development.  For example, in 2011-2012, the 
MRC released a Highlight Notice, prioritising translational research in NTDs(41).  This remains a 
priority for the MRC’s Infection and Immunity Board(42).  Funds from research councils/S&T 
agencies are usually disbursed through competitive grant systems, where researchers must 
submit project proposals in response to calls for applications. 
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A large part of the support from government aid agencies focuses on  implementation of mass 
treatment administration programs.  This certainly seems to be the main role of USAID(43).  The 
UK DFID is also heavily involved in this area, but also places a lot of emphasis on research to 
combat NTDs(44).  Their contributions are delivered through the WHO TDR initiative and DNDi 
programs(45) 
Philanthropy 
Philanthropic donations for NTD research do not seem to be concentrated in any particular 
disease area.  This funding usually plays a contributing role to specific projects and is focused 
on product development.  Around half of all PDP funding comes from philanthropic 
organisations (principally The Gates Foundation)(1).  Thus, it is important to highlight that, 
although Philanthropists are not as prominent as governments in NTD research funding overall, 
they are often major sources of funding for the development of individual products.  The two 
largest philanthropic funders are The Gates Foundation, providing an average of US$120.3 
million annually in 2007-2011, and The Wellcome Trust, which gave an average of US$10.8 
million annually to NTD research over the same period(1).  The main areas of focus of The 
Gates Foundation are Global Health, Global Development, Education (in the US) and Global 
Policy & Advocacy(46).  Efforts to control NTDs receives strong support from the Gates 
Foundation’s Global Health Division and HAT is one of the “High Opportunity Targets” that they 
focus on(47).  Apart from funding PDPs and other global health organisations, The Gates 
Foundation also has a mechanism for giving grants to researchers.  Concepts with specified 
aims are developed internally, then researchers/organisations are either invited privately or 
publically to apply for grants in a similar way to how they would apply for research council 
grants(48).  The Wellcome Trust operates in a similar way to research councils.  Infectious 
Diseases are included in the list of ‘Research Challenges’ in the Trust’s 2012-2020 Strategic 
Plan(49).  There are also two specific programs which are applicable to NTD product R&D.  
Firstly, the Global Health trials scheme provides funding for late-stage clinical trials of 
‘interventions that will improve health’ in low- and middle-income countries(50).  Secondly, the 
Wellcome Trust’s Pathfinder Awards provide funding for Academic-Industry partnerships for 
R&D for NTDs and Orphan Diseases.  The aim of this initiative is to advance projects from an 
early-stage to a stage where there is enough credibility to attract funds from other sources(51).  
Target validation is not supported by this scheme, so it can be envisaged that this scheme 
would be attractive to researchers working in the discovery and pre-clinical development stages.  
Furthermore, similar lines of research could be funded through other, less specific Wellcome 
Trust Grants. 
There is little information on the role of Philanthropy by wealthy individuals in funding NTD 
research.  It is possible that these individuals will give their donations to PDP brokers, and other 
charities/non-profit organisations, so their contribution is unclear.  Given the engagement of 
such individuals in issues of social importance(52), they should be approached to support R&D 
for NTD product development. 
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Large Pharmaceutical Companies 
Pharmaceutical firms are one of the primary partners of academic/PSNRI organisations for drug 
and vaccine development.  They are also a key partner in NTD drug development.  A search of 
the G-FINDER database, and a review of the signatories to the London Declaration on NTDs 
reveals a significant number of large pharmaceutical corporations that are involved in NTD 
product R&D(1,40).  They are responsible for a large part of the industry participation in NTD 
product development and some companies are engaged in the development of several products 
at a time(38).  In addition to the potentially large amount of funds at their disposal, large 
pharmaceutical firms also contribute to a large extent with in-kind support, ranging from access 
to facilities/compounds, offering of expertise, etc.(1).  There has been a significant increase in 
pharmaceutical industry involvement in NTD product development(1), which has been attributed 
to social and ethical concerns, efforts to improve reputation, and long-term strategic 
considerations(7). 
Much of the increase in funding has been directed towards advancing particular products 
through late-stage trials.  Most of the funding directed towards controlling NTDs is spent 
internally by large pharmaceutical companies(1), so it is likely that one of the main ways of 
partnering with them is through some kind of technology transfer of an invention to the 
company.  Much of the partnering done by large pharmaceutical firms is now shifting to earlier 
stages of development(1,5,7).  One of the biggest strengths of this type of partner is that it is 
one of a few types of organisation that can advance a project from any point in the product life 
cycle to the market.  The 20 or so large, multi-national corporations also have wide networks to 
engage CROs and other partners to carry out different parts of the development work.  
Therefore, these firms can be approached for partnership at any stage in development.  Of the 
largest companies, work in the NTD space is dominated by four of them: GlaxoSmithKline, 
Novartis, Sanofi and Astra Zeneca.  Although they have large amounts of money at their 
disposal, this means that there are really only a small number of individual developers of this 
type to partner with, compared with the biotechnology cohort. 
Biotechnology/Small Pharmaceutical Companies 
It has been shown that technology transfer from Universities to biotechnology firms accounts for 
more new drugs and biologics than that from Universities to pharmaceutical companies (16% 
vs. 8%) (34).  Therefore, biotechnology companies should be considered as one of the primary 
partners for researchers seeking to develop NTD products.  It’s often the case that these 
companies will later partner with or transfer technology to large pharmaceutical companies, but 
some biotechnology companies will advance their products all the way from discovery to 
market(34).  This highlights the extent of some of their capabilities.  Funding from biotech and 
small-pharmaceutical firms accounted for 10.6% of 2011 funding from industry that was 
reported in the G-FINDER report, and made up large/majority contributions in some disease 
areas, such as helminth diseases or trachoma(1). 
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Compared to the biotechnology sector as a whole, a very small proportion of companies are 
involved in NTD product development.  However, participation by biotechnology companies in 
NTD product development is estimated by BVGH to be evident across 41% of the NTD product 
pipeline.  Their participation is also present through all phases of the pharmaceutical product 
development lifecycle, and it exceeds the participation of pharmaceutical companies at all 
stages of development before phase III.  It is possible that biotechnology companies are filling 
very important roles in different parts of the lifecycle, sometimes where large industry 
participation is absent(38). 
When it is appreciated that a main obstacle in finding funding to develop NTD products is a lack 
of commercial potential, it is encouraging that biotechnology firms have played a more 
significant role than large pharmaceutical firms in discovering and developing orphan drugs 
(drugs developed for rare diseases; see discussion on rare diseases and orphan drugs below), 
where the commercial value is typically lower(34).  This is analogous to the situation that has 
drawn some small companies to neglected diseases (this was the case for Zentaris in the 
development of miltefosine, for example) (7).  In lower-income countries, where NTDs are 
present, this may be a further encouragement to engage in NTD product R&D.  In 2011, 28.9% 
of funding reported by biotechnology and small pharmaceutical firms came from countries in 
lower-income countries.  Firms from the emerging markets of India and Brazil are playing a 
particularly prominent role, and there have been significant increases in research directed 
towards treating kinetoplastid diseases in Brazilian firms(1). 
Biotechnology and other smaller firms are limited by the funds available to them.  As their funds 
originate from investments, as opposed to the revenues of large pharmaceutical companies, 
they have less flexibility, thus typically contribute less to NTD product development(38).  
Furthermore, it can be expected that these firms are also less able to offer in-kind contributions 
than their larger counterparts.  PDPs often have to contribute more funding to biotechnology 
firms, than to pharmaceutical firms, making them a more expensive partner for PDP brokers to 
work with(29,38). 
Contract Research Organisations 
Whether conducting neglected disease R&D or not, CROs can be a useful partner for carrying 
out specific studies that researchers may lack the ability to do in their own facilities.  CROs are 
reasonably active in the field of NTD product R&D and partner extensively with PDPs: the DNDi 
website lists 28 different CROs from companies from both developed and developing countries 
as partners(53).  An analysis of traceable external PDP expenditure in 2007 shows that 20.9% 
went to CROs, larger than that which went to large pharmaceutical companies (18%) and 
biotechnology/small pharmaceutical companies (9.3%) (29).  
There are some companies that are combining the role of a traditional pharmaceutical or 
biotechnology company, with contract services.  Founded with money from equity investments, 
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the South Africa-based iThemba raises additional money through contract medicinal chemistry 
services and invests the profit into research for treatments of unmet medical needs in Africa.  
Using this business model, they have successfully generated a pipeline of leads and molecular 
scaffolds active against malarial parasites, TB and HIV(54).  Another company, called Scynexis, 
has played an important role in developing a late-stage HAT compound(55).  This is detailed in 
a case study, later in this chapter.  
Venture Capital 
When a researcher’s commercialisation strategy is to form a new company, after gaining 
seed/start-up capital, larger investments are often sought from venture capitalists(39).   
Venture Capital (VC) firms provide finance in exchange for some form of equity in the company, 
but individual deals can take many forms.  VC firms usually make an investment with the 
assumption that there will be a profitable ‘exit’, at a later date.  This will usually involve the 
company being purchased at a value that is higher than that invested in the company. 
In addition to Private VC firms, Corporate Venture Capital (CVC), coming from large 
corporations, is another source of equity.  There has been an increasing trend in venture capital 
investments to biotechnology/small pharmaceutical firms from large corporations, particularly 
large pharmaceutical companies.  Several large pharmaceutical companies now have venture 
capital arms.  Corporate venturing can be seen as another way that large firms can augment 
their pipelines and access new technologies.  As some private VC firms have moved away from 
the biotechnology sector, Corporate VC has become increasingly important.  Investments are 
reportedly on the increase, with a shift towards earlier stages of development, but these firms 
are often looking for companies that are already venture-backed(56).  
The lack of financial incentive for making such investments for companies in the NTD space is 
probably a reason why venture capital has not been looked at as a significant source for funding 
in this area.  However, this does not preclude it from playing a role.  There will be a number of 
cases mentioned in this chapter, where funds from equity investments have eventually played a 
role in NTD drug development.  Additionally, there is already evidence of a venture capital firm 
engaging in the fight to control neglected diseases.  The Legatum group, a Dubai-based private 
investment firm, is a founder of the END fund, which is a global fund committed to supporting 
mass drug administration to eradicate NTDs in Africa(57). 
Angel Investors 
Angels, wealthy individuals that are usually serial entrepreneurs, make investments in a similar 
manner to venture capitalists, and are another source of funding for new businesses.  Like the 
individual philanthropists, they are individuals who wish to invest in causes that they have some 
kind of interest in.  They often seek to have some influence on the company, too(39).  For 
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reasons already discussed, such an individual is likely to be a philanthropist in the area of NTD 
product R&D.  
7.2.8 Details of partnerships 
7.2.8.1 NTD product development in the 21st century 
One of the most striking things of Pedrique et al.’s analysis of new products for NTDs (see 
products in Table 7.2.2), is that there are very few new innovative products – the majority of 
products are repurposed drugs (denoted NI, for new indication), new fixed dose combinations 
(FDCs) of existing drugs or new formulations (NF) of existing drugs(5).  At first glance, there 
appears to be a promising number of new vaccines introduced in the period studied.  However, 
these only cover two diseases, and two vaccines originate from the same invention.  There are 
only four NCEs on the whole list(5).  As a result, this gives us little information on how a product 
may be developed from the discovery phase, through to product registration. On the other hand, 
they do show evidence of successful product development through the more expensive, later 
stages of development.  Therefore, there are several useful lessons to be learned from these 
successes. 
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Table 7.2.2 - New NTD products approved or recommended during 2000-11. Table reproduced from the work of Pedrique et al.(5), with an additional column on product development history 
(from media reports, WHO documents and scientific literature).  
Generic Name Marketed 
Name(s) 
Indication(s) Formulation Product 
Type 
Regulatory 
Body(s) 
Country Date of 
Approval 
MA Holder Comments on 
Development History 
artemotil   malaria injectable NCE MEB Netherlands 2000 Artecef BV Artecef BV was created 
by ACF Beheer S.A. for 
the purpose of 
developing Artemotil with 
the WHO.  Patent held by 
the WHO Scientific 
Working Group on the 
Chemotherapy of 
Malaria. 
atovaquone plus 
proguanil 
(paediatric) 
Malarone 
Paediatric 
malaria tablet NI FDA USA 2000 GlaxoSmithKline   
proguanil plus 
chloroquine 
Avloclor malaria tablet FDC AFSSAPS France 2001 AstraZeneca   
chloroquine plus 
primaquine 
  malaria tablet FDC ANVISA Brazil 2001 Industria 
quimica do 
Estado de Goias 
S/A - Iquedo, 
Brazil 
  
artesunate   malaria injectable NF ANVISA Brazil 2001 Silvestre Labs 
Quimica e 
Farmaceutica 
Ltda, Brazil 
  
artemether plus 
lumefantrine 
Coartem malaria dispersible 
tablet 
NF Swissmedic Switzerland 2008 Novartis 
Pharma 
Schweiz AG 
Ciba-Geigy, later 
Novartis entered into a 
partnership with the 
Academy of Military 
Medical Sciences in 
China and several private 
Chinese entities to 
develop Coartem.  
Originally marketed as 
Riamet for developed-
world travellers, but was 
produced non-profitably 
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later, following an 
agreement with the 
WHO.  Supported by the 
Global Fund. 
artesunate plus 
amodiaquine 
(ASAQ) 
Coarsucam malaria tablet FDC WHO PQ   2008 Sanofi-Aventis 
Group 
Combination developed 
in parallel by Sanofi and 
the FACT (Fixed Dose 
Artesunate Combination 
Therapy) Consortium - a 
group headed by DNDi, 
and involving 
Farmanguinhos/Fiocruz 
and various other 
academic, clinical and 
CRO partners.  They 
later teamed up to co-
develop the product.  
Compound registration 
and manufacture was 
also initiated in Morocco, 
to build capacity and aid 
registration in endemic 
countries. 
artesunate plus 
mefloquine 
(ASMQ) 
  malaria tablet FDC ANVISA Brazil 2008 Farmanguinhos/ 
Fiocruz, Brazil 
Combination devised by 
WHO TDR staff, with 
support from USAID and 
the Wellcome Trust.  
Developed in a  PDP led 
by the FACT consortium.  
A later technology 
transfer agreement 
allowed production and 
registration in India. 
artemether plus 
lumefantrine 
  malaria oral 
suspension 
NF CDSCO India 2008 Information 
unavailable 
  
arterolane maleate 
plus piperaquine 
phosphate 
Synriam malaria tablet NCE CDSCO India 2011 Ranbaxy labs Invented in a PDP, led by 
MMV, with UK, US and 
Swiss contributors.  MMV 
licensed the IP to 
Ranbaxy in 2003. 
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piperaquine 
tetraphosphate 
plus alpha 
dihydroartemisinin 
Eurartesim malaria tablet NCE EMEA Europe 2011 Sigma-Tau 
Industrie 
Farmaceutiche 
Riunite SpA 
Combination initially 
developed by Professor 
Li Guoqiao of Guangzhou 
University of Traditional 
Chinese Medicine and 
developed in a 
partnership with the 
Holley group, China.  
Further developed for 
Global use in a PDP 
involving MMV. 
artesunate   malaria suppository NF ANVISA Brazil 2000 Nova Quimica 
Farmaceutica 
Ltda, Brazil 
Supporting research was 
funded by WHO TDR, 
several governments and 
two PSNRIs. 
ethambutol plus 
isoniazid plus 
pyrazinamide plus 
rifampicin 
  tuberculosis tablet FDC WHO PQ   2003 Lupin Ltd, India Combination was 
introduced on advice of 
WHO Advisory 
committee. 
ethambutol plus 
isoniazid plus 
rifampicin 
  tuberculosis tablet FDC WHO PQ   2008 Macleods 
Pharmaceuticals 
Ltd, India 
Application submitted by 
MSF and The 
International Union 
against Tuberculosis and 
Lung Disease. 
isoniazid plus 
rifampicin 
  tuberculosis dispersible 
tablet 
NF WHO PQ   2009 Macleods 
Pharmaceuticals 
Ltd, India 
  
isoniazid plus 
pyrazinamide plus 
rifampicin 
  tuberculosis dispersible 
tablet 
NF WHO PQ   2009 Macleods 
Pharmaceuticals 
Ltd, India 
  
moxifloxacin   tuberculosis tablet NI WHO PQ   2010 Cipla Ltd, India Use is currently off-label, 
although recommended 
by WHO; Bayer (after 
withdrawing its patent in 
India) and TB alliance are 
conducting trials to 
register the product. 
levofloxacin   tuberculosis tablet NI WHO PQ   2011 Cipla Ltd, India   
ofloxacin   tuberculosis tablet NI WHO PQ   2011 Cipla Ltd, India   
 
 
6
00
 
benznidazole 
(paediatric) 
  Chagas disease dispersible 
tablet 
NF ANVISA Brazil 2011 Pernambuco 
State 
Pharmaceutical 
Laboratory 
(LAFEPE), 
Brazil 
Partnership with DNDi 
and multiple funders to 
produce new formulation.  
DNDi supported product 
registration. 
miltefosine Impavido visceral 
leishmaniasis 
capsule NI CDSCO India 2002 German 
Remedies Ltd, 
Mumbai 
WHO TDR worked 
closely with Zentaris AG 
(original inventor) to 
clinically develop 
miltefosine for visceral 
leishmaniasis.  WHO 
TDR set up a 
development team and 
several Indian principal 
investigators were 
involved.  Strong 
agreements on patient 
access were put in place.  
Zentaris licensed it to 
German Remedies for 
manufacture and 
Distribution. 
paromomycin   visceral 
leishmaniasis 
injectable NI CDSCO India 2006 Gland Pharma 
United and One 
World Health 
(San Francisco 
[IOWH]) and the 
Bill & Melinda 
Gates 
Foundation 
  
miltefosine Impavido cutaneous 
leishmaniasis 
  NI CDSCO India 2008 German 
Remedies Ltd, 
Mumbai 
Zentaris appear to have 
sponsored further trials in 
this indication 
independently of TDR. 
nitazoxanide Alinia cryptosporidiosis/ 
giardiasis 
oral 
suspension 
NF FDA USA 2002 Romark 
Laboratories, LC 
See below 
nitazoxanide Alinia cryptosporidiosis/ 
giardiasis 
tablet NCE FDA USA 2004 Romark 
Laboratories, LC 
Originally discovered by 
Jean-Francois Rossignol 
in the Pasteur Institute.  
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Rossignol co-founded a 
Romarck to 
commercialise 
nitazoxanide. 
tosufloxacin 
tosilate hydrate 
Ozex cholera granules NF PMDA Japan 2009 Toyama 
Chemical Co, 
Ltd 
A reformulation of Ozex 
tablets. 
bivalent 
inactivated 
vaccine, killed 
whole cells of 
Vibrio cholerae O1 
and O139 
Shanchol cholera oral 
suspension 
vaccine CDSCO India 2009 Shantha Biotech International Vaccine 
Institute altered 
mORCVAX formulation of 
Vabiotech to meet 
International standards, 
with backing from the 
Gates Foundation and 
various international 
development agencies.  
The technology was then 
transferred to Shantha for 
production. 
live pentavalent 
vaccine, for 
prevention of G1, 
G2, G3, G4, and G-
serotypes 
containing P1A[8], 
in Vero cells 
RotaTeq rotavirus oral 
suspension 
vaccine EMEA Europe 2006 Sanofi Pasteur 
MSD, SNC 
Discovered by the 
Philadelphia Childrens 
Hospital and the Wistar 
Institute.  Product 
licensed to Merck and 
Royalty Interest of 
Philadelphia Children's 
Hospital and part royalty 
interest of Wistar institute 
was later sold to 3rd 
parties. 
Live, attenuated 
vaccine, rotavirus 
RIX4414 strain, for 
prevention of G1 
and non-G1 
serotypes (G3, G4, 
and G9), in Vero 
cells 
Rotarix rotavirus oral 
suspension 
vaccine EMEA Europe 2006 GlaxoSmithKline 
Biologicals SA 
Licensed from Avant to 
GSK. This vaccine was 
first registered for use in 
Mexico and the 
Dominican Republic in 
2004, and has been 
approved in more than 35 
countries and the 
European Union. 
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Japanese 
encephalitis virus 
vaccine, freeze-
dried, inactivated, 
Beijing-1 strain, 
Vero cell-derived 
ENCEVAC Japanese 
encephalitis 
injectable vaccine PMDA Japan 2006 Kaketsuken   
Japanese 
encephalitis virus 
vaccine, live 
chimeric viral 
vector 
Imojev Japanese 
encephalitis 
injectable vaccine TGA Australia 2008 Sanofi Pasteur 
Pty Ltd 
Developed by Acambis 
as ChimeriVax-JE.  
Marketing and 
distribution license 
granted to Sanofi.  Target 
markets in South-East 
Asia, presumably for-
profit. 
Japanese 
encephalitis virus 
vaccine, purified, 
formalin-
inactivated, whole 
virus vaccine 
strain SA14-14-2, 
in Vero cells 
Ixiaro Japanese 
encephalitis 
injectable vaccine EMEA Europe 2009 Intercell AG Intercell licensed relevant 
IP from Vaccgen 
International LLC and 
Sanofi Pasteur.  
Distribution by Novartis. 
Japanese 
encephalitis virus 
vaccine, live, 
attenuated strain 
SA14-14-2, in 
primary hamster 
kidney cell 
cultures 
mORCVAX Japanese 
encephalitis 
injectable vaccine CDSCO India 2010 Curevin Pharma 
Pvt 
Curevin are providing 
Vabiotech's vaccine (see 
Shanchol, above). 
Crotalidae 
polyvalent 
immune fab 
(ovine) 
  snakebite injectable biologic 
(anti-
venom) 
FDA USA 2000 Protherics Inc. Developed for North 
American market. 
nifurtimox 
(combination 
therapy with 
eflornithine 
  human African 
trypanosomiasis 
tablet NI WHO EML   2009 Drugs for 
Neglected 
Diseases 
Initiative (DNDi) 
Combination supported 
by research conducted 
by MSF and epicentre. 
zinc   diarrhoea tablet and 
liquid 
NI WHO EML   2006 Newborn and 
Child 
Research performed by 
academics, supported by 
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Development 
Department of 
Child and 
Adolescent 
Health, WHO 
NGOs. 
ribavirin   viral haemorrhagic 
fevers 
intravenous 
and oral 
NI WHO EML   2007 Biorisk 
Reduction for 
Dangerous 
Pathogens 
Team (BDP), 
WHO 
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Regarding the products listed in Table 7.2.2, it can be seen that a variety of different 
organisations filed for registration and hold marketing authorisations (MA) (i.e. are authorised to 
market and sell the product).  The majority is made up of pharmaceutical manufacturers, mainly 
large pharmaceutical corporations and smaller firms in the industry.  There are also some PDP 
brokers and transnational organisations, serving a similar role to PDP brokers, in the list: DNDi, 
the Newborn and Child Development Department of Child and Adolescent Health of the WHO, 
and the Biorisk Reduction for Dangerous Pathogens Team of the WHO.   
The aminoglycoside antibiotic, paromomycin was launched in 2006 as a treatment for visceral 
leishmaniasis (VL) with joint marketing authorisation going to Gland Pharma United, the Institute 
for One World Health (IOWH) and the Gates Foundation.   IOWH has a role as a PDP broker, 
but also carries out R&D activities.  Originally discovered in the 1950s, paromomycin was 
shown to have efficacy in the treatment of VL in the early 1960s.  There was a long history of 
use and development of paromomycin by trans-national NGOs and public health authorities, 
MSF and WHO TDR, but the discontinuation of paromomycin production and the cessation of 
development almost prevented this treatment from having a place in VL therapy.  In 1999, 
IOWH began completion of paromomycin development and received funding from the Gates 
Foundation to realise this goal.  They partnered with Indian pharmaceutical company, Gland 
Pharma, to ensure production(58,59).  This is an example of a successful PDP, which highlights 
a number of key strategies.  IOWH is a non-profit developer, so they were able to develop a 
treatment where a significant commercial incentive did not exist.  They were able to do this, only 
with philanthropic support.  It was also important to engage a producer in a country where VL 
was endemic.   
The case of paromomycin highlights another important pattern seen in Table 7.2.2: 18 of the 33 
industrial MA holders are based in developing countries where NTDs are prevalent, India and 
Brazil.  These two countries are also the two largest developing country funders of NTD 
research(1). 
Most of the products in Table 7.2.2 were developed in a partnership, or there was some form of 
technology transfer between different entities.  Another trend seen here is that almost all 
products that are marketed in lower- or middle-income country markets and/or on a not-for-profit 
basis received some form of public, philanthropic or NGO support in their development.  The 
WHO or PDPs were involved in supporting research (see artemotil, Synriam®, ASMQ, 
miltefosine and others) and product registrations (see benznidazole [paediatric]).  State-owned 
pharmaceutical firms were involved in the development of several products in Brazil, and 
academic/PSNRIs were the home institutions of the original inventors of several of the products 
(e.g. artemisinin derivatives, such as artemether and artesunate).  Even in some cases, where a 
product was originally targeted towards developed country markets (e.g. Coartem® for 
travellers), engagement by one of the aforementioned organisations (the WHO in the case of 
Coartem®) was the key factor in enabling patient access in lower-income countries. 
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The results of the upsurge in NTD drug development and the emergence of new strategies have 
not yet been seen in full.  The analysis above provides a somewhat misleading picture of the 
current state of NTD drug development.  The BVGH global health primers shows 
pharmaceutical development projects at every stage in the development life cycle.  In March 
2012, 190 drugs and 225 drugs were reported as being in ‘active development’ for 23  different 
NTDs(60).  Thus it is important to analyse some of the partnerships of drugs in development.  
Fexinidazole, a new treatment for HAT is in late clinical trials and is a great example of the 
effectiveness of the PDP strategy for developing NTD products.  Case studies of other products, 
which have required the use of innovative business models or strategies, are discussed near 
the end of this chapter. 
Fexinidazole 
Fexinidazole is being developed in a PDP driven by DNDi in partnership with Sanofi, the Swiss 
Tropical Health Institute and HAT platform partners, a consortium of at least 18 national HAT 
control programs, research institutes and NGOs(3,61). Fexinidazole, a broad spectrum 
nitroimidazole antibiotic, was in preclinical development to treat bacterial infections in the 1970s, 
before efficacy against T. brucei infection was discovered in the 1980s.  It was not developed 
further for either indication, but it was re-discovered during a large characterisation of 700+ 
compounds, initiated by DNDi in 2005(62,63).   DNDi was responsible for much of the R&D: 
preclinical, clinical and pharmaceutical.  Sanofi carried out industrial development, registration 
and manufacturing.  Members of the HAT platform, particularly the national control programs of 
the Democratic Republic of the Congo (DRC) and the Central African Republic (CAR), along 
with Médecins Sans Frontières (MSF) were responsible for clinical trials.  DNDi list a number of 
funders, ranging from the Gates Foundation to government international aid departments(61).  
Fexinidazole is expected to be available on the market in 2014(64). 
7.2.9 Benefits of different options 
The presence of different potential partners at different stages of the development lifecycle 
means that several different approaches can be taken to commercialisation of research in this 
area.  Whether the IP protecting an invention is sold, licensed, or used as a foundation for 
forming a new company, partnering with other organisations is essential.  This is evident when 
looking at the development histories of most drugs for NTDs(4,7,29) (see Table 7.2.2), and is a 
key characteristic of pharmaceutical development when the IP originates from academic/PSNRI 
labs(34). 
Chesbrough & Schwartz describe how an effective product co-development partnership should 
look to leverage the capabilities of the respective partners.  In order for such partnerships to be 
successful, the business objectives of each partner should be aligned(65).  An example of 
business objectives for the commercialisation of the research presented in this thesis are: 
 Gain evidence of the efficacy of compounds that are effective in killing trypanosomes 
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 Optimise leads to increase efficacy 
 Prove in vitro and in vivo safety of new leads 
 Prove in-human efficacy of new anti-trypanosomal drug (clinical trials) 
 Register new treatment for HAT/Chagas Disease 
 Large-scale manufacture and distribution of new drug for HAT/Chagas Disease 
Perhaps, a reason for the success of the partnership models used in NTD product development 
is the alignment of these objectives.  Different partners can contribute to projects in a 
complimentary manner, utilising capabilities that are required for the success of the project, but 
without perceiving any threats to their core business model.  For example, a reason for the 
collaboration by large pharmaceutical companies in early stages of R&D (i.e. discovery) is that 
projects are pre-competitive at that stage – the outcomes do not bring the collaborators into 
competition with each other. 
The main questions for academic/PSNRI researchers to address when trying to commercialise 
research that could lead to a new NTD product, revolve around where to find funding, who to 
partner with and at what stage(s). 
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7.2.9.1 The most appropriate option? 
Table 7.2.3 - Market segmentation matrix, adapted from G Moore's 'Crossing The Chasm'(66). This tool is usually 
used to identify an initial market segment for a new product launch.  In a similar manner, here it is used to 
identify the most appropriate type of organisation to partner with.  A higher score indicates a more favourable 
option.  
Key Criteria for 
Partner 
Selection 
Segment 1 
Research 
Councils and 
Philanthropists 
Segment 2 
PDP Brokers 
Segment 3 
Large 
Pharmaceutical 
Companies 
Segment 4 
Biotechnology 
Companies 
Is the partner 
well-funded? 
Are they readily 
accessible? 
4 3 5 3 
Do they have a 
compelling 
reason to 
partner with us? 
5 5 3 2 
Can we, with the 
help of the 
partner, deliver 
a whole product 
to the market? 
2 5 5 3 
Is there no 
entrenched 
competition that 
could prevent 
us from getting 
a fair shot? 
3 3 4 4 
If we enter into 
partnership, will 
their references 
allow us to 
leverage entry 
into additional 
partnerships 
with others? 
4 5 4 3 
Total Score 
(5=high/certainly, 
3=medium, 
1=low/unsure) 
18 21 21 15 
 
Using Moore’s market segment rating grid(66), it is possible to compare the relative strengths of 
potential partners (or ‘market segments’).  PDP brokers and large pharmaceutical firms appear 
as the best initial partners.  In reality, partnership with one type of third party does not preclude 
a partnership with another.  The analysis does highlight PDP brokers as the most appropriate 
partner for a number of reasons.  They have access to funds, they have extensive networks 
with which to find partners and they have project management capabilities.  Large 
pharmaceutical companies share many of these capabilities.  However, PDP brokers have a 
business model that is designed specifically for the development of NTD products.  A large 
pharmaceutical company may actually be limited by their business model, which requires profit, 
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so a third party may need to be engaged to support non-profitable efforts, as has been the case 
with some NTD products developed in partnership with them.   
From an academic/PSNRI researcher’s perspective, an important advantage of engaging with 
one of the two preferred partners is that it relieves them of the significant effort of securing funds 
for several different development activities and then constructing partnership agreements with 
numerous third parties.  One concern in “handing off” projects, particularly when IP is sold or 
licensed without further participation from the inventors, is a loss of control over the progression 
of the product’s development.  Large pharmaceutical companies are sometimes forced to 
discontinue the development of a project for financial reasons(29).  In this respect, either 
engaging a PDP or ensuring that partnership agreements involve continued participation would 
be a safer option. 
In NTD product R&D, royalties are generally not a concern for academics/PSNRIs.  However, 
this would be more of a concern if a new company was formed around the IP.  For the institution 
as a whole, forming a new company and taking equity in it can have a significantly higher return 
than licensing to third parties(67).  Given the desire for profitability for traditional start-up funders 
(i.e. venture capitalists) it would not be advisable to follow this strategy, in the absence of a 
product that can become profitable. 
From a public health perspective, the most favourable outcome is an effective new drug to treat 
trypanosomiasis that is made available to the target population within the shortest time possible, 
and at the lowest cost to all parties involved.  It is clear that the available evidence strongly 
points to the PDP model as the most effective approach to achieve this(7,29). 
7.2.10 Evidence for Partnerships 
 
Figure 7.2.5 - Summary of the pharmaceutical development lifecycle, from discovery to registration and approval.  
Timelines and patient numbers informed by DiMasi et al.(68), S Blank(69) and the FDA(70).  
7.2.10.1 Technology transfer in the pharmaceutical industry 
Co-development partnerships are not unique to the NTD field, where pharmaceuticals are 
concerned.  When seeking a partner, it is important to understand their motivations for entering 
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a partnership, as well as anything that may discourage a potential partner from entering into an 
agreement.  An analysis of the evidence to support a particular project is warranted. 
Pharmaceutical development can be an incredibly costly and risky process.  An analysis of drug 
development success rates showed that only 19% of drugs entering clinical trials between 1993 
and 2004 eventually attained clinical approval.  This number was a little higher for co-developed 
(in-licensed or out-licensed drugs), than for drugs developed solely by one of the 50 
pharmaceutical companies analysed in the study (27% vs. 16%).  This may indicate that the 
licensors of new drugs usually prove efficacy at phase I or phase II, before licensing out to a 
third party.  Encouragingly, systemic anti-infective drugs had a higher success rate of 24%, 
particularly at the transition from phase II to phase III development.  This may be due to clearer 
clinical end points(71).   Achieving the dual objectives of forming an effective partnership and 
eventually gaining clinical approval rely heavily on gaining evidence to support your project. 
In an analysis of biologic drug licensing deals from biotechnology to large pharmaceutical 
companies, Kalamus and Pinkus report that the majority of deals occur between the preclinical 
phase and phase II.  However, phase II appears to be the preferred time(72).   
In their analysis, Kalamas and Pinkus show that both parties could generate value by entering 
into agreements earlier.  Under-pricing by large pharmaceutical companies was stated as a 
cause of delayed deal making(72).  With this problem removed in the case of not-for profit 
endeavours, deals should be made earlier, so that researchers can start to exploit the 
capabilities of their better-resourced partners sooner.  
It has been reported that, after a shift towards deals made after in-human proof-of-concept, 
early-stage pharmaceutical industry deals are re-emerging: they represented more than 60% of 
‘big buyer’ deals in 2011-2012.  Large pharmaceutical companies are also forming more early-
stage partnerships directly with academia.  These partnerships often involve payments at 
milestones, when key research objectives have been met.  They are sometimes tied to ‘options’ 
where, at the completion of all research objectives (i.e. phase II trials), the company can acquire 
the IP, or even an IP-holding company (where a small company is involved).  This kind of 
arrangement allows the large companies to reduce their exposure to risk, whilst still enabling 
researchers to advance projects(73).  
7.2.10.2 When to partner and with what supporting evidence 
The most favourable time to start partnering largely depends on the commercialisation strategy 
followed by the researchers.  In the absence of commercial considerations, it would even be 
advantageous to seek partners at the discovery phase.  If an academic/PSNRI researcher is 
developing a product that may have some commercial value, then they may wish to attempt 
technology transfer later in the development lifecycle.  In either case, researchers in an 
academic/PSNRI or in a small company may reach what is often termed “The Valley of Death” 
or the “Darwinian Sea”, which is the point where more funds are required to develop a product, 
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but there is a lack of willing partners to fund the development of a product, which may still carry 
a high risk of failure(74,75).  As highlighted by Kalamas & Pinkus, having the opportunity to use 
the capabilities of a well-resourced partner, early in the development process, should also be 
seen as an advantage(72). 
The vast sums of money and significant amount of labour required to optimise products and 
demonstrate their safety can be out of the reach of most academic/PSNRI researchers(27).  It 
can cost hundreds of thousands of dollars to outsource labour-intensive tasks, and in vitro and 
in vivo toxicology studies can cost over US$ 1million(36).  Animal studies, which can be very 
expensive, can play a vital role in demonstrating efficacy(74).  In these situations, an alternative 
to licensing to industry is to partner with a well-resourced academic drug discovery centre to 
carry out some of this work(27).  There are also a number of programs to support translational 
research originating from academic/PSNRI research.  One such program is the NIH’s 
Therapeutics for Rare and Neglected Diseases program (TRND).  TRND aims to collaborate 
with researchers of rare and neglected diseases “with the goal of moving promising therapeutics 
into human trials”(76). 
Aside from gaining access to funding, there are other advantages to partnering with larger 
partners (e.g. pharmaceutical companies) which are due to the partner’s greater experience.  A 
review of strategic alliances between biotech companies and pharmaceutical companies 
between 1988 and 2000, gives some clues as to what these advantages are.  It was shown that 
in the more complex trials of phase II and phase III, a drug is significantly more likely to proceed 
to the next phase, if the licensee (e.g. large pharmaceutical company) has more experience.  In 
phase I trials, which are less complex, there is only a small advantage in this respect(77). 
An advantage of being affiliated to academic institutions or PSNRI is that the capabilities (e.g. 
biological and clinical expertise) of the institution can be made use of at several points in the 
lifecycle, as has been done in the development of other products for NTDs or low-income 
markets (78).  Many academic institutions are now engaged in translational research and there 
are several established ‘drug discovery centres’ at institutions across the US(27,28).  However, 
once large scale trials are needed, these institutions become limited, so one should seek to 
partner with a PDP broker and/or large pharmaceutical company, and an organisation 
experienced in public health (e.g. WHO, MSF). 
There are now several studies that can be used to ‘de-risk’ drug development projects(79).  
They are often used in a standardised way in the pharmaceutical industry, but it is often said 
that, in respect to these studies, expectations held by licensees in large pharmaceutical 
companies and their licensors, are mismatched.  There is little specific information on these 
expectations and how they affect the partnering decisions of funders of NTD product R&D.  
Thus, this will be the subject of future research.   
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7.2.11 The role of other incentives 
Clearly, a fundamental problem in funding R&D for NTD products is the lack of financial 
incentive for investors to support it.  As discussed above, this limits the number of options a 
product developer can choose from to advance their product towards the market.  In recognition 
of this long-standing problem, several different policies and market incentives have been 
proposed to create a market incentive for the development of products to meet an unmet 
medical need, where little/no market incentive exists(80–82).  Amongst numerous proposals, 
two market incentives that have been implemented are the FDA’s Priority Review Voucher 
(PRV) and Advance Purchase/Market Commitments (AMCs).  They are both examples of “pull” 
mechanisms, which provide monetary incentives for the completion of research. 
7.2.11.1 Priority Review Voucher 
When the FDA considers a new drug to provide “significant improvements in the safety or 
effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to 
standard applications”, it can be reviewed under ‘priority review’.  This means that the FDA 
promises to take action on a new drug application within 6 months of receiving it, compared to 
the standard 10 months(83).  This can have the effect of reducing the overall time of review by 4 
to 12 month, thus saving companies significant amounts of money(6).  The PRV is a voucher 
granted to successful applicants of new drugs or vaccines that confer to the FDA’s guidelines:  
they “offer major advances in treatment or…where no adequate therapy exists” for a specified 
list of tropical diseases.  The PRV can be traded or sold, and allows the final user to gain priority 
review for a new drug application that wouldn’t otherwise receive priority review designation.  At 
present there is some uncertainty on the impact that the PRV will have.  It has been estimated 
that the value of a PRV could range between US$50 and US$500 million, depending on the 
therapeutic area that the PRV is used in.  We also lack information from past experience.  
Novartis were the first organisation to be awarded a PRV in 2009 following the approval of 
Coartem®, but they used that to gain priority review for another Novartis product.  Given the 
potential for a high value PRV, the utility of this incentive can be substantial from an NTD 
researcher’s perspective.  However, the PRV is not awarded until development is complete, so 
it does not alleviate the shortage of funds during earlier- stage development(22).  The PRV 
could be of some advantage to researchers using a spin-out company strategy, as its potential 
value could be used to attract the equity investments required to fund early-stage R&D.  
However there has been some criticism and scepticism shown towards the PRV 
program(21,22).  It is not entirely certain how investors will respond to this program(81).  
Conversely, a survey conducted to assess the impact of the PRV program showed that the PRV 
had positively influenced decisions to continue investment in R&D for NTD products.  The PRV 
was not a primary reason for pursuing NTD product R&D(22) and a separate study estimated 
that the PRV would not be sufficient to make an R&D venture profitable on its own(81).  
Nevertheless, the PRV could be a useful addition to a researcher’s tools for attracting support 
for R&D.  
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7.2.11.2 Advance Purchase/Market Commitments 
AMCs have been proposed as another way to increase private-sector participation in NTD R&D.  
An AMC is a legally-binding agreement that ensures that a company is paid a set amount of 
money for providing enough product to treat a set amount of patients, provided that the 
company produces a product that meets agreed specifications(18,19,80).  This incentivises 
R&D by guaranteeing some return on a company’s investment.  Although AMCs remove market 
uncertainty for the investor, their payment still relies on a product being successful, and we 
have little evidence pertaining to how investors are responding to this.  An AMC has proven to 
be successful in encouraging development of a Meningococcal C vaccine in the UK(80), and 
the first AMC for a neglected disease was implemented for pneumococcal vaccine development 
in 2007(84).  Many of the potential advantages of PRVs apply for AMCs, but again, they do not 
supply up-front funds to finance R&D.  They do have an additional advantage from a public 
health perspective, which is that they encourage rapid access for patients requiring the new 
product(19). 
7.2.11.3 Research prizes 
Research prizes or medical innovation prizes have been proposed as another mechanism to 
encourage research into treatments for diseases with unmet medical need.  Furthermore, they 
have been seen as a way to widen patient access to innovative medicines by de-linking R&D 
costs from the prices of the medical products that they create(85–87).  These prizes award a 
fixed sum of money to the individual or group who matches the specific research goal of the 
competition.  There are numerous historical examples of prizes given for specific research 
outcomes that provide some benefit to human health(88).  The setting up of research prize 
funds has been debated at the national and international level, but no large scale, public-sector 
system exists yet(85).  However, there are prize funds or innovation prize-granting 
organisations operating in the private sector.  Two of the largest of these are the Innovation 
Management firm, Innocentive(89), and the non-profit Xprize fund(90).  These organisations 
advertise specific innovation problems, which are attached to prizes of a specific value.  A 
researcher or company looking to advance a product already in development would need to 
hope that their research aims are aligned with those of a particular competition.  Alternatively, 
researchers may choose to begin research in response to a competition.  As of yet, no specific 
prize funds exist for NTDs, but the experience of the non-profit Prize4Life fund may prove the 
effectiveness of this approach.  Prize4Life offers a prize of US$1 million for discoveries that 
advance the understanding and treatment of the debilitating and life-threatening disease, 
amyotrophic lateral sclerosis (ALS).  A US$1 million dollar prize was awarded in 2011 for the 
discovery of an ALS biomarker.  A prize fund of US$1 million was reopened in 2012 to find an 
ALS treatment, following the failure to find an effective treatment during the last competition, 
which occurred in 2008-10(91).  Researchers should remain alert to competitions posted by 
prize-giving organisations, such as Innocentive, Nesta(92) and Xprize. 
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7.2.12 Roads less travelled 
The very particular difficulties faced by researchers in the NTD space have demanded that a 
number of innovative commercialisation strategies are attempted.  In some cases, a new 
company has been set up with an innovative business model that facilitates the development of 
a product with little/no profit-making potential.  For example, in order to develop the antimalarial 
artemotil, ACF Beheer SA formed a new company, Artecef BV, which partnered with the WHO 
TDR program to bring the product to market.  The following section gives further case studies 
and examples of the different strategies used by researchers to develop pharmaceuticals and 
medical devices for patient populations with little purchasing power. 
7.2.12.1 The role of different indications/applications 
The findings of the G-FINDER report suggest that, at least amongst industry funders of NTD 
product R&D, there is a shift towards more contributions to projects that might result in a semi-
commercial (profitable) product.  The analysis of the drugs studied by Pedrique and colleagues 
in Table 7.2.2 also highlights this trend towards the development of products with profitable 
applications.  When a product has an additional indication for a disease where there is a market 
with commercial value, commercialisation for the profitable application can help to fund the 
development or production of that product for its original intended use.  A factor contributing to 
Sanofi making eflornithine freely available to HAT patients, was that they were producing the 
drug as part of their Vaniqa® product, which is used to treat hirsutism in women (primarily in 
developed countries)(93).  Other products, such as several of the malaria treatments on the 
market, find application in the developed world, which can help subsidise the donation of those 
same products to developing-country markets.  Below, creative commercialisation strategies 
which exploit these situations are described. 
Case Study: The Infectious Disease Research Institute (IDRI) 
The IDRI is a non-profit research institute that specialises in applying knowledge of immunology 
to the discovery and development of products to diagnose, prevent and treat neglected tropical 
diseases, including Chagas Disease and Leishmaniasis.  They benefited from their non-profit 
status, by being able to engage with stakeholders involved in the use of their products, but they 
suffered from the inconsistency of the grant funding that was available to them.  To bring in 
larger sums and more sustainable sources of money, they span out companies to 
commercialise products that had profitable developed-world applications.  IDRI licensed their 
vaccine adjuvant technologies to these companies and sometimes held equity in them, so the 
money earned from royalties or acquisitions could be used to serve their NTD product 
development aims(94). 
 
614 
 
A trypanosomiasis treatment with additional indications 
A product resulting from the research presented in this thesis could potentially have uses for 
other disease indications.  The results of BLAST searches using the L-threonine 3-
dehydrogenase (TDH) protein or gene sequences from Trypanosoma brucei, show that similar 
proteins and genes have been identified in Staphylococcus aureus, Clostridium difficile, 
Enterococcus faecium and Enterococcus faecialis.  These organisms are all associated with 
nosocomial infections and represent urgent medical needs.  There is a strong case for new 
antibiotics to treat infections by drug resistant bacteria, such as methicillin-resistant Staph 
aureus (MRSA) and vancomycin-resistant Enterococcus (VRE)(95,96). 
The global market for therapeutics for MRSA infection has been estimated to grow from 
US$2659.7 million in 2011 to US$3468 million in 2019(97) and the global market for 
therapeutics for C. difficile infections has been set to grow from US$314.2 million to US$314.2 
million, over the same period(98).  If a treatment developed for trypanosomiasis came from this 
research, and it was also effective in killing these bacterial pathogens, there would be clear 
commercial potential.  In this case, a sensible strategy would be to license the IP to for-profit 
spin outs, as in the IDRI case study.  If they were successful in attracting investment, the money 
gained through licensing could be used to further the development of the trypanosomiasis 
treatment.  Spin outs would also allow the University to recover more value from the 
commercialisation of these products.  Similar scenarios can also be envisaged for drugs which 
targeted other targets shared amongst several important pathogens. 
7.2.12.2 Rare disease/orphan drug strategy 
The Orphan Drug Legislation passed in the US and the EU established packages of push and 
pull mechanisms to spur drug development for rare diseases, where the market size is too small 
to expect a significant return on investment.  Drugs for these rare diseases are termed ‘Orphan 
Drugs’.  The criteria and benefits of each piece of legislation are outlined in Table 7.2.4.  
Several other countries have enacted similar laws to achieve the same goals.  These laws have 
been successful in encouraging the development of orphan drugs, which may not have been 
developed otherwise, due to a lack of commercial viability.  Pursuing research in this area has 
also been adopted as a commercial strategy for several biotechnology and pharmaceutical 
firms, for whom orphan drugs may be as profitable as non-orphan drugs(28,99–101).  Due to 
their low incidence in developed countries, several NTDs are classified under the 
aforementioned legislation as rare diseases; several NTD drug and vaccine development 
programs have taken advantage of some of the benefits provided under the legislation(80).  As 
with orphan drugs, regulatory authorities may also apply some flexibility when approving 
products for NTD indications(102).  However, orphan drug legislation has been nowhere near 
as effective in promoting R&D for NTDs, as it has for other rare diseases.  In developed 
countries, orphan drug developers have taken advantage of market exclusivity and the 
purchasing power of public health authorities or insurance companies to charge extremely high 
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prices(103).  This sort of financial incentive does not exist for products for NTDs, thus the utility 
of the orphan drug legislation is limited, and the benefits should be exploited alongside other 
mechanisms(104).  The push mechanisms tied to orphan drug policies are particularly useful to 
NTD product developers as they offset several of the product development costs. 
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Table 7.2.4. Summaries of the designation criteria and incentives of the USA and EU Orphan Drug/Rare Disease 
laws(105–107).  
 FDA – USA EMA – European Union 
Designation Criteria  Disease affects fewer than 
200 000 people in the US, 
or 
 Product is a vaccine, 
diagnostic or preventative 
drug and is intended to be 
administered to less than 
200 000 people per year in 
the US, or 
 Disease affects more than 
200 000 people or product 
is a preventative drug 
intended to treat more 
than 200 000 people per 
year, and R&D costs cannot 
be expected to be 
recovered by sales in the 
US. 
 Disease must be life-
threatening or chronically 
debilitating, and 
 Prevalence of the disease must 
be less than 5 in 10 000 in the 
EU, or it must be likely that 
marketing would not generate 
significant returns on the 
investment for development, 
and 
 No satisfactory method of 
diagnosis, prevention or 
treatment is available, or, if 
such a method exists, the 
medicine must be of significant 
benefit to those affected by 
the condition. 
Benefits/Incentives  50% tax credit for costs of 
clinical trials in the US 
 7-year market exclusivity – 
protection from 
competition from a drug 
for the same indication 
 Fast-track review of 
registration application 
 Written recommendations 
given on the preclinical 
studies and clinical trials 
required. 
 Protocol assistance 
 10-year market exclusivity – 
protection from competition 
from similar drugs with similar 
indications 
 2-year extension of market 
exclusivity if paediatric 
investigation plan followed 
 More incentives for SMEs – 
administrative and procedural 
assistance. 
 Some EU member states 
(including the UK), offer tax 
credits for R&D 
 
Case Study: Niprisan 
Although not an infectious disease or NTD, sickle cell anaemia is a disease with a high prevalence in 
several lower-income countries in Africa and suffers from a shortage of safe and effective treatments.  
In Nigeria, where 150 000 children are born with sickle cell anaemia annually, the country’s National 
Institute for Pharmaceutical Research and Development (NIPRD) identified a traditional herbal 
treatment that was effective in treating the disease.  In collaboration with the Philadelphia Children’s 
Hospital, NIPRD obtained evidence of in vivo efficacy for the treatment in animal models and later, in 
humans.  The treatment, named Niprisan, was licensed to US biotechnology firm, Xechem, which 
gained orphan drug designation for Niprisan in the US, due to the low prevalence of sickle cell 
anaemia there, and developed it to the point of gaining FDA approval.  Unfortunately, these factors 
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were not enough to ensure success.  The product did not seem to be economically viable and 
Xechem filed for bankruptcy some years later.  However, this is an example of how orphan drug 
legislation can be used to aid drug development.  The reported benefits of the designation were: 
“waiving of registration fees, additional funding, and an increase in investor confidence”(108). 
7.2.12.3 Multiple Indications 
There is another way in which an Orphan Drug Designation may be useful, from a commercial 
standpoint.  The development of a drug for an NTD or rare disease can be accelerated and partly 
funded through receipt of an orphan drug designation, then that same drug may be developed for use 
in a more common disease (e.g. bacterial infection).  Alternatively, the knowledge gained through 
development of the original drug can be applied in the pursuit of drugs for more common diseases.  
This strategy is currently being applied with rare diseases by some companies in the pharmaceutical 
industry(101).  It is therefore plausible that an NTD drug with other indications could help to attract an 
industry partner. 
 
7.2.12.4 Exploiting technologies 
Case study: Anacor Pharmaceuticals 
The case of Anacor Pharmaceuticals, a US-based biotechnology firm, provides an example of how a 
for-profit company is able to leverage its technology to develop treatments for NTDs, on a not-for-
profit basis.  Anacor was set up around a boron chemistry platform that was discovered through 
academic research.  The unique, boron-based compounds that Anacor holds the IP for have a 
distinctive geometry and reactivity, and have demonstrated efficacy in several diseases.  To allow 
Anacor to apply this technology to NTDs, it entered into an agreement with DNDi, to whom it offered a 
non-exclusive, royalty-free license.  This class of the compounds, termed oxaboroles, were found to 
hold much potential as HAT treatments.  DNDi partnered with the CRO, Scynexis to develop this 
further and the resulting lead, SCYX-7158 has entered in-human trials(55).  For Anacor to be able to 
increase their participation in the NTD space, the leadership constructed a business plan, where 
grants from PDPs and other NTD R&D funders would allow them to carry out NTD R&D without 
interfering with their shareholder-funded commercial R&D activities(109). 
This example highlights a number of key points.  Principally, it underlines the role of PDPs and other 
funding sources in engaging for-profit entities in the industrial sector.  It also shows how alteration of a 
for-profit firm’s business model can allow their participation in NTD product R&D.  Other similar 
examples of business model alignment can be found in the Global Health Innovation Insight Series, 
produced by the Centre for Social Innovation, at Stanford University’s Business School(110). 
Equity investments by the Gates Foundation 
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In 2011, the Gates Foundation made its first equity investment in a biotechnology firm.  Liquidia, a 
company based in North Carolina, USA, have attracted interest from several investors, for its novel 
vaccine technology.  The purpose of the US$10 million investment by the Gates Foundation is to 
support the application of Liquidia’s technology to diseases where there is no viable market(111).  
According to foundation executives, this is the first case of a new approach to supporting product 
development for global health(112) and this may represent a new source of equity for a for-profit 
company engaged in NTD product development.  In 2013, the foundation bought US$5 million of 
common stock in Anacor Pharmaceuticals as part of an agreement that included additional grants of 
US$17.7 million to support NTD drug discovery and compound library development(113). 
7.2.12.5 Open Source Drug Discovery 
Open Source Drug Discovery is being used as a way to foster collaboration and to take advantage of 
the different skills of researchers involved in drug discovery. The six laws of Open Source Drug 
Discovery are: 
 All data are open and all ideas are shared 
 Anyone can take part at any level of the project 
 There will be no patents 
 Suggestions are the best forms of criticism 
 Public discussion is much more valuable than private email 
 The project is bigger than, and is not owned by, any given laboratory. 
Although there are several concerns over whether the lack of intellectual property will make it difficult 
to attract funders, development partners and manufacturers, the open source approach has been 
successful in achieving the aims of combining the abilities and resources of a wide range of 
researchers(114).  This has found utility, particularly in NTD drug development.  Perhaps the most 
well-known open-source drug discovery project is the Open Source Malaria consortium.  This project 
is funded by MMV, centred in Sydney and involves contributors from around the world(114,115).  This 
campaign has resulted in the chemical synthesis of various leads, some of which have been tested in 
vivo (animal models)(116).  A similar project, looking for new drugs to treat tuberculosis is also 
active(117).  The Tropical Disease Initiative is a further example of an open source initiative with 
similar aims, targeted at a broader set of diseases(118,119). 
As all of these examples are in the early stages of development, it is difficult to see how successful 
they will be in delivering new treatments to the clinic.  Setting up an interface for a whole community 
of researchers can be an endeavour requiring significant effort.  However, the Open Source approach 
can be a potentially useful option for a researcher who is limited by the capabilities available to them. 
7.2.12.6 Crowd-funding 
Crowd-funding, the process where large numbers of investors make small investments in a particular 
venture, as opposed to a few investors contributing large amounts, is a growing trend that is 
beginning to gain traction in the biotechnology and pharmaceutical industries.  It has been proposed 
as another source of funding for early-stage product development(120).  In 2012, 200 investors 
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gained a profitable exit through a French organisation, called WiSEED when an angel investor bought 
their equity stake in antibacterial drug discovery company, ANTABIO(121).  There are now proposals 
to set up tax-deducted crowd-funding platforms in the UK:  Citizen’s Innovation Funds(122).  For 
investors to buy equity in a private limited company, the law must allow for this.  Legislation that does 
allow private companies to raise money through crowd-funding has been passed in the US(121).   
Crowd-funding does not always involve equity investments, so it could be used by researchers to 
support specific R&D activities.  In recent years, two web-based crowd-funding platforms, 
Petridish.org and Experiment.com have been established to allow scientists to crowd-fund individual 
research projects.  Founded in response to funding shortages and a lack of support for certain ideas, 
Experiment.com proves that this approach can be successfully utilised to fund NTD product R&D.  
One researcher sought US$6500 to fund the testing of an FDA-approved drug in an animal model of 
Chagas Disease.  Her success in raising the funds allows her to clear the final “obstacle…before the 
drug can be used in clinical trials”(123).  Although the amount raised is relatively small, this is a clear 
example of how crowd-funding may be used to bring one’s research to a point where it is easier to 
seek other partners/funders.  The website has also been used to successfully raise money for 
projects targeting malaria and helminth infections(124). 
 
7.2.13 Lessons from other industries 
Evidence of the different strategies for advancing development of NTD products has largely been 
drawn from experience within this area and in pharmaceutical R&D in general.  However, there are 
other lessons to be learned from the experiences of businesses in areas that are not specific to 
pharmaceutical R&D.  Additionally, strategies from charitable/social sector organisations are also 
described below. 
7.2.13.1 Support for start-ups and small businesses 
When seeking seed capital and/or funds for early-stage product development, there are a number of 
sources of support in the public and private sector.  There are several government-funded initiatives 
to promote the foundation of new companies, particularly in technology.  For example, the UK 
government’s Technology Strategy Board offers R&D funding in a number of strategic areas to 
academics and small businesses(125). 
Business incubators aid the development of early-stage companies by giving various types of support, 
ranging from expertise and facilities to funding and mentoring.  Incubators are usually run by 
government, universities, private consortiums or large corporations(126,127).  They now play a 
prominent role in the development of technology start-ups and are increasingly being used by large 
pharmaceutical companies to partner with smaller firms and bulk up their pipelines(128). 
Business Plan Competitions are another source of important seed funds or R&D funds.  A useful 
example of this can be seen in the founding of Respira Design, a non-profit company specialising in 
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the design of low-cost devices for asthma treatments for use in low-income settings.  When 
developing their first product, the founders struggled to gain support from investors to fund proof-of-
concept studies.  They were able to find this money by reaching the finals of the Ashoka 
Changemakers competition(78).  
7.2.13.2 University alumni donations 
Alumni donations provide a substantial source of income for universities and PSNRIs.  They are often 
used to fund specific initiatives and may be tapped into to support NTD programs.  The University of 
British Columbia’s Neglected Global Diseases Initiative, a cross-departmental research group, was 
built through donations from alumni and other donors(129). 
7.2.13.3 Microdonations 
Just as Crowd-funding aims to raise relatively large amounts of money, from relatively small 
contributions and from a large number of investors/donors, microdonations raise money using a 
similar philosophy.  A microdonation is a “low value donation ‘embedded’ into activities or transactions 
that consumers are already undertaking”.  The Pennies fundraising scheme, run by UK-based The 
Pennies Foundation, raised more than £250 000 in 12 months by asking consumers to donate a 
penny when making purchases in the UK(130).  Similar initiatives have been used to raise funds to 
fight HIV/AIDS and tuberculosis(131,132). 
The consumer activity at university-owned or university-housed stores could be harnessed in a similar 
manner to raise money for research.  This would require a significant organisational effort, however, 
but it could raise substantial funds. 
7.2.13.4 Social Investment 
The utility of the start-up strategy for developing a new treatment is limited by the lack of profitability of 
the target market for trypanosomiasis.  However, a non-profit business model could be useful if this 
strategy were pursued.  Like academic/PSNRI researchers, charities and social enterprises are in 
constant search of funds to carry out their work.  Furthermore they need particularly large amounts of 
money in order to expand their capabilities.  These organisations are now being aided by a recent 
trend termed ‘Social Investment’.  Funds are given in the form of long-term debt, which is similar to an 
equity investment(133).  Many of these investments require that the recipient has an underlying 
source of revenue, therefore excluding a pre-revenue pharmaceutical/biotechnology start-up.  
However, a new type of social investment, the Social Impact Bond (SIB), is becoming a useful tool for 
some non-profits.  SIBs, which were founded by a group called Social Finance in the UK, are issued 
by the public sector to private sector investors, for work carried out by charitable organisations.  The 
original investors only receive a return if the work of the charity has a measurable social impact that is 
cost-saving for the government.  In this way, the charity receives up-front funds but bears no financial 
risk(134,135).  As this is a relatively new initiative, it does not seem to have received any attention 
from the drug development or NTD communities, but it could feasibly be used for financing R&D.  
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7.2.14 Conclusion 
The NTD R&D landscape 
A dramatic increase in awareness and advocacy for NTD product R&D has been witnessed over the 
last decade.  This is evident in the increased activity in the area and the evolution in product 
development and commercialisation strategies.  Public-Private partnerships have always been a 
feature of NTD product R&D, but the emergence of the PDP as the primary model for product 
development is welcome progress.  Unfortunately, reports of funding inconsistencies and research 
gaps for some diseases persist(5,38).  Following the global financial crisis, there has been a decrease 
in funding from philanthropic sources and some government aid agencies.  This is of concern 
because they are the principal funders of PDPs(1).  Despite these concerns, researchers working 
towards developing products for NTDs are in a better position to do so than a decade ago.  In addition 
to the increased funding and awareness, the experience of others is providing evidence of several 
new ways to attract funding to the cause.  Researchers and other stakeholders of NTD product 
development should also look to the future, as new incentives, such as tax credits(136,137) and 
Medical R&D treaties(138), could result from recent proposals. 
Limitations of this analysis 
This chapter has aimed at providing insight into the main considerations to be taken account of when 
developing a treatment for a NTD.  Thus, many aspects of pharmaceutical R&D, and how it is carried 
out for NTDs, have been broadly reviewed.  However, in reality, some concerns, such as the specifics 
of licensing deals, intellectual property and target product profiles all demand deep analyses of their 
own.  These concerns have all been eluded to here, but deeper analyses have focused on the most 
important and immediate problems faced when advancing this research.  Specific evidence on the 
best stage of development to transfer technology was found to be lacking, so this will be the subject of 
future research.  
 
7.2.14.1 How to commercialise this research 
Opinion on the best course of action 
Given the therapeutic area, the most appropriate mechanism for commercialising the results of this 
research would be through licensing to external partners.  In the absence of other, profitable 
indications, the effort and seed capital required to found a spin-out company would not be worth it.  If 
the drug/series of compounds showed efficacy in diseases with a market, then commercialisation 
along those lines should be carried out separately through licensing of the original IP.  Profits from 
those endeavours could be used to support development of the original product. 
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A large, well-resourced partner, such as a PDP broker or large pharmaceutical company, may be 
sought for partnership as early as possible to make use of their capabilities and accelerate 
development.  Ownership of IP and research objectives should be agreed upon and aligned as early 
as possible, to prevent any issues once co-development starts. 
PDP brokers seem to engage with researchers once a viable product (e.g. a lead compound with 
some in vitro efficacy) has been found.  Therefore, with this research, a partnership with a 
pharmaceutical or biotechnology firm should be used to bring the research to this point. 
The greatest possible number of funding sources, government incentives and other support should be 
taken advantage of.  The options will be different, depending on the commercialisation route followed; 
different options are available to non-profit organisations than to for-profit organisations.  Drawing 
support from numerous sources is advantageous and may prove to be essential to advance a product 
all the way to the market. 
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